<SEC-DOCUMENT>0001493152-18-003208.txt : 20180312
<SEC-HEADER>0001493152-18-003208.hdr.sgml : 20180312
<ACCEPTANCE-DATETIME>20180312084619
ACCESSION NUMBER:		0001493152-18-003208
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180312
DATE AS OF CHANGE:		20180312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corbus Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001595097
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464348039
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37348
		FILM NUMBER:		18682207

	BUSINESS ADDRESS:	
		STREET 1:		100 RIVER RIDGE DRIVE
		CITY:			NORWOOD
		STATE:			MA
		ZIP:			02062
		BUSINESS PHONE:		617-963-0103

	MAIL ADDRESS:	
		STREET 1:		100 RIVER RIDGE DRIVE
		CITY:			NORWOOD
		STATE:			MA
		ZIP:			02062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SAV Acquisition Corp
		DATE OF NAME CHANGE:	20131220
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[X]</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[&nbsp;&nbsp;]</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE TRANSITION PERIOD FROM ________ TO ________.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMISSION
FILE NUMBER: 001-37348</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-4348039</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation
        or organization)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>500
                                         River Ridge Drive</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Norwood,
        Massachusetts</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>02062</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of principal executive offices)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Zip
    Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(617)
963-0100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(b) of the Act: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title
    of each class</U></B></FONT></TD>
    <TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, par value $0.0001 per share</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Global Market</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(g) of the Act: None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [&nbsp;&nbsp;]
No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [&nbsp;&nbsp;]
No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of the registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 22%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer [X]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
    not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company [&nbsp;&nbsp;]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company [X]</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [&nbsp;&nbsp;] No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2017, the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate
market value of the common stock held by non-affiliates of the registrant was approximately $294,882,116, based on the closing
price of the registrant&rsquo;s common stock on June 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 6, 2018, the number of shares outstanding of the registrant&rsquo;s common stock, $0.0001 par value per share, was 57,134,677.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Documents
incorporated by reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
of the registrant&rsquo;s proxy statement for the 2018 annual meeting of stockholders to be filed pursuant to Regulation 14A within
120 days after the registrant&rsquo;s fiscal year ended December 31, 2017, are incorporated by reference in Part III of this Form
10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
REPORT ON FORM 10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEAR ENDED DECEMBER 31, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART III</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART IV</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</FONT></A></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals,
expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties
and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be
materially different from future results, performance or achievements expressed or implied by such forward-looking statements.
All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify
these forward-looking statements through our use of words such as &ldquo;may,&rdquo; &ldquo;can,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;assume,&rdquo; &ldquo;should,&rdquo; &ldquo;indicate,&rdquo; &ldquo;would,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plan,&rdquo; &ldquo;point to,&rdquo;
&ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;potential&rdquo;
and other similar words and expressions of the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking
statement made by us. These factors include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    lack of operating history;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    current and future capital requirements and our ability to satisfy our capital needs;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete required clinical trials of our product and obtain approval from the FDA or other regulatory agents in
    different jurisdictions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain or protect the validity of our patents and other intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain key executive members;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interpretations
    of current laws and the passages of future laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our business model by investors;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses and capital requirements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support growth.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 30.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 30.95pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein
or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking
statements. Please see &ldquo;Risk Factors&rdquo; for additional risks which could adversely impact our business and financial
performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated
by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations,
beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations,
beliefs or projections will result or be achieved or accomplished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>Item
1. BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned
by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this report and the
information incorporated herein, including logos, artwork, and other visual displays, may appear without the &reg; or &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend
our use or display of other companies&rsquo; trade names, service marks or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. Other trademarks, trade names and service marks appearing in this report are the
property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase 3, clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to
treat rare, chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Our product, lenabasum, is
a novel synthetic, oral, endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes without
causing immunosuppression. We are currently developing lenabasum to treat four life-threatening diseases: systemic sclerosis (SSc),
cystic fibrosis (CF), dermatomyositis (DM) and systemic lupus erythematosus (SLE).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is a synthetic, rationally-designed, oral small-molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2
found on activated immune cells, fibroblasts and other cell types including muscle and bone cells. Lenabasum stimulates the production
of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous
pathways. These pathways are activated in healthy individuals during the course of normal immune responses but are dysfunctional
in patients with chronic inflammatory and fibrotic diseases. By its binding to CB2, lenabasum drives innate immune responses from
the activation phase into the resolution phase. CB2 plays a central role in modulating and resolving inflammation by, in effect,
turning heightened inflammation &ldquo;off&rdquo; and restoring homeostasis. This has been demonstrated in animal models lacking
CB2 as well as humans with genetic polymorphism in the CB2 gene, as these exhibit excessive inflammation and fibrosis in response
to activators of the innate immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lenabasum has generated
positive clinical data in three consecutive Phase 2 studies in diffuse cutaneous SSc, CF and skin-predominant DM. Lenabasum is
currently being evaluated in a Phase 3 SSc study that is expected to enroll 354 patients, a Phase 2b CF study that is expected
to enroll 415 patients (that is being supported by a development award for up to $25 million (the &ldquo;2018 CFF Award&rdquo;)
from the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;)), and a Phase 2 SLE study that is expected to enroll 100 patients and
is being funded by a grant through the National Institutes of Health (&ldquo;NIH&rdquo;). In DM, the Company plans to consult
with the FDA on the protocol design for the next clinical study, which the Company expects to commence before the end of 2018.
Open-label extension studies are ongoing in SSc and DM following the completion of the Phase 2 studies in these indications.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration, or the FDA, granted lenabasum Orphan Designation as well as Fast Track Status for both SSc
and CF. The European Medicines Authority, or the EMA, granted lenabasum Orphan Designation for both SSc and CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development status of lenabasum is summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1-: Clinical development pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 249; width: 500"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Development </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis (Scleroderma) </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On-Going
Phase 3 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, we initiated a Phase 3 double-blind placebo-controlled multi-center international clinical study (&ldquo;RESOLVE-1&rdquo;)
in diffuse cutaneous SSc and the first patient was dosed in January 2018. The RESOLVE-1 study is expected to enroll approximately
354 subjects at 70 sites in North America, Europe, Israel, Japan, South Korea, and Australia. The planned duration of treatment
with study drug is 52 weeks. Subjects will be randomized 1:1:1 to receive lenabasum 5 mg twice per day, lenabasum 20 mg twice
per day, or placebo twice per day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary efficacy outcome of the RESOLVE-1 study will be change from baseline in modified Rodnan Skin Score (&ldquo;mRSS&rdquo;),
a measure of skin fibrosis and a standard clinical trial outcome in SSc. Secondary outcomes of the RESOLVE-1 study include patient
reported outcome of Health Assessment Questionnaire-Disability Index, the American College of Rheumatology Combined Response Index
in diffuse cutaneous Systemic Sclerosis (&ldquo;ACR CRISS&rdquo;) score, a novel composite measure of clinical improvement from
baseline that incorporates change from baseline in mRSS, and lung function and forced vital capacity, % predicted. These same
outcomes were evaluated in the Phase 2 study as well as the ongoing open-label extension study. The Company expects to complete
the study and report top-line data in the first half of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Encouraging
Data from Open Label Extension Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thirty-six
subjects with diffuse cutaneous SSc received open-label dosing with lenabasum at 20 mg twice per day following 16 weeks participation
in the preceding double-blinded placebo-controlled part of the lenabasum Phase 2 study. Patients had a mean of about 20 weeks
off treatment from the end of lenabasum dosing during the placebo-controlled period before starting open-label dosing. Lenabasum
was administered in addition to standard-of-care treatments for SSc, including concomitant immunosuppressive drugs in 92% of subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Efficacy
Outcomes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
modified Rodnan Skin Score (mRSS), the primary outcome for the Phase 3 study of lenabasum in SSc, improved by a mean (SD) of -8.4
in the 32 subjects who had completed 28 weeks open-label dosing at the time of data analyses, compared to baseline at the start
of the Phase 2 double-blind placebo-controlled portion of the study. 75% of 36 subjects who received open-label dosing with lenabasum
achieved a degree of improvement in mRSS (reduction &ge; 5 points and &gt; 25% baseline) from the study start that has been previously
associated with improved survival in SSc. A third of subjects reached a mRSS &le; 10 points and 22% achieved a mRSS score <U>&lt;
</U>5 points.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ACR CRISS score increased over time with lenabasum open-label dosing and reached a median of 71% at 28 weeks, with 44% of subjects
achieving an ACR CRISS score &ge; 70%. For comparison, the median ACR CRISS score was 32% at 48 weeks in the Phase 2 study
of tocilizumab in diffuse cutaneous SSc patients and 24% at 12 months in a study of cyclophosphamide in diffuse cutaneous SSc
patients with interstitial lung disease. Patient-reported disability, function, skin symptoms and global assessment of health
all improved from study start and start of open-label dosing. Forced vital capacity (FVC) % predicted was stable during lenabasum
treatment (mean change 0.3% predicted from study start) in contrast to the natural history of a decline in FVC in the disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2-: mRSS Results from Phase 2 Study-Primary Outcome Measure for Phase 3 RESOLVE -1 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Data are shown for subjects who received lenabasum
during double-blinded placebo-controlled dosing (N = 26) and during open-label dosing (N = 36 at the start of open-label dosing).
The data show the change in patient mRSS scores from the study start at the beginning of the double-blinded placebo-controlled
dosing period.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 246; width: 550"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3-:ACR CRISS Results from Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_012.jpg" ALT="" STYLE="height: 323; width: 650"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safety</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no severe or serious adverse events (AEs) and no clinically significant laboratory abnormalities related to lenabasum
in the Phase 2 study. Thirty (83%) subjects experienced AEs and 3 (8%) subjects experienced AEs related to lenabasum during open-label
dosing. The AEs experienced by &ge; 10% of subjects were upper respiratory tract illness in 7 (19%) subjects and urinary tract
infection in 5 (14%) subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Double-blinded Placebo-Controlled Part of Phase 2 Systemic Sclerosis Study </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2016, the Company reported positive results from the double-blind, randomized placebo-controlled portion of the Phase
2 study in diffuse cutaneous SSc. This part of the multi-center Phase 2 study evaluated lenabasum&rsquo;s clinical benefit and
safety in 27 subjects who received lenabasum and 15 who received placebo. Subjects had disease duration up to 6 years and were
allowed to receive stable doses of immunosuppressive drugs during this study. Subjects were randomized in a 2 to 1 overall lenabasum
to placebo ratio. Subjects randomized to lenabasum received 5 mg once a day (n = 9), 20 mg once a day (n = 9), or 20 mg twice
a day (n = 9) for the first four weeks, then all lenabasum subjects received 20 mg twice a day for the next 8 weeks. Subjects
randomized to placebo received placebo twice a day for 12 weeks. All subjects were followed off study drug from weeks 13 through
16. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary efficacy objective was to evaluate clinical benefit in all subjects who received lenabasum versus subjects who received
placebo using the ACR CRISS score. Lenabasum out-performed placebo in the ACR CRISS reaching 33% at week 16 (p = 0.044, 1-sided
mixed model repeated measures using rank transformed data) versus 1% for placebo. Lenabasum also outperformed placebo in the mRSS,
the primary outcome for the Phase 3 study, with a mean improvement (reduction) of 4.8 points in mRSS at sixteen weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4-mRSS Primary Endpoint in Phase 3 RESOLVE-1 Improved from Baseline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 318; width: 450"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cystic
Fibrosis </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On-Going
Phase 2B Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-right: 0; margin-bottom: 0; margin-left: 0; text-align: justify">In January
2018, the Company initiated a Phase 2b study in cystic fibrosis which is being supported by an award for up to $25 million from
the Cystic Fibrosis Foundation. The Phase 2b multicenter, double-blinded, randomized, placebo-controlled study is expected to enroll
approximately 415 subjects with CF who are at least 12 years of age and at increased risk for pulmonary exacerbations. The primary
outcome is the event rate of pulmonary exacerbations which is the average number of pulmonary exacerbations per subject per time
period. Secondary efficacy outcomes include other measures of pulmonary exacerbations, change in Cystic Fibrosis Questionnaire-Revised
Respiratory domain score and change in forced expiratory volume in 1 second (FEV1), % predicted. The study will be conducted in
approximately 100 sites across North America, Europe, Israel and Australia. Subjects will be centrally randomized to one of three
cohorts to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day, or placebo twice per day for 28 weeks, with 4 weeks
follow-up off active treatment. This Phase 2b CF study was designed with input from the Therapeutic Development Network of the
Cystic Fibrosis Foundation and the European Cystic Fibrosis Society Clinical Trials Network. The Company expects to complete this
study and report top line data in the first half of 2020.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Phase 2 Cystic Fibrosis Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In March 2017, the Company completed
a double-blind placebo-controlled Phase 2 study in CF and reported positive results. The Phase 2 study evaluated multiple doses
of lenabasum compared to placebo for the treatment of patients with CF. The 16-week study dosed 85 adult CF patients with baseline
(FEV1) percent predicted &ge; 40%, who were enrolled without regard to their specific CFTR mutation or infecting pathogens and
continued with all baseline treatment regimens.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
successfully achieved the primary objective of the study by demonstrating an acceptable safety and tolerability profile at all
doses with no serious or severe adverse events related to the study drug. Lenabasum cohorts showed a dose-dependent reduction
in a number of acute pulmonary exacerbations defined as those requiring intravenous (IV) antibiotics compared to placebo. Patients
in the highest dose cohort of lenabasum (20 mg orally, twice per day) had a 75% reduction in the annualized rate of pulmonary
exacerbations requiring IV antibiotics compared to placebo cohort. Additionally, lenabasum caused a consistent reduction in multiple
inflammatory cell types in sputum, including total leukocytes, neutrophils, eosinophils, and macrophages. Inflammatory mediators,
including interleukin-8, neutrophil elastase, and immunoglobulin G, were also reduced in sputum by lenabasum in a dose-dependent
manner. These patient data provide evidence of biological activity of lenabasum in resolving ongoing innate immune responses in
lungs of CF patients and support the observed reduction in pulmonary exacerbations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5-Lenabasum Reduced Pulmonary Exacerbations in Completed Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_013.jpg" ALT="" STYLE="height: 275; width: 650"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6-Lenabasum Reduced Inflammation in the Sputum in Completed Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_011.jpg" ALT="" STYLE="height: 287; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cystic Fibrosis Foundation Therapeutics, Inc. (&ldquo;CFFT&rdquo;), the non-profit drug discovery and development affiliate of
the Cystic Fibrosis Foundation supported the prior Phase 2 study with a $5 million development award. To date the Company has
received two development awards with total potential payments of up to $30 million from the CFF to support the clinical development
of lenabasum in CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dermatomyositis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Phase 2 Dermatomyositis Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In October 2017, the Company
completed the double-blind placebo-controlled part of the Phase 2 study in skin-predominant DM and reported positive results.
The mean improvement (reduction) in the primary efficacy outcome, the Cutaneous Dermatomyositis Disease Area and Severity Index
(&ldquo;CDASI&rdquo;) activity score, an outcome measure of skin disease severity, was 9.3 points for lenabasum treatment versus
a reduction of 3.7 points for placebo treatment (p = 0.04,2-sided MMRM) at sixteen weeks. Lenabasum also outperformed placebo
in multiple secondary efficacy outcomes studied. Lenabasum was well tolerated with no severe or serious side effects associated
with the drug. No subjects dropped out. The dermatomyositis trial was funded by a grant from the National Institute of Arthritis
and Musculoskeletal and Skin Diseases of the National Institutes of Health to the University of Pennsylvania Perelman School of
Medicine.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The single center trial enrolled 22 adults
at a 1 to 1 ratio of lenabasum to placebo cohorts. At baseline, subjects in each cohort had a mean CDASI activity score in the
severe range and skin symptoms in the extremely severe range despite background treatment with immunosuppressive drugs in 19 of
the 22 subjects. Demographic parameters, CDASI activity scores, patient-reported outcomes, and use of immunosuppressive drugs at
baseline were similar for lenabasum and placebo cohorts. Subjects received lenabasum 20 mg QD through week 4, then lenabasum 20
mg BID through week 12 with safety and efficacy follow-up thereafter through week 16. All subjects remained on their background
standard-of-care therapy throughout the study. In DM, the Company plans to consult with the FDA on the protocol design for the
next clinical study, which the Company expects to commence before the end of 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7-Lenabasum Demonstrated Clinically Meaningful Improvement in CDASI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_014.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_015.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dermatomyositis
Open Label Study</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company commenced open-label dosing of subjects in Phase 2 DM clinical study. The same safety and efficacy
endpoints evaluated in the double-blinded, placebo-controlled part of the Phase 2 study are continuing to be assessed throughout
open-label dosing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus (SLE) </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">In December 2017 a
Phase 2 clinical study of lenabasum was initiated for the treatment of systemic lupus erythematosus and patient
dosing commenced in February 2018. The Phase 2 SLE clinical trial is being conducted by the Autoimmunity Centers of
Excellence (ACE) program, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health (NIH).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
randomized, double-blind, placebo-controlled, Phase 2 trial is being conducted at 15 sites in the U.S. and is expected to enroll
100 adult SLE patients with active musculoskeletal disease, which is the most common disease manifestation of SLE. Subjects will
be randomized in a 1:1:1:1 ratio to one of four cohorts to receive placebo or three different doses of lenabasum for 3 months,
with 1-month follow-up. The primary efficacy outcome assesses pain from active musculoskeletal disease, and secondary efficacy
outcomes include other assessments of active musculoskeletal disease, overall disease activity using SLE Responder Index, SLE
Disease Activity Index (&ldquo;SLEDAI&rdquo;) and British Isles Lupus Activity Group (&ldquo;BILAG&rdquo;) scoring systems, and
patient-reported outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenabasum&rsquo;s
Unique and Novel Mechanism of Action as a Pro-Resolving Drug</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is a synthetic, rationally-designed, oral small-molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2,
found on activated immune cells, fibroblasts and other cell types including muscle and bone cells. Lenabasum stimulates the production
of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous
pathways. These pathways are activated in healthy individuals during the course of normal immune responses but are dysfunctional
in patients with chronic inflammatory and fibrotic diseases. By its binding to the CB2 receptor, lenabasum drives innate immune
responses from the activation phase through completion of the resolution phase. The CB2 receptor plays a central role in modulating
and resolving inflammation by, in effect, turning heightened inflammation &ldquo;off&rdquo; and restoring homeostasis. This has
been demonstrated in animal models lacking CB2 as well as humans suffering from polymorphism in the CB2 gene, as these exhibit
abnormal immune responses and a propensity for chronic inflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key aspect of the body&rsquo;s innate immune response is its activation phase when inflammatory cells are recruited to the site
of tissue infection/injury whereupon these cells act to destroy the infection and/or repair tissue damage. The next phase in a
normal innate immune response is its resolution phase, during which the nature of the infiltrating immune cells changes from pro-inflammatory
to pro-resolving, the infectious pathogens are eliminated, residual cellular debris and immune cells are cleared from the tissue,
and tissue repair processes are eventually halted when they are no longer needed. In chronic inflammatory and fibrotic diseases,
the innate immune responses are &ldquo;stuck&rdquo; in the initial activation phase. This failure to progress through the resolution
phase causes chronic tissue infiltration with inflammatory cells and chronic activation of healing processes that cause tissue
scarring, or fibrosis. The key event that propels an innate immune response from its activation phase to its resolution phase
is a &ldquo;class switch&rdquo; from production of pro-inflammatory lipid mediators such as prostaglandins and leukotrienes to
a family of SPMs (Figure 8) which include lipoxins, resolvins, protectins, and marescins. If an innate immune response
persists in the activation phase and does not progress through resolution, chronic inflammation and fibrosis can result, causing
organ dysfunction, organ failure, severe morbidity and even death. There are hundreds of life-long chronic and incurable inflammatory
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8-Lenabasum&rsquo;s Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_009.jpg" ALT="" STYLE="height: 332; width: 700"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is designed to restore immune system homeostasis, by harnessing the body&rsquo;s own physiologic pathways to transition the innate
immune response from the activation phase to the resolution phase. If the innate immune response is &ldquo;stuck&rdquo; in the
activation phase, tissue damage, fibrosis and persistent infection are expected consequences. Endogenous progression of the innate
immune response through its resolution phase has been shown to clear inflammation, stop fibrosis, and promote pathogen clearance.
Lenabasum&rsquo;s unique mechanism of action is different than anti-inflammatory drugs that inhibit the production or functions
of distinct pro-inflammatory mediators that initiate or are active during the activation phase. Activation of an innate immune
response is necessary to clear infections, however drugs that interfere with the activation phase carry the risk of immunosuppression
and may have other undesirable side effects. In contrast, lenabasum is designed to transition an innate immune response from its
activation phase to resolution phase. Lenabasum&rsquo;s CB2 agonist activity initiates a class switch in bioactive lipid mediators
from inflammation-activating mediators to pro-resolving mediators. Lenabasum acts to impact and activate multiple pathways including:
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in production of SPMs and anti-inflammatory eicosanoids, with a concomitant decrease in production of pro-inflammatory eicosanoids.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in production of anti-inflammatory cytokines, coupled with a decrease in production of pro-inflammatory cytokines and pro-fibrotic
    growth factors.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in influx of non-inflammatory macrophages with a decrease in influx and accumulation of inflammatory cells and pro-fibrotic
    myofibroblasts.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in bacterial clearance. SPMs stimulate production of bactericidal peptides, enhance phagocytosis and killing of bacteria by
    neutrophils and macrophages.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in apoptosis of inflammatory cells, including neutrophil and pro-fibrotic cells, including fibroblasts.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in clearance of apoptotic cells and cellular debris by non-inflammatory macrophages.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effect
of Lenabasum in a Human Model of Inflammatory Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Derek Gilroy, Professor of Experimental
Inflammation and Pharmacology at University College of London evaluated the effects of lenabasum in a clinical research model of
inflammation and its resolution in healthy volunteers. In this model, inflammation was triggered in healthy individuals by the
subcutaneous injection of heat-killed E. coli. Blood flow to the site of inflammation was measured with laser Doppler techniques.
Suction blisters were generated over the site of inflammation, and cells and inflammatory mediators were measured in the blister
fluid at different times after the injection of E. coli. In this study twenty two subjects received either lenabasum at 5 mg or
20 mg twice a day or placebo prior to the procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data demonstrated that both doses of lenabasum
exerted potent anti-inflammatory effects by inhibiting neutrophil infiltration, and increased the clearance of bacteria as measured
by local endotoxin levels, both key determinants of inflammation. Controlling neutrophils is considered highly important for treating
many diseases driven by chronic inflammation. In addition to inhibiting neutrophil accumulation, lenabasum also enhanced clearance
of the injected bacteria. The data were published in January 2018 in the peer-reviewed &ldquo;Clinical Pharmacology &amp; Therapeutics&rdquo;
journal in a paper entitled: &ldquo;Potent anti-inflammatory and pro-resolving effects of lenabasum in a human model of self-resolving
acute inflammation.&rdquo; The findings in this paper provide additional evidence for lenabasum&rsquo;s unique mechanism
of action to modulate the trafficking of key harmful effector cells to the site of infection and injury without compromising internal
host defense mechanisms, and instead enhancing it. This dual mechanism of action of lenabasum combines the inhibition of lipid
mediators that normally reduce the immune system&rsquo;s ability to clear bacteria with the inhibition of pro-inflammatory lipid
mediators. We believe this unique activity of lenabasum ultimately drives the inflammatory response down the pro-resolution
pathway.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9- Lenabasum Increases Pro-Resolving Lipid Mediators in Humans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_008.jpg" ALT="" STYLE="height: 323; width: 700"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
10- Lenabasum also Decreases Inflammatory Lipid Mediators in Humans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_007.jpg" ALT="" STYLE="height: 316; width: 700"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from this human clinical model demonstrated that lenabasum activates the resolution of innate immune responses and is the
first experimental therapeutic shown to activate the &ldquo;pro-resolution&rdquo; pathway in humans. These results are
consistent with previous findings from experiments that evaluated lenabasum&rsquo;s effects in animal models of inflammation
and support lenabasum&rsquo;s potential to deliver therapeutic benefit in chronic inflammatory diseases as a first-in-class
pro-resolution drug. The results identify the CB2 receptor, the therapeutic target of lenabasum, as a key link between the
innate immune response and the endocannabinoid system acting as an upstream activator of the resolution of innate immunity.
The top dose of lenabasum in this study at 20 mg twice a day is the same as the highest dose in the Phase 3 SSc clinical
trial and the Phase 2b CF trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity for Lenabasum in Inflammatory and Fibrotic Diseases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are many different chronic, serious inflammatory and fibrotic diseases that could be addressed by treatment with lenabasum. Some
examples of chronic, serious diseases characterized by inflammation with variable degrees of fibrosis include genetic diseases
such as cystic fibrosis, nonalcoholic steatohepatitis (&ldquo;NASH&rdquo;), myelofibrosis, lung diseases including idiopathic
pulmonary fibrosis, bronchiolitis obliterans, and sarcoidosis and autoimmune diseases including systemic sclerosis, systemic lupus
erythematosus, myositis, rheumatoid arthritis, vasculitis, primary biliary cirrhosis .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
autoimmune diseases, four out of the five top selling drugs in the U.S. are anti-inflammatory biologic drugs which had total sales
of $41 billion in 2016. These drugs however suppress the immune systems and thus leave patients susceptible to serious infections.
Lenabasum, on the other hand, is designed to resolve inflammation without immunosuppression and is an oral pill, which potentially
positions it as a front-line, first choice for autoimmune and other serious inflammatory and fibrotic diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenabasum
Market Opportunity for Current Indications Being Developed </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Autoimmune
Disorders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
sclerosis is a chronic, systemic autoimmune disease characterized by activation of innate and adaptive immune systems, an obliterative,
proliferative vasculopathy of small blood vessels, and fibrosis of the skin and multiple internal organs. Approximately 90,000
people in the United States and Europe have SSc. The disease affects mainly adults (80% of SSc patients are women) with mean age
of onset about 46 years of age in the United States and the majority of patients between 45-64 years of age.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
commonly used system classifies SSc patients into those with more wide-spread skin thickening (diffuse cutaneous SSc, about 45%
of patients) and those with more restricted skin thickening (limited cutaneous SSc, about 55% of patients). There is significant
overlap in the clinical manifestations for these two groups of SSc patients and no known significant differences in disease pathogenesis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSc
can affect multiple internal organs in the body, including the lungs, heart, kidneys, joints, muscles, esophagus, stomach and
intestines. Clinically apparent organ involvement that occurs in more than a third of these patients includes thickened skin,
Raynaud&rsquo;s phenomenon, esophageal symptoms, pulmonary fibrosis, restrictive lung disease, edematous skin, joint contractures,
digital ulcers, and muscle weakness. Less frequently occurring, yet life-threatening manifestations include pulmonary artery hypertension
(about 1 in 5 patients), cardiac conduction blocks (about 1 in 10 patients), and renal crisis (about 1 in 50 patients). In the
US, SSc is the most deadly of the systemic autoimmune diseases. The median disease duration for an individual who dies of SSc
is 7.1 years from the onset of symptoms. About 85% of deaths caused by SSc are the result of pulmonary fibrosis, pulmonary artery
hypertension, or cardiovascular disease, such as sudden death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
SSc the innate immune system fails to transition from the activation phase to the resolution phase. Individuals with SSc who have
interstitial lung disease have an imbalance of bioactive lipid mediators, causing a predominance of inflammatory mediators versus
resolving mediators. The preponderance of inflammatory mediators correlates positively with the degree of inflammation in the
lungs and negatively with forced vital capacity, a measure of lung fibrosis. Excessive activation of the pathways which cause
fibrosis including TGF&beta;, myofibroblast accumulation, and production of collagen and other extracellular matrix proteins are
all present in SSc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Currently, there are
no FDA-approved therapies specifically for SSc, although therapies have been approved for the pulmonary artery hypertension
associated with this disease. Immunosuppressants with significant toxicities are commonly used to treat SSc, however, as far
as we know, there is a general absence of clinical data to support their use. For example, systemic corticosteroids are used
frequently in SSc patients despite concerns about toxic side effects and precipitation of renal crisis.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is general agreement in the SSc community that an effective anti-inflammatory and anti-fibrotic drug would address
a significant unmet medical need in SSc, especially a drug that is orally administered, can be used chronically with other commonly
prescribed medications for SSc, and is not immunosuppressive. We believe such a therapy would be positively received by the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dermatomyositis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermatomyositis
is a serious and rare autoimmune idiopathic inflammatory myopathy with characteristic cutaneous findings. About 70,000 individuals
in the U.S. suffer from dermatomyositis. Dermatomyositis usually strikes adults, with most common age of adult onset between 50-60
years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
systemic disorder most frequently affects the skin and muscles, and DM can also include interstitial lung disease/restrictive
lung disease, arthritis, gastrointestinal and cardiac involvement. Inflammatory muscle disease associated with DM can cause discomfort
and significant weakness of the proximal muscles of the arms and legs and of the trunk. Dermatomyositis can include damaging inflammation
elsewhere in the body, for example: lung inflammation that leads to lung fibrosis and restrictive lung disease; heart inflammation
that causes arrhythmia, congestive heart failure, and pericarditis, inflammation of muscles in the esophagus that causes swallowing
problems or aspiration pneumonia, and arthritis. DM patients may have active skin disease despite successful treatment of their
muscle and/or lung disease. The skin findings in DM can be disfiguring and are inflammatory rashes characterized by redness and
itching in exposed areas of the skin, around the eyes, on the hands, and in a &ldquo;shawl&rdquo; distribution on the scalp, hands,
upper back, and photo-exposed areas. Due to this chronic inflammation, patients with DM have an increased risk of malignancy,
most commonly in older patients By itself, skin involvement in DM has a large negative impact on quality of life, comparable to
that of cutaneous lupus erythematosus and vulvodynia, and much higher than those of many dermatologic diseases. The pathophysiology
of DM is consistent with a patient&rsquo;s inherent inability to adequately resolve innate immune responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapy
for DM involves both general measures and specific measures to control the muscle disease and the skin disease. In addition, some
patients with DM need treatment for other systemic manifestations or complications. The muscle component is treated by administering
corticosteroids, typically with an immunosuppressive agent. The skin disease is treated by avoiding sun exposure and by using
sunscreens and photoprotective clothing, as well as with topical corticosteroids, and antimalarial agents. Antimalarial therapy
frequently is ineffective or can cause drug reactions. Antimalarial-refractory disease is then treated with systemic therapies
that may additionally cause toxicity, including systemic glucocorticoids, immunosuppressive therapies such as methotrexate, mycophenolate
mofetil, or intravenous immunoglobulin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that an effective drug that controls inflammation in the skin, muscles, and other organs will address a significant unmet
medical need in <FONT STYLE="background-color: white">DM</FONT>, particularly a drug that is orally administered, can be used
chronically with other commonly prescribed medications for the disease, and is not immunosuppressive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
lupus erythematosus, or SLE, is a prototypical autoimmune disease with a wide array of clinical manifestations, including arthritis,
rash, photosensitivity, oral ulcers, pleuritis, pericarditis, kidney problems, seizures and psychosis and blood cell abnormalities.
About 500,000 individuals in the U.S. and in the E.U. suffer from SLE. The musculoskeletal system is the most commonly involved
system in SLE. Patients with SLE have an increased frequency of related autoimmune problems, such as Sjogren&rsquo;s syndrome
and antiphospholipid syndrome that require additional treatments. SLE may occur with other autoimmune conditions, such as thyroiditis,
hemolytic anemia, and idiopathic thrombocytopenia purpura. Accelerated atherosclerosis among SLE patients is responsible for premature
mortality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pathology of SLE involves chronic activation of the innate immune system by immune complexes, with activation of the complement
cascade, increased production of type 1 interferons and other mediators of inflammation and resultant tissue inflammation and
damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
specifically approved by the FDA for SLE are limited to aspirin, corticosteroids, hydroxychloroquine and belimumab. Physicians
commonly treat SLE disease manifestations with immunosuppressive or corticosteroid therapies that have significant toxicities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that an effective drug that controls inflammation in the joints and skin as well as improves overall disease activity
will address a significant unmet medical need in <FONT STYLE="background-color: white">SLE</FONT>, particularly a drug that is
orally administered, can be used chronically with other commonly prescribed medications for the disease, and is not immunosuppressive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cystic
Fibrosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Cystic fibrosis is a
life-long, progressive, debilitating, and life-threatening autosomal recessive disease. Cystic fibrosis is caused by mutations
in the gene Cystic Fibrosis Transmembrane Conductance Regulator or CFTR. <FONT STYLE="background-color: white">The CFTR serves
as a central hub to modulate transport, trafficking, and signaling in cells. </FONT>Given multiple roles of CFTR in cellular activation
and homeostasis, mutation of the CFTR gives rise to multiple disorders in respiratory, digestive and reproductive organs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current median life expectancy of cystic fibrosis patients is about 40 years. According to the Cystic Fibrosis Foundation, 30,000
Americans and a total of 75,000 people in the United States and Europe suffer from cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CFTR mutations lead to defective ion transport, with reduced chloride and bicarbonate secretion and sodium hyper-absorption, followed
by water hyper-absorption, by airway epithelia and other cell types. The resultant reduced height of epithelial lining fluid and
decreased hydration of mucus results in abnormally thick and sticky mucus, which obstructs the lumen into which the mucus is secreted
and reduces mucociliary clearance of bacteria. The dysfunction in ion transport in CF patients is reflected in abnormal sweat
chloride levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">The negative effects
caused by CFTR gene mutations are not restricted to ion channels, but also extend to dysfunction of the innate immune system.
The nature of the abnormalities in CF is consistent with inability of innate immune responses to make the transition out
of the activation phase and into and through the resolution phase. Specialized Pro-Resolving Lipid Mediators (SPMs) that
initiate the transition to resolution phase of innate immune responses have been found to be deficient relative to pro-inflammatory
lipid mediators that initiate its activation phase, and this reduction correlates with poor recovery of lung function following
an acute pulmonary exacerbation in children. The preponderance of activated neutrophils and pro-inflammatory macrophages in inflamed
tissue, reduced neutrophil apoptosis, high levels of neutrophil proteases that reflect persistent neutrophil activation, reduced
clearance of neutrophils by macrophages, ineffective clearance of certain bacteria such as <I>P. aeruginosa</I>, and excessive
activation of fibrotic pathways all show the inability of individuals with CF to resolve their innate immune responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">An overview of the disease progression in
cystic fibrosis is provided in Figure 11.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
11: Factors involved in cystic fibrosis progression </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 167; width: 650"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of obstructing secretions, recurrent infections, hyper-inflammation, and activated fibrotic pathways in the lungs, individuals
with CF develop bronchiectasis, pulmonary fibrosis, mixed obstructive/restrictive lung disease, and, eventually, respiratory failure.
They may also have chronic sinusitis and nasal polyps. The same pathophysiologic events of obstruction, infection, chronic inflammation,
and tissue damage/fibrosis occur in the gastrointestinal system, which can lead to bowel obstructions, fat malabsorption, bacterial
overgrowth, gut dysmotility, malnutrition, growth retardation, low weight, pancreatic insufficiency, cystic fibrosis-related diabetes,
gallstones, and liver failure including cirrhosis. Adult males with cystic fibrosis have degeneration of the ductus deferens and
sterility. End-stage organ involvement in cystic fibrosis is sometimes treated with transplantation, especially lung transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
therapies for cystic fibrosis include mucolytics to breakdown mucus, antibiotics to fight bacterial infection, and drugs that
act to restore some functionality to the faulty CFTR protein in specific genetic sub-populations of patients, including Kalydeco&trade;,
Orkambi&trade; and the recently approved Symdeco&trade;. Drugs that are designed to partially restore ion channel functions of
mutant CFTR protein are not necessarily able to correct the dysfunction of the innate immune system. For example, ivacaftor treatment
has not been associated with reduction in sputum neutrophils or neutrophil derived proteases in CF patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
CF patients appear to have dysfunction in resolution of the innate immune system, no matter which CFTR mutations a given patient
has. This is borne out by the incidence of pulmonary exacerbations which according to the CF registry occur at an annual rate
of 17,000 case per year and an event rate of 0.70 times per patient per year. A pulmonary exacerbation is acute worsening of the
patient&rsquo;s day-to-day signs and symptoms of lung disease and is associated with worsening of inflammation at the start of
the exacerbation. Failure to resolve lung inflammation during a pulmonary exacerbation is associated with treatment failure, such
as need to change antibiotics, prolonged antibiotic therapy, early recurrent of pulmonary exacerbation, and failure to recover
lung function lost during the exacerbation. Pulmonary exacerbations in CF are associated with reduced survival, lung function,
and patient quality of life and increased health-care burden. The annual average pulmonary exacerbation hospitalization related
costs in the U.S. vary from $30,000 for a &ldquo;mild&rdquo; exacerbation to as high as $120,000 in patients with severe lung
disease. Currently, there are no approved drugs used to address pulmonary exacerbations, a key driver of morbidity and mortality
in cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is general agreement in the CF community that an effective drug that will reduce hyper-inflammation and help reduce
the rate of pulmonary exacerbations would address a significant unmet medical need in CF, especially a drug that is orally administered,
can be used chronically with other prescribed medications for CF, is not immunosuppressive, and has anti-fibrotic effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
Treatment Alternatives for Chronic, Serious Diseases Characterized by Chronic Inflammation and Fibrosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
currently used to treat chronic serious inflammatory and fibrotic diseases are divided broadly into several groups: non-steroidal
anti-inflammatory drugs (NSAIDS), anti-malarial agents, systemic corticosteroids, and other immunosuppressive agents. The choice
of agent or combination generally depends upon the underlying disease, and physician and patient preferences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potency of NSAIDs in the treatment of chronic, serious diseases, inflammatory and fibrotic diseases is often too limited to control
disease activity, requiring patients to receive additional treatment with anti-malarial drugs, systemic corticosteroids or immunosuppressive
agents. Anti-malarial therapy is used as a baseline treatment for chronic inflammation in certain autoimmune diseases, typically
SLE and DM, especially in patients with milder manifestations of disease. Anti-malarial therapy is frequently ineffective in controlling
chronic, serious inflammation, or can cause adverse drug reactions. Antimalarial-refractory disease is then treated with systemic
therapies that may cause additional toxicity, including systemic corticosteroids and immunosuppressive agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
corticosteroids are commonly prescribed for treatment of chronic, serious diseases characterized by chronic inflammation and fibrosis,
such as cystic fibrosis, SSc, and DM. Chronic corticosteroid use is limited by toxicities that include growth retardation, iatrogenic
Cushings&rsquo;s Disease, hypertension, high glucose levels/diabetes, obesity, brittle bones/osteoporosis, aseptic necrosis of
bone, immunosuppression/increased infection, glaucoma, depression, and psychosis. Thus, safer yet potent alternatives to steroids
have long been sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
other immunosuppressive drugs are used to treat chronic, serious, inflammatory diseases, to achieve disease control and to curtail
the need for corticosteroids. These include biological agents, such as monoclonal antibodies or fusion proteins, which target
a very specific molecule in a key disease pathway. These drugs have a number of disadvantages including parental administration
and increased associated incidence of malignancy and infection. Non-biologic immunosuppressive agents that are used to treat chronic,
serious inflammation include methotrexate, mycophenolate, leflunomide, cyclophosphamide, and azathioprine, among others. Intravenous
immunoglobulin is used occasionally to treat refractory chronic, serious inflammatory diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Lenabasum</B><B> As a Pro Resolving
Drug with a Novel Mechanism of Action Has Safety Advantages versus Anti-Inflammatory Drugs, Steroids and
Immunosuppressive Agents</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corticosteroids
and NSAIDs exert their effect by inhibiting the activation of inflammation. In simple terms, both classes of drugs inhibit inflammation
by &ldquo;interfering&rdquo; with the biochemical pathways in the cell that promote and sustain inflammation. For example, NSAIDs
directly inhibit the activity of the COX 1 and COX 2 enzymes that are responsible for generating pro-inflammatory eicosanoids.
A drawback of this approach is that it one arm of the eicosanoid pathway (e.g. COX but not LOX) is inhibited resulting in a buildup
in LOX-derived inflammatory mediators which leads to gastrointestinal and cardiovascular side effects (termed &ldquo;molecular
shunting&rdquo;). Lenabasum on the other hand triggers endogenous pathways that resolves inflammation and halts fibrosis without
immunosuppression Therefore lenabasum potentially offers a new and unique mechanism to treat a spectrum of rare, chronic, serious
inflammatory and fibrotic diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Autoimmune
Disorders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytotoxic
and immunosuppressive medications are used to control overall disease activity in SSc. In a one-year study of 2,739 SSc patients
in the U.S., 44.3% received corticosteroids, 4.8% received mycophenolate mofetil, 2.7% received cyclophosphamide, and 0.5% received
cyclosporine. In a report of 7,655 patients in the European Scleroderma Trials and Research Group database, the percentage of
SSc patients receiving immunosuppressant treatments were: prednisone (43.5%) with median dose of 8 mg/day; cyclophosphamide (15.9%);
methotrexate (13.7%); azathioprine (6.4%); mycophenolate mofetil (4.2%), d-penicillamine (2.1%), and rituximab (1%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>DM</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
medications for DM involve both treatments to reduce overall disease activity and specific treatments to control the muscle disease
and the skin disease. The muscle component is treated by administering corticosteroids, typically with an immunosuppressive agent.
The skin component of the disease is treated by avoiding sun exposure and by using sunscreens and photoprotective clothing, as
well as with topical corticosteroids, antimalarial agents such as hydroxychloroquine and immunosuppressive medications such as
methotrexate, azathioprine, mycophenolate mofetil, or intravenous immunoglobulin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to DM, current medications for SLE involve treatments to reduce overall disease activity and specific treatments for a given organ
involvement. Commonly used medications include NSAIDs, topical corticosteroids, antimalarial agents, prednisone, belimumab, and
other immunosuppressive medications such as mycophenolate, methotrexate, azathioprine, and cyclophosphamide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cystic
Fibrosis </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
importance of treating inflammation in cystic fibrosis is confirmed in the Cystic Fibrosis Foundation&rsquo;s Strategic Plan,
2014-2018. While treatment with systemic corticosteroids and ibuprofen are effective in improving the symptoms of cystic fibrosis,
the side effects associated with chronic treatment using these drugs are significant. Specifically, long term usage of oral corticosteroids
in children are associated with glucose intolerance, cataract formation, multiple bone fractures secondary to osteoporosis or
osteopenia, Cushing disease effects, and anorexia nervosa as well as growth retardation. The use of high dose ibuprofen is limited
by the years of treatment it takes to show benefit, a need to monitor levels closely in the patient, and the increased risk of
gastrointestinal bleeding. As a result, these drugs have limited long-term use in cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
therapies routinely used by cystic fibrosis patients routinely include antibiotics, such as Cayston from Gilead and TOBI from
Novartis, and mucolytics, such as Pulmozyme from Genentech. In addition, Vertex currently markets the only approved drugs that
specifically target the defective CFTR protein, Kalydeco and Orkambi.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
autoimmune disorders such as SSc, DM and SLE, physicians treat patients with a number of drugs including potent immunosuppressants
and cytotoxics to try to reduce the autoimmune response characteristic of the disease. These drugs have not proven to be very
effective thus there remains a high unmet need for safe and effective drugs to treat these autoimmune disorders. Several companies,
including Roche, Boehringer Ingelheim, Bayer, Inventiva, Bristol Myers and Sanofi, are actively working to develop new drugs for
treating the inflammation and/or fibrosis in SSc. To the best of our knowledge, lenabasum offers a unique mode of action to treat
SSc being one of the few oral drugs with the potential to resolve inflammation and halt fibrosis without immunosuppression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous drug therapies currently used to treat CF patients, targeting different aspects of this complex disease. Inhaled
and oral antibiotics address the pulmonary microbial infection. Mucolytics address the accumulation of mucus in the lungs. Bronchodilators
and hydration agents are also used to help improve pulmonary function. Targeting of the inflammatory component of the disease
is currently done by high dose Ibuprofen and oral corticosteroids. While these offer some clinical benefit, they are not used
chronically due to their adverse side effects which include immunosuppression and metabolic changes (steroids) as well as the
risk of gastrointestinal bleeding (ibuprofen). Thus, there is a clear and urgent unmet medical need for safe and effective inflammation-targeting
drugs for the chronic treatment of CF that could potentially have a beneficial impact on morbidity and mortality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
emerging area of CF therapy is the development of correctors and potentiators of CFTR. In January 2012, Vertex launched Kalydeco&trade;,
or ivacaftor, the first ever cystic fibrosis drug specifically targeting the underlying genetic defect in the CFTR ion channel.
Kalydeco is a small synthetic oral molecule that helps potentiate the function of the G551D mutant CFTR protein, resulting in
improved forced expiratory volume in one second (a measure of obstruction of airflow in the lungs) by approximately 10% in cystic
fibrosis patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
combination drug from Vertex, Orkambi&trade; (lumacaftor/ivacaftor) combination treatment targets a larger population of homozygote
&Delta;F508 CFTR mutation patients. Orkambi was approved by the FDA on July 2, 2015. <FONT STYLE="color: #333333">In clinical
studies, the lung function of patients taking Orkambi improved by a range of 2.6 percentage points to 3 percentage points, compared
with that of patients receiving placebo</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
other companies are developing drugs for CF targeting CFTR either as a protein or mRNA transcript. These are highlighted in the
table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="11" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected
    CF Products in Development</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanism</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutation</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stage</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PTC
    Therapeutics</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ataluren</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ribosome
    read thru (nonsense mutations)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    1, nonsense</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UK
    CF Gene Therapy Consortium</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pGM169/GL67A</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene
    therapy</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhaled</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2b</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QBW251</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentiator</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gating</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bayer</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Riociguat</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stimulates
    sGC enzyme</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F508del
    homozygous</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flatley
    Discovery Lab</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDL169</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corrector</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F508del</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galapagos
    / AbbVie</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLPG1837
    / ABBV-974</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentiator</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gating</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProQR</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QR-010</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RNA
    oligonucleotide</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhaled</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F508del
    homozygous</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celtaxsys</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acebilustat</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-inflammatory-inhibits
    production of LTB4</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteostasis</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PTI130</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFTR
    amplifier</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred expenses of approximately $26,039,000, $15,437,000 and $5,889,000 for research and development activities for the years
ended December 31, 2017, 2016 and 2015, respectively. These expenses include cash and non-cash expenses relating to the development
of our clinical and pre-clinical programs for lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed patent applications directed to lenabasum, compositions and methods for treating disease using lenabasum. If granted,
the resulting patents would expire on dates ranging from 2031 to 2034, subject to extension under certain circumstances. The patent
application filings are directed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    including an improved ultrapure version of lenabasum and uses of the compositions for the treatment of fibrotic conditions
    and inflammatory conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of lenabasum in the treatment of fibrotic diseases; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
    formulations and uses of the formulations for the treatment of disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">On October 31, 2017, the
Company announced that the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) issued U.S. Patent No. 9,801,849 to the Company
with claims covering the use of pharmaceutical compositions comprising lenabasum, Corbus&rsquo; lead product in development for
the treatment of inflammatory diseases. The patent provides to Corbus intellectual property exclusivity regarding
use of lenabasum to treat inflammatory diseases in the United States to February 12, 2034.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">On November 27, 2017,
the Company announced that the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) issued U.S. Patent No. 9,820,964 to the
Company with claims covering the use of pharmaceutical compositions comprising lenabasum for the treatment of fibrotic diseases,
encompassing the Company&rsquo;s lead indications: systemic sclerosis, DM, cystic fibrosis as well as others. The patent provides
to Corbus intellectual property exclusivity in the United States regarding the use of lenabasum through February
12, 2034.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">Lenabasum has been granted
Orphan Drug Designation for both cystic fibrosis and systemic sclerosis in the U.S. and in the European Union. We plan to seek
orphan drug status for lenabasum in DM and possibly other orphan inflammatory diseases from the U.S. Food and Drug Administration
and in Europe. Orphan drug status provides seven years of market exclusivity in the U.S. and ten years in Europe beginning on
the date of drug approval.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for lenabasum
and to operate without infringing the proprietary right of others and to prevent others from infringing our proprietary rights.
We strive to protect our intellectual property through a combination of patents and trademarks as well as through the confidentiality
provisions in our contracts. With respect to lenabasum, we endeavor to obtain and maintain patent protection in the U.S. and internationally
on all patentable aspects of the drug. We cannot be sure that the patents will be granted with respect to any patent applications
we may own or license in the future, nor can we be sure that any patents issued or licensed to us in the future will be useful
in protecting our technology. For this and more comprehensive risks related to our intellectual property, please see &ldquo;Risk
Factors&mdash;Risks Relating to Our Intellectual Property Rights.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we rely on trade secrets and know-how to develop and maintain our competitive position. For example,
aspects of our proprietary technology platform are based on unpatented trade secrets and know-how related to the manufacturing
of lenabasum. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary technology and processes,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors,
contractors and commercial partners. These agreements are designed to protect our proprietary information and, in the case of
the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third
party. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies
for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the
extent that our contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights
in related or resulting know-how and inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to seek trademark protection in the U.S. and outside of the U.S. where available and when appropriate. We intend to
use these registered marks in connection with our pharmaceutical research and development as well as our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
and Supply for Lenabasum </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 24.5pt; text-align: justify">We have developed and validated a good
manufacturing practice, or GMP, process to manufacture lenabasum active pharmaceutical ingredient (&ldquo;API&rdquo;) and drug
product through our contract manufacturers. Our existing API contract manufacturer has produced multi-Kg scale bulk batches under
GMP for our on-going clinical studies and is under agreement to produce sufficient API required prior to submitting an NDA filing
with the FDA. We do not own or operate manufacturing facilities for the production of lenabasum. We expect to depend on third-party
suppliers and manufacturing organizations for all of our clinical trial quantities of raw materials and drug substance. Lenabasum
is a synthetic molecule and there are readily available supplies of all raw materials necessary for the manufacture of lenabasum.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
Matters </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Government
Regulation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements
at any time during the product development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. These sanctions could include the US FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial
suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or
civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product development activities related to lenabasum or products that we may develop or acquire in the future will be subject to
extensive regulation by various government authorities, including the FDA, other federal, state and local agencies and comparable
regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical development, testing,
manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
Generally, before a new drug can be sold, considerable data demonstrating its quality, safety and efficacy must be obtained, organized
into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority. The data are
often generated in two distinct development states: pre-clinical and clinical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
of Drugs in the United States </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
or other products that we may develop or acquire in the future must be approved by the FDA before they may be legally marketed
in the United States. For new chemical entities, the pre-clinical development stage generally involves synthesizing the active
component, developing the formulation and determining the manufacturing process, as well as carrying out non-human toxicology,
pharmacology and drug metabolism studies that support subsequent clinical testing. These pre-clinical laboratory and animal tests
are often performed under the FDA&rsquo;s Good Laboratory Practices regulations. A drug&rsquo;s sponsor must submit the result
of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature
and a proposed clinical protocol to the FDA as part of an IND application, which is a request for authorization from the FDA to
administer an investigational drug or biological product to humans. Similar filings are required in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development can generally be divided into three sequential phases that may overlap, Phase 1, Phase 2 and Phase
3 clinical trials. In Phase 1, generally, small numbers of healthy volunteers are initially exposed to single escalating doses
and then multiple escalating doses of the product candidate. The primary purpose of these studies is to assess the metabolism,
pharmacologic action and general safety of the drug. Phase 2 trials typically involve studies in disease-affected patients to
determine the dose required to produce the desired benefits, common short-term side effects and risks. Phase 2 studies are typically
well-controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several
hundred subjects. Phase 3 trials are intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3
studies usually include from several hundred to several thousand subjects and are closely controlled and monitored. In addition
to these Phase 1-3 trials, other trials may be conducted to gather additional safety, pharmacokinetic and pharmacodynamic information.,
Pharmaceutical products with active ingredients equal or similar to those already approved by the FDA often have more streamlined
development programs than compounds entirely new to the agency, often skipping Phase 1 and 2 trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical plan must be submitted to the FDA prior to commencement of a clinical trial. If the FDA has concerns about the clinical
plan or the safety of the proposed studies, they may suspend or terminate the study at any time. Studies must be conducted in
accordance with good clinical practice and reporting of study progress and any adverse experiences is required. Studies are also
subject to review by independent institutional review boards responsible for overseeing studies at particular sites and protecting
human research study subjects. An independent institutional review board may also suspend or terminate a study once initiated.
Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that once
begun, issues will not arise that could cause the trial to be suspended or terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. Sometimes, these
studies are used to gain additional experience from the treatment of patients in the intended therapeutic condition. In certain
instances, the FDA may mandate the performance of Phase 4 studies. In other situations, post-approval studies aim to gain additional
indications for a medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Protocol Assessment </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Food, Drug, and Cosmetic Act directs the FDA to meet with sponsors, pursuant to a sponsor&rsquo;s written request, for
the purpose of reaching agreement on the design and size of clinical trials intended to form the primary basis of an efficacy
claim in an NDA. If an agreement is reached, the FDA will reduce the agreement to writing and make it part of the administrative
record. This agreement is called a special protocol assessment, or SPA. While the FDA&rsquo;s guidance on SPAs states that documented
SPAs should be considered binding on the review division, the FDA has latitude to change its assessment if certain exceptions
apply. Exceptions include public health concerns emerging that were unrecognized at the time of the protocol assessment, identification
of a substantial scientific issue essential to the safety or efficacy testing that later comes to light, a sponsor&rsquo;s failure
to follow the protocol agreed upon, or the FDA&rsquo;s reliance on data, assumptions or information that are determined to be
wrong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Review
and Approval in the United States </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
pivotal or Phase 3 trial completion, data are analyzed to determine safety and efficacy. Data are then filed with the FDA in a
New Drug Application, or an NDA, along with proposed labeling for the product and information about the manufacturing and testing
processes and facilities that will be used to ensure product quality. In the United States, FDA approval of an NDA must be obtained
before marketing a pharmaceutical product. The NDA must contain proof of safety, purity, potency and efficacy, which entails extensive
pre-clinical and clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during
the review process. The review and evaluation of applications by the FDA is extensive and time consuming and may take several
years to complete. The FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether they comply with current good manufacturing practice requirements and may also audit data from clinical and pre-clinical
trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that the FDA will act favorably or quickly in making such reviews and significant difficulties or costs may be
encountered in our efforts to obtain FDA approvals. The FDA may require that certain contraindications, warnings or precautions
be including in the product labeling, or may condition the approval of the NDA on other changes to the proposed labeling, development
of adequate controls and specifications, or a commitment to conduct post-marketing testing or clinical trials and surveillance
programs to monitor the safety of approved products that have been commercialized. Further, the FDA may place conditions on approvals
including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA
concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved
REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such
as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals
may be withdrawn for non-compliance with regulatory standards or if problems occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Drug Designation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan product designation
must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or
shorten the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation
makes a company eligible for grant funding of up to $500,000 per year for four years to defray costs of clinical trial expenses,
tax credits for clinical research expenses and potential exemption from the FDA application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s
orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval
of another applicant&rsquo;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient
quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If
a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not
be entitled to orphan drug exclusivity. We have received orphan drug designation for lenabasum for cystic fibrosis and systemic
sclerosis. There can be no assurance that we will receive orphan drug designation for lenabasum for DM, or additional orphan diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Drug
Development in Europe </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, our future products may also be subject to extensive regulatory requirements. Similar to the United States,
the marketing of medicinal products is subject to the granting of marketing authorizations by regulatory agencies. . Also, as
in the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant
regulatory controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Review
and Approval in the European Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicinal
Products require a marketing authorization before they may be placed on the market in the European Economic Area (EEA), comprising
the member states of the European Union as well as Iceland, Liechtenstein and Norway. There are various application procedures
available, depending on the type of product involved. The centralized procedure gives rise to marketing authorizations that are
valid throughout the EEA. Applicants file marketing authorization applications with the European Medicines Agency (EMA) where
they are reviewed by a relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use (CHMP).
The EMA forwards CHMP opinions to the European Commission, which uses them as the basis for deciding whether to grant a marketing
authorization. The centralized procedure is compulsory for medicinal products that (1) are derived from specified biotechnology
processes, (2) contain a new active substance (not yet approved on November 20, 2005) indicated for the treatment of certain diseases,
such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders, viral diseases or autoimmune diseases and other immune dysfunctions,
(3) are orphan medicinal products or (4) are advanced therapy medicinal products (such as gene therapy, somatic cell therapy and
tissue engineered products). For medicines that do not fall within these categories, an applicant may voluntarily submit an application
for a centralized marketing authorization to the EMA, as long as the CHMP agrees that (i) the medicine concerned contains a new
active substance (not yet approved on November 20, 2005), (ii) the medicine is a significant therapeutic, scientific, or technical
innovation, or (iii) if its authorization under the centralized procedure would be in the interest of public health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization
applications to the national medicines regulators through one of three procedures: (1) a national procedure, which results in
a marketing authorization in a single EEA member state; (2) the decentralized procedure, in which applications are submitted simultaneously
in two or more EEA member states; and (3) the mutual recognition procedure, which must be used if the product has already been
authorized in at least one other EEA member state, and in which the EEA member states are required to grant an authorization recognizing
the existing authorization in the other EEA member state, unless they identify a serious risk to public health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
authorization applications must usually include the results of clinical trials. Clinical trials of medicinal products in the EEA
must be conducted in accordance with EEA and national regulations and the International Conference on Harmonization guidelines
on GCP. Prior to commencing a clinical trial in a particular EEA member state, the sponsor must obtain a clinical trial authorization
from the competent authority and a positive opinion from an independent ethics committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, companies developing a new medicinal product must agree a Paediatric Investigation Plan (PIP) with the EMA and must conduct
pediatric clinical trials in accordance with that PIP, unless a waiver applies, e.g., because the relevant disease or condition
occurs only in adults. The marketing authorization application for the product must include the results of pediatric clinical
trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric
clinical trials must be completed at a later date.&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Marketing
Requirements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA and
other federal and state regulatory authorities, including, among other things, monitoring and recordkeeping activities, reporting
to applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated
safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising
requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses
or in patient populations not described in the drug&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;), and limitations
on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label
uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the products or labeling or
changes of site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received
or may result in a lengthy review process.. The FDA regulations require the products be manufactured in specific approved facilities
and in accordance with current good manufacturing practices, and NDA holders must list their products and register their manufacturing
establishments with the FDA. These regulations also impose certain organizational, procedural and documentation requirements with
respect to manufacturing and quality assurance activities. Drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
with current good manufacturing practice and other laws. NDA holders using contract manufacturers, laboratories or packagers are
responsible for the selection and monitoring of qualified firms. These firms are subject to inspections by the FDA at any time,
and the discovery of violative conditions could result in enforcement actions that interrupt the operation of any such facilities
or the ability to distribute products manufactured, processed or tested by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Regulatory Matters </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities
in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions
of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the
Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state
and local governments. These regulations include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal healthcare program anti-kickback law which prohibits, among other things, persons from soliciting, receiving or providing
remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing
or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid
programs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to
be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent.
The government may assert that a claim including items or services resulting from a violation of the federal healthcare program
anti-kickback law or related to off-label promotion constitutes a false or fraudulent claim for purposes of the federal false
claims laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the Federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers
of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s
Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value
made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf
of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians
and their immediate family members; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security
and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security
standards directly applicable to &ldquo;business associates&rdquo;&mdash;independent contractors or agents of covered entities
that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH
also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable
to business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages
or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing
federal civil actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;The
Lanham Act and federal antitrust laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;state
law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services
reimbursed by any third party payer, including commercial insurers, and state laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by
federal laws, thus complicating compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
traceability, and storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
handling of any controlled substances must comply with the U.S. Controlled Substances Act and the Controlled Substances Import
and Export Act. In the United States, our product candidate, lenabasum, is currently classified as Schedule I controlled substance
as defined in the Controlled Substance Act (&ldquo;CSA&rdquo;). This designation is based on lenabasum&rsquo;s chemical structure
and pharmacology (namely, it being a synthetic endocannabinoid mimetic that binds to the CB2 receptor). Even though lenabasum&rsquo;s
mechanism of action is to modulate the immune system and results to date from clinical studies have demonstrated the drug has
no psychotropic effects (which we believe is unlike other members of its chemical class), the DEA classifies lenabasum as a Schedule
I substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I controlled substances are pharmaceutical products subject to specific regulations under the CSA, that establishes, among other
things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the DEA. All parties responsible for the manufacturing, distribution and testing the drug in clinical studies
must apply for and obtain a license from the DEA before they are permitted to perform these activities with lenabasum. Furthermore,
these parties must have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent
drug loss and diversion. All licensed facilities are required to renew their registrations annually if they intend to continue
to work with our drug. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances.
We have been working with our manufacturers, distributors, exporters and clinical sites to obtain the necessary licenses to work
with lenabasum. The parties responsible for the manufacturing, distribution and export of lenabasum have already applied for and
have been granted DEA licenses and a number of institutions responsible for conducting our current clinical studies have also
been granted DEA licenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal
law, because the states are separate jurisdictions, they may separately schedule drugs, as well. While some states automatically
schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. The requirement
for state registrations could also result in delay of the manufacturing, distribution of lenabasum or in the completion of our
current clinical studies. We and our manufacturing vendors and clinical sites must also obtain separate state registrations, permits
or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those
from the DEA or otherwise arising under federal law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-Party
Payer Coverage and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Significant uncertainty
exists as to the coverage and reimbursement status of any of our drug candidates that ultimately may obtain regulatory approval.
In both the United States and foreign markets, our ability to commercialize our product candidates successfully, and to attract
commercialization partners for our product candidates, depends in significant part on the availability of adequate financial coverage
and reimbursement from third-party payers, including, in the United States, governmental payers such as the Medicare and Medicaid
programs, managed care organizations, and private health insurers. Medicare is a federally funded program managed by the CMS,
through contractors and plans that develop certain coverage policies and process claims for certain healthcare
items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients
whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded
and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific laws
and regulations that govern its individual program. Each payer has its own process and standards for determining whether it
will cover and reimburse a procedure or particular product. Private payers often rely on the lead of the governmental payers in
rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually
a significant gating issue for successful introduction of a new product. The competitive position of some of our products will
depend, in part, upon the extent of coverage and adequate reimbursement for such products and for the procedures in which such
products are used. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge,
reduction or denial by the government and other payers.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">The United States Congress
and state legislatures may, from time to time, propose and adopt initiatives aimed at cost containment, which could impact our
ability to sell our product candidates profitably. For example, the two-year spending law signed by the President of United States
on February 9, 2018 (the &ldquo;2018 Spending Law&rdquo;) includes a provision raising the manufacturer discount to 70%
in 2019 in the Medicare Part D coverage gap, also known as the &ldquo;donut hole.&rdquo; Under prior law, manufacturers were required
to provide a 50% discount on prescription drugs purchased in the donut hole. Manufacturers of branded drugs will face much higher
liabilities from donut hole payments beginning in 2019, estimated at multiple billions of dollars for some of the largest companies.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of pharmaceuticals continues to generate substantial governmental and third-party payer interest. We expect that the pharmaceutical
industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care
organizations and additional legislative proposals. Our results of operations could be adversely affected by current and future
healthcare reforms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
third-party payers also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse
healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted
or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on
our ability to obtain adequate prices for our product candidates and operate profitably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for
its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched
in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had 47 full time employees at December 31, 2017. All of our employees are engaged in administration, finance, clinical, manufacturing,
regulatory and business development functions. We believe our relations with our employees are good. We anticipate that the number
of employees will grow as we continue to develop our product candidates. In addition, we utilize and will continue to utilize
consultants, clinical research organizations and third parties to perform our pre-clinical studies, clinical studies, manufacturing
and regulatory functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.
We will remain an emerging growth company until the earlier of (1) January 1, 2020, (2) the last day of the first fiscal year
in which our annual gross revenues exceed $1.07 billion, (3) the date on which we become a &ldquo;large accelerated filer&rdquo;
as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our common
stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal
quarter or (4) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as we remain an &ldquo;emerging growth company,&rdquo; we may take advantage of certain exemptions from various reporting
requirements that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited
to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure
obligations regarding executive compensation and financial statements in our periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote to approve executive compensation and shareholder approval of any
golden parachute payments not previously approved. We are choosing to &ldquo;opt out&rdquo; of the extended transition periods
available under the JOBS Act for complying with new or revised accounting standards, and intend to take advantage of the other
reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
Pharmaceuticals, Inc. (formerly known as JB Therapeutics Inc.), was incorporated on April 24, 2009 under the laws of the State
of Delaware. On April 11, 2014, JB Therapeutics, Inc. completed a merger with Corbus Pharmaceuticals Holdings, Inc. and changed
its name to Corbus Pharmaceuticals, Inc. Upon the consummation of the merger, Corbus Pharmaceuticals, Inc. became a wholly owned
subsidiary of Corbus Pharmaceuticals Holdings, Inc. which continues to operate the business of Corbus Pharmaceuticals, Inc. Our
principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts 02062, and our telephone number is (619)
963-0100. Our website address is <U>www.corbuspharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through the Investor Relations link on our website, <U>www.corbuspharma.com</U>, access to
press releases and investor presentations, as well as all materials that we file electronically with the SEC, including our annual
report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after electronically filing such materials
with, or furnishing them to, the SEC. During the period covered by this Form 10-K, we made all such materials available through
our website as soon as reasonably practicable after filing such materials with the SEC. You may also read and copy any materials
filed by us with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549, and you may obtain
information on the operation of the Public Reference Room by calling the SEC in the United States at 1-800-SEC-0330. In addition,
the SEC maintains an Internet website, <U>www.sec.gov</U>, that contains reports, proxy and information statements and other information
that we file electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>Item
    1A.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
    FACTORS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our common stock is speculative and illiquid and involves a high degree of risk including the risk of a loss of
your entire investment. You should carefully consider the risks and uncertainties described below and the other information contained
in this report and our other reports filed with the Securities and Exchange Commission. The risks set forth below are not the
only ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and
financial condition. If any of the following risks actually materialize, our business, financial condition and/or operations could
suffer. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money
that you pay for our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Related to our Company and our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a clinical stage pharmaceutical company with a limited operating history</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company with a limited operating history. We have to complete clinical studies and receive
regulatory approval of a New Drug Application, or NDA, before commercial sales of a product can commence. The likelihood of success
of our business plan must be considered in light of the problems, substantial expenses, difficulties, complications and delays
frequently encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive environment
in which we operate. Pharmaceutical product development is a highly speculative undertaking, involves a substantial degree of
risk and is a capital-intensive business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies
in the early stages of development, especially clinical pharmaceutical companies such as ours. Potential investors should carefully
consider the risks and uncertainties that a company with a limited operating history will face. In particular, potential investors
should consider that we cannot assure you that we will be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully implement or execute our current business plan, and we cannot assure you that our business plan is sound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully manufacture our clinical product and establish commercial drug supply;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtain Drug Enforcement Administration, or DEA, licenses necessary for the manufacturing of lenabasum and for evaluating lenabasum
in our clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully complete the clinical trials necessary to obtain regulatory approval for the marketing of lenabasum;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
secure market exclusivity and/or adequate intellectual property protection for lenabasum;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
attract and retain an experienced management and advisory team;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
secure acceptance of lenabasum in the medical community and with third party payors and consumers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
launch commercial sales of lenabasum, whether alone or in collaboration with others; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
raise sufficient funds in the capital markets to effectuate our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully execute any one of the foregoing, our business may not succeed and your investment will be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable
future. We may never become profitable or, if we achieve profitability, be able to sustain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur substantial expenses without corresponding revenues unless and until we are able to obtain regulatory approval
and successfully commercialize lenabasum. We have been engaged in developing lenabasum since 2009. To date, we have not generated
any revenue from lenabasum and we expect to incur significant expense to complete our clinical program for lenabasum in the United
States and elsewhere. We may never be able to obtain regulatory approval for the marketing of lenabasum in any indication in the
United States or internationally. Even if we are able to commercialize lenabasum or any other product candidate, there can be
no assurance that we will generate significant revenues or ever achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net losses for the years ended December 31, 2017, 2016 and 2015 were approximately $32,422,000, $19,999,000 and $8,851,000, respectively.
As of December 31, 2017, we had an accumulated deficit of approximately $65,698,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to obtain FDA approval for lenabasum, we would expect that our research and development expenses will continue to increase
as we advance clinical trials for indications for the treatment of cystic fibrosis, systemic sclerosis, DM and systemic lupus
erythematosus, or SLE. We may elect to pursue FDA approval for lenabasum in other indications, which will result in significant
additional research and development expenses. As a result, we expect to continue to incur substantial losses for the foreseeable
future, and these losses will increase. We are uncertain when or if we will be able to achieve or sustain profitability. If we
achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and
remain profitable would impair our ability to sustain operations and adversely affect the price of our common stock and our ability
to raise capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
cash or cash equivalents will only fund our operations for a limited time and we will need to raise additional capital to support
our development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently operating
at a loss and expect our operating costs will increase significantly as we incur further costs related to the clinical trials
for lenabasum. As of December&nbsp;31, 2017, our consolidated cash and cash equivalents balance was approximately $62.5&nbsp;million.
On January 5, 2018, we entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (&ldquo;January 2018 Sales Agreement&rdquo;)
with Cantor Fitzgerald &amp; Co. (&ldquo;Cantor Fitzgerald&rdquo;) pursuant to which Cantor Fitzgerald is serving as our sales
agent to sell up to $50 million of shares of our common stock through an &ldquo;at the market offering,&rdquo; of which we have
sold 1,500,000 shares for net proceeds of $11.3 million to date. On January 26, 2018, we entered into the Cystic Fibrosis Program
Related Investment Agreement (the &ldquo;Investment Agreement&rdquo;) with the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;),
a non-profit drug discovery and development corporation, pursuant to which we received a development award for up to $25 million
in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical Trial (the &ldquo;Phase 2b Clinical Trial&rdquo;)
of lenabasum in patients with cystic fibrosis, of which we received $6.25 million to date. The remainder
of the Award is payable to us incrementally upon the achievement of the remaining milestones related to the progress of
the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect our cash and
cash equivalents of approximately $62.5 million at December 31, 2017 together with the $11.3 million of net proceeds received
to date from the January 2018 Sales Agreement and the up to $25 million of proceeds that we expect to receive under the 2018 CFF
Award, of which we have received $6.25 million to date, to be sufficient to meet our operating and capital requirements
through the end of the fourth quarter of 2019, based on current planned expenditures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the January 2018 Sales Agreement and the Investment Agreement, we do not currently have any arrangements or credit facilities
in place as a source of funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable
terms, or at all, including pursuant to the January 2018 Sales Agreement due to limiting terms contained therein and sales thereunder
being subject to market conditions and pursuant to the Investment Agreement due to the dependency of our receiving future payments
thereunder on our achieving certain milestones described therein. If we are not successful in raising additional capital, we may
not be able to continue as a going concern. We may seek additional capital through a combination of private and public equity
offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses
and require that our assets secure such debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders to waive certain
rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required
to delay, scale back or eliminate the development of business opportunities and our operations and financial condition may be
materially adversely affected. We can provide no assurances that any additional sources of financing will be available to us on
favorable terms, if at all. In addition, if we are unable to secure sufficient capital to fund our operations, we may choose to
pursue, as an alternative, strategic collaborations that could require us to share commercial rights to lenabasum with third parties
in ways that we currently do not intend or on terms that may not be favorable to us. If we choose to pursue additional indications
and/or geographies for lenabasum or otherwise expand more rapidly than we presently anticipate we may also need to raise additional
capital sooner than expected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Development, Regulatory Approval, Manufacturing and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend entirely on the success of lenabasum. If we are unable to generate revenues from lenabasum, our ability to create stockholder
value will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
only product candidate currently is lenabasum, for which we have completed Phase 1 safety studies and are evaluating in subsequent
clinical studies. We do not generate revenues from any FDA approved drug products and have no other product candidates in development.
There is no guarantee that our clinical trials will be successful or that we will continue with clinical studies to support an
approval from the FDA for any indication. We note that most drug candidates never reach the clinical development stage and even
those that do have only a small chance of successfully completing clinical development and gaining regulatory approval. Therefore,
our business currently depends entirely on the successful development, regulatory approval and commercialization of lenabasum,
which may never occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain any required regulatory approvals for lenabasum, we will not be able to commercialize our only product
candidate and our ability to generate revenue will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may be unsuccessful, which would materially harm our business. Even if our ongoing clinical trials are successful,
we will be required to conduct additional clinical trials to establish lenabasum&rsquo;s safety and efficacy, before a New Drug
Application, or NDA, can be filed with the FDA for marketing approval of lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success
in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim
results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur
at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize lenabasum. The research, testing, manufacturing,
labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of
drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries,
which regulations differ from country to country. We are not permitted to market lenabasum as a prescription pharmaceutical product
in the United States until we receive approval of an NDA from the FDA or comparable regulatory agencies for sales in foreign markets
until we receive the requisite approval from such countries. In the United States, the FDA generally requires the completion of
clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality
before an NDA is approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs
in development, only a small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for
commercialization. We have never submitted an NDA to the FDA or comparable applications to other regulatory authorities. If our
development efforts for lenabasum, including regulatory approval, are not successful for its planned indications, or if adequate
demand for lenabasum is not generated, our business will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
of necessary regulatory approval is subject to a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA or comparable foreign regulatory authorities or institutional review boards, or IRBs, may disagree with the design or
implementation of our clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we may not be able to provide acceptable evidence of lenabasum&rsquo;s safety and efficacy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required
by the FDA, European Medicines Agency, or EMA, or other comparable foreign regulatory authorities for marketing approval;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the dosing of lenabasum in a particular clinical trial may not be at an optimal level;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
patients in our clinical trials may suffer adverse effects for reasons that may or may not be related to lenabasum;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the data collected from clinical trials may not be sufficient to support the submission of an NDA or other submission or to obtain
regulatory approval in the United States or elsewhere;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
rendering our clinical data insufficient for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain regulatory approval for lenabasum for the foregoing or any other reasons will prevent us from commercializing this product
candidate as a prescription product, and our ability to generate revenue will be materially impaired. We cannot guarantee that
regulators will agree with our assessment of the results of our clinical trials or that such trials will be considered by regulators
to have shown safety or efficacy of our product candidates. The FDA, EMA and other regulators have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require
additional clinical trials, or pre-clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical
and clinical testing could delay, limit or prevent regulatory approval of a product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing the applications necessary to gain regulatory approvals and expect to rely on consultants
and third party contract research organizations, or CROs, with expertise in this area to assist us in this process. Securing FDA
approval requires the submission of pre-clinical, clinical and/or pharmacokinetic data, information about product manufacturing
processes and inspection of facilities and supporting information to the FDA for each therapeutic indication to establish a product
candidate&rsquo;s safety and efficacy for each indication. Lenabasum may prove to have undesirable or unintended side effects,
toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use with
respect to one or all intended indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially
based upon, among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which
regulatory approval is sought and the substantial discretion of the regulatory authorities. Changes in the regulatory approval
policy during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory
review for a submitted product application may cause delays in the approval or rejection of an application. Regulatory approval
obtained in one jurisdiction does not necessarily mean that a product candidate will receive regulatory approval in all jurisdictions
in which we may seek approval, but the failure to obtain approval in one jurisdiction may negatively impact our ability to seek
approval in a different jurisdiction. Failure to obtain regulatory marketing approval for lenabasum in any indication will prevent
us from commercializing the product candidate, and our ability to generate revenue will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials
may not be predictive of future trial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of pre-clinical studies and early clinical trials may not be predictive of the
results of later-stage clinical trials. We cannot assure you that the FDA will view the results as we do or that any future trials
of lenabasum will achieve positive results. Product candidates in later stages of clinical trials may fail to show the desired
safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of companies
in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse
safety profiles, notwithstanding promising results in earlier trials. Any future clinical trial results for lenabasum may not
be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a number of factors could contribute to a lack of favorable safety and efficacy results for lenabasum. For example,
such trials could result in increased variability due to varying site characteristics, such as local standards of care, differences
in evaluation period and surgical technique, and due to varying patient characteristics, including demographic factors and health
status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Lenabasum
is our only product candidate in development. If we fail to successfully commercialize lenabasum, we may need to acquire additional
product candidates and our business will be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized any product candidates and do not have any other compounds in pre-clinical testing, lead optimization
or lead identification stages beyond lenabasum. We cannot be certain that lenabasum will prove to be sufficiently effective and
safe to meet applicable regulatory standards for any indication. If we fail to successfully commercialize lenabasum as a treatment
for cystic fibrosis, systemic sclerosis, DM, SLE or any other indication, whether as a stand-alone therapy or in combination with
other treatments, our business would be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive regulatory approval for lenabasum, we still may not be able to successfully commercialize this product, and the
revenue that we generate from its sales, if any, may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of lenabasum will depend upon its acceptance by the medical community, including
physicians, patients and health care payors. The degree of market acceptance of lenabasum will depend on a number of factors,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
demonstration of clinical safety and efficacy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
relative convenience, pill burden and ease of administration;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the prevalence and severity of any adverse effects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 55.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 55.6pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 55.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the willingness of physicians to prescribe lenabasum and of the target patient population to try new therapies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
safety, tolerability and efficacy of lenabasum compared to competing products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the introduction of any new products that may in the future become available to treat indications for which lenabasum may be approved;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
new procedures or methods of treatment that may reduce the incidences of any of the indications in which lenabasum may show utility</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
pricing and cost-effectiveness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inclusion or omission of lenabasum in applicable treatment guidelines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the effectiveness of our or any future collaborators&rsquo; sales and marketing strategies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
limitations or warnings contained in FDA-approved labeling;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including
Medicare and Medicaid, private health insurers and other third-party payors; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
lenabasum is approved, but does not achieve an adequate level of acceptance by physicians, health care payors and patients, we
may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical
community and third-party payors on the benefits of lenabasum may require significant resources and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
lenabasum successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies
the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited
or subject to restrictions or post-approval commitments that render lenabasum not commercially viable. For example, regulatory
authorities may approve lenabasum for fewer or more limited indications than we request, may not approve the price we intend to
charge for lenabasum, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve
lenabasum with a label that does not include the labeling claims necessary or desirable for the successful commercialization of
that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals, such as risk
management plans and a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the drug. If the FDA concludes
a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS,
if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. The FDA may also require a REMS for an approved product
when new safety information emerges. Any of these limitations on approval or marketing could restrict the commercial promotion,
distribution, prescription or dispensing of lenabasum. Moreover, product approvals may be withdrawn for non-compliance with regulatory
standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially
harm the commercial success of lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain marketing approval for lenabasum, we will be subject to ongoing obligations and continued regulatory review, which
may result in significant additional expense. Additionally, lenabasum could be subject to labeling and other restrictions and
withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience
unanticipated problems with lenabasum.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain United States regulatory approval of lenabasum for an indication, the FDA may still impose significant restrictions
on its indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming
post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and efficacy. Lenabasum
will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution,
safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information.
These requirements include registration with the FDA, continued compliance with current Good Clinical Practices regulations, or
cGCPs, for any clinical trials that we conduct post-approval, continued compliance with the CSA and ongoing review by the DEA.
In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the
FDA and other regulatory authorities for compliance with current Good Manufacturing Practices, or cGMP, requirements relating
to quality control, quality assurance and corresponding maintenance of records and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to sales and marketing activities by us or any future partner, advertising and promotional materials must comply with
FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in
other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of
the U.S. Prescription Drug Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes,
depending on the nature of the change. We may also be subject, directly or indirectly through our customers and partners, to various
fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state
laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate
in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government
drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities
are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist
in many of these areas in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if lenabasum is approved for an indication, our product labeling, advertising and promotion would be subject to regulatory
requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription
products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&rsquo;s
approved labeling. If we receive marketing approval for lenabasum, physicians may nevertheless legally prescribe our products
to their patients in a manner that is inconsistent with the approved label. However, if we are found to have promoted such off-label
uses, we may become subject to significant liability and government fines. The federal government has levied large civil and criminal
fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion.
The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional
conduct is changed or curtailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity
or frequency or problems with the facility where the product is manufactured, or if we or our manufacturers fail to comply with
applicable regulatory requirements, we may be subject to the following administrative or judicial sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory
product recalls;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
issuance of warning letters or untitled letters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
injunctions or the imposition of civil or criminal penalties or monetary fines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension of any ongoing clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product
license approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension of, or imposition of restrictions on, operations, including costly new manufacturing requirements; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product seizure or detention or refusal to permit the import or export of product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize lenabasum and generate revenue. Adverse
regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product
liability exposure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no sales and marketing organization. If we are unable to secure a sales and marketing partner or establish satisfactory
sales and marketing capabilities, we may not successfully commercialize lenabasum.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, we have no sales or marketing personnel. In order to commercialize products that are approved for commercial sales, we
must either collaborate with third parties that have such commercial infrastructure or develop our own sales and marketing infrastructure.
If we are not successful in entering into appropriate collaboration arrangements, or recruiting sales and marketing personnel
or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing lenabasum, which would
adversely affect our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into
such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties.
Our future revenues may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales
and marketing infrastructure we may not realize a positive return on this investment. In addition, we will have to compete with
established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing
personnel. Factors that may inhibit our efforts to commercialize lenabasum without strategic partners or licensees include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe lenabasum;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to
companies with more extensive product lines; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
unforeseen costs and expenses associated with creating an independent sales and marketing organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete
effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
We have competitors in a number of jurisdictions, many of which have substantially greater name recognition, commercial infrastructures
and financial, technical and personnel resources than we have. Established competitors may invest heavily to quickly discover
and develop novel compounds that could make lenabasum obsolete or uneconomical. Any new product that competes with an approved
product may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially
successful. Other competitive factors, including generic competition, could force us to lower prices or could result in reduced
sales. In addition, new products developed by others could emerge as competitors to lenabasum. If we are not able to compete effectively
against our current and future competitors, our business will not grow and our financial condition and operations will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recently
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize lenabasum
and affect the prices we may obtain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval for lenabasum, restrict or regulate post-approval
activities and affect our ability to profitably sell lenabasum. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the
impact of such changes on the marketing approvals of lenabasum, if any, may be. In addition, increased scrutiny by the U.S. Congress
of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent
product labeling and post-marketing testing and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States,
under the Medicare Modernization Act, or MMA, Medicare Part D provides coverage to the elderly and disabled for outpatient prescription
drugs through prescription drug plans offered by private insurers. The MMA also authorizes Medicare Part D prescription
drug plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. The Part
D plans use their formulary leverage to negotiate rebates and other price concessions from drug manufacturers. Also under the
MMA, Medicare Part B provides coverage to the elderly and disabled for physician-administered drugs on the basis of the drug&rsquo;s
average sales price, a price that is calculated according to regulatory requirements and that the manufacturer reports to Medicare
quarterly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Both Congress and the
Centers for Medicare &amp; Medicaid Services (CMS), the agency that administers the Medicare program, from time to time consider
legislation, regulations, or other initiatives to reduce drug costs under Medicare Parts B and D. For example, under the 2010
Affordable Care Act, drug manufacturers are required to provide a 50% discount on prescriptions for branded drugs filled while
the beneficiary is in the Medicare Part D coverage gap, also known as the &ldquo;donut hole.&rdquo; Under the 2018 Spending
Law, the discount will increase to 70% in 2019. There have been legislative proposals to repeal the &lsquo;non-interference&rdquo;
provision of the MMA to allow CMS to leverage the Medicare market share to negotiate larger Part D rebates. Further cost reduction
efforts could decrease the coverage and price that we receive for lenabasum and could seriously harm our business. Private payors
often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement
under the Medicare program may result in a similar reduction in payments from private payors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2010 Affordable Care Act is intended to broaden access to health insurance and reduce or constrain the growth of healthcare spending.
Further, the Affordable Care Act imposes a significant annual fee on companies that manufacture or import branded prescription
drug products. It also increased the amount of the rebates drug manufacturers must pay to state Medicaid programs, required that
Medicaid rebates be paid on managed Medicaid utilization, and increased the additional rebate on &ldquo;line extensions&rdquo;
(such as extended release formulations) of solid oral dosage forms of branded products. The law also contains substantial provisions
affecting fraud and abuse compliance and transparency, which may require us to modify our business practices with healthcare practitioners,
and incur substantial costs to ensure compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
President and the majority party in both Houses of the U.S. Congress have indicated their desire to repeal the Affordable Care
Act. It is unclear whether, when and how that repeal will be effectuated and what the effect on the healthcare sector will be.
In addition to the potential repeal of the Affordable Care Act, there are indications that the Medicaid program may be restructured,
which could lead to revisions in Medicaid coverage for prescription drugs. While we are unable to predict what legislation, if
any, may potentially be enacted, to the extent that future changes affect how our product candidates could be paid for and/or
reimbursed by the government and private payers, our business could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example,
the Budget Control Act of 2011 included, among other things, provisions that have led to 2% across-the-board reductions in Medicare
payment amounts. Several states have adopted or are considering adopting laws that require pharmaceutical companies to provide
notice prior to raising prices and to justify price increases. We expect that additional healthcare reform measures will be adopted
in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services,
and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory
burdens and other risks and uncertainties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future profitability will depend, in part, on our ability to commercialize lenabasum in foreign markets for which we intend to
rely on collaborations with third parties. If we commercialize lenabasum in foreign markets, we would be subject to additional
risks and uncertainties, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our customers&rsquo; ability to obtain reimbursement for lenabasum in foreign markets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our inability to directly control commercial activities because we are relying on third parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
different medical practices and customs in foreign countries affecting acceptance in the marketplace;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
import or export licensing requirements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
longer accounts receivable collection times;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
longer lead times for shipping;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
language barriers for technical training;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reduced protection of intellectual property rights in some foreign countries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
foreign currency exchange rate fluctuations; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
sales of lenabasum could also be adversely affected by the imposition of governmental controls, political and economic instability,
trade restrictions and changes in tariffs, any of which may adversely affect our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we market lenabasum in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws,
we may be subject to civil or criminal penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA enforces laws and regulations which require that the promotion of pharmaceutical products be consistent with the approved
prescribing information. While physicians may prescribe an approved product for a so-called &ldquo;off label&rdquo; use, it is
unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any
company which engages in such conduct may be subject to significant liability. Similarly, industry codes in the European Union
and other foreign jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries
enforce violations of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with
our label, regulatory agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute
other civil or criminal enforcement proceedings. In addition to FDA restrictions on marketing of pharmaceutical products, several
other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing
practices in the pharmaceutical industry. These laws include the U.S. Anti-Kickback Statute, U.S. False Claims Act and similar
state laws. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business
activities could be subject to challenge under one or more of these laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration
to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item
or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
broadly to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary
managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our
practices may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, recent
health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends
the intent requirement of the U.S. Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer
needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Health Care Reform Law provides
that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. Federal false claims laws prohibit any person
from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making,
or causing to be made, a false statement to get a false claim paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past few years, pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged
promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants and
other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by
federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare or
Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce
liability for Medicaid rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute and the
U.S. False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states,
apply regardless of the payor. Sanctions under these federal and state laws may include substantial civil monetary penalties,
exclusion of a manufacturer&rsquo;s products from reimbursement under government programs, substantial criminal fines and imprisonment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are, and will be, completely dependent on third parties to manufacture lenabasum, and our commercialization of lenabasum could
be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable
foreign regulatory authorities, fail to provide us with sufficient quantities of lenabasum or fail to do so at acceptable quality
levels or prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the active pharmaceutical ingredient,
or the finished lenabasum drug product in tablet form, for use in our clinical trials or for commercial product, if any. As a
result, we will be obligated to rely on contract manufacturers if and when lenabasum is approved for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by our contract manufacturers to manufacture lenabasum must be approved by the FDA pursuant to inspections that
will be conducted after we submit our NDA to the FDA. We do not control the manufacturing processes of, and are completely dependent
on, our contract manufacturing partners for compliance with cGMPs for manufacture of both active drug substances and finished
drug products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating
to lenabasum. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the
strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their
manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture
of lenabasum or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which
would significantly impact our ability to develop, obtain regulatory approval for or market lenabasum, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign
agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&rsquo;
compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations
could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market
lenabasum, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect our business. In addition, we will not have control over the ability of our contract manufacturers
to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers to comply
with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory approval for or market
lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them,
and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we
cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers
or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing
processes for our active pharmaceutical ingredient, or API, or our finished lenabasum product or should cease doing business with
us, we could experience significant interruptions in the supply of lenabasum or may not be able to create a supply of lenabasum
at all. Were we to encounter manufacturing issues, our ability to produce a sufficient supply of lenabasum might be negatively
affected. Our inability to coordinate the efforts of our third party manufacturing partners, or the lack of capacity available
at our third party manufacturing partners, could impair our ability to supply lenabasum at required levels. Because of the significant
regulatory requirements that we would need to satisfy in order to qualify a new bulk or finished product manufacturer, if we face
these or other difficulties with our current manufacturing partners, we could experience significant interruptions in the supply
of lenabasum if we decided to transfer the manufacture of lenabasum to one or more alternative manufacturers in an effort to deal
with the difficulties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally,
we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may
involve several risks, including a potential inability to obtain critical materials and reduced control over production costs,
delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems
at suppliers could delay shipment of lenabasum, increase our cost of goods sold and result in lost sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that our manufacturing and supply partners will be able to manufacture lenabasum at commercial scale on a cost-effective
basis. If the commercial-scale manufacturing costs of lenabasum are higher than expected, these costs may significantly impact
our operating results. In order to reduce costs, we may need to develop and implement process improvements. However, in order
to do so, we will need, from time to time, to notify or make submissions with regulatory authorities, and the improvements may
be subject to approval by such regulatory authorities. We cannot be sure that we will receive these necessary approvals or that
these approvals will be granted in a timely fashion. We also cannot guarantee that we will be able to enhance and optimize output
in our commercial manufacturing process. If we cannot enhance and optimize output, we may not be able to reduce our costs over
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidate, lenabasum, is currently classified as a Schedule I controlled substance subject to U.S. controlled substance
laws and regulations, including regulations of the Drug Enforcement Agency and the U.S. Food and Drug Administration. Failure
to obtain the necessary licenses and registrations and failure to comply with these laws could result in the delay in the manufacturing
and distribution of lenabasum and could delay the completion of clinical studies. Such delays and the cost of compliance with
these laws and regulations, could adversely affect our business operations and our financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our product candidate, lenabasum, is currently classified as a Schedule I controlled substance as defined in
the Controlled Substance Act (&ldquo;CSA&rdquo;). This designation is based on lenabasum&rsquo;s chemical structure and pharmacology
(namely, it being a synthetic endocannabinoid mimetic that binds to the CB2 receptor). Even though lenabasum&rsquo;s mechanism
of action is to modulate the immune system and results to date from clinical studies have demonstrated the drug has no psychotropic
effects (which we believe is unlike other members of its chemical class), the DEA classifies lenabasum as a Schedule I substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I controlled substances are pharmaceutical products subject to specific regulations under the CSA, which establishes, among other
things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the DEA. All parties responsible for the manufacturing, distribution and testing of the drug in clinical studies
must apply for and obtain a license from the DEA before they are permitted to perform these activities with lenabasum. Furthermore,
these parties must have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent
drug loss and diversion. All licensed facilities are required to renew their registrations annually if they intend to continue
to work with our drug. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances.
We have been working with our manufacturers, distributors, exporters and clinical sites to obtain the necessary licenses to work
with lenabasum. The parties responsible for the manufacturing, distribution and export of lenabasum have already applied for and
have been granted DEA licenses and a number of institutions responsible for conducting our current clinical studies have also
been granted DEA licenses. However, the failure to maintain the necessary registrations, and the delay or failure of additional
clinical sites to obtain DEA registrations, could delay the manufacturing, distribution and export of lenabasum and could delay
the completion of the clinical studies. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance
resulting in loss or diversion, could result in regulatory action that could have a material adverse effect on our business, financial
condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings
to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. In
addition, if the FDA, DEA, or any foreign regulatory authority determines that lenabasum may have potential for abuse, it may
require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance
has an abuse potential, which could increase the cost and/or delay the launch of lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></p><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal
law, because the states are separate jurisdictions, they may separately schedule drugs, as well. While some states automatically
schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. The requirement
for state registrations could also result in delay of the manufacturing and distribution of lenabasum or in the completion of
our clinical studies. We and our manufacturing vendors and clinical sites must also obtain separate state registrations, permits
or licenses in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those
from the DEA or otherwise arising under federal law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing and distribution of lenabasum is subject to the DEA&rsquo;s annual manufacturing and procurement quota requirements.
The annual quota allocated to us or our contract manufacturers for the controlled substances in lenabasum may not be sufficient
to complete clinical trials. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&rsquo;,
procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which
could have a material adverse effect on our business, financial position and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delays
in shipping lenabasum could have a material adverse effect on our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
import and export of lenabasum requires import and export licenses. However, because lenabasum is currently a Schedule I controlled
substance in the United States, in addition to the FDA and U.S. Customs and Border Protection, its import and export is also regulated
by the DEA. We may not be granted, or if granted, maintain, such licenses for import or export from the authorities these regulatory
agencies. Even if we obtain the relevant licenses, shipments of lenabasum may be held up in transit by any of these authorities,
which could cause significant delays and may lead to product batches which no longer meet specifications for use in clinical trials
or commercial distribution. Such events could result in delayed development timelines, increased expenses and partial or total
loss of revenue from lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect that we will rely on third parties to assist us in conducting clinical trials for lenabasum. If these third parties do
not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval
for or commercialize lenabasum and our business would be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to enter into agreements with third-party CROs to assist us in conducting and managing our clinical programs, including
contracting with clinical sites to perform our clinical studies. We plan to rely on these parties for execution of clinical studies
for lenabasum and we will control only certain aspects of conducting the clinical studies. Nevertheless, we will be responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific
standards, and our reliance on CROs and clinical sites will not relieve us of our regulatory responsibilities. We and our CROs
will be required to comply with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of
the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development.
The FDA enforces these cGCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites.
If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials
comply with cGCPs. In addition, our clinical trials must be conducted with products produced under cGMP regulations and will require
a large number of test subjects. Our failure or the failure of our CROs or clinical sites to comply with these regulations may
require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement
action up to and including civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to design the clinical trials for lenabasum in consultation with CROs, we expect that the CROs will manage all of the
clinical trials conducted at contracted clinical sites. As a result, many important aspects of our drug development programs would
be outside of our direct control. In addition, the CROs and clinical sites may not perform all of their obligations under arrangements
with us or in compliance with regulatory requirements. If the CROs or clinical sites do not perform clinical trials in a satisfactory
manner, or if they breach their obligations to us or fail to comply with regulatory requirements, the development and commercialization
of lenabasum for the subject indication may be delayed or our development program materially and irreversibly harmed. We cannot
control the amount and timing of resources these CROs and clinical sites will devote to our program or lenabasum. If we are unable
to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of
our clinical trials, which could significantly delay commercialization and require significantly greater expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements
with alternative CROs or clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials
may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize
lenabasum. As a result, our financial results and the commercial prospects for lenabasum would be harmed, our costs could increase
and our ability to generate revenue could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
termination or suspension of or delays in the commencement or completion of any necessary studies of lenabasum for any indications
could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;
<FONT STYLE="font-size: 10pt">The commencement and completion of clinical studies can be delayed for a number of reasons, including
delays related to:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA failing to grant permission to proceed and placing the clinical study on hold;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects failing to enroll or remain in our trials at the rate we expect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a facility manufacturing lenabasum being ordered by the FDA or other government or regulatory authorities to temporarily or permanently
shut down due to violations of cGMP requirements or other applicable requirements, or cross-contaminations of product in the manufacturing
process;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any changes to our manufacturing process that may be necessary or desired;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects choosing an alternative treatment for the indications for which we are developing lenabasum, or participating in competing
clinical studies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects experiencing severe or unexpected drug-related adverse effects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reports of similar technologies and products raising safety and/or efficacy concerns;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
third-party clinical investigators losing their license or permits necessary to perform our clinical trials, not performing our
clinical trials on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGCP requirements,
or other third parties not performing data collection and analysis in a timely or accurate manner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inspections of clinical study sites by the FDA or IRBs finding regulatory violations that require us to undertake corrective action,
result in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study, or that prohibit
us from using some or all of the data in support of our marketing applications;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities
for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to
use some or any of the data produced by such contractors in support of our marketing applications;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
one or more IRBs refusing to approve, suspending or terminating the study at an investigational site precluding enrollment of
additional subjects, or withdrawing its approval of the trial; reaching agreement on acceptable terms with prospective CROs and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs
and trial sites;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
deviations of the clinical sites from trial protocols or dropping out of a trial;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
adding new clinical trial sites;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability of the CRO to execute any clinical trials for any reason; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
government or regulatory delays or &ldquo;clinical holds&rdquo; requiring suspension or termination of a trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
development costs for lenabasum will increase if we have delays in testing or approval or if we need to perform more or larger
clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend
study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA and IRBs for reexamination,
which may impact the costs, timing or successful completion of that study. If we experience delays in completion of, or if we,
the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical study sites suspend or terminate
any of our clinical studies of lenabasum, its commercial prospects may be materially harmed and our ability to generate product
revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow down our development and
approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm
our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, termination
or suspension of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial of
regulatory approval of lenabasum. In addition, if one or more clinical studies are delayed, our competitors may be able to bring
products to market before we do, and the commercial viability of lenabasum could be significantly reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been granted orphan drug designation in the United States and in the European Union for lenabasum for the treatment of cystic
fibrosis and systemic sclerosis. We also intend to seek orphan drug status for lenabasum for the treatment of DM. Upon receipt
of regulatory approval, orphan drug status will provide us with seven years of market exclusivity in the United States under the
Orphan Drug Act. However, there is no guarantee that the FDA will grant orphan drug designation for lenabasum for DM or any other
indication, which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation. <FONT STYLE="background-color: white">Moreover,
there can be no assurance that another company also holding orphan drug designation for the same indication or which may receive
orphan drug designation in the future will not receive approval prior to us, in which case our competitor would have the benefit
of the seven years of market exclusivity, and we would be unable to commercialize our product for the same indication until the
expiration of the seven-year period. Even if we are the first to obtain approval for the orphan drug indication, there are circumstances
under which a competing product may be approved for the same indication during our seven-year period of exclusivity.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no
reasonable expectation that the cost of developing and making a drug available in the Unites States for this type of disease or
condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly
by the FDA. Orphan designation does not convey any advantage in or shorten the duration of regulatory review and approval process.
In addition to the potential period of exclusivity, orphan designation makes a company eligible for grant funding of up to $400,000
per year for four years to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption
from the FDA application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s
orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval
of another applicant&rsquo;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient
quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If
a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not
be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan drug designation for lenabasum for
the treatment of DM, or other inflammatory disease indications, if we elect to seek such applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
fast track designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory
review or approval process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates may
treat indications that do not qualify for priority review vouchers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received fast track designation for lenabasum for the treatment of cystic fibrosis and systemic sclerosis in the United States
and European Union and may seek fast track designation or priority review of applications for approval of our product candidate
for future indications. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates
the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. If
a product candidate offers major advances in treatment, the FDA may designate it eligible for priority review. The FDA has broad
discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for these
designations, we cannot assure you that the FDA would decide to grant them. Even if we do receive fast track designation or priority
review, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA
may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
breakthrough therapy designation granted by the FDA for our product candidate may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that our product candidate will receive marketing approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied for, and may in the future apply for, a breakthrough therapy designation of our product candidate for future indications.
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed
early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing
the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also
be eligible for accelerated approval if the relevant criteria are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
of a product candidate as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe our product
candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make
such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a
faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and
does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough
therapies, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time
period for FDA review or approval will not be shortened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-party
coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully market lenabasum will depend in part on the level of reimbursement that government health administration
authorities, private health coverage insurers and other organizations provide for the cost of our products and related treatments.
Countries in which lenabasum is expected to be sold through reimbursement schemes under national health insurance programs frequently
require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent
price increases. In certain countries, including the United States, government-funded and private medical care plans can exert
significant indirect pressure on prices. We may not be able to sell lenabasum profitably if adequate prices are not approved or
coverage and reimbursement is unavailable or limited in scope. Increasingly, third-party payors attempt to contain health care
costs in ways that are likely to impact our development of products including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
failing to approve or challenging the prices charged for health care products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
introducing reimportation schemes from lower priced jurisdictions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
limiting both coverage and the amount of reimbursement for new therapeutic products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or
investigational by third-party payors; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusing to provide coverage when an approved product is used in a way that has not received regulatory marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Intellectual Property Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on maintaining and obtaining additional patent protection for our technologies, products
and processes, successfully defending these patents against third-party challenges and successfully enforcing these patents against
third party competitors. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific
and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations
of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that
may be allowable in our pending applications or, the enforceability of our existing and future patents. Our pending patent applications
for lenabasum and its uses may never be approved by United States or foreign patent offices and the existing patents and patent
applications relating to lenabasum and related technologies may be challenged, invalidated or circumvented by third parties and
may not protect us against competitors with similar products or technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of our current and future protection for our proprietary rights is uncertain, because legal means afford only limited protection
and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive
advantage at all. For example, others have filed, and in the future are likely to file, patent applications covering products
and technologies that are similar, identical or competitive to lenabasum, or important to our business. We cannot be certain that
any patents or patent application owned by a third party will not have priority over patents and patent applications filed by
us, or that we will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent
offices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets to protect technology, especially in cases when we believe patent protection is not appropriate or
obtainable. However, trade secrets are difficult to protect. While we require employees, academic collaborators, consultants and
other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other
proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and
information in which we may have rights. If we cannot maintain the confidentiality of our proprietary technology and other confidential
information, our ability to receive patent protection and our ability to protect valuable information owned by us may be imperiled.
Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming,
and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to maintain or obtain additional patent protection or trade secret protection for lenabasum or our technologies, third
parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our
ability to generate revenues and attain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on the trademarks we may develop to distinguish our products from the products of our competitors. We cannot guarantee
that any trademark applications filed by us or our business partners will be approved. Third parties may also oppose such trademark
applications, or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully challenged,
we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources
to advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks
we use, or that we will have adequate resources to enforce these trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Lenabasum
may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and
commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been
characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third party patent
rights that may be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences
in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally,
because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents
that may be infringed by commercialization of lenabasum or any future product candidate. There may be certain issued patents and
patent applications claiming subject matter that we may be required to license in order to research, develop or commercialize
lenabasum, and we do not know if such patents and patent applications would be available to license on commercially reasonable
terms, or at all. Any claims of patent infringement asserted by third parties would be time-consuming and may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
result in costly litigation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
divert the time and attention of our technical personnel and management;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
prevent us from commercializing a product until the asserted patent expires or is held finally invalid or not infringed in a court
of law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
require us to cease or modify our use of the technology and/or develop non-infringing technology; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
require us to enter into royalty or licensing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
no third party has asserted a claim of infringement against us, others may hold proprietary rights that could prevent lenabasum
from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating
to lenabasum or our processes could subject us to potential liability for damages and require us to obtain a license to continue
to manufacture or market lenabasum or any future product candidates. We cannot predict whether we would prevail in any such actions
or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In
addition, we cannot be sure that we could redesign lenabasum or any future product candidates or processes to avoid infringement,
if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary
licenses, could prevent us from developing and commercializing lenabasum or a future product candidate, which could harm our business,
financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies, including several major pharmaceutical companies, have conducted research on anti-inflammatory and anti-fibrosis
therapies which resulted in the filing of many patent applications related to this research. If we were to challenge the validity
of these or any issued United States patent in court, we would need to overcome a statutory presumption of validity that attaches
to every issued United States patent. This means that, in order to prevail, we would have to present clear and convincing evidence
as to the invalidity of the patent&rsquo;s claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to challenge the validity of these or any issued United States patent in an administrative trial before the Patent Trial
and Appeal Board in the United States Patent and Trademark Office, we would have to prove that the claims are unpatentable by
a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on questions of infringement,
validity or enforceability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully
used or disclosed alleged confidential information or trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is commonplace in our industry, we employ individuals who were previously employed at other pharmaceutical companies, including
our competitors or potential competitors. Although no claims against us are currently pending, we may be subject in the future
to claims that our employees or prospective employees are subject to a continuing obligation to their former employers (such as
non-competition or non-solicitation obligations) or claims that our employees or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these
claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction
to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are not aware of any asserted third-party claims challenging inventorship on our patents or ownership of our intellectual property,
we may in the future be subject to claims that former employees, strategic partners, commercial counterparties or other third
parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to
require our employees and contractors who may be involved in the conception or development of intellectual property to execute
agreements assigning such intellectual property to us, we cannot fully control the enforcement of these policies by third parties
with which we contract, nor can we be certain that assignment agreements between us and our employees, between us and our counterparties,
or between our counterparties and their employees, will effectively protect our interests as to any party who conceives or develops
intellectual property that we regard as our own. Among other issues, the assignment of intellectual property rights may not be
self-executing, the assignment agreements may be breached, or we may have disputes arise from conflicting obligations of consultants
or others who are involved in developing our product candidates. As we approach potential commercialization of our product candidates,
we are more closely analyzing all facts that we believe might be used to assert an inventorship claim against us. Determinations
like these involve complex sets of fact and applications of sometimes-unsettled patent law, resulting in inherent uncertainties
regarding ownership rights. Determining the history of development of certain of our intellectual property is made more difficult
by the fact that certain of our intellectual property was developed by other companies for other indications before being acquired
by us. Consequently, we cannot be sure that we have all of the documentary records relevant to such an analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
claims challenging inventorship are made against us, we may need to resort to litigation to resolve those claims. If we fail in
defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of valuable intellectual property rights or the right to assert those rights against third-parties
marketing competing products. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Company-Related Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2017, we had 47 full-time employees. As our development and commercialization plans and strategies develop, we
will need to expand the size of our employee base for managerial, operational, sales, marketing, financial and other resources.
Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit,
maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount
of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
Our future financial performance and our ability to commercialize lenabasum and any other future product candidates and our ability
to compete effectively will depend, in part, on our ability to effectively manage our future growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
capital raises may dilute our existing stockholders&rsquo; ownership and/or have other adverse effects on our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced
and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences
and privileges senior to those of our common stock. If we raise additional funds by issuing debt securities, these debt securities
would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions
on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements,
we may be required to relinquish some rights to our technologies or candidate products, or to grant licenses on terms that are
not favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. In addition, the loss of the services of certain key employees, including Yuval Cohen, our Chief Executive
Officer, Mark Tepper, our President and Chief Scientific Officer, Barbara White, our Chief Medical Officer and Sean Moran, our
Chief Financial Officer would adversely impact our business prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete in the highly competitive pharmaceuticals industry depends in large part upon our ability to attract highly
qualified managerial, scientific and medical personnel. In order to induce valuable employees to remain with us, we intend to
provide employees with stock options that vest over time. The value to employees of stock options that vest over time will be
significantly affected by movements in the price of our common stock that we will not be able to control and may at any time be
insufficient to counteract more lucrative offers from other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has expertise in many different aspects of drug development and commercialization. However, we will need to hire
additional personnel as we further develop lenabasum. Competition for skilled personnel in our market is intense and competition
for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our
efforts to retain valuable employees, members of our management, scientific and medical teams may terminate their employment with
us on short notice. In connection with the merger in April 2014 with Corbus Pharmaceuticals, Inc., our wholly-owned subsidiary,
we entered into employment agreements with certain of our executive officers. However, these employment arrangements provide for
at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. The
loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results
or financial condition. In particular, we believe that the loss of the services of Yuval Cohen, Ph.D., our Chief Executive Officer,
Mark Tepper, Ph.D., our President and Chief Scientific Officer, Barbara White, M.D., our Chief Medical Officer and Sean Moran,
C.P.A., M.B.A., our Chief Financial Officer, would have a material adverse effect on our business. Our success also depends on
our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior,
mid-level, and senior scientific and medical personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk
profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances
for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer.
If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize
product candidates would be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of lenabasum.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face a potential risk of product liability as a result of the clinical testing of lenabasum and will face an even greater risk
if we commercialize lenabasum or any other future product. For example, we may be sued if any product we develop, including lenabasum,
or any materials that we use in our products allegedly causes injury or is found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects
in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims
could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability
claims, we may incur substantial liabilities or be required to limit commercialization of lenabasum. Even successful defense would
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result
in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for lenabasum or any future products that we may develop;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend the related litigation;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&rsquo;s time and our resources;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;substantial
    monetary awards to trial participants or patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize lenabasum; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the value of our stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. We intend to obtain product liability
insurance covering our clinical trials. Although we will maintain such insurance, any claim that may be brought against us could
result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in
excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to
a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a
settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may acquire businesses, assets or products, or form strategic alliances, in the future, and we may not realize the benefits of
such acquisitions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional businesses, assets or products, form strategic alliances or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies,
we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our
existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any
new delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following
any such acquisition, we will achieve the expected synergies to justify the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
affiliates may control our company for the foreseeable future, including the outcome of matters requiring stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers, directors, and five percent stockholders collectively owned approximately 19.6% of our outstanding shares of common
stock as of December 31, 2017. This concentration of voting power and control could have a significant effect in delaying, deferring
or preventing an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders
with interests different from those entities and individuals. Certain of these individuals also have significant control over
our business, policies and affairs as officers or directors of our company. Therefore, you should not invest in reliance on your
ability to have any control over our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active, liquid trading market for our common stock may not be sustained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
our common stock is traded on the Nasdaq Global Market, or Nasdaq, and as we are in our early stages, an investment in our company
may require a long-term commitment, with no certainty of return. If we are unable to maintain an active, liquid active trading
market:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
investors may have difficulty buying and selling or obtaining market quotations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
market visibility for shares of our common stock may be limited; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a lack of visibility for shares of our common stock may have a depressive effect on the market price for shares of our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lack of an active market could impair your ability to sell your shares at the time you wish to sell them or at a price that you
consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may
also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire
additional intellectual property assets by using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently listed on the Nasdaq Global Market. If we are unable to maintain listing of our securities on the Nasdaq Global
Market or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain
financing could be impaired and it may be more difficult for our stockholders to sell their securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our common stock is currently listed on the Nasdaq Global Market, we may not be able to continue to meet the exchange&rsquo;s
minimum listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid
market for our common stock does not develop or is sustained, our common stock may remain thinly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If,
for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from
trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all
of the following may occur, each of which could have a material adverse effect on our stockholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    liquidity of our common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    market price of our common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;our
    ability to obtain financing for the continuation of our operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    number of institutional and general investors that will consider investing in our common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    number of investors in general that will consider investing in our common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    number of market makers in our common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    availability of information concerning the trading prices and volume of our common stock; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    number of broker-dealers willing to execute trades in shares of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock may be significantly volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our common stock may be volatile and subject to wide fluctuations in response to factors including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;actual
    or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;changes
    in financial or operational estimates or projections;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;conditions
    in markets generally;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;changes
    in the economic performance or market valuations of companies similar to ours; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;general
    economic or political conditions in the United States or elsewhere.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, the market prices of biotechnology companies like ours have been highly volatile due to factors, including, but not
limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any delay or failure to conduct a clinical trial for our product or receive approval from the FDA and other regulatory agencies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments or disputes concerning a company&rsquo;s intellectual property rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
technological innovations of such companies or their competitors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in market valuations of similar companies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
announcements by such companies or their competitors of significant contracts, acquisitions, strategic partnerships, joint ventures,
capital commitments, new technologies, or patents; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
failure to complete significant transactions or collaborate with vendors in manufacturing a product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating
performance of particular companies. These market fluctuations may also materially and adversely affect the market price of shares
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of shares by existing stockholders could cause our stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2017, we had outstanding options to purchase an aggregate of 7,844,966 shares of our common stock at a weighted
average exercise price of $3.75 per share and warrants to purchase an aggregate of 1,288,500 shares of our common stock at a weighted
average exercise price of $1.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2018, pursuant to the terms of the Investment Agreement, we issued a warrant to CFF to purchase an aggregate of 1,000,000
shares of our common stock (the &ldquo;CFF Warrant&rdquo;). The CFF Warrant is exercisable at a price equal to $13.20 per share
and was immediately exercisable for 500,000 shares of our common stock. Upon completion of the final milestone set forth in the
Investment Agreement and receipt of the final payment from CFF to us pursuant to the Investment Agreement, the CFF Warrant will
be exercisable for the remaining 500,000 shares of our common stock. The CFF Warrant expires on January 26, 2025. Any shares of
our common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of such outstanding options and warrants will result in further dilution of your investment. If our existing stockholders
sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this
could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and
the performance of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, your ability to achieve
a return on your investment will depend on appreciation in the price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of our
common stock in the foreseeable future. Consequently, investors must rely on sales of their common stock after price appreciation,
which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that shares of
our common stock will appreciate in value or even maintain the price at which our investors have purchased their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company,&rdquo; and will be able take advantage of reduced disclosure requirements applicable to
&ldquo;emerging growth companies,&rdquo; which could make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and,
for as long as we continue to be an &ldquo;emerging growth company,&rdquo; we intend to take advantage of certain exemptions from
various reporting requirements applicable to other public companies but not to &ldquo;emerging growth companies,&rdquo; including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. We will remain an emerging growth company until the earlier of (1) January 1, 2020, (2) the
last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (3) the date on which we become a &ldquo;large
accelerated filer&rdquo; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if
the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most
recently completed second fiscal quarter or (4) the date on which we have issued more than $1 billion in non-convertible debt
during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take advantage of these reporting exemptions described above until we are no longer an &ldquo;emerging growth company.&rdquo;
Under the JOBS Act, &ldquo;emerging growth companies&rdquo; can also delay adopting new or revised accounting standards until
such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption
from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as
other public companies that are not &ldquo;emerging growth companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors
find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading
market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
incur significantly increased costs and devote substantial management time as a result of operating as a public company, , and
we expect these costs to increase particularly after we are no longer an &ldquo;emerging growth company.&rdquo;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. For example,
we are required to comply with certain of the requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and
Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC, including the establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. We expect that compliance
with these requirements will increase our legal and financial compliance costs and will make some activities more time consuming
and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and
other business matters to devote substantial time to these public company requirements. In particular, we expect to incur significant
expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley
Act. In addition, after we are no longer qualify as an &ldquo;emerging growth company,&rdquo; we expect to incur additional management
time and cost to comply with the more stringent reporting requirements applicable to companies that are deemed accelerated filers
or large accelerated filers, including complying with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act. We currently do not have an internal audit function, and we will need to hire or contract for additional accounting and financial
staff with appropriate public company experience and technical accounting knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing
of such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud
may materially harm our company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proper
systems of internal controls over financial accounting and disclosure are critical to the operation of a public company. As of
December 31, 2017, we had 47 full-time employees, which results in a lack of segregation of duties, and we may be unable to effectively
establish such systems, especially in light of the fact that we expect to operate as a publicly reporting company. This would
leave us without the ability to reliably assimilate and compile financial information about our company and significantly impair
our ability to prevent error and detect fraud, all of which would have a negative impact on our company from many perspectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we do not expect that disclosure controls or internal control over financial reporting will prevent all error and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
system&rsquo;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints
and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Failure of our control systems to detect or prevent error or fraud could materially adversely impact us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to complete our analysis of our internal controls over financial reporting in a timely manner, or these internal
controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result,
the value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by our management on, among other things,
the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses
identified by our management in our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and
testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable
to assert that our internal controls are effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to assert that our internal control over financial reporting is effective, or, if applicable, our independent registered
public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence
in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline, and we
may be subject to investigation or sanctions by the SEC. We will also be required to disclose changes made in our internal control
and procedures on a quarterly basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
remediation efforts may not enable us to avoid a material weakness in our internal control over financial reporting in the future.
Any of the foregoing occurrences, should they come to pass, could negatively impact the public perception of our company, which
could have a negative impact on our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
dissolution of our company, you may not recoup all or any portion of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the proceeds and/or assets
of our company remaining after giving effect to such transaction, and the payment of all of our debts and liabilities and distributions
required to be made to holders of any outstanding preferred stock will then be distributed to the stockholders of common stock
on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of common stock, or any
amounts, upon such a liquidation, dissolution or winding-up of our Company. In this event, you could lose some or all of your
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our merger in April 2014 with Corbus Pharmaceuticals, Inc., our wholly-owned subsidiary, our ability to utilize our
federal net operating loss, carryforwards and federal tax credit prior to that date may be limited under Sections 382 of the Internal
Revenue Code. The limitations apply if an &ldquo;ownership change,&rdquo; as defined by Section 382, occurs. Generally, an ownership
change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect &ldquo;five percent
shareholders&rdquo; increases by more than 50 percentage points over their lowest ownership percentage at any time during the
applicable testing period (typically three years). In addition, future changes in our stock ownership, which may be outside of
our control, may trigger an &ldquo;ownership change&rdquo; and, consequently, Section 382 limitations. As a result, if we earn
net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset United
States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability
to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 22, 2017,
President Trump signed into law new tax legislation, or the Tax Act, which significantly reforms the Internal Revenue Code of
1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of
the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense
to 30% of adjusted earnings (except for certain small businesses); limitation of the deduction of net operating losses generated
in tax years beginning after December 31, 2017 to 80% of taxable income, indefinite carryforward of net operating losses generated
in tax years ending after 2017 and elimination of net operating loss carrybacks for net operating losses generated
in tax years ending after 2017; one-time taxation of offshore earnings at reduced rates regardless of whether they
are repatriated; current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations, mandatory
capitalization of research and development expenses beginning in 2022; immediate deductions for certain new investments instead
of deductions for depreciation expense over time; further deduction limits on executive compensation; and modifying, repealing
and creating many other business deductions and credits, including the reduction in the orphan drug credit from 50% to 25% of
qualifying expenditures. We continue to examine the impact this tax reform legislation may have on our business. Notwithstanding
the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business and financial
condition could be adversely affected. The impact of this tax reform on holders of our common stock is also uncertain and could
be adverse. This periodic report does not discuss any such tax legislation or the manner in which it might affect us or our stockholders
in the future. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
certificate of incorporation, as amended, allows for our board to create new series of preferred stock without further approval
by our stockholders, which could adversely affect the rights of the holders of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. We anticipate
that our board of directors will have the authority to issue up to 10,000,000 shares of our preferred stock without further stockholder
approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to
holders the preferred right to our assets upon liquidation and the right to receive dividend payments before dividends are distributed
to the holders of common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock
that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative
voting power of our common stock or result in dilution to our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>Item
    1B.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNRESOLVED
    STAFF COMMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>Item
    2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal offices are located at 500 River Ridge Drive, Norwood, MA 02062. On August 21, 2017, we entered into a lease agreement
(&ldquo;the August 2017 Lease Agreement&rdquo;) with the same landlord, pursuant to which we agreed to lease 32,733 square feet
of office space. The initial term of the August 2017 Lease Agreement is for a period of seven years and commenced in February
2018. The base rent pursuant to the August 2017 Lease Agreement ranges from approximately $470,000 for the first year to approximately
$908,000 for the seventh year. We believe our facilities are adequate for our foreseeable needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>Item
    3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
    PROCEEDINGS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal
proceedings arising in the ordinary course of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>Item
    4.</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINE
    SAFETY DISCLOSURES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>Item
    5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKET
    FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Market
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the <FONT STYLE="background-color: white">Nasdaq Global Market </FONT>under the symbol &ldquo;CRBP.&rdquo;
Our shares of common stock began trading on the <FONT STYLE="background-color: white">Nasdaq Capital Market under the symbol &ldquo;CRBP&rdquo;
effective April 16, 2015</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table contains information about the range of high and low sale prices for our common stock for each quarter during
the last two years. The source of these high and low sales prices was the <FONT STYLE="background-color: white">Nasdaq Global
Market and </FONT>the <FONT STYLE="background-color: white">Nasdaq Capital Market</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiscal
    Year Ended December 31, 2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">High
    Sales Price</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low
    Sales Price</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
    Quarter,</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.50</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.15</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Second
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.45</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.30</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Third
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.90</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.60</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fourth
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.75</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.40</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiscal
    Year Ended December 31, 2016</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">High
    Sales Price</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low
    Sales Price</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
    Quarter</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.95</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.01</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Second
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.85</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.78</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Third
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.88</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.68</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fourth
    Quarter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.78</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.65</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We do not intend to declare or pay cash dividends on our common
stock for the foreseeable future, but currently intend to retain any future earnings to fund the development and growth of our
business. The payment of cash dividends if any, on the common stock will rest solely within the discretion of our board of directors
and will depend, among other things, upon our earnings, capital requirements, financial condition, and other relevant factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Record
Holders</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 6, 2018, there are approximately 91 record holders of shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
Return Performance Graph.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graph below compares the cumulative total return of holders of our common stock with the cumulative total returns of the <FONT STYLE="background-color: white">Russell
2000 (the &ldquo;RUT I</FONT>ndex&rdquo;), and the <FONT STYLE="background-color: white">S&amp;P Biotechnology Select Industry
Index (the &ldquo;S&amp;P Index&rdquo;)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graph tracks the performance of a $100 investment in our common stock, in the RUT Index, and the S&amp;P Index (with the reinvestment
of all dividends) from November 25, 2014, the date which we first registered under the Securities Exchange Act, to December 31,
2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 310; width: 850"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0.25in; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>Item
6.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELECTED
                                         FINANCIAL DATA </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
    Statements of Operations Data</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 35%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue
    from awards</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,440,195</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,911,424</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">648,382</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    expenses:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,038,965</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,436,735</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,888,659</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,255,535</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">210,670</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,964,046</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,459,747</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,613,416</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,391,638</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">346,606</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,003,011</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,896,482</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,502,075</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,647,173</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">557,276</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,562,816</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,985,058</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,853,693</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,647,173</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(557,276</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income (expense):</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    income (expense), net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">183,112</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">477</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">977</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21,906</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44,360</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    currency exchange gain (loss)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(41,908</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,094</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,977</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,570</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,692</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of warrant liability</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28,448</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,978</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forgiveness
    of interest on note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,466</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain
    on settlement of debt</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,006</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income (expense), net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">141,204</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,617</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,954</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">106,688</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(45,074</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,998,675</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,850,739</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,540,485</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(602,350</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.65</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.49</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.28</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.13</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average number of common shares outstanding, basic and diluted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,176,953</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,137,518</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">31,350,145</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,159,861</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,964,788</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
    Balance Sheet Data</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
    December 31,</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 35%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Working
    capital (deficit)</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,300,055</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,504,340</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,084,757</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,794,961</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(343,346</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,978,161</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,888,182</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,875,303</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,600,773</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">305,520</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Long-Term Liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">989,925</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,356</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">260,260</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">331,243</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Stockholders&rsquo; Equity (Deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,783,561</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,919,235</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,985,010</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,862,733</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,783,198</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis of our financial condition and results of operations should be read together with our financial
statements and the related notes and the other financial information included elsewhere in this Annual Report. This discussion
contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere
in this Annual Report, particularly those under &ldquo;Risk Factors.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase 3, clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to
treat rare, chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Our product, lenabasum, is
a novel synthetic, oral, endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes without
causing immunosuppression. We are currently developing lenabasum to treat four life-threatening diseases: systemic sclerosis (SSc),
cystic fibrosis (CF), dermatomyositis (DM) and systemic lupus erythematosus (SLE).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is a synthetic, rationally-designed, oral small-molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2
found on activated immune cells, fibroblasts and other cell types including muscle and bone cells. Lenabasum stimulates the production
of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous
pathways. These pathways are activated in healthy individuals during the course of normal immune responses but are dysfunctional
in patients with chronic inflammatory and fibrotic diseases. By its binding to CB2, lenabasum drives innate immune responses from
the activation phase into the resolution phase. CB2 plays a central role in modulating and resolving inflammation by, in effect,
turning heightened inflammation &ldquo;off&rdquo; and restoring homeostasis. This has been demonstrated in animal models lacking
CB2 as well as humans with genetic polymorphism in the CB2 gene, as these exhibit excessive inflammation and fibrosis in response
to activators of the innate immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
has generated positive clinical data in three consecutive Phase 2 studies in diffuse cutaneous SSc, CF and skin-predominant DM.
Lenabasum is currently being evaluated in a Phase 3 SSc study that is expected to enroll 354 patients, a Phase 2b CF study that
is expected to enroll 415 patients (that is being supported by a development award (the &ldquo;2018 CFF Award&rdquo;) from the
Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;)), and a Phase 2 SLE study that is expected to enroll 100 patients and is being
funded by a grant through the National Institutes of Health (&ldquo;NIH&rdquo;) grant. In DM, the Company plans to consult with
the FDA on the protocol design for the next clinical study, which the Company expects to commence before the end of 2018. Open-label
extension studies are ongoing in SSc and DM following the completion of the Phase 2 studies in these indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration, or the FDA, granted lenabasum Orphan Designation as well as Fast Track Status for both SSc
and CF. The European Medicines Authority, or the EMA, granted lenabasum Orphan Designation for both SSc and CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have devoted substantially all of our efforts to business planning, research and development, recruiting management
and technical staff, acquiring operating assets and raising capital. Our research and development activities have included conducting
pre-clinical studies, developing manufacturing methods and the manufacturing of our drug lenabasum for clinical trials and conducting
clinical studies in patients. Three of the four clinical programs for lenabasum have been supported, by non-dilutive awards and
grants. The National Institutes of Health, or NIH, is funding the majority of the clinical development costs for the DM and SLE
Phase 2 clinical trials, and the Phase 2 clinical trial in cystic fibrosis has been supported by a $5 million award from the Cystic
Fibrosis Foundation Therapeutics, Inc., or CFFT, a non-profit drug discovery and development affiliate of the Cystic Fibrosis
Foundation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Operations Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company and have not generated any revenues from the sale of products. We have never been
profitable and at December 31, 2017, we had an accumulated deficit of approximately $65.7 million. Our net losses for the years
ended December 31, 2017, 2016 and 2015 were approximately $32,422,000, $19,999,000 and $8,851,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses
to increase significantly in connection with our ongoing activities to develop, seek regulatory approval of and commercialize
lenabasum. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations
through public or private equity or debt financings or other sources, which may include government grants and collaborations with
third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital
as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We
will need to generate significant revenues to achieve profitability, and we may never do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect
our expenses will increase substantially in 2018 and in the future in connection with our ongoing activities, as we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    clinical trials for lenabasum in scleroderma, cystic fibrosis, DM, systemic lupus erythematosus and other indications;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our research and development efforts;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
    clinical study materials and develop commercial scale manufacturing capabilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approval for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    personnel to support development of our product candidates; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate
    as a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenues from the sales of products. We do not expect to generate revenue from product sales unless
and until we successfully complete development and obtain regulatory approval for the marketing of lenabasum, which we expect
will take a number of years and is subject to significant uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $2,440,195, $1,911,424 and $648,382 of revenue from awards in the years ended December 31, 2017, 2016 and December
31, 2015, respectively, related to an award agreement (the &ldquo;2015 CFFT Award Agreement) we entered into in fiscal 2015 with
the CFFT, pursuant to which we received a development award (the &ldquo;2015 CFFT Award&rdquo;) for up to $5 million in funding.
We received a total of $5 million in payments under the 2015 CFFT Award as outlined below. The payments received under the 2015
CFFT Award were recorded as deferred revenue when the triggering event to receive those amounts occurred and were amortized on
a straight-line basis over the expected duration of the remaining performance period under the 2015 CFFT Award, which concluded
in the third quarter of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the execution of the 2015 CFFT Award Agreement, we received a payment of $1,250,000 in May 2015. In November 2015, we received
a second payment of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, we received a
third payment from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical
trial patient. In January 2017, we received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone
in December 2016 related to completing the final visit for the final patient. In November 2017, we received the fifth and final
payment from the CFFT in the amount of $500,000 for achieving a milestone in September 2017 related to completing the final integrated
statistical report related to the Phase 2 CF clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Award agreement, we are obligated to make royalty payments to CFFT contingent upon commercialization of lenabasum
in the Field of Use (as defined in the CFFT Award Agreement) as follows: (i) a royalty payment equal to five times the amount
we receive under the CFFT Award Agreement, up to $25 million, payable in three equal annual installments following the first commercial
sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum, (ii) a royalty payment
to CFFT equal to the amount we receive under the CFFT Award Agreement, up to $5 million, due in the first calendar year in which
the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million, and (iii) royalty payment(s) to CFFT
of up to approximately $15 million if we transfer, sell or license lenabasum in the Field of Use other than for certain clinical
or development purposes, or if we enter into a change of control transaction, with such payment(s) to be credited against the
royalty payments due upon commercialization. The Field of Use is defined in the CFFT Award Agreement as the treatment in humans
of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity pneumonitis, pneumoconiosis, primary ciliary
dyskinesis, sarcoidosis and silicosis. Either CFFT or we may terminate the CFFT Award Agreement for cause, which includes our
material failure to achieve certain commercialization and development milestones. Our payment obligations, if any, would survive
the termination of the CFFT Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt">On January
26, 2018, we entered into the Cystic Fibrosis Program Related Investment Agreement (&ldquo;Investment Agreement) with the Cystic
Fibrosis Foundation (&ldquo;CFF&rdquo;), a non-profit drug discovery and development corporation, pursuant to which we received
a development award for up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical Trial (the
&ldquo;Phase 2b Clinical Trial&rdquo;) of lenabasum in patients with cystic fibrosis of which we received $6.25 million to date.
The remainder of the 2018 CFF Award is payable to us incrementally upon the achievement of the remaining milestones
related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement. We will assess this agreement
for accounting under ASC 606 in the first quarter of 2018, including if this agreement falls under the scope of such standard.
We have not yet determined the potential effect the new standard will have on our consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, we are obligated to make certain royalty payments to CFF, including a royalty payment
of one and one-half times the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval
of lenabasum in the United States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon
approval in another major market, as set forth in the Investment Agreement (the &ldquo;Approval Royalty&rdquo;). At our election,
we may satisfy the first of the two Approval Royalties in registered shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are obligated to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty
days after any quarter in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments
to CFF of one percent of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any
quarter in which such net sales occur, and (iii) royalty payments to CFF of ten percent of any amount that we and our stockholders
receive in connection with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment
or prevention of CF, or a change of control transaction, except that such payment shall not exceed five times the amount of the
2018 CFF Award, with such payments to be credited against any other net sales royalty payments due. Either CFF or we may terminate
the Investment Agreement for cause, which includes our material failure to achieve certain commercialization and development milestones.
Our payment obligations survive the termination of the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are incurred for the development of lenabasum and consist primarily of payroll and payments to contract
research and development companies. To date, these costs are related to generating pre-clinical data and the cost of manufacturing
lenabasum for clinical trials and conducting clinical trials. These costs are expected to increase significantly in the future
as lenabasum is continued to be evaluated in additional later stage clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll, rent and professional services such as accounting and legal services.
We anticipate that our general and administrative expenses will increase significantly during 2018 and in the future as we increase
our headcount to support our continued research and development and the potential commercialization of our product candidates.
We also anticipate increased expenses related to audit, legal, and tax-related services associated with maintaining compliance
with NASDAQ exchange listing and SEC requirements, director and officer insurance, and investor relations costs associated with
being a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Expense), Net</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net consists primarily of interest income we earn on interest-bearing accounts, interest expense incurred on
our outstanding debt, and foreign currency exchange transaction losses and gains.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an ongoing basis, we evaluate our estimates and judgments for all assets and liabilities, including those related to stock-based
compensation expense and accrued research and development expense. We base our estimates and judgments on historical experience,
current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances.
This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that full consideration has been given to all relevant circumstances that we may be subject to, and the consolidated financial
statements accurately reflect our best estimate of the results of operations, financial position and cash flows for the periods
presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
Research and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing financial statements, we are required to estimate and accrue expenses, the largest of which are
research and development expenses. This process involves: communicating with our applicable personnel to identify services that
have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service
when we have not yet been invoiced or otherwise notified of actual cost; estimating and accruing expenses in our financial statements
as of each balance sheet date based on facts and circumstances known to us at the time; and periodically confirming the accuracy
of our estimates with selected service providers and making adjustments, if necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of estimated research and development expenses that we accrue include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to CROs in connection with nonclinical studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to contract manufacturers in connection with the production of lenabasum for clinical trials ;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to CRO and research institutions in connection with conducting of clinical studies; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">professional
    service fees for consulting and related services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our expense accruals related to clinical studies on our estimates of the services performed pursuant to contracts with multiple
research institutions and clinical research organizations that conduct and manage clinical studies on our behalf. The financial
terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these
contracts depend on factors, such as the successful enrollment of patients and the completion of clinical study milestones. Our
service providers invoice us monthly in arrears for services performed. In accruing service fees, we estimate the time period
over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that
we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services,
our actual expenses could differ from our estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not experienced significant changes in our estimates of accrued research and development expenses following each
applicable reporting period. However, due to the nature of estimates, we cannot assure you that we will not make changes to our
estimates in the future as we become aware of additional information regarding the status or conduct of our clinical studies and
other research activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options are granted with an exercise price at no less than fair market value at the date of the grant. The stock options normally
expire ten years from the date of grant. Stock option awards vest upon terms determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation costs resulting from the issuance of stock-based awards to employees, members of our Board of directors
and consultants. The fair value of each option grant was estimated as of the date of grant using the Black-Scholes option-pricing
model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards,
which is generally the vesting period. Due to our limited operating history, we estimated our volatility in consideration of a
number of factors, including the volatility of comparable public companies and, commencing in 2015, we also included the volatility
of our own common stock. We use historical data, as well as subsequent events occurring prior to the issuance of the consolidated
financial statements, to estimate option exercise and employee forfeitures within the valuation model. The expected term of options
granted to employees under our stock plans is based on the average of the contractual term (generally 10 years) and the vesting
period (generally 48 months). The expected term of options granted under the 2014 Plan, all of which qualify as &ldquo;plain vanilla&rdquo;
per SEC Staff Accounting Bulletin 107, is based on the average of the 6.25 years. For non-employee options, the expected term
is the contractual term and stock options granted to non-employee consultants are revalued at the end of each reporting period
until vested and changes in their fair value are recorded as adjustments to expense over the related vesting period. The risk-free
rate is based on the yield of a U.S. Treasury security with a term consistent with the option. We estimate the forfeiture rate
at the time of grant and revise it, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures
were estimated based on management&rsquo;s expectation through industry knowledge and historical data. We have never paid dividends
on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have
assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes option pricing model
for the years ended December 31, 2017, 2016 and 2015 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free interest rate</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.70</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term in years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.00</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.66</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.73</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86.36</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.39</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.68</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    forfeiture rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.83</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Emerging
Growth Company Status</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 107(b) of the Jumpstart Our Business Startups Act of 2012, emerging growth companies can delay adopting new or revised
accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves
of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of Year Ended 2017 to 2016</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
from Awards. </B>We have recognized approximately $2,440,000 and $1,911,000 of revenue from awards in the years ended December
31, 2017 and December 31, 2016, respectively, related to the funding from the 2015 CFFT Award. We have received a total of $5
million in payments since the inception of the 2015 CFFT Award as outlined below. The payments received under the 2015 CFFT Award
were recorded as deferred revenue when the triggering event to receive those amounts occurred and were amortized on a straight-line
basis over the expected duration of the remaining performance period under the 2015 CFFT Award, which concluded in the third quarter
of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the execution of the 2015 CFFT Award Agreement, we received a payment of $1,250,000 in May 2015. In November 2015, we received
a second payment of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, we received a
third payment from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical
trial patient. In January 2017, we received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone
in December 2016 related to completing the final visit for the final patient. In November 2017, we received the fifth and final
payment from the CFFT in the amount of $500,000 for achieving a milestone in September 2017 related to completing the final integrated
statistical report related to the Phase 2 CF clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development. </B>Research and Development expenses for the year ended December 31, 2017 totaled approximately $26,039,000,
an increase of $10,602,000 over the $15,437,000 recorded for the year ended December 31, 2016. The increase in fiscal 2017 as
compared to fiscal 2016 was primarily attributable to increases of approximately $6,577,000 in clinical trial costs, $2,646,000
in compensation costs, and $1,379,000 in stock-based compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative.</B> General and Administrative expense for the year ended December 31, 2017 totaled approximately $8,964,000,
an increase of $2,504,000 over the $6,460,000 recorded for year ended December 31, 2016. The increase in fiscal 2017 as compared
to fiscal 2016 was primarily attributable to increases of approximately $1,152,000 in stock-based compensation expense, $429,000
in compensation costs, $289,000 in investor relations and public company costs, $260,000 in recruiting costs, $150,000 in insurance
costs, and $113,000 in consulting expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Expense), Net.</B> Other income, net for fiscal 2017 was approximately $141,000 as compared to other expense, net of approximately
$14,000 recorded for fiscal 2016 and was primarily attributable to an increase in net interest income of approximately $183,000
due to increased cash balances in 2017 as compared to 2016, offset partially by increases in foreign currency exchange transaction
losses of approximately $28,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of Year Ended 2016 to 2015</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
from Awards. </B>We have recognized approximately $1,911,000 and $648,000 of revenue related to the 2015 CFFT Award in the years
ended December 31, 2016 and December 31, 2015, respectively. As of December 31, 2016, we had billed and received a total of $4.5
million in payments since the inception of the 2015 CFFT Award as outlined below The payments received under the 2015 CFFT Award
were recorded as deferred revenue when the triggering event to receive those amounts occurred and were amortized on a straight-line
basis over the expected duration of the remaining performance period under the 2015 CFFT Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the execution of the 2015 CFFT Award Agreement, we received a payment of $1,250,000 in May 2015. In November 2015, we received
a second payment of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, we received a
third payment from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical
trial patient. In January 2017, we received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone
in December 2016 related to completing the final visit for the final patient. In November 2017, we received the fifth and final
payment from the CFFT in the amount of $500,000 for achieving a milestone in September 2017 related to completing the final integrated
statistical report related to the Phase 2 CF clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development. </B>Research and Development expenses for the year ended December 31, 2016 totaled approximately $15,437,000,
an increase of $9,548,000 over the $5,889,000 recorded for the year ended December 31, 2015. The increase in fiscal 2016 as compared
to fiscal 2015 was primarily attributable to increases of $7,132,000 in clinical trial costs, $1,447,000 in compensation costs,
and $969,000 in stock-based compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative.</B> General and Administrative expense for the year ended December 31, 2016 totaled approximately $6,460,000,
an increase of $2,847,000 over the $3,613,000 recorded for year ended December 31, 2015. The increase in fiscal 2016 as compared
to fiscal 2015 was primarily attributable to increases of approximately $1,251,000 in stock-based compensation expense, $997,000
in compensation costs, $375,000 in investor relations costs, and $213,000 in legal costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Expense), Net.</B> Other expense, net for fiscal 2016 was approximately $14,000 as compared to other income, net of approximately
$3,000 recorded for fiscal 2015 and was primarily attributable to an increase in foreign currency exchange transaction losses
recorded during fiscal 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Since inception, we have
experienced negative cash flows from operations. We have financed our operations primarily through sales of equity-related securities.
In addition, the majority of the costs of the DM and SLE clinical trials have been or are expected to be funded by NIH
grants, and our Phase 2 cystic fibrosis clinical trial was partially funded by the 2015 CFFT Award. Our Phase 2b cystic fibrosis
trial is being supported by the 2018 CFF Award. At December 31, 2017, our accumulated deficit since inception was approximately
$65,698,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2017, we had total current assets of approximately $65,505,000 and current liabilities of approximately $8,205,000
resulting in working capital of approximately $57,300,000. Net cash used in operating activities for the year ended December 31,
2017 was approximately $27,797,000, which includes a net loss of approximately $32,422,000, adjusted for non-cash expenses of
approximately $6,855,000 principally related to stock-based compensation expense of $5,694,000 and deferred rent of $914,000,
and for approximately $2,230,000 of cash used by net working capital items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in investing activities for the year ended December 31, 2017 totaled approximately $707,000, which was principally related
to construction costs in the fourth quarter of 2017 to build out our office space that we began occupying in February 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2017 totaled approximately $76,008,000. On February 28, 2017,
we entered into a securities purchase agreement providing for the issuance and sale of 3,887,815 shares of our common stock in
a registered direct offering to institutional and accredited investors at a purchase price of $7.00 per share with net proceeds
to us totaling $27,177,102. In November 2016, we entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (&ldquo;2016
Sales Agreement&rdquo;) with Cantor Fitzgerald pursuant to which Cantor Fitzgerald served as our sales agent to sell up to $35
million of shares of our common stock through an &ldquo;at the market offering.&rdquo; During the year ended December 31, 2017,
we received net proceeds of approximately $13,404,000 from sales of our common stock pursuant to the 2016 Sales Agreement, net
of 3% commission paid to Cantor Fitzgerald. All sales of common stock under the 2016 Sales Agreement occurred in the first quarter
of 2017, and we did not sell any shares of our common stock under the 2016 Sales Agreement during the remainder of 2017. The 2016
Sales Agreement was terminated in connection with the October 2017 Offering discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2017, we consummated an underwritten public offering of shares of our common stock pursuant to which we sold an aggregate
of 5,347,500 shares of our common stock to institutional investors at a purchase price of $7.00 per share with net proceeds to
us totaling approximately $35,181,000 (&ldquo;October 2017 Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2017, we also received proceeds of approximately $189,490 from the issuance of 272,734 shares of our
common stock upon the exercise of stock options to purchase common stock. Cash provided by financing activities for the year ended
December 31, 2017 included proceeds from issuances of notes payable of $415,265, partially offset by principal payments on notes
payable of $354,161 in connection with our loan agreements with financing companies. The terms of the loan that we entered into
in November 2017 stipulate equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest
accrues on this loan at an annual rate of 2.35%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, we entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (&ldquo;January 2018 Sales Agreement&rdquo;)
with Cantor Fitzgerald pursuant to which Cantor Fitzgerald is serving as our sales agent to sell up to $50 million of shares of
our common stock through an &ldquo;at the market offering,&rdquo; of which we have sold 1,500,000 shares for net proceeds of $11.3
million to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect our cash and
cash equivalents of approximately $62.5 million at December 31, 2017 together with the $11.3 million of net proceeds received
from the January 2018 Sales Agreement and the up to $25 million of proceeds that we expect to receive under the 2018 CFF Award,
of which we have received $6.25 million to date, to be sufficient to meet our operating and capital requirements through
the end of the fourth quarter of 2019, based on current planned expenditures. The remainder of the up to $25 million 2018
CFF Award is payable to us incrementally upon the achievement of the remaining milestones related to the progress of the
Phase 2b Clinical Trial, as set forth in the Investment Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise significant additional capital to continue to fund operations and the clinical trials for lenabasum. We may
seek to sell common stock, including sales under our January 2018 Sales Agreement, preferred stock or convertible debt securities,
enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to
raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may
result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If
we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these
securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement
could require us to relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically,
on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable
to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or
all of our planned clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about our known contractual obligations as of December 31, 2017. It does not reflect contractual
obligations that may have arisen or may arise after that date. Except for historical facts, the information in this section is
forward-looking information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="18" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payments
    due by period</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
    Obligations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
    2019-2020</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
    2021-2022</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
    Fiscal 2022</B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease obligations (1)</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,474,623</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,333</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,408,201</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,685,750</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,935,339</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    lease obligations (2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,922</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,543</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">379</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,479,545</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">449,876</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,408,580</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,685,750</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,935,339</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 21, 2017, we entered into a lease agreement (&ldquo;the August 2017 Lease Agreement&rdquo;) with the initial term of
    a period of seven years which commenced in February 2018. The base rent pursuant to the August 2017 Lease Agreement ranges
    from approximately $470,000 for the first year to approximately $908,000 for the seventh year. The September 2016 Amendment
    was terminated upon the commencement date of the August 2017 Lease Agreement. Additionally, the August 2017 Lease Agreement
    required us to provide a standby irrevocable letter of credit of $400,000, which may be reduced, if we are not in default
    under the August 2017 Lease Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement date,
    respectively, We entered into an unsecured letter of credit with a commercial bank for $400,000 in connection with the August
    2017 Lease Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 30, 2015, we entered into a lease agreement for a copier machine. The machine was placed in service in January 2016.
    The lease is for a three-year term and includes a bargain purchase option at the end of the term.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may enter into contracts in the normal course of business with clinical research organizations for clinical trials and clinical
supply manufacturing and with vendors for pre-clinical research studies, research supplies and other services and products for
operating purposes. These contracts generally provide for termination on notice, and therefore, we believe that our non-cancelable
obligations under these agreements are not material. As of December 31, 2017, other than our leases in the table above, we had
no material Contractual Obligations or Commitments that will affect our future liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>Item
    7A.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of three months or less. The
primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly
increasing risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general
level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in
market interest rates would not be expected to have a material impact on our financial condition and/or results of operation.
We do not have any foreign currency or other derivative financial instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>Item
    8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
pages F-1 through F-20 following the Exhibit Index of this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><A NAME="a_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>Item
    9A.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTROLS
    AND PROCEDURES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Evaluation
of Our Disclosure Controls</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&rsquo;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our chief financial officer, to allow timely decisions regarding
required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including
our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure controls
and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer
and principal financial officer concluded that, as of December 31, 2017, our disclosure controls and procedures were effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Management&rsquo;s
Report on Internal Control Over Financial Reporting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including
our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control
over financial reporting based on criteria established in the framework in <I>Internal Control &mdash; Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission</I>. Based on this evaluation, our management concluded
that our internal control over financial reporting was effective as of December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our independent registered public accounting firm because we are an &ldquo;emerging
growth company,&rdquo; and may take advantage of certain exemptions from various reporting requirements that are applicable to
public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being required to comply
with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Changes
in Internal Controls over Financial Reporting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2017, there have been no changes in our internal control over financial reporting that have materially
affected or are reasonably likely to materially affect our internal controls over financial reporting. From time to time, we make
changes to our internal control over financial reporting that are intended to enhance its effectiveness and which do not have
a material effect on our overall internal control over financial reporting. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>Item
    9B.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
    INFORMATION </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>PART
III</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_018"></A>Item
    10.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_019"></A>Item
    11.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
    COMPENSATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated herein by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_020"></A>Item
    12.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_021"></A>Item
    13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_022"></A>Item
    14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
    ACCOUNTING FEES AND SERVICES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_023"></A>PART
IV</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_024"></A>Item
    15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS,
    FINANCIAL STATEMENT SCHEDULES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
List of Documents filed as part of this Report</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)
Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related notes, together with the report of EisnerAmper LLP appear at pages F-1 through F-19 following
the Exhibit List as required by Part II, Item 8 &ldquo;Financial Statements and Supplementary Data&rdquo; of this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)
Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
are omitted because they are either not required, not applicable, or the information is otherwise included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(3)
Exhibits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed with this report or incorporated by reference herein certain exhibits as specified below pursuant to Rule 12b-32
under the Exchange Act. See Exhibit Index following the signature page to this report for a complete list of documents filed with
this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: bottom; width: 0.8in; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.15in; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217005930/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 26, 2017).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217005930/ex3-2.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 26, 2017).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Merger Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-2.htm" STYLE="-sec-extract: exhibit">Form of Replacement Warrant (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-3.htm" STYLE="-sec-extract: exhibit">Form of Investor Warrant (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-4.htm" STYLE="-sec-extract: exhibit">Form of Additional Replacement Warrant (incorporated by reference to Exhibit 4.4 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-5.htm" STYLE="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-6.htm" STYLE="-sec-extract: exhibit">Registration Rights Agreement (incorporated by reference to Exhibit 4.6 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312514416997/d823238dex44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock Certificate, $0.0001 par value (incorporated herein by reference to Exhibit 4.1 of the Company&rsquo;s Registration Statement on Form S-3 filed with the SEC on November 10, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex4-8.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant to Purchase Common Stock, dated as of January 26, 2018, issued to the Cystic Fibrosis Foundation*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agency Agreement, dated March 27, 2014, between the Company and Aegis Capital Corporation (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, dated March 21, 2014, between the Company and Orchestra Medical Ventures (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: bottom; width: 0.8in; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.15in; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-3.htm" STYLE="-sec-extract: exhibit">Form of Subscription Agreement for the Company&rsquo;s 2014 Private Placement (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-4.htm" STYLE="-sec-extract: exhibit">Form of Voting Agreement, dated April 11, 2014, by and among the Company and the stockholders named therein (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-5.htm" STYLE="-sec-extract: exhibit">2014 Equity Compensation Plan (incorporated by reference to Exhibit 10.5 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). &dagger;</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-6.htm" STYLE="-sec-extract: exhibit">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.6 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). &dagger;</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-7.htm" STYLE="-sec-extract: exhibit">Form of Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-8.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Agreement (incorporated by reference to Exhibit 10.8 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-9.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated April 11, 2014, between the Company and Yuval Cohen (incorporated by reference to Exhibit 10.9 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-10.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated April 11, 2014, between the Company and Mark Tepper (incorporated by reference to Exhibit 10.10 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-11.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated June 19, 2014, between the Company and Sean Moran (incorporated by reference to Exhibit 10.11 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-12.htm" STYLE="-sec-extract: exhibit">Agreement and Plan of Merger, dated March 27, 2014, by and among the Company, Corbus Pharmaceuticals Acquisition, Inc. and JB Therapeutics, Inc. (incorporated by reference to Exhibit 10.12 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-13.htm" STYLE="-sec-extract: exhibit">Subscription Agreement, dated April 2009, between Sumner Burstein and JB Therapeutics, Inc. (which is now known as Corbus Pharmaceuticals, Inc.) (incorporated by reference to Exhibit 10.13 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-14.htm" STYLE="-sec-extract: exhibit">Letter Agreement, dated April 29, 2009, between JB Therapeutics, Inc. (which is now known as Corbus Pharmaceuticals, Inc.) and Sumner Burstein (incorporated by reference to Exhibit 10.14 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414058605/v390155_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.15 of the Company&rsquo;s Registration Statement on Amendment No. 1 to Form S-1 filed with the SEC on September 30, 2014). &dagger;</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312515114246/d900328dex1015.htm" STYLE="-sec-extract: exhibit">Letter Agreement, dated August 18, 2014, between the Company and Barbara White (incorporated herein by reference to Exhibit 10.15 of the Company&rsquo;s Post-Effective Amendment No. 1 to Form S-1 filed with the SEC on March 31, 2015).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312515184856/d908885dex101.htm" STYLE="-sec-extract: exhibit">Award Agreement, dated April 9, 2015, between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company (incorporated herein by reference to Exhibit 10.1 of the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2015).#</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex101_14.htm" STYLE="-sec-extract: exhibit">Amendment No.1 to Employment Agreement, dated April 11, 2016, between the Company and Yuval Cohen (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex102_15.htm" STYLE="-sec-extract: exhibit">Amendment No.1 to Employment Agreement, dated April 11, 2016, between the Company and Mark Tepper (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex103_16.htm" STYLE="-sec-extract: exhibit">Amendment No.1 to Amended and Restated Employment Agreement, dated April 11, 2016, between the Company and Sean Moran (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016).</A> &dagger;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: bottom; width: 0.8in; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.15in; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex104_17.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated April 11, 2016, between the Company and Barbara White (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016).</A> &dagger;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016020500/crbp-ex101_39.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated June 10, 2016, between Company and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 10, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216013495/ex10-1.htm" STYLE="-sec-extract: exhibit">Consulting Agreement, dated September 20, 2016, between Company and Orchestra Medical Ventures, LLC (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 21, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-2.htm" STYLE="-sec-extract: exhibit">Lease, dated May 30, 2014, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-3.htm" STYLE="-sec-extract: exhibit">First Amendment to Lease, dated August 27, 2015, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-4.htm" STYLE="-sec-extract: exhibit">Second Amendment to Lease, dated March 30, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-5.htm" STYLE="-sec-extract: exhibit">Third Amendment to Lease, dated September 13, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.5 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312516776585/d302766dex11.htm" STYLE="-sec-extract: exhibit">Controlled Equity Offering<SUP>SM </SUP>Sales Agreement, dated November 23, 2016, by and between Corbus Pharmaceuticals Holdings, Inc. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 23, 2016.)</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217001977/ex10-1.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated February 28, 2017, between Company and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on February 28, 2017).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217009730/ex10-1.htm" STYLE="-sec-extract: exhibit">Lease Agreement, dated August 21, 2017, by and between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 22, 2017).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217009730/ex10-2.htm" STYLE="-sec-extract: exhibit">Guarantee, dated August 21, 2017, by Corbus Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 22, 2017).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218000239/ex1-2.htm" STYLE="-sec-extract: exhibit">Controlled Equity OfferingSM Sales Agreement, dated January 5, 2018, by and between Corbus Pharmaceuticals Holdings, Inc. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company&rsquo;s Registration Statement on Form S-3 filed with the SEC on January 5, 2018).</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex10-33.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cystic Fibrosis Program Related Investment Agreement, dated January 26, 2018, between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company.#*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex23-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of EisnerAmper LLP.*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex31-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex31-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex32-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex32-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Schema Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Label Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation Linkbase Document.*</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
    treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been submitted separately
    to the SEC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or compensation plan, contract or arrangement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>Item
    16.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
    10-K SUMMARY</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
    PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2018</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    YUVAL COHEN</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 45%; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 38%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 38%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    YUVAL COHEN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                         Executive Officer and Director</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Executive Officer)</FONT></P></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP ROWSPAN="2" STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    SEAN MORAN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ALAN HOLMER</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Holmer</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    DAVID HOCHMAN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Hochman</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    RENU GUPTA</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renu
    Gupta</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    AVERY CATLIN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avery
    Catlin</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    PARIS PANAYIOTOPOULOS</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2018</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paris
                                         Panayiotopoulos&nbsp;</FONT></P></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 89%; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; padding-left: 0.1in; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    Number</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Corbus
    Pharmaceuticals Holdings, Inc. Financial Statements-December 31, 2017:</U></B></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2017 and December 31, 2016</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2017, 2016 and 2015</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&rsquo; Equity for the Years Ended December 31, 2017, 2016 and 2015</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_030"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016 and 2015</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12.25pt; font: 10pt Times New Roman, Times, Serif; text-indent: -12.25pt"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_026"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and Stockholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
Pharmaceuticals Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Opinion
on the Financial Statements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Corbus Pharmaceuticals Holdings, Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of December 31, 2017 and 2016,
and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each of the years in the three-year
period ended December 31, 2017, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In
our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company
as of December 31, 2017 and 2016, and the consolidated results of their operations and their cash flows for each of the years in
the three-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States
of America.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
for Opinion </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
EisnerAmper LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EISNERAMPER
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iselin,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
12, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_027"></A>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,537,495</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,992,257</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,991</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    receivable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    subscriptions receivable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">330,413</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,808,244</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">930,261</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,504,730</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,402,931</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,432,655</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,251</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,776</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,978,161</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,888,182</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND STOCKHOLDERS&rsquo; EQUITY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,861</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">271,757</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,130,295</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,419,921</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,741,519</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,256,455</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue, current</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,940,195</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    rent, current</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,263</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,204,675</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,898,591</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    rent, noncurrent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">989,550</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,724</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,632</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,194,600</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,968,947</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and Contingencies</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2017 and 2016, 55,603,427 and 44,681,745 shares issued
    and outstanding at December 31, 2017 and 2016, respectively</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,560</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,468</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,476,102</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,191,256</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,698,101</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,276,489</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,783,561</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,919,235</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&rsquo; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,978,161</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,888,182</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_028"></A>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                         the Years Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                         31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    from awards</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,440,195</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,911,424</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">648,382</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,038,965</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,436,735</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,888,659</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,964,046</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,459,747</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,613,416</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,003,011</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,896,482</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,502,075</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,562,816</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,985,058</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,853,693</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">183,112</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">477</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">977</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency exchange gain (loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(41,908</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,094</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,977</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense), net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141,204</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,617</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,954</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,421,612</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,998,675</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850,739</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.65</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.49</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.28</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,176,953</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,137,518</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,350,145</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_029"></A>Statements
of Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid-in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&rsquo;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2014</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,938,332</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,287,214</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,427,075</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,862,733</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,153,302</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,153,302</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock upon exercise of warrants, net of issuance costs of $509,215</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,615,674</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,162</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,812,963</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,814,125</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock upon exercise of stock options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,128</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,584</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,589</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850,739</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850,739</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2015</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,605,134</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,761</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,259,063</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,277,814</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,985,010</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,163,534</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,163,534</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock, net of issuance costs of $260,179</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,148,695</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,300,309</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,300,924</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock&nbsp;&nbsp;upon exercise of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">601,030</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,190</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock upon exercise of stock options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,886</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">467,160</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">467,192</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,998,675</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,998,675</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,681,745</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,468</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,191,256</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,276,489</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,919,235</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,694,489</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,694,489</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock, net of issuance costs of $2,969,837</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,648,948</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,065</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,400,894</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,401,959</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock upon exercise of stock options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,734</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,463</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,490</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,421,612</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,421,612</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,603,427</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,560</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,476,102</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,698,101</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,783,561</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_030"></A>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,421,612</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,998,675</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850,739</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,694,489</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,163,534</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,153,302</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">255,652</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87,664</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,943</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)
    loss on foreign exchange</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,490</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,094</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,977</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    rent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">913,563</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,987</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in operating assets and liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    (increase) in grants receivable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,000,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in prepaid expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,877,983</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(553,745</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(105,959</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in other assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(40,776</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Decrease)
    increase in accounts payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(885,797</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,890,876</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">972,194</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,514,521</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,660,461</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,788</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Decrease)
    increase in deferred revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,940,195</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88,577</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,851,618</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,796,628</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,571,227</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,624,830</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from investing activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
    of property and equipment</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707,429</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(353,032</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(114,037</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 30pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707,429</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(353,032</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(114,037</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from financing activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of notes payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">415,265</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">348,750</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">207,750</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    payments on notes payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(354,161</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(239,012</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(190,120</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of common stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,891,699</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,699,133</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,328,929</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    costs paid for common stock financings</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,940,685</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63,830</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(509,215</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    payments under capital lease obligations</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,832</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,175</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,008,286</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,741,866</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,837,344</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase in cash, cash equivalents, and restricted cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,504,229</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,817,607</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,098,477</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents, and restricted cash at beginning of the year</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,192,257</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,374,650</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,276,173</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents, and restricted cash at end of the year</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,696,486</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,192,257</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,374,650</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of cash flow information and non cash transactions:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid during the period for interest</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,377</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,586</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    acquired under capital lease obligation</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,638</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
    of property and equipment included in accounts payable or accrued expenses</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">579,734</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,107</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpaid
    stock issuance costs</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,501</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,349</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_031"></A>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NATURE
    OF OPERATIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
Pharmaceuticals Holdings, Inc. (&ldquo;CPHI&rdquo; or &ldquo;the Company&rdquo;) is a clinical stage pharmaceutical company, focused
on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development,
recruiting management and technical staff, acquiring operating assets and raising capital. . The Company&rsquo;s business is subject
to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes
profitable and it may never achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIQUIDITY
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research
funding, development of its product candidates and its preclinical and clinical programs, strategic alliances and the development
of its administrative organization. The Company has incurred recurring losses since inception and as of December 31, 2017, had
an accumulated deficit of $65,698,101.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, the Company entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (&ldquo;January 2018 Sales
Agreement&rdquo;) with Cantor Fitzgerald &amp; Co. (&ldquo;Cantor Fitzgerald&rdquo;) pursuant to which Cantor Fitzgerald is serving
as the Company&rsquo;s sales agent to sell up to $50 million of shares of the Company&rsquo;s common stock through an &ldquo;at
the market offering,&rdquo; of which 1,500,000 shares have been sold for net proceeds of $11.3 million to date. (See Note 15).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 26, 2018, the Company
entered into the Cystic Fibrosis Program Related Investment Agreement (&ldquo;Investment Agreement&rdquo;) with the Cystic Fibrosis
Foundation (&ldquo;CFF&rdquo;), a non-profit drug discovery and development corporation, pursuant to which the Company received
a development award for up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical Trial (the
&ldquo;Phase 2b Clinical Trial&rdquo;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25
million to date. The Company expects the remainder of the 2018 CFF Award will be paid to the Company incrementally upon the
achievement of the remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment
Agreement. (See Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company expects the cash on
hand of $62,537,495 at December 31, 2017 together with the $11.3 million of net proceeds received from the January 2018 Sales
Agreement and the $6.25 million that the Company has received to date under the 2018 CFF Award, to be sufficient to meet
its operating and capital requirements at least 12 months from the filing of this 10-K.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including
delaying or discontinuing certain clinical activities. The Company will need to raise significant additional capital to continue
to fund the clinical trials for lenabasum. The Company may seek to sell common or preferred equity or convertible debt securities,
enter into a credit facility or another form of third-party funding, or seek other debt financing. The sale of equity and convertible
debt securities may result in dilution to the Company&rsquo;s stockholders and certain of those securities may have rights senior
to those of the Company&rsquo;s common shares. If the Company raises additional funds through the issuance of preferred stock,
convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict
the Company&rsquo;s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically,
on the progress of the Company&rsquo;s clinical development programs. Funding may not be available when needed, at all, or on
terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or
eliminate some or all of the Company&rsquo;s planned clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT
    ACCOUNTING POLICIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of preparing financial statements in conformity with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates
are related to stock based compensation expense, the accrual of research, product development and clinical obligations, and the
expected performance period under the 2015 CFFT Award (See Note 8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the registration of its common stock and the subsequent public listing of the common stock, the Company had granted stock options
at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management.
The Company&rsquo;s board of directors determined the estimated fair value of the common stock based on a number of objective
and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices
at which the Company sold shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash,
Cash Equivalents, and Restricted Cash</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months
from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months.
At December 31, 2017 and 2016, cash equivalents were comprised of money market funds. The Company had no marketable investments
at December 31, 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash as of December 31, 2017 and 2016 included a collateral account for the Company&rsquo;s corporate credit cards and is classified
in current assets in the amount of $108,991 and $150,000, respectively. Additionally, as of December 31, 2017 and 2016 restricted
cash included a stand-by letter of credit issued in favor of a landlord for $50,000 which was classified in current assets as
of December 31, 2017 and in noncurrent assets as of December 31, 2016 (See Note 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
cash equivalents, and restricted cash consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">206,510</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,127,530</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
    market fund</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,330,985</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,864,727</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,537,495</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,992,257</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash, current</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,991</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash, noncurrent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,991</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    cash, cash equivalents, and restricted cash shown in the statement of cash flows</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,696,486</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,192,257</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued
expenses approximate their fair value based on the short-term nature of these instruments. The carrying values of the notes payable
approximate their fair value due to the fact that they are at market terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property
and Equipment </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated life for the Company&rsquo;s property and equipment is as follows: three years for computer hardware and software and
three to five years for office furniture and equipment. The Company&rsquo;s leasehold improvements and assets under capital lease
are amortized over the shorter of their useful lives or the respective leases. See Note 4 for details of property and equipment
and Note 5 for operating and capital lease commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses and Development Award Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonrefundable
advance payments for goods or services that have the characteristics that will be used or rendered for future research and development
activities pursuant to executory contractual arrangements with third party research organizations are deferred and recognized
as an expense as the related goods are delivered or the related services are performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
amounts received under the development award received from the CFFT (See Note 8), the Company recognized those amounts when the
triggering event to receive those payments occurred, with those amounts being amortized on a straight-line basis over the expected
duration of the remaining performance period of the development program under the award, which concluded in the third quarter
of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accruals
for Research and Development Expenses and Clinical Trials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its
obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in
connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from
contract to contract and may result in payment terms that do not match the periods over which materials or services are provided
under such contracts. The Company&rsquo;s objective is to reflect the appropriate expenses in its financial statements by matching
those expenses with the period in which services are performed and efforts are expended. The Company determines accrual estimates
by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials,
or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual
results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on
the facts and circumstances known to it at that time. The Company&rsquo;s clinical trial accruals are dependent upon the timely
and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect
its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services
performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that
are too high or too low for any particular period. For the years ended December 31, 2017, 2016 and 2015, there were no material
adjustments to the Company&rsquo;s prior period estimates of accrued expenses for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leases
and Deferred Rent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its office space. Leases are evaluated and classified as operating or capital leases for financial reporting purposes.
The Company&rsquo;s office space leases qualify as operating leases. For operating leases that contain rent escalations and rent
holidays, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease
and records the difference between the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement
allowances received from the lessor are recorded as a reduction to rent expense over the term of the lease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentrations
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts
or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation
insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Segment
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker, or decision making group, in making decisions regarding resource allocation and assessing
performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which
is developing and commercializing therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December
31, 2017 and 2016, all of the Company&rsquo;s assets were located in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the
financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted
laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred
tax asset when it is not more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly,
given the cumulative losses since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax
assets in order to eliminate the deferred tax assets amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
positions taken or expected to be taken in the course of preparing the Company&rsquo;s tax returns are required to be evaluated
to determine whether the tax positions are &ldquo;more-likely-than-not&rdquo; of being sustained by the applicable tax authority.
Tax positions not deemed to meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be
recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the
financial statements as of December 31, 2017 or 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets
may not be recoverable. An impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&rsquo;s
carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets
in relation to the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal
to the excess of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value
of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2017, 2016 and 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share-based
Payments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors
as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based
award. The fair value of each option grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing
model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards,
which is generally the vesting period. Stock options granted to non-employee consultants are revalued at the end of each reporting
period until vested using the Black-Scholes option-pricing model and the changes in their fair value are recorded as adjustments
to expense over the related vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 30, 2016, the FASB issued ASU No. 2016-09, <I>Compensation&mdash;Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting </I>(&ldquo;ASU 2016-09&rdquo;)<I>. </I>ASU 2016-09 simplifies several aspects of the accounting
for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding
requirements, as well as classification in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU
2016-09 it did not elect to account for forfeitures as they occur but rather to continue to estimate forfeitures at grant date.
As a result, the adoption of ASU 2016-09 did not have an impact on the Company&rsquo;s consolidated financial statements. ASU
2016-09 also removed the requirement to recognize the excess tax benefits in respect of share based payments only when realized
(See Note 9).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss Per Common Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share of the Company&rsquo;s common stock has been computed by dividing net loss by the weighted average
number of shares outstanding during the period. For years in which there is a net loss, options and warrants are anti-dilutive
and therefore excluded from diluted loss per share calculations. The following table sets forth the computation of basic and diluted
earnings per share for the years ended December 31, 2017, 2016 and 2015:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted net loss per share of common stock:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,421,612</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,998,675</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 11%; text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,850,739</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average shares of common stock outstanding</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,176,953</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,137,518</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,350,145</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share of common stock-basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.65</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.49</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.28</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the following potentially dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded
from the computation of dilutive weighted average shares outstanding as the inclusion would be antidilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,288,500</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,288,500</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,969,250</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,844,966</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,610,179</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,982,065</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,133,466</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,898,679</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,951,315</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue
Recognition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued guidance codified in <I>Accounting Standards Codification (ASC) 606, Revenue Recognition &mdash; Revenue
from Contracts with Customers</I> (&ldquo;ASC 606&rdquo;) which amends the guidance in former <I>ASC 605, Revenue Recognition</I>,
and is effective for public companies for annual and interim periods beginning after December 15, 2017. Specifically, the new
standard differs from the current accounting standard in many respects, such as in the accounting for variable consideration received,
including milestone payments or contingent payments. Under the Company&rsquo;s accounting policy prior to the adoption of ASC
606 in the first quarter of 2018, milestone payments were initially recognized only in the period that the payment-triggering
event occurred or was achieved (See Note 8). ASC 606, however, may require a company to recognize such payments before the payment-triggering
event is completely achieved based on the Company&rsquo;s estimate of the amount of consideration to which it will be entitled
in exchange for transferring the services, subject to management&rsquo;s assessment of whether it is probable that a significant
reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration
is subsequently resolved. The Company adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according
to which the cumulative effect of initially applying ASC 606 is recognized at the date of initial application. Since the Company
has concluded its performance obligations and has completed recognizing revenue under the agreement with CFFT in the third quarter
of 2017 (See Note 8), there was no cumulative effect to record at the date of the Company&rsquo;s adoption of ASC 606. The Company
will assess any new agreements it enters into, including the 2018 CFF Award, (See Note 15) under ASC 606, including if such agreements
fall under the scope of such standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accounting
for Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU No<B>. </B>2016-02, <I>Leases (Topic 842) </I>(&ldquo;ASU 2016-02&rdquo;)<I>. </I>Under ASU
2016-02, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months.
Consistent with current GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by
a lessee primarily will depend on its classification as a finance or operating lease. However, unlike current GAAP, which requires
only capital leases to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the
balance sheet. ASU 2016-02 will take effect for fiscal years, and interim periods within those fiscal years, beginning after December
15, 2018, with early application permitted. The adoption of ASU 2016-02 will have an impact on the Company&rsquo;s financial position
as the Company has operating lease commitments for office space as of December 31, 2017 with future non-cancelable lease payments
amounting to $5,474,623 (see Note 5) for which ASU 2016-02 would apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTY
    AND EQUIPMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and Equipment consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    hardware and software</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,522</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,131</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and equipment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">287,048</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,138</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,244</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,219</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction
    in progress</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,181,730</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, gross</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,796,544</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">543,488</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    accumulated depreciation</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(363,889</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(108,237</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,432,655</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,251</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was approximately $256,000, $88,000 and $44,000 for the years ended December 31, 2017, 2016 and 2015, respectively. At
December 31, 2017, construction in progress consisted of purchased property and equipment not placed in service until the Company&rsquo;s
relocation into 32,733 square feet of office space in February 2018 (See Note 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2015, the Company entered into a lease agreement for a copier machine. The cost of the machine was approximately
$12,000 and is included in office furniture and equipment category in the table above. The lease payments commenced when the machine
was placed in service in January 2016. The machine is being amortized over the life of the lease, which is for a three-year term
and includes a bargain purchase option at the end of the term. See Note 5 for details of this capital lease commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS
    AND CONTINGENCIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Lease Commitment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, the Company amended its commercial lease for office space to expand into an additional 4,088 square feet of office
space within the same building for an aggregate total of 10,414 square feet of leased office space (&ldquo;September 2016 Amendment&rdquo;).
The Company began occupying this space in early November 2016 and the final lease payment was to be due in January 2021. The September
2016 Amendment required an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was
terminated upon the commencement date of the August 2017 Lease Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2017, the Company entered into a lease agreement (&ldquo;August 2017 Lease Agreement&rdquo;) with the same landlord,
pursuant to which the Company agreed to lease 32,733 square feet of office space (&ldquo;Leased Premises&rdquo;). The initial
term of the August 2017 Lease Agreement is for a period of seven years which began with the Company&rsquo;s occupancy of the Leased
Premises in February 2018. The base rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately
$908,000 for the seventh year. Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company
for $1,080,189 of leasehold improvements. The reimbursements have been deferred and will be recognized as a reduction of rent
expense over the term of the lease. Additionally, the August 2017 Lease Agreement required a standby irrevocable letter of credit
of $400,000, which may be reduced, if the Company is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000
on the third and fourth anniversary of the commencement date, respectively, The Company entered into an unsecured letter of credit
for $400,000 in connection with the August 2017 Lease Agreement for which it incurred interest expense of $9,743 in year ended
December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the
difference between the rents paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and
deferred rent, noncurrent in the Company&rsquo;s balance sheet as of December 31, 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Company&rsquo;s non-cancelable lease agreements in effect at December 31, 2017, the future minimum rent commitments
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 81%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,333</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">623,958</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">784,243</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">830,600</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">855,150</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,935,339</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,474,623</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
rent expense for the years ended December 31, 2017, 2016 and 2015 was $356,547, $229,705 and $55,496, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
Lease Commitment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease payments commenced when the machine was placed in service in January 2016. The lease is for a three-year term and includes
a bargain purchase option at the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current
portion of this capital lease obligation is classified in accrued expenses and the long-term portion of the capital lease obligation
is classified in other long-term liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital
lease commitments are as follows as of December 31, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 81%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,543</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">379</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    future minimum lease payments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,922</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(291</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    capital lease obligations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,631</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,256</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    portion</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for this capital lease obligation for the years ended December 31, 2017, 2016 and 2015 was $712, $1,286 and $0, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
commitments under the Company&rsquo;s development award agreements- see Note 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
    PAYABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2015, the Company entered into a loan agreement with a financing company for $207,750 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulated equal monthly payments of principal and interest payments of $23,397 over
a nine month period. Interest on this loan was accrued at an annual rate of 3.25%. This loan was fully repaid in July 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2016, the Company entered into a loan agreement with a financing company for $348,750 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over
a nine-month period. Interest on this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2017, the Company entered into a loan agreement with a financing company for $415,265 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over
a ten-month period. Interest accrues on this loan at an annual rate of 2.35%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2017 and 2016 included $368,976 and $378,750, respectively, related to these
insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for notes payable for the years ended December 31, 2017, 2016 and 2015 totaled $3,632, $3,115 and $2,440, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCRUED
    EXPENSES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    clinical operations and trials costs</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,003,799</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,647,490</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    product development costs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,255,439</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">713,426</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,335,672</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">778,250</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    other</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">146,609</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117,289</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,741,519</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,256,455</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEVELOPMENT
    AWARD AND DEFERRED REVENUE </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2015, the Company entered into an award agreement (the &ldquo;2015 CFFT Award Agreement &ldquo;) with the CFFT pursuant
to which it received a development award (the &ldquo;2015 CFFT Award&rdquo;) for up to $5 million in funding. The funding from
the 2015 CFFT Award supported a first-in-patient Phase 2 clinical trial of the Company&rsquo;s oral anti-inflammatory drug lenabasum
in adults with cystic fibrosis (&ldquo;CF&rdquo;). The Company has received $5.0 million in payments since the inception of the
2015 CFFT Award as outlined below. The payments received under the 2015 CFFT Award were recorded as deferred revenue when the
triggering event to receive those amounts had occurred and were amortized on a straight-line basis over the expected duration
of the remaining performance period under the 2015 CFFT Award which concluded in the third quarter of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the execution of the 2015 CFFT Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the
Company received a second payment of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016,
the Company received a third payment from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related
to dosing the median clinical trial patient. In January 2017, the Company received a fourth payment from the CFFT in the amount
of $1,000,000 for achieving a milestone in December 2016 related to completing the final visit for the final patient, which was
billed by the Company to CFFT in December 2016 and was classified in grants receivable as of December 31, 2016. The Company received
the final payment from CFFT in the amount of $500,000 in November 2017 for achieving the final milestone in September 2017 related
to the issuance to CFFT of the final integrated statistical report for to the Phase 2 CF clinical trial. At that time the Company
had completed all its performance obligations under the contract and therefore the performance period had concluded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the 2015 CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization
of lenabasum in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five
times the amount the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments
following the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale
of lenabasum, (ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up
to $5 million, due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed
$500 million, and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses
lenabasum in the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change
of control transaction, with such payment(s) to be credited against the royalty payments due upon commercialization. The Field
of Use is defined in the 2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD
hypersensitivity pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company
may terminate the agreement for cause, which includes the Company&rsquo;s material failure to achieve certain commercialization
and development milestones. The Company&rsquo;s payment obligations, if any, would survive the termination of the 2015 CFFT Award
Agreement. For the years ended December 31, 2017, 2016 and 2015, in respect of the 2015 CFFT Award Agreement, the Company recognized
revenue of $2,440,195, $1,911,424 and $648,382, respectively. Deferred revenue consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,940,195</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,940,195</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long
    term portion</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 15 for the Investment Agreement entered into by the Company after the balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCOME
    TAXES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 24.5pt; text-align: justify">No provision or benefit for federal or state income
taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company has provided
a full valuation allowance against its deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">At December&nbsp;31, 2017 and 2016,
the Company had federal net operating loss carryforwards of approximately $56,536,000 and $28,644,000, respectively, of which
federal carryforwards will expire in varying amounts beginning in 2029. At December&nbsp;31, 2017 and 2016, the Company had Massachusetts
net operating loss carryforwards of approximately $53,110,000 and $26,573,000, respectively. In the first quarter of 2017,
the Company adopted ASU 2016-09, which removed the requirement to recognize the deferred tax assets on excess tax benefits in
respect of share based payments only when realized. As such, during the year ended December 31, 2017, the Company&rsquo;s gross
deferred tax assets and corresponding valuation allowance each included a one-time increase in respect of an additional federal
and state net operating losses of $1,432,000. The adoption of ASU 2016-09 did not have an impact on the Company&rsquo;s balance
sheet, results of operations, cash flows or statement of stockholders&rsquo; equity because the Company has a full valuation allowance
on its deferred tax assets. Utilization of net operating losses may be subject to substantial annual limitations due to the &ldquo;change
in ownership&rdquo; provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in
the expiration of net operating losses before utilization. The Company has not yet conducted a study to determine if any such
changes have occurred that could limit the Company&rsquo;s ability to use the net operating losses and tax credit carryforwards.
The Company also had research and development tax credit carryforwards at December&nbsp;31, 2017 and 2016 of approximately
$1,283,000 and $736,000, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&rsquo;s net deferred tax asset are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOL
    carryforward</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,229,127</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,860,828</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,213,347</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,690</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,724,248</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,177,650</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,654</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">302,943</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    temporary differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,292</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,214</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subtotal</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,328,668</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,240,325</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,328,668</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,240,325</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax asset</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has maintained a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance
is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be
realized. Since the Company cannot determine that it is more likely than not that it will generate taxable income, and thereby
realize the net deferred tax assets, a full valuation allowance has been provided. The valuation allowance increased by $5,088,343
and $7,860,985 in 2017 and 2016, respectively, due to the increase in deferred tax assets, primarily due to net operating loss
carryforwards. The Company has no uncertain tax positions at December 31, 2017 and 2016 that would affect its effective tax rate.
Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations
by tax authorities for all years for which a loss carryforward is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax benefits computed using the federal statutory income tax rate differs from the Company&rsquo;s effective tax rate primarily
due to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    provision at statutory rate</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.00</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.00</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.00</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    taxes, net of federal benefit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.66</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.76</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.76</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-2.05</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0.65</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0.62</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.59</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.67</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax rate change</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-24.11</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.60</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0.13</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in valuation reserve</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-15.69</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-39.31</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-40.85</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Tax Cut and Jobs Act of 2017</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the Tax Cut and Jobs Act (the &ldquo;Tax Act&rdquo;) was enacted into law. The Tax Act, among other things,
contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of
35% to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain
small businesses); limitation of the deduction of net operating losses generated in tax years beginning after December 31, 2017
to 80% of taxable income, indefinite carryforward of net operating losses generated in tax years after 2018 and elimination of
net operating loss carrybacks; changes in the treatment of offshore earnings regardless of whether they are repatriated; current
inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations, mandatory capitalization of research
and development expenses beginning in 2022; immediate deductions for certain new investments instead of deductions for depreciation
expense over time; further deduction limits on executive compensation; and modifying, repealing and creating many other business
deductions and credits, including the reduction in the orphan drug credit from 50% to 25% of qualifying expenditures. As of December
31, 2017, we have made a reasonable estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures
by reducing our net federal and state deferred tax assets by $7,815,832 for the reduction in corporate tax rate. This adjustment
to our deferred tax assets is offset against the valuation allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Additionally, the SEC staff
has issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond one year of the
enactment date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&ldquo;SAB 118&rdquo;) was issued to address the application
of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including
computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. Because the Company is
still in the process of analyzing certain provisions of the Tax Act, the Company has determined that the adjustment to its deferred
taxes was a provisional amount as permitted under SAB 118.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
    STOCK </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized 150,000,000 shares of common stock, $0.0001 par value per share, of which 55,603,427 shares, 44,681,745
shares, and 37,605,134 shares were issued and outstanding as of December 31, 2017, 2016, and 2015, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2015, the Company issued 11,666,802 shares of common stock upon the exercise of warrants and stock
options to purchase common stock and the Company received net proceeds of $10,819,714 from these exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Company completed a sale of shares of its common stock pursuant to the terms of a securities purchase agreement
under which the Company sold an aggregate of 5,960,000 shares of its common stock in a registered direct offering to investors
at a purchase price of $2.50 per share with gross proceeds to the Company totaling approximately $14,900,000 less issuance costs
of $25,222. On February 28, 2017, the Company entered in a securities purchase agreement providing for the issuance and sale by
the Company of 3,887,815 shares of its common stock in a registered direct offering to institutional and accredited investors
at a purchase price of $7.00 per share with gross proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company entered into a sales agreement with Cantor Fitzgerald under which the Company could direct Cantor Fitzgerald
as its sales agent to sell common stock under an &ldquo;At the Market Offering&rdquo; (&ldquo;Sales Agreement&rdquo;). Sales of
common stock under the Sales Agreement were made pursuant to an effective registration statement for an aggregate offering of
up to $35 million. Under the Sales Agreement, the Company was obligated to pay Cantor a 3% commission on gross proceeds. In 2016,
the Company sold 188,695 shares of our common stock under the Sales Agreement at an average selling price of approximately $8.54
per share (net of 3% commission paid to Cantor Fitzgerald) which resulted in proceeds of approximately $1,621,182 and net proceeds
of approximately $1,426,145 net of incurred issuance costs. Approximately $330,413 of these proceeds were classified in stock
subscriptions receivable as of December 31, 2016 because the Company did not receive these proceeds until January 2017. During
the year ended December 31, 2017, in the first quarter, the Company sold 1,413,633 shares of its common stock under the Sales
Agreement at an average selling price of approximately $9.71 per share for gross proceeds of $13,724,591 and net proceeds of $13,268,208.
The Company did not sell any shares of its common stock under the Sales Agreement in the second or third quarter of 2017 and terminated
the Sales Agreement in connection with the October 2017 Offering discussed below. The aggregate amount sold under the Sales Agreement
as described above was approximately $15.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 15 for the January 2018 Sales Agreement entered into by the Company and Cantor Fitzgerald after the balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2017, the Company consummated an underwritten public offering of shares of its common stock pursuant to which the
Company sold an aggregate of 4,650,000 shares of its common stock to institutional investors at a purchase price of $7.00 per
share with gross proceeds to the Company totaling $32,550,000, less estimated issuance costs incurred of approximately $2,184,000.
The Company also granted the underwriters a 30-day option to purchase up to an additional 697,500 shares of common stock on the
same terms as the underwriters were purchasing the base number of shares, which they exercised in November 2017 with net proceeds
to us totaling $4,589,550.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2017, the Company issued 272,734 shares of common stock upon the exercise of stock options and warrants
to purchase common stock and the Company received net proceeds of $189,490 from these exercises. During the year ended December
31, 2016, the Company issued 927,916 shares of common stock upon the exercise of stock options and warrants to purchase common
stock and the Company received net proceeds of $468,442 from these exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCK
    OPTIONS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the Company adopted the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &ldquo;2014 Plan&rdquo;).
Pursuant to the 2014 Plan, the Company&rsquo;s Board of Directors may grant incentive and nonqualified stock options and restricted
stock to employees, officers, directors, consultants and advisors. On January 1, 2017, pursuant to an annual evergreen provision
contained in the 2014 Plan, the number of shares reserved for future grants was increased by 3,127,722 shares. As of December
31, 2017, there was a total of 13,043,739 shares reserved for issuance under the 2014 Plan and there were 4,460,334 shares available
for future grants. Options issued under the 2014 Plan  generally vest over 4 years from the date of grant in multiple tranches
and are exercisable for up to 10 years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an annual evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under
the 2014 Plan shall automatically increase on January 1 of each year by at least seven percent (7%) of the total number of shares
of common stock outstanding on December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any
year, the Board of Directors may determine that such increase will provide for a lesser number of shares. In accordance with the
terms of the 2014 Plan, effective as of January 1, 2018, the number of shares of common stock available for issuance under the
2014 Plan increased by 2,500,000 shares, which was less than seven percent (7%) of the outstanding shares of common stock on December
31, 2017. As of January 1, 2018, the 2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares available
for future grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share-based
Compensation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued and outstanding for the years ended December 31, 2017, 2016 and 2015, the Company recorded non-cash, stock-based
compensation expense of $5,694,489 ($4,640,646 for employees and $1,053,843 for non-employees), $3,163,534 ($2,104,939 for employees
and $1,058,595 for non-employees) and $1,153,302 ($672,071 for employees and $481,231 for non-employees), respectively, net of
estimated forfeitures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award for employees is estimated on the date of grant and for non-employees is estimated at the end
of each reporting period using the Black-Scholes option pricing model that uses the assumptions noted in the following table.
Due to its limited operating history, the Company estimated its volatility in consideration of a number of factors, including
the volatility of comparable public companies and, commencing in 2015, the Company also included the volatility of its own common
stock, taking into account the expected life of the option. The Company uses historical data, as well as subsequent events occurring
prior to the issuance of the financial statements, to estimate option exercises and employee terminations in order to estimate
its forfeiture rate. The expected term of options granted under the 2014 Plan, all of which qualify as &ldquo;plain vanilla&rdquo;
per SEC Staff Accounting Bulletin 107, is based on the average between the vesting period and the contractual life of the options
which is 6.25 years. For non-employee options, the expected term is the contractual term. The risk-free rate is based on the yield
of a U.S. Treasury security with a term consistent with the option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average assumptions used principally in determining the fair value of options granted to employees were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 55%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free interest rate</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.70</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term in years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.66</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.73</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86.01</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.39</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.68</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    forfeiture rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.83</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2017, the assumptions used in determining the fair value of options granted to nonemployees included
risk free interest rate ranging from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years,
expected volatility ranging from 85.58% to 89.58%, and estimated forfeiture rate of 5%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of option activity for years ended December 31, 2017 and 2016 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR><FONT STYLE="font-size: 10pt">Average </FONT><BR><FONT STYLE="font-size: 10pt">Exercise
    </FONT><BR><FONT STYLE="font-size: 10pt">Price</FONT></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR><FONT STYLE="font-size: 10pt">Average </FONT><BR><FONT STYLE="font-size: 10pt">Remaining
    </FONT><BR><FONT STYLE="font-size: 10pt">Contractual </FONT><BR><FONT STYLE="font-size: 10pt">Term in </FONT><BR><FONT STYLE="font-size: 10pt">Years</FONT></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR><FONT STYLE="font-size: 10pt">Value</FONT></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2015</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,982,065</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,020,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.42</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(326,886</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,610,179</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.54</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,681,500</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.28</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(272,734</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,979</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.53</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,844,966</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.75</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.72</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,433,877</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    at December 31, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,514,977</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.98</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.02</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,444,225</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was $6.22, $3.81
and $1.41 per share, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2017,
2016 and 2015 was approximately $2,092,964. $1,004,321 and $152,531, respectively. As of December 31, 2017 there was approximately
$12,542,918 of total unrecognized compensation expense, related to non-vested share-based compensation arrangements. The unrecognized
compensation expense is estimated to be recognized over a period of 2.87 years at December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
summary of non-vested stock options for the years ended December 31, 2017 and 2016 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR><FONT STYLE="font-size: 10pt">Average </FONT><BR><FONT STYLE="font-size: 10pt">Fair
    </FONT><BR><FONT STYLE="font-size: 10pt">Value</FONT></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested
    at December 31, 2015</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,035,254</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.85</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,020,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.69</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,194,600</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34,380</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonvested
    at December 31, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,826,274</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.86</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,681,500</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.22</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,003,806</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.60</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,979</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.03</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested
    at December 31, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,329,989</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.61</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANTS
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2017, there were warrants outstanding to purchase 1,288,500 shares of common stock with a weighted average exercise
price of $1.00 and a weighted average remaining life of 1.41 years. No warrants were exercised during the year ended December
31, 2017. During the year ended December 31, 2016, warrants to purchase 679,500 shares of common stock were exercised on a cashless
basis resulting in the issuance of 599,780 shares and 1,250 shares of common stock were exercised on a for cash basis. There were
no warrants issued or cancelled during the year ended December 31, 2017 or 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrant issued to CFF after the balance sheet date &ndash; see Note 15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    PARTY TRANSACTIONS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2016, the Company entered into a consulting agreement (the &ldquo;2016 Consulting Agreement&rdquo;) with Orchestra
Medical Ventures, LLC (&ldquo;Orchestra&rdquo;), of which a member of the Company&rsquo;s Board of Directors, David Hochman, is
Managing Partner. Under this agreement, Orchestra rendered a variety of consulting and advisory services relating principally
to identifying and evaluating strategic relationships, licensing opportunities, and business strategies. The term of the 2016
Consulting Agreement commenced on September 20, 2016 and expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting
Agreement, the Company paid to Orchestra cash compensation in an aggregate amount of $100,000. In connection with this agreement,
the Company granted an equity incentive award to Mr. Hochman consisting of options to purchase 50,000 shares (&ldquo;Option Shares&rdquo;)
of common stock (the &ldquo;Option Award&rdquo;) pursuant to the Company&rsquo;s 2014 Equity Compensation Plan, of which fifty
percent (50%) vested on the three (3) month anniversary of the date of grant of the Option Award and the remainder of the Option
Shares vested on the six (6) month anniversary of the date of grant of the Option Award. The Option Shares were granted with an
exercise price of $7.14 per share. The Company recorded stock-based compensation expense of approximately $222,000 during the
year ended December 31, 2016 and $171,000 during the first quarter of 2017 in respect of the Option Award. No stock-based compensation
expense was recorded after the first quarter of 2017 related to the Option Shares as they were fully vested in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY
    FINANCIAL INFORMATION (UNAUDITED)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarters
    Ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2017</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                                                                                                           30, 2017</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
                                                                                                                           30, 2017</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2017</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 26%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    from awards</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,293,697</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,186</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">796,312</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,366,112</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,763,660</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,622,511</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,286,682</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,380,125</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,878,090</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,130,587</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,575,244</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,746,237</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,641,750</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,753,098</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,861,926</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,452,540</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,291,564</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,956,786</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,861,926</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income (expense), net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,366</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,271</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,402</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,073</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency exchange gain (loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,265</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,594</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,212</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,163</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense), net</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,899</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,323</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,810</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">168,236</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,465,439</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,296,887</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,965,596</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,693,690</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.16</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.14</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.20</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,381,482</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,193,726</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,221,597</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,828,680</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarters
    Ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2016</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                         30, 2016</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
                                         30, 2016</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2016</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 26%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
    from awards</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,598</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,598</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">742,558</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">375,670</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,173,933</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,567,003</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,315,632</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,380,167</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,109,889</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,021,225</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,760,696</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,567,937</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,283,822</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,588,228</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,076,328</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,948,104</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,887,224</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,191,630</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,333,770</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,572,434</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income (expense), net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,360</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,049</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,731</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency exchange gain (loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">343</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,810</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,729</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,102</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense), net</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,017</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,239</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,998</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,159</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,892,241</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,189,391</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,346,768</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,570,275</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.08</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.11</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.12</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.17</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,605,210</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,748,452</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,783,504</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,348,543</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
    EVENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Evergreen
Provision</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an annual evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under
the 2014 Plan shall automatically increase on January 1 of each year by at least seven percent (7%) of the total number of shares
of common stock outstanding on December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any
year, the Board of Directors may determine that such increase will provide for a lesser number of shares. In accordance with the
terms of the 2014 Plan, effective as of January 1, 2018, the number of shares of common stock available for issuance under the
2014 Plan increased by 2,500,000 shares, such amount being less than seven percent (7%) of the outstanding shares of common stock
on December 31, 2017. As of January 1, 2018, the 2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares
available for future grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>At
the Market Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, the Company entered into a sales agreement with Cantor Fitzgerald under which the Company may direct Cantor Fitzgerald
as its sales agent to sell common stock up to an aggregate offering of up to $50 million under an &ldquo;At the Market Offering&rdquo;
(&ldquo;January 2018 Sales Agreement&rdquo;). Sales of common stock under the January 2018 Sales Agreement were made pursuant
to an effective registration statement for an aggregate offering of up to $50 million. In February 2018, the Company sold 1,500,000
shares of its common stock to an institutional investor under the January 2018 Sales Agreement for which it received net proceeds
of $11,349,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cystic
Fibrosis Program Related Investment Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 26, 2018, the Company
entered into the Cystic Fibrosis Program Related Investment Agreement with the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;)
(&ldquo;Investment Agreement&rdquo;), a non-profit drug discovery and development corporation, pursuant to which the Company received
an award for up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical Trial (the &ldquo;Phase
2b Clinical Trial&rdquo;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25 million to
date. The Company expects that the remainder of the 2018 CFF Award will be paid incrementally upon the Company&rsquo;s achievement
of the remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty
payment of one and one-half times the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of
approval of lenabasum in the United States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award
upon approval in another major market, as set forth in the Investment Agreement (the &ldquo;Approval Royalty&rdquo;). At the Company&rsquo;s
election, the Company may satisfy the first of the two Approval Royalties in registered shares of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company is obligated to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within
sixty days after any quarter in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty
payments to CFF of one percent of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days
after any quarter in which such net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and
its stockholders receive in connection with the license, sale, or other transfer to a third party of lenabasum, if indicated for
the treatment or prevention of CF, or a change of control transaction, except that such payment shall not exceed five times the
amount of the 2018 CFF Award, with such payments to be credited against any other net sales royalty payments due. Either CFF or
the Company may terminate the Investment Agreement for cause, which includes the Company&rsquo;s material failure to achieve certain
commercialization and development milestones. The Company&rsquo;s payment obligations survive the termination of the Investment
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of
the Company&rsquo;s common stock (the &ldquo;CFF Warrant&rdquo;). The CFF Warrant is exercisable at a price equal to $13.20 per
share and is immediately exercisable for 500,000 shares of the Company&rsquo;s common stock. Upon completion of the final milestone
set forth in the Investment Agreement and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement,
the CFF Warrant will be exercisable for the remaining 500,000 shares of the Company&rsquo;s common stock. The CFF Warrant expires
on January 26, 2025. Any shares of the Company&rsquo;s common stock issued upon exercise of the CFF Warrant will be unregistered
and subject to a one-year lock-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>ex4-8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
4.8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Certificate No. F-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES
NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT
THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS
AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO
THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Date: January 26, 2018</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Void
    After: January 26, 2025</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANT
TO PURCHASE COMMON STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B>, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), for value received on January 26,
2018 (the &ldquo;<B>Effective Date</B>&rdquo;), hereby issues to The Cystic Fibrosis Foundation (the &ldquo;<B>Holder</B>&rdquo;)
this warrant (the &ldquo;<B>Warrant</B>&rdquo;) to purchase, 1,000,000 shares (each such share as from time to time adjusted as
hereinafter provided being a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares being the &ldquo;<B>Warrant Shares</B>&rdquo;)
of the Company&rsquo;s Common Stock (as defined below), at the Exercise Price (as defined below), as adjusted from time to time
as provided herein, on or before January 26, 2025 (the &ldquo;<B>Expiration Date</B>&rdquo;), all subject to the following terms
and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Warrant, (i) &ldquo;<B>Business Day</B>&rdquo; means any day other than Saturday, Sunday or any other day on which
commercial banks in the City of New York, New York, are authorized or required by law or executive order to close; (ii) &ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company, par value $0.0001 per share, including any securities issued or issuable
with respect thereto or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend,
stock split, stock combination, recapitalization, reclassification, reorganization or other similar event; (iii) &ldquo;<B>Exercise
Price</B>&rdquo; means $13.20 per share of Common Stock, subject to adjustment as provided herein; (iv) &ldquo;<B>Trading Day</B>&rdquo;
means any day on which the Common Stock is traded (or available for trading) on its principal Trading Market (as defined below);
and (v) &ldquo;<B>Affiliate</B>&rdquo; means any person that, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with, a person, as such terms are used and construed in Rule 144 promulgated under
the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;). For purposes hereof, &ldquo;<B>Trading Market</B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market,
or any other national securities exchange, as well as the OTC Bulletin Board or any tier of the OTC Markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
DURATION AND EXERCISE OF WARRANTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Exercise Period</U>. Commencing on the Effective Date of this Warrant, the Holder may exercise this Warrant for up to 500,000
shares of Common Stock (the &ldquo;<B>Initial Exercise Amount</B>&rdquo;). Upon the Completion of the CF Trial (as defined below),
the Holder may exercise this Warrant for the remaining 500,000 shares of Common Stock (the &ldquo;<B>Additional Exercise Amount</B>&rdquo;)
issuable pursuant to the terms of this Warrant. At no point in time, may the Holder exercise this Warrant for more than 1,000,000
shares of Common Stock in the aggregate. The Holder may exercise this Warrant, in whole or in part (in accordance with the limitations
set forth in this Section 1(a)), on any Business Day on or before 5:00 P.M., Eastern Time, on the Expiration Date, at which time
this Warrant shall become void and of no value. For purposes of this Warrant, the term &ldquo;<B>Completion of the CF Trial&rdquo;
</B>shall mean completion of the final Milestone by the Company and receipt of the final Milestone Payment by the Company from
Cystic Fibrosis Foundation as set forth in Exhibit B to the Cystic Fibrosis Program Related Investment Agreement by and between
Corbus Pharmaceuticals, Inc. and Cystic Fibrosis Foundation dated January 26, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Exercise Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
While this Warrant remains outstanding and exercisable in accordance with Section 1(a) , the Holder may exercise this Warrant
in whole or in part at any time and from time to time by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
delivery to the Company of a duly executed copy of the Notice of Exercise attached as <B>Exhibit A</B>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
surrender of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company
may specify in writing to the Holder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
payment of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise
of the Warrant (such amount, the &ldquo;<B>Aggregate Exercise Price</B>&rdquo;) made in the form of cash, or by certified check,
bank draft or money order payable in lawful money of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Upon the exercise of this Warrant in compliance with the provisions of Section 1(a) and this Section 1(b), the Company shall promptly
issue and cause to be delivered to the Holder a certificate for the Warrant Shares purchased by the Holder. Each exercise of this
Warrant shall be effective immediately prior to the close of business on the date (the &ldquo;<B>Date of Exercise</B>&rdquo;)
that the conditions set forth in this Section 1(b) have been satisfied, as the case may be. On the first Business Day following
the date on which the Company has received each of the Notice of Exercise and the Aggregate Exercise Price (the &ldquo;<B>Exercise
Delivery Documents</B>&rdquo;), the Company shall transmit an acknowledgment of receipt of the Exercise Delivery Documents to
the Company&rsquo;s transfer agent (the &ldquo;<B>Transfer Agent</B>&rdquo;). On or before the second Business Day following the
date on which the Company has received all of the Exercise Delivery Documents (the &ldquo;<B>Share Delivery Date</B>&rdquo;),
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)
Fast Automated Securities Transfer Program, upon the request of the Holder, credit such aggregate number of shares of Common Stock
to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC
through its Deposit Withdrawal Agent Commission system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated
Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Notice of Exercise, a
certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Partial Exercise</U>. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the
number of Warrant Shares referenced by this Warrant for which the Warrant is then currently exercisable. If this Warrant is submitted
in connection with any exercise pursuant to Section 1 and the number of Warrant Shares represented by this Warrant submitted for
exercise is greater than the actual number of Warrant Shares being acquired upon such an exercise, then the Company shall as soon
as practicable after any exercise and at its own expense, issue a new Warrant of like tenor representing the right to purchase
the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Disputes</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute
in accordance with Section 16.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
ISSUANCE OF WARRANT SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record
holder of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner thereof for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company will not, by amendment of its certificate of incorporation, by-laws or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist
in the carrying out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to
protect the rights of the Holder to exercise this Warrant, or against impairment of such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
ADJUSTMENTS OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from
time to time upon the occurrence of certain events described in this Section 3; <U>provided</U>, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less
all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into
shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment,
the Company shall use its commercially reasonable efforts to obtain the necessary stockholder consent to increase the authorized
number of shares of Common Stock to make such an adjustment pursuant to this Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Subdivision or Combination of Stock</U>. In case the Company shall at any time subdivide (whether by way of stock dividend,
stock split or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced and the number of Warrant Shares, the Initial Exercise
Amount and the Additional Exercise Amount shall be proportionately increased, and conversely, in case the outstanding shares of
Common Stock of the Company shall be combined (whether by way of stock combination, reverse stock split or otherwise) into a smaller
number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased and the
number of Warrant Shares, the Initial Exercise Amount and the Additional Exercise Amount shall be proportionately decreased. The
Exercise Price, the Warrant Shares, the Initial Exercise Amount and the Additional Exercise Amount, as so adjusted, shall be readjusted
in the same manner upon the happening of any successive event or events described in this Section 3(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Dividends in Stock, Property, Reclassification</U>. If at any time, or from time to time, all of the holders of Common Stock
(or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become
entitled to receive, without payment therefore:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
any shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common
Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other
distribution, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
additional stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination
of shares or similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect
of which shall be covered by the terms of Section 3(a)(i) above), then and in each such case, the Exercise Price and the number
of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted proportionately, and the Holder hereof shall,
upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon,
and without payment of any additional consideration therefor, the amount of stock and other securities and property (including
cash in the cases referred to above) that such Holder would hold on the date of such exercise had such Holder been the holder
of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares
or all other additional stock and other securities and property. The Exercise Price and the Warrant Shares, as so adjusted, shall
be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii)<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<U>Reorganization, Reclassification, Consolidation, Merger or Sale</U>. If any recapitalization, reclassification or reorganization
of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all
or substantially all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be
entitled to receive stock, securities, or other assets or property (an &ldquo;<B>Organic Change</B>&rdquo;), then, as a condition
of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter
have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable
and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal
to the number of shares of such stock immediately theretofore purchasable and receivable assuming the full exercise of the rights
represented by this Warrant. In the event of any Organic Change, appropriate provision shall be made by the Company with respect
to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provisions for
adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this Warrant) shall
thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof.
The Company will not affect any such consolidation, merger or sale unless, prior to the consummation thereof, the successor corporation
(if other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall assume
by written instrument reasonably satisfactory in form and substance to the Holder executed and mailed or delivered to the registered
Holder hereof at the last address of such Holder appearing on the books of the Company, the obligation to deliver to such Holder
such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase.
If there is an Organic Change, then the Company shall cause to be mailed to the Holder at its last address as it shall appear
on the books and records of the Company, at least 10 calendar days before the effective date of the Organic Change, a notice stating
the date on which such Organic Change is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares for securities, cash, or other property delivered upon
such Organic Change; provided, that the failure to mail such notice or any defect therein or in the mailing thereof shall not
affect the validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise this Warrant
during the 10-day period for the amount of shares of Common Stock for which this Warrant is then currently exercisable commencing
on the date of such notice to the effective date of the event triggering such notice. In any event, the successor corporation
(if other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall be deemed
to assume such obligation to deliver to such Holder such shares of stock, securities or assets even in the absence of a written
instrument assuming such obligation to the extent such assumption occurs by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company
at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each
Holder a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting
forth: (i) such adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at
the time would be received upon the exercise of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Certain Events</U>. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but
the lack of any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the
basic intent and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the
Holder under this Warrant in accordance with the basic intent and principles of such provisions, then the Company&rsquo;s Board
of Directors will, in good faith, make an appropriate adjustment to protect the rights of the Holder; <U>provided</U>, that no
such adjustment pursuant to this Section 3(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
RESERVED</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
TRANSFERS AND EXCHANGES OF WARRANT AND WARRANT SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration of Transfers and Exchanges</U>. Subject to Section 5(c), upon the Holder&rsquo;s surrender of this Warrant, with
a duly executed copy of the Form of Assignment attached as <B>Exhibit B</B>, to the Secretary of the Company at its principal
offices or at such other office or agency as the Company may specify in writing to the Holder, the Company shall register the
transfer of all or any portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in
substantially the form of this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in
similar form, evidencing the remaining acquisition rights not transferred, to the Holder requesting the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Warrant Exchangeable for Different Denominations</U>. The Holder may exchange this Warrant for a new Warrant or Warrants, in
substantially the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares which may
then be purchased hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase
such number of Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed
instructions regarding such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Restrictions on Transfers</U>. This Warrant may not be transferred at any time without: (i) registration under the Securities
Act; or (ii) an exemption from such registration and a written opinion of legal counsel addressed to the Company that the proposed
transfer of the Warrant may be effected without registration under the Securities Act, which opinion will be in form and from
counsel reasonably satisfactory to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Permitted Transfers and Assignments</U>. Notwithstanding any provision to the contrary in this Section 5, the Holder may transfer,
with or without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder&rsquo;s Affiliates
without obtaining the opinion from counsel that may be required by Section 5(c)(ii), <U>provided,</U> that the Holder delivers
to the Company and its counsel certification, documentation, and other assurances reasonably required by the Company&rsquo;s counsel
to enable the Company&rsquo;s counsel to render an opinion to the Company&rsquo;s Transfer Agent that such transfer does not violate
applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
MUTILATED OR MISSING WARRANT CERTIFICATE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Warrant is mutilated, lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in
exchange for and upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new
Warrant, in substantially the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares;
<U>provided</U>, that, as a prerequisite to the issuance of a substitute Warrant, the Company may require satisfactory evidence
of loss, theft or destruction as well as an indemnity from the Holder of a lost, stolen or destroyed Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
PAYMENT OF TAXES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay all transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant
and the Warrant Shares (and replacement Warrants) including, without limitation, all documentary and stamp taxes; <U>provided</U>,
<U>however</U>, that the Company shall not be required to pay any tax in respect of the transfer of this Warrant, or the issuance
or delivery of certificates for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other
than to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
FRACTIONAL WARRANT SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional Warrant Shares shall be issued upon exercise of this Warrant. The Company, in lieu of issuing any fractional Warrant
Share, shall round up the number of Warrant Shares issuable to nearest whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
NO STOCK RIGHTS AND LEGEND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of this Warrant, as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that
may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder
of this Warrant, as such, the rights of a stockholder of the Company or the right to vote for the election of directors or upon
any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or to receive
notice of meetings or other actions affecting stockholders (except as provided herein), or to receive dividends or subscription
rights or otherwise (except as provide herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
certificate for Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued
to any subsequent transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the
following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;),
OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER
OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR
APPLICABLE STATE SECURITIES LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
LOCK-UP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Warrant Shares acquired pursuant to an exercise of this Warrant must not be transferred, sold, hypothecated or otherwise disposed
for a period of one year from the date on which the Share Delivery Date .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
NOTICES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, consents, waivers, and other communications under this Warrant must be in writing and will be deemed given to a party
when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b)
sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee,
if sent by certified mail, return receipt requested, if to the registered Holder hereof; or (d) seven (7) days after the placement
of the notice into the mails (first class postage prepaid), to the Holder at the address, facsimile number, or e-mail address
furnished by the registered Holder to the Company in accordance with the Subscription Agreement by and between the Company and
the Holder, or if to the Company, to it at One Kendall Square, Bldg 200, Cambridge, MA 02139, Attn: Yuval Cohen, CEO (or to such
other address, facsimile number, or e-mail address as the Holder or the Company as a party may designate by notice the other party).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
SEVERABILITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a court of competent jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant
will remain in full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will
remain in full force and effect to the extent not held invalid or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
BINDING EFFECT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant shall be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered
Holder or Holders from time to time of this Warrant and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
SURVIVAL OF RIGHTS AND DUTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant shall terminate and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date
or the date on which this Warrant has been exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
GOVERNING LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant will be governed by and construed under the laws of the State of New York without regard to conflicts of laws principles
that would require the application of any other law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
DISPUTE RESOLUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the
Notice of Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to
agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed
determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two Business Days, submit
via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company&rsquo;s independent,
outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform
the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from
the time it receives the disputed determinations or calculations. Such investment bank&rsquo;s or accountant&rsquo;s determination
or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
NOTICES OF RECORD DATE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
(a) any establishment by the Company of a record date of the holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or other distribution, or right or option to acquire securities of
the Company, or any other right; or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation
of the Company with or into any other corporation, any transfer of all or substantially all the assets of the Company, or any
voluntary or involuntary dissolution, liquidation or winding up of the Company, or the sale, in a single transaction, of a majority
of the Company&rsquo;s voting stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any
combination thereof), the Company shall mail to the Holder at least ten (10) Business Days, or such longer period as may be required
by law, prior to the record date specified therein, a notice specifying; (i) the date established as the record date for the purpose
of such dividend, distribution, option or right and a description of such dividend, option or right; (ii) the date on which any
such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected
to become effective;and (iii) the date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange
their shares of Common Stock for securities or other property deliverable upon such reorganization, reclassification, transfer,
consolation, merger, dissolution, liquidation or winding up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
RESERVATION OF SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall reserve and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise
of this Warrant, free from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to
time be exercisable. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation. Without limiting the generality of the foregoing,
the Company covenants that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this
Warrant and use commercially reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited
to consents from the Company&rsquo;s stockholders or Board of Directors or any public regulatory body, as may be necessary to
enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
NO THIRD PARTY RIGHTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Warrant is not intended, and will not be construed, to create any rights in any parties other than the Company and the Holder,
and no person or entity may assert any rights as third-party beneficiary hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
    PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Yuval Cohen</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OF
EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
be executed by the Holder of Warrant if such Holder desires to exercise Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-indent: 62.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Corbus Pharmaceuticals Holdings, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-indent: 62.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby irrevocably elects to exercise this Warrant and to purchase thereunder, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
full shares of Corbus Pharmaceuticals Holdings, Inc. Common Stock issuable upon exercise of the Warrant and delivery of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
(in cash as provided for in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant to such Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned requests that certificates for such shares be issued in the name of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 23%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 23%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    print name, address and social security or federal employer</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">identification number (if applicable))</FONT></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shares issuable upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire
upon the exercise of the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued
in the name of and delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 23%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 23%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    print name, address and social security or federal employer identification number (if applicable))</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder (print):</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(By:)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title:)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF ASSIGNMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
hereby sells, assigns and transfers to each assignee set forth below all of the rights of the undersigned under the Warrant (as
defined in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set opposite the name of such assignee
below and in and to the foregoing Warrant with respect to said acquisition rights and the shares issuable upon exercise of the
Warrant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Assignee</FONT></TD>
    <TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address</FONT></TD>
    <TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the total of the Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests
that a new Warrant evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to
the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder (print):</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature):</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(By:)
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title:)
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; margin-right: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>3
<FILENAME>ex10-33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.33</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CONFIDENTIAL
TREATMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED
WITH AN ASTERISK [*], HAS BEEN FILED SEPERATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Execution
Copy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CYSTIC
FIBROSIS PROGRAM RELATED INVESTMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>by
and between</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cystic
Fibrosis Foundation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cystic
Fibrosis Program Related Investment Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE I &ndash; DEFINITIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE II &ndash; DEVELOPMENT PLAN</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.7in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Commencement; Objective</FONT></A></TD>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Duration of the Development Plan</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Development Diligence</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Project Advisory Group</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">2.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Delivery of Information to the PAG</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE III &ndash; AWARD PAYMENTS; RECORDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Records; Reporting Obligations; Audits</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE IV &ndash; COMMERCIALIZATION; ROYALTIES</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Development and Commercialization of a Product</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Royalties</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Warrants</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Sales Reports</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Transferee Liability</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE V &ndash; CONFIDENTIALITY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Confidentiality</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">5.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Publicity; Use of Name</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">23</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE VI &ndash; PUBLICATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE VII &ndash; INDEMNIFICATION AND INSURANCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Indemnification by Corbus</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Claims Procedures</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Participation; Assuming Control of the Defense</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Insurance</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">7.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Limitation of Liability</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE VIII &ndash; PATENTABLE INVENTIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Ownership</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Exclusive License Grant</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Preparation</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_030"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Costs</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Abandonment</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">8.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_032"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No License</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_033"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE IX &ndash; TERM AND TERMINATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_034"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Term</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_035"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination by CFF For Cause</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_036"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Termination for CFF Breach</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">30</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_037"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">General Effect of Termination; Survival</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">30</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">9.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_038"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Prior Agreement</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">30</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_039"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE X &ndash; REPRESENTATIONS AND WARRANTIES</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_040"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Representations and Warranties of Corbus</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_041"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Representations and Warranties of CFF</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_042"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ARTICLE XI &ndash; MISCELLANEOUS PROVISIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_043"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Governing Law</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_044"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Dispute Resolution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_045"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Waiver</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_046"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Force Majeure</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_047"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Severability</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_048"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Assignment</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_049"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Counterparts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_050"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Agency</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_051"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Notice</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_052"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Headings</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_053"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Entire Agreement</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">11.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_054"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">No Impairment</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">36</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibits</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -66pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B> &ndash; <A HREF="#a_1">Development Plan</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
B</U></B> &ndash; <A HREF="#a_2">Budget and Milestone Payments</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
C</U></B> - <A HREF="#a_3">CFF Patents</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
D</U></B> &ndash; <A HREF="#a_4">Warrants to CFF</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROGRAM
RELATED INVESTMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made on this 26th day of January, 2018 (the &ldquo;<U>Effective Date</U>&rdquo;)
by and between Corbus Pharmaceuticals, Inc. (&ldquo;Corbus&rdquo;), a Delaware corporation, with its principal office at 100 River
Ridge Drive, Norwood, MA 02062, and Cystic Fibrosis Foundation (&ldquo;<U>CFF</U>&rdquo;), a nonprofit corporation with its principal
offices at 4550 Montgomery Ave, Bethesda, Maryland, 20814. Corbus and CFF are each a &ldquo;<U>Party</U>,&rdquo; and, collectively,
the &ldquo;<U>Parties</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
CFF&rsquo;s principal charitable mission is the discovery and development of drugs to cure or mitigate Cystic Fibrosis, to which
CFF brings significant scientific, human resources and financial support; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Corbus is developing Lenabasum for the treatment of rare, chronic and serious inflammatory and fibrotic diseases including (i)
systemic sclerosis (ii) Cystic Fibrosis (iii) dermatomyositis and (iv) systemic lupus erythematosus; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Corbus desires to prepare for and conduct a Phase 2 Clinical Trial for Lenabasum in cystic fibrosis patients; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>CFF desires to provide an Award to fund the Phase 2 Clinical Trial on the terms and conditions set forth in this Agreement
and Corbus desires to accept the Award;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual covenants set forth in this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_001"></A>ARTICLE
I &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, the terms defined in this Article 1 shall have the following meanings whether used in their singular
or plural forms. Use of the singular shall include the plural and vice versa, unless the context requires otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1
&ldquo;Affiliate&rdquo;</B> shall mean, with respect to any Person, any other Person which directly or indirectly, by itself or
through one or more intermediaries, controls, or is controlled by, or is under direct or indirect common control with, such Person.
The term &ldquo;control&rdquo; as used in this Section 1.1 means the possession, direct or indirect, of the power to direct or
cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract
or otherwise. Control will be presumed if one Person owns, either of record or beneficially, more than fifty percent (50%) of
the voting stock of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2
&ldquo;Agreement&rdquo;</B> means this agreement, together with all appendices, exhibits and schedules hereto, and as the same
may be amended or supplemented from time to time hereafter by a written agreement duly executed by authorized representatives
of each Party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3
&ldquo;Applicable Laws&rdquo;</B> shall mean the applicable laws of any jurisdiction which are applicable to any of the Parties
or their respective Affiliates in carrying out activities hereunder or to which any of the Parties or their respective Affiliates
in carrying out the activities hereunder is subject, and shall include all statutes, enactments, acts of legislature, laws, ordinances,
rules, regulations, notifications, guidelines, policies, directions, directives and orders of any statutory authority, tribunal,
board, or court or any central or state government or local authority or other governmental entity in such jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4
&ldquo;Approval&rdquo;</B> shall mean all approvals from the relevant Regulatory Authority in a given country necessary to market
and sell a pharmaceutical product in such country, including pricing and reimbursement approvals if required for marketing or
sale of such product in such country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5
&ldquo;Approval Date&rdquo; </B>shall mean the date on which an Approval is granted by a relevant Regulatory Authority for the
Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.6
&ldquo;Award&rdquo;</B> shall mean the total amount of funding CFF provides to Corbus pursuant to this Agreement, provided that
the Award shall not exceed Twenty-Five Million Dollars ($25 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.7
&ldquo;Budget&rdquo;</B> shall mean the total amount of monies estimated and agreed to by the Parties for the costs and expenses
of the Phase 2 Clinical Trial as set forth in the Development Plan as shown on <U>Exhibit B</U>, which (a) may be amended from
time to time solely upon the mutual written agreement of the Parties, and (b) shall detail the projected allocation and use of:
the funds to be paid by CFF to Corbus with respect of the Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.8
&ldquo;CFF&rdquo;</B> shall have the meaning set forth in the preamble of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.9
&ldquo;CFF Designees&rdquo;</B> shall have the meaning set forth in Section 2.4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.10
&ldquo;CFF Indemnitee&rdquo;</B> shall have the meaning set forth in Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.11
&ldquo;CFF Patents&rdquo;</B> shall mean any Patents Controlled by CFF or its Affiliates relating to the Phase 2 Clinical Trial
and directed to a CFF Sole Invention which CFF Patents are set forth on <U>Exhibit C</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.12
&ldquo;CFF Sole Invention&rdquo;</B> shall have the meaning set forth in Section 8.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.13
&ldquo;Change of Control&rdquo; </B>shall mean the consummation of a transaction, whether in a single transaction or in a series
of related and substantially contemporaneous transactions, constituting (i) a merger, share exchange or other reorganization,
(ii) the sale by one or more stockholders of a majority of the voting power of Corbus, or (iii) a sale of all or substantially
all of the assets of Corbus (or that portion of its assets related to the subject matter of this Agreement), in which the stockholders
of Corbus immediately prior to such transaction do not own a majority of the voting power of the acquiring, surviving or successor
entity, as the case may be, provided that a Change of Control shall not include a bona fide financing transaction for the benefit
of Corbus (i.e. in which Corbus raises capital for general working or business purposes) in which voting control of Corbus transfers
to one or more persons who acquire shares of Corbus and the existing Corbus shareholders receive no consideration directly or
indirectly in connection with the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.14
&ldquo;Commercially Reasonable Efforts&rdquo;</B> shall mean the level of effort, expertise and resources that is substantially
and materially consistent with industry standards for companies of similar size and financial resources to develop and commercialize
the Product, provided such effort is technically and commercially feasible, devoting the degree of attention and diligence to
such efforts that are substantially and materially consistent with industry standards for a product at a comparable stage of development
with similar market potential, and taking into account, with limitation issues of safety and efficacy, proprietary position, the
regulatory environment, and other relevant scientific and commercial factors for companies of similar size and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.15
&ldquo;Confidential Information&rdquo;</B> shall have the meaning set forth in Section 5.1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.16
&ldquo;Controlled&rdquo;</B> (except in the context of Section 1.1) shall mean the legal authority or right of a Party hereto
to grant a license or sublicense of intellectual property rights to another party, without breaching the terms of any agreement
with a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.17
&ldquo;Corbus Designees&rdquo;</B> shall have the meaning set forth in Section 2.4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.18
&ldquo;Corbus Patents&rdquo;</B> shall mean any Patents Controlled by Corbus or its Affiliates claiming Corbus Development Plan
Technology and directed to a Corbus Sole Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.19
&ldquo;Corbus Sole Invention&rdquo;</B> shall have the meaning set forth in Section 8.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.20
&ldquo;Cystic Fibrosis&rdquo;</B> or <B>&ldquo;CF&rdquo;</B> shall mean any one and/or all of the human diseases commonly known
as cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.21
&ldquo;Default&rdquo;</B> shall have the meaning set forth in Section 9.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.22
&ldquo;Development Plan&rdquo;</B> shall mean the Development Plan attached hereto in <U>Exhibit A</U>, which shall cover the
work performed under the Agreement until the Development Plan Completion Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.23
&ldquo;Development Plan Technology&rdquo;</B> shall mean all intellectual property, data, technical information, know-how, inventions
(whether or not patented), trade secrets, laboratory notebooks, processes and methods at any time discovered or developed in the
performance of the Development Plan under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.24
&ldquo;Development Plan Completion Date&rdquo;</B> shall mean the date on which the last milestone specified in Exhibit B has
been completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.25
&ldquo;Discloser&rdquo;</B> shall have the meaning set forth in Section 5.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.26
&ldquo;Disposition Royalty&rdquo;</B> shall have the meaning set forth in Section 4.2.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.27
&ldquo;Disposition Transaction&rdquo; </B>shall have the meaning set forth in Section 4.2.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.28
&ldquo;Dispute&rdquo;</B> shall have the meaning set forth in Section 11.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.29
&ldquo;Dollars&rdquo;</B> shall have the meaning set forth in Section 3.1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.30
&ldquo;Effective Date&rdquo;</B> shall mean the date set forth in the first paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.31
&ldquo;FDA&rdquo;</B> shall mean the United States Food and Drug Administration, or any successor agency having regulatory jurisdiction
over the manufacture, distribution and sale of drugs in the United States, and its territories and possessions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.32
&ldquo;Field&rdquo;</B> shall mean the use of the Product for the treatment or prevention of Cystic Fibrosis, asbestosis, bronchiectasis,
byssinosis, chronic bronchitis/COPD hypersensitivity pneumonitis, pneumoconiosis, primary ciliary dyskinesia, sarcoidosis and
silicosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.33
&ldquo;First Commercial Sale&rdquo;</B> shall mean the first sale of a Product by Corbus or an Affiliate, licensee, sublicensee,
transferee or successor of Corbus in a country in the Territory following Approval of the Product in that country or, if no such
Approval or similar marketing approval is required, the date upon which a Product is first commercially sold in that country in
an arms-length transaction. For clarity, the supply of a Product as part of a compassionate use or sampling program shall not
constitute a First Commercial Sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.34
&ldquo;GAAP&rdquo; </B>shall mean generally accepted accounting principles consistently applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.35
&ldquo;IND&rdquo;</B> shall mean the investigational new drug application filed with respect to a Product with the FDA pursuant
to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.36
&ldquo;Interest&rdquo;</B> shall mean the Prime Rate plus five (5) percentage points.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.37
&ldquo;Joint Invention&rdquo;</B> shall have the meaning set forth in Section 8.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.38
&ldquo;Joint Patents&rdquo;</B> shall mean any Patents Controlled by Corbus and CFF or their respective Affiliates claiming Development
Plan Technology and directed to a Joint Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.39
&ldquo;Losses&rdquo;</B> shall have the meaning set forth in Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.40
&ldquo;Major Market&rdquo; </B>shall mean Canada, Israel, any member country of the European Union, and the United Kingdom (if
it ceases to be a member of the European Union).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.41
&ldquo;Net Sales&rdquo;</B> shall mean the gross amounts invoiced for sales or other dispositions of the Product to Third Parties
(excluding, for the avoidance of doubt, any sales to Related Parties for resale), less the following deductions actually incurred,
allowed, paid, accrued or otherwise specifically allocated to sales of Product in the Field and for Non-Field Indications (as
applicable) less: (a) customary trade discounts, including trade, cash and quantity discounts or rebates credits or refunds, actually
allowed or taken; (b) credits or allowances actually granted or made for rejection of or return of previously sold Products in
the Field or Non-Field Products (as applicable), including recalls, or for retroactive price reductions and billing errors or
for stocking allowances; (c) governmental and other rebates (or credits or other equivalents thereof) actually granted to managed
health care organizations, commercial insurance companies, pharmacy benefit managers (or equivalents thereof), distributors, national,
state/provincial, local, and other governments, their agencies and purchasers, and reimbursers, or to trade customers; (d) reasonable
fees paid to wholesalers, distributors, selling agents (excluding sales representatives of the Selling Party), group purchasing
organizations, Third Party payors, other contractees and managed care entities, in each case with respect to the Product in the
Field or Non-Field Indications (as applicable); (e) charges separately invoiced for freight, insurance, transportation, postage
and handling; (f) taxes, custom duties or other governmental charges (including any tax such as a value added or similar tax or
government charge but excluding what is commonly known as income tax) levied on or measured by the billing amount for Products
in the Field or Non-Field Indications (as applicable), as adjusted for rebates and refunds; (g) bad debts or provision for bad
debts deductions actually written off during the applicable accounting period; and (h) any other specifically identifiable amounts
included in the Product&rsquo;s gross invoice price that should be credited for reasons substantially equivalent to those listed
above; all as determined in accordance with the selling Party&rsquo;s usual and customary accounting methods, which are in accordance
with GAAP. In no event shall any particular amount identified above be deducted more than once in calculating Net Sales (<I>i.e.</I>,
no &ldquo;double counting&rdquo; of deductions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of any sale or other disposal for value, such as barter or counter-trade, of any Product, or part thereof, other than
in an arm&rsquo;s length transaction exclusively for money, Net Sales shall be calculated as above on the value of the consideration
received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.42
&ldquo;Non-Field Product&rdquo;</B> shall mean any pharmaceutical composition or preparation (in any and all dosage forms) in
final form containing Lenabasum or any derivative thereof that is approved or being developed for a Non-Field Indication. For
clarity, different formulations or dosage strengths of a given Non-Field Product shall be considered the same Non-Field Product
for purposes of this Agreement. In addition, the Parties acknowledge that the same product may be both a Product for use in the
Field and a Non-Field Product (i.e., where such product has more than one indication such that it is for use in the Field and
for Non-Field Indications).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.43
&ldquo;Non-Field Indication&rdquo;</B> shall mean the treatment or prevention of any disease in humans other than those in the
Field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.44
&ldquo;Non-Publishing Party&rdquo;</B> shall have the meaning set forth in Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.45
&ldquo;Party(ies)&rdquo;</B> shall have the meaning set forth in the preamble of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.46
&ldquo;Patents&rdquo;</B> means all existing patents and patent applications and all patent applications hereafter filed, including
any continuation, continuation-in-part, division, provisional, priority, or any substitute applications, any patent issued with
respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplementary protection
certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent,
and all foreign counterparts of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.47
&ldquo;Person&rdquo;</B> means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated
organization or government or political subdivision thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.48
</B>&ldquo;<B>Phase 2 Clinical Trial</B>&rdquo; shall mean a multicenter, randomized, double blind, placebo-controlled Phase 2
clinical trial to evaluate the efficacy and safety of Lenabasum in the treatment of cystic fibrosis which shall be conducted pursuant
to the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.49
&ldquo;Prime Rate&rdquo;</B> shall mean the average prime rate published in the <I>Wall Street Journal </I>during the relevant
period (calculated by dividing (a) the sum of the prime rates for each of the days during the relevant period, by (b) the number
of days in the relevant period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.50
&ldquo;Prior Agreement&rdquo; </B>shall mean the agreement of April 9, 2015 entered into by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.51
&ldquo;Product&rdquo;</B> means Lenabasum in any form, dosage or preparation in finished form, and any derivative thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.52
&ldquo;Project Advisory Group&rdquo;</B> or &ldquo;<B>PAG</B>&rdquo; shall have the meaning set forth in Section 2.4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.53
&ldquo;Publishing Party&rdquo;</B> shall have the meaning set forth in Article VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.54
&ldquo;Recipient&rdquo;</B> shall have the meaning set forth in Section 5.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.55
&ldquo;Recipient Notice Requirement&rdquo;</B> shall have the meaning set forth in Section 5.1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.56
&ldquo;Regulatory Authority&rdquo;</B> shall mean any country, federal, supranational, state or local regulatory agency, department,
bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing
of pharmaceutical products in any country or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.57
&ldquo;Results&rdquo;</B> shall have the meaning set forth in Article VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.58
&ldquo;Securities Regulatory Authority&rdquo;</B> shall have the meaning set forth in Section 5.1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.59
&ldquo;Share Election&rdquo; </B>shall have the meaning set forth in Section 4.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.60
&ldquo;Territory&rdquo;</B> shall mean worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.61
&ldquo;Third Party&rdquo;</B> shall mean any Person which is not a Party or an Affiliate of any Party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.62
&ldquo;Trading Day&rdquo; </B>shall mean any day in which the stock exchange on which Corbus shares are regularly traded is open.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_002"></A>ARTICLE
II &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVELOPMENT PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>2.1
Commencement; Objective</B>. The objective of the Phase 2 Clinical Trial will be to establish clinical proof of principal and
to obtain sufficient information of the Product&rsquo;s safety and efficacy in the Field to permit the design of further clinical
studies and that would satisfy the requirements of 21 CFR 312.21(b). Corbus shall be solely responsible for the conduct of the
Phase 2 Clinical Trial as set forth in the Development Plan. CFF shall provide the financial support hereinafter specified, consultation
and advice as provided herein through its participation on the PAG as provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>2.2
Duration of the Development Plan</B>. The Development Plan shall commence on the Effective Date and shall conclude on the Development
Plan Completion Date, unless extended by mutual agreement of the Parties, or unless earlier terminated in accordance with the
provisions of Article IX hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>2.3
Development Diligence.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1
<U>Generally</U>. Corbus shall use Commercially Reasonable Efforts to conduct the Phase 2 Clinical Trial pursuant to the Development
Plan. In furtherance of the foregoing, and in accordance with the terms and conditions of this Agreement (including, without limitation,
Section 2.3.2 below), Corbus shall commit (i) the level of staffing required by the Development Plan, with such staff that possess
the necessary experience, training and scientific expertise in order for Corbus to fulfill its obligations hereunder, and (ii)
the infrastructure (e.g., laboratories, offices, equipment and facilities) required by the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2
<U>Obligations of Corbus</U>. Subject to the terms and conditions of this Agreement, and without limiting the generality of Section
2.3.1 above, Corbus shall be solely responsible for the sponsorship, conduct and oversight of the Phase 2 Clinical Trial as set
forth in the Development Plan, which such responsibilities shall include, without limitation, utilizing Commercially Reasonable
Efforts to perform its obligations hereunder and complete the Phase 2 Clinical Trial in a timely fashion so as to enable the possibility
of further development and commercialization of the Product in the Field in accordance with Section 4.1; and responding to all
reasonable requests and inquiries of CFF for information in possession of Corbus regarding any of the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>2.4
Project Advisory Group.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1
<U>Composition and Purposes</U>. During the term of the Development Plan, a Program Advisory Group (&ldquo;<U>PAG</U>&rdquo;)
shall facilitate communication between the Parties, and make recommendations, with respect to the Development Plan. The PAG shall
consist of four (4) members, two (2) of whom shall be designated by Corbus (the &ldquo;<U>Corbus Designees</U>&rdquo;), and two
(2) of whom shall be designated by CFF (the &ldquo;<U>CFF Designees</U>&rdquo;). Each Party (i) shall select a Program Coordinator
from among its designees to the PAG (who may be changed at any time or from time to time by such Party), and (ii) may change any
of its designees to the PAG at any time or from time to time. The Program Coordinator of Corbus shall serve as the Chairperson
of the PAG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the generality of the foregoing, the PAG shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
consider, review, reevaluate and discuss the Development Plan, evaluate any proposed revisions or modifications by either Party
to the Development Plan, and give its recommendations regarding any proposed amendments to the Development Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
monitor the progress of the Development Plan, and make recommendations to Corbus&rsquo;s team as needed on next steps to implement
the Development Plan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
determine that the Award has been used as set forth in the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PAG shall terminate on the First Commercial Sale of a Product in the Field or in the event Corbus determines to discontinue development
of the Product for use in the Field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2
<U>Meetings</U>. The PAG shall meet no less frequently than once in each three (3) month period; <U>provided</U>, <U>however</U>,
that the PAG may meet more or less frequently upon mutual agreement of the Program Coordinators. The first meeting of the PAG
shall be held within ninety (90) days of the Effective Date. Meetings of the PAG shall be held at such times and locations as
may be mutually agreed by the Program Coordinators, which times and locations shall be communicated in writing (including, without
limitation, by email) to the other members of the PAG with reasonable advance notice of the meeting. At least one (1) Corbus Designee
and one (1) CFF Designee shall be required to participate in a meeting for such meeting to be deemed a quorum. So long as a quorum
is present at a meeting, the PAG may make, or decide to make, recommendations to Corbus, or take, or decide to take, such actions
as are within the scope of the PAG&rsquo;s authority hereunder. Members of the PAG may attend each meeting either in person or
by means of telephone or other telecommunications device that allows all participants to hear and speak at such meeting simultaneously.
At least ten (10) business days prior to each meeting, Corbus shall deliver (including by email) to CFF a written report detailing
the progress made on the Development Plan since the last meeting of the PAG. Within twenty (20) days after the date of each meeting,
the Corbus Designees shall prepare and deliver (including by email) to the CFF Designees written minutes of such meeting setting
forth in detail all discussions and/or recommendations of the PAG made at such meeting, which such minutes shall be subject to
the prior approval of CFF&rsquo;s Program Coordinator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3
<U>Discussions/Recommendations</U>. As a general matter, and except as otherwise provided for herein, the PAG shall discuss the
items set forth in Section 2.4.1, make unanimous, non-binding recommendations to Corbus as a result of such discussions, and facilitate
communication between the Parties with respect to the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4
<U>Expenses</U>. Each Party shall pay its own expenses (including travel and lodging expenses) incurred in connection with its
participation on the PAG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>2.5
Delivery of Information to the PAG</B>. Corbus shall deliver to each PAG member such information and other data as soon as practicable
following its availability as is necessary to facilitate mutual understanding of the status of, and developments relating to,
the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_008"></A>ARTICLE
III &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AWARD PAYMENTS; RECORDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1
<U>Award Grant and Payments</U>. In accordance with the terms, and subject to the conditions, set forth in this Agreement, CFF
hereby grants the Award to Corbus and Corbus accepts such Award. Corbus shall send invoices in United States Dollars (&ldquo;<U>Dollars</U>&rdquo;)
to CFF for payment of the Award in accordance with the milestones set forth in <U>Exhibit B</U>. CFF shall pay amounts invoiced
by Corbus within [*] days of the receipt of the invoice for amounts expended in accordance with the Budget and milestone schedule.
Except as expressly provided in Sections 4.2.1 (a) and (b), all payments to be made hereunder (including, without limitation,
pursuant to Article IV) shall be made in Dollars and, at the option and direction of the receiving party, shall be made by cashier&rsquo;s
or certified check or by wire transfer of immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2
<U>Limitations</U>. Notwithstanding Section 3.1.1 above or any contrary provision contained herein, CFF shall not be required
to make any payment or additional payment in respect of the Award:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To the extent amounts paid hereunder would exceed of Twenty-Five Million Dollars ($25 million);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
unless at the time such payment is due, the Development Plan is in material compliance with all Applicable Laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
upon the occurrence and/or during the continuance of any uncured default and/or any material breach by Corbus of any of its covenants
or obligations under this Agreement (including, without limitation, Corbus&rsquo;s obligations under Sections 3.1.3 and 3.1.4
below);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
if a case or proceeding (i) under the bankruptcy laws of the United States, or relevant non-U.S. law, now or hereafter in effect
is filed against Corbus or all or substantially all of its assets and such petition or application is not dismissed within sixty
(60) days after the date of its filing or Corbus shall file any answer admitting and not contesting such petition, or (ii) under
the bankruptcy laws of the United States, or relevant non-U.S. law, now or hereafter in effect or under any insolvency, reorganization,
receivership, dissolution or liquidation law or statute of any jurisdiction now or hereafter in effect (whether at law or equity)
is filed by Corbus for all or substantially all of its assets; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
if this Agreement is terminated by either Party in accordance with Article IX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3
<U>Budget</U>. Corbus hereby covenants and agrees to use the Award funds provided by CFF to Corbus hereunder to fund the Phase
2 Clinical Trial in accordance with the Budget (including, without limitation, making applicable payments to subcontractors and
vendors) and Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4
<U>Competition</U>. Corbus hereby agrees and acknowledges that nothing contained herein shall restrict or prevent CFF&rsquo;s
ability to provide funding to, or take any other action with respect to, any Person that competes with a Product, the business,
operations, and/or Development Plan of Corbus; and Corbus hereby waives any claim against CFF with respect to any such competing
activities; provided, however, that CFF shall use Corbus Confidential Information only in accordance with the provisions of this
Agreement, and Corbus does not waive any claims relating to use or misuse of Corbus Confidential Information not in accordance
with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>3.2
Records; Reporting Obligations; Audits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1
<U>Records</U>. Corbus shall prepare and maintain complete and accurate books and records in connection with the Development Plan
in accordance with GAAP (including financial records of expenditures under the Award) and the development and commercialization
of any Product, and shall keep all such books and records in a manner that is consistent with its document retention policy. CFF
shall have the right to inspect such books and records at the offices of Corbus during normal business hours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.2
<U>Response to Inquiries</U>. Corbus personnel (including, without limitation, licensees, sublicensees, transferees, successors
and subcontractors) shall be available to discuss (whether in person or via telephone) with CFF the books and records and/or reports
delivered by Corbus to CFF at such time or times as CFF may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.3
<U>Audit</U>. At the request of CFF, from time to time prior to the first anniversary of the Development Plan Completion Date,
Corbus shall permit agents of an independent, certified public accounting firm appointed by CFF, upon reasonable notice, but not
more often than once a year, to audit and examine such books and records of Corbus as may be necessary for verifying Corbus&rsquo;s
compliance with the terms and conditions hereunder. Any and all records audited and examined by agents of such accounting firm
shall be deemed Corbus&rsquo;s Confidential Information. CFF shall pay the costs of such audit and examination of the books and
records of Corbus, <U>provided</U><I>, </I><U>however</U><I>, </I>that, if such audit and examination reveal a material breach
of this Agreement or a material discrepancy with respect to other information previously provided by Corbus to CFF, then the costs
of such audit and examination shall be borne by Corbus and Corbus shall reimburse CFF for all of the costs and expenses incurred
by CFF in connection with such audit and examination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.4
<U>Reports; Notices</U>. Corbus shall furnish to CFF the following reports and/or notices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As soon as practicable, and in any event within sixty (60) days after the end of each calendar quarter (including the calendar
quarter ending December 31), financial reports which describe the use of the Award funds (including, without limitation, a detailed
breakdown of the actual costs of the Development Plan and how such Award funds have been allocated and in fact used in respect
of the Development Plan), the progress made toward achieving the purposes of the Development Plan, and the development of any
Product, and any other information in possession of Corbus that CFF reasonably requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As soon as practicable after the Development Plan Completion Date, a closing report customary for a Development Plan at such stage
of development which shall (i) be prepared by Corbus or a Corbus-approved Third Party, (ii) be reasonably satisfactory to CFF,
and (iii) set forth Corbus&rsquo;s final analysis, summary tables, data listings, results and conclusions from the Development
Plan and such other information and materials as CFF may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As soon as practicable, and in any event within sixty (60) days after January 1 and June 1 of each fiscal year following the Development
Plan Completion Date, progress reports and status updates on Corbus&rsquo;s activities with respect to the Development Plan Technology
and/or a Product including, without limitation, the development and/or commercialization of any Products, Corbus&rsquo;s compliance
with the terms of this Agreement, and any other information that CFF reasonably requests. Corbus shall include the requirements
of this Section 3.2.4(c) in any agreements with sublicensees relating to the development and/or commercialization of any Products.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_010"></A>ARTICLE
IV &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMERCIALIZATION; ROYALTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>4.1
Development and Commercialization of a Product</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1
<U>Development and Commercialization of a Product</U>. Corbus shall use Commercially Reasonable Efforts to develop and commercialize
the Product in the United States and in one of the other Major Markets; provided however that nothing contained herein shall require
Corbus to initiate any other clinical trials (other than the Phase 2 Clinical Trial described herein) for the Product in the Field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2
<U>Commercialization of Product</U>. Corbus and/or its Affiliates, licensees, sublicensees, transferees and successors shall have
the exclusive rights to develop, commercialize, market, sell and distribute any or all Products throughout the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>4.2
Royalties</B>. Corbus shall make the following payments to CFF:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1
<U>Approval Royalties</U>. Corbus shall make the following royalty payments to CFF in the event of the following Approvals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A royalty payment equal to one and one-half (1.5) times the amount of the Award, such royalty to be paid by Corbus to CFF within
sixty (60) days of the first Approval of the Product in the United States; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A royalty payment equal to one and one-half (1.5) times the amount of the Award such royalty to be paid by Corbus to CFF within
sixty (60) days of the first Approval of the Product in a Major Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first milestone payment due under Section 4.2.1(a) or (b), as the case may be, may be made in cash or, at Corbus&rsquo;s election,
made by notice to CFF within ten (10) days after such Approval, in Corbus shares (the &ldquo;Share Election&rdquo;), provided,
however, that the Share Election shall no longer be applicable after a Change of Control. If Corbus makes the Share Election:
(i) such payment shall be made to the extent available in registered Corbus common shares that can be sold by CFF on the stock
exchange on which Corbus is customarily traded immediately following such transfer of shares to CFF or (ii) if such registered
shares are not available, Corbus shall register such shares within sixty (60) days of the Share Election. The Corbus shares transferred
to CFF as a result of the Share Election shall be determined in accordance with the following sentence to be of equal value to
the cash payment otherwise due. If Corbus makes the Share Election, the number of shares transferred to CFF shall be determined
by (A) dividing an amount equal to 1.5 times the Award by (B) the average share price of Corbus shares determined by adding the
closing prices of Corbus shares on each of the five (5) Trading Days prior to the relevant Approval plus the closing prices of
Corbus shares on the Approval date and each of the four (4) Trading Days thereafter, and dividing such sum by ten 10; provided
that, if the Approval date is not a Trading Day, the fifth (5<SUP>th</SUP>) Trading Day after the Approval date shall be used
for purposes of the foregoing calculation; and further provided, if Corbus must register the Shares after the Share Election,
and if the shares on the effective date of their registration have a lower market value on the date such shares are registered
than the average price calculated in accordance with (B) above, Corbus shall transfer such additional registered shares to CFF
on the effective date of such registration as are necessary to provide CFF with a payment equal to such average.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2
<U>Royalty on Net Sales</U>. Corbus shall pay to CFF:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A royalty equal to two and one-half percent (2.5%) of Net Sales of the Product in the Field within sixty (60) days after any quarter
in which such Net Sales occur; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A royalty equal to one percent (1.0%) of the Net Sales of Non-Field Products within sixty (60) days after any quarter in which
such Net Sales occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3
<U>Disposition Payment</U>. A royalty equal to ten percent (10%) of any amount Corbus and its shareholders receive in connection
with the license, sale, or other transfer to a Third Party of the Product and/or Development Plan Technology (a &ldquo;<U>Disposition
Royalty</U>&rdquo;) and a Change of Control (collectively, a &ldquo;<U>Disposition Transaction</U>&rdquo;), whether such amounts
are received by Corbus upfront, in subsequent milestone payments, or other payment prior to the First Commercial Sale, <U>provided</U>,
<U>however</U>, that the Disposition Royalty shall not exceed five (5) times the amount of the Award, and shall be credited against
the royalties on Net Sales otherwise due under Section 4.2.2 until the full amount of the Disposition Payment has been offset
against such royalties . The Disposition Payment[s] shall be made to CFF with sixty (60) days after Corbus receives any amount
attributable to a Disposition Transaction. Corbus shall notify CFF promptly of any Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>4.3
Warrants</B>. In addition to the royalties specified in Section 4.2, Corbus Pharmaceuticals Holdings, Inc. hereby awards to CFF
warrants entitling CFF upon exercise to one-million (1,000,000) Corbus common shares. Such warrants shall be subject to the terms
specified in <U>Exhibit D</U> to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>4.4
Sales Reports.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1
<U>Reports</U>. Commencing upon Approval of a Product and ending upon the last payment of all royalties under Section 4.2.2, within
sixty (60) days after the end of each quarter, Corbus shall furnish or cause to be furnished to CFF a written sales report or
reports covering the relevant period setting forth in detail the Net Sales of Product during such period divided into sales inside
the Field and for Non-Field Indications. With respect to sales of Products invoiced in Dollars, the Net Sales amounts and the
amounts due to CFF hereunder shall be expressed in Dollars. With respect to sales of Products invoiced in a currency other than
Dollars, the Net Sales and amounts due to CFF hereunder shall be expressed in the domestic currency of the party making the sale,
together with the Dollar equivalent of the amount payable to CFF, calculated by translating foreign currency sales into Dollars
in accordance with Corbus&rsquo;s accounting policies. If any licensee or sublicensee makes any sales invoiced in a currency other
than its domestic currency, the Net Sales shall be converted to its domestic currency in accordance with the licensee&rsquo;s
or sublicensee&rsquo;s normal accounting principles. Corbus shall keep accurate records in sufficient detail to enable the amounts
due hereunder to be determined and to be verified by CFF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2
<U>Independent Accountant</U>. Upon the written request of CFF, at CFF&rsquo;s expense and not more than one time in the twelve
(12) month period following the receipt by CFF of the report required under Section 4.4.1, Corbus shall permit an independent
accountant selected by CFF to have access during normal business hours to those records of Corbus as may be reasonably necessary
to verify the accuracy of the report furnished by Corbus pursuant to this Section 4.4. CFF shall pay the cost of any such examination,
<U>provided</U>, <U>however</U>, that if such examination determines that actual Net Sales were five percent (5%) or greater than
the amount reported by Corbus to CFF, in addition to promptly paying CFF for any additional royalty then due, Corbus shall reimburse
CFF for its reasonable and documented expenses associated with such examination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.3
<U>Interest</U>. In case of any delay in payment by Corbus to CFF not occasioned by force majeure in accordance with Section 11.4,
Interest shall be calculated from the tenth (10<SUP>th</SUP>) day after the date upon which the applicable payment first becomes
due from Corbus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>4.5
Transferee Liability</B>. In the event of a license, sale or other transfer of the Product and/or Development Plan Technology,
Corbus shall cause the licensee, buyer or other transferee to agree to be jointly and severally liable with Corbus for the royalties
specified in Section 4.1 and 4.2, and failing that, such license, sale or other transfer shall be null and void.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_016"></A>ARTICLE
V &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIALITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>5.1
Confidentiality.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1
<U>Definition of Confidential Information</U>. For purposes of this Agreement, &ldquo;<U>Confidential Information</U>&rdquo; shall
mean all information Recipient received from the Discloser in connection with this Agreement, including (a) the financial terms
of this Agreement and any other terms of this Agreement that a Party believes disclosure of which would be harmful to it, and
(b) any other trade secrets, confidential or proprietary information, or any other knowledge, information, data, reports, documents
or materials, owned, developed or possessed by Discloser(as defined below) whether in tangible or intangible form, the confidentiality
of which Discloser takes reasonable measures to protect. &ldquo;<U>Confidential Information</U>&rdquo; shall not, however, include
any information of Discloser that: (a) is already known to Recipient (as defined below) at the time of its disclosure; (b) becomes
publicly known through no wrongful act of Recipient; (c) is received from a Third Party free to disclose it to Recipient and without
any obligations to Discloser to keep confidential; (d) is independently developed by Recipient without use of the Confidential
Information; or (e) is communicated to a Third Party without confidentiality requirements with express written consent of Discloser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2
<U>Non-Disclosure</U>. During the term of this Agreement and for a period of five (5) years thereafter, each Party (&ldquo;<U>Recipient</U>&rdquo;)
shall hold all Confidential Information it receives or received from the other Party (&ldquo;<U>Discloser</U>&rdquo;) in strict
confidence, and, other than as provided herein or without first obtaining the prior written consent of Discloser, Recipient shall
not disclose any Confidential Information of Discloser to any Person, except to directors, officers, employees, consultants, committee
members, volunteers, contractors, subcontractors, licensees, sublicensees, accountants or counsel of Recipient who have a need
to know, who are subject to terms of confidentiality that are no less stringent than such confidentiality terms under this Agreement
and who have been informed of the confidential nature of the information. Recipient shall use not less than a reasonable degree
of care to protect such Confidential Information of Discloser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.3
<U>Required Disclosure</U>. Notwithstanding Section 5.1.2 above, Recipient&rsquo;s disclosure of Confidential Information shall
not be prohibited if such disclosure is required by a legally binding requirement; <U>provided</U>, <U>however</U>, that, Recipient
shall have first given prompt notice to Discloser of any possible requirement and Discloser shall have been afforded a reasonable
opportunity to prevent or limit such disclosure (the &ldquo;<U>Recipient Notice Requirement</U>&rdquo;); <U>provided</U>, <U>further</U>,
that the Recipient Notice Requirement shall not apply to proceedings which, by applicable law, are of a nature that the existence
of such proceedings may not be disclosed or made public in which case Recipient shall take all legally available measures to minimize
or avoid the public disclosure of Discloser Confidential Information. In the event that Recipient discloses any Discloser Confidential
Information pursuant to the immediately preceding sentence, Recipient shall cooperate with Discloser, at Discloser&rsquo;s sole
cost and expense, in the prosecution of any appeal that Discloser decides to pursue. For any disclosures of this Agreement required
by the Securities and Exchange Commission or other body regulating Corbus&rsquo;s or its Affiliates&rsquo; securities (&ldquo;<U>Securities
Regulatory Authority</U>&rdquo;), Corbus shall exercise good faith efforts to give confidential treatment of the information described
in Section 5.1.1, and Corbus shall provide CFF with contemporaneous copies of the requests for confidential treatment filed with
such Securities Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.4
<U>No Use of Confidential Information</U>. Recipient hereby agrees and acknowledges that, other than as provided herein or without
first obtaining Discloser&rsquo;s prior written consent, Recipient shall not use any of Discloser&rsquo;s Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_018"></A>5.2
Publicity; Use of Name.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.1
<U>Mutual Agreement</U>. The Parties shall mutually agree upon the timing and content of any initial press release or other public
announcement relating to this Agreement and the transactions contemplated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.2
<U>Prior Written Consent</U>. Except to the extent already disclosed in the initial press release or other public announcement
referenced in Section 5.2.1 above, and except as may be otherwise provided herein, neither Party shall issue any press release
or make any public announcement concerning the terms of this Agreement or the transactions described herein without the prior
written consent of the other Party, which such consent shall not be unreasonably withheld, conditioned or delayed; <U>provided</U>,
<U>however</U>, that it shall not be unreasonable for any Party to withhold consent with respect to any press release or public
announcement containing any of such Party&rsquo;s Confidential Information; and, <U>provided</U>, <U>further</U>, that this Section
5.2.2 shall not preclude any Party from issuing any such press release or making any such public announcement if such Party reasonably
believes that any such release or announcement is (a) legally required by Applicable Laws, or (b) required by the rules of any
stock exchange on which such Party&rsquo;s (or such Party&rsquo;s Affiliates&rsquo;) securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.3
<U>Advanced Written Copy</U>. In each instance, the Party desiring to issue any press release or to make any public announcement
shall provide the other Party with a written copy of the proposed release or announcement in sufficient time prior to public release
to allow such other Party to comment upon such release or announcement prior to its public release. In addition, each press release
and/or public announcement issued or made pursuant to this Section 5.2 shall include CFF-approved language acknowledging CFF&rsquo;s
funding of the Development Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.4
<U>Trademark and Logos</U>. Except as may be otherwise provided herein, neither Party shall have any right, express or implied,
to use in any manner the name or other designation of the other Party or any other trade name, trademark or logos of the other
Party for any purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.5
<U>Permitted Use of Name and Logo</U>. Notwithstanding the foregoing or any contrary provision contained herein, in connection
with: (a) any description by CFF of its portfolio and of its industry discovery and Development Plan, and/or (b) CFF&rsquo;s fundraising
activities, marketing materials and/or reporting requirements, CFF shall be entitled to use and/or disclose, and Corbus hereby
pre-approves CFF&rsquo;s use and/or disclosure of: (i) the mark &ldquo;Corbus,&rdquo; Corbus&rsquo;s logo and a general description
of Corbus, (ii) the existence and a general description of the nature of this Agreement (excluding financial terms), and (iii)
a general description of the nature of the Development Plan consistent with the confidentiality terms herein; <I>provided, however,
</I>CFF shall properly use any and all Corbus trademarks in a manner so as to not diminish its goodwill. Notwithstanding the foregoing
or any contrary provision contained herein, in connection with: any description by Corbus or its Affiliates of its portfolio and
of its industry discovery and Development Plan, Corbus shall be entitled to use and/or disclose, and CFF hereby pre-approves Corbus&rsquo;s
use and/or disclosure of: (i) a general description of CFF, (ii) the existence and a general description of the nature of this
Agreement (excluding financial terms), and (iii) a general description of the nature of the Development Plan consistent with the
confidentiality terms herein.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_019"></A>ARTICLE
VI &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PUBLICATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties shall publish the Results of the Phase 2 Clinical Trial at the earliest opportunity that is consistent with the protection
of the confidentiality of Development Plan Technology. Corbus reserves the first right to publish or publicly present the data
generated during the performance of, or as a result of, the Development Plan (the &ldquo;<U>Results</U>&rdquo;), subject to the
following terms and conditions. To the extent Corbus decides not to publish or publicly present the Results, Corbus shall in its
sole discretion allow CFF to publish or publicly present such Results in accordance with this Article VI, and such consent will
be binding if, and only if, provided in writing in accordance with the notice provisions contained herein. The Party proposing
to publish or publicly present the Results (the &ldquo;<U>Publishing Party</U>&rdquo;) will submit a draft of any proposed manuscript,
speech, poster or other disclosure to the other Party (the &ldquo;<U>Non-Publishing Party</U>&rdquo;) for comments at least sixty
(60) days prior to submission for publication or oral presentation. The Non-Publishing Party shall notify the Publishing Party
in writing within thirty (30) days of receipt of such draft with its comments, which shall be reasonably incorporated by the Publishing
Party. The comments of the Non-Publishing Party shall include but not be limited to whether such draft contains (a) information
of the Non-Publishing Party which it considers to be Confidential Information under the provisions of Article V hereof, (b) information
that if published would have an adverse effect on a Patent which the Non-Publishing Party intends to file or has filed, or (c)
information, including but not limited to chemical structures of a Product, which the Non-Publishing Party reasonably believes
would be likely to have a material adverse impact on the development or commercialization of a Product. In any such notification,
the Non-Publishing Party shall indicate with specificity its suggestions regarding the manner and degree to which the Publishing
Party may disclose such information. In the case of item (a) above, no Party shall publish the Confidential Information of the
other Party without the prior written consent of such other Party in violation of Article V of this Agreement. In the case of
item (b) above, the Non-Publishing Party may request a delay and the Publishing Party shall delay such publication, for a period
not exceeding an additional ninety (90) days, to permit the timely preparation and filing of a patent application or an application
for a certificate of invention on the information involved. In the case of item (c) above, if the Publishing Party shall disagree
with the Non-Publishing Party&rsquo;s assessment of the impact of the publication, then the issue shall be referred to the Program
Coordinator of each Party who shall attempt in good faith to reach a fair and equitable resolution of this disagreement. If the
disagreement is not resolved in this manner within fourteen (14) days of referral to the respective Program Coordinators, then
the decision of publication shall be subject to the Dispute Resolution provisions at Section 11.2, subject always to the confidentiality
provisions of Article V hereof. The Parties agree that authorship of any publication will be determined based on the customary
standards then being applied in the relevant scientific journal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
shall acknowledge the financial support of CFF in all Development Plan publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_020"></A>ARTICLE
VII &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEMNIFICATION AND INSURANCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_021"></A>7.1
Indemnification by Corbus</B>. Corbus shall indemnify, defend and hold harmless CFF, its Affiliates, and their respective directors,
officers, employees and agents (including, without limitation, the CFF Designees) (each, a &ldquo;<U>CFF Indemnitee</U>&rdquo;),
from and against any and all claims, suits and demands of Third Parties and losses, liabilities, damages for personal injury,
property damage or otherwise, costs, penalties, fines and expenses (including reasonable fees of attorneys) (collectively, &ldquo;<U>Losses</U>&rdquo;)
arising out of or resulting from: (a) the conduct of the Development Plan by Corbus and any breach of, or inaccuracy in, any of
representations or warranties made by Corbus in this Agreement, or any breach or violation of any covenant or agreement of Corbus
in or pursuant to this Agreement; and (b) any claim of infringement or misappropriation of intellectual property with respect
to the Development Plan or any Product. Corbus will have no obligation to indemnify CFF to the extent that the Losses arise out
of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by CFF in this
Agreement, or any breach or violation of any covenant or agreement of CFF in or pursuant to this Agreement, or the negligence
or willful misconduct by or of any of the CFF Indemnitees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_022"></A>7.2
Claims Procedures</B>. Each CFF Indemnitee shall give notice Corbus promptly after receipt by a CFF Indemnitee of notice of the
commencement of any action, suit or proceeding. Subject to Section 7.3, Corbus shall have the right to assume and manage the defense
thereof (with counsel reasonably satisfactory to the CFF Indemnitee), including the right to settle, compromise and/or litigate
with respect to any such claim (but only after obtaining Corbus&rsquo;s prior written consent with respect to any proposed settlement,
compromise or litigation; provided, however, that Corbus shall not be required to obtain the CFF Indemnitee&rsquo;s prior written
consent in connection with any proposed settlement, compromise or litigation if, in connection with and following any such settlement,
compromise or litigation, the CFF Indemnitee (a) has no liability (monetary or otherwise), (b) has not waived any of its rights
and has not admitted to any wrongdoing or guilt, (c) is not subject to any injunction or other equitable or non-monetary relief,
and (d) receives a full and unconditional release of all applicable claims and liability).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_023"></A>7.3
Participation; Assuming Control of the Defense</B>. Notwithstanding Section 7.2 above, CFF may participate in the defense of any
claim at its sole expense, with counsel reasonably acceptable to Corbus; provided, however, if (a) there is a conflict of interest
that would prevent Corbus, on the one hand, and CFF, on the other hand, from being represented by a single law firm in the defense
of such action; in each such instance, or (b) there shall be one or more additional or other defenses available to CFF that are
not available to Corbus, then in each such instance Corbus shall pay the reasonable fees and expenses of one law firm serving
as counsel for CFF, which law firm shall be subject to the prior consent of Corbus, which consent shall not be unreasonably withheld,
conditioned or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_024"></A>7.4
Insurance</B>. Corbus shall maintain at its own expense, with a reputable insurance carrier, coverage for Corbus, its Affiliates,
and their respective employees written on a per occurrence basis commensurate with a reasonable assessment of the risks associated
with the conduct of the Development Plans. Maintenance of such insurance coverage will not relieve Corbus of any responsibility
under this agreement for damages in excess of insurance limits or otherwise. Corbus shall provide CFF with an insurance certificate
from the insurers, brokers or agents evidencing the applicable insurance coverage. At its request, CFF may review Corbus&rsquo;
insurance coverages no more than one time per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>7.5
Limitation of Liability</B>. Neither Party shall be liable to the other Party for any special, indirect, incidental, consequential,
punitive or exemplary damages, including, but not limited to, lost profits, in connection with such Party&rsquo;s breach of this
Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="a_026"></A>ARTICLE
VIII &ndash; </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PATENTABLE INVENTIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_027"></A>8.1
Ownership</B>. All inventions relating to the Development Plan invented, conceived or made and all data and know-how generated
with respect thereto exclusively by Corbus or its Affiliates (directly or through others acting on its behalf) during the term
of this Agreement (a &ldquo;<U>Corbus Sole Invention</U>&rdquo;) and all inventions relating to the Development Plan invented,
conceived or made and all data and know-how generated with respect thereto exclusively by CFF or its Affiliates (directly or through
others acting on its behalf) during the term of this Agreement (a &ldquo;<U>CFF Sole Invention</U>&rdquo;) shall be solely owned
by the Party conceiving or making the invention or generating the data or know-how claimed. All inventions relating to the Development
Plan invented, conceived or made and all data and know-how generated with respect thereto by both Parties or their respective
Affiliates (directly or through others acting on its behalf) during the term of this Agreement (a &ldquo;<U>Joint Invention</U>&rdquo;)
shall be jointly owned by the CFF and Corbus. Inventorship shall be determined in accordance with United States laws of inventorship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_028"></A>8.2
Exclusive License Grant</B>. CFF hereby grants, and agrees to grant to Corbus, the consideration of which is acknowledged, an
exclusive (even as to CFF) fully paid up worldwide license with the right to grant sublicenses to all its rights under the CFF
Patents and Joint Patents for all purposes and to CFF Sole Inventions, Joint Inventions, and all information, methods, data and
know-how that CFF controls and is useful to the Development Plan. CFF acknowledges and agrees that it does not retain any rights
to any Sole Invention or any Joint Invention or any Patents claiming such Inventions for any purpose whatsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_029"></A>8.3
Preparation</B>. Corbus will control in its sole discretion the preparation, filing, prosecution, maintenance and enforcement
of all Corbus Patents, CFF Sole Inventions, CFF Patents and Joint Patents. CFF will have the right to review, and Corbus will
deliver to CFF, all patent applications related to CFF Sole Inventions and Joint Inventions prior to their filing. Notwithstanding
the foregoing, nothing herein shall obligate Corbus to prepare or file a patent application directed to any Sole Invention or
Joint Invention. CFF agrees to execute any documents of assignment, declaration, or otherwise reasonably necessary for Corbus
to file, prosecute, maintain and enforce the Corbus Patents, CFF Patents and Joint Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_030"></A>8.4
Costs</B>. Corbus shall be responsible for all costs incurred in the preparation, prosecution, maintenance and enforcement of
Corbus Patents, CFF Patents, and Joint Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_031"></A>8.5
Abandonment</B>. Notwithstanding any contrary provision contained herein, prior to Corbus (or any Affiliate, licensee, sublicensee,
transferee or successor of Corbus) abandoning any Patent or patent application related to any Product (including abandonment for
failure to pay any required fees) for any reason, Corbus shall promptly notify CFF, or cause CFF to be notified, of such pending
abandonment, whereupon CFF shall have the right and opportunity to prosecute or maintain the applicable Patent at CFF&rsquo;s
own expense. Corbus hereby agrees to exercise its good faith efforts to obtain such consents, on CFF&rsquo;s behalf, as may be
necessary, advisable and/or appropriate for CFF to exercise its rights under this Section 8.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_032"></A>8.6
No License</B>. Nothing herein shall be construed as a grant or obligation of grant of any license of any kind or a change of
title from Corbus to CFF or any Third Party under any Patent owned or controlled by Corbus unless explicitly stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><A NAME="a_033"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>ARTICLE
IX &ndash; </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM AND TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_034"></A>9.1
Term</B>. This Agreement shall become effective as of the Effective Date and, unless earlier terminated pursuant to the other
provisions of this Article IX, shall terminate at such time as when there are no longer any payment obligations owing from Corbus
to CFF under Article IV hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_035"></A>9.2
Termination by CFF For Cause</B>. Notwithstanding any provision contained herein or in any other document to the contrary, CFF
may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement upon the occurrence
of any of the following events (each, a &ldquo;<U>Default</U>&rdquo;) (provided, however, that, in each instance (other than pursuant
to Section 9.2(c)), Corbus shall have thirty (30) days following the earlier of Corbus&rsquo;s receipt of written notice from
CFF to Corbus of the occurrence of a Default or Corbus becoming aware of such Default to cure such Default):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.2.1
Any material breach or default by Corbus in the performance of any of its material covenants or obligations hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.2.2
Any representation or warranty made by Corbus in this Agreement is not true in any material respects as of the date made; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.2.3
A case or proceeding (i) under the bankruptcy laws of the United States now or hereafter in effect is filed against Corbus or
all or substantially all of its assets and such petition or application is not dismissed within sixty (60) days after the date
of its filing or Corbus shall file any answer admitting and not contesting such petition, or (ii) under the bankruptcy laws of
the United States now or hereafter in effect or under any insolvency, reorganization, receivership, dissolution or liquidation
law or statute of any jurisdiction now or hereafter in effect (whether at law or equity) is filed by Corbus for all or substantially
all of its assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_036"></A>9.3
Termination for CFF Breach</B>. Corbus may, without prejudice to any other remedies available to it at law or in equity, terminate
this Agreement in the event CFF shall have (a) materially breached or defaulted in the performance of any of its material covenants
or obligations hereunder or (b) any representation or warranty made by CFF in this Agreement is not true in any material respects
as of the date made, and such breach or default shall have continued for thirty (30) days after written notice thereof was provided
to CFF by Corbus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_037"></A>9.4
General Effect of Termination; Survival.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.4.1
Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to
the benefit of any Party prior to such termination or expiration. Such termination or expiration shall not relieve any Party from
obligations which are expressly indicated to survive termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.4.2
If this Agreement is terminated for any reason, all of the Parties&rsquo; rights and obligations under, and/or the provisions
contained in Sections 3.2 and 9.4 and Articles IV, V, VI, VII, VIII, X and XI shall survive termination or expiration of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.4.3
Subject to Section 8.4, upon termination or expiration of this Agreement, Corbus will retain ownership or exclusive rights to
the Corbus Development Plan Technology and the inventions licensed to it by CFF pursuant to Article VIII of this Agreement (including
intellectual property rights).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_038"></A>9.5
Prior Agreement. </B>The Parties previously entered into the Prior Agreement. The terms of the Prior Agreement are not intended
to be affected by this Agreement, and whether or not this Agreement is terminated, the Prior Agreement shall remain in full force
and effect.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><A NAME="a_039"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>ARTICLE
X &ndash; </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_040"></A>10.1
Representations and Warranties of Corbus</B>. Corbus represents and warrants to CFF that: (i) this Agreement has been duly executed
and delivered by Corbus and constitutes the valid and binding obligation of Corbus, enforceable against Corbus in accordance with
its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium
and other laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles; (ii) the execution,
delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Corbus and its directors
and stockholders; (iii) the individual executing this Agreement on behalf of Corbus is duly authorized to do so; and (iv) no provision
contained in this Agreement violates any other agreement to which Corbus is bound or otherwise subject; and (v) without the Award
provided for in this Agreement, the development of the Product for use in the Field either would not be conducted by Corbus or
would be substantially delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_041"></A>10.2
Representations and Warranties of CFF</B>. CFF represents and warrants to Corbus that: (a) this Agreement has been duly executed
and delivered by CFF and constitutes the valid and binding obligation of CFF, enforceable against CFF in accordance with its terms,
except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other
laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles; (b) the execution, delivery
and performance of this Agreement have been duly authorized by all necessary action on the part of CFF and its directors; (c)
the individual executing this Agreement on behalf of CFF is duly authorized to do so; and (d) no provision contained in this Agreement
violates any other agreement to which CFF is bound or otherwise subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><A NAME="a_042"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>ARTICLE
XI &ndash; </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS PROVISIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><A NAME="a_043"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1
Governing Law</B>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Maryland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_044"></A>11.2
Dispute Resolution.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11.2.1
In the event of any dispute, claim or controversy arising out of, relating to or in any way connected to the interpretation of
any provision of this Agreement, the performance of either Party under this Agreement or any other matter under this Agreement,
including any action in tort, contract or otherwise, at equity or law (a &ldquo;<U>Dispute</U>&rdquo;), either Party may at any
time provide the other Party with written notice specifying the nature and terms of such Dispute in reasonable detail. As soon
as practicable after receipt of such notice, the chief executive officers of each of the Parties or their designees shall meet
at a mutually agreed upon time and location for the purpose of resolving such Dispute. Each Party shall engage in good faith discussions
and/or negotiations for a period of up to thirty (30) days to attempt to resolve the Dispute or negotiate an interpretation or
revision of the applicable portion of this Agreement which is mutually agreeable to both Parties without the necessity of formal
dispute resolution procedures relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11.2.2
In the event that such Dispute is not resolved by the Parties in accordance with subparagraph (a), either Party may pursue the
resolution of such Dispute in a court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_045"></A>11.3
Waiver</B>. No provision of this Agreement may be waived except in writing by both Parties hereto. No failure or delay by either
Party hereto in exercising any right or remedy hereunder or under applicable law will operate as a waiver thereof, or a waiver
of any right or remedy on any subsequent occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_046"></A>11.4
Force Majeure</B>. Neither Party will be in breach hereof by reason of its delay in the performance of or failure to perform any
of its obligations hereunder, if that delay or failure is caused by strikes, acts of God or the public enemy, riots, incendiaries,
interference by civil or military authorities, compliance with governmental priorities for materials, or any fault beyond its
reasonable control. In such event Corbus or CFF, as the case may be, shall immediately notify the other Party of such inability
and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from
such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the
extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_047"></A>11.5
Severability</B>. Should one or more provisions of this Agreement be or become invalid, then the Parties hereto shall attempt
to agree upon valid provisions in substitution for the invalid provisions, which in their economic effect come so close to the
invalid provisions that it can be reasonably assumed that the Parties would have accepted this Agreement with those new provisions.
If the Parties are unable to agree on such valid provisions, the invalidity of such one or more provisions of this Agreement shall
nevertheless not affect the validity of the Agreement as a whole, unless the invalid provisions are of such essential importance
for this Agreement that it may be reasonably presumed that the Parties would not have entered into this Agreement without the
invalid provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_048"></A>11.6
Assignment</B>. This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent
of the other Party; provided, however, that either Party may assign this Agreement, without the consent of the other Party, (i)
to any of its Affiliates, if the assigning Party unconditionally guarantees the full performance of its Affiliate&rsquo;s obligations
hereunder, or (ii) in connection with such Party&rsquo;s merger, consolidation or transfer, license or sale of all or substantially
all of the assets of such Party to which this Agreement relates, provided, that the successor, surviving entity, purchaser of
assets, transferee, or other similar party, as applicable, expressly assumes in full in writing such Party&rsquo;s obligations
under this Agreement. Any purported assignment in contravention of this Section 11.6 shall, at the option of the non-assigning
Party, be null and void and of no effect. No assignment shall release either Party from responsibility for the performance of
any accrued obligation of such Party hereunder. This Agreement shall be binding upon and enforceable against the successor to,
or any permitted assignees from, either of the Parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_049"></A>11.7
Counterparts</B>. This Agreement may be executed in duplicate, each of which shall be deemed to be original and both of which
shall constitute one and the same Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_050"></A>11.8
No Agency.</B> Nothing herein contained shall be deemed to create an agency, joint venture, partnership or similar relationship
between CFF and Corbus. Notwithstanding any of the provisions of this Agreement, neither Party to this Agreement shall at any
time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of the other
Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities in connection with or relating
to the obligations of each Party under this Agreement shall be made, paid, and undertaken exclusively by such Party on its own
behalf and not as an agent or representative of the other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_051"></A>11.9
Notice</B>. All communications between the Parties with respect to any of the provisions of this Agreement will be sent to the
addresses set out below, or to such other addresses as may be designated by one party to the other by notice pursuant hereto,
by prepaid, certified air mail (which shall be deemed received by the other Party on the seventh (7<SUP>th</SUP>) business day
following deposit in the mails), or by facsimile transmission, or other electronic means of communication (which shall be deemed
received when transmitted), with confirmation by first class letter, postage pre-paid, given by the close of business on or before
the next following business day, or by a nationally recognized overnight courier (which shall be deemed received on the date of
delivery):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    to CFF:</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr.
    Preston Campbell, III</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President
    and CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4550
    Montgomery Ave.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Suite
    1100N</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bethesda,
    Maryland 20814</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fax:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E-mail:
    <U>Pcampbell@cff.org</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kenneth
    I. Schaner, Esq.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Schaner
    &amp; Lubitz, PLLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4550
    Montgomery Ave.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Suite
    1100N</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bethesda,
    Maryland 20814</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone:
    240-482-2848</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fax:
    202-470-2241</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E-mail:
    <U>ken@schanerlaw.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    to Corbus:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yuval
    Cohen, CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Corbus
    Pharmaceuticals, Inc</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100
    River Ridge Drive</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Norwood,
    MA 02062</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone:
    617-963-0100</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fax:
    617-663-6085</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E-mail:
    <U>ycohen@CorbusPharma.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lowenstein
    Sandler LLP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65
    Livingston Avenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Roseland,
    New Jersey 07068</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attn:
    Michael J. Lerner, Esq.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone:
    973-597-6395</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">E-mail:
    <U>mlerner@lowenstein.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_052"></A>11.10
Headings</B>. The paragraph headings are for convenience only and will not be deemed to affect in any way the language of the
provisions to which they refer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_053"></A>11.11
Entire Agreement</B>. This Agreement contains the entire understanding of the Parties relating to the matters referred to herein,
and may only be amended by a written document, duly executed on behalf of the respective Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_054"></A>11.12
No Impairment</B>. Corbus will not, by amendment of its organizational or governing documents, or through reorganization, recapitalization,
consolidation, merger, dissolution, sale, transfer or assignment of assets, issuance of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms, provisions, covenants or agreements of this Agreement,
but rather will at all times in good faith assist in the carrying out of all such terms, provisions, covenants and agreements
and in the taking of all such actions as may be necessary, advisable or appropriate in order to protect the rights of CFF against
impairment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>[Remainder
of page intentionally left blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the undersigned have executed this Research, Development and Commercialization Agreement as of the date first
written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CYSTIC
    FIBROSIS FOUNDATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CORBUS
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Preston Campbell</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preston
    Campbell</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President
    and CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Signature Page]</P></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="a_1"></A>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Development
Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>A
Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Trial
to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INVESTIGATIONAL
PRODUCT: </B>Lenabasum</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INDICATION:
</B>Cystic fibrosis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INVESTIGATIONAL
SITES/LOCATIONS: </B>Up to 100 sites in North America, Europe, Israel and Australia are planned</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OBJECTIVES
AND ENDPOINTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<FONT STYLE="letter-spacing: -0.15pt">P</FONT><FONT STYLE="letter-spacing: -0.05pt">r</FONT><FONT STYLE="letter-spacing: 0.15pt">i</FONT><FONT STYLE="letter-spacing: -0.05pt">m</FONT>a<FONT STYLE="letter-spacing: -0.05pt">r</FONT>y
<FONT STYLE="letter-spacing: -0.05pt">e</FONT><FONT STYLE="letter-spacing: 0.05pt">ff</FONT>ica<FONT STYLE="letter-spacing: -0.05pt">c</FONT>y
o<FONT STYLE="letter-spacing: 0.05pt">b</FONT>j<FONT STYLE="letter-spacing: -0.1pt">e</FONT><FONT STYLE="letter-spacing: 0.05pt">ct</FONT>ive</B></FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<FONT STYLE="letter-spacing: -0.15pt">P</FONT><FONT STYLE="letter-spacing: -0.05pt">r</FONT><FONT STYLE="letter-spacing: 0.15pt">i</FONT><FONT STYLE="letter-spacing: -0.05pt">m</FONT>a<FONT STYLE="letter-spacing: -0.05pt">r</FONT>y
<FONT STYLE="letter-spacing: -0.05pt">e</FONT><FONT STYLE="letter-spacing: 0.05pt">ndp</FONT>oi<FONT STYLE="letter-spacing: 0.05pt">n</FONT>t</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 18.6pt 0 5.1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
        <FONT STYLE="letter-spacing: -0.05pt">e</FONT>v<FONT STYLE="letter-spacing: -0.05pt">a</FONT>luate the <FONT STYLE="letter-spacing: -0.05pt">e</FONT>f<FONT STYLE="letter-spacing: -0.05pt">f</FONT><FONT STYLE="letter-spacing: 0.15pt">i</FONT><FONT STYLE="letter-spacing: -0.05pt">ca</FONT><FONT STYLE="letter-spacing: 0.2pt">c</FONT>y
        of l<FONT STYLE="letter-spacing: -0.05pt">e</FONT>n<FONT STYLE="letter-spacing: -0.05pt">a</FONT>b<FONT STYLE="letter-spacing: -0.05pt">a</FONT>sum
        20 mg twice <FONT STYLE="letter-spacing: 0.1pt">p</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>r d<FONT STYLE="letter-spacing: 0.15pt">a</FONT>y
        (<FONT STYLE="letter-spacing: 0.1pt">B</FONT><FONT STYLE="letter-spacing: -0.15pt">I</FONT>D) <FONT STYLE="letter-spacing: -0.05pt">c</FONT>ompa<FONT STYLE="letter-spacing: -0.05pt">re</FONT>d
        to pla<FONT STYLE="letter-spacing: -0.05pt">ce</FONT>bo in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he tr<FONT STYLE="letter-spacing: 0.05pt">e</FONT><FONT STYLE="letter-spacing: -0.05pt">a</FONT>t<FONT STYLE="letter-spacing: 0.05pt">m</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>nt
        of <FONT STYLE="letter-spacing: 0.15pt">c</FONT><FONT STYLE="letter-spacing: -0.25pt">y</FONT>st<FONT STYLE="letter-spacing: 0.05pt">i</FONT>c
        fib<FONT STYLE="letter-spacing: -0.05pt">r</FONT>osis (C<FONT STYLE="letter-spacing: -0.05pt">F</FONT>) <FONT STYLE="letter-spacing: 0.2pt">b</FONT>y
        <FONT STYLE="letter-spacing: -0.05pt">a</FONT>s<FONT STYLE="letter-spacing: 0.15pt">s</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>ss<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
        the r<FONT STYLE="letter-spacing: -0.1pt">a</FONT><FONT STYLE="letter-spacing: 0.15pt">t</FONT>e of p<FONT STYLE="letter-spacing: -0.05pt">u</FONT>l<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on<FONT STYLE="letter-spacing: -0.05pt">a</FONT><FONT STYLE="letter-spacing: 0.2pt">r</FONT>y
        <FONT STYLE="letter-spacing: -0.05pt">e</FONT><FONT STYLE="letter-spacing: 0.1pt">x</FONT><FONT STYLE="letter-spacing: -0.05pt">ace</FONT>rb<FONT STYLE="letter-spacing: -0.1pt">a</FONT>t<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons
        <FONT STYLE="letter-spacing: -0.05pt">(</FONT><FONT STYLE="letter-spacing: 0.05pt">P</FONT>E<FONT STYLE="letter-spacing: 0.1pt">x</FONT>)
        using prim<FONT STYLE="letter-spacing: 0.05pt">a</FONT><FONT STYLE="letter-spacing: 0.2pt">r</FONT>y d<FONT STYLE="letter-spacing: -0.05pt">e</FONT>finit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
        of <FONT STYLE="letter-spacing: 0.05pt">P</FONT>Ex</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.3pt 0 4.9pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">R</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.05pt">a</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">te
        of <FONT STYLE="letter-spacing: 0.05pt">P</FONT>Ex using prim<FONT STYLE="letter-spacing: -0.05pt">a</FONT><FONT STYLE="letter-spacing: 0.05pt">r</FONT>y
        d<FONT STYLE="letter-spacing: 0.05pt">e</FONT>finit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on of <FONT STYLE="letter-spacing: 0.05pt">P</FONT>Ex
        with <FONT STYLE="letter-spacing: 0.05pt">l</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>n<FONT STYLE="letter-spacing: -0.05pt">a</FONT>b<FONT STYLE="letter-spacing: -0.05pt">a</FONT>sum
        20 mg B<FONT STYLE="letter-spacing: -0.15pt">I</FONT><FONT STYLE="letter-spacing: 0.15pt">D</FONT>, <FONT STYLE="letter-spacing: -0.05pt">c</FONT>ompa<FONT STYLE="letter-spacing: 0.05pt">r</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>d
        to pla<FONT STYLE="letter-spacing: -0.05pt">ce</FONT>bo, du<FONT STYLE="letter-spacing: -0.05pt">r</FONT>i<FONT STYLE="letter-spacing: 0.15pt">n</FONT>g
        the t<FONT STYLE="letter-spacing: 0.05pt">r</FONT><FONT STYLE="letter-spacing: -0.05pt">ea</FONT><FONT STYLE="letter-spacing: 0.15pt">t</FONT>ment
        p<FONT STYLE="letter-spacing: -0.05pt">e</FONT>riod</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Secondary
efficacy objective</B></FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Secondary
endpoints</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
        To evaluate the efficacy of lenabasum 20 mg BID compared to placebo in the treatment of CF by assessing other efficacy
        endpoints</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.
                                         Event rate of PEx using secondary definition of PEx with lenabasum 20 mg BID compared
                                         to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.
        Time to first new PEx using primary definition of PEx with lenabasum 20 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.
        Time to first PEx using secondary definition of PEx with lenabasum 20 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.
        Change from baseline in CFQ-R respiratory symptom domain with lenabasum 20 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e.
        Change from baseline in FEV1 %</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">predicted
        with lenabasum 20 mg BID</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">compared
        to placebo</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
                                         To evaluate the efficacy of lenabasum 5 mg BID compared to placebo in the treatment of
                                         CF</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.
                                         Rate of pulmonary exacerbations (PEx) using primary definition of PEx with lenabasum
                                         5 mg BID compared to placebo, during the treatment period</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.
                                         Event rate of PEx using secondary definition of PEx with lenabasum 5 mg BID compared
                                         to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.
        Time to first new PEx using primary definition of PEx with lenabasum 5 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.
        Time to first PEx using secondary definition of PEx with lenabasum 5 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e.
        Change from baseline in CFQ-R respiratory symptom domain with lenabasum 5 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f.
        Change from baseline in FEV1 % predicted with lenabasum 5 mg BID compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Tertiary
                                         efficacy objective</B></FONT></P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Tertiary
                                         endpoints</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.9pt; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.9pt; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.9pt; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.9pt; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*]</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11.65pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Pharmacokinetic
    (PK) objectives </B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PK
    endpoints</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Safety
                                         objectives </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Safety
                                         endpoints </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         evaluate safety of lenabasum 20 mg BID and lenabasum 5 mg BID treatment and placebo treatment</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
                                         TEAEs</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.3pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
        Changes in vital signs, physical examination, blood and urine laboratory safety tests and electrocardiograms</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
                                         evaluate tolerability of lenabasum 20 mg BID and lenabasum 5 mg BID treatment</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Treatment
                                         discontinuations with lenabasum treatments compared to placebo</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STUDY
DESIGN:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
is a multicenter, double-blind, randomized, placebo-controlled, parallel group trial of efficacy and safety of treatment of CF
subjects with lenabasum 20 mg BID and lenabasum 5 mg BID.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
trial includes analyses of event rate of and time to PEx. In this study, primary definition of PEx is based on the physician decision
to treat with oral, intravenous or inhaled antibiotic(s) in the presence of at least 4/12 Fuch&rsquo;s criteria. [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
target population is males and females with CF &ge; 12 years of age with FEV1 &ge; 40% predicted and &lt; 100% predicted in
12 months before screening. The target population will be enriched for subjects with increased risk of a new PEx [*].
Subjects must have 2 or 3 new PEx treated with intravenous (IV) antibiotics in the 12 months before screening. Alternatively,
if the subject had only 1 new PEx treated with IV antibiotics in the last 12 months, then that subject must have &ge; 1 other
new PEx treated with oral antibiotics in the last 12 months before screening; [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
Table 1 below for the eligibility criterion by number of new PEx in the 12 months before screening.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Table
1 Eligibility by Number of New PEx in 12 Months before Screening</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New
                                         PEx treated with</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>intravenous
                                         antibiotics, N</B></FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New
                                         PEx treated with oral</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>antibiotics,
                                         N</B></FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Eligible
        by PEx criteria</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2
    or 3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
    requirement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ge;
    1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0,
    &gt; 3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
    applicable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]
subjects will be screened to identify a target of 415 eligible subjects. [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subjects
will be randomized centrally to treatment assignment before dosing in a 2:1:2 ratio to 1 of 3 treatment cohorts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
Cohort 1: Lenabasum 20 mg BID, n = 166</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Cohort 2: Lenabasum 5 mg BID, n = 83</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Cohort 3: Placebo BID, n = 166.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Duration
and Visits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].
Active dosing with study drug is 28 weeks. [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]
they will return 4 weeks after the last dose of study drug [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Efficacy
Assessments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CFQ-R
    questionnaire at screening, [*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Safety
Assessments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STUDY
SCHEMATIC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUBJECTS
(PLANNED): </B>415 subjects</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PATIENT
POPULATION:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Target
population for this study is subjects &ge; 12 years of age with known diagnosis of CF, with history of prior PEx in the last 12
months, [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STUDY
PRODUCTS, DOSE AND MODE OF ADMINISTRATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Study
drugs are [*] of lenabasum 20 mg, lenabasum 5 mg and placebo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lenabasum:
    The preparation of lenabasum that will be used in this study is [*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Placebo:
    [*]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lenabasum
and placebo capsules are identical in terms of appearance. Both are packaged in the same type container closures with the same
number of capsules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DURATION
OF TREATMENT: </B>28 weeks</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DISCONTINUATION
FROM TREATMENT: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Removal
of Subjects from Therapy or Assessments:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
individual subject will have study drug permanently discontinued if any of the following occur in the subject in question:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Withdrawal
    of consent</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pregnancy</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    serious TEAE probably or definitely-related to lenabasum</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    life-threatening AE.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Premature
Termination or Suspension of the Study:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
study may be suspended or prematurely terminated if there is sufficient reasonable cause. If any of the following events occur
in a subject during enrollment, study entry and randomization of new subjects into the study will be suspended until review of
the event in question occurs by the Data Monitoring Committee (DMC):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Administration
of study drug may continue during the time of review in subjects who are already receiving study drug, based on the judgment of
the Chief Medical Officer of Corbus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
expedited and cumulative review of safety data and the circumstances of the event(s) in question will be conducted by the DMC,
with additional external expertise as needed, to make recommendations to Corbus whether screening, randomization, and/or dosing
can resume or should be discontinued, whether the protocol should be modified, or whether the study should be discontinued permanently.
Upon consideration of a cumulative review of safety and other data, the study can be discontinued permanently by Corbus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written
notification, documenting the reason for study suspension or termination, will be provided by Corbus to the investigators and
the respective country regulatory authorities. If the study is suspended or prematurely terminated, the investigators will promptly
inform the reviewing Independent Ethics Committee/Institutional Review Board (hereafter referred to as the Ethics Committee or
EC) at each site and will provide the reason(s) for the suspension or termination. Review and approval by the reviewing EC at
each site is required for resumption of the study in the event the study is interrupted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATISTICAL
ANALYSES:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Statistical Analysis Plan will be completed before database locking and unblinding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
study is expected to enroll approximately 415 subjects, with ~166 subjects each in the lenabasum 20 mg BID and placebo BID cohorts
and ~83 subjects in the lenabasum 5 mg BID cohort [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Efficacy
comparisons will be made between each dose of lenabasum and placebo. The event rate of new PEx will be compared between the lenabasum
and placebo groups [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
time to first PEx, [*] will be used for comparing the [*] between the active and placebo groups. [*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]
endpoints such as [*], change in CFQ-R domain scores, change in FEV1 % predicted, [*],[*],[*], and [*] will be analyzed using
[*].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U><A NAME="a_2"></A>Milestone
Payments and Budget</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Milestone
Payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Milestone</B></FONT></P></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Milestone
    Payment</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Expected
    Milestone Completion Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Upon
    Contract Execution</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10%
    ($2,500,000)</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15%
    ($3,750,000)</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[*]</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>BUDGET</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>[*][NOTE:
Approximately seven pages of this Exhibit B for which confidential treatment has been requested have been omitted and filed separately
with the Securities and Exchange Commission.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U><A NAME="a_3"></A>EXHIBIT
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CFF
Patents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U><A NAME="a_4"></A>Exhibit
D</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants
Awarded to CFF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrant
Certificate No. F-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NEITHER
THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES
NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT
THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS
AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO
THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective
    Date: January 26, 2018</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Void
    After: January 26, 2025</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CORBUS
PHARMACEUTICALS HOLDINGS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WARRANT
TO PURCHASE COMMON STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Corbus
Pharmaceuticals Holdings, Inc.</B>, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), for value received on January 26,
2018 (the &ldquo;<B>Effective Date</B>&rdquo;), hereby issues to The Cystic Fibrosis Foundation (the &ldquo;<B>Holder</B>&rdquo;)
this warrant (the &ldquo;<B>Warrant</B>&rdquo;) to purchase, 1,000,000 shares (each such share as from time to time adjusted as
hereinafter provided being a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares being the &ldquo;<B>Warrant Shares</B>&rdquo;)
of the Company&rsquo;s Common Stock (as defined below), at the Exercise Price (as defined below), as adjusted from time to time
as provided herein, on or before January 26, 2025 (the &ldquo;<B>Expiration Date</B>&rdquo;), all subject to the following terms
and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
used in this Warrant, (i) &ldquo;<B>Business Day</B>&rdquo; means any day other than Saturday, Sunday or any other day on which
commercial banks in the City of New York, New York, are authorized or required by law or executive order to close; (ii) &ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company, par value $0.0001 per share, including any securities issued or issuable
with respect thereto or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend,
stock split, stock combination, recapitalization, reclassification, reorganization or other similar event; (iii) &ldquo;<B>Exercise
Price</B>&rdquo; means $13.20 per share of Common Stock, subject to adjustment as provided herein; (iv) &ldquo;<B>Trading Day</B>&rdquo;
means any day on which the Common Stock is traded (or available for trading) on its principal Trading Market (as defined below);
and (v) &ldquo;<B>Affiliate</B>&rdquo; means any person that, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with, a person, as such terms are used and construed in Rule 144 promulgated under
the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;). For purposes hereof, &ldquo;<B>Trading Market</B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market,
or any other national securities exchange, as well as the OTC Bulletin Board or any tier of the OTC Markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DURATION
    AND EXERCISE OF WARRANTS </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
<U>Exercise Period</U>. Commencing on the Effective Date of this Warrant, the Holder may exercise this Warrant for up to 500,000
shares of Common Stock (the &ldquo;<B>Initial Exercise Amount</B>&rdquo;). Upon the Completion of the CF Trial (as defined below),
the Holder may exercise this Warrant for the remaining 500,000 shares of Common Stock (the &ldquo;<B>Additional Exercise Amount</B>&rdquo;)
issuable pursuant to the terms of this Warrant. At no point in time, may the Holder exercise this Warrant for more than 1,000,000
shares of Common Stock in the aggregate. The Holder may exercise this Warrant, in whole or in part (in accordance with the limitations
set forth in this Section 1(a)), on any Business Day on or before 5:00 P.M., Eastern Time, on the Expiration Date, at which time
this Warrant shall become void and of no value. For purposes of this Warrant, the term &ldquo;<B>Completion of the CF Trial&rdquo;
</B>shall mean completion of the final Milestone by the Company and receipt of the final Milestone Payment by the Company from
Cystic Fibrosis Foundation as set forth in Exhibit B to the Cystic Fibrosis Program Related Investment Agreement by and between
Corbus Pharmaceuticals, Inc. and Cystic Fibrosis Foundation dated January 26, 2018.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
<U>Exercise Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
While this Warrant remains outstanding and exercisable in accordance with Section 1(a) , the Holder may exercise this Warrant
in whole or in part at any time and from time to time by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)
delivery to the Company of a duly executed copy of the Notice of Exercise attached as <B>Exhibit A</B>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)
surrender of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company
may specify in writing to the Holder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(C)
payment of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise
of the Warrant (such amount, the &ldquo;<B>Aggregate Exercise Price</B>&rdquo;) made in the form of cash, or by certified check,
bank draft or money order payable in lawful money of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
Upon the exercise of this Warrant in compliance with the provisions of Section 1(a) and this Section 1(b), the Company shall promptly
issue and cause to be delivered to the Holder a certificate for the Warrant Shares purchased by the Holder. Each exercise of this
Warrant shall be effective immediately prior to the close of business on the date (the &ldquo;<B>Date of Exercise</B>&rdquo;)
that the conditions set forth in this Section 1(b) have been satisfied, as the case may be. On the first Business Day following
the date on which the Company has received each of the Notice of Exercise and the Aggregate Exercise Price (the &ldquo;<B>Exercise
Delivery Documents</B>&rdquo;), the Company shall transmit an acknowledgment of receipt of the Exercise Delivery Documents to
the Company&rsquo;s transfer agent (the &ldquo;<B>Transfer Agent</B>&rdquo;). On or before the second Business Day following the
date on which the Company has received all of the Exercise Delivery Documents (the &ldquo;<B>Share Delivery Date</B>&rdquo;),
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)
Fast Automated Securities Transfer Program, upon the request of the Holder, credit such aggregate number of shares of Common Stock
to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC
through its Deposit Withdrawal Agent Commission system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated
Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Notice of Exercise, a
certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
<U>Partial Exercise</U>. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the
number of Warrant Shares referenced by this Warrant for which the Warrant is then currently exercisable. If this Warrant is submitted
in connection with any exercise pursuant to Section 1 and the number of Warrant Shares represented by this Warrant submitted for
exercise is greater than the actual number of Warrant Shares being acquired upon such an exercise, then the Company shall as soon
as practicable after any exercise and at its own expense, issue a new Warrant of like tenor representing the right to purchase
the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
<U>Disputes</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute
in accordance with Section 16.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ISSUANCE
    OF WARRANT SHARES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
The Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
The Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record
holder of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner thereof for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
The Company will not, by amendment of its certificate of incorporation, by-laws or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist
in the carrying out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to
protect the rights of the Holder to exercise this Warrant, or against impairment of such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ADJUSTMENTS
    OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from
time to time upon the occurrence of certain events described in this Section 3; <U>provided</U>, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less
all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into
shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment,
the Company shall use its commercially reasonable efforts to obtain the necessary stockholder consent to increase the authorized
number of shares of Common Stock to make such an adjustment pursuant to this Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
<U>Subdivision or Combination of Stock</U>. In case the Company shall at any time subdivide (whether by way of stock dividend,
stock split or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced and the number of Warrant Shares, the Initial Exercise
Amount and the Additional Exercise Amount shall be proportionately increased, and conversely, in case the outstanding shares of
Common Stock of the Company shall be combined (whether by way of stock combination, reverse stock split or otherwise) into a smaller
number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased and the
number of Warrant Shares, the Initial Exercise Amount and the Additional Exercise Amount shall be proportionately decreased. The
Exercise Price, the Warrant Shares, the Initial Exercise Amount and the Additional Exercise Amount, as so adjusted, shall be readjusted
in the same manner upon the happening of any successive event or events described in this Section 3(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
<U>Dividends in Stock, Property, Reclassification</U>. If at any time, or from time to time, all of the holders of Common Stock
(or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become
entitled to receive, without payment therefore:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)
any shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common
Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other
distribution, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)
additional stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination
of shares or similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect
of which shall be covered by the terms of Section 3(a)(i) above), then and in each such case, the Exercise Price and the number
of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted proportionately, and the Holder hereof shall,
upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon,
and without payment of any additional consideration therefor, the amount of stock and other securities and property (including
cash in the cases referred to above) that such Holder would hold on the date of such exercise had such Holder been the holder
of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares
or all other additional stock and other securities and property. The Exercise Price and the Warrant Shares, as so adjusted, shall
be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii)<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)
<U>Reorganization, Reclassification, Consolidation, Merger or Sale</U>. If any recapitalization, reclassification or reorganization
of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all
or substantially all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be
entitled to receive stock, securities, or other assets or property (an &ldquo;<B>Organic Change</B>&rdquo;), then, as a condition
of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter
have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable
and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal
to the number of shares of such stock immediately theretofore purchasable and receivable assuming the full exercise of the rights
represented by this Warrant. In the event of any Organic Change, appropriate provision shall be made by the Company with respect
to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provisions for
adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this Warrant) shall
thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof.
The Company will not affect any such consolidation, merger or sale unless, prior to the consummation thereof, the successor corporation
(if other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall assume
by written instrument reasonably satisfactory in form and substance to the Holder executed and mailed or delivered to the registered
Holder hereof at the last address of such Holder appearing on the books of the Company, the obligation to deliver to such Holder
such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase.
If there is an Organic Change, then the Company shall cause to be mailed to the Holder at its last address as it shall appear
on the books and records of the Company, at least 10 calendar days before the effective date of the Organic Change, a notice stating
the date on which such Organic Change is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares for securities, cash, or other property delivered upon
such Organic Change; provided, that the failure to mail such notice or any defect therein or in the mailing thereof shall not
affect the validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise this Warrant
during the 10-day period for the amount of shares of Common Stock for which this Warrant is then currently exercisable commencing
on the date of such notice to the effective date of the event triggering such notice. In any event, the successor corporation
(if other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall be deemed
to assume such obligation to deliver to such Holder such shares of stock, securities or assets even in the absence of a written
instrument assuming such obligation to the extent such assumption occurs by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
<U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company
at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each
Holder a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting
forth: (i) such adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at
the time would be received upon the exercise of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
<U>Certain Events</U>. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but
the lack of any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the
basic intent and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the
Holder under this Warrant in accordance with the basic intent and principles of such provisions, then the Company&rsquo;s Board
of Directors will, in good faith, make an appropriate adjustment to protect the rights of the Holder; <U>provided</U>, that no
such adjustment pursuant to this Section 3(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RESERVED</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TRANSFERS
    AND EXCHANGES OF WARRANT AND WARRANT SHARES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
<U>Registration of Transfers and Exchanges</U>. Subject to Section 5(c), upon the Holder&rsquo;s surrender of this Warrant, with
a duly executed copy of the Form of Assignment attached as <B>Exhibit B</B>, to the Secretary of the Company at its principal
offices or at such other office or agency as the Company may specify in writing to the Holder, the Company shall register the
transfer of all or any portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in
substantially the form of this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in
similar form, evidencing the remaining acquisition rights not transferred, to the Holder requesting the transfer. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
<U>Warrant Exchangeable for Different Denominations</U>. The Holder may exchange this Warrant for a new Warrant or Warrants, in
substantially the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares which may
then be purchased hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase
such number of Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed
instructions regarding such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
<U>Restrictions on Transfers</U>. This Warrant may not be transferred at any time without: (i) registration under the Securities
Act; or (ii) an exemption from such registration and a written opinion of legal counsel addressed to the Company that the proposed
transfer of the Warrant may be effected without registration under the Securities Act, which opinion will be in form and from
counsel reasonably satisfactory to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
<U>Permitted Transfers and Assignments</U>. Notwithstanding any provision to the contrary in this Section 5, the Holder may transfer,
with or without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder&rsquo;s Affiliates
without obtaining the opinion from counsel that may be required by Section 5(c)(ii), <U>provided,</U> that the Holder delivers
to the Company and its counsel certification, documentation, and other assurances reasonably required by the Company&rsquo;s counsel
to enable the Company&rsquo;s counsel to render an opinion to the Company&rsquo;s Transfer Agent that such transfer does not violate
applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MUTILATED
    OR MISSING WARRANT CERTIFICATE </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Warrant is mutilated, lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in
exchange for and upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new
Warrant, in substantially the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares;
<U>provided</U>, that, as a prerequisite to the issuance of a substitute Warrant, the Company may require satisfactory evidence
of loss, theft or destruction as well as an indemnity from the Holder of a lost, stolen or destroyed Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PAYMENT
    OF TAXES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company will pay all transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant
and the Warrant Shares (and replacement Warrants) including, without limitation, all documentary and stamp taxes; <U>provided</U>,
<U>however</U>, that the Company shall not be required to pay any tax in respect of the transfer of this Warrant, or the issuance
or delivery of certificates for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other
than to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FRACTIONAL
    WARRANT SHARES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
fractional Warrant Shares shall be issued upon exercise of this Warrant. The Company, in lieu of issuing any fractional Warrant
Share, shall round up the number of Warrant Shares issuable to nearest whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NO
    STOCK RIGHTS AND LEGEND </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
holder of this Warrant, as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that
may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder
of this Warrant, as such, the rights of a stockholder of the Company or the right to vote for the election of directors or upon
any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or to receive
notice of meetings or other actions affecting stockholders (except as provided herein), or to receive dividends or subscription
rights or otherwise (except as provide herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
certificate for Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued
to any subsequent transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the
following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;),
OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER
OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR
APPLICABLE STATE SECURITIES LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LOCK-UP
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
Warrant Shares acquired pursuant to an exercise of this Warrant must not be transferred, sold, hypothecated or otherwise disposed
for a period of one year from the date on which the Share Delivery Date .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOTICES
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
notices, consents, waivers, and other communications under this Warrant must be in writing and will be deemed given to a party
when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b)
sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee,
if sent by certified mail, return receipt requested, if to the registered Holder hereof; or (d) seven (7) days after the placement
of the notice into the mails (first class postage prepaid), to the Holder at the address, facsimile number, or e-mail address
furnished by the registered Holder to the Company in accordance with the Subscription Agreement by and between the Company and
the Holder, or if to the Company, to it at One Kendall Square, Bldg 200, Cambridge, MA 02139, Attn: Yuval Cohen, CEO (or to such
other address, facsimile number, or e-mail address as the Holder or the Company as a party may designate by notice the other party).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SEVERABILITY
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
a court of competent jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant
will remain in full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will
remain in full force and effect to the extent not held invalid or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BINDING
    EFFECT </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Warrant shall be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered
Holder or Holders from time to time of this Warrant and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SURVIVAL
    OF RIGHTS AND DUTIES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Warrant shall terminate and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date
or the date on which this Warrant has been exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GOVERNING
    LAW </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Warrant will be governed by and construed under the laws of the State of New York without regard to conflicts of laws principles
that would require the application of any other law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DISPUTE
    RESOLUTION </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the
Notice of Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to
agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed
determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two Business Days, submit
via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company&rsquo;s independent,
outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform
the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from
the time it receives the disputed determinations or calculations. Such investment bank&rsquo;s or accountant&rsquo;s determination
or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOTICES
    OF RECORD DATE </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Upon
(a) any establishment by the Company of a record date of the holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or other distribution, or right or option to acquire securities of
the Company, or any other right; or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation
of the Company with or into any other corporation, any transfer of all or substantially all the assets of the Company, or any
voluntary or involuntary dissolution, liquidation or winding up of the Company, or the sale, in a single transaction, of a majority
of the Company&rsquo;s voting stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any
combination thereof), the Company shall mail to the Holder at least ten (10) Business Days, or such longer period as may be required
by law, prior to the record date specified therein, a notice specifying; (i) the date established as the record date for the purpose
of such dividend, distribution, option or right and a description of such dividend, option or right; (ii) the date on which any
such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected
to become effective;and (iii) the date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange
their shares of Common Stock for securities or other property deliverable upon such reorganization, reclassification, transfer,
consolation, merger, dissolution, liquidation or winding up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RESERVATION
    OF SHARES </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company shall reserve and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise
of this Warrant, free from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to
time be exercisable. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation. Without limiting the generality of the foregoing,
the Company covenants that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this
Warrant and use commercially reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited
to consents from the Company&rsquo;s stockholders or Board of Directors or any public regulatory body, as may be necessary to
enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NO
    THIRD PARTY RIGHTS </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Warrant is not intended, and will not be construed, to create any rights in any parties other than the Company and the Holder,
and no person or entity may assert any rights as third-party beneficiary hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[SIGNATURE
PAGE FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CORBUS
    PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 54%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:
    &nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBIT
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOTICE
OF EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(To
be executed by the Holder of Warrant if such Holder desires to exercise Warrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
Corbus Pharmaceuticals Holdings, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
undersigned hereby irrevocably elects to exercise this Warrant and to purchase thereunder, [ ] full shares of Corbus Pharmaceuticals
Holdings, Inc. Common Stock issuable upon exercise of the Warrant and delivery of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$[
] (in cash as provided for in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant to such Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
undersigned requests that certificates for such shares be issued in the name of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
                                         print name, address and social security or federal employer identification number (if
                                         applicable))</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
the shares issuable upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire
upon the exercise of the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued
in the name of and delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
    print name, address and social security or federal employer identification number (if applicable))</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Holder (print): </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Signature):
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(By:)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Title:)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBIT
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FORM
OF ASSIGNMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FOR
VALUE RECEIVED, [ ] hereby sells, assigns and transfers to each assignee set forth below all of the rights of the undersigned
under the Warrant (as defined in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set opposite the
name of such assignee below and in and to the foregoing Warrant with respect to said acquisition rights and the shares issuable
upon exercise of the Warrant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
                                         of Assignee</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number
                                         of Shares</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
the total of the Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests
that a new Warrant evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to
the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Holder (print): </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Signature):
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(By:)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Title:)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
23.1</B></FONT></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
consent to the incorporation by reference in the Registration Statements of Corbus Pharmaceuticals Holdings, Inc. on Form S-3 (No.
333-222447) and Form S-8 (Nos. 333-200350, 333-201898, 333-210428 and 333-216547) of our report dated March 12, 2018, on our audits
of the consolidated financial statements as of December 31, 2017 and 2016 and for each of the years in the three-year period ended
December 31, 2017, which report is included in this Annual Report on Form 10-K to be filed on or about March 12, 2018. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    EisnerAmper LLP</I></FONT></TD>
    <TD STYLE="width: 50%; font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EISNERAMPER
    LLP</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Iselin,
    New Jersey</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2018</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Yuval Cohen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K for the period ended December 31, 2017 of Corbus Pharmaceuticals Holdings, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Sean M. Moran, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K for the period ended December 31, 2017 of Corbus Pharmaceuticals Holdings, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting and Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Executive Officer Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.
This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act
and is not intended to be used for any other purpose. In connection with the accompanying Annual Report on Form 10-K of Corbus
Pharmaceuticals Holdings, Inc. for the year ended December 31, 2017, each of the undersigned hereby certifies in his capacity
as an officer of Corbus Pharmaceuticals Holdings, Inc. that to such officer&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
The Annual Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 12, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Financial Officer Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section&nbsp;1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Certification is being filed pursuant to 18 U.S.C. Section&nbsp;1350, as adopted by Section&nbsp;906 of the Sarbanes-Oxley Act
of 2002. This Certification is included solely for the purposes of complying with the provisions of Section&nbsp;906 of the Sarbanes-Oxley
Act and is not intended to be used for any other purpose. In connection with the accompanying Annual Report on Form 10-K of Corbus
Pharmaceuticals Holdings, Inc. for the year ended December&nbsp;31, 2017, each of the undersigned hereby certifies in his capacity
as an officer of Corbus Pharmaceuticals Holdings, Inc. that to such officer&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Annual Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp;Sean
    Moran</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;March
    12, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting and Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ': [<# 2(  A$! Q$!_\0
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M0 [-+FH\T9H DS2YJ/-.S0,=129HH 6BDHH YBBEHH,Q***6@ HHHH ****
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M? ^I2"!);FPM[F9=T=M/-MD8?[H!_P ]:AL_"%]<VES<R75C:Q6TI@E:>XP
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M_P"SM/M=MJQW6T/EL?8G/2GZ5;R:5X1M?)O+&UN[V5;@M=2[ 5!! ''/1?\
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MBT^_X?\ !&G#L_O_ . ;JZ5<?\]K'_P/A_\ BZD72[C_ )[6/_@=!_\ %UA
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M/@_^+J*;_D7[/_K[G_\ 0(JS#4PYY*]_Z^\<E!/9_?\ \ U#H]S_ ,]]/_\
M!A!_\733HUS_ ,]]/_\ !A!_\764:::NT^_X?\$S?)V?W_\  -7^QKG_ )[Z
M?_X,+?\ ^+I/[&N?^>^G_P#@QM__ (NL@TAHM/O^'_!$O9]G]_\ P#7_ +%N
M?^>VG_\ @QM__BZ/[&NO^>^G_P#@QM__ (NL:BE:??\ #_@C]SL_O_X!L_V-
M<_\ /?3_ /P8P?\ Q=']C7/_ #WT_P#\&,'_ ,76-11:??\ #_@CM#L_O_X!
ML_V-<_\ /?3_ /P8V_\ \72?V-<_\]]._P#!C!_\76/13M/O^'_!"T.S^_\
MX!L_V-<_\]]/_P#!C!_\72_V/<_\]]._\&-O_P#%UBT46GW_  _X(K4^S^__
M (!M?V/<_P#/?3O_  8V_P#\71_8]S_SWT[_ ,&-O_\ %UBTE%I]_P /^"%J
M?9_?_P  V_['N?\ GOI__@QM_P#XNG1Z%>R,5CDL78*6(6_@)P 23]_H "?P
MK"K2T/\ X_Y?^O.Z_P#1$E*?/%-W_#_@EQC3E)*S^_\ X!9_L>Y_Y[Z=_P"#
M&W_^+H_L>Y_Y[Z=_X,;?_P"+K$HIVGW_  _X)%J?9_?_ , VO[&N?^>^G?\
M@Q@_^+H_L:Y_Y[Z=_P"#&#_XNL6BBT^_X?\ !"U/L_O_ . ;7]C7/_/?3O\
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M?[(N/^?C3O\ P8V__P 73WT.\B8+)+8(Q4, U_ #@@$'[_0@@CZUSU:>M_\
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M_LJ;_GXT[_P8V_\ \77/T46GW_#_ ((6AV?W_P# .@_LJ;_GYT[_ ,&%O_\
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M_P#!A!_\77+4M'+/O^'_  1VAV?W_P# .I_LY_\ GZT[_P &$'_Q=+_9S_\
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M[-.!IE+FF2R4-3@U0YIV: N3!J7=4(:EW4#N3;J7=46ZC=0.Y+NI=U1;J-U
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M_P#3[_Y"_P#KUT IXI?ZSYI_S]_\EC_D'LX]CG?^$3_Z??\ R%_]>C_A$O\
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M#_\ I^_\@_\ V5+_ ,(A_P!/W_D'_P"RKJ.*.*/]:<U_Y^_^2Q_R#V<3E_\
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MO_PAW'_'_P#^0?\ [*KND^%?LVM6%Q]LW^7<1OL\K&<,#ZUMU8L_^/\ MO\
MKJO_ *$*TI<2YI4G&$JNC?\ +'_(TIP7.CC_ /A#_P#I_P#_ "#_ /94O_"'
M?]/_ /Y!_P#LJZ>BL_\ 6C-?^?O_ )+'_(SY(G+_ /"'?]/_ /Y!_P#LJ/\
MA#O^G_\ \@__ &5=111_K3FO_/W_ ,EC_D')$Y?_ (0W_I__ /(/_P!E1_PA
MO_3_ /\ D'_[*NHHH_UHS7_G[_Y+'_(.2)RO_"&G_G__ /(/_P!E1_PAI_Y_
M_P#R#_\ 95U5%'^M.:_\_?\ R6/^0<B.0N_"$T-JTD%SYSKSY?E[<_3DUS)!
M!((P1U%>K5S7B+0?M&Z]M$_?#F1!_'[CW_G7T.1\55)U?88Z5[[2T5O)VLK>
M?W^4RAU1QM)2TE??F8E%%%,0M%)2TABUU@_Y FC_ /7J_P#Z/EKDZZL?\@71
MO^O1_P#T?+653=?UT92^%_UU0P44"BF8F%5BRO;C3KQ+NUD\N:,Y5]H..,=#
MQWJ"IK2TFO[N*UMT+2R,%4>II.UM1*]]#H3\0/$9C*B\C5B,&18$#?RK"MKF
M[_M..YAD=KLRAU<\L7SP>>O/K6])X-6W=HI_$&D13KPT;3_=/H3BN?O+7['=
MRP>?!/Y9QYL#[D;Z'O6-/V-_<1O6]O;]XW]YTWQ#OI)];@LI)?,:TMU61L ;
MI",L>..>*J6_CG7K:".%+B(K$H6,M A*@# [5SE:VOZ(="OH;<W G\V!9MP3
M;C=GCJ?2A4Z<8JG+4)5JDIRJQT^?W%275;Z;5!J4ER[7@<.)#U!'3V_"KVI^
M*=6U:.);F=/W4@E5HXU1MXZ'(&<UC45K[..FFQE[6>NN^YTW_">^(-HW7,+2
M 8$C6Z%OSQ6/'K6H1)?HEQA;_P#X^1L7Y^2?3CJ>F*H4E)48+9(IUJCWD_O+
M=KJ=W8V]S!;R^7%=)LE7:#O7TY''7M2VFIWEA;75O;3;(KI/+G7:#O7GCD<=
M3TJG4]I +J\B@::.%9'"F64X5,]R?2J<8]40IR5K,EEU.[GTV#3Y)LVMNQ>*
M/:!M)Z\XR>O>MB#QUX@AMU@^V)(%7:K20HS ?4CG\:PKJW%K=S6ZS1S"-RHE
MB.5?'<'TJ"H=.G):HM5*D'HVGL/EE>>9Y9#EW8LQQC)/)Z4RBBM-D9MWU8M+
M3:4&F(=2YIM%-$V'9HS3<TM,!V:7=3** ),T9IE&:!W'YHS3,TN: N.S29I*
M* +=]_R+>G_]?EQ_Z!#62*UK[_D6]/\ ^ORX_P#0(:R17YWF_P#OM3^NB/07
MPKT0\5V'P[TF#5/$;?:H8YH886<I(H923@#(/U/Y5QXZUZ=\-D6PT'5M6DX
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M=Q_'_P#6KG*_9>'J>,IX*,<6]>BZI>?]:+\,)VOH%%%%>X2%%)2TQBUU8_Y
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M-:GJVD7UH8[30(K.;<"LR7#-@=Q@\&NC\2Z8=7\;:1IX8H)K2/<PZA1N)_'
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M_P#(A[1'=45PG_"1:K_S]?\ D-?\*/\ A(M5_P"?K_R&O^%'^I./_GA]\O\
MY$/:([NBN#_X2+5?^?K_ ,AK_A1_PD6J_P#/U_Y#7_"C_4K'_P \/OE_\B'M
M$=Y17(Q:WJ+:'=W)N,RQW,,:ML7A660D8QCJJ_E5#_A(]5_Y^O\ R&O^%2N"
M\>_MP^^7^13FE8[VBN"_X2/5?^?O_P AK_A2?\)'JW_/W_Y#3_"J_P!2L?\
MSP^^7_R)/M4=]17 _P#"1ZM_S]_^0T_PH_X2/5O^?O\ \AI_A1_J5C_YX??+
M_P"1#VJ.^HK@?^$DU;_G[_\ (:?X4?\ "2:M_P _?_D-/\*/]2L?_/#[Y?\
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M_P#(:_X5'^I6/_GA]\O_ )$S]HCO:*X'_A(]6_Y^_P#R&G^%'_"1ZM_S]_\
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MII*4TE "'K12TE(84E+2=J!A24M)0 5IZ%_R$)O^O.Z_]$25F5IZ%_R$)O\
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M+U.WX_\  "T.[^[_ ()F&D-:?_"0ZU_T&=0_\"7_ ,:;_P )%K?_ $&-0_\
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M_P"$CUW_ *#.H_\ @2_^-'_"1Z[_ -!G4?\ P)?_ !HO4[?C_P  +0[O[O\
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M%/\ XT?\)'KO_0:U'_P*?_&C]YV_'_@!:'=_=_P3,HK2_P"$DUW_ *#6H_\
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M6H_^!3_XT7J=OQ_X 6AW_#_@F;6EX=_Y&;2?^OR+_P!#%'_"1ZY_T&M1_P#
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M0A_Z\K7_ -)XZC[:^?Z%KX'ZK]3,HHHK0@;12FDI#"EI** %I:;2TP%HI**
M'4E%% !1244 +24E% S4@_Y%>_\ ^OVV_P#0)ZS*TX/^17O_ /K]MO\ T">L
MNLX;O^NB+ELO3]6+124M:$!2TE+0,**** "BBB@ I:2B@84M)2T %%%% !6G
MX=_Y&?2?^OR'_P!#%9E:?AW_ )&;2?\ K\A_]#%9U?X<BZ7QHS:2EI*T)"DI
M:2@!*2EHH 2BBB@!**** $HHHH *2EHH 2BBB@ KJ#_R!M&_Z]7_ /1\M<O7
M4'_D#:-_UZO_ .CY:RJ;K^NC']F7]=4044M%,P,BEI**0QU%(**!"T49HS3
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MW_\ 'U_QKK!3A2_URQW\D/N?^8>RB<C_ &)J/_/O_P"/K_C2_P!AZC_S[_\
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M[UZ1XOT@WFCV,UREJNJF=(7:WSMDW'&.>3V//3FK7BSQ'-X>N;+3["W@>01
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M\GE  >61@XZ'.013-3\06%SHL>FV5K+!&&4D'& HYX.<DY]:X'^V\'_CW_\
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M ,B?_6I?ZLYI_P ^O_)H_P"8<\3?%/%<[_PDO_3I_P"1/_K4[_A)_P#IS_\
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M_D;_ .QH_P!5LU_Y]?\ DT?\P]I$ZOBCBN4_X3+_ *</_(W_ -C2_P#"9?\
M3A_Y&_\ L:/]5LU_Y]?^31_S#VD3J:*Y]/%&_39[S[)CRIHXMGF==RN<YQVV
M?K[56_X3'_IP_P#(W_V-+_5C-?\ GU_Y-'_,;G%'4T5RW_"9?].'_D;_ .QH
M_P"$R_Z</_(W_P!C3_U7S7_GU_Y-'_,/:1.IHKE_^$R_Z</_ "-_]C1_PF7_
M $X?^1O_ +&C_5?-?^?7_DT?\PYXG445RW_"9?\ 3A_Y&_\ L:/^$R_Z</\
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M ,P31O\ KU?_ -'RUE/=?UT97V7_ %U17HIU%,P,6D[4M)2$%)2TE PHHHI
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M^H?^!R?_ !FCG?;\O\PY5_,OQ_R,NDK4,^B_] _4/_ Y/_C-)Y^B?] _4/\
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M]"_Z!VH_^#!/_C-'GZ%_T#M1_P#!@G_QFCG?;\O\PY%_,OQ_R,JEK3\[0O\
MH':C_P"!\?\ \9I?.T+_ *!VH_\ @>G_ ,9HYWV_+_,.5?S+\?\ (S**U/.T
M/_H':C_X'I_\9H\[0_\ H':C_P"!Z?\ QFCG?;\O\Q\J[K\?\C,HK4\_0_\
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M+Y^A_P#0.U#_ ,#D_P#C-7SOM^7^9'(N_P"?^1F45I^?H?\ T#M0_P# Y/\
MXS1Y^A_] [4/_ Y/_C-'.^WY?YARKO\ G_D9E%:?GZ'_ - [4/\ P.3_ .,T
M>?H?_0.U#_P.3_XS1SOM^7^8<J[_ )_Y&925I^?H?_0.U'_P.3_XS1Y^A_\
M0.U'_P #D_\ C-'.^WY?YAR+O^?^1F4E:GGZ)_T#M1_\#T_^,TGG:'_T#M1_
M\#T_^,T<[[?E_F'(N_Y_Y&925J>=H?\ T#M1_P# ]/\ XS2>=H?_ $#M1_\
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M/^M%'_GV_O0O8ON4Z,U>$:?W%_*GB*/^XOY4O]::/_/M_>@]B^YG45J"*/\
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MT_KHRU\+_KJB/%%/Q108G+58T^U^W:C;6F_R_/F2+?C.W<0,X[]:KUI>'_\
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M_P#P80?_ !='M8=Q^RJ=F9M%:/\ 8EW_ ,]=/_\ !C!_\71_8EW_ ,]=/_\
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M"N_^>VG_ /@Q@_\ BZ/:P[A[.?9F;16E_85W_P ]M/\ _!C!_P#%T?V%=_\
M/;3_ /P8P?\ Q='M8=P]G/LS,HK3_L*[_P">VG_^#&#_ .+I?["N_P#GKIW_
M (,8/_BZ/:P[A[.?9F6*T]#_ .0A+_UYW7_HB2E_L*[_ .>VG_\ @Q@_^+J_
MHVBW27TC&6R(-K<+\M_ QYA<#H_3GKVZGBHJ5(<CU+I4Y\ZT>YSM.K2_L*[_
M .>VG_\ @Q@_^+H_L.[_ .>VG_\ @Q@_^+K3VL.YG[*?9F<*=6A_8=W_ ,]M
M/_\ !C!_\73AH=W_ ,]M/_\ !A!_\72]I3[C]E/LS.IU:/\ 8EW_ ,]M/_\
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MM/\ _!C!_P#%T?V'=_\ /;3_ /P8P?\ Q=:>VAW,_93[&916C_85W_SVT_\
M\&,'_P 71_85W_SVT_\ \&,'_P 71[6GW#V4^QFT5I_V%=_\]=/_ /!C!_\
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M4D'\#43G"4E9_P!697+)1=U_5T-HI**HP.4HI:2J,!****!A1112 *6FTM,
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MIO\ TU_\=_\ KTO]8<M_Y^?A+_(/9R[%"BM#^R_^FW_CO_UZ<-*_Z;?^.?\
MUZ7^L66?\_/PE_D'LY=C.K2T7_C^D_Z\[K_T1)2_V3_TW_\ '/\ Z]6["R^R
M3O)YI;=%)'@+C[\;)G\-V?PJ:G$66N#7M/PE_D7"#4DV85+6K_8__3?_ ,<_
M^O2C1O\ IO\ ^.?_ %Z?^LF6?\_?PE_D3R2,L"EK5&C?]-__ !S_ .O3AHO_
M $\?^.?_ %Z7^LF5_P#/W_R67^0^21E 4ZM0:-_TW_\ '/\ Z]._L7_IX_\
M'/\ Z]+_ %ERS_G[_P"2R_R'R2,FBM?^Q/\ IX_\<_\ KTO]A_\ 3Q_XY_\
M7H_UFRO_ )^_^2R_R#DD8]%;/]A?]//_ (Y_]>E_L#_IY_\ (?\ ]>E_K-E7
M_/W_ ,EE_D'(S$I*W?\ A'_^GK_R'_\ 7H_X1W_IZ_\ (?\ ]>C_ %GRK_G[
M_P"2R_R#DD85)6__ ,(Y_P!/?_D/_P"O1_PC7_3W_P"0_P#Z]+_6?*O^?O\
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M,HI:*T(&T4M% "4E+10 E)BG44#$I*=10(2DI:* $I*6DH 2DI:* $KL(/\
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M!PIXI@IXJ6,44X4T4X5(#A3A313A4L!PI:04M2 4444 %%%% !1110 4444
M+TK&U;5A;@V]N<S'[S?W?_KT:MJXM@;>W.9C]YO[G_UZYK))))R3U-?<\.<.
M>VMBL4O=Z+OYOR[+KZ;Q*71 <DDDY)ZDT44M?HQD%%%% "T444#-"'_D7;W_
M *^H/_0)JSZT(?\ D7;W_KZ@_P#0)JSZB&[_ *Z(N6R_KJPI*6BK)$I*6B@!
MM-I])0 RDIU)3$-HI:2@!*2G4E #:*6DH *T/#__ ",FE_\ 7Y#_ .ABL^M'
M0/\ D9-+_P"OR'_T,5%7X)%TOC1F44M)5D!24M% "4E+10 E%+10 E%+24Q"
M4E.I* $IM.I* $I*6B@!M=E;_P#("TC_ *]W_P#1\M<=796W_(!TG_KW?_T?
M+653IZ_HRU\+_KJAM%.Q109G*8K0T$?\5%IO_7U%_P"ABJ.*,4W&ZL8J5G<[
M/Q!X+\07WB"_N;>P+PRS,Z-YT8R"?0MFG>#]-O-*\2:C:7L/E3KI\A*;@V,[
M2.02*XK%&*P]A-T_9MZ6MM_P3J^LT_:^V47>]]_^ 6-/NFL-1M;M<YAE63 [
MX.:]$UJRBT6S\0ZS$5VZD$CMB#VD&7/\S^%>9XKH=5U*U;PMI.E64OF&+=-<
M_(1B0]!R.< D<45Z;E*-OGZ;_I^(L-64(ROZKUV7Y_@7O"L$NH>&/$&GVRB2
MZD6)TCR 6 8YQFI]"T^ZTO2/%-K>0F*862DH2#P=V.E<8A96#(Q5AT(.#2L6
M=BSL68]23DTYT7+FUT?_  /\A4\1&,8Z:QOU[_+S.C\)_P#'KKW_ &#)?Y&M
MS1+B\N?!5O#I5O:W5U:S,)89U5B%8DA@"??^=<!BGHSQMN1F5O53@TJN'Y[Z
M]OP"CB'3LK=_Q.MUN;Q +.T@U/3[>TM&N%91"BKEQ[ ^E5O'HQXQNO\ =C_]
M!%<X[/(VZ1V9O5CDTF*JE2Y)*7:_XV_R"=?F4EKK;=]K^7F=-X^Y\7S_ /7.
M/_T$5T=Q;6UQ\3+I;B*&5Q:!H(YL%6D"KC@_C7FV*49!!!((Z$4O8/D4;[)K
M[[?Y&BQ?ORDX[M/[CTW2$\77'VV'5TQ;2VLJ11D1+F0C@ +STS7/>'+.>X\/
M>)-(CBS?'R\0E@"=K'(_#%<HTDC.':1V<=&)Y%-#NK[U=@^<[@>:E8=V>RO;
M9=G?N-XI7BVF[7W?=6['8:)IEW%INN^';B(0ZC/''+#$[CY\'. <X].]&D:/
M>^&M/U>^U6$6RO:-!$KN"9'8=  3Z5QK.[/O9F+==Q/-))))*09)'<CIN.:;
MHR=]=]]/R)C7A'EM%^[>VOSUT[G7^'E\:6^EQ/I<)FL)"2D<GELIYP>"<@9^
ME7=3:VTSQ3X?N)(;:SOV4&]CAP$0GC)P<#J:X))I8L^7(Z9Z[6(S49))))))
MZDT2P_-/F=ON_,E8CEI\BOTW>B]--#OX_"6LQ>.#?&U'V07K3>;YBX*ELCOG
M//2J8C\1-XQUJ7P_N\Q+AA+M9,8+'&0W!Z&N.:61D5&D8JO12>!35=D8,C%6
M'0@X--4)=6GI;;_@C>(A]E-7=]_7;3S/0-=CO)_"5Y<^(K&TM[]9$6UE155Y
M.?FS@],9KSRI))))6W2.SMC&6.:CJZ-+V::,Z]7VC3[=]V%)FES3:U,1U%)2
MT )2T44P-&Y4-X;L,C_E\N/_ $""LWRU]/UK4G_Y%JQ_Z_+C_P! AK-KC6$P
M]1N4Z:;[M(UG*2=D^B_(38OI2[1Z44M/ZAA/^?4?_ 5_D3SR[A@4M%%']GX3
M_GU'_P !7^0<\NXNXTOF-ZTVBE_9^#_Y]1_\!7^0<\NX[S']?TH\Z3^]^E,H
MH_L[!_\ /J/_ ("O\@YI=Q_VB7^]^@I?M,W]_P#05%24O[.P?_/F/_@*_P @
MYI=R;[5/_?\ T%.%W/\ \]/T%044?V;@O^?,?_ 5_D'-+N6/MEQ_ST_\=%*+
MVX_YZ?\ CHJO2BE_9N"_Y\Q_\!7^0<TNY9%]<_\ /3_QT5?TNXEGNY(Y7#*+
M>>0 @#YEB=E/X$ UDBM'1/\ C_E_Z]+G_P!$R5G4RW!\C_<Q_P# 5_D:4VW-
M$(OKG_GK_P".BG"_N?\ GI_XZ*JBG5?]F8'_ )\Q_P# 5_D*[+(O[G_GK_XZ
M/\*=]ON?^>O_ (Z/\*JTM']EX'_GS#_P%?Y!=EK[?<_\]?\ QT4O]H77_/7_
M ,='^%5:6E_9>!_Y\P_\!7^0[LM?VC=?\]?_ !T?X4O]I7?_ #U_\='^%5**
M/[+P/_/F'_@*_P @NRW_ &E=_P#/;_QT?X4O]IWG_/;_ ,='^%4Z*/[*P/\
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MD-+2&D,2BBB@84M)2T( HHHI@:4__(M6/_7Y<?\ H$-9U:$__(LV/_7Y<?\
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M>&G_ /@O@_\ B*H4E'LH=B>>K_,R_P#VQ<_\\+#_ ,%\'_Q%)_;%U_SQT_\
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MW'[X_P#GRT__ , XO_B*-\?_ #Y:?_X Q?\ Q-1T4O9P[![6?<?OC_Y\M/\
M_ &+_P")I-\7_/G8?^ 47_Q%-HI^SAV%[6?<7='_ ,^>G_\ @#%_\11NC_Y\
M]/\ _ &+_P"(III*?LX=@]K/N/\ ,C_Y\M/_ / &+_XBD\R/_GRT_P#\ 8?_
M (BF4E'LH=A\\_YF/\R/_GST_P#\ 8O_ (BFRR-((P515C78B1QJBJ,D\!0!
7U)/XTVDH48QV1FZDY*S8VBE-%62?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E ZT# 2(  A$! Q$!_\0
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MH^K0_GE_X$'(N_XGD7_"B=$_Z!D'_@9-_C1_PHG1/^@9!_X&3?XUZ[]KMO\
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M]!*S_P"_Z_XT?4O[TOO8<J[_ (GE/_"B=$_Z!D'_ (&3?XT?\*)T3_H&0?\
M@9-_C7JW]LZ7_P!!*S_[_K_C1_;.E_\ 02L_^_Z_XT?4O[TOO8<J[_B>4_\
M"B=$_P"@9!_X&3?XT?\ "B=$_P"@9!_X&3?XUZM_;.E_]!*S_P"_Z_XT?VSI
M?_02L_\ O^O^-'U+^]+[V'*N_P")Y3_PHG1/^@9!_P"!DW^-'_"B=$_Z!D'_
M (&3?XUZM_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^-'U+^]+[V'*N_XGE/_
M  HG1/\ H&0?^!DW^-'_  HG1/\ H&0?^!DW^->K?VSI?_02L_\ O^O^-']L
MZ7_T$K/_ +_K_C1]2_O2^]ARKO\ B>4_\*)T3_H&0?\ @9-_C1_PHG1/^@9!
M_P"!DW^->K?VSI?_ $$K/_O^O^-2P7]G<MM@NX)6](Y Q_0TOJ:_FE][#D7?
M\3R3_A1.B?\ 0,@_\#)O\:/^%$Z)_P! R#_P,F_QKV.BCZI'^>7_ ($Q\B[O
M[SQS_A1.B?\ 0,@_\#)O\:/^%$Z)_P! R#_P,F_QKV%G5!EF"CU)Q4?VNV_Y
M^(O^^Q2>%@MYR_\  A<B[O[SR+_A1.B?] R#_P #)O\ &C_A1.B?] R#_P #
M)O\ &O7?M=M_S\1?]]BC[7;?\_$7_?8I?5H?SR_\"#D7?\3R+_A1.B?] R#_
M ,#)O\:/^%$Z)_T#(/\ P,F_QKUW[7;?\_$7_?8H^UVW_/Q%_P!]BCZM#^>7
M_@0<B[_B>1?\*)T3_H&0?^!DW^-'_"B=$_Z!D'_@9-_C7KOVNV_Y^(O^^Q1]
MKMO^?B+_ +[%'U:'\\O_  (.1=_Q/(O^%$Z)_P! R#_P,F_QH_X43HG_ $#(
M/_ R;_&O7?M=M_S\1?\ ?8H^UVW_ #\1?]]BCZM#^>7_ ($'(N_XGD7_  HG
M1/\ H&0?^!DW^-'_  HG1/\ H&0?^!DW^->N_:[;_GXB_P"^Q1]KMO\ GXB_
M[[%'U:'\\O\ P(.1=_Q/(O\ A1.B?] R#_P,F_QH_P"%$Z)_T#(/_ R;_&O7
M?M=M_P _$7_?8H^UVW_/Q%_WV*/JT/YY?^!!R+O^)Y%_PHG1/^@9!_X&3?XT
M?\*)T3_H&0?^!DW^->N_:[;_ )^(O^^Q1]KMO^?B+_OL4?5H?SR_\"#D7?\
M$\B_X43HG_0,@_\  R;_ !H_X43HG_0,@_\  R;_ !KUW[7;?\_$7_?8H^UV
MW_/Q%_WV*/JT/YY?^!!R+O\ B>1?\*)T3_H&0?\ @9-_C1_PHG1/^@9!_P"!
MDW^->N_:[;_GXB_[[%'VNV_Y^(O^^Q1]6A_/+_P(.1=_Q/(O^%$Z)_T#(/\
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M?XUZ[]KMO^?B+_OL4?:[;_GXB_[[%'U:'\\O_ @Y%W_$\B_X43HG_0,@_P#
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MG2;?48H+B!)P2(KB/9(N"1RO;I5ZI>#H)V<%]Q7)#L8?_"):1_SQ?_OX:/\
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M6Y67K.N1:*UD);6[G^USK OV:+?L)_B;T7WH6#H-V4%]P.$%T*__  B6D?\
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MH?R+[@Y(]C#_ .$2TC_GB_\ W\-'_"):1_SQ?_OX:W**/JE#^1?<')'L8?\
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M^1?<')'L8?\ PB6D?\\7_P"_AH_X1+2/^>+_ /?PUN44?5*'\B^X.2/8P_\
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M_D;+7_KPC_\ 0WI5/]YAZ2_0'\:^9R&A?\C#IO\ U]1?^ABOM;PO_P @1/\
MKH__ *$:^*="_P"1ATW_ *^HO_0Q7VMX7_Y B?\ 71__ $(T2_WJ/^%_F@?Q
MKT-FBBBNHL**** "BL1_$L":F;;[)<FW6<6K7@"^4LQQA>N[J0,XQDXK;H K
M7T/GVCIZBO/X+F?0M7\T+G!(*GHRGJ*[?4/$&BZ3,L&I:O86<K+O6.XN4C8K
MTR Q''!_*L#4=9\&WX);Q)HP;U^W1?\ Q595:2J1MMV?9BDKHVK?Q+I<\09K
MD1-W608(J7^W])_Y_H?SKAF?PKGY?%6CX_Z_H_\ &D\SPO\ ]#7H_P#X'1_X
MUE;$KK'\2??\CNO[?TG_ )_H?SH_M_2?^?Z'\ZX7S/"__0UZ/_X'1_XT>9X7
M_P"AKT?_ ,#H_P#&G_M/]W\0]_R.Z_M_2?\ G^A_.C^W])_Y_H?SKA?,\+_]
M#7H__@='_C1YGA?_ *&O1_\ P.C_ ,:/]I_N_B'O^1W7]OZ3_P _T/YT?V_I
M/_/]#^=<+YGA?_H:]'_\#H_\:/,\+_\ 0UZ/_P"!T?\ C1_M/]W\0]_R.Z_M
M_2?^?Z'\Z/[?TG_G^A_.N%\SPO\ ]#7H_P#X'1_XT>9X7_Z&O1__  .C_P :
M/]I_N_B'O^1W7]OZ3_S_ $/YT?V_I/\ S_0_G7"^9X7_ .AKT?\ \#H_\:/,
M\+_]#7H__@='_C1_M/\ =_$/?\CNO[?TG_G^A_.C^W])_P"?Z'\ZX7S/"_\
MT->C_P#@='_C1YGA?_H:]'_\#H_\:/\ :?[OXA[_ )'=?V_I/_/]#^=']OZ3
M_P _T/YUPOF>%_\ H:]'_P# Z/\ QH\SPO\ ]#7H_P#X'1_XT?[3_=_$/?\
M([K^W])_Y_H?SH_M_2?^?Z'\ZX7S/"__ $->C_\ @='_ (T>9X7_ .AKT?\
M\#H_\:/]I_N_B'O^1W7]OZ3_ ,_T/YT?V_I/_/\ 0_G7"^9X7_Z&O1__  .C
M_P :/,\+_P#0UZ/_ .!T?^-'^T_W?Q#W_([K^W])_P"?Z'\Z/[?TG_G^A_.N
M%\SPO_T->C_^!T?^-'F>%_\ H:]'_P# Z/\ QH_VG^[^(>_Y'=?V_I/_ #_0
M_G1_;^D_\_T/YUPOF>%_^AKT?_P.C_QH\SPO_P!#7H__ ('1_P"-'^T_W?Q#
MW_([K^W])_Y_H?SH_M_2?^?Z'\ZX7S/"_P#T->C_ /@='_C1YGA?_H:]'_\
M Z/_ !H_VG^[^(>_Y'=?V_I/_/\ 0_G1_;^D_P#/]#^=<+YGA?\ Z&O1_P#P
M.C_QH\SPO_T->C_^!T?^-'^T_P!W\0]_R.Z_M_2?^?Z'\Z/[?TG_ )_H?SKA
M?,\+_P#0UZ/_ .!T?^-'F>%_^AKT?_P.C_QH_P!I_N_B'O\ D=U_;^D_\_T/
MYT?V_I/_ #_0_G7"^9X7_P"AKT?_ ,#H_P#&CS/"_P#T->C_ /@='_C1_M/]
MW\0]_P CNO[?TG_G^A_.C^W])_Y_H?SKA?,\+_\ 0UZ/_P"!T?\ C1YGA?\
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M;+_OH_X4?\+(\&_]##9?]]'_  KB/^$?^'?_ $%O#O\ X%Q__%4?\(_\._\
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MC_\ @='_ (T?[3_=_$/?\CNO[?TG_G^A_.C^W])_Y_H?SKA?,\+_ /0UZ/\
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M+_\ 0UZ/_P"!T?\ C1_M/]W\0]_R.Z_M_2?^?Z'\Z/[?TG_G^A_.N%\SPO\
M]#7H_P#X'1_XT>9X7_Z&O1__  .C_P :/]I_N_B'O^1W7]OZ3_S_ $/YT?V_
MI/\ S_0_G7"^9X7_ .AKT?\ \#H_\:/,\+_]#7H__@='_C1_M/\ =_$/?\CN
MO[?TG_G^A_.C^W])_P"?Z'\ZX7S/"_\ T->C_P#@='_C1YGA?_H:]'_\#H_\
M:/\ :?[OXA[_ )'=?V_I/_/]#^=']OZ3_P _T/YUPOF>%_\ H:]'_P# Z/\
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M7S/"_P#T->C_ /@='_C1YGA?_H:]'_\  Z/_ !H_VG^[^(>_Y'=?V_I/_/\
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M7TG^K;Z&OD'XO?\ (V6O_7A'_P"AO6=3_>8>DOT$_C7S.0T+_D8=-_Z^HO\
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M7?\ X$?_ %J/^%7>&/\ GE=_^!'_ -:NSHKYGZW7_G?WG%SR[G&?\*N\,?\
M/*[_ / C_P"M1_PJ[PQ_SRN__ C_ .M79T4?6Z_\[^\.>7<XS_A5WAC_ )Y7
M?_@1_P#6KKM&^!?@J^TF"YEAOO,?.<7)]2/2I:]$\,_\B]:_1O\ T(UZ&6UZ
ME2JU.3>AM1DW+5G"?\* \#?\\;__ ,"C_A1_PH#P-_SQO_\ P*/^%>HT5[9T
M'EW_  H#P-_SQO\ _P "C_A6)XD^"O@[2XK=K>&]S(Q!S<YZ#Z5[97*^-O\
M46?^^W\JY<;*4*$I1=G_ ,$BHVHMH\<_X5=X8_YY7?\ X$?_ %J/^%7>&/\
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M_P"% >!O^>-__P"!1_PKTNS_ ./*W_ZYK_*IJ^IC\*.Y'EW_  H#P-_SQO\
M_P "C_A1_P * \#?\\;_ /\  H_X5ZC15 >$>(?@[X1TS4$A@AO=IC#'-QGG
M)]O:LG_A5WAC_GE=_P#@1_\ 6KU3QC_R&(_^N _F:YZOG,5B:T:\HQDTKG).
M<E)V9QG_  J[PQ_SRN__  (_^M1_PJ[PQ_SRN_\ P(_^M79T5S_6Z_\ ._O(
MYY=SC/\ A5WAC_GE=_\ @1_]:K>F?";PI=ZI;6\D-YLD?:<7'M]*ZBM#0O\
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M .!'_P!:C_A5WAC_ )Y7?_@1_P#6KLZ*/K=?^=_>'/+N<<GPM\+M(H,5W@L
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M,\0_\@"\_P"N?]165?\ A2]'^1,OA9YQ12JK.P5%+,>@49)J;[%=_P#/K/\
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M #V3_OW_ /7HV7'_ #V3_OW_ /7J:B@"'9<?\]D_[]__ %Z-EQ_SV3_OW_\
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M'4$G_LR[S*A'DO\ P?[)]Z^/$^XOTK[(U'_D&7?_ %Q?_P!!-?&R?<7Z5Z6
MVD<>+Z#J***] XPHHHH ]X^!:R'PMJ6QU4?;CU7/_+-/>O4MEQ_SV3_OW_\
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M J_HF3K=GM.#YG!(SV-4*T-"_P"0[9?]=/Z&M:/\6/JOS0X[H]$V7'_/9/\
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M%9% VG *9_B/O7GU>B^&_P#D7[3_ '3_ .A&O4RK^,_3]3:A\1?V7'_/9/\
MOW_]>C9<?\]D_P"_?_UZFHKWSJ(=EQ_SV3_OW_\ 7KE_&8D$5GO<-\SXPN.P
M]ZZZN4\;?ZJR_P!Y_P"0KCS#_=I?UU1G5^!G(4445\P<84444 .C_P!:G^\/
MYUZELG_Y[)_W[_\ KUY;'_K8_P#>'\Z]8KVLHVG\OU.BAU(=EQ_SV3_OW_\
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M?\\4_P"_G_UJFHH AWW'_/%/^_G_ -:C?<?\\4_[^?\ UJFHH AWW'_/%/\
MOY_]:C?<?\\4_P"_G_UJFHH AWW'_/%/^_G_ -:C?<?\\4_[^?\ UJFHH AW
MW'_/%/\ OY_]:C?<?\\4_P"_G_UJFHH AWW'_/%/^_G_ -:C?<?\\4_[^?\
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M,7W_ %V?^=<6-P4</%-.]S.I34$>A6C3_8X,1(1Y:_Q^WTJ;?<?\\4_[^?\
MUJ+/_CRM_P#KFO\ *IJ^AC\*.I;$.^X_YXI_W\_^M1ON/^>*?]_/_K5-15#.
M$\7%SJT>]0I\D< Y[FL"NA\8_P#(8C_ZX#^9KGJ^6QG^\3]3BJ?$PHHHKE("
MK^B9&MV>T GS. 3CL:H5H:%_R';+_KI_0UK1_BQ]5^:''='HF^X_YXI_W\_^
MM1ON/^>*?]_/_K5-17UQWD.^X_YXI_W\_P#K4;[C_GBG_?S_ .M4U% 'EVHY
M_M.[R,'SGR/Q-5JM:E_R%+O_ *[/_P"A&JM?'U/C?J_S9P/<****@05TO@XN
M+RZV*&/EKU;'<US5=/X*_P"/V[_ZYK_,UUX'_>(?UT9=+XT=;ON/^>*?]_/_
M *U&^X_YXI_W\_\ K5-17U!VD.^X_P">*?\ ?S_ZU4]7:<Z/>;HD \ELD/[?
M2M*J6L?\@6]_ZXM_*LZO\.7H_P F*6S/,J***^0. **** "O0?#S3#0;0+&I
M7:<$OC^(^U>?5Z+X;_Y%^T_W3_Z$:]3*OXS]/U-J'Q%_?<?\\4_[^?\ UJ-]
MQ_SQ3_OY_P#6J:BO?.HAWW'_ #Q3_OY_]:N7\9&0Q6?F(J_,^,-GL/:NNKE/
M&W^JLO\ >?\ D*X\P_W:7]=49U?@9R%%%%?,'&%%%% #H_\ 6I_O#^=>I;[C
M_GBG_?S_ .M7EL?^MC_WA_.O6*]K*-I_+]3HH=2'?<?\\4_[^?\ UJE&<#(P
M>XI:*]DZ!LG^K;Z&OD'XO?\ (V6O_7A'_P"AO7U])_JV^AKY!^+W_(V6O_7A
M'_Z&]<M3_>8>DOT(?QKYG(:%_P C#IO_ %]1?^ABOM;PO_R!$_ZZ/_Z$:^*=
M"_Y&'3?^OJ+_ -#%?:WA?_D")_UT?_T(T2_WJ/\ A?YH'\:]"7Q%K2^']$GU
M P-.R%4CB4X+NS!5&>W)'-<S<^.M0M]2F_XE4+:;93PVE[-Y_P ZRR8R$&,$
M*6 -;OC*73HO"MZ=5AEFM2%7RH3AV<L-H4]CNQ@UPCR:397=M8G2-1DTS3;V
M-[Z=[L$&ZEVD&4=9-I(YS@&NHL]8HHHH **** "BBB@ HHHH **** "BBB@
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MOEKXE_\ )1];_P"NR_\ HM:^I:^6OB7_ ,E'UO\ Z[+_ .BUKMP/QOT.;%?
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M1"'$QYX<<$@Y/0@^]+I.E7.F(0;J*5IYWGNB(=H9F  " 'Y0,#KG//<UC_\
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M* .$UKQA&=<L+>&\DM((KN)9D>%U>;<,XY'"C(SW)X[<]W4%S:07?D^?'O\
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M_P#?/_UZFHH A^T'_GA+_P!\_P#UZ/M!_P">$O\ WS_]>IJ* (?M!_YX2_\
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M_?/_ ->IJ* (?M!_YX2_]\__ %Z/M!_YX2_]\_\ UZFHH A^T'_GA+_WS_\
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M,-65*3;1E6INHK(X7P)\1_"NB^"=+TZ_U(Q74$961/(D;!W$]0N.];=Q\4/
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M -=G_P#0C56OCZGQOU?YLX'N%%%%0(*Z?P5_Q^W?_7-?YFN8KI_!7_'[=_\
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MB?>&-WWB"!BNOKG+CPIYDT\5M>_9M,N71[BS2!3N*A1\K?P@A5!&#TXQ71T
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M]Q?RH ;Y\/\ SU3_ +Z%'GP_\]4_[Z%.\M/[B_E1Y:?W%_*@!OGP_P#/5/\
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M^5'EI_<7\J &^?#_ ,]4_P"^A1Y\/_/5/^^A3O+3^XOY4>6G]Q?RH ;Y\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\
MOHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%
M0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z
M?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?9
M8?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\
MOHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%
M0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z
M?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?9
M8?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\
MOHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%
M0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z
M?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?9
M8?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\
MOHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%
M0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?98?[I_P"^C0!-14/V6'^Z
M?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\ OHT 345#]EA_NG_OHT?9
M8?[I_P"^C0!-14/V6'^Z?^^C1]EA_NG_ +Z- $U%0_98?[I_[Z-'V6'^Z?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX\L*K2]$0J<DK)G(?\);J'_0,_\ 0O\ "D;Q7?LC*=,ZC'\7^%=A15_5J_\
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M&R.E=:VEV3ZB]^]NK7+P?9V<\YCSG;CIUJC'X4T:*WFMQ:N8I0%*O/(VP Y
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MF:=="XM5N4<.S[3=RLA9LY)4MM.<GM0!L4444 %9.OS36D%I>1S-''#=1F<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSI'_ #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\
MP#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_
MS_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A?.D?\_X_\ WH^M+^
M27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IH
MKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?
M\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A
M?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#
M>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<
M'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X
M7SI'_/\ C_P#>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P
MWH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\
M/^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+
M^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\
M6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/
M^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%
M\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A?.D?\_X_\ WH
M^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y
M,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A
M?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#
M>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\
MC_P#>CZTOY)?<'/Y,]H/0UYO_8VIGX/PZ;]@G^VB=6-OM^<#[3NSCZ<US_\
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MQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\
MC_P#>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'
M_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>
MCZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3
M/::*\6_X7SI'_/\ C_P#>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_
M #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C
M_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_
M , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A?.D?\_X_\ WH^M+^27W!
MS^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_
M (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_
M\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'_/\ C_P#>C_A?.D?
M\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X7SI'_/\ C_P#>CZT
MOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_  #>CZTOY)?<'/Y,
M]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W!S^3/::*\6_X7SI'
M_/\ C_P#>C_A?.D?\_X_\ WH^M+^27W!S^3/::*\6_X7SI'_ #_C_P  WH_X
M7SI'_/\ C_P#>CZTOY)?<'/Y,]IHKQ;_ (7SI'_/^/\ P#>C_A?.D?\ /^/_
M  #>CZTOY)?<'/Y,]IHKQ;_A?.D?\_X_\ WH_P"%\Z1_S_C_ , WH^M+^27W
M!S^3/::"0 23@#J:\5/QYTC!_P!/'_@&]<QXA^.@N8GBLXY[DGIYF(HOR')_
M&E]9D](4Y7\U;\PYWT1Z3\1/'5CI.E2,908$/ !YFD[*OJ/?V]J^4+^^GU*_
MGO;EMTT[EV/N>P]AT'M5K6]>U'Q!>FZU"<R,.$0<*@]%':LVKHT91;J5'>3_
M  79!&+6KW"BBBN@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_012.jpg
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' Q,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#['/(T<=V%5D!&>6"DE <=2*0_$"P&HM$+*\:P6Z%FVHA!Y EZ8SG.,\9Z4
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M\,06UM<V3ZC'JZ:H5(9( 5&-BX&<?A7I%4M5U>PT2Q:]U*Y6WMU(4NP)Y/0
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MH&*[D8$9!P1D>A!% $E%%% !1153^T[+^U_[*\\?;O(^T>3@Y\O.W=GIUXH
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ML)+B47LD!#.$+*T00[@I/&/>L34)K[4/#?A;5[[6Y;R6]U6-GMV"!$(9@-@
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M\.:/'86]BFGPK:V\HGBC48"R#HWN>>]/?0=+DDOY&LHR^H*$NCS^] & #^%
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M2K&XU.WU&6UC>\MU*Q3$?,@/!Q^9IDNBZ=-->326D;27L7DW+'/[Q,8P?PH
MX'3=4UJRUKP<\VKW-W'K5J7N890NP$1AAMP!@\CG/./>LQ]>UB7P;#XB/B*X
MCO;J^$+V8*!$7S"-JKC(.!G.>0>?6O4/["TP2:?)]CCWZ>NRT//[I< 8'X 5
MPTWPYOKJ_87!T<0O<B:2\BMRERZAMVW:/D&>Y% '1^-=1DLM/M(8+R[MY[JY
M6)$LXE::;U52Q 3_ 'NU4? .I:E=3:W8ZC+</]BN52,7+H\J C)5F3@FNFU7
M1M.UNV6WU*T2XC1PZAL@JP[@CD4W2]"TS1?._LVRCMO.V^8(\_-@8!/OS0!Y
M[XGUG7-/US4;E[O4?[/@D3RIM-:*6.W7C*RQ$9SUY8BM&?4;WQ#XFU6TBU^7
M2K/3[.*>!H@J^:73?YC[ARHX!''X5TU]X/\ #^I7[7UYI4$MPV"SD'Y\=-P!
MP?QI^J^%=#UN:.;4M-@N)(UVH[ @A?3C&1[4 <Q<:AJ&K>)=,T)/$!AMFTS[
M8]]9!%-T^[;\I.X <9P/>L6+Q'K^IZ?I%LNK-',^LRZ>]["BCSHP!A\=.Y_*
MO0]2\,:)J]O;P7VFP31VXVP@KCRQZ C&!P./:I$\/Z3%#911V$*1V3^9;*BX
M$;>HQWH X#5]0UV#Q%-H5M?:K)'I]B)5F@:$22.>?,D+X!49Q@>G:NSTF\EO
M_!4=UKBK&[VK_:O+8$;0""P*YZ@9X]:L:OX8T779HY=3T^*YDC&U7;(('7&0
M1D>U:4-O#;6\=O#$D<,:A$C4855 P !Z4 >;^&;C7)=:@7P\VIR>'@X\U]84
M8V9_Y8M]\\9QV]:[+Q7=V>F^'+W4KNVAG%K$6C65 PWGA1SZD@5M56U#3[35
M;)[.^@6>W<@M&W0X((_4"@#S/6-"70O!6A0W 4O=ZO;S:HY4 -NW$ANVT' ]
M.*M0:$FN>)_&FFVTPMH!+92QNB!E255W?=X!Y!R*]#OK"UU.REL[V!)[>48>
M-QD'O4&DZ)INA6IMM,LX[:)FW,$_B/J2>30!P $FBZB(Y/\ B8065\';:/+6
M?4+AN .NU45L]\%A7>Z%JRZYH\.H+"T/F%U:-B"596*D9'7E337\/:5)ITE@
MUJ#;R3&X8;VW&0MNW[L[@<\YS5JPL+73+&*SLH1#;Q A$!)QDY/)Y/))H LT
M444 %%%% !1110 4444 %%%% !02 ,GI16%XFU%[.S$<1Q)(<"IG-0BY/9";
MLKDLVL2S7+6NF6XN)4^_(QPB?4]Z46>MR?,^JQ0G^[%;A@/Q-6],L4TZPCMU
M'S 9<_WF/4U<K&-*4U>HWZ)V2^X23>YD?V=K'_0<_P#)1/\ &C^SM8_Z#G_D
MHG^-:]%5["'=_>_\PY49']G:Q_T'/_)1/\:/[.UC_H.?^2B?XUKU%<7,5K"T
MLSA449)-)T(+5M_>_P#,.5&;_9VL?]!S_P E$_QH_L[6/^@Y_P"2B?XTR+5=
M1O5\RRTT>2?NR3R;=WT%/^T:[_SXVO\ W]-8KV3U7,__  +_ #)]WS_$/[.U
MC_H.?^2B?XT?V=K'_0<_\E$_QH^T:[_SXVO_ ']-'VC7?^?&U_[^FBU/M+_R
M;_,-//\ $/[.UC_H.?\ DHG^-']G:Q_T'/\ R43_ !H^T:[_ ,^-K_W]-'VC
M7?\ GQM?^_IHM3[2_P#)O\PT\_Q#^SM8_P"@Y_Y*)_C1_9VL?]!S_P E$_QH
M^T:[_P ^-K_W]-'VC7?^?&U_[^FBU/M+_P F_P PT\_Q#^SM8_Z#G_DHG^-'
M]G:Q_P!!S_R43_&C[1KO_/C:_P#?TT?:-=_Y\;7_ +^FBU/M+_R;_,-//\0_
ML[6/^@Y_Y*)_C1_9VL?]!S_R43_&C[1KO_/C:_\ ?TT?:-=_Y\;7_OZ:+4^T
MO_)O\PT\_P 0_L[6/^@Y_P"2B?XT?V=K'_0<_P#)1/\ &C[1KO\ SXVO_?TT
M?:-=_P"?&U_[^FBU/M+_ ,F_S#3S_$/[.UC_ *#G_DHG^-']G:Q_T'/_ "43
M_&C[1KO_ #XVO_?TT?:-=_Y\;7_OZ:+4^TO_ ";_ ##3S_$/[.UC_H.?^2B?
MXT?V=K'_ $'/_)1/\:/M&N_\^-K_ -_31]HUW_GQM?\ OZ:+4^TO_)O\PT\_
MQ#^SM8_Z#G_DHG^-']G:Q_T'/_)1/\:/M&N_\^-K_P!_31]HUW_GQM?^_IHM
M3[2_\F_S#3S_ !#^SM8_Z#G_ )*)_C1_9VL?]!S_ ,E$_P :/M&N_P#/C:_]
M_31]HUW_ )\;7_OZ:+4^TO\ R;_,-//\0_L[6/\ H.?^2B?XT?V=K'_0<_\
M)1/\:/M&N_\ /C:_]_31]HUW_GQM?^_IHM3[2_\ )O\ ,-//\0_L[6/^@Y_Y
M*)_C1_9VL?\ 0<_\E$_QH^T:[_SXVO\ W]-(U_K%NIDFTQ)(QU\F7+#\.]'[
MOJI?^3?YAIY_B+_9VL?]!S_R43_&C^SM8_Z#G_DHG^-7K.^@OK47$+?*>"#P
M5/H?>N4OO'%U<:Q/I/AG19-7N+?BXF\X101'T+GJ?;_Z];T\/&HKQ;M_B?\
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M1]HUW_GQM?\ OZ:/M&N_\^-K_P!_31:GVE_Y-_F&GG^(?V=K'_0<_P#)1/\
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M/YUAB?X,OZ[$S^%G7T445N4%%%% !7*>()C<:U96+']T\J!AZY(%=77':O\
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M"_#((MKXB6*"6"(:S,(X9?O1KL3"GDXP.W:NZK&<>631I%\RN%%%%24%%%%
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M\:UM2[O\!WGV1VW]L:9_T$;/_O\ K_C1_;&F?]!&S_[_ *_XUQ/_  J+P_\
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MT?VQIG_01L_^_P"O^-<3_P *B\/_ //LOYG_ !H_X5%X?_Y]5_,_XT6I=W^
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MQTOVJW_Y^(O^^Q1]JM_^?B+_ +[%<U_PAL?_ #W:C_A#8_\ GNU*]?LOO?\
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M]O\ GD_YC_&C>W_/)_S'^-/HH 9O;_GD_P"8_P :-[?\\G_,?XT^B@!F]O\
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M$_[Z% #Z*9YT7_/1/^^A1YT7_/1/^^A0 ^BF>=%_ST3_ +Z%'G1?\]$_[Z%
M#Z*9YT7_ #T3_OH4>=%_ST3_ +Z% #Z*9YT7_/1/^^A1YT7_ #T3_OH4 /HI
MGG1?\]$_[Z%'G1?\]$_[Z% #Z*9YT7_/1/\ OH4>=%_ST3_OH4 /HIGG1?\
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M_P \?_'A0!+146^7_GC_ ./"C?+_ ,\?_'A0!+146^7_ )X_^/"C?+_SQ_\
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M.QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **SVU[1T8JVK6*L#@@W" @_G2?\)!HO\
MT%[#_P "4_QI\K["NC1HK._X2#1?^@O8?^!*?XT?\)!HO_07L/\ P)3_ !HY
M7V"Z[FC15.VU;3;R7RK74+2>0C.R*96./H#5RDTUN,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BJ]_*\&G7,T9P\<3LI]P"17'6?B'6+V\BMDGB5I&
MP"8Q@5S5\5"C)1DG=D2FHNS.YHK%^S>(?^?^U_[]_P#UJ/LWB'_G_M?^_?\
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MBB@ HHHH **** "BBB@ KD/$_P#R&+/_ 'A_.NOKD/$__(8L_P#>'\ZPQ/\
M!E_78F?PLZNX=8[:5W0NJH2449+#'0#O7">&KJUU+Q#$-/T^"WAMXRZB>Z::
M2-2=N%3<5B/MZ5W]<XM]:WGB$(=,LVE@F,:W#SQ^:I'4A?O?_6K<HUM5O'L;
M$S1JK2-)'$F[H&=U0$^P+9_"JJ7]_+ILKHL N()GBD8([J0I/*H.23Q\N>,G
MDXYTYX(KF!X9XUDB<896&0:J-HNG-;+;FT3RDY51D8.2<CWY//4Y/K0!)IEV
MU_I=K=O&(WFB5W0'.QB.5S['(JP9HP2"PR*(88[>%(88UCB0!511@*!V I]
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MA)=6&<@CMC!Y/'OR,@%^BH;6YBO;6*Y@8M%*H="01D'V/(J:@ HHHH ****
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M[B33S:IJ3IYDADG<Q@F4DDD<$87H,#L,<Y-;5% $5M$8+6*$E244+E4"CCT
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M SR8O^>:?]\BCR8O^>:?]\BGT4 4=4BC&D7I$: B!^W^R:\SKT_5?^0/>_\
M7O)_Z":\PKPLV^./I^IS5]T%%%%>28!74>#$5[B[W*&^5>HSW-<O74^"O^/B
M[_W%_F:[,!_O$?ZZ&E+XT==Y,7_/-/\ OD5G:[%&-$NR(U!\OJ!6I6=KW_(#
MO/\ KG7T5?\ A2]'^1U2V9YM1117R)PA1110!V/@U$>TNMRJ?W@ZCVKIO)B_
MYYI_WR*YOP7_ ,>=U_UT'\JZ>OJ,#_N\?ZZG92^!&-XEBC7P_=%44'Y.0/\
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M12%"<!U616*_B 1SQS67-I$USX7U/3VLQ&]RL[PP[EVH6)VJ<'&<X)[9/4T
M=)12#A0*:48G_6N/; _PH ?13-C?\]7_ "'^%&QO^>K_ )#_  H ?13-C?\
M/5_R'^%&QO\ GJ_Y#_"@!]%,V-_SU?\ (?X4;&_YZO\ D/\ "@!]%,V-_P ]
M7_(?X4;&_P">K_D/\* 'T4S8W_/5_P A_A1L;_GJ_P"0_P * 'T4S8W_ #U?
M\A_A1L;_ )ZO^0_PH ?13-C?\]7_ "'^%&QO^>K_ )#_  H \YU[_D.7G_72
MK$'B?4K>".&-H]D:A%RG8#%5M=&-;NP23^\ZFL^OE9U9TZLW!VU?YG$VU)V-
MS_A+-4_OQ?\ ?%-D\4ZG+$\;-%M=2I^3L:Q:*7UJN_ML7/+N7]$_Y#=G_P!=
M17I=>9Z*,ZU9C./WHY%>D[&_YZO^0_PKULI_AR]?T-Z&S'UY;??\A"Y_ZZM_
M,UZ?L;_GJ_Y#_"O+[W_C_N?^NK?S-3F_PP^85]D04445X9S!6OX9_P"1AM?^
M!_\ H!K(K6\- GQ!:@$C[_(_W#6^&_C0]5^94/B1Z)13-C?\]7_(?X4;&_YZ
MO^0_PKZP[CX_UC_D-W__ %\R?^A&J57=8_Y#=_\ ]?,G_H1JE7T*V1Y#W"BB
MBF(]!^#/_)0HO^O:7^0KZ/KYO^#0)^(,0#$?Z-+R/H*^C=C?\]7_ "'^%>3C
M?XOR/0POP#Z*9L;_ )ZO^0_PHV-_SU?\A_A7&= ^BF;&_P">K_D/\*-C?\]7
M_(?X4 /HIFQO^>K_ )#_  HV-_SU?\A_A0 ^BF;&_P">K_D/\*-C?\]7_(?X
M4 /HIFQO^>K_ )#_  HV-_SU?\A_A0 ^BF;&_P">K_D/\*-C?\]7_(?X4 /H
MIFQO^>K_ )#_  HV-_SU?\A_A0!7U7_D#WO_ %[R?^@FO,*],U1&&D7O[US^
MX?C _NGVKS.O"S;XX^GZG-7W04445Y)@%=3X*_X^+O\ W%_F:Y:NH\&*6N+O
M#%?E7ICU-=F _P!XC_70TI?&CLJSM>_Y =Y_USJ]L;_GJ_Y#_"L[748:)=DR
M,?W?0X_PKZ*O_"EZ/\CJELSSFBBBOD3A"BBB@#L_!?\ QYW7_70?RKIZY;P:
MI-I=8=E_>#ICTKIMC?\ /5_R'^%?48'_ '>/]=3LI? C,\3?\B]=?\ _]#%>
M=UZ#XE1AX?NB9&/W.#C^^/:O/J\K-?XR]/U9C7^(****\PQ"NX\&_P#('E_Z
M^#_Z"M</7;>#U)TB7#LO[\\#']U?:O0RS_>%Z,UH_&=)6+XJ_P"0#+_OK_.M
M?8W_ #U?\A_A6+XI4C0I29&/S+P<>OTKW,5_ GZ,Z9_"S@J***^3.$**** .
M^\)_\@-?^NC5N5@^%%)T12)&'[QN!C_"MQ5*YRY;ZXKZO"?P(>AVP^%#JQM(
M_P"0KJ__ %V7^5;-8VD?\A75_P#KLO\ *G5_B0]7^0WNC9HHHK<H**** "BB
MB@ HHHH **** "BBB@ HHHH *Y#Q/_R&+/\ WA_.NOKD/$__ "&+/_>'\ZPQ
M/\&7]=B9_"SKZ***W*"BBB@ HHHH ***JZDTR:7=M;[O/$+F/:,G=M.,#US0
M!:HKEHI+N:(SZ;=3/ MSLMQ.7._(C.3NY901(#GH"2/N@5JZ!>RWVF(\T,T4
MB80F4Y9SM!)/ YR2",<$$=J -2BBB@ HHK&OO$UEI]Y):RQ7#.F,E%!'(!]?
M>LZE6%-7F[(3DEN:EP\T<#-!$)91]U&?:#]3@X'X&L)/%#^2)I=.>.(;E>3>
M=JN&=0O*C&2J_>VGYQQUJ*X\5:5=0-#+!>%&QG;A2,'(((8$'([5 -=T$6OV
M8V=VT6YF(<[BQ8$$DE\GJ>M8_7</_.OZ^1/M(=SJH)EN(%D0@@\'!Z$<$?@<
MBI*YF#Q7I5M$(HK>["9+<@$Y)))R6SU)JQ;^++"YN8H$BN0TCA 2JXR3CUIK
M&4&[*:#VD>YO4445TEGFVO?\AR\_ZZ5G5HZ]_P AR\_ZZ5G5\C7_ (LO5_F<
M$MV%%%%9"+^B?\ANS_ZZBO2Z\TT3_D-V?_745Z77O93_  Y>OZ'30V85Y;??
M\A"Y_P"NK?S->I5Y;??\A"Y_ZZM_,U.;_##YA7V17HHHKPSF"M?PS_R,-K_P
M/_T UD5K^&?^1AM?^!_^@&M\-_&AZK\RH?$CT.BBBOK#N/CS6/\ D-W_ /U\
MR?\ H1JE5W6/^0W?_P#7S)_Z$:I5]"MD>0]PHHHIB/0?@S_R4*+_ *]I?Y"O
MH^OG#X,_\E"B_P"O:7^0KZ/KR<;_ !?D>AA?@"BBL7_A,/#'_0QZ1_X'1?\
MQ5<B3>R-VTMRUJ^J'2;5KDVDL\2(TDC(RJ$5>OWB.3V%5H/$=M/?26@BE1TD
M"$R84 99<G/3E>G?>G]ZLS5M9\,:JUN?^$RLK7R&WA8;RV8,W&"1(&&1CCT_
M*DO]4\(:DRO<>*=/+J,*POX>!M93@9QR&.?P]!3Y)=A<T>YUM%8O_"8>&/\
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M +Z_SK:K%\5?\@&7_?7^=>YBOX$_1G3/X6>?T445\F<(4444 =]X3_Y :_\
M71JW*P_"?_(#7_KHU;E?5X3^!#T.V'PH*QM(_P"0KJ__ %V7^5;-8VD?\A75
M_P#KLO\ *G5_B0]7^0WNC9HHHK<H**** "BBB@ HHHH **** "BBB@ HHHH
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MW8L+&6Z9=R189^<87/S'\!D_A656C"M'EFKHF45+1GA?]H>.?^B=WW_@4/\
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M &:3YQ($WD%<8 X(SGJ.G-*6)JR7*WH.-&$7=(X<_$?QR/\ FE=]_P"# ?\
MQNFR?$3QT\;*/A;?J2" PU <>_\ JZ]2HK U/#O^$E^)7_0E:Q_X,#_\31_P
MDOQ*_P"A*UC_ ,&!_P#B:]LN9OL]K-/MW>6C/C.,X&:RVUR2TB\S4K5(4,/G
M(T,WF C*@@Y5<?>7VKE^ITO/[W_F1[.)Y/\ \)+\2O\ H2M8_P#!@?\ XFC_
M (27XE?]"5K'_@P/_P 37L%IK=E>K;M [,+A4:,[?O!E9@?R1ORI\&H/-K%Y
M8-;-&+>**19"P/F!RXX Z ;._P"7J?4Z7G][_P P]G$\JTOQG\0["21I_A[J
MEV&& LFH?=]^4-:?_"Q_'/\ T2N^_P#!@/\ XW7J%%;PA&$>6)25M$>577C_
M ,<W-G/;_P#"K;Y?-C9-WV\'&1C/^KKE_P"T/'/_ $3N^_\  H?_ !->^UBW
MNOM97;6[6FYEF0<2?\L"H+2].BG(Q[=>:SK8:E6:=17L*4(RW/'/[0\<_P#1
M.[[_ ,"A_P#$T?VAXY_Z)W??^!0_^)KUE/'&BK*(KNYCMI65Y%5FSF,;BK>O
MS*N[IWQG-/L_&6E:A=VT%I,LOVC>J;&!.]2N5P.#\K;B<\ 5C_9^&_E_%D^R
MAV/(_P"T/'/_ $3N^_\  H?_ !-:NB>*?'.CR3/_ ,*TOIO, &/MH7&/^ &O
M5)]<MX=;MM+7:\LC;9&W@>6=A8#'4DX_#(]1G4JZ>#H4Y*48ZKU&J<4[I'E_
M_"Q_'/\ T2N^_P#!@/\ XW5>_P#'GCF]L9K;_A5U\GF+MW?;P<?AY=>L45TR
MBI)I]2WJ>!?VAXY_Z)W??^!0_P#B:/[0\<_]$[OO_ H?_$UZY/XH%JV9K,B-
M4D\UEDSMD7S,(!CG/E/SQ_#QS41\>>'XS.DU]$DT'$D>\<,#M(R<=&XR<>O2
MN/\ L_#?R_BS/V4.QY1_:'CG_HG=]_X%#_XFC^T/'/\ T3N^_P# H?\ Q->R
M:5XDLM8O9K>T82; KJRG.Z-D5@Y';EL >Q]\3OJ5SY]Y"EDJM;JC*T\X174E
M@6) .T#:3Z^PH_L_#?R_BP]E#L>7:+XN\<Z/#+'_ ,*ROIO,8-G[:%Q_Y#-:
M?_"Q_'.0/^%5WW/_ %$!_P#&Z]&TV[:_T^*Y:'RC)GY=V01D@$' R"!D<#@B
MK5=5.G&G%1CLBTDE9'DFI^.?'.HZ=+:?\*OOH_,Q\WVX'&"#T\OVKG?[0\<_
M]$[OO_ H?_$U[[7-GQ9@;38GS!;Y*B7_ )>><0 X^]\IY^G'-95<+2K2YIJ[
M)E",M6>3?VAXY_Z)W??^!0_^)H_M#QS_ -$[OO\ P*'_ ,37K,GCOP_$+C??
MQ;H)!$ZAU^]ST)(_NMUQT]Q6AINNV>J7<T%JXD,:I(&4Y!1T5E8^F=QP/]DU
ME_9^&_E_%B]E#L>+?VAXY_Z)W??^!0_^)K<T;QEXYTBS>W_X5C?2[I"^[[<%
M[ 8_U9]*]'?6[A+F:V^QPM,KI&@6XR,L3@.=ORG:-V!NZCU&='3[L7UC'<;-
MA;(9<YVL"01GOR#S6E+"4:4N:"L_F.-.,7='G'_"Q_'.<?\ "J[[_P & _\
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MBK<>9#T=KJ4LW.0');+@'H&R!6G10!2L])L;")XK:W"1NJJR%BP(50HX)ZX
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M9X[FG1:A:2R)$+B(3. 1"9%W] <8SZ$4 5KC0=/N;.VM729(;5MT(AN9(BA
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MN7^0YYRN#6C;P16MO'!"FR*-0JKZ 5)10 4R6*.>%X95#QR*593T(/!%/HH
MH?V+IVT+]F7 MA:CYC_JAT7K^O6FQZ'8Q2P2J+G?#PK&ZE);DD;\M\^"3C=G
M&>*T:* ,_P#L33Q8W%FL#)!<*$E5)77< H7J#D'  R.3CFHU\.Z<%A!2X?R3
ME3)=RN2,@[6+,=RY ^5LCVK4HH **** "L;2/^0KJ_\ UV7^5;-8NB$27^K2
MK]TW&T'Z"L*O\2'J_P B7NC:HHHK<H**** "BBB@ HHHH **** "BBB@ HHH
MH *P/%&FO>V8DB&73FM^D(!&#TI-)JS YGP_XAA-NME?2>5-'\JN_ 8=@3ZU
MTP(8 @@@]"*PM2\,6UZYD0^6Y]*S1X2NDX2[('L:P4:M-<L;->MG^MR?>6B.
MPHKD/^$5O/\ G\;\S1_PBMY_S^-^9I\];^5??_P O+L=?17(?\(K>?\ /XWY
MFC_A%;S_ )_&_,T<];^5??\ \ +R['7T5R'_  BMY_S^-^9H_P"$5O/^?QOS
M-'/6_E7W_P# "\NQU]%<A_PBMY_S^-^9H_X16\_Y_&_,T<];^5??_P  +R['
M7T5R'_"*WG_/XWYFC_A%;S_G\;\S1SUOY5]__ "\NQU]%<A_PBMY_P _C?F:
M/^$5O/\ G\;\S1SUOY5]_P#P O+L=?17(?\ "*WG_/XWYFC_ (16\_Y_&_,T
M<];^5??_ , +R['7T5R'_"*WG_/XWYFC_A%;S_G\;\S1SUOY5]__   O+L=?
M17(?\(K>?\_C?F:/^$5O/^?QOS-'/6_E7W_\ +R['7T5R'_"*WG_ #^-^9H_
MX16\_P"?QOS-'/6_E7W_ / "\NQU]%<A_P (K>?\_C?F:/\ A%;S_G\;\S1S
MUOY5]_\ P O+L=?17(?\(K>?\_C?F:/^$5O/^?QOS-'/6_E7W_\  "\NQU]%
M<A_PBMY_S^-^9H_X16\_Y_&_,T<];^5??_P O+L=?17(?\(K>?\ /XWYFC_A
M%;S_ )_&_,T<];^5??\ \ +R['7T5R'_  BMY_S^-^9H_P"$5O/^?QOS-'/6
M_E7W_P# "\NQU]%<A_PBMY_S^-^9H_X16\_Y_&_,T<];^5??_P  +R['7T5R
M'_"*WG_/XWYFC_A%;S_G\;\S1SUOY5]__ "\NQU]%<A_PBMY_P _C?F:/^$5
MO/\ G\;\S1SUOY5]_P#P O+L=?17(?\ "*WG_/XWYFC_ (16\_Y_&_,T<];^
M5??_ , +R[$D_A"670[+3A=H&MX+B(OL.&\U&4'&>V[/X5#J/@;[>;D"[2%9
MVE.4CY4/;K"!U[%<_CBG?\(K>?\ /XWYFC_A%;S_ )_&_,T<];^5??\ \ +R
M[%JU\+O!X>U?3VGC$^HHZLZ!RJDQB,'YF8G@#O[=JC_X1)OM$$WVB/='J,-Z
M3LY*I (MN?J"?QJ'_A%;S_G\;\S1_P (K>?\_C?F:.>M_*OO_P" %Y=B6^\)
MW%YXGCU0W=KY23QS*6M?](C"XS&L@(^1L<@@\$BJDG@N_-B+>+4;93]BN;$L
MT#',<K!L_>^\,8].:F_X16\_Y_&_,T?\(K>?\_C?F:.>M_*OO_X 7EV"_P#"
M+SWS3RRQ36/VA[J2#RB99-T'E,@;.,>GY=JT/!VESZ5X=ABN]_VN1C),9,;B
M>B[L<9"!0?I6?_PBMY_S^-^9H_X16\_Y_&_,T<];^5??_P  +R['7T5R'_"*
MWG_/XWYFC_A%;S_G\;\S1SUOY5]__ "\NQU]%<A_PBMY_P _C?F:/^$5O/\
MG\;\S1SUOY5]_P#P O+L=?17(?\ "*WG_/XWYFC_ (16\_Y_&_,T<];^5??_
M , +R['7T5R'_"*WG_/XWYFC_A%;S_G\;\S1SUOY5]__   O+L=?17(?\(K>
M?\_C?F:/^$5O/^?QOS-'/6_E7W_\ +R['7T5R'_"*WG_ #^-^9H_X16\_P"?
MQOS-'/6_E7W_ / "\NQU]%<A_P (K>?\_C?F:/\ A%;S_G\;\S1SUOY5]_\
MP O+L=?17(?\(K>?\_C?F:/^$5O/^?QOS-'/6_E7W_\  "\NQU]%<A_PBMY_
MS^-^9H_X16\_Y_&_,T<];^5??_P O+L=?17(?\(K>?\ /XWYFC_A%;S_ )_&
M_,T<];^5??\ \ +R['7T5R'_  BMY_S^-^9H_P"$5O/^?QOS-'/6_E7W_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %7 >8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_PE6C?\_G_D)_\ "MBBB]+L_O\ ^ '+6_F7W/\ S,?_ (2K1O\ G\_\A/\
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MS_R$_P#A1_PE6C?\_G_D)_\ "MBBB]+L_O\ ^ '+6_F7W/\ S,?_ (2K1O\
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M_P ^UQ_WR/\ &C[6?^?:X_[Y'^-6*B%Q$;IK8./.5!(5]%)(!_,&D,9]K/\
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M/#7_ '[;_P"-UZG10!Y9_9OQJ_Z#GAK_ +]M_P#&Z/[-^-7_ $'/#7_?MO\
MXW7J=% 'CNEZ?\86CN?LNM>'%474H?=&W+[CN(_=],U?_LWXU?\ 0<\-?]^V
M_P#C==[H'^HOO^O^?_T,UK4 >6?V;\:O^@YX:_[]M_\ &Z/[-^-7_0<\-?\
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M^N?]36R_@OU7Y,YW_O"_PO\ -&O1116)T!1110 4444 %%%% !1110 4444
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M?\* '7-K!>6[07,2RQ-U5AD5AFVU'P^SRV>^^TT?\NI/[R$?[!/4>U;>;O\
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M_NP_]]'_  K*I24M5HUU_K=>1K3JN&CU3Z?UL_,6UNH+RW2>WD62-QD,*FK
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MFME_!?JOR9SO_>%_A?YHUZ***Q.@**** "BBB@ HHHH **** "BBB@ HHHH
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MN?\ 4ULOX+]5^3.=_P"\+_"_S1KT445B= 4444 %%%% !1110 4444 %%%%
M!1110!R'C#_C\L?^NJ?^A5U]<AXP_P"/RQ_ZZI_Z%77UK+^''U?Z&,?XTO1?
MJ0W$,$B,\X&T1LK,6P IZ_RJC86FD1R1W%D8RS[@C+,6#8X..>:L:N8ET:],
MP<Q"!RPC&6QM/3WKE;&\N(98KNZ>XOV@>5OLZ6@MY(3C+NX9^?E88 Z[NA[9
M&QUUW>):!"\4\F\X'DQ,^/K@<5S.HZP'UVUD&IB"WAO!;FW#[-YPV]F]1G
MZ<$]Q76J0RAE(((R".],E@BF,9D0,8WWIG^%L$9_4T 24R5S'&66-I"/X5QD
M_G3Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^
MV3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_
M )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\
MQ56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^
MV3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_
M )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\
MQ56Z* *GVR;_ )\+C\T_^*H^V3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*H^
MV3?\^%Q^:?\ Q56Z* *GVR;_ )\+C\T_^*K#U.PM+W6;66XTF5WD5P^6 W8
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M8G0%%%% !1110 4444 %%%% !1110 4444 <AXP_X_+'_KJG_H5=?7(>,/\
MC\L?^NJ?^A5U]:R_AQ]7^AC'^-+T7ZF;K-]+:6<B6\%S)</&WEM#"7"MCC/;
MKZU4TN0/?*Q_M?>4()NH%5?H2%'\ZL:LUU;W=E>06<EY'$766*)@&4-C#@$@
M-C!&.OS&HHKBZU'6;:2.SN[6VMT<R23J$\PL  H7.??)'8>M9&QK31O(%V3O
M%@\[ IS^8-8&IZ?>/?&?2HKNWO&GC9YGN/W#("H8E-Q!R@Q]W.<=.M='10 4
MUUWH5#,N>Z]:=10!7^RM_P _,_YC_"C[*W_/S/\ F/\ "K%% %?[*W_/S/\
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M\>DW_7-OY5F^%O\ D6;#_KG_ %-;+^"_5?DSG?\ O"_PO\T:]%%%8G0%%%%
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M_P >DW_7-OY5F^%O^19L/^N?]36R_@OU7Y,YW_O"_P +_-&O1116)T!1110
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M:K/H%U)Y]K?F/4[$V<8ND<AO/B^1W10 -V,'!.#WKO([2VAC>.*WB1'^\JH
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M_,4?\)LO_0)N_P Q71?8+3_GWC_*C[!:?\^\?Y4>TA_)^+#V57_GX_N1SO\
MPFR_] F[_,4?\)LO_0)N_P Q71?8+3_GWC_*C[!:?\^\?Y4>TA_)^+#V57_G
MX_N1SO\ PFR_] F[_,4?\)LO_0)N_P Q71?8+3_GWC_*C[!:?\^\?Y4>TA_)
M^+#V57_GX_N1SH\;+G_D$W?YBE'B/5M0;R[#2C%NX\V9L[??%=#]@M?^>$?Y
M5,D4<8PB*OT%'M(+:"_$/8U'O4?W)?H9FCZ,-/WSS2-/=RG+ROR?H/05K445
MG*3D[LVA",(\L5H%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_013.jpg
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 R<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K/U#6+;3V6([I;IQ^[MXQEW_PJ+6]4.G6P6%0]U*=D
M,?=F-+I&DBS3[3<GS;^49EE;D@_W1Z 5K&*2YY;?G_P#"<Y.7LZ>_5]O^#_P
M[((7U^^&YDMM/C/0,/-?^8 IYTW6"<_VZ1]+5*V**/:OHDOE_F"H*WO2;^;_
M $L8_P#9NL?]!YO_  %2C^S=8_Z#S?\ @*E;%%'M9>7W+_(/J\.[^]_YF/\
MV;K'_0>;_P !4H_LW6/^@\W_ ("I6Q11[67E]R_R#ZO#N_O?^9C_ -FZQ_T'
MF_\  5*/[-UC_H/-_P" J5L44>UEY?<O\@^KP[O[W_F8_P#9NL?]!YO_  %2
MC^S=8_Z#S?\ @*E;%%'M9>7W+_(/J\.[^]_YF/\ V;K'_0>;_P !4H_LW6/^
M@\W_ ("I6Q11[67E]R_R#ZO#N_O?^9C_ -FZQ_T'F_\  5*/[-UC_H/-_P"
MJ5L44>UEY?<O\@^KP[O[W_F8_P#9NL?]!YO_  %2C^S=8_Z#S?\ @*E;%%'M
M9>7W+_(/J\.[^]_YF/\ V;K'_0>;_P !4H_LW6/^@\W_ ("I6Q11[67E]R_R
M#ZO#N_O?^9C_ -FZQ_T'F_\  5*/[-UC_H/-_P" J5L44>UEY?<O\@^KP[O[
MW_F8_P#9NL?]!YO_  %2C^S=8_Z#S?\ @*E;%%'M9>7W+_(/J\.[^]_YF/\
MV;K'_0>;_P !4H_LW6/^@\W_ ("I6Q11[67E]R_R#ZO#N_O?^9C_ -FZQ_T'
MF_\  5*/[-UC_H/-_P" J5L44>UEY?<O\@^KP[O[W_F8_P#9NL?]!YO_  %2
MC^S=8_Z#S?\ @*E;%%'M9>7W+_(/J\.[^]_YF/\ V;K'_0>;_P !4H_LW6/^
M@\W_ ("I6Q11[67E]R_R#ZO#N_O?^9C_ -FZQ_T'F_\  5*/[-UC_H/-_P"
MJ5L44>UEY?<O\@^KP[O[W_F8_P#9NL?]!YO_  %2C^S=8_Z#S?\ @*E;%%'M
M9>7W+_(/J\.[^]_YF/\ V;K'_0>;_P !4H_LW6/^@\W_ ("I6Q11[67E]R_R
M#ZO#N_O?^9C_ -FZQ_T'F_\  5*4:?K"G(US=[-:IC]#6O11[67E]R']7AW?
MWO\ S,.2]UK3Y!]ILX[RW_BEMLAP/]P]?PK3LK^UU"#S;659%Z$=U/H1V-6:
MP]4LSILCZQIZ8E3YKF)>DR=_Q'7--<M32UG^'S(DIT?>O>/6^Z]._H_D;E%1
M6UQ%=VT=Q"VZ.10RGVJ6LFK.S.A--70444UW6-"S' %(8V>XAMH6EGD6.->K
M,< 5C?VQJ&H28TFQ!@_Y^KG*H?H.IJO:Q/XENY+JY.=,B<K%#VE8?Q'VKI%5
M44*H 4#  Z 5LU&GHU=_@O\ @G,G.MK%VC^+_P E^+,DV.LR#+:RD9]([52/
MU-)_9NL?]!YO_ 5*V**7M9=E]R+]A'N_O?\ F8_]FZQ_T'F_\!4H_LW6/^@\
MW_@*E;%<I\0[R^LO"X?3KM[6YDNX(A*G50S@'^='M9>7W+_(7U>'=_>_\S3_
M +-UC_H/-_X"I1_9NL?]!YO_  %2N3MO%]^=1E%RP^VZ;I-R][9@X4SQLN&^
MC#D'T:KU[XZGM;>ZD2RB?R=(BU$#S#RSMC;TZ>]'M9>7W+_(/J\.[^]_YF]_
M9NL?]!YO_ 5*/[-UC_H/-_X"I7)WGC_6[&XOX9M%M-UBL$\Q6Y) BD(  ^7E
MN?IP:@N?%^K>'[SQ#>-;+>:=;:FD3F6X(=%95&V-<'IG/;K1[67E]R_R#ZO#
MN_O?^9V?]FZQ_P!!YO\ P%2C^S=8_P"@\W_@*E86G>-KO4M4D6'3<Z>)IX1*
M%DW*8P3N8[=H#$$8SD9%:WA+6M1U_2$U&^L(K.*95: )+O+#N3QQ[4>UEY?<
MO\@^KP[O[W_F3_V;K'_0>;_P%2C^S=8_Z#S?^ J5R]KX_P!4NKBPD&DVJV.I
M7,MI:.;@EPZY"EQC@$CMR*O>"Y=7NM#U2]O9T^U37$PB=IVD1"K,N-IP%4$=
MNHY-'M9>7W+_ "#ZO#N_O?\ F;7]FZQ_T'F_\!4H_LW6/^@\W_@*E<+IGB+5
M= M=4?7#J,FMVMF]QY%S,K6UPH<#?'M'RXX'XU<\3>+[R73=9M+=?L[V^G6U
MXD\,I#YD897V^M'M9>7W+_(/J\.[^]_YG7?V;K'_ $'F_P# 5*/[-UC_ *#S
M?^ J5Q.L>-M1$]QIE]9?9;JUO;,9L[Q@"DI/!8#MCD=#6M9^/Y;N_N'73)&T
MN)[B/SD5RRF)2=S';M ;! &<CC/6CVLO+[E_D'U>'=_>_P#,Z#^S=8_Z#S?^
M J4?V;K'_0>;_P !4KD;_P 6>*)/!BZW%9V-FEQ) 8"LQD8([XPWRXR<K] 3
MW%;D/B74$\5Q:/?VUK:(RJ%=C)^_<IN/E-MVG!XP2#P:/:R\ON7^0?5X=W][
M_P S2_LW6/\ H/-_X"I1_9NL?]!YO_ 5*RO%7C"X\.Z@EI'8K<//:E[4;B#+
M-YBIY?3T<&L^3QB^J1V;P1%8OMEA&6AG*_O)06=#@<A> 1WS1[67E]R_R#ZO
M#N_O?^9TO]FZQ_T'F_\  5*/[-UC_H/-_P" J5P,'B3Q)>Z)<7$\L;3Q>(([
M6(12>7N ?!C) 'R=.3DG)R*[CPSKEUK*:C%>VT4%U87;6L@A<NC8 (() />C
MVLO+[E_D'U>'=_>_\R;^S=8_Z#S?^ J4?V;K'_0>;_P%2N(TR]\076NB6UNM
M5EB34KJ.[\U1]F2!68*%)'WAQT-/\&ZIKKZ!=ZM,-2N95M'DC:^G3[-*58\+
MCYE.!C)]Z/:R\ON7^0?5X=W][_S.T_LW6/\ H/-_X"I1_9NL?]!YO_ 5*J>$
MO$DWBJUN;Y;9(+(.(X"),NQP-VX?PX)P/7K7+7G]HZ1X@UE?[>U:X@TO3TOT
MBDG7$C9;*L=OW3M H]K+R^Y?Y!]7AW?WO_,[3^S=8_Z#S?\ @*E']FZQ_P!!
MYO\ P%2N8N/'6L0R6EF=&A34+FW:\$7F/(!$,;1\BD[B<]L"I[WQU<6=U:,U
MG%]GDDMX[B+]YYT#2J#\QV[ 1G[I.31[67E]R_R#ZO#N_O?^9T']FZQ_T'F_
M\!4H_LW6/^@\W_@*E<9#XXURP3Q#<7T%O<K;:BME;1HQ&UV( '"Y*@<YZD\5
M<7Q[JK366F_V*L>JW=Y);Q>>SQPNB*&,@+*&P0>F*/:R\ON7^0?5X=W][_S.
MG_LW6/\ H/-_X"I1_9NL?]!YO_ 5*P/!.J:E-X!N[]]]Y?1RW!1)9"VXJ3A-
MWIVK/M?B@]Z-D&GQF:2UB:!3(<27#% T73^'S%H]K+R^Y?Y!]7AW?WO_ #.O
M_LW6/^@\W_@*E']FZQ_T'F_\!4KC;CQ)K<5^(=-*Y?7WLY!<S%@P"Y"CY3L7
M@].F!ZU'#XOU;1]9U 36XN["3719;Y+@[HMP& BX^Z,'\Z/:R\ON7^0?5X=W
M][_S.V_LW6/^@\W_ ("I1_9NL?\ 0>;_ ,!4K8HH]K+R^Y?Y!]7AW?WO_,Q_
M[-UC_H/-_P" J4/%KULFZ*YM;PC^"2+RR?Q!Q6Q11[5]4ON0>PCT;7S?ZW,J
MPUH3S"UO;=[*\/W8I#P_NIZ&M6JFHZ;;:G;^5<+R#E'7AD/J#VJGH]Y<F6;3
MK_'VJW^Z_P#SUC[/_C1*,9+FCI;=?Y"C*4)*$];[/]'Y_GZFO11161T!1110
M 4444 %%%% !1110 4444 %%%(WW3]* .6@']J^,C(W,5DA(!_O$X'^?:NJK
ME?"_.LZN3URG_LU=56M5[+LE_F84%\4N[?X:!11161N%<E\1-1N]+\/6]S92
M3)+]N@4B%L,ZEN5_'I76U4U#3+/58$AOH!-&DBRJI)&'4Y!X]#0!QNC:]= :
M[JNL3FWU"V<(-*FN-D5NAQL/&=Q;/WL'T%6O^$VNXT>.33$-TE_#9[/,>-6\
MQ-P;YT##'N/I6[>^&=&U&[FNKNQ22>>(0RON8;T!! .#V(!!ZC%9^I>"M/O(
MH8H(U1#>Q75SYCO(9@@(P23G.#U]J ,V#Q1=ZAXAL;26/[(]IJ$]M=)'-OCE
M MV<'.!QT/(XQ4<OQ"EMXKJ273HG1+![Z%XI7VNJD#&609SD<KD5TUIX9T:R
MV?9[%%*2/*&+,Q+LI5F))RQ*DCG-5QX,T 1M']@W(T#6V&FD8"(]4&6X7V'3
MM0!#;>*'CGOH]5M%MQ;0PW :W9Y\I(2 " N<@CG -<-JGC+4K#Q1JMW;W-S-
MIMS#]GM86#+Y<S0*\9"D9!)R.W6O5(K"U@NWNXX0L\D:Q,^3RJYVC\,FJEQX
M=TB[G>:>QCDDDG2Y9F)YD085NO8<4 <?HGB+4]%\/6-G>F34=4GU">T\R5W.
M"FXDG:K,?NX  K2D\6F#9J%U8W4+)I=Q<O;F0@9215QM(')[,<8!Z<UOS^'M
M*N8?*EM!M\]KD%79665L[F# Y!.3T/>B/P]I,4*1)91^6EN]J%))'E.064Y/
M.2,\\T <Q=>/;^R@/GZ$PG^U6]O&2[I')YN<8+(#D$8/'?-='JT][%X5O)I)
M[:QO1;-^]\S,<3XX.X@<9QR14:>$-!2/8-/4CSHY\O([-OC^X<DYX[#I6M<V
M\-W;2VUQ&LL,JE'1AD,IX(- 'FVFZ[?Z)J=T+]M5CDCTR2X6PO9EG28H>728
M$D>F,5IZI\1&TX7!&FB3R=+@U#_78SYCA=G3MG.:Z"S\(Z#8R220:>F^2$P,
MTCM(?+/51N)P/85$/!'AT1S1_P!FJRS0K!)NE=BT:D,%R6Z @?EB@#-U7QM<
MZ"BIJ6F)]JGM_-M(K>8N)I-X7R\E1S\RG\3Z4^3Q)+I^H:K+-;N8[62T6ZW7
M!*Q+(/F9%QP%)Y]>M=%=Z1I]]-9S75K'+)9OYENS?\LVQC(ILVBZ=<"_$MJC
MB_4)= D_O !@ ^G![4 <ZOC2YFLK>>*Q@5KRXE2SCEF<M-$G20*B,QSZ <#!
MS2^'?$%QKNOP7!#PP3Z2)C;;]RJ_G,I/;GCKBMNY\-:/=Q64<UDI6R39;;79
M3&N,$ @@X(&".]2V&AZ;I;QM96BPF.'R$VDG";BVWD^I)H Y;Q+9SIXNT."+
M5M4AAU*:43QQ73*H"H"-H_AYJ+_A+9=+U.>Q@M9KJ235UT]3<W9(!,8(8?*<
M#U'/<UVESIMI=WEK=SPAY[1F:!R3\A88/Z54?PUH[W8NFLD,XNA>;]S?ZX#
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M],MY3(9 K&4 2%HT.['3/R\U8,\00.94"DX!W#&?2E,T2LRM(@*C+ L.![T
M5VT^%@H;!"G< 8TX/7/W::-,MQ$T051&WWD\M,'G/(VU9,\0.#*F<XQN'7_)
MIZLKC*L&'J#F@"J-/B42!6*^:,/M1!N[<X%0Z%_R!X?J_P#Z&:T:SM"_Y \'
MU?\ ]#- %'2/^1HUWZP_^@UOU@:1_P C1KOUA_\ 0:WZVK_'\E^2.?"_PWZR
M_-A7'>.?]5#]178UQWCG_50_448?^-'U%C/]WGZ,[$=**!THK$Z0HHHH ***
M* "BBB@ KB_$7BW4M,;4[2PM8)]0@EB-M$P/SQ-&78D9ZC9)T]J[2LF;PY83
M>)H=?<2?;8H#;@!AL*G/48Z\GOWH PT^(%A$TSW3 QLY^SK%C<R+&C.QW$#A
MF( ')QP#6C%XST:XU2/3X)R\LA55;C;N9-ZKUS]WOC';.:BM/ VE:?!:1V4E
MS!):B58YE96?;(VYE.Y2",XQQD8ZUH6_A^UM-3FOH)9D:<AIHQM*2,%V[CE<
M@X Z$#CI0!D:3XZL;S0#J$P+- L2W+0@"-97Q\@+$<C(R3P,\FN@L-2BU'31
M?01R;"&PAQN."1@8)!Z<$'!]:SK7PG8V-N8;.:Y@5H(X6,97YO+)*L<K@GD@
MY&".HK0TG2;;1K,VUMN*M(TK%L9+,<DX  'T  H R]%\2F\BU&;5%ATY;:]-
MNBS2*I V@@,<XW<]C4EMXA>\\6-I<$&;-+>1S<'_ ):2*R A?4#?R?7CL:N6
M^AV,!O-T0G6[N#<R+, X#D <#'M5.U\&:%9:U'JMK9"&Y0/C8QVY8@EL>O7V
MY- &]1110 4444 %%%% !1110 4444 %9^N7=SI^AWM[:(CS6\1E"OG!"\D<
M>P-:%,FB2>"2&09212K#U!&#0!Y_J_Q"N[/4=4AM;>"6!85_LZ3!/G3;HU93
M@\X,@Z>AK67XBZ B3>?<.GDQL[-LR'VL$;: 2?O$  XSU''-3V?@31K*RTFU
M03NFEW#7$#.X+%B23NXY&<>G05(W@S39-.N=-DDN7L)]W^CEEQ&2^_*D+NX;
MIDF@#,N_B/I<#6TX?9:B:2&Z#KN=6$>Y0NTD$DD=":V?^$JL1K$6EM#<+=/L
M#*0OR%QD C=D^Y ('K27'A2QO8HH[^6>\6/S /-V#(=-A!VJ.W3WI7\+6DL]
MG)-=7<HM#$T:2,A&Z/[ISMR.@)P0#W% &7XX\4ZAX>DT^*P2VS<>8TLMS%(Z
M1JH')\O)'7K6K/KZIH4MS:/;7]]%;"5H;>5<9*YSR<A>_/.*?K?AVVUW9Y]U
M>P!4>-A;3E!(C<,K#D$'\_0U8BT73[>P:SM[9(8V@^SED4!M@7:!GJ<#UH Y
MFY\5:VOAG1M8MK*SD6YA26Y1W(+LVW$<2CDL<G&>.*[5264$@@D9P>U<\W@^
MV\G2XH-1U"W&F0^3;F)TSC !)RAYP,9KH5&U0,DX&,GJ: %HHHH **** "LG
M7_\ 46/_ %_0_P#H5:U9.O\ ^HL?^OZ'_P!"K2C\:_KN8XC^$_ZZHUJ***S-
M@HHHH **** "BBB@ HHHH **** "D;[I^E+2-]T_2@#EO"W_ "&-7^J?^S5U
M5<KX6_Y#&K_5/_9JZJM*NZ]%^1C1^%^K_,****S-BM_:%GY,DWVF+RXFV.V[
MA3Z&LWQ$P:#364@@W\!!'?FD/AN,V\D/VAB':,G*\$(,*#_7^E5M<L(X(]&;
MS9F:&[@B&9#A@#U*C@GWQ0!TM%%% !1110 4444 %%%% !1110 4444 9.F_
M\AS6O^NL7_HI:UJR#%-8ZX)5EC:'4)0KH8SN0K$>0V<?P>G>M>KGO<2"BBBH
M&%%%% !1110 4444 %17%O'=0-#*NY&ZBI:*32:LP*CZ=;DHT:"%T;<&C4 _
MRIHM;D7C.;R7RR@ ^[UR>V,5=I" P((!!Z@U#I1Z(7*B&T=W@R[%F#NN2!SA
MB!T^E<V=!UMAJ]C]IL%TV_>=PRJ_G(9!QWV\']*WET](9$>V\N)E+9S'G.XY
M[$4L\=^4 BG@#;AG]T1QGG^*DI2C'5"NTCDX/!%PVG-#>-8-,T5TN$1BBO(L
M:JRANF-F3C'6C5/!FI:AJ-W<&\M=DL,T290@X=%4;@.#@KUZG\*ZZ8WD<+NK
MQ.R@D*(CD^WWJ0Z@@&?(NO\ OPW^%4ZB6^@[G'7_ (*U6_TB>U-SIL$ES+(\
MD<,#+$FZ-44IW!^7)&<$GVILO@&\G.IQF\MHH;V!T.Q68EV"X)W9QRO.T@'C
M@8KNH)DN($FC)*.H921CBI*I--70SS:X^'.J7S7$UW>V#3S?:6^6-@JO)"D:
MD9S]TIG-=;X9T*308]0C9XC'<W;3QK&,!%*J,8^H)_&MRBF 5G:%_P @>#ZO
M_P"AFM&L[0O^0/!]7_\ 0S0!1TC_ )&C7?K#_P"@UOU@:1_R-&N_6'_T&M^M
MJ_Q_)?DCGPO\-^LOS85QWCG_ %4/U%=C7'>.?]5#]11A_P"-'U%C/]WGZ,[$
M=**!THK$Z0IKN(XV=ONJ"3]*=01D8/2@#'L];EOM.GN8[+;(L:S11M)]]&&5
M)(!P<9R,'&.,U=TR]_M'38+ORS'YBY*$]#G!'(![=P#["H%T#38X7BC@:-')
M)"2NO7CC!XQ@8].V*NVUM%:6Z00*5C08 ))/XD\D^YH 4W$0."XI/M$/_/05
M+10!%]HA_P">@H^T0_\ /05+10!%]HA_YZ"C[1#_ ,]!4M% $7VB'_GH*/M$
M/_/05+10!%]HA_YZ"C[1#_ST%2T4 1?:(?\ GH*/M$/_ #T%2T4 1?:(?^>@
MH^T0_P#/05+10!%]HA_YZ"I%8,H(.0:6B@"&\NH[*RGNI<^7#&TC;1S@#)Q6
M9%K<TVF7EP+';<VI&Z$R9&"H<'< 3]UAP 3G(&>M:[HDD;1R*&1@0RL,@CT-
M9Z:#IT=LUO'"Z1MG(25P>W.0<Y&T 'L!@<4 6=/O!J&G6]XJ&,31A]C'E<CH
M:D^T1#_EH*6""*V@2"% D:#"J.PJ2@"+[1#_ ,]!1]HA_P">@J6B@"+[1#_S
MT%'VB'_GH*EHH B^T0_\]!1]HA_YZ"I:* (OM$/_ #T%'VB'_GH*EHH B^T0
M_P#/04?:(?\ GH*EHH B^T0_\]!1]HA_YZ"I:* (OM$/_/04?:(?^>@J6B@!
M 00".AK*U_\ U%C_ -?T/_H5:U9.O_ZBQ_Z_H?\ T*M*/QK^NYCB/X3_ *ZH
MUJ***S-@HHHH **** "BBB@ HHHH **** "D;[I^E+2-]T_2@#EO"W_(8U?Z
MI_[-755ROA;_ )#&K_5/_9JZJM*NZ]%^1C1^%^K_ #./O=:N?^$O>RT_4;>/
M:J))#<,75G.<!4 !!]3NQ[5UD!E:",SJJRE1O53D!L<@'TKEIDCC\50>8S+)
M)+F,8F&X!C_TTVGO_#C':NMK,V"L7Q)_J=._["$'_H5;58OB3_4Z=_V$(/\
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M1_I__3M_X]5JBGR>;"Q3L;PW+W$3F/S(7VG8>.@_^N/PJ+0O^0/!]7_]#-:
M15+%5 +')('4UGZ%_P @>#ZO_P"AFG!-*S=P11TC_D:-=^L/_H-;]8&D?\C1
MKOUA_P#0:WZZ*_Q_)?DC#"_PWZR_-A7'>.?]5#]178UQWCG_ %4/U%&'_C1]
M18S_ '>?HSL1TK&O/%&FV6J1Z?*TIG:01G;&2%SMY)],N@^K"MD=*\^N]0U"
M?QE' =%:&*1T9IGBMS<!5< 8)?)C)&<XR.@[8Q.D]!HHJ-YX8Y(XY)45Y"0B
MLP!8CK@=Z )**A>ZMXS('GB4Q+NDW.!L'J?04^*6.>)989$DC895T8$'Z$4
M/HJOJ%Y'IVG7-[*K-';Q-*P7J0HR<?E7"_\ "X-#_P"?'4/^^$_^*K2%&I45
MX*Y,IQCNST*BO/?^%P:'_P ^.H?]\)_\51_PN#0_^?'4/^^$_P#BJT^JUOY6
M3[6'<]"HK(\.>(;7Q-IAO[2*:.,2&/;* #D 'L3ZUKUA*+B[/<M.ZN@HHHI#
M"BBB@ HHHH **** "BBB@ HJ-YX8Y8XGE19),[$9@"V.N!WIKW=M'YN^XB7R
M@&DW.!L!Z$^E $U%,BECGB66*19(V&5=#D$>QJIK&J0Z+I-SJ-PCO% NYEC
M+$9QQGZTTFW9 ]"]17GO_"X-#_Y\=0_[X3_XJC_A<&A_\^.H?]\)_P#%5O\
M5:W\K,_:P[GH5%>>_P#"X-#_ .?'4/\ OA/_ (JNN\/Z[;>(])34;6.6.)V9
M0LH ;(..Q-1.A4@KR5BE.,M$S4HHHK(H**** "BBB@ HHHH **** "LG7_\
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M(^;&TD ],5U59FP5B^)/]3IW_80@_P#0JVJQ?$G^IT[_ +"$'_H5 &U1110
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M?HW_ 'T:\4["2BH_(C]&_P"^C1Y$?HW_ 'T: )**C\B/T;_OHT>1'Z-_WT:
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MY75$3 R^[E2.<8(SU]*I:[J%K/'HZQS*7GO()8T)PS*3UQ0!T=%%% !1110
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M)G\+/G>BBBOI#SPKW3X7&3_A!X-JJ1YTO5L?Q?2O"Z]W^%G_ "(UO_UVE_\
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M#I!?0L 568@\@B!^?TI?ML7]R?\ [\/_ (5FZ6]S9:5:VJ6$\RQ1*@D$D0W
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M%X9U6.6*7[=)YBQ&-G#G<WWL<[NF6R1[<8KLJ*S-C-L$O;2R2&2$2.I)+"3
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MP]#S**)7^](L8+*@+ G+'H. ??\ *EAM_.S\RH P3)!Y8G ''T/Y4D<OE_\
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MY+\D<^%_AOUE^;"N.\<_ZJ'ZBNQKCO'/^JA^HHP_\:/J+&?[O/T9V(Z5S2>
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MBO;2*Y@;='(NY36M17C&:]/FO^ <])\LY4WWNO1_\$FHHHK(Z HHHH ****
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MQL ?D^Q/M63)X^U"'4XI'CMFA%J3);)*#YC"X\LF(@98GL"?7ZUZ*((0<B)
M=NW.T=/3Z4""$%2(HP5^[\HX^E '/:#XI?6-8N+%[5$"QM*C(^XH!(8]L@Q\
MK$J3CT^E=+3515+%5 +')('6G4 8VNSW]M-ITEM<I%;M=113(8\M)N<# )Z#
M&>V?I69XB\3ZCI6I&VM+6TDC 0;II&4[F25AT'3]T?SKJRH;&0#@YYI&C1CE
MD4GU(_SZF@#BK'QW-J&K:?;1VEO'%<^0&#RGS/WL+2[E&,%1C;GUS7;UFOH6
MGR:K%J31.;B( 1CS&V*0" 0F=H."1G'>M*@ KE/&FJWFEFP:UOH;="7>6-W"
M/.%V_)&2K MSP.,_G75TUXTDV[T5MIR,C.#ZT <IKWBN^TO7CIUK:6TJB&)]
MTLI4YD9U'0'@%0?SJ"#QM<7=[IRQ6]JD-RMMO224^;F8$Y48P5&,9]:[%HHV
M;<R*6]2.:H2Z%83ZI#J$D;F:$ (OF-Y8QG!V9VY&>N* -*BBB@ HHHH *YSQ
M1>7\%UI-O8R7"M<S2*ZVYC#L!&S#!D^4<@5T=(54D$J"1T)'2@#SA?%^N:0]
M_;Z@UK<7EN(0R.P1%(M_,DVD#DDCC)[\>E:]YXTFMEO72V@98Y!##&92)%;<
MJ[Y!C 3YP<YZ?7CK6@A<DM$C$G)RH/-+Y,7S?NT^88;Y1R/0T <!9>.KR;6(
MBT,1@FBMA]F64,X9Y)(RT>!\PR 3D\ 5T7AWQ')K=Q<PR01IY:)*K1/N 5\X
M1O20;>1[BMWR8@P81IN7@':,BE5$3.U57)R<#&30 ZN$D\12/?ZB+7Q"DEI!
M*L5PS^4K0$S*K%!C.U5)!9LC./0UW=1"UMP6(@B!<88[!S]: ..U#Q=?Z5X8
MTF]$,-S/=1R.[2L4#*D32;A@=2%_6JEU\0[N"P,@L;1)QYSGS9R$*I$D@4''
M+D2 8]C7?-%&X :-2!P 1T[50U/0M/U>)(KN)S&A)VQR,@;(P0P4C<".,&@"
MW93FZL+>X90K2Q*Y [$@&N/U+Q#-%J6K1Z?J_FM:1/Y\+B,"$_)]P8W-M!9B
M3D=OIVR(L:*B*%51@ #  IGV>$2&00Q[VZMM&3^- '%CQ7>VN@07,#PZ@9M3
MDLX)YF"AXP7VME!@_=[#FI8O&=W-HPO/LUI#*[QE!+,?+5'A\WYFQ][ *^F2
M*[#R8MBIY:;5^Z-HP/I574-)M-3L_LLZNL60?W,AC/'3E2./:@##O]>O1I&A
M7T#VEO)>X9UN7VQ<PL^"<9Z@5D:SXVO(-,NGMD2WE>!ITEG? B MXGVKQR^9
M. ?0_AW2VMNEO';B&/R8U"HFT84 8  I[0Q.,-&C#.<%0><8_E0 RT=I;*"1
MSEFC5B?4D5FZ\X,FF6_\4E[&1]%.36QP!Z 5S]DRZYKG]HJ#]ELLQ0D_QN?O
M-]*UI*S<WLOZ1SXAW2IK=_EHW^!T%%%%9'0%%%% !1110 4444 %%%% !111
M0 4444 5=0L8M0M6AD'4<'TKC8Y-3\*74B1Q&>S=LE#_ #![5WE,DC252KJ&
M![$5<)N/H9U*:GY-;/L9%IXJTFZC4O<BWD(^:.;Y2#]>E6_[;TK_ *"-K_W]
M%5[CPYIUP26A /L!5?\ X1'3?[GZ"JO2?1_@1:NNJ?R?Z,T/[;TK_H(VO_?T
M4?VWI7_01M?^_HK/_P"$1TW^Y^@H_P"$1TW^Y^@H_=>?X!^_\OQ-#^V]*_Z"
M-K_W]%']MZ5_T$;7_OZ*S_\ A$=-_N?H*/\ A$=-_N?H*/W7G^ ?O_+\30_M
MO2O^@C:_]_11_;>E?]!&U_[^BL__ (1'3?[GZ"C_ (1'3?[GZ"C]UY_@'[_R
M_$T/[;TK_H(VO_?T4?VWI7_01M?^_HK/_P"$1TW^Y^@H_P"$1TW^Y^@H_=>?
MX!^_\OQ-#^V]*_Z"-K_W]%']MZ5_T$;7_OZ*S_\ A$=-_N?H*/\ A$=-_N?H
M*/W7G^ ?O_+\30_MO2O^@C:_]_11_;>E?]!&U_[^BL__ (1'3?[GZ"C_ (1'
M3?[GZ"C]UY_@'[_R_$T/[;TK_H(VO_?T4?VWI7_01M?^_HK/_P"$1TW^Y^@H
M_P"$1TW^Y^@H_=>?X!^_\OQ-#^V]*_Z"-K_W]%']MZ5_T$;7_OZ*S_\ A$=-
M_N?H*/\ A$=-_N?H*/W7G^ ?O_+\30_MO2O^@C:_]_11_;>E?]!&U_[^BL__
M (1'3?[GZ"C_ (1'3?[GZ"C]UY_@'[_R_$T/[;TK_H(VO_?T4?VWI7_01M?^
M_HK/_P"$1TW^Y^@H_P"$1TW^Y^@H_=>?X!^_\OQ-#^V]*_Z"-K_W]%']MZ5_
MT$;7_OZ*S_\ A$=-_N?H*/\ A$=-_N?H*/W7G^ ?O_+\30_MO2O^@C:_]_11
M_;>E?]!&U_[^BL__ (1'3?[GZ"C_ (1'3?[GZ"C]UY_@'[_R_$T/[;TK_H(V
MO_?T4?VWI7_01M?^_HK/_P"$1TW^Y^@H_P"$1TW^Y^@H_=>?X!^_\OQ-#^V]
M*_Z"-K_W]%']MZ5_T$;7_OZ*S_\ A$=-_N?H*/\ A$=-_N?H*/W7G^ ?O_+\
M30_MO2O^@C:_]_11_;>E?]!&U_[^BL__ (1'3?[GZ"C_ (1'3?[GZ"C]UY_@
M'[_R_$T/[;TK_H(VO_?T4?VWI7_01M?^_HK/_P"$1TW^Y^@H_P"$1TW^Y^@H
M_=>?X!^_\OQ-#^V]*_Z"-K_W]%']MZ5_T$;7_OZ*S_\ A$=-_N?H*/\ A$=-
M_N?H*/W7G^ ?O_+\30_MO2O^@C:_]_10=<TH#/\ :-K_ -_16?\ \(CIO]S]
M!3D\)Z8K9\H'Z@4?NO/\ _?^7XB77BFT4&/3U:^N#PJ1@[?Q:ETS3;F>]_M3
M5&W3D?NH?X81[>]:EM86UHH6&)5^@JS0ZB2M!6_,%2<FI5'>W3I_P?F%%%%9
M&X4$9&#110!Q^N:!<07?]H::SI*#GY.HJ?3O&,9)AU:(VLHZ2 $JW]174U2N
MM)L[S_6PKGU K2-33EDKK\C&5)\W/!V?X/U7ZK48NNZ2XR-1ML>\@%+_ &WI
M7_01M?\ OZ*H'PEII.?+_04G_"(Z;_<_04_W7G^ OW_=?B:']MZ5_P!!&U_[
M^BC^V]*_Z"-K_P!_16?_ ,(CIO\ <_04?\(CIO\ <_04?NO/\ _?^7XFA_;>
ME?\ 01M?^_HH_MO2O^@C:_\ ?T5G_P#"(Z;_ '/T%'_"(Z;_ '/T%'[KS_ /
MW_E^)H?VWI7_ $$;7_OZ*/[;TK_H(VO_ ']%9_\ PB.F_P!S]!1_PB.F_P!S
M]!1^Z\_P#]_Y?B:']MZ5_P!!&U_[^BC^V]*_Z"-K_P!_16?_ ,(CIO\ <_04
M?\(CIO\ <_04?NO/\ _?^7XFA_;>E?\ 01M?^_HH_MO2O^@C:_\ ?T5G_P#"
M(Z;_ '/T%'_"(Z;_ '/T%'[KS_ /W_E^)H?VWI7_ $$;7_OZ*/[;TK_H(VO_
M ']%9_\ PB.F_P!S]!1_PB.F_P!S]!1^Z\_P#]_Y?B:']MZ5_P!!&U_[^BC^
MV]*_Z"-K_P!_16?_ ,(CIO\ <_04?\(CIO\ <_04?NO/\ _?^7XFA_;>E?\
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M#]_Y?B:']MZ5_P!!&U_[^BC^V]*_Z"-K_P!_16?_ ,(CIO\ <_04?\(CIO\
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M!1E)&>7&,9QUXS7944 >;+J'BV:)();K4K63[8RBX33O-40;%8EAY62<DJN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_011.jpg
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 S4# 2(  A$! Q$!_\0
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MJ5Q-J<LTEL\$!:,JZMR6Z8 (]?3K0EAJ.EZ1X)UN33;JZATQ)$N;1(B94WY
M8*?3^@H Z?6/B+I5MX7N]5TR9;F>&18!#)&ZE9#D@,, @8#'/3C&:2+Q4=07
MPK<0:I';KJ#,LT+6S'SV 4,JDCY<'/)ZYK*U6XN/$O@SQ/-:>&9K'S?+\IWB
MVSW>T@DLH&> ..3U]J@;[3JDOP^N(M.OHTM7:.<2P$&/:J+D^@)!P30!UVJ>
M.?#NCWSV5W?XGCYE6.)Y/*'^T5!Q5B^\6Z'IMG97ES?HMM>G$$JJ65OQ X_&
MN"@GNO"%]XGLK[0+_4&U2=Y;>:W@\Q)E;.%8]NO(YZGVS"_AS4[+P_X%LKBT
MFEDAU(2W"*A80HT@;#8Z  \Y]Z /1-'\5:/KUU/:V%TS7, W20R1-&X'KA@.
M.1^8JP^N:='J\NER3[+N*W^TLC*0/+SC<#C!KF+6RN5^,M[>&VE%L^EA!-Y9
MV%MR<;NF>/TK.^*.EZH9K#5='MYIIVBFL)UA0LQ213@G'89;GU(H ZE?&WA]
MM .MK?9L!+Y)D\I\[_3;C/Z5EW/BMM,?Q5=2W\=TFFI$8K00,AA9@<*S8^;<
M<<\X]JY+3O"6HV7C"U\-M;ROH45Q%J#3;#L9TBP03TY;M6P-+OIM1^(RK:3_
M .EVZ+;DQD"4^4XPI[\D#CUH AOOB+<R^%-%U6UGC@EEOT@OOW)VJ""S ;NV
M,<BNTTGQ;HNMW\MC8W3-=1KO,4D+QL5X^8;@,CD5YK+'=:IX%\,6*:3J DL-
M2BCN$EMF&1@DL/\ 9YQDXKK9;*Y_X7+!>"VE^S?V64,PC.S=N/&[IGIQ0!=\
M5:Y?Z7XB\,V=I*J0W]TT=P"@.Y1M[GIU/2K6I^-_#^CZA)8WE\5GB ,H2%W$
M6>FXJ"!G(K*\:V=S<^*O!\L%O-+'#>LTKHA8(/DY8CH..]<;JFGW^E:WXEM;
MJ/7I(]1F:6(:= KQW*/GY68J<$9QQ[\>H!Z9J/B_0]*FM8KN]"M=1>;!LC9Q
M(O;!4'.>P[TNG^+M#U/3[N^M[Y?(L_\ CY\Q61HNOW@1GL?RKCX]$N;3QIX)
M06ETUO:6+K(\B[_*.QL*S 8R#@5"EOK%A?\ Q!NK#37DFE:(VPD@)67EMQ4$
M8<@$G'/.* .PTKQMH.LZA'8V=VYN)5+Q)) \?F*!DE2P&> :YGPS\2;46%X?
M$5\1/'>O&K);,52/Y0NXJN!SNZ\UCZ(E]=>-_#-^\>N3Q1))'-/>VWEI&YC(
MVHJC"KD@9_7BJVCWEWHWA37]'N?#FJ2W&I3SBW=+4E6W*%&[N,'GIWH ]/U/
MQ7HVDQ6KW-X&-VNZW2%&E:5<9R H/&.]11>-/#\VBR:LFH+]DCD\IR48,'_N
M[<;L^V*X:ZAUS0(/#6FSI?1645F1<76G6PFG64[OW88@[0!@<=<GK6?I>DS_
M /"):_'?Z)J\P.IB=%&4N4'.)5R,.P[X]30!Z7I_B[1M3:Z2"XD6:TC,LT,L
M+QNB>NU@"1]/44DGC#0XO#D6OO=L--E;8DOE/DG<5^[C/4'M7%>%%UV[U+5K
M59]2N]+DL&1)]3MO*D\T\*H8Y+8Y[X]NF><N)-2G^%EOX:30-6^VVLY:9C:M
ML \QF&#U)^8<8[&@#U?4O&6A:1?R6-Y=LETD8D,2PNS$'IC .?Z52_X61X5,
M<4@U/,<A WB"3:A/0,=ORGCO]>E5+.QG_P"%NWUX]K)Y']EJB3-&=F[<N0&Z
M9QFN,M]&U!/@K?6G]FW0NWO@XA\AO,(W)SMQGH* /7=3N+J#2;FXT^W%U=+&
M6ABW !V[<^E<3!KWBC1]=T&WUN:TN!K!(>UBBV/:GCH03N SSGT/UKK;R^ET
MGPPUY':2W,T%NI6WC4EG;  &!SUKSCP=J-R_B8:EKNAZU/K%Y((DN'M2L%HA
M.,+GH,'D^GXD@%FY\<>(GTV_\46;VG]CV=[]F6R:/+2ID#>7Z@_,/\CGTU+F
M-[-;H']TT?F9Q_#C->,7%CJECX:U/P,FCWTMY<:@)(+A(LPM%N4ABW;[OX9]
MJ]@:V-OH9M5RQCMO+&!UPN* ,&/XD>%9%A<:D1'*VT2-!($5O1F*X!^O;GI5
M_2O%^B:U?265E=EKB-/,V21-'N3^\-P&17F4VC:@?@G:68TVZ^U_;B[0B!O,
MQN;DKC/3'-=3KVD75Y\1D%O%)%!)H4MN+D(?+C8EP 6Z#&0<4 :LGQ'\*QK,
MS:D?+B.TR"%RK'.,*<88\]NW/2NEFEQ9R2QGI&64_AD5XAJU[=VWPM/AVYT"
M\AEL909;MT A'[PX9&_B)W8X[$G->ULI.E%0"6\C&._W: /*]+\4^([WPRVL
MR>+])@E17;[%/#&&;:3@<'/....];5YXRUA_#_A/4%C6SFU.]2*XCV9!0L1D
M;N0".1]:XS1+;3+7PT+/5? NL7>HX?\ ?I:,,Y)V\Y!XX[5M2:5X@'A?P='J
M,%W-=1:JDCJRL[Q1;N-_I@>O3I0!LC4?%FL^--=TS3-8M[.WT]H]BRVROD,.
MF>O8UK>#_$FHZCJ&J:)K44*ZEIK*&D@SLE4]& /3M^8X%<Y#JUUX9^(/B6[E
MT+5KR&[:(1/:VQ8':O// []JV/!&FZA/K^M^)]0LY+$:BRK!;3#$@1>[#MT'
MZ^U '1ZSXFTG0#$NHW7ERS?ZJ)$9W?Z*H)J*'Q=H,^BR:PNHQ"QB;9)(P*E&
M_NE2,Y]L5RWBF&[T?XBZ;XG;3KF_T]+4V[BVC\QX6^;G;Z?-U^M4-?M-0\2>
M&!J5GX8-FL&IB[:U*A9KR,9R[(!][GIR3S[9 .UT;QCH6O79M+"\+7(7?Y4D
M;1L5]0& R/I5,_$?PLN"=1;;YGELWD2;4;./F.WC\:PK2XN/%OQ#TG5K32+Z
MPM-.@D$\]W#Y9D+ @(/7&?U-8EMI%^OPB\26QTZY%U-J.](C"V]QOBY QDC@
M_K0!Z+IOC+0M6U7^S;.]WW)4N@,;*)%'4H2,,.#T]*H#XE>%60.-28INVLWV
M>3"?[WR\#ZUF3:=<)XZ\%216DH@M[*6.1UC.V/\ =$ ,>@Y]:X7POJCQ> M<
MTB/1;Z\FOYY(X9K>#>FXJHPQ[;>&_&@#U_5/%FC:1':O<W>XW:[[=84:5I%Q
MG("@\8[U#_PFWA\Z$-9%_P#Z#YWD&3RWRK_W2,9%<5?1ZUH4?AK3ITOX;**Q
MVSW.FVRS3B7G,88@[1TY'7)Z]L*;2-4;X;ZM9G3=0%RVM^:(I(6:0H5'S' Y
MZ<D4 >FKX^\-MIYOEOR8?.\A,0OND? .%7&6X(Z>HJY9^*]$OM+N=1AOD%M:
MY^T%U*-$?1E(R#^'-<E\1-*O%U70-5M([S['9%TE-A&'EASC#*I!]/TK"_X1
MJ]UGPOXFNK*#5_/NVB8'4 JO=>6V[(0 8./S/XT =#J/Q!AO-;\/6VA7A,5W
M>".X62W*EXR0 5W#IUY%=)XP\2)X6\.S:B4$DV1'"C D,YR0#CH, G\/>N&O
M]1N/$NO^$9K7P[J5I%87:B9YK8JL>2ORC'\(V]>.U=KX[LY[_P $:M;VT32S
M-#E409+8(. .YXH BM?&^CCPK9ZS?WBPI*%1OW3 M+CYE5<9/.:T=$\3:3XB
M6;^S;KS7A.)8V1D=/JK &O/[B2[EM?"/B--'O[BUTE3;W-FT/[T-L"^8J]P"
M,Y]AT[:_AA+G6_'U_P")DTZYTZP-H+95N8_+>X?(.['H ,9^GO@ ZG6?$ND^
M'Y+9-4NQ;_:=_E%E8@[0">0..H^M4!XPTW5-#U>XT>[W75C;2.4DB9&1@I()
M5@,C(KGOB3,UOXE\(3I9O>&*XE?R$&6?'EG@=SQD>]58H[OQ#KOB37[?2[RS
MM3H\EFB7$)22XD(SD+WZ8_*@#H-&\96T'@G2M5U^\"W%X"HV1$M(VXC"JH]A
MVK6T_P 6Z)J=A=WL%ZJPV?\ Q\^:IC,7^\& /:O/F;6M,\$>$8([6\@B$CB\
MEALQ)/ -WR[58';G)YZ\#Z&C!H&JZKI_C.W@M=362[%M-;G4%(DG"$L03C&[
M&..W H ])TOQMH&L7R65G>DW$@+1+)"\?F@=U+ 9Z&HAX^\-F_-I_:(SYOD^
M:8W\K?\ W?,QMS^-86FZQ+KT^GZ=!X4N8)(+1HI+Z\@$?V-MF/W9()/(Z#!Z
M>]<7;:1>_P!BQ>&+VU\1O.MP5:U@B06_WB=XD*GCGJ?Y4 =W)XX32O'6MZ?J
MMWML;>*$VT20EWR4#-]T$GJ3STKI%\4:*^@C6QJ$0T[_ )['(YSC&,9SGMC-
M<.;JY\-_$G7-3FT74;VS>W@A6XMX-YSY:=.F02N"1T(%9)\+:Q)X#%VNG29.
ML'4_[-QA_)QC;M]?;T/X4 >CZ-XQT+7KLVEA>%KD+O\ *DC:-BOJ P&1]*9X
MRUFXTC1D2P8#4KZ=+2TR <2.<;L'T&3Z9Q7,VEQ<>+?B'I.K6FD7UA::=!()
MY[N'RS(6! 0>N,_J:T?'T;1ZCX5OF_X][?58UE/9=Q&"?;C]: )CK>I6_P 2
M;'P^UP);1M.\Z1FC4,\@W#=D=,XZ#BNIO+RWT^SEN[N9(;>)=SR.<!17GGB2
MZNM&^*EKK TG4;VU33O*)M("_P Q9^,]/UJ?Q#>WGCKP3JUI8:1J=G/#Y3B*
M[A\LS@-DA>>?N_GB@#HM*\<>'M9OELK._P SN,QK)$\?F#_9W 9Z4E[XY\.Z
M=J,UC<ZAMF@_UQ6)V6,]@S 8!_&N/GGN?&6L^&H+#0;[35TJ99KB6YA\M(E7
M;\BGO]W&..W'7%59;[P]!XMT:;0[N^:_EGGCO(D!A*,I^^QZ;>3CUR* /4=,
MU*UU?3H;^RD,EM,-R.5*Y&<=#SVJW7F6EZUJNB_"K2I]-LD?; 6DN)7 6(>;
MC&WJQ.>.WK6IXG\4:SIVI:DVGBT^QZ1!#-<QS*2\_F,1A2#\N /SH U8-8N;
M7QW<Z)>S>9!=6XNK$E0-F,AX^!STW#/:NDKA=31KWXN>'VA!Q;6$L\OLK!E&
M?Q-=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37
M19$9'4,K @@]"*=10!QB?#'0DVQ>=J+622^:MBUT3 &_W?\ Z]=G110 4444
M %%%% !1110 4444 %9'AWPY8>&+"6ST_P WRI9C,WFMN.X@ ]NGRBM>B@ H
MHHH **** "BBB@ HHHH S-1T&SU34]-O[CS//TYV>#:V!EL9R._05IT44 %%
M%% !1110 4444 %4=8TJVUO2KC3KP,8)P Q0X8$$$$'U! -7J* &Q(8XD0NS
ME5 WMU;W..].HHH *Y*_^'FCWU]>W2W&HVOVX[KJ&VN2D<Q[[EQSU/YFNMHH
M RKKP_8W/AW^P@'ALA&D:B(@,JJ01R0?2J6L^#--UR_>[N9[R/S8TCN(89=L
M<ZJVY0XQS@^A%=%10!GVNCVUIJM[J2F1[F["*Y<@A%48"KQP.2?K6A110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !03CK13)?]4U #Z*** "BBB@ HHHH **
M** "BBB@ HHHH *"<#)HIDO^I?\ W30 ^BD7[H^E+0 4444 %%%% !1110 4
M444 %%%% !03@9-%,E_U+_[IH ?1110 4444 %%%% !1110 4444 %%%% !1
M12-]T_2@!0<C(Z44R'_41_[H_E3Z "BBB@ HHHH **** "BBB@ HHHH ***0
M]#0 O6BFQ_ZI/]T4Z@ HHHH **** "BBB@ HHHH **** "J6LWDFGZ'J%["%
M:6WMI)4#C()521G';BKM97B?_D4]9_Z\9_\ T6U &9\._$EYXN\":;KE_'!'
M=77F[T@4A!ME=!@$D]%'>NHKS_X)?\DAT+_MX_\ 2B2O0* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "F2_ZIJ?3)?\ 5-0 ^BBB@ HHHH **** "BBB@ HHHH **** "F2_
MZE_]TT^F2_ZE_P#=- #E^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH
M *9+_J7_ -TT^F2_ZE_]TT /HHHH **** "BBB@ HHHH **** "BBB@ I&^Z
M?I2TC?=/TH ;#_J(_P#='\J?3(?]1'_NC^5/H **** "BBB@ HHHH **** "
MBBB@ I#T-+2'H: $C_U2?[HIU-C_ -4G^Z*=0 4444 %%%% !1110 4444 %
M%%% !65XG_Y%/6?^O&?_ -%M6K65XG_Y%/6?^O&?_P!%M0!RGP2_Y)#H7_;Q
M_P"E$E>@5Y_\$O\ DD.A?]O'_I1)7H% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]4U/
MIDO^J:@!]%%% !1110 4444 %%%% !1110 4444 %,E_U+_[II],E_U+_P"Z
M: '+]T?2EI%^Z/I2T %%%% !1110 4444 %%%% !1110 4R7_4O_ +II],E_
MU+_[IH ?1110 4444 %%%% !1110 4444 %%%% !2-]T_2EI&^Z?I0 V'_41
M_P"Z/Y4^F0_ZB/\ W1_*GT %%%% !1110 444C'"D^E "T5Q-[XHU-M7>SLF
MMHEC3<S31%\\XXPRXIO]N^(/^?O3_P#P$?\ ^.5$JL(NS9#J13LSN**X?^W?
M$'_/WI__ ("/_P#'*/[=\0?\_>G_ /@(_P#\<J?;T^XO:Q.XI#T-<1_;OB#_
M )^]/_\  1__ (Y2?V[X@_Y^]/\ _ 1__CE'MZ?</:Q.WC_U2?[HIU<,NN:^
MJ@"[L.!C_CT?_P".4O\ ;OB#_G[T_P#\!'_^.4>WI]P]K$[BBN'_ +=\0?\
M/WI__@(__P <H_MWQ!_S]Z?_ . C_P#QRCV]/N'M8G<45P_]N^(/^?O3_P#P
M$?\ ^.4?V[X@_P"?O3__  $?_P".4>WI]P]K$[BBN'_MWQ!_S]Z?_P" C_\
MQRC^W?$'_/WI_P#X"/\ _'*/;T^X>UB=Q17#_P!N^(/^?O3_ /P$?_XY1_;O
MB#_G[T__ ,!'_P#CE'MZ?</:Q.XHKA_[=\0?\_>G_P#@(_\ \<H_MWQ!_P _
M>G_^ C__ !RCV]/N'M8G<5E>)_\ D4]9_P"O&?\ ]%M7.?V[X@_Y^]/_ / 1
M_P#XY6=KVMZZ_AW5$DN; HUI*& M7!QL/0^91[>GW#VL2S\$O^20Z%_V\?\
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MB@ HHHH *S9+ZZ$MY$=.N)(XVVQR)L 8;%.?F89Y)' QQ]:TJ9+_ *E_]TT
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M=31'+4^)EBBJ_P!NL_\ GZ@_[^"C[=9_\_4'_?P5ARR[$%BBJ_VZS_Y^H/\
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M%%% !1110 4444 %,E_U+_[II],E_P!2_P#NF@!R_='TI:1?NCZ4M !1110
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M[9':TC?=/TKB_)N_^@OJ'_?Q?_B:/(N_^@OJ'_?Q?_B:/8ON'MD=E#_J(_\
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MBK-% %;?>_\ /O;_ /?]O_B*-][_ ,^]O_W_ &_^(JS10!6WWO\ S[V__?\
M;_XBJ6K/>?V9<;H( -AZ3$]O]VM:J>JHSZ9<*HR2A_E0!PWA[/D7F0 ?M)Z'
M/\"5L5BZ:SZ=]JBN+>Y#-/O4I [ C:HZ@>QJ]_:,?_/"\_\  63_  KLBURH
MY9)\S+E%4_[1C_YX7G_@+)_A1_:,?_/"\_\  63_  IW7<GE?8N453_M&/\
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M7V+E%4QJ41&1!>?^ LG^%']HQ_\ /"\_\!9/\*+KN'*^Q<HJG_:,?_/"\_\
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M +\G_P"*J>B@"#9=_P#/>'_OR?\ XJF2I=^4_P"^A^Z?^6)_^*JU3)?]2_\
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M/L5J*L_V/K7_ $#A_P!_A_A1_8^M?] X?]_A_A1]1Q'\OY?YA[*?8K50UO\
MY &H_P#7K+_Z":V/['UK_H'#_O\ #_"J.M:/K'_"/ZFSV*HBVDI8F4<#8?:G
M' XA23Y?R_S!4YWV-7X)?\DAT+_MX_\ 2B2H/%D.N:?\3=)\0Z=H%UJUM!IT
MEO(MO(BD,S9'WB*G^"7_ "2'0O\ MX_]*)*] KZ0[SQ7XAZIJ;#1=8M-.;3-
M<U)9M#DL9Y5,K13 A'^4]%<;A[FN@'@86GQ \/K%IJSZ+IVAO9B615*B3/&0
M?XB"3G'<UW4^AZ5=:O!JUQIUK+J-NFR&Y>(&2->> 3R.I_,UH4 >,Z%X)U/3
M=(^'I_L?R+JPGN'U%E"AHPP;!8@\YR/6N=^'FDZCK?@_PC:67A]H/LVK_;Y-
M:S&%,22/N7(._<?NX(Q@#MT^B" 1@]#573]-LM)LH[+3K2&TM8\[(84"(N3D
MX ]R30!Y%9>!]4A\,OG1MNI'Q8M\&POF" 2J=X;/3;GC-0:UX3UZ0>*-#C\*
M_:[G6-5-W:ZYYD>V&-F4C))WJ4 ( 'J<>_MU% 'DFIZ+K%CXB\0Q-X,B\2#5
M;BWFMKNY:,1JJJJE9,\J%VDC YK,UG0)[SXO#P]9SQ/I>J2V^KZE#$P(A,&Y
M60KV#MLZ]\>E>W50M-#TJPU&ZU"TT^VAO;LYGG2,!Y/J>IH \J\5>#M;U+5O
M'UGIVD,G]LPVLMG?*45&,87S(R<Y!<@CT/>J</A'6]0T3Q&]QH>JL9[&WMEM
MYI[6T>9DD#Y188]N4P<,WW@<<=O<** /(?"]SXC\':=K^J:AI%Q<6(-NMK]M
M2W@O9R3M;>T9.[;GC=DGH.N*]&\5Z9<ZSX1U?3+.01W-U:211,3@;F4@9/8=
MJUG1)  ZJP!!PPSR#D'\Z=0!XW:^']<U7PC<Z)%X-BT6]AT+[$VH2-&'GE&W
M]VA4G*/@DL3WK'_X0SQ'?Z7K\W]C:G%/)HJ6,:7#6L0E<2*VQ8X4 (7!P['.
M.,>GOE% 'D.J^$M7NX?%*-H\]S'=Z5IT,4<=RL+2/%DL%8@@,IP<$8.,=ZSM
M,T'Q=+:7FF3:9='3-0U"RC-S>6\$=WY*MOE,IB)W* H4%B2=W'>O;Z* /'O$
MO@O4]0B^)$L>C^=<:BUI_9[D*6D"JN[:3TP0?2F>(_!&IFY\4QZ3H^VWN] M
M[:W6$*JR2JXRN,CD 5[)10!%;*4M858894 (]\5+110 4444 %%%% !1110
M4444 %%%% !3)?\ 5-3Z9+_JFH ?1110 4444 %%%% !1110 4444 %%%% !
M3)?]2_\ NFGTR7_4O_NF@!R_='TI:1?NCZ4M !1110 4444 %%%% !1110 4
M444 %,E_U+_[II],E_U+_P"Z: 'T444 %%%% !1110 4444 %%%% !1110 4
MC?=/TI:1ONGZ4 -A_P!1'_NC^5/ID/\ J(_]T?RI] !1110 4444 %%%% !1
M110 R6:.%=TCA5]365_PE?A__H-:?_X$I_C5/QFQ72'P2.#_ "KF-/\ ^0;:
M_P#7%/Y"MJ5)3O=F56IR6.S_ .$K\/\ _0:T_P#\"4_QH/BOP_@_\3JP_P#
ME/\ &N4HK;ZLNYC]9?8ZF/Q5X?$:@ZU8=!_R\)_C3O\ A*_#_P#T&M/_ / E
M/\:Y2BCZLNX?67V.K_X2OP__ -!K3_\ P)3_ !H_X2OP_P#]!K3_ /P)3_&N
M4HH^K+N'UE]CJ_\ A*_#_P#T&M/_ / E/\:/^$K\/_\ 0:T__P "4_QKA[O5
M],L)TAO-0M;>5QE4EF56(SC."?6K$]Q!:P//<31PPH,M)(P55'N3P*7U:/<?
MUA]CL/\ A*_#_P#T&M/_ / E/\:/^$K\/_\ 0:T__P "4_QKA_[8TP6)OCJ%
MJ+0'!G,RA ?3.<5<5E= Z,&5AD$'((I_5H]P^L/L=9_PE?A__H-:?_X$I_C1
M_P )7X?_ .@UI_\ X$I_C7*44?5EW%]9?8ZO_A*_#_\ T&M/_P# E/\ &C_A
M*_#_ /T&M/\ _ E/\:Y2BCZLNX?67V.K_P"$K\/_ /0:T_\ \"4_QK,\1^)M
M"F\+ZO''K%@SM93*JBX0DDH>!S6/6?KO_(O:G_UZ2_\ H!I/#*VXUB'V-/X)
M?\DAT+_MX_\ 2B2O0*\_^"7_ "2'0O\ MX_]*)*G\3_$&3P[X\T7P\=.66WU
M!4,MT9=IAW2>6#C'(W%>_>N0ZCN:*X;0/B$VM_$/6O#7V!8;;38Y'6[,N?,*
M.J-QC  )/.>U;NE>,O#>MWSV6F:S:75PBERD<F25'!(_O >HS0!N45@67C?P
MQJ,MU%9ZW9SO:QM+*$DSA%^\P_O =R,TD?CGPM+IUQJ":[9&SMRBRS>9\JLP
MRHSW)'8<T =!16(GC'PY)I4>J)K5F;%YA )_-&T2'HI_NGZXK'UWXBZ39>#[
M_7M&N;75!92Q1R1I-C:7D5/FXR/O$CCG% '9T5BV?B_PY?Q7DMKK5C)'9#=<
MN)@!$O\ >)/\/OTINF^,O#>KV]U/8ZS:2Q6B>9<-YFWRT_O'.,+[]* -RBL'
M3O&OAK5YC#8:U:3R"%IRJOC;&IY8YZ >_P!:=8^,?#FHVEW=6FM64D%FN^XD
M\T 1K_>.>WOT- &Y165HWB;1?$/G#2=2@NFAQYB(WS)GH2#S@]CWK5) !).
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M-_\ $4?V+X@_Y]+/_P "&_\ B*Z/;0[F'L9]B"BIET;Q R@_9+/D9_X^&_\
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MVTEO*D81HY"I((&.JDC]:T_[%\0?\^EG_P"!#?\ Q%']B^(/^?2S_P# AO\
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MZ/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH *9+_ *E_]TT^F2_ZE_\
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M%%% !1110 4R7_4O_NFGTR7_ %+_ .Z: '+]T?2EI%^Z/I2T %%%% !1110
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M@JYOH01%<Z<\R!NH#1DC/YT>S@[V#GD:?P2_Y)#H7_;Q_P"E$E>@5Y_\$O\
MDD.A?]O'_I1)5+QO?WEM\2]$@@NYXH7TF_=HTD*JS+&Q!(!ZCL:Y#<]-HKD?
MAG>SW7PRT2\O;B6>9K8M)-*Y=F^8\DGDUS'C#QOIWB32=,3POJMS?[M4BBN+
M33Y)()[E"CDHKX!4<;B<@8'44 >JT5POPHU&ZU#PG.+Z^FN;FWOYX&BN&9YK
M4*W$,C-RS*._O[5J>-_$]UX6TW3[FTLH[R6ZU"&S$3R;,^82.#V/% '345YQ
M=?$?5-)BUNQU+2;4ZU83VL,"6UP3#.;@XC.YE!7&#GCMQ45_XZUJV;Q1I.J6
M5I;WFFZ4LT<MI,SK++)E4"[@"/F*CGG/K0!Z917E-[XVUKPI!K.E6>FVM[;^
M%[2S,]Q<7+J\P=!G'!RQ.3DGMWS3M2\<ZO?Z1X@L+JQBL6E\,2:Q92VUPS/&
MC*5"N<##@X.5X'O0!ZI167X:D>7PKI$DCL\CV4+,S')8E!DDUJ4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]4U/IDO^J:@
M!]%%% !1110 4444 %%%% !1110 4444 %,E_P!2_P#NFGTR7_4O_NF@!R_=
M'TI:1?NCZ4M !1110 4444 %%%% !1110 4444 %,E_U+_[II],E_P!2_P#N
MF@!]%%% !1110 4444 %%%% !1110 4444 %(WW3]*6D;[I^E #8?]1'_NC^
M5/ID/^HC_P!T?RI] !1110 4444 %%%% !1110 4444 %<_XXT.Y\2^"M4T:
MSDACN+J((C3$A =P/) )[>E=!2'H: ,;P]X<M- 2YD@EN9[B\9'GGN9C([;5
M"J,GL ,"MJFQ_P"J3_=%.H YZ/P;ID6N2ZM%)=I,[R2K&)CY<<LB[7D5>S$#
MK[GCFDE\%Z9-K$&IRRWCSQ&%W4SG9/)$"(Y)%[L,]>.WI7144 <8OPO\-".Y
MB>.[E@FA>!(I+EBMNCN)&$8_A^< YY/'I6YHGANQT*VN8H&GN'NIO/N)KJ0R
MR2O@#))] H  ]*UZ* "CM110!YIKG_(XV/\ UU?_ -%O4FIZ3I^LVRV^I6D5
MU"KAPDJY ;!&?R)_.NLU#PO8:E<+--Y@D1MRM'(R$'!'52#T)JO_ ,(9I_\
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M HHHH **** "BBB@ HHHH **** "BBB@ IDO^J:GTR7_ %34 /HHHH ****
M"BBB@ HHHH **** "BBB@ IDO^I?_=-/IDO^I?\ W30 Y?NCZ4M(OW1]*6@
MHHHH **** "BBB@ HHHH **** "F2_ZE_P#=-/IDO^I?_=- #Z*** "BBB@
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M#)<J@^\QY+$GDD^IJ_2(-J*#U Q2T 847@WP[!+>2PZ5#%)>*4G>,E2REMQ
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M6# XZ\\]ZKP_#SPM;P1PQ:7A([]-24&XE)^TJ,"0DMDG'8\'N#73T4 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HGMH)'WR01LWJR FI:* (FMH'&'AC89W8* \^M2T44 %%%% !
M1110 4444 %%%% !1110 4444 11VT$3;HX8T;U5 #4M%% !1110 4444 %%
M%% !1110 4444 %1R6\$K;I(8W;IEE!-244 1M;PNI5H8V4G<05!!/K]:> %
M    '  I:* "BBB@ HHHH **** "BBB@ HHHH **** (TMX(WWI#&K>JJ :D
MHHH **** "BBB@ HHHH **** "BBB@ IDD,4I4R1HY7E2R@X^E/HH C:W@<,
M'AC8,<G*@Y/K3U4*H50 !P .U+10 4444 %%%% !1110 4444 %%%% !2$ @
M@@$'J#2T4 ,CBCA7;&BHOHHP*?110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ2((K H-B'')/&"./7)[U3\2>([_ $?4EC0VMM:^4K++=02LDSDG*>8AQ%@
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MO1;?2WGF22>XN;@CS;BX?>[@?=&>  ,G  '4T 4[VY:X\7Z=I>/W45O)?/\
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M;>& B:VN+1\OM\E9'R'''.!VXZ"NL' H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_009.jpg
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &5 U4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M
M%-#9[4N: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T
MA; Z4 .HIH8FG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111D>M !129'K2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !113))4AC:21E1$!9F8X  [DT /J.:>*WA:6:1(XU&69V
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M $--[_X__P#%T?\ "):O_P!#3>_D_P#\778=Z*GVT^_Y?Y%_5Z?]-_YG'_\
M"):O_P!#3>_D_P#\71_PB6K_ /0TWOY/_P#%UV%%'MI]_P O\@^KT_Z;_P S
MC_\ A$M7_P"AIO?R?_XNC_A$M7_Z&F]_)_\ XNNPHH]M/O\ E_D'U>G_ $W_
M )G'_P#"):O_ -#3>_D__P 71_PB6K_]#3>_D_\ \77844>VGW_+_(/J]/\
MIO\ S./_ .$2U?\ Z&F]_)__ (NC_A$M7_Z&F]_)_P#XNNPHH]M/O^7^0?5Z
M?]-_YG'_ /"):O\ ]#3>_D__ ,71_P (EJ__ $--[^3_ /Q==A11[:??\O\
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MR:X;0M?\1ZSJBVHNU5%YE;R5^5?RZUZ*!P,\TZM)TWRR"A751<T+HP_^$/\
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M0X13M8%6J-7YG][_ ,S#_P"$.\-?] #2_P#P#C_PH_X0[PU_T -+_P# ./\
MPK=HI<J[#]K4_F?WO_,PO^$.\-?] #2__ ./_"C_ (0[PU_T -+_ / ./_"M
MVBCE78/:U/YG][_S,+_A#O#7_0 TO_P#C_PH_P"$.\-?] #2_P#P#C_PK=HQ
M1RKL'M:G\S^]_P"93T_3+'2X&AL+.WM8F;<4@C"*6Z9P!UX%6^@I<54O[:2\
MLI;>.X>W=Q@2QGE>>U4DC.3>^[+.1ZTN?>N7_P"$6U#_ *&34/\ OH_XT?\
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M)+U)H?PX^B"BBBLS4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)_[\R?\ QRC_ (7;XF_Y\])_[\R?_'*\VR:,FCV]3^8/[)P/_/I?C_F>D_\
M"[?$O_/GI/\ WYD_^.4G_"[/$O\ SYZ3_P!^9/\ XY7F^31DT>WJ=P_LG _\
M^E^/^9Z1_P +L\2_\^>D_P#?F3_XY2_\+M\2_P#/GI/_ 'YD_P#CE>;9-&31
M[>IW#^R<#_SZ7X_YGI/_  NWQ-_SYZ3_ -^9/_CE'_"[?$W_ #YZ3_WYD_\
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M[?A6H!BEJ959-66B\BH48Q?,]7YC0M.HHK,V"BBB@ KS'XV_\BI8_P#7^O\
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MM&*BDD%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 49HIK9P:!,;#
M<17$*RPR+)&PRK*<@BI,UY%H'B:YT*9H\&6T9LM$3T]U]Z]1T[4K;5+-+JVD
MW1M^8/H?0UM5H2IZO8PHXB%71;ERDR*,BO,?$GQ;;P]XAO-*_L47'V=E'F?:
MMF[*@]-AQU]:YYSC!7D=^'PU7$RY*2NST[(HZUXY_P +U/\ T+@_\#O_ +77
MHO@[Q&?%6@1ZH;7[-O9E\OS-^,$CK@?RJ8583=HLVQ&78G#QYZL;+U0S6?#]
M]J^HKNU)XM.VC= G!)[_ (=.N:T=-T2PTI-MI;(AQ@N1EC]3UK1HK=SDX\M]
M#SE2BI<UM1,>U I:*@T"BBB@ HHHH **** "O,?C;_R*EC_U_K_Z+DKTZO,?
MC;_R*EC_ -?Z_P#HMZRK_P -G?EG^^4_5'@]%%%>0?HH=#2YYI** %S[T9I*
M* L.+9Z]O:C/%-HQFBX60N>,4N[--Q10%D.S]/RHSS3:* LA:2BB@ HHHH ^
MDOA9_P DXTOZS?\ HUZ[2N*^%A'_  KG2QWS-_Z->NUKV*7P+T1^:X[_ 'JI
M_B?YL****T.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*X_Q=
M_P C#X<_Z^O_ &=*["N/\7?\C#X<_P"OK_V=*VH?Q/O_ "9S8G^'\U^:.P[T
MM)WI:Q.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BB@]* #-%<EXEO
M]4AUS3[#3[P6_P!H4Y)16&<]>13_ .R_%>/^0]#_ . Z_P#Q-:^ST3;2N8.L
M^9Q46['545RO]E^*_P#H/0_^ Z__ !-']E^*_P#H/0_^ Z__ !-+V:_F7X_Y
M#]K+^1_@=517*_V7XK_Z#T/_ (#K_P#$T?V7XK_Z#T/_ (#K_P#$T>S7\R_'
M_(/:R_D?X'545RO]E^*_^@]#_P" Z_\ Q-']E^*_^@]#_P" Z_\ Q-'LU_,O
MQ_R#VLOY'^!U5%<K_9?BO_H/0_\ @.O_ ,31_9?BO_H/0_\ @.O_ ,31[-?S
M+\?\@]K+^1_@=517*_V7XK_Z#T/_ (#K_P#$T?V7XK_Z#T/_ (#K_P#$T>S7
M\R_'_(/:R_D?X'545RO]E^*_^@]#_P" Z_\ Q-']E^*_^@]#_P" Z_\ Q-'L
MU_,OQ_R#VLOY'^!U5%<K_9?BO_H/0_\ @.O_ ,31_9?BO_H/0_\ @.O_ ,31
M[-?S+\?\@]K+^1_@=51D>M<K_9GBL?\ ,>A_\!U_PH\(ZE?:A%?"_N/.>&78
MIV*N/R H=/W7)-.PE6]Y1<6KG59'K1D>M>-?\)/K7;49A^(H_P"$GUO_ *",
MWYBNI8";5[HYGF,$[69[+FBO&O\ A)];_P"@C-^8H_X2?6_^@C-^8H^H3[H7
M]HP[,]EHKQK_ (2?6_\ H(S?F*/^$GUO_H(S?F*/J$^Z#^T8=F>RT5XU_P )
M/K?_ $$9OS%'_"3ZW_T$9OS%'U"?=!_:,.S/9:*\:_X2?6_^@C-^8H_X2?6_
M^@C-^8H^H3[H/[1AV9[+17C7_"3ZW_T$9OS%'_"3ZW_T$9OS%'U"?=!_:,.S
M/9<T5XU_PD^M_P#01F_,4?\ "3ZW_P!!&;\Q1]0GW0?VC#LSV6FL1M/->.?\
M)/K?_01F_,4'Q-K1_P"8C-^='U"?= \QAV9E-]X_6KVE:S>:-<^=:R8!^_&>
M5?ZC^M4.IR>M%>GR)QY7J>5SM2YHZ'LFAZ]:ZW:"2%PLP'[R(GE#_A[U:DTR
MPFD,DME;22-U9XE)/XXKQ>TNY[&Z2YMY#'*AR"*]0\.>*H-;402@17BKDIGA
M_=?\*\G$X1T]8ZH]G"8WG]V3LS6_L?3/^@=:?]^%_P *M6]O#;1^7!%'$G94
M4*/R%2CI17&DCO<I/=A1113)"BBB@ HHHH **** "BBB@ KG_%7A2S\7:?%9
M7TMQ%'%*)@T! .0".X/'S5T%%)I-69<)RIR4H.S1YE_PI+P]_P _VJ_]_(__
M (BC_A27A[_G^U7_ +^1_P#Q%>FT5G["GV.S^U,9_P _']YYE_PI+P]_S_:K
M_P!_(_\ XBC_ (4EX>_Y_M5_[^1__$5Z;11["GV#^U,9_P _']YYE_PI+P]_
MS_:K_P!_(_\ XBC_ (4EX>_Y_M5_[^1__$5Z;11["GV#^U,9_P _']YYE_PI
M+P]_S_ZK_P!_(_\ XBL'QC\+='\/>&+K4[2[U"2:$IM65T*G+JO("@]#ZU[6
M>E<C\2UW> =1'O%_Z,6HJ4::@VD:T,RQ;JQ4JCM=?F<?HGPAT/4]"T^_FO-2
M66YMXY75'0*"R@G&4]ZT1\$O#W_/]JO_ '\C_P#B*[3PN,>$M&'I90?^@"MF
MG&C3<4[$U<SQBJ22J/=_FSS+_A27A[_G^U7_ +^1_P#Q%'_"DO#W_/\ :K_W
M\C_^(KTVBJ]A3[$?VIC/^?C^\\R_X4EX>_Y_M5_[^1__ !%'_"DO#W_/]JO_
M '\C_P#B*]-HH]A3[!_:F,_Y^/[SS+_A27A[_G^U7_OY'_\ $4?\*2\/?\_V
MJ_\ ?R/_ .(KTVBCV%/L']IXS_GX_O,GP[H5OX<T6#2[5YI(8=VUIB"QW,6.
M< #J?2M:BBM$K:(XI2E.3E)W;"BBBF2%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 E<?XN_Y&'PY_U]?^SI785Q_B[_ )&'PY_U]?\ LZ5M0_B?
M?^3.;$_P_FOS1V'>EI.]+6)TA1110 4444 %%%% !1110 4444 %%%% !111
M0 4'I10>E ''Z]_R.NA_0_S-=AVKC]>_Y'70_H?YFNP[5M4^&'I^K.>C\4_7
M] HICRQHZJSJ&;[H)P3]*C%U 8_,$R;,XW;AC/UK$WNB>FD\5 ][:QL4>XB5
MAU!< BG;XIMT:NI.,D!N0#0UW"YQ-YXH>/Q*T@O%6R@G6!H1SN7!#/[X.*U)
MI[C4O$-S8KJ$EI!!"DB>3M!?=W)(/ K5_LW3;?31IAC1+5P4$9<C=D\\YSG)
MJ&]T71[B*W@O((V$8"1;I"&P. ,YR?I6_/#L<W)/6[OKW,Y[RX@U#0H?[3%S
M'*\JRRI@"3 &,XXR*DMWGU'7M8L_ML\<,0AV-"PRAQD@9!ZU?N=,T>:T%A-!
M;^5$-PCW;=@]>#D?6I=.MM+TNS/V(0Q0%N6#Y!/U)I.4;:+4:A+FU>GKY6.4
M>:_BT76KP:K>F2TNGMXP67& R@$\=>36QH1GDNE:5M8QY>?]+,?ED\=-O-7Y
M=-THV=Q#(J"WO)#+(#(0)&.#D'/L.E06NBZ%HUV)X8X[>?;@%IFZ'V)H<XN-
MK:B5.49)WT]3=%+5>.[MY&VQSQL3V5P32BZ@,AC$J&0?P[AG\JQLSINB>BHA
M/$691(I9/O#(R/K3HY$EC#QL&4]"IR#0%T.;M7(>!_NZM_U\G^M=>W:N0\$=
M-6_Z^3_6MJ?\.7R_,PJ_Q8?/\CS3O11WHKW(_"CY^6["NCU73+FXT_2'L[*:
M4&T&]HHBPSD]2!UK#BL;R>(RPVD\D:]62,D#ZD4[SKV&%#YDZ1-D(=Q"G'4#
MMW'YUG/WFG%K0UA[J:DMSN+5;:#3H)I%6(+I:.9!"K$'=UP>I^M4([NPU"6^
M^SKYIATF?=,\*H6;(QP..!Q7*Q+>3Q2&);B2.-/GV!B%7WQT%+:VM[<!_L<%
MQ*,8?R49N#V.*Y_JZU;EJ;K$-V2CH=O)'=MKL%L;%&TAH5,Q>W4(!LR3OQZ^
M]8OA,6T>LW\CHLD,-K+(H89& R\_E6-''J=WO@CCO)@O#HH9MOU':JV)H'="
M'C?[K+R#]#51H^[*/-NOZ8I5_>4N4[^>RLK'2-2LX8HRR@7 ? .%>0A1GV51
M^=1^)(Y(Q=K;I<A0 -BZ>OEA>-W[S;GIDYS7&M::G&J;[>[4381,HPW^@'K]
M*1_[3,,S-]K,41V2D[B$/3#>E9K#J]^=&DJ]U;E.VNH9W\2W-K=648T39\\C
MP!%0; <A\#G=[FJD&GP-?:;>2QPK;VVE12,92%0R-D+N/3D\_A7+/#JLT"EX
MKUXI"H4LK$,3TQZYI9;#5X[=FGM+U(% R9(W"@=NM'LDE;G2Z?I]XG6;=^1O
MK_7D;]V)K/6]/O(/LWDWYC24Q*DD>\$!@O! ]?QJ_=EI;W6!;0037UHRK:1>
M4N51L;B%Q\QX[Y_G7&R6FH6\"22V]U%#G<K.C*N?49I/L]^+QE\FY^U*N]AM
M;>!CKZU?L(M+WEI_G_2)5:479Q>K_3^F=CI]N);S19M1M4CU"2:4,IB"%XPA
MP67CO[53UY[>;0&F@_TO_2-OG^2D9@Q_"=N#SQ[?I7-^3J!D,_EW)<1B0R;6
MR$[-GTJ+;<B)/EF\N<_+P<2$'''KS25%<W-S ZSY>7E(:*L7%C>6@!N;6>$-
MP#)&5!_.J]=JDGL<;36C"G([QNKHQ5U.0P."#3:*8CT/POXR6X"V6J2!9ND<
MQX#^Q]#[]Z[=3D9[5X+UKTKP->ZI<6)CN8PUG&-L4K9#'V'J/>O+Q>&C#WX_
M<>O@\5*7N3^\[&BD%+7GGI!1110 4444 %%%% !1110 4444 %%%% !112$X
MH 6BF;AVH!H >>E<K\1!N\#:@/>/_P!&+74;ATK'\4:5-K?AVYT^W:-99=F#
M(2!PX8YQGL*SJJ\&EV-*,E&I%OHT/\-#'A721_TYP_\ H K7'2J.DV;V&CV=
MI(RL\$"1L5Z$A0./RJY3AI%7)J.\VUW8ZBL::2ZFU:2T^U-;1^6'CV("9/4[
MFR.#VQZ'O6K"ACB1&D9R!@LV,GZXJUJ)JQ)116=J^H'3[;<B@R.=JYZ#WII.
M3LB)245=FC17!R:G>R.6-U*,]E<@?I3?M]Y_S]S_ /?UJZ/JLNYS?7(]COJ*
MX'[?>?\ /W/_ -_6H^WWG_/W/_W]:CZK+N+ZY'L=]17 _;[S_G[G_P"_K4?;
M[S_G[G_[^M1]5EW#ZY'L=]17 _;[S_G[G_[^M1]OO/\ G[G_ ._K4?59=P^N
M1['?45P/V^\_Y^Y_^_K4?;[S_G[G_P"_K4?59=P^N1['?45P/V^\_P"?N?\
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M7O\ WPO_ ,52CXB:2!C[->_]\+_\52E&K*/*XE0E1A+F4CKV[5R'@C[NK?\
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MEJ<TW=W"BBBJ)"BBB@ HHHH **** "BBB@ HHHH *#R,444 -" 4NT>E+10
MFT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10 FT>E&T>E+10
MFT>E&T>E+10 FT>E&T>E+10 FT4FP4ZB@!NP4;13J* $VBC:*6B@!-HHVBEH
MH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBFLHVFGTUC\IH$]CP=O
MO'ZU/965QJ%RMO:Q-)(W8=O<^@JWI&AW>MW9CMUPBG]Y*WW5'^->IZ'H5MH=
MIY,&69CEY&'+'_#VKV*N*C2BDM6>)1PDJLVWHBEX=\+6NCP)+(HDO2/FD/.W
MV7TK<GE\FWDEQDHI;'K@5+BN(U"^UT75W&HN?(WNHQ;Y&W)[[?2O Q>*<%SR
MNV^QZZ4:44HHT=+\4S7^I06CVL:"0G+!B<8!/]*Z8'->6VDES%=1O:A_M"YV
M;%W'./3![9KM/#=SJ<_VG^T1*,;?+\R+9ZYQP,]JX<#C95'R3NW?>V@J=1O1
MF_129I:]4V"BBB@ HHHH **** "BBB@ HHHH **** "C%%% ')^-_$6HZ/'I
M5AI"6_\ :.JW@M(9;@$QPC!+.0.I&.!7/>)M9\;>$?!6OZA?7>F73VIM_L5Y
M' 49M\JJX>/)' ;C!KM/$GAG3_%.FBRU 2J$D$L,T+[)89!T=&[$<_G7.#X4
MZ.VA:MI=SJFLW;:J8OM-Y=70DGQ&P9 &*X R/3^E &'H'C+7[[Q++I%GJ]AJ
MPFT^2:"6[TZ73]DZGY5VM\SKR"=O0>G?=\(>(M5U+Q+J>E7-Y;:G;64$?GWE
MO#Y:171)#P*<_. ,'/4=#S3;?X56$5R]U<>(O$E_=""6"">]O_,>V$B[7:,[
M?E8@D9YK:\,^%8_"=G'96NJWT]E%'LCMYT@"J<YW92-6+>Y)ZTGY@:EQHNGW
M<L4EQ;K*8CE%8DJI]<=.U7@H P.E&[BEI1C&/PH=V &****H05S_ (I_U%O_
M +Y_E705B>)+>2:S1T7(C;+8],=:THNU1&-=7INQRE7K?59;>T^S>3!)'G.)
M%)_K5&BO3<5):GE1DXO0NOJ<A='B@MX'0Y#11[2?K23:@9E<?9;9&?JRQ\_J
M:IT5/LX]BO:R[EJ:_EG2V5E0"W&%P#STZ_E4W]L7/VJ2X*1$R*%92IVD?G6?
M13]G'L+VDEU+TNJ32VHMO+A6(,& 12,?K4CZU/),)F@MC*OW7V'*_3FLVBE[
M*/8?M9=R[%JD\:2HZQS+*VYA(N>?PQ3I=6GF:!F2',.=HV<8/8C\*H44>RCO
M8/:RM:Y?;59?)DBBA@A63[QC7!/ZT)JTZP11-'#((O\ 5LZY*_K5"BCV4>P>
MUE>]S0&LW OGN]D7F,FPC!QC\ZA6_E73VL@J>6QW$X.?\\55HI^SCV!U)/J6
M+F\DNHH(W50(4V+M'4>_Y57HI5!9@J@DDX '>FDHHEMR9VVC_P#()MO]P5?J
MIIT+V]A!$XPRJ 15NO)E\3/9A\*"DQ2T4BCD?%VN:C;:QHGA[1Y(8+_5GE/V
MJ>+S$ABB7<Y"Y&YCD #IUK!U[6O&/ACPK>3ZI>Z<94OX(;:_M[=F+Q.X#,\/
M9@#P%)S^1/8>)O"MCXJM(8KJ:ZMIK>3S;>[LY?*GA;!!*OVR#@C_  K"'PMT
MD:!=Z6VJ:R\EW<QW4U^]T&N6D0@J=Y7 Q@=!F@#G]$\7>)M5U74](TO6-+U*
M5;!;BWN[VQDL/+D\S:5,399U"Y.X# . >M='X)\0WNO:IKEK)<Q:EIEF\<=O
MJ4<'EK,Y4^8G]UMI Y'KWXJF?A'I<D-Z+S7O$5]/=VWV4W-Y>B62.+<&94)7
M #8P<@\$^M=)X>T)/#-I'81ZI=7-LD82""=($$8']WRXT)SD9SG^>2UQ7L7Y
M-%T^6\CNY+=7FB&(V?G9SG@'@5>V^YH!S2U*A%;(844450!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1D4M% %6Q
ML+?3K5;>UC$<:]AW/J:L@4M% )6V"H+F,RVTL:XW.A4?4BIZ*35U8#C]'\.7
M]EJUO<S"+RXR=VULGE2/3WKI-0^UK92&Q5#<8^3><"K>*"*PI8>%*#C#J3&"
MBK(YFS\3M;RBVUJ!K28='VG8W^?QKHXIXIXQ)$ZNC<AE.0:CNK2"[@:*>))$
M(Z,*YT>&[W3;CS='O=BL?FAF)*X_#_/O4)UJ3L_>7X_Y,GWH^:.J!S14,'G"
M%//*>9CYMF<9]LU+FNI.ZN:"T4F11FF M%%(>] "YHK(AOKZ\>;[+!"D<4K1
M9F<[B5."=H' [CGD8-:JYP,]>^*2=QM-;CJ***8@HHHH **** "BBB@ /2L7
MQ5G_ (1RZ_X!_P"ABMH]*QO%'/AVZ_X!_P"ABL<0_P!U+T&MRWI&3H]D3U^S
MQ_\ H(J]5'2?^0/9?]<(_P#T$5>%52^!>B_) PHHHK004C*&!! (/K2T4 4F
MTFQ9BQM8LGT&*3^Q[#_GUCJ]15<TNY'LX]BC_8]A_P ^L=']CV'_ #ZQU>HH
MYY=P]G#L4?['L/\ GUCH_L>P_P"?6.KU%'/+N'LX=BC_ &/8?\^L=']CV'_/
MK'5ZBCGEW#V<.Q1_L>P_Y]8Z/['L/^?6.KU%'/+N'LX=BC_8]A_SZQT?V/8?
M\^L=7J*.>7</9P[%'^Q[#_GUCH_L>P_Y]8ZO44<\NX>SAV*/]CV'_/K'3XM-
MM('WQ6\:L.AQR*MT4<TNXU"*Z"8I:**DH**** "BBB@!.]<?XN_Y&'PY_P!?
M/_LR5V%<?XN_Y&'PY_U]?^SI6U#X_D_R9SXGX/FOS.PI:3O2UB= 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$QL/^>-U_WRO^-'_"8V'_/&Z_[Y7_&CZ[A_YT'M(]SHZ*YS_A,;#_GC=?\
M?*_XT?\ "8V'_/&Z_P"^5_QH^NX?^=![2/<Z.BN<_P"$QL/^>-U_WRO^-'_"
M8V'_ #QNO^^5_P :/KN'_G0>TCW.CHKG/^$QL/\ GC<_]\K_ (UH:5K,&K&4
M0)*OEXW;P!USZ'VJX8JC.7+&2;&IQ>B9IT445N4%%%% !1110 4444 %%%%
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MC\_R'2^)'74445],=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<YXOO;FQTR*2
MUF:)S,%)7TVG_P"M71URGCK_ )!$'_7P/_037+C9..'DT14=H-G*?\)#J_\
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MCYA[&)YW_P (UJ__ #Z?^1%_QH_X1K5_^?3_ ,B+_C7HE%']ET?,/8Q/._\
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MHKY"QYQG:SI0U:TCC68PS0S+/#+MW;)%Z$COU-01V.L3QW"7]];,DD+1+'!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? O@# 2(  A$! Q$!_\0
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MQ;Q2><?D!; 7;WSZY[T*AAG;?[_.PWB<6KZK[O*YV'_"QM'_ .?>^_[]I_\
M%4?\+&T?_GWOO^_:?_%5Q,?AYO[5AL)K^Q65I1'(BW"EHSZ$>OMZ\4ESX>FC
MU2\M8;BV:&U!>6<RC9$NX@;SV;CIUI_5\+>U_P 2?K6-M>WX?\$[?_A8VC_\
M^]]_W[3_ .*H_P"%C:/_ ,^]]_W[3_XJN(7PQJ;WXLXTCDD:#[1&4D!61.@*
MG\:S;VT:QO)+622)WCP&,3[ER1G&?QJHX7#2=D_Q(EC<7%7DOP/2?^%C:/\
M\^]]_P!^T_\ BJ/^%C:/_P ^]]_W[3_XJN7\1>'K+3M/6:R>9I8?+^T+(00
MX.UAQZC%)?\ A^RLO"KWF^4ZA%Y)E7(VKYA&!C'4*16:HX5I/75V-GB,8FT[
M:*YU/_"QM'_Y][[_ +]I_P#%4?\ "QM'_P"?>^_[]I_\57%/X6U%$89MS<+%
MYS6HF!F">NVGZ/X<GO)+"XF:W6WN)@%BDF"O,H/S;1U.!FJ>'PJ5[_B0L5C7
M)1M^!V7_  L;1_\ GWOO^_:?_%4?\+&T?_GWOO\ OVG_ ,57#2:.\^HZIY+P
M6UG:W3Q>9/)M5?G(5<GJ>*NVVA"VLO$":A /M5E;AXR&. 2"01@\]J'A\,E?
M7[^__#C6*QC=M.NMNU_\CK/^%C:/_P ^]]_W[3_XJC_A8VC_ //O??\ ?M/_
M (JO+Z*U^HT?/[SG_M+$=U]QZA_PL;1_^?>^_P"_:?\ Q5'_  L;1_\ GWOO
M^_:?_%5Y?11]1H^?WA_:6([K[CU#_A8VC_\ /O??]^T_^*H_X6-H_P#S[WW_
M '[3_P"*KR^BCZC1\_O#^TL1W7W'J'_"QM'_ .?>^_[]I_\ %4?\+&T?_GWO
MO^_:?_%5Y?11]1H^?WA_:6([K[CU#_A8VC_\^]]_W[3_ .*H_P"%C:/_ ,^]
M]_W[3_XJO+Z*/J-'S^\/[2Q'=?<>H?\ "QM'_P"?>^_[]I_\51_PL;1_^?>^
M_P"_:?\ Q5>7T4?4:/G]X?VEB.Z^X]0_X6-H_P#S[WW_ '[3_P"*H_X6-H__
M #[WW_?M/_BJ\OHH^HT?/[P_M+$=U]QZA_PL;1_^?>^_[]I_\51_PL;1_P#G
MWOO^_:?_ !5>7T4?4:/G]X?VEB.Z^X]0_P"%C:/_ ,^]]_W[3_XJC_A8VC_\
M^]]_W[3_ .*KR^BCZC1\_O#^TL1W7W'J'_"QM'_Y][[_ +]I_P#%4?\ "QM'
M_P"?>^_[]I_\57E]%'U&CY_>']I8CNON/4/^%C:/_P ^]]_W[3_XJC_A8VC_
M //O??\ ?M/_ (JO+Z*/J-'S^\/[2Q'=?<>H?\+&T?\ Y][[_OVG_P 51_PL
M;1_^?>^_[]I_\57E]%'U&CY_>']I8CNON/4/^%C:/_S[WW_?M/\ XJC_ (6-
MH_\ S[WW_?M/_BJ\OHH^HT?/[P_M+$=U]QZA_P +&T?_ )][[_OVG_Q5'_"Q
MM'_Y][[_ +]I_P#%5Y?11]1H^?WA_:6([K[CU#_A8VC_ //O??\ ?M/_ (JC
M_A8VC_\ /O??]^T_^*KR^BCZC1\_O#^TL1W7W'J'_"QM'_Y][[_OVG_Q536G
MC[2KR\@M8X+P/-(L:ED7 ).!GYO>O*:T-"_Y&'3/^ON+_P!#%*6"HJ+>OWEP
MS&NY).WW'M]%%%>,>^%%%% !1110!XAKO_(PZG_U]R_^AFL^O4[SP!IU[>SW
M3W5TKS2-(P4K@$G/''O4'_"M],_Y_+O\U_PKV8XVBHI7_ ^?GEU=R;26_<\S
MHKTS_A6^F?\ /Y=_FO\ A1_PK?3/^?R[_-?\*KZ]1[_@3_9N([+[SS.BO3/^
M%;Z9_P _EW^:_P"%'_"M],_Y_+O\U_PH^O4>_P" ?V;B.R^\\SHKTS_A6^F?
M\_EW^:_X4?\ "M],_P"?R[_-?\*/KU'O^ ?V;B.R^\\SHKTS_A6^F?\ /Y=_
MFO\ A1_PK?3/^?R[_-?\*/KU'O\ @']FXCLOO/,Z*],_X5OIG_/Y=_FO^%'_
M  K?3/\ G\N_S7_"CZ]1[_@']FXCLOO/,Z*],_X5OIG_ #^7?YK_ (4?\*WT
MS_G\N_S7_"CZ]1[_ (!_9N([+[SS.BO3/^%;Z9_S^7?YK_A1_P *WTS_ )_+
MO\U_PH^O4>_X!_9N([+[SS.BO3/^%;Z9_P _EW^:_P"%'_"M],_Y_+O\U_PH
M^O4>_P" ?V;B.R^\\SHKTS_A6^F?\_EW^:_X4?\ "M],_P"?R[_-?\*/KU'O
M^ ?V;B.R^\\SHKTS_A6^F?\ /Y=_FO\ A1_PK?3/^?R[_-?\*/KU'O\ @']F
MXCLOO/,Z*],_X5OIG_/Y=_FO^%'_  K?3/\ G\N_S7_"CZ]1[_@']FXCLOO/
M,Z*],_X5OIG_ #^7?YK_ (4?\*WTS_G\N_S7_"CZ]1[_ (!_9N([+[SS.BO3
M/^%;Z9_S^7?YK_A1_P *WTS_ )_+O\U_PH^O4>_X!_9N([+[SS.BO3/^%;Z9
M_P _EW^:_P"%'_"M],_Y_+O\U_PH^O4>_P" ?V;B.R^\\SHKTS_A6^F?\_EW
M^:_X4?\ "M],_P"?R[_-?\*/KU'O^ ?V;B.R^\Y2]UXKX=T>RT^_N89X1)]H
M6%GCZGY<D8!K37Q#IDGBJ2XEN7^RS::MK)-L8E7ZGMD_6MC_ (5OIG_/Y=_F
MO^%'_"M],_Y_+O\ -?\ "N9U<,^KZ].YU*CBUT73KV,#^U=%M+70K.UOI)TL
MK_S99&@9,K@Y8#'3GIUK(;4K8Z1XDB\QO,O[I7A&QLR+YI)SQQQZUVW_  K?
M3/\ G\N_S7_"C_A6^F?\_EW^:_X4*KA^[^[SN#H8I[12^?E8YC^T-'N=5T\W
M3*T$&EI 6DA9D28;L97'S 9'2K<>NZ7%?:!B\61+)YC/)':&%1N QA0.G4>O
M%;G_  K?3/\ G\N_S7_"C_A6^F?\_EW^:_X4.KAW]I_=Z_YC5'%+[*^_T_R.
M1.JV9\/>(+<2GS[V]66%=C?.OFAL]../6GZ!?V=OI6IVEQJ<NG27)B\N>)'9
MAM8DXV\\CCKWKJ_^%;Z9_P _EW^:_P"%'_"M],_Y_+O\U_PJO;X?E<;O6W3M
M;_(CZMBN=2LM+]>]_P#,XB:/26FU"235[FZ980T$K1/F:3'W3NR>P&:?X:U2
MWTO4V:\0M:3Q-#, ,D*?_P!5=I_PK?3/^?R[_-?\*/\ A6^F?\_EW^:_X57U
MF@XN+;L_(GZGB%-3C%)KS.4@ET'0M4L;JPOY[[9."R& H(X\'))/4].E%W<Z
M1IVE:E!IU^][/J$B<&!D$:A]Q+$]3VKJ_P#A6^F?\_EW^:_X4?\ "M],_P"?
MR[_-?\*CV]%N[D_N^9:PV(2:4$OGY6,2_P#$&F377B"2.X)6ZL%@A/EM\SA2
M,=/?KTK(\,7UMI^HS275RULCV[QB55+%6(X( YKLO^%;Z9_S^7?YK_A1_P *
MWTS_ )_+O\U_PHC6P\8N-WKY!+#XJ4U-Q6GF<S>:O8K;:;91ZE<:G)#>+/)>
M7$3*8T'51NY.>M%QK-A-:ZO&ETZ-=:HDT3+&V=@<$MTXP.>:Z;_A6^F?\_EW
M^:_X4?\ "M],_P"?R[_-?\*2JX?N_N^93HXI_97W^5CF]2U?3FETZ8W$5_?Q
M7BRRW45J8CY0[-D#+9 JU'J^C0W>M6T5^##J+?:!<O9EUC<NQV,C [ATYQWK
M:_X5OIG_ #^7?YK_ (4?\*WTS_G\N_S7_"E[3#VMS/[OF/V6*3ORK[_*QSB:
MY;P7MR\FKFZ5=,DMX9([0PJCGHJ@ 'MUKDXE"1* ,<#->G_\*WTS_G\N_P U
M_P */^%;Z9_S^7?YK_A6M/$T(:IO[C&KA,345FE]YC?V_H\_B.<7<ADTN>RB
MBE)C;[Z'(XQG_P#76?<:_;W6C:OYCG[3=WZ30Q%#S&K+C/&!A5%=3_PK?3/^
M?R[_ #7_  H_X5OIG_/Y=_FO^%9JIAEU?W&KI8MIJRZ]>Z,5]9T.SUJ\\26U
M[+/>31'98M P._:%P7Z;>*JV5]HLMKH=S?WTL%UIHVF!(&??\V001P/>ND_X
M5OIG_/Y=_FO^%'_"M],_Y_+O\U_PI>TP_P#,_N_KN/V6*;^%??UT=_P.<M-8
ML)H]8MY+N.V$]^]U!--:><K L>"I!QQ@CBFMKEL8/$"SZDUW)<VJ0P2_9C&'
M(!X"@< 9ZFNE_P"%;Z9_S^7?YK_A1_PK?3/^?R[_ #7_  I^TP_=_=Z?Y"]E
MB[?"OO\ 7_,\SHKTS_A6^F?\_EW^:_X4?\*WTS_G\N_S7_"NGZ]1[_@<G]FX
MCLOO/,Z*],_X5OIG_/Y=_FO^%'_"M],_Y_+O\U_PH^O4>_X!_9N([+[SS.BO
M3/\ A6^F?\_EW^:_X4?\*WTS_G\N_P U_P */KU'O^ ?V;B.R^\\SHKTS_A6
M^F?\_EW^:_X4?\*WTS_G\N_S7_"CZ]1[_@']FXCLOO/,Z*],_P"%;Z9_S^7?
MYK_A1_PK?3/^?R[_ #7_  H^O4>_X!_9N([+[SS.BO3/^%;Z9_S^7?YK_A1_
MPK?3/^?R[_-?\*/KU'O^ ?V;B.R^\\SHKTS_ (5OIG_/Y=_FO^%'_"M],_Y_
M+O\ -?\ "CZ]1[_@']FXCLOO/,Z*],_X5OIG_/Y=_FO^%'_"M],_Y_+O\U_P
MH^O4>_X!_9N([+[SS.BO3/\ A6^F?\_EW^:_X4?\*WTS_G\N_P U_P */KU'
MO^ ?V;B.R^\\SHKTS_A6^F?\_EW^:_X4?\*WTS_G\N_S7_"CZ]1[_@']FXCL
MOO/,Z*],_P"%;Z9_S^7?YK_A1_PK?3/^?R[_ #7_  H^O4>_X!_9N([+[SS.
MBO3/^%;Z9_S^7?YK_A1_PK?3/^?R[_-?\*/KU'O^ ?V;B.R^\\SHKTS_ (5O
MIG_/Y=_FO^%'_"M],_Y_+O\ -?\ "CZ]1[_@']FXCLOO/,Z*],_X5OIG_/Y=
M_FO^%'_"M],_Y_+O\U_PH^O4>_X!_9N([+[SS.BO3/\ A6^F?\_EW^:_X4?\
M*WTS_G\N_P U_P */KU'O^ ?V;B.R^\\SK0T+_D8=,_Z^XO_ $,5WG_"M],_
MY_+O\U_PJ>S\ :=97L%TEU=,\,BR*&*X)!SSQ[5,L;1<6K_@5#+JZDFTM^YU
ME%%%>,?0!1110 4444 %%%% !1110 4444 %%%% !1139-_E/Y6WS-IV[NF>
MV?:@!U%>:VOC#Q#<*L,5Q83Q7.HPV%OJ:6K+$7*N9MB%_G52FT-D D]\5)I/
MQ6M1X3AU?7-/OXMN\3W%K9226X*R-'D/@@9*]">,XH ]&HH!R ?6B@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@"IJ>I6NCZ;/?WLA2WA7+D*6/7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >?>*_!6L>(_$L]S8WB:-"+/ROMEN[^==L<_NY &
M \L>OWO0BMWP&GD^$;:V:QM+*2VEFMY(;-F:(.DK*Q4MR<D$\\Y/4U+J^B:Q
M?WQGLO%%WIT.T#R(K:%USZY92>:MZ#I#:%I LVNY;V7S99GFD55:1Y'9SP,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M. OX$UZ-16U*I3C&:G"[:T=[6=]_/MJ)IG*_\)J__0J>)?\ P"7_ .+JC?\
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M*UQ%6E4:]E#E^;9K6J4YM>SAR_.YRO\ PFK_ /0J>)?_  "7_P"+H_X35_\
MH5/$O_@$O_Q==517.8'*_P#":O\ ]"IXE_\  )?_ (NC_A-7_P"A4\2_^ 2_
M_%UU5% '*_\ ":O_ -"IXE_\ E_^+JK)\1[6+4X=-?P[XA6]FC:6.$V:[F1<
M D?/T&17:5S=DVBZ]XMN=0MTD>^T7=8--NP@+X9U SR1A>2/IGF@"'_A-7_Z
M%3Q+_P" 2_\ Q='_  FK_P#0J>)?_ )?_BZZJB@#RKQ1XJM]Y7_A%-32:Z0J
M6NRT1R>!M520?TJ/PIXGAC:*!O"FI236D*C?:%I&) VDE&( '6O6:*[UC(>P
M]ER:][O\O3H=GUJ/L?9\NO>[_(Q]'U]M7GDB.C:M8[%W;[V 1JW/0$,>:V**
M*X#C"BBB@ HHHH **** "BBB@ KC_'.NZOIDEC::-+;PSS0W5R\L\1D&V"/=
MLQD?>) SV&:["L+Q-X2TSQ9:P0:E]H40L61[>8Q/A@59<C^%@<$=Z /,_&WQ
M#T76O VDQRW2Q:I+-87D]JL;GRU)21N<8( .>M=K_P +9\#_ /0>3_P'E_\
MB:ZZUM8+&TAM+:)8H(4$<<:]%4#  _"IJ;W$MCB_^%L^!_\ H/)_X#R__$T?
M\+9\#_\ 0>3_ ,!Y?_B:[2BD,XO_ (6SX'_Z#R?^ \O_ ,32'XM^!5&3K\8'
MO!+_ /$UVM8'BFSTS6(+'1K^^-M+<W4<MNJD;I&A(EP,]L+S0!E?\+9\#_\
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MR.AZ \]" : .!\):#-XJM]-UK4;B^D15$Y%XSK<6UT-I+6\G'[F13G;RN,
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MQP7$7D3&%A-'M)( Y'J.>M7J "BBB@ HHHH **** "BBB@ IJ(D8(1%7)+'
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MG\BZ,2I.\02,IOW+Q\Y<#(!('--T^[\43ZAIIOWNK9S':$KY#F-P44S!PL9
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M))'%-&[Q';(JL"4/H?2I:$[["33V"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5*]TC3M2=7O;&WN&52H,L8;Y3U'T/I5VB@!  H    X
M %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.%5J%E'Y[OL<5*BZ=9JG90ZK7=ZZ=/4N4445U':%%%% !1110 4444 %%%%
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MD9KWFTM+>PLX;2UB6&WA01QQH,!5 P *?0GJ0:OID.LZ3<Z=.[I%.NUFC(W
M9[9K&E\":)<ZK=WEY";N&Z+.UE<*KP!V\O<X!&<GRDZD@8. ,UTU%(9P?P\L
M;33=:\96=C;16UM%JJB.*)0JJ/(C/ '2N\KB_!7_ ",WC?\ ["R_^B(Z[2@
MHHHH *CN(%N;:6!R0DJ%&(.#@C%25%<W$5I;M/,6$:XR54L>3CH 32=K:BE:
MSOL>=PZ#X<L/$:>'[DSW32H3E^-CG!4 C&. ?SKT6"".VMXX(4"11J$11V &
M *YI]3T=O$\5Z48N+5E\PVDFX'<,?PYZ9Y]ZZ2VN8KN!9X2QC;."R%3P<="
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MWD9FSQ\WRD8Q^E<%3&.%?V37;YW/,JX]T\1[%Q[6\[]M>AZ;1117>>F%%%%
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M:)0Q;("_?<E2P&$/3!->E44 <;H_BV^U&]M(+A+"W$A(P9-QNAO=<Q;&8<!
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M@FU"[C$@_LR2Y\F%8!Y'DN&((4G=,<_Q$$?P\'6P=+FQX*_Y&;QO_P!A9?\
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MK%9!-J=Y?;R,&Y$8V?38B_KFO(?$'B3XHS:PJ+X15(K:Y2>%$B:=00" #(I
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M"FU!W7?8RJ**DU!W1Z)69<^(]#LKA[>ZUG3X)T^_'+<HK+]03D=17'CX*^$
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MM[Z%=0\^"59DW7LA&Y3D9&<$9'2N\KB.0**** "BBB@ HHHH **** "BBB@
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M&BFCTZSAM4GE,TB1+M4N<9..W2@"]1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110! EG:QW$EPEM$L\I#22
M! &8@8!)ZG X^E3T44 %%%% !1110 4444 %%%% &9K7A_3?$$$<6HP-((F+
MQ.LC(T3XQN4@@AAV/:FZ+H%GHL3&*.-[N4?O[ORD26<CH7*@9/J>YY[UJT4
M%%%% !1110 4444 %%%% !1110 448HQ0 448HQ0 448HQ0 448HQ0 448HQ
M0 THA=7**74$!B.0#U_D*=1BC% !11BC% !11BC% !11BC% !11BC% !7-:[
MX)TS6I7O$::QU;S!+%J-LV)HW"A1@G@K@ %>A^O-=+BC% %>ULX;13Y<<8D?
MF618PID;NQP.M6*,48H **,48H **,48H **,44 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_007.jpg
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &# UD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@#F]
M4\:Z;I&I2V-Q!=M+%C<8T4KR >,L/6J?_"Q]'_Y]K[_OA/\ XJN0\;?\C???
M]L__ $6M<_7KTL%2E!2?5=SPJV85X5)15K)OH>G_ /"Q]'_Y]K[_ +X3_P"*
MH_X6/H__ #[7W_?"?_%5YA15_4:/G]YE_:6([K[CT_\ X6/H_P#S[7W_ 'PG
M_P 51_PL?1_^?:^_[X3_ .*KS"BCZC1\_O#^TL1W7W'I_P#PL?1_^?:^_P"^
M$_\ BJ/^%CZ/_P ^U]_WPG_Q5>844?4:/G]X?VEB.Z^X]/\ ^%CZ/_S[7W_?
M"?\ Q5'_  L?1_\ GVOO^^$_^*KS"BCZC1\_O#^TL1W7W'I__"Q]'_Y]K[_O
MA/\ XJC_ (6/H_\ S[7W_?"?_%5YA11]1H^?WA_:6([K[CT__A8^C_\ /M??
M]\)_\51_PL?1_P#GVOO^^$_^*KS"BCZC1\_O#^TL1W7W'I__  L?1_\ GVOO
M^^$_^*H_X6/H_P#S[7W_ 'PG_P 57F%%'U&CY_>']I8CNON/3_\ A8^C_P#/
MM??]\)_\51_PL?1_^?:^_P"^$_\ BJ\PHH^HT?/[P_M+$=U]QZ?_ ,+'T?\
MY]K[_OA/_BJ/^%CZ/_S[7W_?"?\ Q5>844?4:/G]X?VEB.Z^X]/_ .%CZ/\
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MJ&8<AT;##C_/6D\+AU)0=[OS*CC<5*#J*UEY'9?\+'T?_GVOO^^$_P#BJ/\
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M$($D^9LG)SG^5'U7#W277S[!]=Q2BY.RM;IW.W_X6/H__/M??]\)_P#%4?\
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MK[_OA/\ XJC_ (6/H_\ S[7W_?"?_%5YA11]1H^?WA_:6([K[CT__A8^C_\
M/M??]\)_\51_PL?1_P#GVOO^^$_^*KS"BCZC1\_O#^TL1W7W'I__  L?1_\
MGVOO^^$_^*H_X6/H_P#S[7W_ 'PG_P 57F%%'U&CY_>']I8CNON/3_\ A8^C
M_P#/M??]\)_\51_PL?1_^?:^_P"^$_\ BJ\PHH^HT?/[P_M+$=U]QZ?_ ,+'
MT?\ Y]K[_OA/_BJ/^%CZ/_S[7W_?"?\ Q5>844?4:/G]X?VEB.Z^X]/_ .%C
MZ/\ \^U]_P!\)_\ %4?\+'T?_GVOO^^$_P#BJ\PHH^HT?/[P_M+$=U]QZ?\
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M$^(O^@?_ .1H_P#XJC_A"?$7_0/_ /(T?_Q5'MZ7\R^\/J];^1_<<_170?\
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MM5AI27NI^)I2MU<^3= BPMIO+,Q+=6]ADG\ZS?\ A"/$6\-_9YW#@'SX^/\
MQZD'@?Q"N=NGD9ZXGC&?_'J?)37PS7].X>TJM^]3;V[]K?\ !.F8%/&'A9/*
M:$K:.IC:3S"F%(VENY'2L>"ZN+K0/&+7%Q+-B4%?,8D+\[#@=N@_(507P-X@
M3&W3L8&!B>/I_P!]4?\ "#>(-FS^SOE]//CQ_P"A4E3IV^-?T[C=6JWI3?\
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MB!0TWV%]BD9RV5P.?>J7_"#>(-H7^SN <@>?'U_[ZIW_  A/B+_H'D?2>/\
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M79=3LO#\EZCVX5;H7NV)HMO3:00!_P#KKFKRZN;?X<:''!<RQ"6>02&)RI8
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MWI?S+[P^KUOY']QS]%=!_P (3XB_Z!__ )&C_P#BJ/\ A"?$7_0/_P#(T?\
M\51[>E_,OO#ZO6_D?W'/T5T'_"$^(O\ H'_^1H__ (JC_A"?$7_0/_\ (T?_
M ,51[>E_,OO#ZO6_D?W'/T5T'_"$^(O^@?\ ^1H__BJ/^$)\1?\ 0/\ _(T?
M_P 51[>E_,OO#ZO6_D?W'/T5T'_"$^(O^@?_ .1H_P#XJC_A"?$7_0/_ /(T
M?_Q5'MZ7\R^\/J];^1_<<_170?\ "$^(O^@?_P"1H_\ XJC_ (0GQ%_T#_\
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M\1?] _\ \C1__%4>WI?S+[P^KUOY']QS]%=!_P (3XB_Z!__ )&C_P#BJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M00?9B3[UZ]7F>DW"3?'F^1=5M[TQZ1.K0Q6XC:U/G0_([ _.>^30!Z91110
M444BLKC*L&'3(.: %HHHH **** "BBB@"O?7UKIEE->WL\=O;0KNDED.%4>I
M-<[_ ,+,\$_]#/IG_?\ %=510!S(^(/AAUW1ZF9%(^5X[>5U/N"%P1]*PH/%
MT:1V F\4^8\5RSW3#3)1YT1SA!\G';G_  KT.B@#FO\ A/\ PU_S_P O_@)-
M_P#$59T_Q?H>J7T=G9W<DD\F=JFWE4' )/+*!T!K<HH **** "BBB@ HHHH
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MT?V9="?[.X20A2,$YQC(Y!P>17AN23LS>-.<HN<4VEN^U]KFK1113("BBB@
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M\9^,;+P3I$6HWUO<3I+.L"I"!G)!.220.BGZ_J,;0/BGIOB3Q>FAV%A=>5)
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M5).VMF]==W=67;0=1116AR!1110 4444 %%%% !1110 4444 %%%% !1110
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MYGQ)IUC!\5_!5]#96\=Y<37@GN$B422A;5@NY@,G X&>E(9WU%%% ",H92K
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M,%E>/(.1Q@@8YY.:G\$^&9/#MM<&6RL+)I]@%O9SS3*@7.,O(>>O0*N/4]A
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MH\9549YHD82..N<DJ-QZ[:Y?[?JY_::LM)O-3DN["UFGEM8W*9B\RT9RN%Y
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M"./_ .$G\6?]$^OO_!E:?_%T?\)/XL_Z)]??^#*T_P#BZ["B@9Q__"3^+/\
MHGU]_P"#*T_^+H_X2?Q9_P!$^OO_  96G_Q==A39)%BB>1R0J L2!G@4 <)9
M>/M>U&ZOK:T\"WTDUC*(;E?[0MAL<J&QDOSP1TS5W_A)_%G_ $3Z^_\ !E:?
M_%UJ>%KS2M8TQ]<TJU$,6HRO(TF!NF*DH'.">H4=>0.#@UN4 <?_ ,)/XL_Z
M)]??^#*T_P#BZ/\ A)_%G_1/K[_P96G_ ,77844 <?\ \)/XL_Z)]??^#*T_
M^+H_X2?Q9_T3Z^_\&5I_\77844 <?_PD_BS_ *)]??\ @RM/_BZ/^$G\6?\
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M_P >H_X3JZ_Z$?Q7_P" T'_QZNPHH X__A.KK_H1_%?_ (#0?_'J/^$ZNO\
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ML+SQ5I^EV<D$UE>VTDL-^LH:.:16 \J,KD%@-Q(.#C&,T 4_,^)__/KX0_\
M BY_^(H\SXG_ //KX0_\"+G_ .(KM:* //=3L/B7JMMY$J>&(HSD-Y%[=)N!
M&"#\G(HTVQ^)FF6_D1KX8E3C'GWMTY4 8P/DX%>A45?M)<O)?0KGER\M]#'T
M!O$C13_\)''I*29'D_V=)(P([[MX'/3I6Q114$A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!2UBXN+30[^YLU1KJ&VDDA5P2I<*2H..V<5XUI\R>-]>#!K^9AM:^T^*]
M.[3IY=NV[MWR R84':>5#' Y(KW$@,I5@"",$'O5'2]$TS1+6.VTRQ@M88UV
M(L: 8&<XSU//- %3PYX=BT""8B7S;NZ*R7<B+Y<<LH&#(L>2J%NIQU-;5%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]4#+JXZ6EBW_ &].O_M,TGG:Q_SXV/\ X&O_ /&J -"BL_SM8_Y\;'_P-?\
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M#2=/N((;UX8Y;@,8@T>=P49;H.PJ*QU#0M6G$-H;>>3R5G \G'[MB0#R/8T
M*OA_0Y)_.6R@:42Q3[@<D/&NU&Z]5' ]JUZK-IUBWWK.W/UB7_"F_P!EZ?\
M\^-M_P!^5_PH MT54_LO3_\ GQMO^_*_X4?V7I__ #XVO_?E?\* +=%,BBC@
MC$<4:1H.BHH 'X4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[]F &4\,<[AB@#I**JZ9?QZII=KJ$*.D5S$LJ+)C=M89&<$CI@]:M4 %%%%
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MMQ?+"HF%L,1AL?PCTJ_110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_@IG_\ B:[6B@#BO^%HZ%_SY:Y_X*9__B:/^%HZ%_SY:Y_X*9__ (FNUHH
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M&)8QCME9&.3]*Z&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH :Y98V95W, 2%SC)]*\8?X@WGB%[-EUFXT>TNPKW4,,:FYTUPN%)RO[RW=
MG0EL<=,@$X]IKG-&\#Z%H6HR:C9VSF]<R?OY)69E1R#Y8[;!@87''U)).H="
MMX*\-7OA^&X:YEAA%RQ:2QMN;=)0Q!EBSR@<88IR 2<5UE%% !1110 4444
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MQZY))/)))))/))JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML<D2EV#!2&W-(S?EA@/SK.M-!U6SM4TN+4K==*A5TB5;<^:4((5&8L1A<CD
M$[1TYSTE% ''6'@A[2X,LEW%(-I 'E],VL,'K_TR)^C8J[-X4CN[/P_;74OF
M1Z6FUP"RF4^48\@@@CDYKI** .7U'P=!<1W<5EY%K%-8_9458_N,9"Y;WR3D
M]R>:S)? =_<ZA<SW6JQ2Q2+.B1^4P 6259.5W; 1L .%!;J3VKNZ* .='A@?
MVQ-?-)$PDU5=0"F/D!;40!<^N1NS[UB3> ;^4V,2ZM&MK:R6\OEB-UR8IC+C
MY6 8'H-P.WL.>.]HH Y&V\)7UMI<=D+ZU86;0?8V-L?F$3EAYQW98G/;&#EN
MIQ5S0?#<NDW\EY-=1RR3)(9%CBV*'>5I#M&3@#=CU/7O7144 <U;>%GA_LT/
M<(XL]7NM1(V?>$WGX7V(\\<_[-9'_"O'^U6#F_+10Q6T<J&6=5)A;<"JI*J'
M/&-P.T\\]*[RB@#,T+3)='TJTT\O$\<$6TLJD%FSR?I6*WAK5KN749+V]LVF
MN1B&X6)BT 5PT:A2<;00"0,%B.3TQUM% &"FAW<NG7B7=U"UW=WD=U(T495%
MV&,!0"2?NQ#G/4GZ5=BTQE\0W6J23;Q);1V\4>/]6%9V8_\  BRY_P!P5HT4
M <M<^'-3FNM;BBO;2/3]7E5YMT+-*J^3'$RJ=P&2$.#VST.*SI?AZ\M_?S-J
M!,<[7,D6Z2=]CS$G!C,OE[020<(,C'3DGNJ* *.E6MU;6\GVV6WDGEE:1OL\
M7EH,] !DD].I.3^0K!O/!9O=&N+,ZC+%,TU[+$\:J5!N&<_,K \@.1D8/+8(
MS7644 9<^E27>@W.D7-PQBFM#:^<G$F"FUF],]Q@5A1>%-52\.H->Z=]L1X'
MB5;5A$?+CDC^8;\\B4D$'@@=<5V-% &#HF@7&C/N%S#*7BCCDQ$4&1)*[%1D
M[1F7 &3@#O6E>61NKK3Y@X46EP9B"/O9BD3'_C^?PJY10!S.C>'+[2&MT^VV
M\L%C;O:V2^2RL(V=3^\.XY(5%48 [GO@6-3\.R:A?:C<I=+$US9P01$IN\N2
M*2217(R,C+KQQT//-;U% '+?\(_K"SOJ,6H62ZE,THE)MV,05TB7Y1OSD>2A
MY//S=,C":7X:O]-U2S)N;:?3K"!+:SC=7WPQA I/!VESCEB.AP,9.>JHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q K(# 2(  A$! Q$!_\0
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M^?6#_O\ G_XBCDEV#VD>YIT5F?VC=?\ /K!_W_/_ ,11_:-U_P ^L'_?\_\
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MO^?6#_O^?_B*.278/:1[FG169_:-U_SZP?\ ?\__ !%']HW7_/K!_P!_S_\
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MT;K_ )]8/^_Y_P#B*.278/:1[FG169_:-U_SZP?]_P __$4?VC=?\^L'_?\
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MFKBV]LED+);>%;41^4( @";,8V[>F,<8IW]E>(O^@?9_^!A_^(H_LKQ%_P!
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M*/[*\1?] ^S_ / P_P#Q%'MJ7\P>PK_RDOF>]'F>]1?V5XB_Z!]G_P"!A_\
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MAU[Q ]Q%(Q\RVTUF91&>SR+_ 'N.!VXSSP/;: "BBB@ HHHH **** "BBB@
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M);\,-P.0<&+J#S6KOHWT>R0>V91_MKQ%_P!"]:?^#+_[51_;7B+_ *%ZT_\
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MWIG@\D^"M#R2?] A&2<_P"LYQY36G/F-JBBBH-0HHHH **** "BBB@ HHHH
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M:R&6,)MQNVE<G(/\+,/Q]:MP,54,BP\:7-VT(ETI(Q-]L"A+L,=UN^TCYE4
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MA;YUY2$YC'W>Q_/O4\D[(T]K3NRQ+XL>/5TTW[)$9)1<"-EGWA3$"1OPN%W
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M:3A.^G];E*I"VO\ 6PZW\;G4-)GU/3]/\VWMK..[F66;RWPR%]J@*02%!ZD
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M?Q0^)OC#P_\ $35=,TS67M[.$Q^7$(8VVYC4GDJ3U)H^LS#ZE3\SV;R]5_Z
MEY_W]@_^.4>7JO\ T!+S_O[!_P#'*QO@KXEU?Q5X*N+_ %J\-U<I?O$KE%7"
M!$(&% '5C^=>CT?69A]2I^9R/EZK_P! 2\_[^P?_ !RCR]5_Z EY_P!_8/\
MXY7744?69A]2I^9R/EZK_P! 2\_[^P?_ !RCR]5_Z EY_P!_8/\ XY7744?6
M9A]2I^9R/EZK_P! 2\_[^P?_ !RCR]5_Z EY_P!_8/\ XY7744?69A]2I^9R
M/EZK_P! 2\_[^P?_ !RCR]5_Z EY_P!_8/\ XY7744?69A]2I^9R/EZK_P!
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MD6I?]"OJ'_@1;?\ QRCE8<T>YT-%<]_PD6I?]"OJ'_@1;?\ QRC_ (2+4O\
MH5]0_P# BV_^.4<K#FCW.AHKGO\ A(]0'+>%]2V]]L]L3^7FUL65_;W\;M Q
MS&VR1&4JT;8!PP/0X(/T(-#30TT]BS1112&%%%84OB5G*-INDWNHP,H87$+1
M)&P/3!=U+>N0,>]%KB;2W-VBN>_X2+4O^A7U#_P(MO\ XY1_PD6I?]"OJ'_@
M1;?_ !RGRL7-'N2>+?#]QXDT-K&SUF^TBY#B2.ZLI61@0",-M(W*<],^GI7Q
MSXA\,:]H?B%]-U:SN/[0ED)0D%S<$L1N4_Q9/?\ K7V%_P )%J7_ $*^H?\
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MP +1P /RI?[>M_\ GVOO_ 5_\*+,.9&I167_ &];_P#/M??^ K_X4?V];_\
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MQJ;_ (2+41_S*^H?^!%M_P#'*.5AS1[G0T5SW_"1:E_T*^H?^!%M_P#'*/\
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M4=#WYQ19C4DS1HHHI#"BBB@ HHHH R]0 &IVC_Q"&4#\6C_PI-])JAQ?VO\
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ME$%/LP9&_-6(J]NK*UILRZ1_V$X/_0JF<?=9=.?O([*BBBN0[PHHHH ****
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M_P#!;/\ _$T?VJ?^@;J__@MG_P#B:+T^Z"U;L_N-&"..UMXK>%0D42!$4=E
MP!5>30]/\3C6-)U.'S;6XM;<, <$'=*00>Q!JNNIL[!5TS5MQ.!G3YE'YE0!
M^-;^A65U#+=W=W$(6FV)''N!8(N3EL< DLW )X [Y RKRCRZ,WPL)^TNUH>
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,]".(# 2(  A$! Q$!_\0
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M+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\
M'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M
M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/+_QX_P"-']GVO_/+
M_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/
M^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_
M9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V?:_\\O\
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M_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\
MC5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V
M?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH K?V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C
M5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K
M_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:
M* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\
MSR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_
M !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH
MK?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_S
MR_\ 'C_C5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'
MC_C1_9]K_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K
M?V?:_P#/+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_
M ,>/^-6:* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^
M-']GVO\ SR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?
MV?:_\\O_ !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_Q
MX_XU9HH K?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\
MC1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]
MK_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_
M (U9HH K?V?:_P#/+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-'
M]GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_
M #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_
MXU9HH K?V?:_\\O_ !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?
M:_\ /+_QX_XU9HH K?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\
MSR_\>/\ C1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5
MFB@"M_9]K_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_
M ,\O_'C_ (U9HH K?V?:_P#/+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+
M_P >/^-']GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:*
M *W]GVO_ #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_
M\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\
MQX_XT?V?:_\ /+_QX_XU9HH K?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:*
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M6T__ (\8_P ?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110!S-%%% &[I__ !XQ_C_,U9JMI_\
MQXQ_C_,U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.5DN(VD;YE_=(=Y"KGY\87D-\W." ;_PLOIM+^$_B#4+=4::UFN9XQ("5++
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M FHJ'S)_^??_ ,?%,:YD61(S!\SYQ\X[4 6:*A\R?_GW_P#'Q1YD_P#S[_\
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M_P"/B@":BH?,G_Y]_P#Q\4>9/_S[_P#CXH FHJ'S)_\ GW_\?%'F3_\ /O\
M^/B@":BJ[SRHC.T'"C)^<4)/*Z*ZP<,,CYQ0!8HJ'S)_^??_ ,?%'F3_ //O
M_P"/B@":BH?,G_Y]_P#Q\4>9/_S[_P#CXH FHJ'S)_\ GW_\?%->>5$9V@X4
M9/SB@"Q15=)Y7176#AAD?.*=YD__ #[_ /CXH FHJ'S)_P#GW_\ 'Q1YD_\
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M0_X\9/P_F*LU6U#_ (\9/P_F*LT %%%% !1110 56@_X_KK_ (!_*K-5H/\
MC^NO^ ?RH LT444 %%%% !1110!6G_X_K7_@?\JLU6G_ ./ZU_X'_*K- !11
M10 4444 %5O^8I_VQ_\ 9JLU6_YBG_;'_P!FH LT444 %%%% !1110!6O/\
MEW_Z[+5FJUY_R[_]=EJS0 4444 %%%% !5:?_C^M?^!_RJS5:?\ X_K7_@?\
MJ +-%%% !1110 4444 5M0_X\9/P_F*LU6U#_CQD_#^8JS0 4444 %%%% !4
M5S_QZS?[A_E4M17/_'K-_N'^5 !;?\>L/^X/Y5+45M_QZP_[@_E4M !1110
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MZ[-5FJUG_P O'_79J +-%%% !1110 4444 5H/\ C^NO^ ?RJS5:#_C^NO\
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M )>/^NS59H **** "BBB@ JM_P Q3_MC_P"S59JM_P Q3_MC_P"S4 6:***
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M@"MI_P#QXQ_C_,U9JMI__'C'^/\ ,U9H **** "BBB@"*Y_X]9O]P_RHMO\
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M HHHH **** .9HHHH W=/_X\8_Q_F:LU6T__ (\8_P ?YFK- !1110 4444
M%%%% !1110 56G_X_K7_ ('_ "JS5:?_ (_K7_@?\J +-%%% !1110 4444
M5O\ F*?]L?\ V:K-5O\ F*?]L?\ V:K- !1110 4444 %5KS_EW_ .NRU9JM
M>?\ +O\ ]=EH LT444 %%%% !1110!6U#_CQD_#^8JS5;4/^/&3\/YBK- !1
M110 4444 %5H/^/ZZ_X!_*K-5H/^/ZZ_X!_*@"S1110 4444 %%%% %:?_C^
MM?\ @?\ *K-5I_\ C^M?^!_RJS0 4444 %%%% !5;_F*?]L?_9JLU6_YBG_;
M'_V:@"S1110 4444 %%%% %:\_Y=_P#KLM6:K7G_ "[_ /79:LT %%%% !11
M10 56G_X_K7_ ('_ "JS5:?_ (_K7_@?\J +-%%% !1110 4444 5M0_X\9/
MP_F*LU6U#_CQD_#^8JS0 4444 %%%% !45S_ ,>LW^X?Y5+45S_QZS?[A_E0
M 6W_ !ZP_P"X/Y5+45M_QZP_[@_E4M !1110 4444 17/_'K-_N'^5%M_P >
ML/\ N#^5%S_QZS?[A_E1;?\ 'K#_ +@_E0!+1110 4444 %%%% %:S_Y>/\
MKLU6:K6?_+Q_UV:K- !1110 4444 %5M/_X\8_Q_F:LU6T__ (\8_P ?YF@"
MS1110 4444 %%%% %:#_ (_KK_@'\JLU6@_X_KK_ (!_*K- !1110 4444 %
M5O\ F*?]L?\ V:K-5O\ F*?]L?\ V:@"S1110 4444 %%%% %:S_ .7C_KLU
M6:K6?_+Q_P!=FJS0 4444 %%%% !5;_F*?\ ;'_V:K-5O^8I_P!L?_9J +-%
M%% !1110 4444 5H/^/ZZ_X!_*K-5H/^/ZZ_X!_*K- !1110 4444 %5I_\
MC^M?^!_RJS5:?_C^M?\ @?\ *@"S1110 4444 %%%% %;_F*?]L?_9JLU6_Y
MBG_;'_V:K- !1110 4444 %5KS_EW_Z[+5FJUY_R[_\ 79: +-%%% !1110
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M?Y46W_'K#_N#^5 $M%%% !1110 4444 5K/_ )>/^NS59JM9_P#+Q_UV:K-
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M%/\ MC_[-5F@ HHHH **** "JUY_R[_]=EJS5:\_Y=_^NRT 6:*** "BBB@
MHHHH K:A_P >,GX?S%6:K:A_QXR?A_,59H **** "BBB@ JM!_Q_77_ /Y59
MJM!_Q_77_ /Y4 6:*** "BBB@ HHHH K3_\ ']:_\#_E5FJT_P#Q_6O_  /^
M56: "BBB@ HHHH *K?\ ,4_[8_\ LU6:K?\ ,4_[8_\ LU %FBBB@ HHHH *
M*** *UY_R[_]=EJS5:\_Y=_^NRU9H **** "BBB@ JM/_P ?UK_P/^56:K3_
M /']:_\  _Y4 6:*** "BBB@ HHHH K:A_QXR?A_,59JMJ'_ !XR?A_,59H
M**** "BBB@ J*Y_X]9O]P_RJ6HKG_CUF_P!P_P J "V_X]8?]P?RJ6HK;_CU
MA_W!_*I: "BBB@ HHHH BN?^/6;_ '#_ "HMO^/6'_<'\J+G_CUF_P!P_P J
M+;_CUA_W!_*@"6BBB@ HHHH **** *UG_P O'_79JLU6L_\ EX_Z[-5F@ HH
MHH **** "JVG_P#'C'^/\S5FJVG_ /'C'^/\S0!9HHHH **** "BBB@"M!_Q
M_77_  #^56:K0?\ ']=?\ _E5F@ HHHH **** "JW_,4_P"V/_LU6:K?\Q3_
M +8_^S4 6:*** "BBB@ HHHH K6?_+Q_UV:K-5K/_EX_Z[-5F@ HHHH ****
M "JW_,4_[8_^S59JM_S%/^V/_LU %FBBB@ HHHH **** *T'_']=?\ _E5FJ
MT'_']=?\ _E5F@ HHHH **** "JT_P#Q_6O_  /^56:K3_\ ']:_\#_E0!9H
MHHH **** "BBB@"M_P Q3_MC_P"S59JM_P Q3_MC_P"S59H **** "BBB@ J
MM>?\N_\ UV6K-5KS_EW_ .NRT 6:*** "BBB@ HHHH K:A_QXR?A_,59JMJ'
M_'C)^'\Q5F@ HHHH **** "JVH?\>,GX?S%6:K:A_P >,GX?S% %FBBB@ HH
MHH **** (KG_ (]9O]P_RHMO^/6'_<'\J+G_ (]9O]P_RHMO^/6'_<'\J ):
M*** "BBB@ J*Y_X]9O\ </\ *I:BN?\ CUF_W#_*@ MO^/6'_<'\JEJ*V_X]
M8?\ <'\JEH **** "BBB@ JM9_\ +Q_UV:K-5K/_ )>/^NS4 6:*** "BBB@
M HHHH K0?\?UU_P#^56:K0?\?UU_P#^56: "BBB@ HHHH K:A_QXR?A_,59J
MMJ'_ !XR?A_,59H **** "BBB@ HHHH K:?_ ,>,?X_S-6:K:?\ \>,?X_S-
M6: "BBB@ HHHH BN?^/6;_</\J+;_CUA_P!P?RHN?^/6;_</\J+;_CUA_P!P
M?RH EHHHH **** "BBB@"M9_\O'_ %V:K-5K/_EX_P"NS59H **** "BBB@
MJMI__'C'^/\ ,U9JMI__ !XQ_C_,T 6:*** "BBB@ HHHH K0?\ ']=?\ _E
M5FJT'_']=?\  /Y59H **** "BBB@ JM_P Q3_MC_P"S59JM_P Q3_MC_P"S
M4 6:*** "BBB@ HHHH K?\Q3_MC_ .S59JM_S%/^V/\ [-5F@ HHHH ****
M"JT__']:_P# _P"56:K3_P#']:_\#_E0!9HHHH **** "BBB@"M/_P ?UK_P
M/^56:K3_ /']:_\  _Y59H **** "BBB@ HHHH **** "BBB@#F:*** -W3_
M /CQC_'^9K"\:>,8O"&GVKI9M?W]Y.L%K91R!7E)ZGH3@<#A3\S*.^:W=/\
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M_P"/B@!EG_R\?]=FJS5&U>4>?MASF5B?F'!]*L>9/_S[_P#CXH FHJ'S)_\
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M #[_ /CXH FHJ'S)_P#GW_\ 'Q1YD_\ S[_^/B@":BH?,G_Y]_\ Q\4>9/\
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M3\/YBK-5M0_X\9/P_F*LT %%%% !1110 56@_P"/ZZ_X!_*K-5H/^/ZZ_P"
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M_@'\JLT %%%% !1110 56_YBG_;'_P!FJS5;_F*?]L?_ &:@"S1110 4444
M%%%% %:S_P"7C_KLU6:K6?\ R\?]=FJS0 4444 %%%% !5;_ )BG_;'_ -FJ
MS5;_ )BG_;'_ -FH LT444 %%%% !1110!6@_P"/ZZ_X!_*K-5H/^/ZZ_P"
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M_P#EX_Z[-5F@ HHHH **** "JVG_ /'C'^/\S5FJVG_\>,?X_P S0!9HHHH
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MFJS5;_F*?]L?_9J +-%%% !1110 4444 5K/_EX_Z[-5FJUG_P O'_79JLT
M%%%% !1110 56_YBG_;'_P!FJS5;_F*?]L?_ &:@"S1110 4444 %%%% %:#
M_C^NO^ ?RJS5:#_C^NO^ ?RJS0 4444 %%%% !5:?_C^M?\ @?\ *K-5I_\
MC^M?^!_RH LT444 %%%% !1110!6_P"8I_VQ_P#9JLU6_P"8I_VQ_P#9JLT
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M /'C'^/\S0!9HHHH **** "BBB@"M!_Q_77_  #^56:K0?\ ']=?\ _E5F@
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M0 4444 %%%% %;_F*?\ ;'_V:K-5O^8I_P!L?_9JLT %%%% !1110 56O/\
MEW_Z[+5FJUY_R[_]=EH LT444 %%%% !1110!6U#_CQD_#^8JS5;4/\ CQD_
M#^8JS0 4444 %%%% !5:#_C^NO\ @'\JLU6@_P"/ZZ_X!_*@"S1110 4444
M%%%% %:?_C^M?^!_RJS5:?\ X_K7_@?\JLT %%%% !1110 56_YBG_;'_P!F
MJS5;_F*?]L?_ &:@"S1110 4444 %%%% %:\_P"7?_KLM6:K7G_+O_UV6K-
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MKGQ6UD=GV1I&C4 <C&<'/OC]:[J.(A2HTE+[5DC6,U&,;]3K:***[C4****
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M%%% $5S_ ,>LW^X?Y46W_'K#_N#^5%S_ ,>LW^X?Y46W_'K#_N#^5 $M%%%
M!1110 5%<_\ 'K-_N'^52U%<_P#'K-_N'^5 !;?\>L/^X/Y5+45M_P >L/\
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M"]14/F3_ //O_P"/BCS)_P#GW_\ 'Q0!-14/F3_\^_\ X^*/,G_Y]_\ Q\4
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M/,G_ .??_P ?% $U17/_ !ZS?[A_E2>9/_S[_P#CXJ.>28V\H,&!L.3O''%
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M^??_ ,?% $U%0^9/_P ^_P#X^*/,G_Y]_P#Q\4 345#YD_\ S[_^/BCS)_\
MGW_\?% #(/\ C^NO^ ?RJS5&%Y1>7)$.2=N1N''%6/,G_P"??_Q\4 345#YD
M_P#S[_\ CXH\R?\ Y]__ !\4 345#YD__/O_ ./BCS)_^??_ ,?% $U5O^8I
M_P!L?_9J?YD__/O_ ./BJ^^7^T<^3\WE8V[ATSUH O45#YD__/O_ ./BCS)_
M^??_ ,?% $U%0^9/_P ^_P#X^*/,G_Y]_P#Q\4 345#YD_\ S[_^/BCS)_\
MGW_\?% #+/\ Y>/^NS59JC:O*//VPYS*Q/S#@^E6/,G_ .??_P ?% $U%0^9
M/_S[_P#CXH\R?_GW_P#'Q0!-14/F3_\ /O\ ^/BCS)_^??\ \?% $U5O^8I_
MVQ_]FI_F3_\ /O\ ^/BJ^^7^T<^3\WE8V[ATSUH O45#YD__ #[_ /CXH\R?
M_GW_ /'Q0!-14/F3_P#/O_X^*/,G_P"??_Q\4 345#YD_P#S[_\ CXH\R?\
MY]__ !\4 ,@_X_KK_@'\JLU1A>47ER1#DG;D;AQQ5CS)_P#GW_\ 'Q0!-14/
MF3_\^_\ X^*/,G_Y]_\ Q\4 345#YD__ #[_ /CXH\R?_GW_ /'Q0!-5:?\
MX_K7_@?\J?YD_P#S[_\ CXJO,\IO+8F'!&[ W#GB@"]14/F3_P#/O_X^*/,G
M_P"??_Q\4 345#YD_P#S[_\ CXH\R?\ Y]__ !\4 345#YD__/O_ ./BCS)_
M^??_ ,?% #/^8I_VQ_\ 9JLU1WR_VCGR?F\K&W<.F>M6/,G_ .??_P ?% $U
M%0^9/_S[_P#CXH\R?_GW_P#'Q0!-14/F3_\ /O\ ^/BCS)_^??\ \?% $U5K
MS_EW_P"NRT_S)_\ GW_\?%5[IY3Y&Z'&)5(^8<GTH O45#YD_P#S[_\ CXH\
MR?\ Y]__ !\4 345#YD__/O_ ./BCS)_^??_ ,?% $U%0^9/_P ^_P#X^*/,
MG_Y]_P#Q\4 ,U#_CQD_#^8JS5&^>4V<@:':..=P/<58\R?\ Y]__ !\4 35Y
M[XV^?Q!"O_3!1_X\U=YYD_\ S[_^/BN!\4LTOBB(,F#MC&W/O7FYK_N]O-&-
M?X#T)U#HR'HP(K@? S&/6YXCW@/YAA7=>9/_ ,^__CXK@= 9K;QE)&$RV^5-
MN<=,G^E&-TKT9>=@J_'%GHE5M0_X\9/P_F*CN[\V-K)<SQ;8HQECN!K(_P"$
MGT_4+9XTD$;''$AVGK^M=TJU.,E&4DFS5R2=FSI**A\V?_GW_P#'Q1YD_P#S
M[_\ CXK09-14/F3_ //O_P"/BCS)_P#GW_\ 'Q0!-14/F3_\^_\ X^*/,G_Y
M]_\ Q\4 +<_\>LW^X?Y46W_'K#_N#^513R3&WE!@P-AR=XXXH@DF%O$!!D;!
M@[QSQ0!:HJ'S)_\ GW_\?%'F3_\ /O\ ^/B@":BH?,G_ .??_P ?%'F3_P#/
MO_X^* )JBN?^/6;_ '#_ "I/,G_Y]_\ Q\5'/),;>4&# V')WCCB@"6V_P"/
M6'_<'\JEJK!),+>("#(V#!WCGBI/,G_Y]_\ Q\4 345#YD__ #[_ /CXH\R?
M_GW_ /'Q0!-14/F3_P#/O_X^*/,G_P"??_Q\4 356L_^7C_KLU/\R?\ Y]__
M !\57M7E'G[8<YE8GYAP?2@"]14/F3_\^_\ X^*/,G_Y]_\ Q\4 345#YD__
M #[_ /CXH\R?_GW_ /'Q0!-14/F3_P#/O_X^*/,G_P"??_Q\4 4;K4;?2WN[
MFY8A 448&23CH*XPW$6K^-X9XB6B>:,KD8X4#M^%7/&D[92%EVEW#D9ST7'_
M +-67X45CXCMBJ;BH<XSC^$UX>-KRJ8J-#HFCEJR;FH$_BK35TG5DEM08HIE
MWKM.-K9Y _3\ZV_ ^FF&UFOY%PTWR1Y_NCJ?Q/\ *MR_L8M3C6.\L1*JG*YD
MP0?J*LQF2*-8X[4*B@!5#  "NJEEZAB76Z=%YFD:-I\QE0>&((/$#ZJ)F.69
MQ%MZ,>IS^)K1U6U^VZ5=6^,EXR%^O;]<5-YD_P#S[_\ CXH\R?\ Y]__ !\5
MV1H4XQE&*LG>_P S11232/)4O'339;+^!Y5D_($?U'Y5H:K9?9M$T>;',L;E
MC_P+(_0U/JOAZ\36I!':R+;2/O#@95 3SD]!BMKQE"5T2U @\M(9 B_-G VD
M8_05\]'"U%2JN:^%67WW_KU.-4WRROT.ETR;[1I=I-G)>%6/UQ5JL'PO/,_A
MVTQ#N"AESN Z,:V/,G_Y]_\ Q\5]%0ESTHR[I?D=D7>*9-14/F3_ //O_P"/
MBCS)_P#GW_\ 'Q6I1-14/F3_ //O_P"/BCS)_P#GW_\ 'Q0 S3_^/&/\?YFK
M-4;%Y19QA8=PYYW =S5CS)_^??\ \?% $U%0^9/_ ,^__CXH\R?_ )]__'Q0
M!-14/F3_ //O_P"/BCS)_P#GW_\ 'Q0 MS_QZS?[A_E1;?\ 'K#_ +@_E44\
MDQMY08,#8<G>..*())A;Q 09&P8.\<\4 6J*A\R?_GW_ /'Q1YD__/O_ ./B
M@":BH?,G_P"??_Q\4>9/_P ^_P#X^* )J*A\R?\ Y]__ !\4>9/_ ,^__CXH
M 99_\O'_ %V:K-4;5Y1Y^V'.96)^8<'TJQYD_P#S[_\ CXH FHJ'S)_^??\
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MS)_^??\ \?%5]\O]HY\GYO*QMW#IGK0!>HJ'S)_^??\ \?%'F3_\^_\ X^*
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M_P"7C_KLU6: "BBB@ HHHH *K:?_ ,>,?X_S-6:K:?\ \>,?X_S- %FBBB@
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M6@"S1110 4444 %%%% %;4/^/&3\/YBK-5M0_P"/&3\/YBK- !1110 4444
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MX_KK_@'\JLU6@_X_KK_@'\JLT %%%% !1110 56_YBG_ &Q_]FJS5;_F*?\
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M _NQ(7"^K$ ?TK4\+V U#5FB;[@@DS^(V_\ LU4["T<ZS';.,.DAWC_=Y/\
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MHH *K:?_ ,>,?X_S-6:K:?\ \>,?X_S- %FBBB@ HHHH **** *T'_']=?\
M /Y59JM!_P ?UU_P#^56: "BBB@ HHHH *K?\Q3_ +8_^S59JM_S%/\ MC_[
M-0!9HHHH **** "BBB@"M_S%/^V/_LU6:K?\Q3_MC_[-5F@ HHHH **** "J
MT_\ Q_6O_ _Y59JM/_Q_6O\ P/\ E0!9HHHH **** "BBB@"M/\ \?UK_P #
M_E5FJT__ !_6O_ _Y59H **** "BBB@ HHHH **** "BBB@#F:*** -W3_\
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M_*@"S1110 4444 %%%% %;4/^/&3\/YBK-5M0_X\9/P_F*LT %%%% !1110
M5%<_\>LW^X?Y5+45S_QZS?[A_E0 6W_'K#_N#^52U%;?\>L/^X/Y5+0 4444
M %%%% $5S_QZS?[A_E1;?\>L/^X/Y47/_'K-_N'^5%M_QZP_[@_E0!+1110
M4444 %%%% %:S_Y>/^NS59JM9_\ +Q_UV:K- !1110 4444 %5M/_P"/&/\
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MK-_N'^5%M_QZP_[@_E1<_P#'K-_N'^5%M_QZP_[@_E0!+1110 4444 %%%%
M%:S_ .7C_KLU6:K6?_+Q_P!=FJS0 4444 %%%% !5;3_ /CQC_'^9JS5;3_^
M/&/\?YF@"S1110 4444 %%%% %:#_C^NO^ ?RJS5:#_C^NO^ ?RJS0 4444
M%%%% !5;_F*?]L?_ &:K-5O^8I_VQ_\ 9J +-%%% !1110 4444 5O\ F*?]
ML?\ V:K-5O\ F*?]L?\ V:K- !1110 4444 %5I_^/ZU_P"!_P JLU6G_P"/
MZU_X'_*@"S1110 4444 %%%% %:?_C^M?^!_RJS5:?\ X_K7_@?\JLT %%%%
M !1110 4444 %%%% !1110!S-%%% &[I_P#QXQ_C_,U9JMI__'C'^/\ ,U9H
M **** "BBB@ HHHH **** "JT_\ Q_6O_ _Y59JM/_Q_6O\ P/\ E0!9HHHH
M **** "BBB@"M_S%/^V/_LU6:K?\Q3_MC_[-5F@ HHHH **** "JUY_R[_\
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M6;_</\J+;_CUA_W!_*BY_P"/6;_</\J+;_CUA_W!_*@"6BBB@ HHHH ****
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M_H?Q"';=<K_X^!_\57CXC#QPRH\O26_J<TX*'+;N>A4445[)TA1110!6T_\
MX\8_Q_F:LU6T_P#X\8_Q_F:LT %%%% !1110!%<_\>LW^X?Y46W_ !ZP_P"X
M/Y47/_'K-_N'^5%M_P >L/\ N#^5 $M%%% !1110 4444 5K/_EX_P"NS59J
MM9_\O'_79JLT %%%% !1110 56T__CQC_'^9JS5;3_\ CQC_ !_F: +-%%%
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M(YGN S,JNB@% N 2'R<,<8QSUIVO?$:^T[Q-?:+I7A2^U=K%8_/EA9L*SKN
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M2-HQE@R\9.*\Z\:?!74=:\3W6HZ/=V$-K<R_:3'.\@993R_0-D%LMG(QNQC
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MJ'_2?^F/ZT?Z3_TQ_6@":BH?])_Z8_K1_I/_ $Q_6@":JW_,4_[8_P#LU/\
M])_Z8_K5?]__ &C_ ,L]_E>^,9H O45#_I/_ $Q_6C_2?^F/ZT 345#_ *3_
M -,?UH_TG_IC^M $U%0_Z3_TQ_6C_2?^F/ZT ,O/^7?_ *[+5FJ-UY_[C=Y?
M^M7&,]:L?Z3_ -,?UH FHJ'_ $G_ *8_K1_I/_3']: )J*A_TG_IC^M'^D_]
M,?UH FJM/_Q_6O\ P/\ E3_])_Z8_K5>;S_MEMGR]WS8QG'2@"]14/\ I/\
MTQ_6C_2?^F/ZT 345#_I/_3']:/])_Z8_K0!-14/^D_],?UH_P!)_P"F/ZT
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MHS>?]LML^7N^;&,XZ593S]PW^7M[XSF@"6BBB@ HHHH **** "BBB@ HHHH
MYFBBB@#=T_\ X\8_Q_F:BU:WU&ZL6ATN_AL;ALCSY+;SMH((RJ[E&X'!!.1Q
MR#FI=/\ ^/&/\?YFK- 'FW@[X5W'@W7!J=IKL,Y,/V>2.6Q/,99&;!$O#?(
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MS%/^V/\ [-5FJW_,4_[8_P#LU6: "BBB@ HHHH *K7G_ "[_ /79:LU6O/\
MEW_Z[+0!9HHHH **** "BBB@"MJ'_'C)^'\Q5FJVH?\ 'C)^'\Q5F@ HHHH
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M** "BBB@"M!_Q_77_ /Y59JM!_Q_77_ /Y59H **** "BBB@ JM_S%/^V/\
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M\MF?'T7 _GFO SB;E.,%T5_OT.3$.[2.L\)OGP_?1_W9E;\\?X5VM<#X1?\
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MFYEJJ:_O(QK=/4]!(R"#T-<!X&)37)T/_/!OS#+7H%>?>%?W7BV9/:1?U_\
MK48S3$47YL*GQQ/0:***](V"JW_,4_[8_P#LU6:K?\Q3_MC_ .S4 0ZUJ TS
M29[G(WA<(/5CP*\F9F8DLQ))R23U-=-XJUM-7GAL[/<\<;G)Q]]^@Q_GO6-<
M:>UIK(L'.YA(J'WSC_&OF<RK.O5]S6*T^;.*M+FEILC;\$W;6VL2V<F5$RD;
M3V=>?Y9KT"O._$"-H_BU;R,85F6<8[_WA^8/YUWUO=V]TI:WGCE Z[&!Q]:]
M/+I<BE0D]8O\#:B[7@^AF^*FV>&KP^RC\V K$\+P";PEJ2L,AVD7_P <%:OC
M%MOAN<?WF0?^/ _TJ#P9%N\..IZ/*_\ ("E47-CDO[K_ !"6M6WD9/@)O].N
MU]8P?UKNZ\^\#.(]7N0Y"C[.223TPRUT]WXKTBT?8;GS6SR(1NQ^/2C+ZT(8
M6+FTM_S"C)*FKLVJ*9#-'<0I-$P>-U#*P[@TRZF%M9SSGI'&S_D,UZ?,K<W0
MWOU'I+'(S*DB,R'#!6!*_6GUYIX3O6M_$4>]B1<9C8D]2>1^H%>EURX/%+$T
M^>UM3.G/G5PJM/\ \?UK_P #_E5AF"J68@ <DGM5.2:)[FUE21&CPYWA@1T]
M:ZKHT.*\+_/XOE;_ *Z']:[36;?[5HMY#C):)B/J!D?J*XOP9^\\1S/_ -,G
M/_CPKT(@$8/2O,RV*GAI)]6S"BKP9X[:VKW3R*G_ "SB>0_11FNR\$7J1Z9>
MQRN%2!O-)/92.?\ T&M#2_"EOIEU<3><TJRHT:H5QM4]>>]<")Y]/-[: X\P
M&&3\&'^&/QKSHTYX"4*LUJ^;_@&*3I-2?F>G:7K-GJZR&U=CY9PP88//0UH5
MYUX)NO)UPPD\3QE<>XY'\C7HM>S@<0\11YY;G32GSQNRK.<7MJ3T^?\ E7,:
M=XKN+WQ*+;Y/L<CE$&.1UP<^_P#6M3Q3=&TTXR X8HZ#ZL /ZUP.C$KKE@1Q
M_I$8_P#'A7+C\5.G6IP@^MW]]C.K4:DDCUNBBBO6.@**** "BBB@ HHHH **
M** .9HHHH W=/_X\8_Q_F:LU6T__ (\8_P ?YFK- !1110 4444 %%%% !11
M10 56G_X_K7_ ('_ "JS5:?_ (_K7_@?\J +-%%% !1110 4444 5O\ F*?]
ML?\ V:K-5O\ F*?]L?\ V:K- !1110 4444 %5KS_EW_ .NRU9JM>?\ +O\
M]=EH LT444 %%%% !1110!6U#_CQD_#^8JS5;4/^/&3\/YBK- !1110 4444
M %5H/^/ZZ_X!_*K-5H/^/ZZ_X!_*@"S1110 4444 %%%% %:?_C^M?\ @?\
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M48! Y')%8G@V)KS7Y[V3DQJSD_[3'_#->3BZL*U:E3@[M2U^1SU)*4HQ7<]
MKS[1OW7CZ1/6>9?_ $+_  KT&O/;O_0?B K= UPAS[,!G^9K3,='2GVDBJVG
M*_,]"HI&8*I9B !R2>U5;K5+.SL_M<MPGD]F4YW'T&.M>A*48J\G8U;2W+=9
MU_-]GDN9LX\NT9ORJ$>)=-.E'4/,?R0_EE=OS;O3'TYK%UCQ!87NG7;6TX+O
M;A C#:V2XR.>O'I7/5Q5)0;4E>UUKZD2J1MN4/!%A#=7T]Q-&'-N%*9[,<\_
MI7277AF"ZU^/5&F8;2K-%M^\R]#GMT%4? D.W2[B;'+S;?P '^)KJJY\#AJ<
ML+#G7G_D12@G!7.9\9:5-?V4$]M$TLL+$%4&25/MWY KF_#4\VE>)(H;A&B,
MO[IT88(W<KD?7%>E5Y_XSC:UU^"Z3@M&K _[2G_]58YA05*:Q47JFKDUH\K]
MHC1\=7WEVUO8J!^\/F,?0#I_7\JT?!R[?#<!_O,Y_P#'B/Z5R=Q-+XK\1Q>7
M"PB^5,==J \D_F:]%M[>*TMT@@0)$@PJCM5X1NOBIUU\.R'3]Z;GT/)II'M;
MJ]B7C>6B/TW _P!*OC14_P"$5;5BS^9YF O\.W.,_G1K&CZ@-;NUCLYW#RM(
MA2,L"I/!XKKKC3F@\#/:.N'CM][#T8?,?UKS:&%E.5136D4[>IC&FVW?H)X,
MNTET*. R*9(F8;,\XSG./3FI_$][%#H5[&LJ&4J%V!AG!('3Z&O/-/AOY)]V
MGI.95X+0@Y7/')'2F7MK<65Y);W0Q,N"PSGJ,]?QK19C-8;DY.EK]/\ ARO;
M/DM82+S;4P7:C&'RA]U(/]17:>(?$]S8W5FMEL\N2%9CN7.X$G _3]:S+S3O
M^*$L;@+\\<A=C_LL2/\ XFL1)&U"[L89!G:$@^HW<?H:P4ZF&BZ<79R46B+N
M"LNMCH=<\76^I:0UK;13QR2$;RX&,=2 0?I7-QWUU%:/9H[".0YV]^1SCZ\5
MZ+_PB>A@_P#'C_Y%?_&I)])L/[6LI_LL8D4$ C_9'''3BO0J8'%59\\YJ^VE
M]NILZ523NV5O"^A_V59^=,O^ES ;O]@=E_Q_^M6_117K4:4:4%".R-XQ459!
M7G?B#0;Y_$$[6UI+)%.P=7125R>N3VYSUKT2BLL5A8XF*C)VL*I34U9GF^LV
MA\/:_:S0#Y%5'7'<KPP_''ZUV^H:Y8Z;;0SSR-LF_P!6$&21C.?IR*RO&]E]
MHTA+E1EK=\G_ '3P?UQ7$7NHR7EK90/G%M&4'OR?Z8'X5Y52L\#4J0AULT<\
MI>R;2.A\9ZI'>R6EI;-O7:)25[[ONC\N?QK4M?"*)_9<YG,<]KM:1=N0Y#;L
M9SQR2,USGA.R%YKD4D@W1P_,<^H'R_R_2O2ZWP=+ZTY8BLM[6^7_  2Z<>>\
MY!1117KG0%%%% !1110 4444 %%%% ',T444 ;NG_P#'C'^/\S5FJVG_ /'C
M'^/\S5F@ HHHH **** "BBB@ HHHH *K3_\ ']:_\#_E5FJT_P#Q_6O_  /^
M5 %FBBB@ HHHH **** *W_,4_P"V/_LU6:K?\Q3_ +8_^S59H **** "BBB@
M JM>?\N__79:LU6O/^7?_KLM %FBBB@ HHHH **** *VH?\ 'C)^'\Q5FJVH
M?\>,GX?S%6: "BBB@ HHHH *K0?\?UU_P#^56:K0?\?UU_P#^5 %FBBB@ HH
MHH **** *T__ !_6O_ _Y59JM/\ \?UK_P #_E5F@ HHHH **** "JW_ #%/
M^V/_ +-5FJW_ #%/^V/_ +-0!9HHHH **** "BBB@"M>?\N__79:LU6O/^7?
M_KLM6: "BBB@ HHHH *K3_\ ']:_\#_E5FJT_P#Q_6O_  /^5 %FBBB@ HHH
MH **** *VH?\>,GX?S%6:K:A_P >,GX?S%6: "BBB@ HHHH *BN?^/6;_</\
MJEJ*Y_X]9O\ </\ *@ MO^/6'_<'\JEJ*V_X]8?]P?RJ6@ HHHH **** (KG
M_CUF_P!P_P J+;_CUA_W!_*BY_X]9O\ </\ *BV_X]8?]P?RH EHHHH ****
M "BBB@"M9_\ +Q_UV:K-5K/_ )>/^NS59H **** "BBB@ JMI_\ QXQ_C_,U
M9JMI_P#QXQ_C_,T 6:*** "BBB@ HHHH K0?\?UU_P  _E5FJT'_ !_77_ /
MY59H **** "BBB@ JM_S%/\ MC_[-5FJW_,4_P"V/_LU %FBBB@ HHHH ***
M* *UG_R\?]=FJS5:S_Y>/^NS59H **** "BBB@ JM_S%/^V/_LU6:K?\Q3_M
MC_[-0!9HHHH **** "BBB@"M!_Q_77_ /Y59JM!_Q_77_ /Y59H **** "BB
MB@ JM/\ \?UK_P #_E5FJT__ !_6O_ _Y4 6:*** "BBB@ HHHH K?\ ,4_[
M8_\ LU6:K?\ ,4_[8_\ LU6: "BBB@ HHHH *K7G_+O_ -=EJS5:\_Y=_P#K
MLM %FBBB@ HHHH \^UC]]X^CC[":%?\ T'_&O0:\^;]]\0_I<#_QT?\ UJ]!
MKS<OUE5EWD8T=Y/S/--/_=>*+E/]N1?U_P#K4_QI)O\ $+K_ ,\XU7^O]:;C
MR_&LX];B7]<U5\2R>;XBO6]'V_D /Z5Y565L)*']]G/)VIM>9J>#]&M]1EFN
M[I3(L+ *AZ,>N3ZUZ !@8'2N;\$0^7H3/CF29F_  #^E=)7LY=2C##Q:6KU9
MTT8I004445W&H5C^*1GPW>C_ &5/_CPK8K+\2#=X=O1_TSS^HK*NKTI+R?Y,
MF?PLR/ ;9TNY7TFS_P".C_"NKKC_  "V;:]7T=3^A_PKL*Y\O=\-#^NK)H_
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M "BBB@"MJ'_'C)^'\Q5FJVH?\>,GX?S%6: "BBB@#-UO2(]:L?LSR&,JP=7
MS@].GXU7T_PMI=BD9:!9YT',DF3D^NW.!6U16,L/2E/VDHILEPBW=H\[\3(-
M,\61W,:[0=DP ]C@_P#H-=QINIVVJVOVBU8E-VTAA@@^AKG/&^FW%S]EN;>!
MY=@99-BY('4'CMUJCX1U+[%I^JDX/E1B95/<@$?_ !->73J/#XR=-_#*[_"_
M^9A&7)4:Z,I*//\ &L ]+B/],?X5U'C6#S= ,F.895;\^/ZUS7AB"YO_ !''
M>&,LB,7D<# !P<?K79^(H_,\/7RXSB,M^7/]*,/'VN&K2M\3;""YH2?<I^#)
M_.\/(F>89&3_ -F_K705R/@*3-E>1_W9 WYC_P"M775WX&7-AH/R-:3O!!14
M%W=PV-K)<W#[8HQDFJ^GZQ9:G")+>8<DC8YPW'7BNAU(*7(WJ7=7L<]XMU^\
ML;Q+*TD6,&/=(VT$G.>.?;^=6?!^L76I17$-TP=H0NU@ #@YXX^E<SJKKJ_B
MJ;RV#QEL*0<@A5YQ^1K2\!-B_NT]8@?R/_UZ\2EB:DL;\7NMM>6B.6,Y.KOH
M;/C2Y:WT$HAQYTBQGZ<G^E<C<Z>L'A2SO/XYKALGVP0!_P".D_C70^/9,6=G
M'_>D9OR'_P!>FZA9F3X?6N!S$J38^O7]&-/%P]K7J_W8CJ+FE+R1N^')/,\.
MV3>D>W\B1_2M2N;\$W7G:&82>8)"N/8\_P R:Z2O5PD^>A"7DC>F[Q3"BBBN
M@LK6?_+Q_P!=FJS5:S_Y>/\ KLU6: "LKQ*_E^';UO5-OYD#^M:M<[XUF\KP
M^4S_ *V55_F?Z5SXJ7+0F_)D5':+.?\ "OAZWU5'NKIF:*-]GE#C<< \G\:B
M>"/1_'$44*[(5F0*,DX5@/7ZFNG\&0^5X>1\?ZV1G_7']*P?&T$EOK-O>JIV
M.@PW^TI_PQ7CSP\:6#IU8K5--_U]QSN"C34D=]5;3_\ CQC_ !_F:-/O8]1L
M(;N+[DBYP>QZ$?G1I_\ QXQ_C_,U[\9*236S.M.^I9HHHI@%%%% !1T&3157
M4Y##I5Y*.J0.P_!32D^5-]A-V1P&@6<&M^(IS=1^9$P>5ER1G)]1]:[ZPTRS
MTR-TLX!$KG+<DD_B:Y+P#&#/?2]U5%_,G_"NXKS<LI1]BJC7O-O4QH17+S=0
MK@O&UO);ZQ;WJJ=CH &_VE)_IBN]JKJ-A#J=C):SCY7'![J>Q%=.,H.O2<%O
MNOD:5(<\;'->(]>AN_#$36S8-TVUESRN.6!_''YUSVE>'M1U5D79)#;8W"20
M';@_W?7/M5#4+*?3KR2TGR&C/'H0>X^M>L6,7D6%M#C'EQ*OY "O)HTWCJ[=
M;3E25CGBO:R][H>1-++'#):EOD\P,R_[0R/ZFM>?PY/_ &=:W-HLDSR0B1XP
M,D GMCKVK-U./RM5O(_[L[C_ ,>->G6,7D26T.,>7:*OY8%8X'"1KRG"?31>
M6K)I4U-M,@\,64MCH4,4Z%)6+.RGJ,GC/X8K8HHKZ.E35."@NAV15E8*Q]>T
M"/7$A!G,+Q$X8+NR#C(QD>E;%%%2G&I%PFKIA**DK,I:9I5KI-L(;9,9^^Y^
M\Y]35VBBG&$8148JR0))*R*W_,4_[8_^S5890ZE6 *D8(/<57_YBG_;'_P!F
MJS5#*ECIEGIJ.MG L0<Y;!)S^=9NN>&+?69EG$I@G'#.%W!A[C(Y]ZW:*RG0
MISA[.4=.Q+A%JS6ABZS9I;^$KBUCSLB@ &?]G'^%<!H2>9KUBO\ TW4_D<UZ
M?J4#7.EW<"#+R0NJCW(.*X3PUH]_'K]O)/9SQ1Q$LS2(5'0XY/7G%>3CZ+>(
MI<JTT_!F%6/OQL>BU6G_ ./ZU_X'_*K-5I_^/ZU_X'_*O;.DLT444 %%%% %
M>_MQ=:?<6Y&?,C9?S%>9>']-35=7CMI=WE;69]IP0 /\<5ZK5.TTJQL;B6>V
MMUCDE^^P)Y[_ (?A7#BL'[>I";V6_H95*?/),J6.DVVD26T%L&(+.S,YRS''
M>M>JT_\ Q_6O_ _Y59KLA",(J,59(T225D%%%%4,**** "BBB@ HHHH ****
M .9HHHH W=/_ ./&/\?YFK-5M/\ ^/&/\?YFK- !1110 4444 %%%% !1110
M 56G_P"/ZU_X'_*K-5I_^/ZU_P"!_P J +-%%% !1110 4444 5O^8I_VQ_]
MFJS5;_F*?]L?_9JLT %%%% !1110 56O/^7?_KLM6:K7G_+O_P!=EH LT444
M %%%% !1110!6U#_ (\9/P_F*LU6U#_CQD_#^8JS0 4444 %%%% !5:#_C^N
MO^ ?RJS5:#_C^NO^ ?RH LT444 %%%% !1110!6G_P"/ZU_X'_*K-5I_^/ZU
M_P"!_P JLT %%%% !1110 56_P"8I_VQ_P#9JLU6_P"8I_VQ_P#9J +-%%%
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M&Q7H->?>%/WWBR:7_9D?\S_]>O0:\W*]:4I=Y,QH?"WYGF]\/+\;R_\ 7?\
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M%;\3+#ZR9?HHHKZ ZRM!_P ?UU_P#^56:K0?\?UU_P  _E5F@ HHHH ****
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M \;C#*>XKT*E%2HNDNUC9QO'E.7\&:M;&P73GE"W"LQ16XW \\>_7BNCT_\
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M>CKYUM/BGXPTZTL=8O-334+8W4T,EF]M''O$:1,?G5003YW&!P5!.X'%?15
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M45#_ *3_ -,?UH_TG_IC^M $U%0_Z3_TQ_6C_2?^F/ZT 345#_I/_3']:/\
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M,?UH_P!)_P"F/ZT 356_YBG_ &Q_]FI_^D_],?UJO^__ +1_Y9[_ "O?&,T
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M>KD_K7KK-<JI8^3@#/>O'2<G)KESIZ07K^AGB>AZ/X*&/#X/K*Q_E715SGA
M3CP]$4\O:7<\YSUK=_TG_IC^M>G@U;#P]$;T_@0MS_QZS?[A_E1;?\>L/^X/
MY5%/]H^SR[O*QL.<9]*(/M'V>+;Y6-@QG/I7266J*A_TG_IC^M'^D_\ 3']:
M )J*A_TG_IC^M'^D_P#3']: )JBN?^/6;_</\J3_ $G_ *8_K4<_VC[/+N\K
M&PYQGTH EMO^/6'_ '!_*I:JP?:/L\6WRL;!C.?2I/\ 2?\ IC^M $U%0_Z3
M_P!,?UH_TG_IC^M $U%0_P"D_P#3']:/])_Z8_K0!-5:S_Y>/^NS4_\ TG_I
MC^M5[7S_ -_M\O\ UK9SGK0!>HJ'_2?^F/ZT?Z3_ -,?UH 8VG63ERUG;L7;
M<V8E.X^IXY-60 !@<"H?])_Z8_K1_I/_ $Q_6DHI;(+$U%0_Z3_TQ_6C_2?^
MF/ZTP&0?\?UU_P  _E5FJ,/G_;+G'E[OESG..E6/])_Z8_K0!-14/^D_],?U
MH_TG_IC^M $U%0_Z3_TQ_6C_ $G_ *8_K0 S4/\ CQD_#^8JS5&^\_[')O\
M+V\9QG/458_TG_IC^M $U%0_Z3_TQ_6C_2?^F/ZT 345#_I/_3']:/\ 2?\
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MVSY>[YL8SCI5E//W#?Y>WOC.: ):*** "BBB@ HHHH **** "BBB@#F:***
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M !_6O_ _Y59H **** "BBB@ JM_S%/\ MC_[-5FJW_,4_P"V/_LU %FBBB@
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MT'_']=?\ _E5FJT'_']=?\ _E5F@ HHHH **** "JT__ !_6O_ _Y59JM/\
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M\?UU_P  _E5FO6.@**** "BBB@ JM_S%/^V/_LU6:K?\Q3_MC_[-0!9HHHH
M**** "BBB@"M_P Q3_MC_P"S59JM_P Q3_MC_P"S59H **** "BBB@ JM/\
M\?UK_P #_E5FJT__ !_6O_ _Y4 6:*** "BBB@ HHHH K3_\?UK_ ,#_ )59
MJM/_ ,?UK_P/^56: "BBB@ HHHH **** "BBB@ HHHH YFBBB@#=T_\ X\8_
MQ_F:LU6T_P#X\8_Q_F:LT %%%% !1110 4444 %%%% !5:?_ (_K7_@?\JLU
M6G_X_K7_ ('_ "H LT444 %%%% !1110!6_YBG_;'_V:K-5O^8I_VQ_]FJS0
M 4444 %%%% !5:\_Y=_^NRU9JM>?\N__ %V6@"S1110 4444 %%%% %;4/\
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M-5M/_P"/&/\ '^9H LT444 %%%% !1110!6@_P"/ZZ_X!_*K-5H/^/ZZ_P"
M?RJS0 4444 %%%% !5;_ )BG_;'_ -FJS5;_ )BG_;'_ -FH LT444 %%%%
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MHHHH **** "BBB@"M/\ \?UK_P #_E5FJT__ !_6O_ _Y59H **** "BBB@
MJM_S%/\ MC_[-5FJW_,4_P"V/_LU %FBBB@ HHHH **** *UY_R[_P#79:LU
M6O/^7?\ Z[+5F@ HHHH **** "JT_P#Q_6O_  /^56:K3_\ ']:_\#_E0!9H
MHHH **** "BBB@"MJ'_'C)^'\Q5FJVH?\>,GX?S%6: "BBB@ HHHH *BN?\
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M*** "BBB@"M9_P#+Q_UV:K-5K/\ Y>/^NS59H **** "BBB@ JM_S%/^V/\
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MK#_N#^52T %%%% !1110 56L_P#EX_Z[-5FJUG_R\?\ 79J +-%%% !1110
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MS0 4444 %%%% !5;_F*?]L?_ &:K-5O^8I_VQ_\ 9J +-%%% !1110 4444
M5K/_ )>/^NS59JM9_P#+Q_UV:K- !1110 4444 %5O\ F*?]L?\ V:K-5O\
MF*?]L?\ V:@"S1110 4444 %%%% %:#_ (_KK_@'\JLU6@_X_KK_ (!_*K-
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MK_P/^56:J7.[[9:[,;OGQGITH MU@^,3CPW/[LG_ *$*V/\ 2?\ IC^M8/C
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M]15C_2?^F/ZT 345#_I/_3']:/\ 2?\ IC^M $U%0_Z3_P!,?UH_TG_IC^M
M$U5H/^/ZZ_X!_*G_ .D_],?UJO#Y_P!LN<>7N^7.<XZ4 7J*A_TG_IC^M'^D
M_P#3']: )J*A_P!)_P"F/ZT?Z3_TQ_6@":BH?])_Z8_K1_I/_3']: &3_P#'
M]:_\#_E5FJ,WG_;+;/E[OFQC..E6/])_Z8_K0!-14/\ I/\ TQ_6C_2?^F/Z
MT 345#_I/_3']:/])_Z8_K0!-5;_ )BG_;'_ -FI_P#I/_3']:K_ +_^T?\
MEGO\KWQC- %ZBH?])_Z8_K1_I/\ TQ_6@":BH?\ 2?\ IC^M'^D_],?UH FH
MJ'_2?^F/ZT?Z3_TQ_6@!EY_R[_\ 79:LUF/<_:EB:*>VE59PN8GW -Z&KO\
MI/\ TQ_6@":BH?\ 2?\ IC^M'^D_],?UH FK'U[Q/I?AN%7U"<AWSLBC&YW^
M@_J<5>GFFMX))Y6A6.-2[L<\ #)->)F6Z^(?CF(M$5A<A2HSB.%>3D]L\_B:
MZ*%)3;<MD95:CC9+=G>V_P 5_#T]PD317T(8X\R6-=J_7#$_I77S'-[:$=/G
M_E7FWBSX:MY5M)X=L(PP8K-&)SD@XP<NW;G\ZI_#G6M0CU[^P[J4NJB3RUE.
M?+<#Y@#Z8!X]JTG1IRASTGMNB(U)1ERS/7Z*A_TG_IC^M'^D_P#3']:XSH)J
M*A_TG_IC^M'^D_\ 3']: )J*A_TG_IC^M'^D_P#3']: &:A_QXR?A_,59JC?
M>?\ 8Y-_E[>,XSGJ*L?Z3_TQ_6@":BH?])_Z8_K1_I/_ $Q_6@":BH?])_Z8
M_K1_I/\ TQ_6@":HKG_CUF_W#_*D_P!)_P"F/ZU'/]H^SR[O*QL.<9]* );;
M_CUA_P!P?RJ6JL'VC[/%M\K&P8SGTJ3_ $G_ *8_K0!-14/^D_\ 3']:/])_
MZ8_K0!-14/\ I/\ TQ_6C_2?^F/ZT +<_P#'K-_N'^5%M_QZP_[@_E44_P!H
M^SR[O*QL.<9]*(/M'V>+;Y6-@QG/I0!:HJ'_ $G_ *8_K1_I/_3']: )J*A_
MTG_IC^M'^D_],?UH FHJ'_2?^F/ZT?Z3_P!,?UH 99_\O'_79JLU1M?/_?[?
M+_UK9SGK5C_2?^F/ZT 345#_ *3_ -,?UH_TG_IC^M $U%0_Z3_TQ_6C_2?^
MF/ZT 356T_\ X\8_Q_F:?_I/_3']:KV/G_8X]GE[><9SGJ: +U%0_P"D_P#3
M']:/])_Z8_K0!-14/^D_],?UH_TG_IC^M $U%0_Z3_TQ_6C_ $G_ *8_K0 R
M#_C^NO\ @'\JLU1A\_[9<X\O=\N<YQTJQ_I/_3']: )J*A_TG_IC^M'^D_\
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M_'^9JS5;3_\ CQC_ !_F:LT %>?6'PAT72+V6[TG5=:T^21)(A]FN4&R-^J
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M:7WZ$T[TVK[,]"HHHKWCK*W_ #%/^V/_ +-5FJW_ #%/^V/_ +-5F@ HHHH
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M*?\ ;'_V:@"S1110 4444 %%%% %:S_Y>/\ KLU6:K6?_+Q_UV:K- !1110
M4444 %5O^8I_VQ_]FJS5;_F*?]L?_9J +-%%% !1110 4444 5H/^/ZZ_P"
M?RJS5:#_ (_KK_@'\JLT %%%% !1110 56G_ ./ZU_X'_*K-5I_^/ZU_X'_*
M@"S1110 4444 %%%% %;_F*?]L?_ &:K-5O^8I_VQ_\ 9JLT %%%% !1110
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MB23CVJY!8VEK+++;VL$4DIS(\<84N?<CK7GUYXXU;4I_(TFW,0;[H5/,D/\
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MIU+OEEN:?_,4_P"V/_LU6:K?\Q3_ +8_^S59KTC<**** "BBB@ JM>?\N_\
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M_@'\JLT %%%% !1110 56_YBG_;'_P!FJS5;_F*?]L?_ &:@"S1110 4444
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MKT]G N%5E5%^JC'\ZW? EHLEU=7;\M&H1<^^<G]/UK>U'1+.75K;4F#^=YJ
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M&6,E[6Z,F?E";6'XG(Q^1JI%\5TFNU"V48B)QL+G?^>,5JL)6?0S>)I)7O\
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M)8X KS.]\5ZWX@N$M=,BDMP3PENQ+GZMQ@?E2CPGXHU.0)?RNJ#HUQ<^8!]
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MM?\ @?\ *K-5I_\ C^M?^!_RH XOQY)G4;6/^[$6_,__ %JPM:L_L.K3V^,
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MUW6-"[L%4<DL< 5E?\)1H8D\O^TH-V[;UXS]>F/>J492V1,IQC\3L:]5I_\
MC^M?^!_RJ6*>&==T,J2+ZHP(_2HI_P#C^M?^!_RJ2BS1110 4444 %%%% '!
M^/O!#:])%J-E)##=( DWF9 =>QX!Y'\OI75Z#I$6A:):Z;$VX0IAGQC<Q.6/
MXDFK&H?\>,GX?S%6:TE5E*"@WHB5"*DY+<****S*"BBB@ K'\56WVSPGJL(&
M6-L[*/4@9'ZBMBHKG_CUF_W&_E3B[-,35U8\Q^#]\@.IV#-\YV3(OJ.0Q_\
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MQ,Y'[Q0<'CL>0<5@VOPAL?[. N]0N/MQ4Y:+;Y2GZ$9(_$9]JX_4](U;X?\
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MGX6\1P1?98[&20*,6\D2AT]MI';VXIE]XNT7P_'+]KN0SM<,HBAP[#&,Y Z
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MJ%Z#\JU:*:G);,3A%[HH1VEM=K,MS;Q3*L[$"1 P!_&KX    P!5:S_Y>/\
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M/J0,5-<ZC96<;/<7448"[\,XR1Z@=37G5KX"UB[1Y;IXK>3/ D?<6]\C-/\
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M;Q?J?^ER?:=Z\H))MC9]AD8_2B/P-K]Z6FN7ACE)Y\^8LS>^5!_G7H_^G?\
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MW_\ 'J +-%5O]._Z=_\ QZC_ $[_ *=__'J +-%5O]._Z=__ !ZC_3O^G?\
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M1*E>T9:K\K#Y81ER36FZ.JDT?3)6W2:=:.?5H%/]*6XC2&.UCB14195"JHP
M/85<JM>?\N__ %V6O6<F]V=*BELB6:"*YB:*>))8VZHZA@?P-,@LK2U_X][6
M&'_KG&%_E4]%%W:P65[A1112&%%%% %;4/\ CQD_#^8JS5;4/^/&3\/YBK-
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M4>@"X%7:[Z<>2"CV2-HJR2"BBBK&%%%% !5;_F*?]L?_ &:K-5O^8I_VQ_\
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MY59JM/\ \?UK_P #_E5F@ HHHH **** "BBB@ HHHH **** .9HHHH W=/\
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MFBBB@ HHHH **** *T__ !_6O_ _Y59JM/\ \?UK_P #_E5F@ HHHH ****
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M'/S8_"N\(R,'I5RQ4*<OW2WW)5&4E[[/#M&^(>MZ#:Q6LMM#-;A0$$J%6P
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M@"S1110 4444 %%%% %;_F*?]L?_ &:K-5O^8I_VQ_\ 9JLT %%%% !1110
M56G_ ./ZU_X'_*K-5I_^/ZU_X'_*@"S1110 4444 %%%% %:?_C^M?\ @?\
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M** "BBB@"M9_\O'_ %V:K-5K/_EX_P"NS59H **** "BBB@ JMI__'C'^/\
M,U9JMI__ !XQ_C_,T 6:*** "BBB@ HHHH K0?\ ']=?\ _E5FJT'_']=?\
M /Y59H *YS7_  3H_B.]AN[U9EFC&TF%POF+V#<'],&NCHJHRE%WB["<5)69
MR^E^ -"TC61J=K'-YB9\N-Y-R1GID9&<_4FNHHHHE.4W>3N"BH[!5;_F*?\
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MHMO^/6'_ '!_*@"6BBB@ HHHH **** *UG_R\?\ 79JLU6L_^7C_ *[-5F@
MHHHH **** "JVG_\>,?X_P S5FJVG_\ 'C'^/\S0!9HHHH **** "BBB@"M!
M_P ?UU_P#^56:K0?\?UU_P  _E5F@ HHHH **** "JW_ #%/^V/_ +-5FJW_
M #%/^V/_ +-0!9HHHH **** "BBB@"M_S%/^V/\ [-5FJW_,4_[8_P#LU6:
M"BBB@ HHHH *K3_\?UK_ ,#_ )59JM/_ ,?UK_P/^5 %FBBB@ HHHH ****
M*T__ !_6O_ _Y59JM/\ \?UK_P #_E5F@ HHHH **** "BBB@ HHHH ****
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M5)J'_'C)^'\Q5FH]G'GY[:]Q65[A1115C"BBB@ JM!_Q_77_  #^56:K0?\
M']=?\ _E0!9HHHH **** "BBB@"M/_Q_6O\ P/\ E5FJT_\ Q_6O_ _Y59H
M**** "BBB@ JM_S%/^V/_LU6:K?\Q3_MC_[-0!9HHHH **** "BBB@"M>?\
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M?F@!#/NR9#P <>N/YTJN;0Y9*GO;1_UV%+$*SL>AVFI0ZKH[W4&0K(P*GJI
MY%7+;_CUA_W!_*O.M+OKKP]J,UC=@I%(-LBGG!(X8?I^%=O'K6F164+O?0;=
MH7AP3G'H*Z\+C(U*?[QVDM[Z&E.HI+7<TZ*@FNX(;)[MI 8%3?N7G(]JYK3?
M&8OM72VDMEB@E.U&W98'MGZUM4Q-*G*,9/5[%RG&+2?4ZRBBL]=<TII'3^T+
M<,AP=T@7\L]?PK64XQ^)V&VEN:%%4H=8TZXN?LT-Y#)+C.U6SGZ'H:R=7\7V
M>GEHK8"ZG'!VGY%^I[_A64\32A'GE)6$YQ2NV;5G_P O'_79JLUYW_PE^IR
MQVD,:2.Y<E5+D_04C>,]85E#+"I0_,/+QN]CS_+%<CS7#KO]QG]8@>BT5DV'
MB+3;RSCG>Z@@=A\T<LH4J?QK3BECFC$D4BR(>C*<@_C7?"K"HKQ=S523V'T4
M458PJMI__'C'^/\ ,U9JMI__ !XQ_C_,T 6:*** "BBB@ HHHH K0?\ ']=?
M\ _E5FJT'_']=?\  /Y59H **** "BBB@ JM_P Q3_MC_P"S59JM_P Q3_MC
M_P"S4 6:**Q/$^K_ -E:6WEMBXF^2/'4>K?A_/%9U:D:4'.6R%*2BKLVZ*\[
M\->(AI@NUO))'C*;T4DDE\]!Z9S^E2ZGXUEOK&2V@M3;L_!D$N2!W["N%9I0
M]GSO1]C)5X\MV=_4%W>VUA 9[J98HP<9;U_K7G&G>)-3TB%K=0'5L,JS*25S
MSQR.O6IO(UKQ3?1>>KK&/XRA5$'<CU-9_P!J*<;4HMS?0GV]U[JU.UT?4;2^
M$YMITD_>LV.AP>^#S6G7GESX6O[-WN=,D>7RG*@*<2#'<8Z_A37OO%LJ!2E\
M .?EM]I_,+5?7ZE/W:U-W\M4/VK6DD=3XJU,:?H\B*^)YQY: =<=S^7\Q6)X
M.T+>8M7E<C:S"*/'7C&<_G^55[+PKJ>K3BYU25XE;D^8<R$?3M^/Y5W<,,=O
M D,2A8T4*JCL*5*G/$U_;U8VBMD_S",7.7-):$E%%%>J;A5;_F*?]L?_ &:K
M-5O^8I_VQ_\ 9J +-%%% !1110 4444 5H/^/ZZ_X!_*K-5H/^/ZZ_X!_*K-
M !1110 4444 %5I_^/ZU_P"!_P JLU6G_P"/ZU_X'_*@"S1110 4444 %%%%
M %;_ )BG_;'_ -FJS5;_ )BG_;'_ -FJS0 4444 %%%% !5:\_Y=_P#KLM6:
MK7G_ "[_ /79: +-%%% !1110 4444 5M0_X\9/P_F*LU6U#_CQD_#^8JS0
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MM+]F,DZ2%FE'#G@K@!LKC!SMSG!&.TT+XC6-[\/)?%&HKY;69,5Y%;HS8ER
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M/]H^SR[O*QL.<9]* ,#Q=!YOA>"3',3(V?8C']17&KK&H+:):)<R+ J%-BG
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M_2?^F/ZT?Z3_ -,?UH FHJ'_ $G_ *8_K1_I/_3']: )JK7G_+O_ -=EI_\
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M@_E4M16W_'K#_N#^52T %%%% !1110!%<_\ 'K-_N'^5%M_QZP_[@_E1<_\
M'K-_N'^5%M_QZP_[@_E0!+1110 4444 %%%% %:S_P"7C_KLU6:K6?\ R\?]
M=FJS0 4444 %%%% !5;3_P#CQC_'^9JS5;3_ /CQC_'^9H LU!>V<-_9R6MP
MI,<@P<=1Z$5/12:4E9[ U<YK3O!EG979GGE-TH^Y&Z8 ^O/-8WC*U:RUFWOX
M1M\P @CLZX_IBN^K \86?VK0)' R\#"0?3H?T/Z5YV*P=..&E&FK6U^XQJ4T
MH-1-FSN4O+.&Y3[LJ!Q[9%<%@:GX_((#*+CD'H0@_P#L:U?"FM6\.A20W$Z*
M]L6949@"RXSQZ\YK.\%0M<ZY<7;C.Q"2?]IC_P#KK"M66)]A%=7=_(B4N?E1
M;UCPO:%-1N+42))"HD6-2-O3)XQGIFN4M;2\EBEN[5'(MB&9DZKZ']*]5A_X
M_KO_ (!_*I8+:"V4K!#'$I.2(U"@G\*UKY73J5%*/NKR[]RIT%)W6ASGA_Q9
M%>IY&H,D,R+GS68*K_GT-=+%-'/&)(I$D0]&1@17$:IX0O+C7':U5%M)FWER
MP^3/48Z]?2J%YI.K^&'%U#.?*W >9$QQ[!A_^L5G#%XFA%JM!M+J)5)Q7O+8
M])K.U;6;71X5>X8[GR$11DG']*X6/Q=JJ7[7)D#*1CR3]P<>E,G@USQ$S7CV
M\DBHGRD+M7'7"^OZFG/-%.#5"+<O3\0=>Z]U:E:UL;G6%O[HR%G@C\UR>2Y]
M/RS^55+2TN+^Y2VMT,DK9VKG'3GO7>^#--GL=/GDN86BDF<85Q@[0.,C\36K
M#9VMMJI,%M#$3#R8XPN?F]JYJ65NK"$Y.U]^^Y$:',DV<%=:1XCCM4AGANY(
M!@+&LGF 8Z< G%=WH-@=-T:WMV7$FW=(/]H\G\NGX5I45Z>'P,*$W--O2VIM
M"DH.X4445VFH4444 5K/_EX_Z[-5FJUG_P O'_79JLT %%%% !1110 56_YB
MG_;'_P!FJS5;_F*?]L?_ &:@"S1110 4444 %%%% %:#_C^NO^ ?RJS5:#_C
M^NO^ ?RJS0 4444 %%%% !5:?_C^M?\ @?\ *K-5I_\ C^M?^!_RH LT444
M%%%% !1110!6_P"8I_VQ_P#9JLU6_P"8I_VQ_P#9JLT %%%% !1110 56O/^
M7?\ Z[+5FJUY_P N_P#UV6@"S1110 4444 %%%% %;4/^/&3\/YBK-5M0_X\
M9/P_F*LT %%%% !1110 56U#_CQD_#^8JS5;4/\ CQD_#^8H LT444 %%%%
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MY_R[_P#79:LU6O/^7?\ Z[+5F@ HHHH **** "JT_P#Q_6O_  /^56:K3_\
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MH LT444 %%%% !1110!6G_X_K7_@?\JLU6G_ ./ZU_X'_*K- !1110 4444
M%%%% !1110 4444 <S1110!NZ?\ \>,?X_S-6:K:?_QXQ_C_ #-6: "BBB@
MHHHH **** "BBB@ JM/_ ,?UK_P/^56:K3_\?UK_ ,#_ )4 6:*** "BBB@
MHHHH K?\Q3_MC_[-5FJW_,4_[8_^S59H **** "BBB@ JM>?\N__ %V6K-5K
MS_EW_P"NRT 6:*** "BBB@ HHHH K:A_QXR?A_,59JMJ'_'C)^'\Q5F@ HHH
MH **** "JT'_ !_77_ /Y59JM!_Q_77_  #^5 %FBBB@ HHHH **** *T_\
MQ_6O_ _Y59JM/_Q_6O\ P/\ E5F@ HHHH **** "JW_,4_[8_P#LU6:K?\Q3
M_MC_ .S4 6:*** "BBB@ HHHH K7G_+O_P!=EJS5:\_Y=_\ KLM6: "BBB@
MHHHH *K3_P#']:_\#_E5FJT__']:_P# _P"5 %FBBB@ HHHH **** *VH?\
M'C)^'\Q5FJVH?\>,GX?S%6: "BBB@ HHHH *BN?^/6;_ '#_ "J6HKG_ (]9
MO]P_RH +;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HHHH BN?\ CUF_W#_*
MBV_X]8?]P?RHN?\ CUF_W#_*BV_X]8?]P?RH EHHHH **** "BBB@"M9_P#+
MQ_UV:K-5K/\ Y>/^NS59H **** "BBB@ JMI_P#QXQ_C_,U9JMI__'C'^/\
M,T 6:*** "BBB@ HHHH K0?\?UU_P#^56:K0?\?UU_P#^56: "BBB@ HHHH
M*K?\Q3_MC_[-5FJW_,4_[8_^S4 6:*** "BBB@ HHHH K6?_ "\?]=FJS5:S
M_P"7C_KLU6: "BBB@ HHHH *K?\ ,4_[8_\ LU6:K?\ ,4_[8_\ LU %FBBB
M@ HHHH **** *T'_ !_77_ /Y59JM!_Q_77_  #^56: "BBB@ HHHH *K3_\
M?UK_ ,#_ )59JM/_ ,?UK_P/^5 %FBBB@ HHHH **** *W_,4_[8_P#LU6:K
M?\Q3_MC_ .S59H **** "BBB@ JM>?\ +O\ ]=EJS5:\_P"7?_KLM %FBBB@
M HHHH **** *VH?\>,GX?S%6:K:A_P >,GX?S%6: "BBB@ HHHH *K:A_P >
M,GX?S%6:K:A_QXR?A_,4 6:*** "BBB@ HHHH BN?^/6;_</\J+;_CUA_P!P
M?RHN?^/6;_</\J+;_CUA_P!P?RH EHHHH **** "HKG_ (]9O]P_RJ6HKG_C
MUF_W#_*@ MO^/6'_ '!_*I:BMO\ CUA_W!_*I: "BBB@ HHHH *K6?\ R\?]
M=FJS5:S_ .7C_KLU %FBBB@ HHHH **** *T'_']=?\  /Y59JM!_P ?UU_P
M#^56: "BBB@ HHHH K:A_P >,GX?S%6:K:A_QXR?A_,59H **** "BBB@ HH
MHH K:?\ \>,?X_S-6:K:?_QXQ_C_ #-6: "BBB@ HHHH BN?^/6;_</\J+;_
M (]8?]P?RHN?^/6;_</\J+;_ (]8?]P?RH EHHHH **** "BBB@"M9_\O'_7
M9JLU6L_^7C_KLU6: "BBB@ HHHH *K:?_P >,?X_S-6:K:?_ ,>,?X_S- %F
MBBB@ HHHH **** *T'_']=?\ _E5FJT'_']=?\ _E5F@ HHHH **** "JW_,
M4_[8_P#LU6:K?\Q3_MC_ .S4 6:*** "BBB@ HHHH K?\Q3_ +8_^S59JM_S
M%/\ MC_[-5F@ HHHH **** "JT__ !_6O_ _Y59JM/\ \?UK_P #_E0!9HHH
MH **** "BBB@"M/_ ,?UK_P/^56:K3_\?UK_ ,#_ )59H **** "BBB@ HHH
MH **** "BBB@#F:*** -W3_^/&/\?YFK-5M/_P"/&/\ '^9JS0 4444 %%%%
M !1110 4444 %5I_^/ZU_P"!_P JLU6G_P"/ZU_X'_*@"S1110 4444 %%%%
M %;_ )BG_;'_ -FJS5;_ )BG_;'_ -FJS0 4444 %%%% !5:\_Y=_P#KLM6:
MK7G_ "[_ /79: +-%%% !1110 4444 5M0_X\9/P_F*LU6U#_CQD_#^8JS0
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M4 %M_P >L/\ N#^52U%;?\>L/^X/Y5+0 4444 %%%% $5S_QZS?[A_E1;?\
M'K#_ +@_E1<_\>LW^X?Y46W_ !ZP_P"X/Y4 2T444 %%%% !1110!6L_^7C_
M *[-5FJUG_R\?]=FJS0 4444 %%%% !5;3_^/&/\?YFK-5M/_P"/&/\ '^9H
M LT444 %%%% !1110!6@_P"/ZZ_X!_*K-5H/^/ZZ_P" ?RJS0 4444 %%%%
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M9J +-%%% !1110 4444 5H/^/ZZ_X!_*K-5H/^/ZZ_X!_*K- !1110 4444
M5M0_X\9/P_F*LU6U#_CQD_#^8JS0 4444 %%%% !1110!6T__CQC_'^9JS5;
M3_\ CQC_ !_F:LT %%%% !1110!%<_\ 'K-_N'^5%M_QZP_[@_E1<_\ 'K-_
MN'^5%M_QZP_[@_E0!+1110 4444 %%%% %:S_P"7C_KLU6:K6?\ R\?]=FJS
M0 4444 %%%% !5;3_P#CQC_'^9JS5;3_ /CQC_'^9H LT444 %%%% !1110!
M6@_X_KK_ (!_*K-5H/\ C^NO^ ?RJS0 4444 %%%% !5;_F*?]L?_9JLU6_Y
MBG_;'_V:@"S1110 4444 %%%% %;_F*?]L?_ &:K-5O^8I_VQ_\ 9JLT %%%
M% !1110 56G_ ./ZU_X'_*K-5I_^/ZU_X'_*@"S1110 4444 %%%% %:?_C^
MM?\ @?\ *K-5I_\ C^M?^!_RJS0 4444 %%%% !1110 4444 %%%% ',T444
M ;NG_P#'C'^/\S5/Q%K+Z%HTM[#IMYJ-P/EAM;2)G:1STSM!VKQRQZ>Y(!H7
M_B/^P+.R']C:OJ/GB0YTZU\[R]I'W^1C.[CUP?2K6@>(O[>:Y']C:OIWD;.=
M1M?)\S=G[O)SC;SZ9'K0!Q'P\^)FK>,?%MSIUW:64%FMI)<Q"$.77$B*JEBV
M&X<Y(49(Z#I5?5/B=K]QXEU[3] L=-2VT6VGGG;4-Y>00-MD*[#CDD;0>H&2
M1G Y#X%?\CW-_P!@F3_T;#6-X"AEME\5P3Q/%-%X8OHY(Y%*LC#8"I!Y!!!&
M* /4/^%MO_PK;^W_ .S?^)E]J_L_R\_N?/V;]_7=LV\XZY^7./GJOI?Q.U^W
M\2Z%I^OV.FO;:U;03P-I_F!XQ.VV,MO.."#N Z Y!.,'PUM-O%B35?LS_87=
MK47 Y7S0 Q0^AVL",]><9P<==XVLY]0F\'V-K'YES<^&]/ABCW!=SL751D\#
M)(ZT =EXT^-6HZ+XGN].T>TL)K2VE^S&2=)"S2CASP5P V5Q@YVYS@C'::%\
M1K&]^'DOBC45\MK,F*\BMT9L2Y "H#_>WH1S@;\%N":Q/%OP6L_$OB&?5;?5
M?L G997@6T#CS?XF!#+][J<@DL6.><#BH-*2\T^_>QF>;PYX45Y?FM_,CU6^
M&X[V5 08S\JG+,5AV\KO9E /9/!NIZYK>CC5M7ALK:&\Q+96]ON9TA/*F1R<
M,2".@&.IY.U>CKYUM/BGXPTZTL=8O-334+8W4T,EF]M''O$:1,?G5003YW&!
MP5!.X'%?15 !5:?_ (_K7_@?\JLU!-"[RQ2(5#1YX;H<B@">BH?])_Z8_K1_
MI/\ TQ_6@":BH?\ 2?\ IC^M'^D_],?UH FHJ'_2?^F/ZT?Z3_TQ_6@!G_,4
M_P"V/_LU6:J^5<?:/.S%G9LQSZYJ3_2?^F/ZT 345#_I/_3']:/])_Z8_K0!
M-14/^D_],?UH_P!)_P"F/ZT 356O/^7?_KLM/_TG_IC^M1RQ7$NS)B&QPXQG
MM0!:HJ'_ $G_ *8_K1_I/_3']: )J*A_TG_IC^M'^D_],?UH FHJ'_2?^F/Z
MT?Z3_P!,?UH 9J'_ !XR?A_,59JK/%<3PM&QB /<9J3_ $G_ *8_K0!-14/^
MD_\ 3']:/])_Z8_K0!-14/\ I/\ TQ_6C_2?^F/ZT 356@_X_KK_ (!_*G_Z
M3_TQ_6HTBN$FDD!BS)C(YXQ0!:HJ'_2?^F/ZT?Z3_P!,?UH FHJ'_2?^F/ZT
M?Z3_ -,?UH FHJ'_ $G_ *8_K1_I/_3']: &3_\ ']:_\#_E5FJKQ7#S1R$Q
M9CS@<\YJ3_2?^F/ZT 345#_I/_3']:/])_Z8_K0!-14/^D_],?UH_P!)_P"F
M/ZT 356_YBG_ &Q_]FI_^D_],?UJ/RKC[1YV8L[-F.?7- %JBH?])_Z8_K1_
MI/\ TQ_6@":BH?\ 2?\ IC^M'^D_],?UH FHJ'_2?^F/ZT?Z3_TQ_6@!EY_R
M[_\ 79:LU5EBN)=F3$-CAQC/:I/])_Z8_K0!-14/^D_],?UH_P!)_P"F/ZT
M345#_I/_ $Q_6C_2?^F/ZT 356G_ ./ZU_X'_*G_ .D_],?UJ-XKAYHY"8LQ
MYP.><T 6J*A_TG_IC^M'^D_],?UH FHJ'_2?^F/ZT?Z3_P!,?UH FHJ'_2?^
MF/ZT?Z3_ -,?UH 9J'_'C)^'\Q5FJL\5Q/"T;&( ]QFI/])_Z8_K0!-14/\
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M#_I/_3']:/\ 2?\ IC^M #/^8I_VQ_\ 9JLU5\JX^T>=F+.S9CGUS4G^D_\
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MZS?[A_E1;?\ 'K#_ +@_E3)$N9(V0F(!@1WHC2YCC5 8B% '>@"Q14/^D_\
M3']:/])_Z8_K0!-14/\ I/\ TQ_6C_2?^F/ZT 35%<_\>LW^X?Y4G^D_],?U
MILB7,D;(3$ P([T /MO^/6'_ '!_*I:KQI<QQJ@,1"@#O3O])_Z8_K0!-14/
M^D_],?UH_P!)_P"F/ZT 345#_I/_ $Q_6C_2?^F/ZT 356L_^7C_ *[-3_\
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M_F*?]L?_ &:K-5?*N/M'G9BSLV8Y]<U)_I/_ $Q_6@":BH?])_Z8_K1_I/\
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MP+EL]SUR.*S'^%6CV6J2>(5UC7DU".5[LSP-&S[SEF(18CNSDC: 00<8(.*
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M7A?1?#2ZE::!&;6-84+02W(W^68Q)O!*J 8\[@-X8DG 8=Z/A5IX\.?\(_\
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M6\4.HJ[YP9M-N(DX!/+.@4=.Y]NM:=%% 'G?QJ^W?\*_;[)_Q[_:XOMOW?\
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M 9YZ9SU]#6!X;^'&C>%-7EU#3+K4D#@C[*UT?) YVY4 %]H) WEL9SUYKKZ
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MO53[1.)#YTCI@JY;U##<%QMR3\N"08=,^&>BZ?#;6MQ<7VIV%JSR0V.H2))
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MXG<IE9!&7 (#1H@+9.\AS]W+ _?4 L[+Q?I_C?0XM.UCQ/JUHTZM=S7EG/!
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MYAC=B <J0A5E  ._.,JN/7M<^'FC:_X=TO1;M[E8=-5$@GC*>:55-FTL5/!
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M Q].=H)X(4U[(GP@TB/2;C2H];UU+"XD666!;B/8SKT./+^GUVJ3G:N-6_\
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M!$9!'N,@]JR_"/@#3?!4]S)IEY?.MRBI)'<-&RG:3M/" Y&6'7'S'(/&.KH
M*RO$NNP>&?#=]K%PN]+6/<J9(\QR0J+D XW,5&<<9R>*U:Y;Q?X$L?&K6ZZG
MJ.I1V\ )2VMY$6/><@N04)+8.,D\#.,9.0#Y]NX-7\':IH^K$WPU1D^V2R7D
M<L8>?S&+H2P1G&PQA\$@EV&X@UZ'\8O$%U!;>'M5T+5K^WAU"UED#07,L2R(
M!&R'9D8.'/. >0#T&.]U_P "0^)["WLM6US59X(&\P >0FY_GPQ*Q#G:Y7 P
M, <9R3Y7\1/ %UI%MI>E>'X]=U2WB6>4Q/ 9DMRY3[K+& -Q5B5R<8S@;LL
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MU[A!!#:V\=O;Q)%#$@2..-0JHH&  !P !VH ()EN((YD#A)%#J)$*, 1GE6
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M:=;B2=W3]S]HE+*I4'DD*"",%2P[T =9%\4_!L\J10ZL\LLC!4CCLYV9F/
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MJMQ*CW$\K273+&8VD4D-B/<9 <D%B?F((V9^C]+U"+5](LM2@5UAO($N(UD
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MD-K;KD;I&QN(!.U1U9L X49)QP*HZ=XOT+5M#O=:LK[S=/LM_P!HE\F1=FQ
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MYSCGTK7;P;XBM_$ESJFG>-[V.":4R"RNX#<QJI8,4P7 "Y! VA2%X![GMJ*
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M\@SSZUKZGX-\17>NC5K'QO>V$C1H'MU@,D D";&9(V?:%/7:0V#DY)QCMJ*
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MG'WNO/3BF^$O#-KX2\/0:3:MYFPEY9B@5I9">6./P SDA549.,UMT4 %%%%
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M.1QT-:M% '!^!?AY<^![RZDAUB&Z@NP@GC>S*MA ^W:WF$#E^<@YQVZU?O/
MT6I_$*V\57]TDJV<*Q6UF+<8!7<0SL2=Q#.S# 7!"?W3GK:* "BBB@ HHHH
M**** "BBB@ HHHH YFBBB@#=T_\ X\8_Q_F:LU6T_P#X\8_Q_F:LT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 <S1110!NZ?_P >,?X_S-6:K:?_ ,>,?X_S
M-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@'V=R!"CQ[&E,C8 (0R#!4CD'/%<5=Z3XM^'=RVI:7=S'39<-%J5F1);W$9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YFBBB@#=T_P#X\8_Q_F:LU6T__CQC_'^9
MJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7E^I?"RZTSQ3!XB\&75G931R[_L5TA\E,A@^TJ"0I!QLP,9;##"@>H44
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M!BJ*%V% ,80G.[T&.]=S10 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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FD?Y'_&@#8HK'_M6?^Y'^1_QH_M6?^Y'^1_QH HT4[;QUHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_014.jpg
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  6 ;<# 2(  A$! Q$!_\0
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M!].**XKX86+Z;I>JV<I)EBO\.3_>\J,G]2:* .PN-/LKMP]S9V\S@8#2Q*Q
M_$4HL+,3QSBT@$T2[(Y/+&Y%] <<#VHHH <MI;)LVV\0\LDIA!\I/7'IG)S4
M4>EZ?$FR.QM47T6%0.N?3UY^M%% "_V9I_V86WV&V^SAMXB\I=H;UQC&?>A]
M,L)!$)+&V<1,6C#1*=A)R2..#110 Y["SEN/M$EI \V /,:,%L Y'/7KS3EM
M+965EMX@RL64A!D$]2/<]Z** #[);?9Q;_9XO('2/8-HYSTZ=:/LEMG/V>+/
MF>;G8/O]-WU]Z** ,^\\.:??:A8W4L2[;02A8-B^6_F ;MRXYZ9K22WAC<.D
M,:N$$88* 0HZ+]/:BB@!L-G:VTDDD%M#$\IW2-&@4N?4D=:1K*T>U-JUK"UN
MW6(Q@H><].G6BB@!'L+.2**)[2!HX2#$K1@A"/[HQQ^%/-M ;;[,8(S!MV^4
M4&W'ICIBBB@"+^S;'[*MK]BMOLZG*Q>4NP'V&,4]+*UC2-$MH56([HPL8 0^
MH]*** %DM;>5F:2")V=/+8L@)9?[I]O:F1:?900I##9V\<2/O5$B4*K>H '!
M]Z** '7%C:7G_'S:P3\8_>QAN,YQS[@50ET&&?Q#;:O-<3.;5&6VMS@1Q%AA
MF&!DDCCDT44 :%S:6UXBI=6\4ZJVX+*@8 ^O/>E>VMY#(7@B8R+L<E =R^A]
M1[444 +!!#;0K#;Q)%$@PJ1J%4?0"FFTMFBEB-O$8Y23(A08<GJ2.]%% "16
M-I D20VL$:PY\H)& $SUVXZ?A2R6EM+<1W$EO$\\8PDC("R_0]1110 "TM@
M!;Q "3S1\@X?^]]?>GRPQSQF.:-)$)!*NH(XY'%%% $;6=J]TET]M"UP@PLI
M0%U'H#U%21Q1PJ5BC1%)+$*H )/4T44 9FB^'=/T/38[*")9 J&-I944NZDD
MX8@<CGI5Q]-L)'5WLK9F5!&K-$I(4= ..GM110!(MG:K=M=+;0BY8;6F"#>1
MZ$]<5''IMA#&\<5E;(CMO95B4!FZY(QR?>BB@!1IUB+1K06=N+9NL(B78?\
M@.,4UM,M&N+.;R@ILPWD*HPJ;AM/ ]LC\:** *W]@6+ZW/JLL8FFE2--LBJR
MILSAER,@_,>:U*** $90RE6 ((P0>]01V%G#%'%%:0)'&V^-%C "-Z@=CS11
M0 Z*TMH)I9HK>*.64YD=$ +GW/>HKC3+2Z,9DA7Y)UN/E&-TB]"?7M^0HHH
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_015.jpg
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E 8,# 2(  A$! Q$!_\0
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MJ #</44M)M7T'Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^%J>/\ _HE^H_\ D7_XW1_PM3Q__P!$OU'_ ,B__&Z]BHK8P/'?^%J>/_\
MHE^H_P#D7_XW1_PM3Q__ -$OU'_R+_\ &Z]BHH \=_X6IX__ .B7ZC_Y%_\
MC='_  M3Q_\ ]$OU'_R+_P#&Z]BHH \=_P"%J>/_ /HE^H_^1?\ XW1_PM3Q
M_P#]$OU'_P B_P#QNO8J* /'?^%J>/\ _HE^H_\ D7_XW1_PM3Q__P!$OU'_
M ,B__&Z]BHH \=_X6IX__P"B7ZC_ .1?_C='_"U/'_\ T2_4?_(O_P ;KV*B
M@#QW_A:GC_\ Z)?J/_D7_P"-T?\ "U/'_P#T2_4?_(O_ ,;KV*B@#QW_ (6I
MX_\ ^B7ZC_Y%_P#C='_"U/'_ /T2_4?_ "+_ /&Z]BHH \97XJ?$#SG'_"L[
M\C ^3$F5Z\_<[_TJ3_A:GC__ *)?J/\ Y%_^-UZU'_Q_S_\ 7-/YM5B@#QW_
M (6IX_\ ^B7ZC_Y%_P#C='_"U/'_ /T2_4?_ "+_ /&Z]BHH \=_X6IX_P#^
MB7ZC_P"1?_C='_"U/'__ $2_4?\ R+_\;KV*B@#QW_A:GC__ *)?J/\ Y%_^
M-T?\+4\?_P#1+]1_\B__ !NO8J* /'?^%J>/_P#HE^H_^1?_ (W1_P +4\?_
M /1+]1_\B_\ QNO8J* /'?\ A:GC_P#Z)?J/_D7_ .-T?\+4\?\ _1+]1_\
M(O\ \;KV*B@#QW_A:GC_ /Z)?J/_ )%_^-T?\+4\?_\ 1+]1_P#(O_QNO8J*
M /'?^%J>/_\ HE^H_P#D7_XW1_PM3Q__ -$OU'_R+_\ &Z]BHH \=_X6IX__
M .B7ZC_Y%_\ C='_  M3Q_\ ]$OU'_R+_P#&Z]BHH \KT7XD>-M1UNQLKSX=
M7UG;3SI'+<OYF(E)P6.4 X'->J444 %%%% !1110!4U3_D$WO_7!_P#T$U3C
M_P!4G^Z/Y5<U3_D$WO\ UP?_ -!-4X_]4G^Z/Y5G4V1#W(G_ .0IIG_79_\
MT4];E8;_ /(4TS_KL_\ Z*>MRJA\*''J%%-5U?.U@<=<'I3JHH**IKJEB^I-
MIRW*&[5=QB[XXSCUZC\ZN4 4]3TZ'5=/EM)ONN/E8=5;L17-^%]4FL;R30-1
M.V6)ML+'OWQ]".1^5=A7,>,-$>\MEU&S4_;+49(3K(@YP/<=1^([UC5IMM3A
M\2_'R_R[/U.BC4BDZ=3X7^#[_P"?EZ'3T5A>&->36M/&]E^TQ@;\?Q#LP^O\
MZW:NG-5(J43*I3E3DXR"BH/-?[=Y7R^7Y>[ISG.*GJR HHHH **** "BBB@
MHHJ*:;R?+^0MO<)P1QGO0!+1110 4444 5X_^/\ G_ZYI_-JL57C_P"/^?\
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MV^?YB1L3"EC@?>[?A5CY_1?SH =13?G]%_.CY_1?SH =13?G]%_.CY_1?SH
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M<O+CQ +=S";:6:X@6-5^>/RL?,3GG.?3NM=*>!5>&PL[>X:XAM88YG4*TBH
MQ Z G\!^56* &[_]EORHW_[+?E3J* &[_P#9;\J-_P#LM^5.HH ;O_V6_*C?
M_LM^5.HH ;O_ -EORHW_ .RWY4ZB@!N__9;\J-_^RWY4ZB@!N_\ V6_*C?\
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M;^]^E.HH ;AO[WZ48;^]^E.HH ;AO[WZ48;^]^E.HH ;AO[WZ48;^]^E.HH
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MNL#"5Y-DGEEV5050-M/)YP.Y% '344V-B\:L5*D@'#=1]:=0 4444 %(0#U
M-<GIFI7DWC2ZMI+F5[<-,JQ\<;=F,ICY ,MAL_/GM76T )M7^Z/RI0 .E%%
M!16!XDU$Z==:.?MWV=)+P))'QB1,'.21G ./SJGH6H7ESKSQRW,LA*W'VF!A
M\MNRRA8@..,IGZ]: .KHHHH ***XRZUV*"Z\1176JW!CMS$8E@*AT)X**<<?
M-@$GIGDT =D0#U -&U?[H_*L_09)I=!LGN+N.[F,0WSQD%7;N01UK1H 3:O]
MT?E1M7^Z/RI:HZU,;?1;R87)MBD3$3#&5./?B@"[M7^Z/RHVK_='Y5Q US4)
MV\./$]T;>0P+-)'&&6=V4APQ[;2.G')/I7<4 )M7^Z/RHVK_ '1^5+10 FU?
M0?E2US^J:D;3Q7I%M]NV1SI*&MS@!CCY3TSDG@<U!X0U.YU".<7;223;$DD8
MR;E1FW9CV[1L88Y7GJ.: .GHHHH **** "BBB@ HHHH **** "BBB@ HI"P4
M98@#WI/-C_OK^= #J*;YL?\ ?7\Z/-C_ +Z_G0 ZBF^;'_?7\Z/-C_OK^= #
MJ*;YL?\ ?7\Z/-C_ +Z_G0 ZBF^;'_?7\Z/,3^^OYT .HIOFQ_WU_.CS8_[Z
M_G0 ZHYIHK>)I9I$CC7JSG 'XT[S8_[Z_G534[>'4M*N[)I$ GB:/)/0D<&@
M"8WMJ'9#<P[DD6)EWC(<XPI]SD<>]3UPT/AO53.)Y;FTBGN$:>Y=)"=MT ZQ
ME>.0 X_[X%'_  C^J&VMT^V2*H9O,B6Z&48A0'0[>Q5C@\Y8GO0!VD%Q#<AS
M#(KB-S&VT]&'!'U%,N[ZTL(UDN[F&!&.T-*X4$^G-<E/H.I!]1*3QR)<2O)"
M@GV",^9N&1C#!N-PZ_+@&M2]M+P7VFW\,=G<RV]N\$L+RE%!?;EE)!_NXYYP
M: .@!!&1@Y[TM<5>:'JTUU>R0W21O)YNV9;IAO5L;$V]%V^H]/<U'>Z)?V-K
M?SVEPYS'=A$2X=FV,H,04>H8$_C0!VK7$*7$=NTBB:169$SR0,9/X9'YT_>H
M<)N&X@D+GDCU_45Q+:!JKB9X9XK8LLPBC^TM(8MWE<!B,_-L<GTW5(WA^\_T
M>6&8)<+:W,*RR7&6@9R"F,#! P1CMD=<4 =?//%;0//.ZQQ1C<S-T ]:DK@[
MGPYJ4]B(1(KJR2J(9;PA87;;AAM'S# ;@_WCZFNY\V/^^OYT /HIOFQ_WU_.
MCS8_[Z_G0 ZBF^;'_?7\Z4$,,@@CU% "T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &7J=O#<ZAIL<\22IYCG:ZAA]P]C4_]
MCZ9_T#K3_OPO^%-OTF%W97$5N\PB9MRH5!Y4C^(@4[[=<?\ 0*O/^^HO_BZK
M6RL1I=W,[7+&"RTJ:YL['1XVA4R227D6(T0 DD[1GM_GI7,MKR-;+>KX<T^*
M"VM[2:^AEC'FJ9\95.,90')SUZ<5T>NV#>(+.*VN+/58(XYEF_<2P#<5Y 8%
MB&&<'!'4"J<WAZ&YN4GN+/6)6*Q"X5IX0MUY;;D,@##)!/;&>AR*-1^[V_#_
M (!)K.J^&M"NC;WFF*66$3R-#8^8L<9;;N8@=,_C5:X\0>%[:RDN)-(;?$TH
MEMQ8#S8Q&H9RPQT"LIZ_Q"K^I:5#JL]Q-<:7J.^>V%J^R6(?('WC'S]<]ZPO
M$7A6[U*\6YL;"X5FEEG=9Y8AB5TC57'+ @",?*1SGJ*-0]WM^'_ -;5&MTN-
M,L=,T;3VO-05Y5:ZA"I%&@4L6 &2<LHP/7KQ63#J,U]>6VFVVB:+#J'FW4-S
MYL9:/=#LQL( .&$@//3IS6Y?:=+J<%@UU:ZFE_9C*7MM)#&^XKM<@;R,-W4@
MCIZ"LFW\)-;N"DFO*8Y9I(I4EMQ*/-P9 S[COR5!!(R.F>!1J'N]OP_X!N:"
MNF:WHL%^='M8'<LDD1B1MCHQ1@#CD;E.#WJ[<:#I5S \+Z?;*&'5(E4CW! X
M-0Z<@TK3X+&ST:[CMX5VHOF1$_4DR9))Y)/4FIKB^OA _P!GTFX:;'RAWB"Y
M]\/1[W<3Y>WX%2RLK%;IM/O-/LVN$3>LBVZXE3.-Q&.#G@C\1[7_ .Q],_Z!
MUI_WX7_"JMD9K1')TV]EGD.Z69FARY_[[X [#M5K[=<?] J\_P"^HO\ XNF[
MW$K6U_K\ _L?3/\ H'6G_?A?\*/['TS_ *!UI_WX7_"C[=<?] J\_P"^HO\
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MDD]23U-&H>[V_#_@%K^Q],_Z!UI_WX7_  H_L?3/^@=:?]^%_P */MUQ_P!
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>22
<FILENAME>crbp-20171231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CRBP="http://corbuspharma.com/20171231">
    <link:schemaRef xlink:href="crbp-20171231.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-11-01to2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:ThreePointTwoFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-11-01</xbrli:startDate>
        <xbrli:endDate>2015-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:ThreePointTwoFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CRBP:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CRBP:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-30_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_CorporatecreditCardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:CorporatecreditCardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-30to2016-08-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-30</xbrli:startDate>
        <xbrli:endDate>2016-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:OrchestraMedicalVenturesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandAndSixteenConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:TwoPointTwoFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:TwoPointTwoFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-02-27</xbrli:startDate>
        <xbrli:endDate>2017-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-01to2016-11-30_custom_SalesAgreementMember_custom_CantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:CantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-29to2017-01-02_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-29</xbrli:startDate>
        <xbrli:endDate>2017-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_OralAntiinflammatoryDrugMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:OralAntiinflammatoryDrugMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-19</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-05-01to2015-05-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-05-01</xbrli:startDate>
        <xbrli:endDate>2015-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-11-01to2015-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-11-01</xbrli:startDate>
        <xbrli:endDate>2015-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponCommercializationOfTheProductMember_custom_LenabasumMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponCommercializationOfTheProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-19</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_LenabasumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponReachingTheSalesTargetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-19</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponTransferSaleOrLicensingMember_custom_LenabasumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponTransferSaleOrLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-19</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_LenabasumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-19</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CorporatecreditCardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:CorporatecreditCardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-30to2017-01-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-30</xbrli:startDate>
        <xbrli:endDate>2017-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-03to2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-03</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30_custom_SalesAgreementMember_custom_CantorFitzgeraldMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:CantorFitzgeraldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FirstYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">CRBP:FirstYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_SeventhYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">CRBP:SeventhYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FourthAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FourthAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-25</xbrli:startDate>
        <xbrli:endDate>2017-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:SeptemberTwoThousandAndSixteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:SeptemberTwoThousandAndSixteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="C_0001595097_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20151231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_InterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">CRBP:OrphanDrugCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MinimumMember_custom_OrphanDrugCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">CRBP:OrphanDrugCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CantorFitzgeraldAndCoMember_custom_SalesAgreementMember_custom_JanuaryFiveTwoThousandAndEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:JanuaryFiveTwoThousandAndEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SalesAgreementMember_custom_JanuaryTwoThousandAndEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:JanuaryTwoThousandAndEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CRBP:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_FebruaryTwoThousandAndEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FebruaryTwoThousandAndEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-30_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:TwoPointThreeFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:TwoPointThreeFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-06-01to2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-06-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:CantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:CantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:CantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">CRBP:JanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-30to2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-30</xbrli:startDate>
        <xbrli:endDate>2018-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-04to2018-01-05_us-gaap_SubsequentEventMember_custom_AtTheMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:AtTheMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-04</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_PhaseTwoBClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:PhaseTwoBClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-25</xbrli:startDate>
        <xbrli:endDate>2018-01-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisProgramRelatedInvestmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CysticFibrosisProgramRelatedInvestmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationwarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember_custom_InvestmentagreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationwarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationwarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-25</xbrli:startDate>
        <xbrli:endDate>2018-01-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_PhaseTwoBClinicalTrialMember_custom_InvestmentagreementMember_custom_JanuaryTwentySixTwoThousandAndEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:PhaseTwoBClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:JanuaryTwentySixTwoThousandAndEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TwoThousandAndEighteenCffAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:TwoThousandAndEighteenCffAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_StandbyLetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:StandbyLetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_StandbyLetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:StandbyLetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-26_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">CRBP:JanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-28_us-gaap_SubsequentEventMember_custom_AtTheMarketOfferingMember_custom_TwoThousandAndEighteenSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:AtTheMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandAndEighteenSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_InsurancePoliciesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">CRBP:InsurancePoliciesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_InsurancePoliciesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">CRBP:InsurancePoliciesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_MassachusettsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">CRBP:MassachusettsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_MassachusettsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">CRBP:MassachusettsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percentage">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>CRBP:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Installments">
      <xbrli:measure>CRBP:Installments</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-01-01to2017-12-31">Corbus Pharmaceuticals Holdings, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2017-01-01to2017-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2017-01-01to2017-12-31">2017-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-01-01to2017-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-01-01to2017-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-01-01to2017-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <CRBP:MarketableSecuritiesMaturityPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_MinimumMember">P3M</CRBP:MarketableSecuritiesMaturityPeriod>
    <us-gaap:MarketableSecurities contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">0</us-gaap:MarketableSecurities>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">50000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2017-01-01to2017-12-31_custom_ComputerHardwareAndSoftwareMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2017-01-01to2017-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2017-01-01to2017-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfOperatingSegments contextRef="From2017-01-01to2017-12-31" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <CRBP:DeferredTaxAssetsValuationAllowancePercentage contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">1.00</CRBP:DeferredTaxAssetsValuationAllowancePercentage>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:AssetImpairmentCharges contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:Cash contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1127530</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">206510</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">13864727</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62330985</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-32421612</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-19998675</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-32421612</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-10693690</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-7570275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">-7465439</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-19998675</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-8850739</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-8850739</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-7296887</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">-6965596</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-2892241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-4189391</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-5346768</us-gaap:NetIncomeLoss>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">9133466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">7898679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1288500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1288500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">7844966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">6610179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">5951315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1969250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">3982065</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">543488</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1796544</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">188219</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">191244</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="USD" decimals="0">259138</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_custom_ComputerHardwareAndSoftwareMember" unitRef="USD" decimals="0">96131</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="USD" decimals="0">287048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_ConstructionInProgressMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_custom_ComputerHardwareAndSoftwareMember" unitRef="USD" decimals="0">136522</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-30_custom_CopierMachineMember" unitRef="USD" decimals="0">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_ConstructionInProgressMember" unitRef="USD" decimals="0">1181730</us-gaap:PropertyPlantAndEquipmentGross>
    <CRBP:LeaseTerm contextRef="From2015-01-01to2015-12-30_custom_CopierMachineMember">P3Y</CRBP:LeaseTerm>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">108237</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">363889</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <CRBP:AreaOfOfficeSpace contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="sqft" decimals="INF">32733</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember" unitRef="sqft" decimals="INF">10414</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2016-09-01to2016-09-30" unitRef="sqft" decimals="INF">4088</CRBP:AreaOfOfficeSpace>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">356547</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">229705</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FirstYearMember" unitRef="USD" decimals="0">470000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_SeventhYearMember" unitRef="USD" decimals="0">908000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">55496</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">415265</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">348750</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2015-11-01to2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember" unitRef="USD" decimals="0">207750</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2016-10-01to2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember" unitRef="USD" decimals="0">348750</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">207750</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-11-01to2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember" unitRef="USD" decimals="0">415265</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2015-11-01to2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember" unitRef="USD" decimals="0">23397</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2016-10-01to2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember" unitRef="USD" decimals="0">39114</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2017-11-01to2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember" unitRef="USD" decimals="0">41975</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember" unitRef="Percentage" decimals="INF">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember" unitRef="Percentage" decimals="INF">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember" unitRef="Percentage" decimals="INF">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2015-11-01to2015-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_ThreePointTwoFivePercentNotesPayableMember">P9M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2016-10-01to2016-10-31_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointTwoFivePercentNotesPayableMember_custom_OctoberTwoThousandSixteenMember">P9M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2017-11-01to2017-11-30_us-gaap_NotesPayableOtherPayablesMember_custom_TwoPointThreeFivePercentNotesPayableMember">P10M</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">3632</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">3115</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">2440</us-gaap:InterestExpenseDebt>
    <CRBP:AccruedClinicalOperationsAndTrialsCosts contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1647490</CRBP:AccruedClinicalOperationsAndTrialsCosts>
    <CRBP:AccruedClinicalOperationsAndTrialsCosts contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2003799</CRBP:AccruedClinicalOperationsAndTrialsCosts>
    <CRBP:AccruedProductDevelopmentCosts contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">713426</CRBP:AccruedProductDevelopmentCosts>
    <CRBP:AccruedProductDevelopmentCosts contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1255439</CRBP:AccruedProductDevelopmentCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">117289</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">146609</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2016-08-30to2016-08-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_OralAntiinflammatoryDrugMember" unitRef="USD" decimals="0">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-05-01to2015-05-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1250000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2015-11-01to2015-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1250000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2017-01-30to2017-01-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2017-11-01to2017-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_PhaseTwoBClinicalTrialMember" unitRef="USD" decimals="0">6250000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:DeferredRevenue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1940195</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">44681745</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">55603427</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">37605134</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">44681745</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">55603427</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">37605134</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">4468</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">5560</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">8919235</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">57783561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4468</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42191256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-33276489</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">8985010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">123476102</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-65698101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3761</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22259063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-13277814</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2594</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10287214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-4427075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">5862733</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">44681745</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">55603427</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">37605134</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">25938332</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">75401959</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16300924</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1065</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">75400894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">615</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16300309</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="USD" decimals="0">15400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="Shares" decimals="INF">3887815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10648948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember" unitRef="Shares" decimals="INF">1413633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="Shares" decimals="INF">4650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6148695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-06-01to2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember" unitRef="Shares" decimals="INF">5960000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="Shares" decimals="INF">188695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">189490</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">467192</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">27</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">189463</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">32</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">467160</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">5589</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5584</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">272734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">326886</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">272734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">326886</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">11666802</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">51128</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2969837</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">260179</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USD" decimals="0">36291</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember" unitRef="USD" decimals="0">13268208</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">2184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">509215</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-06-01to2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember" unitRef="USD" decimals="0">25222</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-01-01to2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="USD" decimals="0">1426145</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">78891699</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16699133</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USD" decimals="0">27214705</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember" unitRef="USD" decimals="0">13724591</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">32550000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">11328929</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31_custom_CantorFitzgeraldAndCoMember_custom_SalesAgreementMember_custom_JanuaryFiveTwoThousandAndEighteenMember" unitRef="USD" decimals="0">11300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember_custom_JanuaryTwoThousandAndEighteenMember" unitRef="USD" decimals="0">11300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-06-01to2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember" unitRef="USD" decimals="0">14900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="USD" decimals="0">1621182</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-11-01to2017-11-30_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">4589550</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-02-01to2018-02-28_us-gaap_SubsequentEventMember_custom_AtTheMarketOfferingMember_custom_TwoThousandAndEighteenSalesAgreementMember" unitRef="USD" decimals="0">11349000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NatureOfOperations contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 33px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;NATURE OF OPERATIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Corbus Pharmaceuticals Holdings,&#13;Inc. (&amp;#8220;CPHI&amp;#8221; or &amp;#8220;the Company&amp;#8221;) is a clinical stage pharmaceutical company, focused on the development&#13;and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its&#13;inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting&#13;management and technical staff, acquiring operating assets and raising capital. . The Company&amp;#8217;s business is subject to significant&#13;risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable&#13;and it may never achieve profitability.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of the significant accounting&#13;policies followed by the Company in the preparation of the financial statements is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The process of preparing financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at&#13;the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results&#13;could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based&#13;compensation expense, the accrual of research, product development and clinical obligations, and the expected performance period&#13;under the 2015 CFFT Award (See Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Prior to the registration of its&#13;common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not&#13;less than the fair value of its common stock as determined by the board of directors, with input from management. The Company&amp;#8217;s&#13;board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors,&#13;including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold&#13;shares of preferred stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents, and&#13;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company considers only those&#13;investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to&#13;be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2017&#13;and 2016, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2017&#13;and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Restricted cash as of December 31,&#13;2017 and 2016 included a collateral account for the Company&amp;#8217;s corporate credit cards and is classified in current assets&#13;in the amount of $108,991 and $150,000, respectively. Additionally, as of December 31, 2017 and 2016 restricted cash included a&#13;stand-by letter of credit issued in favor of a landlord for $50,000 which was classified in current assets as of December 31, 2017&#13;and in noncurrent assets as of December 31, 2016 (See Note 5).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and restricted&#13;cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,127,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,864,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,992,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash, current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash, noncurrent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,192,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The carrying amounts reported in&#13;the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their&#13;fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair&#13;value due to the fact that they are at market terms.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The estimated life for the Company&amp;#8217;s&#13;property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture&#13;and equipment. The Company&amp;#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their&#13;useful lives or the respective leases. See Note 4 for details of property and equipment and Note 5 for operating and capital lease&#13;commitments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&#13;and Development Award Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Costs incurred for research and&#13;development are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Nonrefundable advance payments for&#13;goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant&#13;to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the&#13;related goods are delivered or the related services are performed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For amounts received under the development&#13;award received from the CFFT (See Note 8), the Company recognized those amounts when the triggering event to receive those payments&#13;occurred, with those amounts being amortized on a straight-line basis over the expected duration of the remaining performance period&#13;of the development program under the award, which concluded in the third quarter of 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accruals for Research and&#13;Development Expenses and Clinical Trials&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As part of the process of preparing&#13;its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with&#13;vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical&#13;trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result&#13;in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&amp;#8217;s&#13;objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which&#13;services are performed and efforts are expended. The Company determines accrual estimates by taking into account discussion with&#13;applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the&#13;course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The&#13;Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it&#13;at that time. The Company&amp;#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research&#13;organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from&#13;amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing&#13;of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For&#13;the years ended December 31, 2017, 2016 and 2015, there were no material adjustments to the Company&amp;#8217;s prior period estimates&#13;of accrued expenses for clinical trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases and Deferred Rent&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company leases its office space.&#13;Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&amp;#8217;s office&#13;space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records&#13;the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between&#13;the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the lessor&#13;are recorded as a reduction to rent expense over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has no significant off-balance-sheet&#13;concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may&#13;from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company&#13;believes the risk of loss is minimal as these banks are large financial institutions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Operating segments are identified&#13;as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating&#13;decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date,&#13;the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing&#13;therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2017 and 2016, all of the Company&amp;#8217;s&#13;assets were located in the United States.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For federal and state income taxes,&#13;deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax&#13;basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in&#13;which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax asset when it is not&#13;more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses&#13;since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate&#13;the deferred tax assets amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Tax positions taken or expected&#13;to be taken in the course of preparing the Company&amp;#8217;s tax returns are required to be evaluated to determine whether the tax&#13;positions are &amp;#8220;more-likely-than-not&amp;#8221; of being sustained by the applicable tax authority. Tax positions not deemed to&#13;meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in&#13;the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December&#13;31, 2017 or 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company continually monitors&#13;events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment&#13;loss is recognized when expected undiscounted cash flows of an asset are less than an asset&amp;#8217;s carrying value. Accordingly,&#13;when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating&#13;performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess of the fair value&#13;of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset may not be recoverable.&#13;No impairment charges were recorded for the years ended December 31, 2017, 2016 and 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-based Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company recognizes compensation&#13;costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement&#13;of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option&#13;grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized&#13;as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.&#13;Stock options granted to non-employee consultants are revalued at the end of each reporting period until vested using the Black-Scholes&#13;option-pricing model and the changes in their fair value are recorded as adjustments to expense over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On March 30, 2016, the FASB issued&#13;ASU No. 2016-09, &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&#13;&lt;/i&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;i&gt;. &lt;/i&gt;ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment&#13;transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification&#13;in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures&#13;as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have&#13;an impact on the Company&amp;#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the excess&#13;tax benefits in respect of share based payments only when realized (See Note 9).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Basic and diluted net loss per share&#13;of the Company&amp;#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding&#13;during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted&#13;loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years&#13;ended December 31, 2017, 2016 and 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,998,675&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(8,850,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,137,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;31,350,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following potentially&#13;dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of dilutive weighted&#13;average shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,969,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,982,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,898,679&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,951,315&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In May 2014, the FASB issued guidance&#13;codified in &lt;i&gt;Accounting Standards Codification (ASC) 606, Revenue Recognition &amp;#8212; Revenue from Contracts with Customers&lt;/i&gt;&#13;(&amp;#8220;ASC 606&amp;#8221;) which amends the guidance in former &lt;i&gt;ASC 605, Revenue Recognition&lt;/i&gt;, and is effective for public companies&#13;for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from the current accounting&#13;standard in many respects, such as in the accounting for variable consideration received, including milestone payments or contingent&#13;payments. Under the Company&amp;#8217;s accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone&#13;payments were initially recognized only in the period that the payment-triggering event occurred or was achieved (See Note 8).&#13;ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely achieved based&#13;on the Company&amp;#8217;s estimate of the amount of consideration to which it will be entitled in exchange for transferring the services,&#13;subject to management&amp;#8217;s assessment of whether it is probable that a significant reversal in the amount of cumulative revenue&#13;recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company&#13;adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of&#13;initially applying ASC 606 is recognized at the date of initial application. Since the Company has concluded its performance obligations&#13;and has completed recognizing revenue under the agreement with CFFT in the third quarter of 2017 (See Note 8), there was no cumulative&#13;effect to record at the date of the Company&amp;#8217;s adoption of ASC 606. The Company will assess any new agreements it enters into,&#13;including the 2018 CFF Award, (See Note 15) under ASC 606, including if such agreements fall under the scope of such standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Accounting for Leases&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;ASU No&lt;b&gt;. &lt;/b&gt;2016-02, &lt;i&gt;Leases (Topic 842) &lt;/i&gt;(&amp;#8220;ASU 2016-02&amp;#8221;)&lt;i&gt;. &lt;/i&gt;Under ASU 2016-02, a lessee will be required&#13;to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current GAAP, the&#13;recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on&#13;its classification as a finance or operating lease. However, unlike current GAAP, which requires only capital leases to be recognized&#13;on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU 2016-02 will take&#13;effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early application&#13;permitted. The adoption of ASU 2016-02 will have an impact on the Company&amp;#8217;s financial position as the Company has operating&#13;lease commitments for office space as of December 31, 2017 with future non-cancelable lease payments amounting to $5,474,623 (see&#13;Note 5) for which ASU 2016-02 would apply.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Property and Equipment consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Computer hardware and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;136,522&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;96,131&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Office furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;287,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;259,138&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;191,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;188,219&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Construction in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,181,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,796,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;543,488&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(363,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(108,237&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,432,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;435,251&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Depreciation expense was approximately&#13;$256,000, $88,000 and $44,000 for the years ended December 31, 2017, 2016 and 2015, respectively. At December 31, 2017, construction&#13;in progress consisted of purchased property and equipment not placed in service until the Company&amp;#8217;s relocation into 32,733&#13;square feet of office space in February 2018 (See Note 5).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 30, 2015, the Company&#13;entered into a lease agreement for a copier machine. The cost of the machine was approximately $12,000 and is included in office&#13;furniture and equipment category in the table above. The lease payments commenced when the machine was placed in service in January&#13;2016. The machine is being amortized over the life of the lease, which is for a three-year term and includes a bargain purchase&#13;option at the end of the term. See Note 5 for details of this capital lease commitment.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Operating Lease Commitment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In September 2016, the Company amended&#13;its commercial lease for office space to expand into an additional 4,088 square feet of office space within the same building for&#13;an aggregate total of 10,414 square feet of leased office space (&amp;#8220;September 2016 Amendment&amp;#8221;). The Company began occupying&#13;this space in early November 2016 and the final lease payment was to be due in January 2021. The September 2016 Amendment required&#13;an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was terminated upon the commencement&#13;date of the August 2017 Lease Agreement discussed below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On August 21, 2017, the Company&#13;entered into a lease agreement (&amp;#8220;August 2017 Lease Agreement&amp;#8221;) with the same landlord, pursuant to which the Company&#13;agreed to lease 32,733 square feet of office space (&amp;#8220;Leased Premises&amp;#8221;). The initial term of the August 2017 Lease Agreement&#13;is for a period of seven years which began with the Company&amp;#8217;s occupancy of the Leased Premises in February 2018. The base&#13;rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately $908,000 for the seventh year.&#13;Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company for $1,080,189 of leasehold improvements.&#13;The reimbursements have been deferred and will be recognized as a reduction of rent expense over the term of the lease. Additionally,&#13;the August 2017 Lease Agreement required a standby irrevocable letter of credit of $400,000, which may be reduced, if the Company&#13;is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement&#13;date, respectively, The Company entered into an unsecured letter of credit for $400,000 in connection with the August 2017 Lease&#13;Agreement for which it incurred interest expense of $9,743 in year ended December 31, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company records the total rent&#13;payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents&#13;paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and deferred rent, noncurrent in&#13;the Company&amp;#8217;s balance sheet as of December 31, 2017 and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Company&amp;#8217;s&#13;non-cancelable lease agreements in effect at December 31, 2017, the future minimum rent commitments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;445,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;623,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;784,243&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;830,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;855,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,935,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,474,623&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Total rent expense for the years&#13;ended December 31, 2017, 2016 and 2015 was $356,547, $229,705 and $55,496, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;b&gt;Capital Lease Commitment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The lease payments commenced when&#13;the machine was placed in service in January 2016. The lease is for a three-year term and includes a bargain purchase option at&#13;the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current portion of this capital lease&#13;obligation is classified in accrued expenses and the long-term portion of the capital lease obligation is classified in other long-term&#13;liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital lease commitments are as follows&#13;as of December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,922&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(291&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Future capital lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Long-term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Interest expense for this capital&#13;lease obligation for the years ended December 31, 2017, 2016 and 2015 was $712, $1,286 and $0, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For commitments under the Company&amp;#8217;s&#13;development award agreements- see Note 8.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;NOTES PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In November 2015, the Company entered&#13;into a loan agreement with a financing company for $207,750 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulated equal monthly payments of principal and interest payments of $23,397 over a nine month period. Interest&#13;on this loan was accrued at an annual rate of 3.25%. This loan was fully repaid in July 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In October 2016, the Company entered&#13;into a loan agreement with a financing company for $348,750 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over a nine-month period. Interest on&#13;this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In November 2017, the Company entered&#13;into a loan agreement with a financing company for $415,265 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest accrues&#13;on this loan at an annual rate of 2.35%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Prepaid expenses and other current&#13;assets as of December 31, 2017 and 2016 included $368,976 and $378,750, respectively, related to these insurance policies.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Interest expense for notes payable&#13;for the years ended December 31, 2017, 2016 and 2015 totaled $3,632, $3,115 and $2,440, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;ACCRUED EXPENSES &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Accrued expenses consisted of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued clinical operations and trials costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,003,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,647,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued product development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,255,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;713,426&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,335,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;778,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;146,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;117,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,741,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,256,455&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;COMMON STOCK &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has authorized 150,000,000&#13;shares of common stock, $0.0001 par value per share, of which 55,603,427 shares, 44,681,745 shares, and 37,605,134 shares were&#13;issued and outstanding as of December 31, 2017, 2016, and 2015, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;During the year ended December 31,&#13;2015, the Company issued 11,666,802 shares of common stock upon the exercise of warrants and stock options to purchase common stock&#13;and the Company received net proceeds of $10,819,714 from these exercises.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In June 2016, the Company completed&#13;a sale of shares of its common stock pursuant to the terms of a securities purchase agreement under which the Company sold an aggregate&#13;of 5,960,000 shares of its common stock in a registered direct offering to investors at a purchase price of $2.50 per share with&#13;gross proceeds to the Company totaling approximately $14,900,000 less issuance costs of $25,222. On February 28, 2017, the Company&#13;entered in a securities purchase agreement providing for the issuance and sale by the Company of 3,887,815 shares of its common&#13;stock in a registered direct offering to institutional and accredited investors at a purchase price of $7.00 per share with gross&#13;proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In November 2016, the Company entered&#13;into a sales agreement with Cantor Fitzgerald under which the Company could direct Cantor Fitzgerald as its sales agent to sell&#13;common stock under an &amp;#8220;At the Market Offering&amp;#8221; (&amp;#8220;Sales Agreement&amp;#8221;). Sales of common stock under the Sales&#13;Agreement were made pursuant to an effective registration statement for an aggregate offering of up to $35 million. Under the Sales&#13;Agreement, the Company was obligated to pay Cantor a 3% commission on gross proceeds. In 2016, the Company sold 188,695 shares&#13;of our common stock under the Sales Agreement at an average selling price of approximately $8.54 per share (net of 3% commission&#13;paid to Cantor Fitzgerald) which resulted in proceeds of approximately $1,621,182 and net proceeds of approximately $1,426,145&#13;net of incurred issuance costs. Approximately $330,413 of these proceeds were classified in stock subscriptions receivable as of&#13;December 31, 2016 because the Company did not receive these proceeds until January 2017. During the year ended December 31, 2017,&#13;in the first quarter, the Company sold 1,413,633 shares of its common stock under the Sales Agreement at an average selling price&#13;of approximately $9.71 per share for gross proceeds of $13,724,591 and net proceeds of $13,268,208. The Company did not sell any&#13;shares of its common stock under the Sales Agreement in the second or third quarter of 2017 and terminated the Sales Agreement&#13;in connection with the October 2017 Offering discussed below. The aggregate amount sold under the Sales Agreement as described&#13;above was approximately $15.4 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;See Note 15 for the January 2018&#13;Sales Agreement entered into by the Company and Cantor Fitzgerald after the balance sheet date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On October 26, 2017, the Company&#13;consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 4,650,000&#13;shares of its common stock to institutional investors at a purchase price of $7.00 per share with gross proceeds to the Company&#13;totaling $32,550,000, less estimated issuance costs incurred of approximately $2,184,000. The Company also granted the underwriters&#13;a 30-day option to purchase up to an additional 697,500 shares of common stock on the same terms as the underwriters were purchasing&#13;the base number of shares, which they exercised in November 2017 with net proceeds to us totaling $4,589,550.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;During the year ended December&#13;31, 2017, the Company issued 272,734 shares of common stock upon the exercise of stock options and warrants to purchase common&#13;stock and the Company received net proceeds of $189,490 from these exercises. During the year ended December 31, 2016, the Company&#13;issued 927,916 shares of common stock upon the exercise of stock options and warrants to purchase common stock and the Company&#13;received net proceeds of $468,442 from these exercises.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;STOCK OPTIONS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In April 2014, the Company adopted&#13;the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &amp;#8220;2014 Plan&amp;#8221;). Pursuant to the 2014 Plan,&#13;the Company&amp;#8217;s Board of Directors may grant incentive and nonqualified stock options and restricted stock to employees, officers,&#13;directors, consultants and advisors. On January 1, 2017, pursuant to an annual evergreen provision contained in the 2014 Plan,&#13;the number of shares reserved for future grants was increased by 3,127,722 shares. As of December 31, 2017, there was a total of&#13;13,043,739 shares reserved for issuance under the 2014 Plan and there were 4,460,334 shares available for future grants. Options&#13;issued under the 2014 Plan generally vest over 4 years from the date of grant in multiple tranches and are exercisable for up to&#13;10 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of an annual&#13;evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically&#13;increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on&#13;December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may&#13;determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective&#13;as of January 1, 2018, the number of shares of common stock available for issuance under the 2014 Plan increased by 2,500,000 shares,&#13;which was less than seven percent (7%) of the outstanding shares of common stock on December 31, 2017. As of January 1, 2018, the&#13;2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares available for future grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Share-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For stock options issued and outstanding&#13;for the years ended December 31, 2017, 2016 and 2015, the Company recorded non-cash, stock-based compensation expense of $5,694,489&#13;($4,640,646 for employees and $1,053,843 for non-employees), $3,163,534 ($2,104,939 for employees and $1,058,595 for non-employees)&#13;and $1,153,302 ($672,071 for employees and $481,231 for non-employees), respectively, net of estimated forfeitures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The fair value of each option award&#13;for employees is estimated on the date of grant and for non-employees is estimated at the end of each reporting period using the&#13;Black-Scholes option pricing model that uses the assumptions noted in the following table. Due to its limited operating history,&#13;the Company estimated its volatility in consideration of a number of factors, including the volatility of comparable public companies&#13;and, commencing in 2015, the Company also included the volatility of its own common stock, taking into account the expected life&#13;of the option. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial&#13;statements, to estimate option exercises and employee terminations in order to estimate its forfeiture rate. The expected term&#13;of options granted under the 2014 Plan, all of which qualify as &amp;#8220;plain vanilla&amp;#8221; per SEC Staff Accounting Bulletin 107,&#13;is based on the average between the vesting period and the contractual life of the options which is 6.25 years. For non-employee&#13;options, the expected term is the contractual term. The risk-free rate is based on the yield of a U.S. Treasury security with a&#13;term consistent with the option.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average assumptions&#13;used principally in determining the fair value of options granted to employees were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.73&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;86.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;90.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;90.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Estimated forfeiture rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For the year ended December 31,&#13;2017, the assumptions used in determining the fair value of options granted to nonemployees included risk free interest rate ranging&#13;from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years, expected volatility ranging&#13;from 85.58% to 89.58%, and estimated forfeiture rate of 5%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of option activity for&#13;years ended December 31, 2017 and 2016 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Exercise &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Remaining &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Contractual &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Term in &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Intrinsic &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,982,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,020,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(326,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(65,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(272,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;29,433,877&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Vested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,514,977&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;23,444,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average grant-date&#13;fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was $6.22, $3.81 and $1.41 per share, respectively.&#13;The aggregate intrinsic value of options exercised during the years ended December 31, 2017, 2016 and 2015 was approximately $2,092,964.&#13;$1,004,321 and $152,531, respectively. As of December 31, 2017 there was approximately $12,542,918 of total unrecognized compensation&#13;expense, related to non-vested share-based compensation arrangements. The unrecognized compensation expense is estimated to be&#13;recognized over a period of 2.87 years at December 31, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As summary of non-vested stock options&#13;for the years ended December 31, 2017 and 2016 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Fair &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,035,254&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,020,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,194,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(34,380&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Nonvested at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,826,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,003,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,329,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <CRBP:WarrantsTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;WARRANTS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;At December 31, 2017, there were&#13;warrants outstanding to purchase 1,288,500 shares of common stock with a weighted average exercise price of $1.00 and a weighted&#13;average remaining life of 1.41 years. No warrants were exercised during the year ended December 31, 2017. During the year ended&#13;December 31, 2016, warrants to purchase 679,500 shares of common stock were exercised on a cashless basis resulting in the issuance&#13;of 599,780 shares and 1,250 shares of common stock were exercised on a for cash basis. There were no warrants issued or cancelled&#13;during the year ended December 31, 2017 or 2016&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For warrant issued to CFF after&#13;the balance sheet date &amp;#8211; see Note 15.&lt;/p&gt;</CRBP:WarrantsTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;RELATED PARTY TRANSACTIONS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On September 20, 2016, the Company&#13;entered into a consulting agreement (the &amp;#8220;2016 Consulting Agreement&amp;#8221;) with Orchestra Medical Ventures, LLC (&amp;#8220;Orchestra&amp;#8221;),&#13;of which a member of the Company&amp;#8217;s Board of Directors, David Hochman, is Managing Partner. Under this agreement, Orchestra&#13;rendered a variety of consulting and advisory services relating principally to identifying and evaluating strategic relationships,&#13;licensing opportunities, and business strategies. The term of the 2016 Consulting Agreement commenced on September 20, 2016 and&#13;expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting Agreement, the Company paid to Orchestra cash compensation&#13;in an aggregate amount of $100,000. In connection with this agreement, the Company granted an equity incentive award to Mr. Hochman&#13;consisting of options to purchase 50,000 shares (&amp;#8220;Option Shares&amp;#8221;) of common stock (the &amp;#8220;Option Award&amp;#8221;)&#13;pursuant to the Company&amp;#8217;s 2014 Equity Compensation Plan, of which fifty percent (50%) vested on the three (3) month anniversary&#13;of the date of grant of the Option Award and the remainder of the Option Shares vested on the six (6) month anniversary of the&#13;date of grant of the Option Award. The Option Shares were granted with an exercise price of $7.14 per share. The Company recorded&#13;stock-based compensation expense of approximately $222,000 during the year ended December 31, 2016 and $171,000 during the first&#13;quarter of 2017 in respect of the Option Award. No stock-based compensation expense was recorded after the first quarter of 2017&#13;related to the Option Shares as they were fully vested in March 2017.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The following table sets&#13;forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(19,998,675&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,850,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,137,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,350,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following&#13;potentially dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of&#13;dilutive weighted average shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,969,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,982,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,898,679&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,951,315&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Property and Equipment consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 69%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;136,522&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96,131&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Office furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;287,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;259,138&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;191,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;188,219&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Construction in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,181,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,796,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;543,488&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(363,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(108,237&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,432,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;435,251&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of&#13;the Company&amp;#8217;s non-cancelable lease agreements in effect at December 31, 2017, the future minimum rent commitments are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;445,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;623,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;784,243&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;830,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;855,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,935,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,474,623&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Pursuant to the terms of&#13;this capital lease agreement, the future minimum capital lease commitments are as follows as of December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,922&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(291&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Future capital lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Long-term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Deferred revenue consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 68%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,940,195&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,940,195&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Long term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average assumptions&#13;used principally in determining the fair value of options granted to employees were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 61%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.73&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;86.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;90.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;90.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated forfeiture rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of option activity&#13;for years ended December 31, 2017 and 2016 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term in&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intrinsic&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 49%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,982,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,020,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(326,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(65,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(272,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,433,877&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,514,977&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,444,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">-4256</us-gaap:CapitalLeaseObligationsCurrent>
    <dei:TradingSymbol contextRef="From2017-01-01to2017-12-31">CRBP</dei:TradingSymbol>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5694489</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">3163534</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5694489</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3163534</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1153302</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1153302</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="AsOf2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember" unitRef="USD" decimals="0">50000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseExpirationDate1 contextRef="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">2021-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and&#13;restricted cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 69%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,127,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,864,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,992,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted cash, current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted cash, noncurrent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,192,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">158991</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2016-12-31_custom_CorporatecreditCardsMember" unitRef="USD" decimals="0">150000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2017-12-31_custom_CorporatecreditCardsMember" unitRef="USD" decimals="0">108991</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2017-12-31_custom_StandbyLetterOfCreditMember" unitRef="USD" decimals="0">50000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2016-12-31_custom_StandbyLetterOfCreditMember" unitRef="USD" decimals="0">50000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">4543</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">379</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <CRBP:CommissionPaidPercentage contextRef="From2016-11-01to2016-11-30_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="Percentage" decimals="INF">0.03</CRBP:CommissionPaidPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2016-12-29to2017-01-02_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">3127722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2017-01-01to2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember" unitRef="Shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2017-12-30to2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">13043739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">15543739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember" unitRef="Shares" decimals="INF">15543739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4460334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">6960334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember" unitRef="Shares" decimals="INF">6960334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear contextRef="From2017-12-30to2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Percentage" decimals="INF">0.07</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember">P4Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember">P9Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">P6Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2092964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1004321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">152531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2017-01-01to2017-12-31">P2Y10M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember" unitRef="Percentage" decimals="INF">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember" unitRef="Percentage" decimals="INF">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.9039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.8601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.9068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">6610179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">7844966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">3982065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">1681500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">3020000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">173979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">-2003806</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">-1194600</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">8.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityCompensationPlanMember" unitRef="USDPShares" decimals="INF">7.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">0.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">6.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">2.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-12-31">P7Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-12-31">P7Y0M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">29433877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">23444225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <CRBP:WarrantsWeightedAverageRemainingContractualTerm contextRef="From2017-01-01to2017-12-31">P1Y4M28D</CRBP:WarrantsWeightedAverageRemainingContractualTerm>
    <CRBP:ClassOfWarrantOrRightIssued contextRef="From2017-01-01to2017-12-31" unitRef="Shares" xsi:nil="true" />
    <CRBP:ClassOfWarrantOrRightIssued contextRef="From2016-01-01to2016-12-31" unitRef="Shares" xsi:nil="true" />
    <CRBP:ClassOfWarrantOrRightCancelled contextRef="From2017-01-01to2017-12-31" unitRef="Shares" xsi:nil="true" />
    <CRBP:ClassOfWarrantOrRightCancelled contextRef="From2016-01-01to2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">5000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisProgramRelatedInvestmentAgreementMember" unitRef="USD" decimals="0">25000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponCommercializationOfTheProductMember_custom_LenabasumMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">25000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">5000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponTransferSaleOrLicensingMember_custom_LenabasumMember" unitRef="USD" decimals="0">15000000</us-gaap:RoyaltyExpense>
    <CRBP:NumberOfInstallments contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_LenabasumMember" unitRef="Installments" decimals="INF">3</CRBP:NumberOfInstallments>
    <CRBP:RoyaltyPaymentSalesTarget contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_LenabasumMember" unitRef="USD" decimals="0">500000000</CRBP:RoyaltyPaymentSalesTarget>
    <CRBP:PaymentDuePeriodAfterTheFirstCommercialSale contextRef="From2015-04-19to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_LenabasumMember">P90D</CRBP:PaymentDuePeriodAfterTheFirstCommercialSale>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">778250</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1335672</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember">2017-03-20</us-gaap:RelatedPartyTransactionDate>
    <dei:EntityFilerCategory contextRef="From2017-01-01to2017-12-31">Accelerated Filer</dei:EntityFilerCategory>
    <CRBP:DevelopmentAwardAndDeferredRevenueTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;DEVELOPMENT AWARD AND DEFERRED REVENUE &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On April 20, 2015, the Company entered&#13;into an award agreement (the &amp;#8220;2015 CFFT Award Agreement &amp;#8220;) with the CFFT pursuant to which it received a development&#13;award (the &amp;#8220;2015 CFFT Award&amp;#8221;) for up to $5 million in funding. The funding from the 2015 CFFT Award supported a first-in-patient&#13;Phase 2 clinical trial of the Company&amp;#8217;s oral anti-inflammatory drug lenabasum in adults with cystic fibrosis (&amp;#8220;CF&amp;#8221;).&#13;The Company has received $5.0 million in payments since the inception of the 2015 CFFT Award as outlined below. The payments received&#13;under the 2015 CFFT Award were recorded as deferred revenue when the triggering event to receive those amounts had occurred and&#13;were amortized on a straight-line basis over the expected duration of the remaining performance period under the 2015 CFFT Award&#13;which concluded in the third quarter of 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Upon the execution of the 2015 CFFT&#13;Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the Company received a second payment&#13;of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, the Company received a third payment&#13;from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical trial patient.&#13;In January 2017, the Company received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone in December&#13;2016 related to completing the final visit for the final patient, which was billed by the Company to CFFT in December 2016 and&#13;was classified in grants receivable as of December 31, 2016. The Company received the final payment from CFFT in the amount of&#13;$500,000 in November 2017 for achieving the final milestone in September 2017 related to the issuance to CFFT of the final integrated&#13;statistical report for to the Phase 2 CF clinical trial. At that time the Company had completed all its performance obligations&#13;under the contract and therefore the performance period had concluded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the 2015&#13;CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization of lenabasum&#13;in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five times the amount&#13;the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments following&#13;the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum,&#13;(ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up to $5 million,&#13;due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million,&#13;and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses lenabasum in&#13;the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change of control transaction,&#13;with such payment(s) to be credited against the royalty payments due upon commercialization. The Field of Use is defined in the&#13;2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity&#13;pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company may terminate the&#13;agreement for cause, which includes the Company&amp;#8217;s material failure to achieve certain commercialization and development milestones.&#13;The Company&amp;#8217;s payment obligations, if any, would survive the termination of the 2015 CFFT Award Agreement. For the years&#13;ended December 31, 2017, 2016 and 2015, in respect of the 2015 CFFT Award Agreement, the Company recognized revenue of $2,440,195,&#13;$1,911,424 and $648,382, respectively. Deferred revenue consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Deferred revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,940,195&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,940,195&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Long term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;See Note 15 for the Investment&#13;Agreement entered into by the Company after the balance sheet date.&lt;/p&gt;</CRBP:DevelopmentAwardAndDeferredRevenueTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityCompensationPlanMember" unitRef="Percentage" decimals="INF">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-03-06" unitRef="Shares" decimals="INF">57134677</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">17888182</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">66978161</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">-33276489</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">-65698101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">42191256</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">123476102</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:PreferredStockValue contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">8968947</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9194600</us-gaap:Liabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">4632</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">375</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">65724</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">989550</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">8898591</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">8204675</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">10263</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1940195</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">3256455</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4741519</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">3419921</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3130295</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">271757</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">332861</us-gaap:NotesPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">17888182</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">66978161</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">435251</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1432655</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">17402931</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">65504730</us-gaap:AssetsCurrent>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1000000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">158991</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">14992257</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62537495</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">40776</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">50176953</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">41137518</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">53828680</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">44348543</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-03to2017-03-31" unitRef="Shares" decimals="INF">46381482</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">31350145</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-04-01to2017-06-30" unitRef="Shares" decimals="INF">50193726</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-07-01to2017-09-30" unitRef="Shares" decimals="INF">50221597</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">37605210</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="Shares" decimals="INF">38748452</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="Shares" decimals="INF">43783504</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-10-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-10-01to2016-12-31" unitRef="USDPShares" decimals="INF">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-03to2017-03-31" unitRef="USDPShares" decimals="INF">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" decimals="INF">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-04-01to2017-06-30" unitRef="USDPShares" decimals="INF">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-07-01to2017-09-30" unitRef="USDPShares" decimals="INF">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="USDPShares" decimals="INF">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">141204</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-13617</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">168236</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2159</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">-12899</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">2954</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-5323</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">-8810</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-5017</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">2239</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-12998</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-41908</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-14094</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">35163</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2102</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">-14265</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1977</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-10594</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">-52212</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">343</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-1810</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-14729</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">183112</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">477</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">133073</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">57</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">1366</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">977</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">5271</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">43402</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-5360</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">4049</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">1731</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-32562816</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-19985058</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-10861926</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-7572434</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">-7452540</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-8853693</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">-7291564</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">-6956786</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-2887224</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-4191630</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-5333770</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">35003011</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">21896482</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">10861926</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">7948104</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">8746237</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">9502075</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">7641750</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">7753098</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3283822</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">4588228</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">6076328</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">8964046</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">6459747</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2575244</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2567937</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">2380125</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">3613416</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">1878090</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">2130587</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">1109889</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">1021225</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">1760696</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">26038965</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">15436735</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">8286682</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">5380167</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">6366112</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">5888659</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">5763660</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">5622511</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">2173933</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">3567003</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">4315632</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2440195</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1911424</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-10-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">375670</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-01-03to2017-03-31" unitRef="USD" decimals="0">1293697</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">648382</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-04-01to2017-06-30" unitRef="USD" decimals="0">350186</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-07-01to2017-09-30" unitRef="USD" decimals="0">796312</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">396598</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">396598</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">742558</us-gaap:Revenues>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">579734</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">34107</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2017-01-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">11638</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">76008286</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">16741866</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">10837344</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">3832</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">3175</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2940685</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">63830</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">509215</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">354161</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">239012</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">190120</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-707429</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-353032</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-114037</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">707429</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">353032</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">114037</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-27796628</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">-13571227</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-4624830</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-1940195</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">88577</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1851618</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1514521</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2660461</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">312788</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-885797</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1890876</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">972194</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-1000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <CRBP:IncreaseDecreaseInDeferredRent contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">913563</CRBP:IncreaseDecreaseInDeferredRent>
    <CRBP:IncreaseDecreaseInDeferredRent contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">75987</CRBP:IncreaseDecreaseInDeferredRent>
    <CRBP:IncreaseDecreaseInDeferredRent contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5694489</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">3163534</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_EmployeesMember" unitRef="USD" decimals="0">4640646</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31_custom_EmployeesMember" unitRef="USD" decimals="0">2104939</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember" unitRef="USD" decimals="0">1053843</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31_custom_NonEmployeesMember" unitRef="USD" decimals="0">1058595</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1153302</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31_custom_EmployeesMember" unitRef="USD" decimals="0">672071</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31_custom_NonEmployeesMember" unitRef="USD" decimals="0">481231</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">40776</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:UseOfEstimates contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The process of preparing financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at&#13;the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results&#13;could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based&#13;compensation expense, the accrual of research, product development and clinical obligations, and the expected performance period&#13;under the 2015 CFFT Award (See Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Prior to the registration of its&#13;common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not&#13;less than the fair value of its common stock as determined by the board of directors, with input from management. The Company&amp;#8217;s&#13;board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors,&#13;including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company&#13;sold shares of preferred stock.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The carrying amounts reported in&#13;the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their&#13;fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair&#13;value due to the fact that they are at market terms.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The estimated life for the Company&amp;#8217;s&#13;property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture&#13;and equipment. The Company&amp;#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their&#13;useful lives or the respective leases. See Note 4 for details of property and equipment and Note 5 for operating and capital lease&#13;commitments.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&#13;and Development Award Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Costs incurred for research and&#13;development are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Nonrefundable advance payments for&#13;goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant&#13;to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the&#13;related goods are delivered or the related services are performed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For amounts received under the&#13;development award received from the CFFT (See Note 8), the Company recognized those amounts when the triggering event to receive&#13;those payments occurred, with those amounts being amortized on a straight-line basis over the expected duration of the remaining&#13;performance period of the development program under the award, which concluded in the third quarter of 2017.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <CRBP:AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accruals for Research and&#13;Development Expenses and Clinical Trials&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As part of the process of preparing&#13;its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with&#13;vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical&#13;trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result&#13;in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&amp;#8217;s&#13;objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which&#13;services are performed and efforts are expended. The Company determines accrual estimates by taking into account discussion with&#13;applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the&#13;course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates.&#13;The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to&#13;it at that time. The Company&amp;#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract&#13;research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different&#13;from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status&#13;and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular&#13;period. For the years ended December 31, 2017, 2016 and 2015, there were no material adjustments to the Company&amp;#8217;s prior&#13;period estimates of accrued expenses for clinical trials.&lt;/p&gt;</CRBP:AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has no significant&#13;off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.&#13;The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However,&#13;the Company believes the risk of loss is minimal as these banks are large financial institutions.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Operating segments are identified&#13;as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating&#13;decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date,&#13;the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing&#13;therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2017 and 2016, all of the Company&amp;#8217;s&#13;assets were located in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For federal and state income taxes,&#13;deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax&#13;basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in&#13;which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax asset when it is not&#13;more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses&#13;since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate&#13;the deferred tax assets amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Tax positions taken or expected&#13;to be taken in the course of preparing the Company&amp;#8217;s tax returns are required to be evaluated to determine whether the tax&#13;positions are &amp;#8220;more-likely-than-not&amp;#8221; of being sustained by the applicable tax authority. Tax positions not deemed&#13;to meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense&#13;in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of&#13;December 31, 2017 or 2016.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company continually monitors&#13;events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An&#13;impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&amp;#8217;s carrying value.&#13;Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to&#13;the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess&#13;of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset&#13;may not be recoverable. No impairment charges were recorded for the years ended December 31, 2017, 2016 and 2015.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-based Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company recognizes compensation&#13;costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement&#13;of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option&#13;grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized&#13;as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.&#13;Stock options granted to non-employee consultants are revalued at the end of each reporting period until vested using the Black-Scholes&#13;option-pricing model and the changes in their fair value are recorded as adjustments to expense over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On March 30, 2016, the FASB issued&#13;ASU No. 2016-09, &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&#13;&lt;/i&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;i&gt;. &lt;/i&gt;ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment&#13;transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification&#13;in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures&#13;as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have&#13;an impact on the Company&amp;#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the&#13;excess tax benefits in respect of share based payments only when realized (See Note 9).&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Basic and diluted net loss per share&#13;of the Company&amp;#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding&#13;during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted&#13;loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years&#13;ended December 31, 2017, 2016 and 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,998,675&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(8,850,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,137,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;31,350,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following potentially&#13;dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of dilutive weighted&#13;average shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,969,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,982,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,898,679&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,951,315&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In May 2014, the FASB issued guidance&#13;codified in &lt;i&gt;Accounting Standards Codification (ASC) 606, Revenue Recognition &amp;#8212; Revenue from Contracts with Customers&lt;/i&gt;&#13;(&amp;#8220;ASC 606&amp;#8221;) which amends the guidance in former &lt;i&gt;ASC 605, Revenue Recognition&lt;/i&gt;, and is effective for public companies&#13;for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from the current accounting&#13;standard in many respects, such as in the accounting for variable consideration received, including milestone payments or contingent&#13;payments. Under the Company&amp;#8217;s accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone&#13;payments were initially recognized only in the period that the payment-triggering event occurred or was achieved (See Note 8).&#13;ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely achieved based&#13;on the Company&amp;#8217;s estimate of the amount of consideration to which it will be entitled in exchange for transferring the services,&#13;subject to management&amp;#8217;s assessment of whether it is probable that a significant reversal in the amount of cumulative revenue&#13;recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company&#13;adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of&#13;initially applying ASC 606 is recognized at the date of initial application. Since the Company has concluded its performance obligations&#13;and has completed recognizing revenue under the agreement with CFFT in the third quarter of 2017 (See Note 8), there was no cumulative&#13;effect to record at the date of the Company&amp;#8217;s adoption of ASC 606. The Company will assess any new agreements it enters into,&#13;including the 2018 CFF Award, (See Note 15) under ASC 606, including if such agreements fall under the scope of such standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Accounting for Leases&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;ASU No&lt;b&gt;. &lt;/b&gt;2016-02, &lt;i&gt;Leases (Topic 842) &lt;/i&gt;(&amp;#8220;ASU 2016-02&amp;#8221;)&lt;i&gt;. &lt;/i&gt;Under ASU 2016-02, a lessee will be required&#13;to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current GAAP, the&#13;recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on&#13;its classification as a finance or operating lease. However, unlike current GAAP, which requires only capital leases to be recognized&#13;on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU 2016-02 will take&#13;effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early application&#13;permitted. The adoption of ASU 2016-02 will have an impact on the Company&amp;#8217;s financial position as the Company has operating&#13;lease commitments for office space as of December 31, 2017 with future non-cancelable lease payments amounting to $5,474,623 (see&#13;Note 5) for which ASU 2016-02 would apply.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">12542918</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <CRBP:NumberOfCommonStockWereExercisedOnCashBasis contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">1250</CRBP:NumberOfCommonStockWereExercisedOnCashBasis>
    <CRBP:LiquidityDisclosuresTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 33px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;LIQUIDITY &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company anticipates operating&#13;losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its&#13;product candidates and its preclinical and clinical programs, strategic alliances and the development of its administrative organization.&#13;The Company has incurred recurring losses since inception and as of December 31, 2017, had an accumulated deficit of $65,698,101.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 5, 2018, the Company&#13;entered into a Controlled Equity Offering&lt;sup&gt;SM&lt;/sup&gt; Sales Agreement (&amp;#8220;January 2018 Sales Agreement&amp;#8221;) with Cantor&#13;Fitzgerald &amp;#38; Co. (&amp;#8220;Cantor Fitzgerald&amp;#8221;) pursuant to which Cantor Fitzgerald is serving as the Company&amp;#8217;s sales&#13;agent to sell up to $50 million of shares of the Company&amp;#8217;s common stock through an &amp;#8220;at the market offering,&amp;#8221;&#13;of which 1,500,000 shares have been sold for net proceeds of $11.3 million to date. (See Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 26, 2018, the Company&#13;entered into the Cystic Fibrosis Program Related Investment Agreement (&amp;#8220;Investment Agreement&amp;#8221;) with the Cystic Fibrosis&#13;Foundation (&amp;#8220;CFF&amp;#8221;), a non-profit drug discovery and development corporation, pursuant to which the Company received&#13;a development award for up to $25 million in funding (the &amp;#8220;2018 CFF Award&amp;#8221;) to support a Phase 2b Clinical Trial (the&#13;&amp;#8220;Phase 2b Clinical Trial&amp;#8221;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25 million&#13;to date. The Company expects the remainder of the 2018 CFF Award will be paid to the Company incrementally upon the achievement&#13;of the remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement. (See&#13;Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company expects the cash on&#13;hand of $62,537,495 at December 31, 2017 together with the $11.3 million of net proceeds received from the January 2018 Sales Agreement&#13;and the $6.25 million that the Company has received to date under the 2018 CFF Award, to be sufficient to meet its operating and&#13;capital requirements at least 12 months from the filing of this 10-K.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Should the Company be unable to&#13;raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing&#13;certain clinical activities. The Company will need to raise significant additional capital to continue to fund the clinical trials&#13;for lenabasum. The Company may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility&#13;or another form of third-party funding, or seek other debt financing. The sale of equity and convertible debt securities may result&#13;in dilution to the Company&amp;#8217;s stockholders and certain of those securities may have rights senior to those of the Company&amp;#8217;s&#13;common shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other&#13;debt financing, these securities or other debt could contain covenants that would restrict the Company&amp;#8217;s operations. Any&#13;other third-party funding arrangement could require the Company to relinquish valuable rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The source, timing and availability&#13;of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company&amp;#8217;s&#13;clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of&#13;necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company&amp;#8217;s&#13;planned clinical trials.&lt;/p&gt;</CRBP:LiquidityDisclosuresTextBlock>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-8490</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">14094</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-1977</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">47504229</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">2817607</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">6098477</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">15192257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62696486</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">12374650</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">6276173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecurities contextRef="AsOf2016-11-30_custom_SalesAgreementMember_custom_CantorFitzgeraldMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">35000000</us-gaap:AvailableForSaleSecurities>
    <CRBP:IssuanceOfCommonStockSharesExercisedOnCashlessBasis contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">599780</CRBP:IssuanceOfCommonStockSharesExercisedOnCashlessBasis>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CRBP:CashCompensationAmount contextRef="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember" unitRef="USD" decimals="0">100000</CRBP:CashCompensationAmount>
    <dei:EntityCentralIndexKey contextRef="From2017-01-01to2017-12-31">0001595097</dei:EntityCentralIndexKey>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Evergreen Provision&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of an annual&#13;evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically&#13;increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on&#13;December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may&#13;determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective&#13;as of January 1, 2018, the number of shares of common stock available for issuance under the 2014 Plan increased by 2,500,000 shares,&#13;such amount being less than seven percent (7%) of the outstanding shares of common stock on December 31, 2017. As of January 1,&#13;2018, the 2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares available for future grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;At the Market Offering&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 5, 2018, the Company&#13;entered into a sales agreement with Cantor Fitzgerald under which the Company may direct Cantor Fitzgerald as its sales agent to&#13;sell common stock up to an aggregate offering of up to $50 million under an &amp;#8220;At the Market Offering&amp;#8221; (&amp;#8220;January&#13;2018 Sales Agreement&amp;#8221;). Sales of common stock under the January 2018 Sales Agreement were made pursuant to an effective registration&#13;statement for an aggregate offering of up to $50 million. In February 2018, the Company sold 1,500,000 shares of its common stock&#13;to an institutional investor under the January 2018 Sales Agreement for which it received net proceeds of $11,349,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Cystic Fibrosis Program Related&#13;Investment Agreement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 26, 2018, the Company&#13;entered into the Cystic Fibrosis Program Related Investment Agreement with the Cystic Fibrosis Foundation (&amp;#8220;CFF&amp;#8221;) (&amp;#8220;Investment&#13;Agreement&amp;#8221;), a non-profit drug discovery and development corporation, pursuant to which the Company received an award for&#13;up to $25 million in funding (the &amp;#8220;2018 CFF Award&amp;#8221;) to support a Phase 2b Clinical Trial (the &amp;#8220;Phase 2b Clinical&#13;Trial&amp;#8221;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25 million to date. The Company&#13;expects that the remainder of the 2018 CFF Award will be paid incrementally upon the Company&amp;#8217;s achievement of the remaining&#13;milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Investment&#13;Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty payment of one and one-half times&#13;the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval of lenabasum in the United&#13;States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon approval in another major market,&#13;as set forth in the Investment Agreement (the &amp;#8220;Approval Royalty&amp;#8221;). At the Company&amp;#8217;s election, the Company may&#13;satisfy the first of the two Approval Royalties in registered shares of the Company&amp;#8217;s common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Additionally, the Company is obligated&#13;to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty days after any quarter&#13;in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments to CFF of one percent&#13;of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any quarter in which such&#13;net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and its stockholders receive in connection&#13;with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment or prevention of CF, or&#13;a change of control transaction, except that such payment shall not exceed five times the amount of the 2018 CFF Award, with such&#13;payments to be credited against any other net sales royalty payments due. Either CFF or the Company may terminate the Investment&#13;Agreement for cause, which includes the Company&amp;#8217;s material failure to achieve certain commercialization and development milestones.&#13;The Company&amp;#8217;s payment obligations survive the termination of the Investment Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Investment&#13;Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&amp;#8217;s common stock&#13;(the &amp;#8220;CFF Warrant&amp;#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable&#13;for 500,000 shares of the Company&amp;#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement&#13;and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable&#13;for the remaining 500,000 shares of the Company&amp;#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares&#13;of the Company&amp;#8217;s common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2017-01-01to2017-12-31_custom_CantorFitzgeraldAndCoMember_custom_SalesAgreementMember_custom_JanuaryFiveTwoThousandAndEighteenMember" unitRef="Shares" decimals="INF">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2018-02-01to2018-02-28_us-gaap_SubsequentEventMember_custom_AtTheMarketOfferingMember_custom_TwoThousandAndEighteenSalesAgreementMember" unitRef="Shares" decimals="INF">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">400000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_ThirdAnniversaryMember" unitRef="USD" decimals="0">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FourthAnniversaryMember" unitRef="USD" decimals="0">200000</us-gaap:LineOfCredit>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1935339</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">623958</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">784243</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">830600</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">855150</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USDPShares" decimals="INF">7.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-12-31_custom_SalesAgreementMember" unitRef="USDPShares" decimals="INF">9.71</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2016-06-30_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="USDPShares" decimals="INF">8.54</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USDPShares" decimals="INF">7.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:InterestPaidNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">12377</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">5586</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-01-01to2017-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-01-01to2017-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-01-01to2017-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityPublicFloat contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">294882116</dei:EntityPublicFloat>
    <us-gaap:AreaOfLand contextRef="AsOf2017-12-31_custom_FebruaryTwoThousandAndEighteenMember" unitRef="sqft" decimals="INF">32733</us-gaap:AreaOfLand>
    <CRBP:OperatingLeaseTerms contextRef="From2017-01-01to2017-12-31">P3Y</CRBP:OperatingLeaseTerms>
    <us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">712</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
    <us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1286</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
    <us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestExpenseLesseeAssetsUnderCapitalLease>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">28644000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">56536000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-12-31_custom_MassachusettsMember" unitRef="USD" decimals="0">53110000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-12-31_custom_MassachusettsMember" unitRef="USD" decimals="0">26573000</us-gaap:OperatingLossCarryforwards>
    <CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear contextRef="From2017-01-01to2017-12-31_custom_FederalMember">2029</CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear>
    <CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear contextRef="From2017-01-01to2017-12-31_us-gaap_StateAndLocalJurisdictionMember">2014</CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="AsOf2017-12-31_us-gaap_ResearchMember" unitRef="USD" decimals="0">1283000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="C_0001595097_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20151231" unitRef="USD" decimals="0">736000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5088343</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">7860985</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">10860828</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">15229127</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">673690</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1213347</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1177650</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1724248</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">302943</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">45654</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">225214</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">116292</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">13240325</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">18328668</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">13240325</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">18328668</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0566</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">0.0476</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">0.0476</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.0205</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">-0.0065</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">-0.0062</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0159</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">0.0133</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">0.0267</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0060</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">-0.0013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.1569</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">-0.3931</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">-0.4085</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember" unitRef="Percentage" decimals="INF">0.80</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">330413</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2016-12-31_custom_SalesAgreementMember_custom_CantorFitzgeraldMember" unitRef="USD" decimals="0">330413</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrantsShares contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">601030</CRBP:IssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrantsShares contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11615674</CRBP:IssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">1250</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">60</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1190</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">10814125</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1162</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10812963</CRBP:IssuanceOfCommonStockUponExerciseOfWarrants>
    <CRBP:IssuanceOfCommonStockUponExerciseOfWarrants contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssued1 contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">225501</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">196349</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1877983</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">553745</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">105959</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;QUARTERLY FINANCIAL INFORMATION (UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Quarters Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;March 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 26%"&gt;&lt;font style="font-size: 10pt"&gt;Revenue from awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,293,697&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;350,186&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;796,312&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Operating expenses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,366,112&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,763,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,622,511&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,286,682&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,380,125&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,878,090&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,130,587&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,575,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,746,237&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,641,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,753,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,861,926&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,452,540&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,291,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,956,786&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,861,926&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other income (expense):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,366&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,271&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;133,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Foreign currency exchange gain (loss)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(14,265&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,594&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(52,212&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;35,163&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Other income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(12,899&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(8,810&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;168,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,465,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,296,887&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,965,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,693,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;46,381,482&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,193,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,221,597&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;53,828,680&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Quarters Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;September 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 26%"&gt;&lt;font style="font-size: 10pt"&gt;Revenue from awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;396,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;396,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;742,558&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;375,670&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Operating expenses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,173,933&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,567,003&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,315,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,380,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,109,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,021,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,760,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,567,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,283,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,588,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,076,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,948,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,887,224&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,191,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,333,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,572,434&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other income (expense):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,731&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Foreign currency exchange gain (loss)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,810&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(14,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Other income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,239&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(12,998&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,892,241&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,189,391&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,346,768&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,570,275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;37,605,210&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,748,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43,783,504&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44,348,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <CRBP:LeasesAndDeferredRentPolicyTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases and Deferred Rent&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company leases its office space.&#13;Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&amp;#8217;s office&#13;space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records&#13;the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between&#13;the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the&#13;lessor are recorded as a reduction to rent expense over the term of the lease.&lt;/p&gt;</CRBP:LeasesAndDeferredRentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents, and&#13;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company considers only those&#13;investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to&#13;be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2017&#13;and 2016, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2017&#13;and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Restricted cash as of December 31,&#13;2017 and 2016 included a collateral account for the Company&amp;#8217;s corporate credit cards and is classified in current assets&#13;in the amount of $108,991 and $150,000, respectively. Additionally, as of December 31, 2017 and 2016 restricted cash included a&#13;stand-by letter of credit issued in favor of a landlord for $50,000 which was classified in current assets as of December 31, 2017&#13;and in noncurrent assets as of December 31, 2016 (See Note 5).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and restricted&#13;cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,127,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,864,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,992,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash, current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash, noncurrent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,192,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <CRBP:SummaryOfNonvestedStockOptionsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As summary of non-vested&#13;stock options for the years ended December 31, 2017 and 2016 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 69%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,035,254&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,020,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,194,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(34,380&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Nonvested at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,826,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,003,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-vested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,329,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</CRBP:SummaryOfNonvestedStockOptionsTableTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Quarters Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 29%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue from awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,293,697&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,186&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;796,312&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,366,112&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,763,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,622,511&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,286,682&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,380,125&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,878,090&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,130,587&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,575,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,746,237&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,641,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,753,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,861,926&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,452,540&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,291,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,956,786&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,861,926&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other income (expense):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,366&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,271&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;133,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign currency exchange gain (loss)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,265&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,594&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(52,212&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,163&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(12,899&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,810&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;168,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,465,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,296,887&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,965,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,693,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;46,381,482&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,193,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,221,597&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,828,680&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Quarters Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 30%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue from awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;396,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;396,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;742,558&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;375,670&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,173,933&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,567,003&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,315,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,380,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,109,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,021,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,760,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,567,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,283,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,588,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,076,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,948,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,887,224&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,191,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,333,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,572,434&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other income (expense):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,731&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign currency exchange gain (loss)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,810&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,239&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(12,998&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,892,241&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,189,391&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,346,768&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,570,275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,605,210&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,748,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,783,504&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,348,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.2411</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="Percentage" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="Percentage" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MinimumMember" unitRef="Percentage" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MaximumMember" unitRef="Percentage" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_InterestExpenseMember" unitRef="Percentage" decimals="INF">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_us-gaap_MaximumMember" unitRef="Percentage" decimals="INF">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_MinimumMember_custom_OrphanDrugCreditMember" unitRef="Percentage" decimals="INF">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember" unitRef="USD" decimals="0">7815832</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2017-01-01to2017-12-31_custom_CantorFitzgeraldAndCoMember_custom_SalesAgreementMember_custom_JanuaryFiveTwoThousandAndEighteenMember" unitRef="USD" decimals="0">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2018-01-04to2018-01-05_us-gaap_SubsequentEventMember_custom_AtTheMarketOfferingMember" unitRef="USD" decimals="0">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">1080189</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:CapitalLeaseObligations contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">4631</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">375</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:InterestExpense contextRef="From2017-01-01to2017-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">9743</us-gaap:InterestExpense>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">255652</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">87664</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">43943</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">5474623</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0500</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0500</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0483</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">3826274</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">3329989</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">2035254</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">4514977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2016-01-01to2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">-173979</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">-34380</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">2.86</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">4.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">5.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="USDPShares" decimals="INF">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">2025-01-26</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">445333</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">4922</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <CRBP:CashEquivalentsAndRestrictedCashMaturityPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_MaximumMember">P3M</CRBP:CashEquivalentsAndRestrictedCashMaturityPeriod>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2017-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">291</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">930261</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2808244</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-12-31_custom_InsurancePoliciesMember" unitRef="USD" decimals="0">368976</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-12-31_custom_InsurancePoliciesMember" unitRef="USD" decimals="0">378750</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Accrued expenses consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 69%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical operations and trials costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,003,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,647,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued product development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,255,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;713,426&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,335,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;778,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;117,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,741,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,256,455&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1432000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">189490</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">468442</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">10819714</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="From2017-12-30to2018-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Percentage" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <CRBP:ForfeituresEstimatedPercentage contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember" unitRef="Percentage" decimals="INF">0.05</CRBP:ForfeituresEstimatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">679500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">1288500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember_custom_InvestmentagreementMember" unitRef="Shares" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CRBP:AmountReceivedForDevelopmentAward contextRef="From2017-01-01to2017-12-31_custom_PhaseTwoBClinicalTrialMember_custom_InvestmentagreementMember_custom_JanuaryTwentySixTwoThousandAndEighteenMember" unitRef="USD" decimals="0">6250000</CRBP:AmountReceivedForDevelopmentAward>
    <CRBP:AmountReceivedForDevelopmentAward contextRef="From2017-01-01to2017-12-31_custom_TwoThousandAndEighteenCffAwardMember" unitRef="USD" decimals="0">6250000</CRBP:AmountReceivedForDevelopmentAward>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 29px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;INCOME TAXES &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 6pt 0 0 24.5pt; text-align: justify"&gt;No provision or benefit&#13;for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and&#13;the Company has provided a full valuation allowance against its deferred tax assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;At December&amp;#160;31, 2017&#13;and 2016, the Company had federal net operating loss carryforwards of approximately $56,536,000 and $28,644,000, respectively,&#13;of which federal carryforwards will expire in varying amounts beginning in 2029. At December&amp;#160;31, 2017 and 2016, the Company&#13;had Massachusetts net operating loss carryforwards of approximately $53,110,000 and $26,573,000, respectively. In the first quarter&#13;of 2017, the Company adopted ASU 2016-09, which removed the requirement to recognize the deferred tax assets on excess tax benefits&#13;in respect of share based payments only when realized. As such, during the year ended December 31, 2017, the Company&amp;#8217;s gross&#13;deferred tax assets and corresponding valuation allowance each included a one-time increase in respect of an additional federal&#13;and state net operating losses of $1,432,000. The adoption of ASU 2016-09 did not have an impact on the Company&amp;#8217;s balance&#13;sheet, results of operations, cash flows or statement of stockholders&amp;#8217; equity because the Company has a full valuation allowance&#13;on its deferred tax assets. Utilization of net operating losses may be subject to substantial annual limitations due to the &amp;#8220;change&#13;in ownership&amp;#8221; provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in&#13;the expiration of net operating losses before utilization. The Company has not yet conducted a study to determine if any such changes&#13;have occurred that could limit the Company&amp;#8217;s ability to use the net operating losses and tax credit carryforwards. The Company&#13;also had research and development tax credit carryforwards at December&amp;#160;31, 2017 and 2016 of approximately $1,283,000 and $736,000,&#13;respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Significant components of&#13;the Company&amp;#8217;s net deferred tax asset are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;NOL carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,229,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,860,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,213,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;673,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,724,248&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,177,650&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,654&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;302,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other temporary differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;225,214&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Subtotal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,240,325&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(13,240,325&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has maintained&#13;a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded&#13;when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company&#13;cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax&#13;assets, a full valuation allowance has been provided. The valuation allowance increased by $5,088,343 and $7,860,985 in 2017 and&#13;2016, respectively, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards. The Company&#13;has no uncertain tax positions at December 31, 2017 and 2016 that would affect its effective tax rate. Since the Company is in&#13;a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities&#13;for all years for which a loss carryforward is available.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Income tax benefits computed&#13;using the federal statutory income tax rate differs from the Company&amp;#8217;s effective tax rate primarily due to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax provision at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-2.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-24.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Increase in valuation reserve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-15.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-39.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-40.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;The Tax Cut and Jobs Act&#13;of 2017&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 22, 2017, the&#13;Tax Cut and Jobs Act (the &amp;#8220;Tax Act&amp;#8221;) was enacted into law. The Tax Act, among other things, contains significant changes&#13;to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation&#13;of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses); limitation of the&#13;deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80% of taxable income, indefinite&#13;carryforward of net operating losses generated in tax years after 2018 and elimination of net operating loss carrybacks; changes&#13;in the treatment of offshore earnings regardless of whether they are repatriated; current inclusion in U.S. federal taxable income&#13;of certain earnings of controlled foreign corporations, mandatory capitalization of research and development expenses beginning&#13;in 2022; immediate deductions for certain new investments instead of deductions for depreciation expense over time; further deduction&#13;limits on executive compensation; and modifying, repealing and creating many other business deductions and credits, including the&#13;reduction in the orphan drug credit from 50% to 25% of qualifying expenditures. As of December 31, 2017, we have made a reasonable&#13;estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures by reducing our net federal and state&#13;deferred tax assets by $7,815,832 for the reduction in corporate tax rate. This adjustment to our deferred tax assets is offset&#13;against the valuation allowance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Additionally, the SEC staff&#13;has issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond one year of the&#13;enactment date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) was issued to address the application&#13;of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including&#13;computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. Because the Company is&#13;still in the process of analyzing certain provisions of the Tax Act, the Company has determined that the adjustment to its deferred&#13;taxes was a provisional amount as permitted under SAB 118.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Significant components of&#13;the Company&amp;#8217;s net deferred tax asset are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;NOL carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,229,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,860,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,213,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;673,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,724,248&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,177,650&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,654&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;302,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other temporary differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;225,214&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Subtotal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,240,325&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(13,240,325&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Income tax benefits computed&#13;using the federal statutory income tax rate differs from the Company&amp;#8217;s effective tax rate primarily due to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax provision at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-2.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-24.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Increase in valuation reserve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-15.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-39.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-40.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <dei:DocumentFiscalYearFocus contextRef="From2017-01-01to2017-12-31">2017</dei:DocumentFiscalYearFocus>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>crbp-20171231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWOybP9z5Z8CekhvWB9bbkKzyMst8G0bitCvaU2wQ4A -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CRBP="http://corbuspharma.com/20171231" elementFormDefault="qualified" targetNamespace="http://corbuspharma.com/20171231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" id="StatementsOfStockholdersEquityParenthetical">
	  <link:definition>00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>00000008 - Disclosure - Nature of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000009 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000011 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000013 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000014 - Disclosure - Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" id="DevelopmentAwardAndDeferredRevenue">
	  <link:definition>00000015 - Disclosure - Development Award and Deferred Revenue</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommonStock" id="CommonStock">
	  <link:definition>00000017 - Disclosure - Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions" id="StockOptions">
	  <link:definition>00000018 - Disclosure - Stock Options</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/Warrants" id="Warrants">
	  <link:definition>00000019 - Disclosure - Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000020 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation" id="QuarterlyFinancialInformation">
	  <link:definition>00000021 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000025 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000027 - Disclosure - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" id="DevelopmentAwardAndDeferredRevenueTables">
	  <link:definition>00000028 - Disclosure - Development Award and Deferred Revenue (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000029 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptionsTables" id="StockOptionsTables">
	  <link:definition>00000030 - Disclosure - Stock Options (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" id="QuarterlyFinancialInformationTables">
	  <link:definition>00000031 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
	  <link:definition>00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" id="SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails">
	  <link:definition>00000035 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" id="SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails">
	  <link:definition>00000036 - Disclosure - Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" id="PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails">
	  <link:definition>00000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" id="CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails">
	  <link:definition>00000040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" id="CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails">
	  <link:definition>00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" id="AccruedExpenses-ScheduleOfAccruedExpensesDetails">
	  <link:definition>00000043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" id="DevelopmentAwardAndDeferredRevenueDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Development Award and Deferred Revenue (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" id="DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails">
	  <link:definition>00000045 - Disclosure - Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" id="IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails">
	  <link:definition>00000047 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
	  <link:definition>00000048 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" id="CommonStockDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" id="StockOptionsDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Stock Options (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" id="StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails">
	  <link:definition>00000051 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" id="StockOptions-SummaryOfOptionActivityDetails">
	  <link:definition>00000052 - Disclosure - Stock Options - Summary of Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" id="StockOptions-SummaryOfNonVestedStockOptionsDetails">
	  <link:definition>00000053 - Disclosure - Stock Options - Summary of Non Vested Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
	  <link:definition>00000054 - Disclosure - Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" id="QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails">
	  <link:definition>00000056 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="CRBP_MarketableSecuritiesMaturityPeriod" name="MarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" type="us-types:durationStringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DeferredTaxAssetsValuationAllowancePercentage" name="DeferredTaxAssetsValuationAllowancePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LeaseTerm" name="LeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AreaOfOfficeSpace" name="AreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccruedClinicalOperationsAndTrialsCosts" name="AccruedClinicalOperationsAndTrialsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccruedProductDevelopmentCosts" name="AccruedProductDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CommissionPaidPercentage" name="CommissionPaidPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantsWeightedAverageRemainingContractualTerm" name="WarrantsWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ClassOfWarrantOrRightCancelled" name="ClassOfWarrantOrRightCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NumberOfInstallments" name="NumberOfInstallments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_RoyaltyPaymentSalesTarget" name="RoyaltyPaymentSalesTarget" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" name="PaymentDuePeriodAfterTheFirstCommercialSale" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" name="DevelopmentAwardAndDeferredRevenueTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" name="AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NumberOfCommonStockWereExercisedOnCashBasis" name="NumberOfCommonStockWereExercisedOnCashBasis" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LiquidityDisclosuresTextBlock" name="LiquidityDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" name="IssuanceOfCommonStockSharesExercisedOnCashlessBasis" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CashCompensationAmount" name="CashCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OperatingLeaseTerms" name="OperatingLeaseTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" name="DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" name="IssuanceOfCommonStockUponExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" name="IssuanceOfCommonStockUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LeasesAndDeferredRentPolicyTextBlock" name="LeasesAndDeferredRentPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" name="SummaryOfNonvestedStockOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" name="CashEquivalentsAndRestrictedCashMaturityPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ForfeituresEstimatedPercentage" name="ForfeituresEstimatedPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AmountReceivedForDevelopmentAward" name="AmountReceivedForDevelopmentAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CopierMachineMember" name="CopierMachineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ThreePointTwoFivePercentNotesPayableMember" name="ThreePointTwoFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ConditionOneMember" name="ConditionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" name="TwoThousandFifteenCFFTAwardArrangementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CorporatecreditCardsMember" name="CorporatecreditCardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OrchestraMedicalVenturesLLCMember" name="OrchestraMedicalVenturesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandAndSixteenConsultingAgreementMember" name="TwoThousandAndSixteenConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" name="SeptemberTwoThousandAndSixteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoPointTwoFivePercentNotesPayableMember" name="TwoPointTwoFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InstitutionalAndAccreditedInvestorsMember" name="InstitutionalAndAccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CantorFitzgeraldMember" name="CantorFitzgeraldMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_EvergreenProvisionMember" name="EvergreenProvisionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OralAntiinflammatoryDrugMember" name="OralAntiinflammatoryDrugMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponCommercializationOfTheProductMember" name="UponCommercializationOfTheProductMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LenabasumMember" name="LenabasumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponReachingTheSalesTargetMember" name="UponReachingTheSalesTargetMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponTransferSaleOrLicensingMember" name="UponTransferSaleOrLicensingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFourteenEquityCompensationPlanMember" name="TwoThousandFourteenEquityCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InstitutionalInvestorsMember" name="InstitutionalInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OctoberTwoThousandSeventeenOfferingMember" name="OctoberTwoThousandSeventeenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" name="CysticFibrosisFoundationTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" name="AugustTwoThousandSeventeenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FirstYearMember" name="FirstYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SeventhYearMember" name="SeventhYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ThirdAnniversaryMember" name="ThirdAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FourthAnniversaryMember" name="FourthAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NovemberTwoThousandSeventeenMember" name="NovemberTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OctoberTwentySixTwoThousandSeventeenMember" name="OctoberTwentySixTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NonEmployeesMember" name="NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" name="FebruaryTwentyEightTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NorwoodMaMember" name="NorwoodMaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AugustTwoThousandFifiteenAmendmentMember" name="AugustTwoThousandFifiteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantAgreementMember" name="WarrantAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" name="AegisCapitalCorpAndOtherAffiliatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TrustMember" name="TrustMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AegisCapitalCorpMember" name="AegisCapitalCorpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JBTOneZeroOneMember" name="JBTOneZeroOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" name="TaxCutAndJobsActOfTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OrphanDrugCreditMember" name="OrphanDrugCreditMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryFiveTwoThousandAndEighteenMember" name="JanuaryFiveTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationMember" name="CysticFibrosisFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" name="JanuaryTwentySixTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PhaseTwoBClinicalTrialMember" name="PhaseTwoBClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwoThousandAndEighteenMember" name="FebruaryTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwoThousandAndEighteenMember" name="JanuaryTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoPointThreeFivePercentNotesPayableMember" name="TwoPointThreeFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DecemberThirtyOneTwoThousandFiveteenMember" name="DecemberThirtyOneTwoThousandFiveteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryOneTwoThousandEighteenMember" name="JanuaryOneTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MarketOfferingMember" name="MarketOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" name="CysticFibrosisProgramRelatedInvestmentAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationwarrantsMember" name="CysticFibrosisFoundationwarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InvestmentagreementMember" name="InvestmentagreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandAndEighteenCffAwardMember" name="TwoThousandAndEighteenCffAwardMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_StandbyLetterOfCreditMember" name="StandbyLetterOfCreditMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandAndEighteenSalesAgreementMember" name="TwoThousandAndEighteenSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InsurancePoliciesMember" name="InsurancePoliciesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MassachusettsMember" name="MassachusettsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardsAbstract" name="DevelopmentAwardsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardTable" name="DevelopmentAwardTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_DevelopmentAwardLineItems" name="DevelopmentAwardLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IncomeTaxesTable" name="IncomeTaxesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_IncomeTaxesLineItems" name="IncomeTaxesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>crbp-20171231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20171231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20171231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20171231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20171231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20171231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20171231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20171231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20171231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20171231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20171231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20171231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20171231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20171231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20171231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20171231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20171231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20171231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20171231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20171231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="loc_CRBPIncreaseDecreaseInDeferredRent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_CRBPIncreaseDecreaseInDeferredRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:title="00000015 - Disclosure - Development Award and Deferred Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000017 - Disclosure - Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000018 - Disclosure - Stock Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000019 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:title="00000021 - Disclosure - Quarterly Financial Information (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Award and Deferred Revenue (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:title="00000031 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000037 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligations" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligations" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:to="loc_us-gaapCapitalLeaseObligations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCosts" xlink:label="loc_CRBPAccruedClinicalOperationsAndTrialsCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CRBPAccruedClinicalOperationsAndTrialsCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedProductDevelopmentCosts" xlink:label="loc_CRBPAccruedProductDevelopmentCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CRBPAccruedProductDevelopmentCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:title="00000044 - Disclosure - Development Award and Deferred Revenue (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:title="00000045 - Disclosure - Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredRevenueNoncurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredRevenueNoncurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000047 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000048 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000049 - Disclosure - Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000050 - Disclosure - Stock Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Non Vested Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000054 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:title="00000056 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000057 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>crbp-20171231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20171231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20171231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20171231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20171231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20171231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20171231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20171231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20171231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20171231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20171231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20171231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20171231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20171231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20171231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20171231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20171231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20171231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20171231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20171231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrants_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrantsShares_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:title="00000015 - Disclosure - Development Award and Deferred Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000017 - Disclosure - Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000018 - Disclosure - Stock Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000019 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:title="00000021 - Disclosure - Quarterly Financial Information (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Award and Deferred Revenue (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:title="00000031 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldAndCoMember" xlink:label="loc_CRBPCantorFitzgeraldAndCoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCantorFitzgeraldAndCoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryFiveTwoThousandAndEighteenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryFiveTwoThousandAndEighteenMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryTwentySixTwoThousandAndEighteenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryTwentySixTwoThousandAndEighteenMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryTwoThousandAndEighteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryTwoThousandAndEighteenMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AmountReceivedForDevelopmentAward" xlink:label="loc_CRBPAmountReceivedForDevelopmentAward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPAmountReceivedForDevelopmentAward_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="loc_CRBPSignificantAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="loc_CRBPSignificantAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPSignificantAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="loc_CRBPCorporatecreditCardsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPCorporatecreditCardsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="loc_CRBPStandbyLetterOfCreditMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPStandbyLetterOfCreditMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapCreationDateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="loc_CRBPMarketableSecuritiesMaturityPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPMarketableSecuritiesMaturityPeriod_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapMarketableSecurities_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_140" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StockOptionsMember" xlink:label="loc_CRBPStockOptionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CRBPStockOptionsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000037 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FebruaryTwoThousandAndEighteenMember" xlink:label="loc_CRBPFebruaryTwoThousandAndEighteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFebruaryTwoThousandAndEighteenMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAreaOfLand_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LeaseTerm" xlink:label="loc_CRBPLeaseTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPLeaseTerm_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCommitmentAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FirstYearMember" xlink:label="loc_CRBPFirstYearMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_CRBPFirstYearMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeventhYearMember" xlink:label="loc_CRBPSeventhYearMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_CRBPSeventhYearMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="loc_CRBPThirdAnniversaryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPThirdAnniversaryMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FourthAnniversaryMember" xlink:label="loc_CRBPFourthAnniversaryMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFourthAnniversaryMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementGeographicalAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseholdImprovementsGross_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLineOfCredit_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpense_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OperatingLeaseTerms" xlink:label="loc_CRBPOperatingLeaseTerms_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPOperatingLeaseTerms_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="loc_us-gaapInterestExpenseLesseeAssetsUnderCapitalLease_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpenseLesseeAssetsUnderCapitalLease_140" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCommitmentAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligations_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent_20" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:label="loc_CRBPThreePointTwoFivePercentNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPThreePointTwoFivePercentNotesPayableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:label="loc_CRBPTwoPointTwoFivePercentNotesPayableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPTwoPointTwoFivePercentNotesPayableMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:label="loc_CRBPTwoPointThreeFivePercentNotesPayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPTwoPointThreeFivePercentNotesPayableMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaapProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaapProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapProductOrServiceAxis" xlink:to="loc_us-gaapProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaapProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductOrServiceAxis" xlink:to="loc_us-gaapProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InsurancePoliciesMember" xlink:label="loc_CRBPInsurancePoliciesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductsAndServicesDomain" xlink:to="loc_CRBPInsurancePoliciesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:title="00000044 - Disclosure - Development Award and Deferred Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="loc_CRBPDevelopmentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardTable" xlink:label="loc_CRBPDevelopmentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPDevelopmentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="loc_CRBPOralAntiinflammatoryDrugMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPOralAntiinflammatoryDrugMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LenabasumMember" xlink:label="loc_CRBPLenabasumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPLenabasumMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="loc_CRBPUponCommercializationOfTheProductMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponCommercializationOfTheProductMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="loc_CRBPUponReachingTheSalesTargetMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponReachingTheSalesTargetMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="loc_CRBPUponTransferSaleOrLicensingMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponTransferSaleOrLicensingMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRoyaltyExpense_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NumberOfInstallments" xlink:label="loc_CRBPNumberOfInstallments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPNumberOfInstallments_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="loc_CRBPRoyaltyPaymentSalesTarget_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentSalesTarget_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenues_160" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:title="00000045 - Disclosure - Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="loc_CRBPIncomeTaxesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesTable" xlink:label="loc_CRBPIncomeTaxesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPIncomeTaxesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FederalMember" xlink:label="loc_CRBPFederalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPFederalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="loc_CRBPOrphanDrugCreditMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_CRBPOrphanDrugCreditMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MassachusettsMember" xlink:label="loc_CRBPMassachusettsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_CRBPMassachusettsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit_170" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000047 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000048 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000049 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_CRBPSecuritiesPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSecuritiesPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_CRBPInstitutionalAndAccreditedInvestorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalAndAccreditedInvestorsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldMember" xlink:label="loc_CRBPCantorFitzgeraldMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPCantorFitzgeraldMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="loc_CRBPInstitutionalInvestorsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPInstitutionalInvestorsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreationDateAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaapAvailableForSaleSecurities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecurities_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommissionPaidPercentage" xlink:label="loc_CRBPCommissionPaidPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPCommissionPaidPercentage_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_210" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000050 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapCreationDateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryOneTwoThousandEighteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandEighteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:to="loc_CRBPJanuaryOneTwoThousandEighteenMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EmployeesMember" xlink:label="loc_CRBPEmployeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPEmployeesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NonEmployeesMember" xlink:label="loc_CRBPNonEmployeesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPNonEmployeesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapStockOptionMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ForfeituresEstimatedPercentage" xlink:label="loc_CRBPForfeituresEstimatedPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPForfeituresEstimatedPercentage_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_210" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Non Vested Stock Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000054 - Disclosure - Warrants (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="loc_CRBPOrchestraMedicalVenturesLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPOrchestraMedicalVenturesLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashCompensationAmount" xlink:label="loc_CRBPCashCompensationAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CRBPCashCompensationAmount_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:title="00000056 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000057 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="loc_CRBPAtTheMarketOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPAtTheMarketOfferingMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenSalesAgreementMember" xlink:label="loc_CRBPTwoThousandAndEighteenSalesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndEighteenSalesAgreementMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisFoundationwarrantsMember" xlink:label="loc_CRBPCysticFibrosisFoundationwarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCysticFibrosisFoundationwarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_100" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>crbp-20171231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property Plant And Equipment By Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short Term Debt Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes Payable Other Payables [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:label="CRBP_ThreePointTwoFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:to="CRBP_ThreePointTwoFivePercentNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ThreePointTwoFivePercentNotesPayableMember_lbl" xml:lang="en-US">Three Point Two Five Percent Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="CRBP_ComputerHardwareAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ComputerHardwareAndSoftwareMember" xlink:to="CRBP_ComputerHardwareAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US">Computer Hardware and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OfficeFurnitureAndEquipmentMember" xlink:to="CRBP_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StockOptionsMember" xlink:label="CRBP_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionsMember" xlink:to="CRBP_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CopierMachineMember" xlink:label="CRBP_CopierMachineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CopierMachineMember" xlink:to="CRBP_CopierMachineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CopierMachineMember_lbl" xml:lang="en-US">Copier Machine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="CRBP_CorporatecreditCardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CorporatecreditCardsMember" xlink:to="CRBP_CorporatecreditCardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CorporatecreditCardsMember_lbl" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:to="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_lbl" xml:lang="en-US">2015 CFFT Award Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party Transactions By Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrchestraMedicalVenturesLLCMember" xlink:to="CRBP_OrchestraMedicalVenturesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember_lbl" xml:lang="en-US">Orchestra Medical Ventures LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:to="CRBP_TwoThousandAndSixteenConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember_lbl" xml:lang="en-US">2016 Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:label="CRBP_TwoPointTwoFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointTwoFivePercentNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoPointTwoFivePercentNotesPayableMember_lbl" xml:lang="en-US">Two Point Two Five Percent Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="CRBP_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SecuritiesPurchaseAgreementMember" xlink:to="CRBP_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:to="CRBP_InstitutionalAndAccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember_lbl" xml:lang="en-US">Institutional and Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SalesAgreementMember" xlink:label="CRBP_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SalesAgreementMember" xlink:to="CRBP_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldMember" xlink:label="CRBP_CantorFitzgeraldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldMember" xlink:to="CRBP_CantorFitzgeraldMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EvergreenProvisionMember" xlink:label="CRBP_EvergreenProvisionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EvergreenProvisionMember" xlink:to="CRBP_EvergreenProvisionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_EvergreenProvisionMember_lbl" xml:lang="en-US">Evergreen Provision [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="CRBP_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="CRBP_OralAntiinflammatoryDrugMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OralAntiinflammatoryDrugMember" xlink:to="CRBP_OralAntiinflammatoryDrugMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OralAntiinflammatoryDrugMember_lbl" xml:lang="en-US">Oral Anti-inflammatory Drug [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="CRBP_UponCommercializationOfTheProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponCommercializationOfTheProductMember" xlink:to="CRBP_UponCommercializationOfTheProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponCommercializationOfTheProductMember_lbl" xml:lang="en-US">Upon Commercialization of The Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LenabasumMember" xlink:label="CRBP_LenabasumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LenabasumMember" xlink:to="CRBP_LenabasumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LenabasumMember_lbl" xml:lang="en-US">Lenabasum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="CRBP_UponReachingTheSalesTargetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponReachingTheSalesTargetMember" xlink:to="CRBP_UponReachingTheSalesTargetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponReachingTheSalesTargetMember_lbl" xml:lang="en-US">Upon Reaching The Sales Target [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="CRBP_UponTransferSaleOrLicensingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponTransferSaleOrLicensingMember" xlink:to="CRBP_UponTransferSaleOrLicensingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponTransferSaleOrLicensingMember_lbl" xml:lang="en-US">Upon Transfer Sale or Licensing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:to="CRBP_TwoThousandFourteenEquityCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember_lbl" xml:lang="en-US">2014 Equity Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:to="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_lbl" xml:lang="en-US">August 2017 Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FirstYearMember" xlink:label="CRBP_FirstYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstYearMember" xlink:to="CRBP_FirstYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FirstYearMember_lbl" xml:lang="en-US">First Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeventhYearMember" xlink:label="CRBP_SeventhYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeventhYearMember" xlink:to="CRBP_SeventhYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SeventhYearMember_lbl" xml:lang="en-US">Seventh Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="CRBP_ThirdAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThirdAnniversaryMember" xlink:to="CRBP_ThirdAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FourthAnniversaryMember" xlink:label="CRBP_FourthAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FourthAnniversaryMember" xlink:to="CRBP_FourthAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FourthAnniversaryMember_lbl" xml:lang="en-US">Fourth Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="CRBP_InstitutionalInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorsMember" xlink:to="CRBP_InstitutionalInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InstitutionalInvestorsMember_lbl" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EmployeesMember" xlink:label="CRBP_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EmployeesMember" xlink:to="CRBP_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NonEmployeesMember" xlink:label="CRBP_NonEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeesMember" xlink:to="CRBP_NonEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NonEmployeesMember_lbl" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:to="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_lbl" xml:lang="en-US">September 2016 Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FederalMember" xlink:label="CRBP_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FederalMember" xlink:to="CRBP_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State And Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:to="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_lbl" xml:lang="en-US">The Tax Cut and Jobs Act of 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="CRBP_OrphanDrugCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrphanDrugCreditMember" xlink:to="CRBP_OrphanDrugCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OrphanDrugCreditMember_lbl" xml:lang="en-US">Orphan Drug Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldAndCoMember" xlink:label="CRBP_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldAndCoMember" xlink:to="CRBP_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp; Co. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryFiveTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryFiveTwoThousandAndEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryFiveTwoThousandAndEighteenMember_lbl" xml:lang="en-US">January 5, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwoThousandAndEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryTwoThousandAndEighteenMember_lbl" xml:lang="en-US">January 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FebruaryTwoThousandAndEighteenMember" xlink:label="CRBP_FebruaryTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwoThousandAndEighteenMember" xlink:to="CRBP_FebruaryTwoThousandAndEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FebruaryTwoThousandAndEighteenMember_lbl" xml:lang="en-US">February 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:label="CRBP_TwoPointThreeFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointThreeFivePercentNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoPointThreeFivePercentNotesPayableMember_lbl" xml:lang="en-US">Two Point Three Five Percent Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreationDateAxis_lbl" xml:lang="en-US">Report Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryOneTwoThousandEighteenMember" xlink:label="CRBP_JanuaryOneTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandEighteenMember" xlink:to="CRBP_JanuaryOneTwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryOneTwoThousandEighteenMember_lbl" xml:lang="en-US">January 1, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="CRBP_AtTheMarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AtTheMarketOfferingMember" xlink:to="CRBP_AtTheMarketOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AtTheMarketOfferingMember_lbl" xml:lang="en-US">At the Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="CRBP_PhaseTwoBClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PhaseTwoBClinicalTrialMember" xlink:to="CRBP_PhaseTwoBClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PhaseTwoBClinicalTrialMember_lbl" xml:lang="en-US">Phase 2b Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:to="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_lbl" xml:lang="en-US">Cystic Fibrosis Program Related Investment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisFoundationwarrantsMember" xlink:label="CRBP_CysticFibrosisFoundationwarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationwarrantsMember" xlink:to="CRBP_CysticFibrosisFoundationwarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CysticFibrosisFoundationwarrantsMember_lbl" xml:lang="en-US">Cystic Fibrosis Foundation warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestmentagreementMember" xlink:label="CRBP_InvestmentagreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestmentagreementMember" xlink:to="CRBP_InvestmentagreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InvestmentagreementMember_lbl" xml:lang="en-US">Investment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_lbl" xml:lang="en-US">January 26, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenCffAwardMember" xlink:to="CRBP_TwoThousandAndEighteenCffAwardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember_lbl" xml:lang="en-US">2018 CFF Award [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="CRBP_StandbyLetterOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StandbyLetterOfCreditMember" xlink:to="CRBP_StandbyLetterOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_StandbyLetterOfCreditMember_lbl" xml:lang="en-US">Stand-by Letter of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenSalesAgreementMember" xlink:label="CRBP_TwoThousandAndEighteenSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenSalesAgreementMember" xlink:to="CRBP_TwoThousandAndEighteenSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandAndEighteenSalesAgreementMember_lbl" xml:lang="en-US">2018 Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InsurancePoliciesMember" xlink:label="CRBP_InsurancePoliciesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InsurancePoliciesMember" xlink:to="CRBP_InsurancePoliciesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InsurancePoliciesMember_lbl" xml:lang="en-US">Insurance Policies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MassachusettsMember" xlink:label="CRBP_MassachusettsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MassachusettsMember" xlink:to="CRBP_MassachusettsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_MassachusettsMember_lbl" xml:lang="en-US">Massachusett [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DocumentAndEntityInformationAbstract" xlink:label="CRBP_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DocumentAndEntityInformationAbstract" xlink:to="CRBP_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscriptions receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2017 and 2016, 55,603,427 and 44,681,745 shares issued and outstanding at December 31, 2017 and 2016, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue from awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Stock issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">(Gain) loss on foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="CRBP_IncreaseDecreaseInDeferredRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncreaseDecreaseInDeferredRent" xlink:to="CRBP_IncreaseDecreaseInDeferredRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Decrease (increase) in grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase in prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase in other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">(Decrease) increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">(Decrease) increase in deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs paid for common stock financings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Principal payments under capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information and non cash transactions:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Assets acquired under capital lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment included in accounts payable or accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Unpaid stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LiquidityDisclosuresTextBlock" xlink:label="CRBP_LiquidityDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LiquidityDisclosuresTextBlock" xlink:to="CRBP_LiquidityDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LiquidityDisclosuresTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardsAbstract" xlink:label="CRBP_DevelopmentAwardsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardsAbstract" xlink:to="CRBP_DevelopmentAwardsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardsAbstract_lbl" xml:lang="en-US">Development Award And Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" xlink:label="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" xlink:to="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock_lbl" xml:lang="en-US">Development Award and Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_WarrantsTextBlock" xlink:label="CRBP_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsTextBlock" xlink:to="CRBP_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WarrantsTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses and Development Award Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:to="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_lbl" xml:lang="en-US">Accruals for Research and Development Expenses and Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:to="CRBP_LeasesAndDeferredRentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock_lbl" xml:lang="en-US">Leases and Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rent Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Capital Lease Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Components of Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Summary of Assumptions Used Principally in Determining Fair Value of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:to="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_lbl" xml:lang="en-US">Summary of Non-Vested Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Quarterly Financial Information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Number of common stock value sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock share sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AmountReceivedForDevelopmentAward" xlink:label="CRBP_AmountReceivedForDevelopmentAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AmountReceivedForDevelopmentAward" xlink:to="CRBP_AmountReceivedForDevelopmentAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AmountReceivedForDevelopmentAward_lbl" xml:lang="en-US">Amount received for development award</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="CRBP_SignificantAccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesTable" xlink:to="CRBP_SignificantAccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="CRBP_SignificantAccountingPoliciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesLineItems" xlink:to="CRBP_SignificantAccountingPoliciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:to="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xml:lang="en-US">Cash equivalents and restricted cash maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MarketableSecuritiesMaturityPeriod" xlink:to="CRBP_MarketableSecuritiesMaturityPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod_lbl" xml:lang="en-US">Marketable investments maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life of all property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="CRBP_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Uncertain tax position</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating lease future non-cancelable lease payments amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market fund</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Restricted cash, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2_lbl" xml:lang="en-US">Restricted cash, noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per share of common stock-basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost of machine</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LeaseTerm" xlink:label="CRBP_LeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTerm" xlink:to="CRBP_LeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="CRBP_CommitmentAndContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesTable" xlink:to="CRBP_CommitmentAndContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CommitmentAndContingenciesTable_lbl" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="CRBP_CommitmentAndContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesLineItems" xlink:to="CRBP_CommitmentAndContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CommitmentAndContingenciesLineItems_lbl" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="CRBP_AreaOfOfficeSpace" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AreaOfOfficeSpace" xlink:to="CRBP_AreaOfOfficeSpace_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AreaOfOfficeSpace_lbl" xml:lang="en-US">Area of office space</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Operating lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Standby letters of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Irrevocable letter of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Incurred interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OperatingLeaseTerms" xlink:label="CRBP_OperatingLeaseTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OperatingLeaseTerms" xlink:to="CRBP_OperatingLeaseTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OperatingLeaseTerms_lbl" xml:lang="en-US">Terms of lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:to="us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less: interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US">Future capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermDebtTypeAxis_2_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal and interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Monthly loan payments term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Annual interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense for notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCosts" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedClinicalOperationsAndTrialsCosts" xlink:to="CRBP_AccruedClinicalOperationsAndTrialsCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCosts_lbl" xml:lang="en-US">Accrued clinical operations and trials costs</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedProductDevelopmentCosts" xlink:label="CRBP_AccruedProductDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedProductDevelopmentCosts" xlink:to="CRBP_AccruedProductDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccruedProductDevelopmentCosts_lbl" xml:lang="en-US">Accrued product development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardTable" xlink:label="CRBP_DevelopmentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardTable" xlink:to="CRBP_DevelopmentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardTable_lbl" xml:lang="en-US">Development Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="CRBP_DevelopmentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardLineItems" xlink:to="CRBP_DevelopmentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardLineItems_lbl" xml:lang="en-US">Development Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2_lbl" xml:lang="en-US">Project [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Development award received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Amount received upon execution of award agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NumberOfInstallments" xlink:label="CRBP_NumberOfInstallments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfInstallments" xlink:to="CRBP_NumberOfInstallments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NumberOfInstallments_lbl" xml:lang="en-US">Number of installments</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:to="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_lbl" xml:lang="en-US">Payment due period after the first commercial sale</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="CRBP_RoyaltyPaymentSalesTarget" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentSalesTarget" xlink:to="CRBP_RoyaltyPaymentSalesTarget_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_RoyaltyPaymentSalesTarget_lbl" xml:lang="en-US">Royalty payment, sales target</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredRevenueCurrent_2_lbl" xml:lang="en-US">Less: current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Long-term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesTable" xlink:label="CRBP_IncomeTaxesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesTable" xlink:to="CRBP_IncomeTaxesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="CRBP_IncomeTaxesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesLineItems" xlink:to="CRBP_IncomeTaxesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:to="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforwards excess stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Deferred tax assets valuation allowance increase</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Reduction of corporate tax rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Taxable income percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">NOL carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other temporary differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax provision at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Income tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Increase in valuation reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Aggregate common stock sold, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US">Aggregate offering amount</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommissionPaidPercentage" xlink:label="CRBP_CommissionPaidPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommissionPaidPercentage" xlink:to="CRBP_CommissionPaidPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CommissionPaidPercentage_lbl" xml:lang="en-US">Commission paid percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Aggregate common stock sold, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Options to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in number of shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate common stock available for stock options granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock option vesting term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Percentage of outstanding common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Option granted expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Option granted risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Option granted expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Option granted expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ForfeituresEstimatedPercentage" xlink:label="CRBP_ForfeituresEstimatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ForfeituresEstimatedPercentage" xlink:to="CRBP_ForfeituresEstimatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ForfeituresEstimatedPercentage_lbl" xml:lang="en-US">Forfeitures estimated, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Average intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based compensation expense, not yet recognized period of recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected term in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xml:lang="en-US">Estimated forfeiture rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Shares Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Average Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Average Intrinsic Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Shares Non-vested , Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Shares Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average fair value non vested, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average fair value, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average fair value non vested, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants outstanding to purchase of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Weighted average exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:to="CRBP_WarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining life of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" xlink:label="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" xlink:to="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis_lbl" xml:lang="en-US">Issuance of common stock shares exercised on cashless basis</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NumberOfCommonStockWereExercisedOnCashBasis" xlink:label="CRBP_NumberOfCommonStockWereExercisedOnCashBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfCommonStockWereExercisedOnCashBasis" xlink:to="CRBP_NumberOfCommonStockWereExercisedOnCashBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NumberOfCommonStockWereExercisedOnCashBasis_lbl" xml:lang="en-US">Number of common stock were exercised on a cash basis</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ClassOfWarrantOrRightIssued" xlink:label="CRBP_ClassOfWarrantOrRightIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ClassOfWarrantOrRightIssued" xlink:to="CRBP_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ClassOfWarrantOrRightCancelled" xlink:label="CRBP_ClassOfWarrantOrRightCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ClassOfWarrantOrRightCancelled" xlink:to="CRBP_ClassOfWarrantOrRightCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ClassOfWarrantOrRightCancelled_lbl" xml:lang="en-US">Number of warrants cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashCompensationAmount" xlink:label="CRBP_CashCompensationAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashCompensationAmount" xlink:to="CRBP_CashCompensationAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CashCompensationAmount_lbl" xml:lang="en-US">Cash compensation amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="us-gaap_RelatedPartyTransactionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Agreement expiry date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xml:lang="en-US">Options to purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Option vested percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options granted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_lbl" xml:lang="en-US">Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Increased number of shares of common stock available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Total reserve under the plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercisable price per sahre</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrant exercisable shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:to="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_doc" xml:lang="en-US">Accruals for research and development expenses and clinical trials [Policy Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedClinicalOperationsAndTrialsCosts" xlink:to="CRBP_AccruedClinicalOperationsAndTrialsCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCosts_doc" xml:lang="en-US">Accrued clinical operations and trials costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedProductDevelopmentCosts" xlink:to="CRBP_AccruedProductDevelopmentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccruedProductDevelopmentCosts_doc" xml:lang="en-US">Accrued product development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AreaOfOfficeSpace" xlink:to="CRBP_AreaOfOfficeSpace_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AreaOfOfficeSpace_doc" xml:lang="en-US">Area of office space.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldMember" xlink:to="CRBP_CantorFitzgeraldMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CantorFitzgeraldMember_doc" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ClassOfWarrantOrRightCancelled" xlink:to="CRBP_ClassOfWarrantOrRightCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ClassOfWarrantOrRightCancelled_doc" xml:lang="en-US">Class of warrant or right cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ClassOfWarrantOrRightIssued" xlink:to="CRBP_ClassOfWarrantOrRightIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ClassOfWarrantOrRightIssued_doc" xml:lang="en-US">Class of warrant or right issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommissionPaidPercentage" xlink:to="CRBP_CommissionPaidPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CommissionPaidPercentage_doc" xml:lang="en-US">Commission paid percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesLineItems" xlink:to="CRBP_CommitmentAndContingenciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CommitmentAndContingenciesLineItems_doc" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesTable" xlink:to="CRBP_CommitmentAndContingenciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CommitmentAndContingenciesTable_doc" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ComputerHardwareAndSoftwareMember" xlink:to="CRBP_ComputerHardwareAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ComputerHardwareAndSoftwareMember_doc" xml:lang="en-US">Computer Hardware and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ConditionOneMember" xlink:label="CRBP_ConditionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ConditionOneMember" xlink:to="CRBP_ConditionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ConditionOneMember_doc" xml:lang="en-US">Condition one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CopierMachineMember" xlink:to="CRBP_CopierMachineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CopierMachineMember_doc" xml:lang="en-US">Copier machine.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CorporatecreditCardsMember" xlink:to="CRBP_CorporatecreditCardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CorporatecreditCardsMember_doc" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisFoundationTherapeuticsIncMember" xlink:label="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" xlink:to="CRBP_CysticFibrosisFoundationTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationTherapeuticsIncMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation Therapeutics, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="CRBP_DeferredTaxAssetsValuationAllowancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage_doc" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardLineItems" xlink:to="CRBP_DevelopmentAwardLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardLineItems_doc" xml:lang="en-US">Development Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardTable" xlink:to="CRBP_DevelopmentAwardTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardTable_doc" xml:lang="en-US">Development Award [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EvergreenProvisionMember" xlink:to="CRBP_EvergreenProvisionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_EvergreenProvisionMember_doc" xml:lang="en-US">Evergreen Provision [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncreaseDecreaseInDeferredRent" xlink:to="CRBP_IncreaseDecreaseInDeferredRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncreaseDecreaseInDeferredRent_doc" xml:lang="en-US">Increase Decrease In Deferred Rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:to="CRBP_InstitutionalAndAccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember_doc" xml:lang="en-US">Institutional And Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTerm" xlink:to="CRBP_LeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LeaseTerm_doc" xml:lang="en-US">Lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MarketableSecuritiesMaturityPeriod" xlink:to="CRBP_MarketableSecuritiesMaturityPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod_doc" xml:lang="en-US">Marketable Securities Maturity Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfInstallments" xlink:to="CRBP_NumberOfInstallments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NumberOfInstallments_doc" xml:lang="en-US">Number of installments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OfficeFurnitureAndEquipmentMember" xlink:to="CRBP_OfficeFurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember_doc" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OralAntiinflammatoryDrugMember" xlink:to="CRBP_OralAntiinflammatoryDrugMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OralAntiinflammatoryDrugMember_doc" xml:lang="en-US">Oral Anti-inflammatory Drug [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrchestraMedicalVenturesLLCMember" xlink:to="CRBP_OrchestraMedicalVenturesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember_doc" xml:lang="en-US">Orchestra Medical Ventures LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:to="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_doc" xml:lang="en-US">Payment due period after the first commercial sale.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentSalesTarget" xlink:to="CRBP_RoyaltyPaymentSalesTarget_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_RoyaltyPaymentSalesTarget_doc" xml:lang="en-US">Royalty payment sales target.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SalesAgreementMember" xlink:to="CRBP_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SecuritiesPurchaseAgreementMember" xlink:to="CRBP_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:to="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_doc" xml:lang="en-US">September 2016 Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase minimum percentage in each year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesLineItems" xlink:to="CRBP_SignificantAccountingPoliciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SignificantAccountingPoliciesLineItems_doc" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesTable" xlink:to="CRBP_SignificantAccountingPoliciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SignificantAccountingPoliciesTable_doc" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionsMember" xlink:to="CRBP_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:to="CRBP_ThreePointTwoFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ThreePointTwoFivePercentNotesPayableMember_doc" xml:lang="en-US">Three point two five percent notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointTwoFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoPointTwoFivePercentNotesPayableMember_doc" xml:lang="en-US">Two Point Two Five Percent Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:to="CRBP_TwoThousandAndSixteenConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember_doc" xml:lang="en-US">2016 Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="CRBP_TwoThousandFourteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember_doc" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponCommercializationOfTheProductMember" xlink:to="CRBP_UponCommercializationOfTheProductMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponCommercializationOfTheProductMember_doc" xml:lang="en-US">Upon Commercialization Of The Product [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponReachingTheSalesTargetMember" xlink:to="CRBP_UponReachingTheSalesTargetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponReachingTheSalesTargetMember_doc" xml:lang="en-US">Upon Reaching The Sales Target [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponTransferSaleOrLicensingMember" xlink:to="CRBP_UponTransferSaleOrLicensingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponTransferSaleOrLicensingMember_doc" xml:lang="en-US">Upon Transfer Sale Or Licensing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsTextBlock" xlink:to="CRBP_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:to="CRBP_WarrantsWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Warrants weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" xlink:to="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardAndDeferredRevenueTextBlock_doc" xml:lang="en-US">Development Award and Deferred Revenue [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:to="CRBP_TwoThousandFourteenEquityCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember_doc" xml:lang="en-US">2014 Equity Compensation Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfCommonStockWereExercisedOnCashBasis" xlink:to="CRBP_NumberOfCommonStockWereExercisedOnCashBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NumberOfCommonStockWereExercisedOnCashBasis_doc" xml:lang="en-US">Number of common stock were exercised on a cash basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LiquidityDisclosuresTextBlock" xlink:to="CRBP_LiquidityDisclosuresTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LiquidityDisclosuresTextBlock_doc" xml:lang="en-US">Liquidity Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" xlink:to="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis_doc" xml:lang="en-US">Issuance of common stock shares exercised on cashless basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashCompensationAmount" xlink:to="CRBP_CashCompensationAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CashCompensationAmount_doc" xml:lang="en-US">Cash compensation amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ForfeituresEstimatedPercentage" xlink:to="CRBP_ForfeituresEstimatedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ForfeituresEstimatedPercentage_doc" xml:lang="en-US">Forfeitures estimated, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorsMember" xlink:to="CRBP_InstitutionalInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InstitutionalInvestorsMember_doc" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OctoberTwentySixTwoThousandSeventeenMember" xlink:label="CRBP_OctoberTwentySixTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OctoberTwentySixTwoThousandSeventeenMember" xlink:to="CRBP_OctoberTwentySixTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OctoberTwentySixTwoThousandSeventeenMember_doc" xml:lang="en-US">October 26, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OctoberTwoThousandSeventeenOfferingMember" xlink:label="CRBP_OctoberTwoThousandSeventeenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OctoberTwoThousandSeventeenOfferingMember" xlink:to="CRBP_OctoberTwoThousandSeventeenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OctoberTwoThousandSeventeenOfferingMember_doc" xml:lang="en-US">October 2017 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:to="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_doc" xml:lang="en-US">August 2017 Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstYearMember" xlink:to="CRBP_FirstYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FirstYearMember_doc" xml:lang="en-US">First Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeventhYearMember" xlink:to="CRBP_SeventhYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SeventhYearMember_doc" xml:lang="en-US">Seventh Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThirdAnniversaryMember" xlink:to="CRBP_ThirdAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ThirdAnniversaryMember_doc" xml:lang="en-US">Third Anniversary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FourthAnniversaryMember" xlink:to="CRBP_FourthAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FourthAnniversaryMember_doc" xml:lang="en-US">Fourth Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NovemberTwoThousandSeventeenMember" xlink:label="CRBP_NovemberTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NovemberTwoThousandSeventeenMember" xlink:to="CRBP_NovemberTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NovemberTwoThousandSeventeenMember_doc" xml:lang="en-US">November 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EmployeesMember" xlink:to="CRBP_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeesMember" xlink:to="CRBP_NonEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NonEmployeesMember_doc" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NonEmployeeStockOptionMember" xlink:label="CRBP_NonEmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeeStockOptionMember" xlink:to="CRBP_NonEmployeeStockOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NonEmployeeStockOptionMember_doc" xml:lang="en-US">Non-Employee Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrants_doc" xml:lang="en-US">Issuance of common stock upon exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares_doc" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestorsMember" xlink:label="CRBP_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestorsMember" xlink:to="CRBP_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" xlink:label="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" xlink:to="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember_doc" xml:lang="en-US">February 28, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NorwoodMaMember" xlink:label="CRBP_NorwoodMaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NorwoodMaMember" xlink:to="CRBP_NorwoodMaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NorwoodMaMember_doc" xml:lang="en-US">Norwood Ma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AugustTwoThousandFifiteenAmendmentMember" xlink:label="CRBP_AugustTwoThousandFifiteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandFifiteenAmendmentMember" xlink:to="CRBP_AugustTwoThousandFifiteenAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AugustTwoThousandFifiteenAmendmentMember_doc" xml:lang="en-US">August Two Thousand Fifiteen Amendment [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OperatingLeaseTerms" xlink:to="CRBP_OperatingLeaseTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OperatingLeaseTerms_doc" xml:lang="en-US">Operating lease terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesTable" xlink:to="CRBP_IncomeTaxesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncomeTaxesTable_doc" xml:lang="en-US">Income Taxes [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesLineItems" xlink:to="CRBP_IncomeTaxesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncomeTaxesLineItems_doc" xml:lang="en-US">Income Taxes [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FederalMember" xlink:to="CRBP_FederalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FederalMember_doc" xml:lang="en-US">Federal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:to="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Deferred tax assets operating loss carryforwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_WarrantAgreementMember" xlink:label="CRBP_WarrantAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantAgreementMember" xlink:to="CRBP_WarrantAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantAgreementMember_doc" xml:lang="en-US">Warrant Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AegisCapitalCorpAndOtherAffiliatesMember" xlink:label="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" xlink:to="CRBP_AegisCapitalCorpAndOtherAffiliatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AegisCapitalCorpAndOtherAffiliatesMember_doc" xml:lang="en-US">Aegis Capital Corp And Other Affiliates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TrustMember" xlink:label="CRBP_TrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TrustMember" xlink:to="CRBP_TrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TrustMember_doc" xml:lang="en-US">Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AegisCapitalCorpMember" xlink:label="CRBP_AegisCapitalCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AegisCapitalCorpMember" xlink:to="CRBP_AegisCapitalCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AegisCapitalCorpMember_doc" xml:lang="en-US">Aegis Capital Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JBTOneZeroOneMember" xlink:label="CRBP_JBTOneZeroOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JBTOneZeroOneMember" xlink:to="CRBP_JBTOneZeroOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JBTOneZeroOneMember_doc" xml:lang="en-US">JBT-101 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:to="CRBP_LeasesAndDeferredRentPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock_doc" xml:lang="en-US">Leases and Deferred Rent [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:to="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_doc" xml:lang="en-US">Summary of Non-Vested Stock Options [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:to="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_doc" xml:lang="en-US">2015 CFFT Award Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LenabasumMember" xlink:to="CRBP_LenabasumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LenabasumMember_doc" xml:lang="en-US">Lenabasum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:to="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_doc" xml:lang="en-US">The Tax Cut and Jobs Act of 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrphanDrugCreditMember" xlink:to="CRBP_OrphanDrugCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OrphanDrugCreditMember_doc" xml:lang="en-US">Orphan Drug Credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldAndCoMember" xlink:to="CRBP_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Cantor Fitzgerald &amp; Co. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryFiveTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryFiveTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 5, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="CRBP_CysticFibrosisFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationMember" xlink:to="CRBP_CysticFibrosisFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 26, 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PhaseTwoBClinicalTrialMember" xlink:to="CRBP_PhaseTwoBClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PhaseTwoBClinicalTrialMember_doc" xml:lang="en-US">Phase 2b Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwoThousandAndEighteenMember" xlink:to="CRBP_FebruaryTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwoThousandAndEighteenMember_doc" xml:lang="en-US">February 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DecemberThirtyOneTwoThousandFiveteenMember" xlink:label="CRBP_DecemberThirtyOneTwoThousandFiveteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DecemberThirtyOneTwoThousandFiveteenMember" xlink:to="CRBP_DecemberThirtyOneTwoThousandFiveteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DecemberThirtyOneTwoThousandFiveteenMember_doc" xml:lang="en-US">December 31 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MarketOfferingMember" xlink:label="CRBP_MarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MarketOfferingMember" xlink:to="CRBP_MarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MarketOfferingMember_doc" xml:lang="en-US">Market Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:to="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_doc" xml:lang="en-US">Cystic Fibrosis Program Related Investment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationwarrantsMember" xlink:to="CRBP_CysticFibrosisFoundationwarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationwarrantsMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestmentagreementMember" xlink:to="CRBP_InvestmentagreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InvestmentagreementMember_doc" xml:lang="en-US">Investment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenCffAwardMember" xlink:to="CRBP_TwoThousandAndEighteenCffAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember_doc" xml:lang="en-US">2018 CFF Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:to="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_doc" xml:lang="en-US">Cash equivalents and restricted cash maturity period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StandbyLetterOfCreditMember" xlink:to="CRBP_StandbyLetterOfCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_StandbyLetterOfCreditMember_doc" xml:lang="en-US">Stand-by Letter of Credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointThreeFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoPointThreeFivePercentNotesPayableMember_doc" xml:lang="en-US">Two Point Three Five Percent Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandEighteenMember" xlink:to="CRBP_JanuaryOneTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryOneTwoThousandEighteenMember_doc" xml:lang="en-US">January 1, 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AtTheMarketOfferingMember" xlink:to="CRBP_AtTheMarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AtTheMarketOfferingMember_doc" xml:lang="en-US">At the Market Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenSalesAgreementMember" xlink:to="CRBP_TwoThousandAndEighteenSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandAndEighteenSalesAgreementMember_doc" xml:lang="en-US">2018 Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AmountReceivedForDevelopmentAward" xlink:to="CRBP_AmountReceivedForDevelopmentAward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AmountReceivedForDevelopmentAward_doc" xml:lang="en-US">Amount received for development award.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InsurancePoliciesMember" xlink:to="CRBP_InsurancePoliciesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InsurancePoliciesMember_doc" xml:lang="en-US">Insurance Policies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MassachusettsMember" xlink:to="CRBP_MassachusettsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MassachusettsMember_doc" xml:lang="en-US">Massachusett [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_3_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_2_lbl" xml:lang="en-US">Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_2_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>crbp-20171231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20171231 10K FY DFN.xfr; Date: 2018%2D03%2D12T04:11:39Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20171231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20171231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20171231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20171231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20171231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20171231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20171231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20171231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20171231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20171231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20171231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20171231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20171231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20171231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20171231.xsd#SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20171231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20171231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20171231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20171231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20171231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20171231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:href="crbp-20171231.xsd#DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20171231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20171231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20171231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20171231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:href="crbp-20171231.xsd#StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20171231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20171231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:href="crbp-20171231.xsd#QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20171231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DocumentAndEntityInformationAbstract" xlink:label="loc_CRBPDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrantsShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="loc_CRBPIncreaseDecreaseInDeferredRent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CRBPIncreaseDecreaseInDeferredRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LiquidityDisclosuresTextBlock" xlink:label="loc_CRBPLiquidityDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPLiquidityDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue" xlink:title="00000015 - Disclosure - Development Award and Deferred Revenue">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardsAbstract" xlink:label="loc_CRBPDevelopmentAwardsAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardAndDeferredRevenueTextBlock" xlink:label="loc_CRBPDevelopmentAwardAndDeferredRevenueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAbstract" xlink:to="loc_CRBPDevelopmentAwardAndDeferredRevenueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000017 - Disclosure - Common Stock">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000018 - Disclosure - Stock Options">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000019 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_WarrantsTextBlock" xlink:label="loc_CRBPWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_CRBPWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000020 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation" xlink:title="00000021 - Disclosure - Quarterly Financial Information (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:label="loc_CRBPAccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPAccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:label="loc_CRBPLeasesAndDeferredRentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPLeasesAndDeferredRentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Award and Deferred Revenue (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaapDeferredRevenueDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaapDeferredRevenueByArrangementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueDisclosureAbstract" xlink:to="loc_us-gaapDeferredRevenueByArrangementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:label="loc_CRBPSummaryOfNonvestedStockOptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CRBPSummaryOfNonvestedStockOptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformationTables" xlink:title="00000031 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldAndCoMember" xlink:label="loc_CRBPCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryFiveTwoThousandAndEighteenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryFiveTwoThousandAndEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryTwentySixTwoThousandAndEighteenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryTwentySixTwoThousandAndEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryTwoThousandAndEighteenMember" xlink:label="loc_CRBPJanuaryTwoThousandAndEighteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryTwoThousandAndEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AmountReceivedForDevelopmentAward" xlink:label="loc_CRBPAmountReceivedForDevelopmentAward" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPAmountReceivedForDevelopmentAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="loc_CRBPSignificantAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPSignificantAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="loc_CRBPSignificantAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_CRBPSignificantAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="loc_CRBPCorporatecreditCardsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPCorporatecreditCardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="loc_CRBPStandbyLetterOfCreditMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPStandbyLetterOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapCreationDateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="loc_CRBPMarketableSecuritiesMaturityPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPMarketableSecuritiesMaturityPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_StockOptionsMember" xlink:label="loc_CRBPStockOptionsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CRBPStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000037 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FebruaryTwoThousandAndEighteenMember" xlink:label="loc_CRBPFebruaryTwoThousandAndEighteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFebruaryTwoThousandAndEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LeaseTerm" xlink:label="loc_CRBPLeaseTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CRBPCommitmentAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_CRBPCommitmentAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FirstYearMember" xlink:label="loc_CRBPFirstYearMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_CRBPFirstYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SeventhYearMember" xlink:label="loc_CRBPSeventhYearMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_CRBPSeventhYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="loc_CRBPThirdAnniversaryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPThirdAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FourthAnniversaryMember" xlink:label="loc_CRBPFourthAnniversaryMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFourthAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementGeographicalAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OperatingLeaseTerms" xlink:label="loc_CRBPOperatingLeaseTerms" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPOperatingLeaseTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease" xlink:label="loc_us-gaapInterestExpenseLesseeAssetsUnderCapitalLease" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpenseLesseeAssetsUnderCapitalLease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CRBPCommitmentAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_CRBPCommitmentAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000042 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaapNotesPayableOtherPayablesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableOtherPayablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:label="loc_CRBPThreePointTwoFivePercentNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPThreePointTwoFivePercentNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:label="loc_CRBPTwoPointTwoFivePercentNotesPayableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPTwoPointTwoFivePercentNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:label="loc_CRBPTwoPointThreeFivePercentNotesPayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPTwoPointThreeFivePercentNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaapProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaapProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductOrServiceAxis" xlink:to="loc_us-gaapProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InsurancePoliciesMember" xlink:label="loc_CRBPInsurancePoliciesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductsAndServicesDomain" xlink:to="loc_CRBPInsurancePoliciesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCosts" xlink:label="loc_CRBPAccruedClinicalOperationsAndTrialsCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CRBPAccruedClinicalOperationsAndTrialsCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AccruedProductDevelopmentCosts" xlink:label="loc_CRBPAccruedProductDevelopmentCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CRBPAccruedProductDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative" xlink:title="00000044 - Disclosure - Development Award and Deferred Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardsAbstract" xlink:label="loc_CRBPDevelopmentAwardsAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardTable" xlink:label="loc_CRBPDevelopmentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAbstract" xlink:to="loc_CRBPDevelopmentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="loc_CRBPDevelopmentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_CRBPDevelopmentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="loc_CRBPOralAntiinflammatoryDrugMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPOralAntiinflammatoryDrugMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_LenabasumMember" xlink:label="loc_CRBPLenabasumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPLenabasumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="loc_CRBPUponCommercializationOfTheProductMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponCommercializationOfTheProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="loc_CRBPUponReachingTheSalesTargetMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponReachingTheSalesTargetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="loc_CRBPUponTransferSaleOrLicensingMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponTransferSaleOrLicensingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NumberOfInstallments" xlink:label="loc_CRBPNumberOfInstallments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPNumberOfInstallments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="loc_CRBPRoyaltyPaymentSalesTarget" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentSalesTarget" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails" xlink:title="00000045 - Disclosure - Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaapDeferredRevenueDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueDisclosureAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueDisclosureAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueDisclosureAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000046 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesTable" xlink:label="loc_CRBPIncomeTaxesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CRBPIncomeTaxesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="loc_CRBPIncomeTaxesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_CRBPIncomeTaxesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_FederalMember" xlink:label="loc_CRBPFederalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="loc_CRBPOrphanDrugCreditMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_CRBPOrphanDrugCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_MassachusettsMember" xlink:label="loc_CRBPMassachusettsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_CRBPMassachusettsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000047 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000048 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000049 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_CRBPSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_CRBPInstitutionalAndAccreditedInvestorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalAndAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CantorFitzgeraldMember" xlink:label="loc_CRBPCantorFitzgeraldMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPCantorFitzgeraldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="loc_CRBPInstitutionalInvestorsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPInstitutionalInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreationDateAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaapAvailableForSaleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CommissionPaidPercentage" xlink:label="loc_CRBPCommissionPaidPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPCommissionPaidPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000050 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapCreationDateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_JanuaryOneTwoThousandEighteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandEighteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:to="loc_CRBPJanuaryOneTwoThousandEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EmployeesMember" xlink:label="loc_CRBPEmployeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NonEmployeesMember" xlink:label="loc_CRBPNonEmployeesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ForfeituresEstimatedPercentage" xlink:label="loc_CRBPForfeituresEstimatedPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPForfeituresEstimatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Non Vested Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000054 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:label="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis" xlink:label="loc_CRBPIssuanceOfCommonStockSharesExercisedOnCashlessBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CRBPIssuanceOfCommonStockSharesExercisedOnCashlessBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_NumberOfCommonStockWereExercisedOnCashBasis" xlink:label="loc_CRBPNumberOfCommonStockWereExercisedOnCashBasis" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CRBPNumberOfCommonStockWereExercisedOnCashBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ClassOfWarrantOrRightIssued" xlink:label="loc_CRBPClassOfWarrantOrRightIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CRBPClassOfWarrantOrRightIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ClassOfWarrantOrRightCancelled" xlink:label="loc_CRBPClassOfWarrantOrRightCancelled" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CRBPClassOfWarrantOrRightCancelled" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="loc_CRBPOrchestraMedicalVenturesLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPOrchestraMedicalVenturesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CashCompensationAmount" xlink:label="loc_CRBPCashCompensationAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CRBPCashCompensationAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails" xlink:title="00000056 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000057 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="loc_CRBPAtTheMarketOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPAtTheMarketOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_TwoThousandAndEighteenSalesAgreementMember" xlink:label="loc_CRBPTwoThousandAndEighteenSalesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndEighteenSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_CysticFibrosisFoundationwarrantsMember" xlink:label="loc_CRBPCysticFibrosisFoundationwarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCysticFibrosisFoundationwarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20171231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755711136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 06, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Corbus Pharmaceuticals Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001595097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,882,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,134,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756009664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,537,495<span></span>
</td>
<td class="nump">$ 14,992,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">158,991<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Stock subscriptions receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">330,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,808,244<span></span>
</td>
<td class="nump">930,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,504,730<span></span>
</td>
<td class="nump">17,402,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,432,655<span></span>
</td>
<td class="nump">435,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">40,776<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,978,161<span></span>
</td>
<td class="nump">17,888,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">332,861<span></span>
</td>
<td class="nump">271,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,130,295<span></span>
</td>
<td class="nump">3,419,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,741,519<span></span>
</td>
<td class="nump">3,256,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,940,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,204,675<span></span>
</td>
<td class="nump">8,898,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, noncurrent</a></td>
<td class="nump">989,550<span></span>
</td>
<td class="nump">65,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,194,600<span></span>
</td>
<td class="nump">8,968,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2017 and 2016, 55,603,427 and 44,681,745 shares issued and outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">5,560<span></span>
</td>
<td class="nump">4,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">123,476,102<span></span>
</td>
<td class="nump">42,191,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(65,698,101)<span></span>
</td>
<td class="num">(33,276,489)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">57,783,561<span></span>
</td>
<td class="nump">8,919,235<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 66,978,161<span></span>
</td>
<td class="nump">$ 17,888,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755879456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">55,603,427<span></span>
</td>
<td class="nump">44,681,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">55,603,427<span></span>
</td>
<td class="nump">44,681,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758086192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 796,312<span></span>
</td>
<td class="nump">$ 350,186<span></span>
</td>
<td class="nump">$ 1,293,697<span></span>
</td>
<td class="nump">$ 375,670<span></span>
</td>
<td class="nump">$ 742,558<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 2,440,195<span></span>
</td>
<td class="nump">$ 1,911,424<span></span>
</td>
<td class="nump">$ 648,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,286,682<span></span>
</td>
<td class="nump">5,622,511<span></span>
</td>
<td class="nump">5,763,660<span></span>
</td>
<td class="nump">6,366,112<span></span>
</td>
<td class="nump">5,380,167<span></span>
</td>
<td class="nump">4,315,632<span></span>
</td>
<td class="nump">3,567,003<span></span>
</td>
<td class="nump">2,173,933<span></span>
</td>
<td class="nump">26,038,965<span></span>
</td>
<td class="nump">15,436,735<span></span>
</td>
<td class="nump">5,888,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,575,244<span></span>
</td>
<td class="nump">2,130,587<span></span>
</td>
<td class="nump">1,878,090<span></span>
</td>
<td class="nump">2,380,125<span></span>
</td>
<td class="nump">2,567,937<span></span>
</td>
<td class="nump">1,760,696<span></span>
</td>
<td class="nump">1,021,225<span></span>
</td>
<td class="nump">1,109,889<span></span>
</td>
<td class="nump">8,964,046<span></span>
</td>
<td class="nump">6,459,747<span></span>
</td>
<td class="nump">3,613,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,861,926<span></span>
</td>
<td class="nump">7,753,098<span></span>
</td>
<td class="nump">7,641,750<span></span>
</td>
<td class="nump">8,746,237<span></span>
</td>
<td class="nump">7,948,104<span></span>
</td>
<td class="nump">6,076,328<span></span>
</td>
<td class="nump">4,588,228<span></span>
</td>
<td class="nump">3,283,822<span></span>
</td>
<td class="nump">35,003,011<span></span>
</td>
<td class="nump">21,896,482<span></span>
</td>
<td class="nump">9,502,075<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(10,861,926)<span></span>
</td>
<td class="num">(6,956,786)<span></span>
</td>
<td class="num">(7,291,564)<span></span>
</td>
<td class="num">(7,452,540)<span></span>
</td>
<td class="num">(7,572,434)<span></span>
</td>
<td class="num">(5,333,770)<span></span>
</td>
<td class="num">(4,191,630)<span></span>
</td>
<td class="num">(2,887,224)<span></span>
</td>
<td class="num">(32,562,816)<span></span>
</td>
<td class="num">(19,985,058)<span></span>
</td>
<td class="num">(8,853,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">133,073<span></span>
</td>
<td class="nump">43,402<span></span>
</td>
<td class="nump">5,271<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="num">(5,360)<span></span>
</td>
<td class="nump">183,112<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange gain (loss)</a></td>
<td class="nump">35,163<span></span>
</td>
<td class="num">(52,212)<span></span>
</td>
<td class="num">(10,594)<span></span>
</td>
<td class="num">(14,265)<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
<td class="num">(14,729)<span></span>
</td>
<td class="num">(1,810)<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="num">(41,908)<span></span>
</td>
<td class="num">(14,094)<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">168,236<span></span>
</td>
<td class="num">(8,810)<span></span>
</td>
<td class="num">(5,323)<span></span>
</td>
<td class="num">(12,899)<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
<td class="num">(12,998)<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
<td class="num">(5,017)<span></span>
</td>
<td class="nump">141,204<span></span>
</td>
<td class="num">(13,617)<span></span>
</td>
<td class="nump">2,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,693,690)<span></span>
</td>
<td class="num">$ (6,965,596)<span></span>
</td>
<td class="num">$ (7,296,887)<span></span>
</td>
<td class="num">$ (7,465,439)<span></span>
</td>
<td class="num">$ (7,570,275)<span></span>
</td>
<td class="num">$ (5,346,768)<span></span>
</td>
<td class="num">$ (4,189,391)<span></span>
</td>
<td class="num">$ (2,892,241)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
<td class="num">$ (19,998,675)<span></span>
</td>
<td class="num">$ (8,850,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">53,828,680<span></span>
</td>
<td class="nump">50,221,597<span></span>
</td>
<td class="nump">50,193,726<span></span>
</td>
<td class="nump">46,381,482<span></span>
</td>
<td class="nump">44,348,543<span></span>
</td>
<td class="nump">43,783,504<span></span>
</td>
<td class="nump">38,748,452<span></span>
</td>
<td class="nump">37,605,210<span></span>
</td>
<td class="nump">50,176,953<span></span>
</td>
<td class="nump">41,137,518<span></span>
</td>
<td class="nump">31,350,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755656400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 2,594<span></span>
</td>
<td class="nump">$ 10,287,214<span></span>
</td>
<td class="num">$ (4,427,075)<span></span>
</td>
<td class="nump">$ 5,862,733<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="nump">25,938,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,153,302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,153,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants, net of issuance costs</a></td>
<td class="nump">$ 1,162<span></span>
</td>
<td class="nump">10,812,963<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,814,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants, net of issuance costs, shares</a></td>
<td class="nump">11,615,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5,584<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">51,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,666,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,850,739)<span></span>
</td>
<td class="num">$ (8,850,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 3,761<span></span>
</td>
<td class="nump">22,259,063<span></span>
</td>
<td class="num">(13,277,814)<span></span>
</td>
<td class="nump">8,985,010<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="nump">37,605,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,163,534<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,163,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants, net of issuance costs</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants, net of issuance costs, shares</a></td>
<td class="nump">601,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">467,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 467,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">326,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">16,300,309<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,300,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">6,148,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,998,675)<span></span>
</td>
<td class="num">(19,998,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">42,191,256<span></span>
</td>
<td class="num">(33,276,489)<span></span>
</td>
<td class="nump">8,919,235<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="nump">44,681,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,694,489<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,694,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">189,463<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 189,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">272,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">75,400,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 75,401,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">10,648,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(32,421,612)<span></span>
</td>
<td class="num">(32,421,612)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 5,560<span></span>
</td>
<td class="nump">$ 123,476,102<span></span>
</td>
<td class="num">$ (65,698,101)<span></span>
</td>
<td class="nump">$ 57,783,561<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="nump">55,603,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IssuanceOfCommonStockUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749161360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 2,969,837<span></span>
</td>
<td class="nump">$ 260,179<span></span>
</td>
<td class="nump">$ 509,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755839744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,421,612)<span></span>
</td>
<td class="num">$ (19,998,675)<span></span>
</td>
<td class="num">$ (8,850,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,694,489<span></span>
</td>
<td class="nump">3,163,534<span></span>
</td>
<td class="nump">1,153,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">255,652<span></span>
</td>
<td class="nump">87,664<span></span>
</td>
<td class="nump">43,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">(Gain) loss on foreign exchange</a></td>
<td class="num">(8,490)<span></span>
</td>
<td class="nump">14,094<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">913,563<span></span>
</td>
<td class="nump">75,987<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Decrease (increase) in grants receivable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses and other current assets</a></td>
<td class="num">(1,877,983)<span></span>
</td>
<td class="num">(553,745)<span></span>
</td>
<td class="num">(105,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="num">(40,776)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">(Decrease) increase in accounts payable</a></td>
<td class="num">(885,797)<span></span>
</td>
<td class="nump">1,890,876<span></span>
</td>
<td class="nump">972,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued expenses</a></td>
<td class="nump">1,514,521<span></span>
</td>
<td class="nump">2,660,461<span></span>
</td>
<td class="nump">312,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">(Decrease) increase in deferred revenue</a></td>
<td class="num">(1,940,195)<span></span>
</td>
<td class="nump">88,577<span></span>
</td>
<td class="nump">1,851,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(27,796,628)<span></span>
</td>
<td class="num">(13,571,227)<span></span>
</td>
<td class="num">(4,624,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(707,429)<span></span>
</td>
<td class="num">(353,032)<span></span>
</td>
<td class="num">(114,037)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(707,429)<span></span>
</td>
<td class="num">(353,032)<span></span>
</td>
<td class="num">(114,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="nump">415,265<span></span>
</td>
<td class="nump">348,750<span></span>
</td>
<td class="nump">207,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(354,161)<span></span>
</td>
<td class="num">(239,012)<span></span>
</td>
<td class="num">(190,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">78,891,699<span></span>
</td>
<td class="nump">16,699,133<span></span>
</td>
<td class="nump">11,328,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance costs paid for common stock financings</a></td>
<td class="num">(2,940,685)<span></span>
</td>
<td class="num">(63,830)<span></span>
</td>
<td class="num">(509,215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments under capital lease obligations</a></td>
<td class="num">(3,832)<span></span>
</td>
<td class="num">(3,175)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">76,008,286<span></span>
</td>
<td class="nump">16,741,866<span></span>
</td>
<td class="nump">10,837,344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">47,504,229<span></span>
</td>
<td class="nump">2,817,607<span></span>
</td>
<td class="nump">6,098,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">15,192,257<span></span>
</td>
<td class="nump">12,374,650<span></span>
</td>
<td class="nump">6,276,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the year</a></td>
<td class="nump">62,696,486<span></span>
</td>
<td class="nump">15,192,257<span></span>
</td>
<td class="nump">12,374,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information and non cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">12,377<span></span>
</td>
<td class="nump">5,586<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Assets acquired under capital lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable or accrued expenses</a></td>
<td class="nump">579,734<span></span>
</td>
<td class="nump">34,107<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Unpaid stock issuance costs</a></td>
<td class="nump">$ 225,501<span></span>
</td>
<td class="nump">$ 196,349<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Deferred Rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748508336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>1.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>NATURE OF OPERATIONS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Corbus Pharmaceuticals Holdings,
Inc. (&#8220;CPHI&#8221; or &#8220;the Company&#8221;) is a clinical stage pharmaceutical company, focused on the development
and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its
inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting
management and technical staff, acquiring operating assets and raising capital. . The Company&#8217;s business is subject to significant
risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable
and it may never achieve profitability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6892316672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LiquidityDisclosuresTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>2.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>LIQUIDITY </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company anticipates operating
losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its
product candidates and its preclinical and clinical programs, strategic alliances and the development of its administrative organization.
The Company has incurred recurring losses since inception and as of December 31, 2017, had an accumulated deficit of $65,698,101.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 5, 2018, the Company
entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (&#8220;January 2018 Sales Agreement&#8221;) with Cantor
Fitzgerald &#38; Co. (&#8220;Cantor Fitzgerald&#8221;) pursuant to which Cantor Fitzgerald is serving as the Company&#8217;s sales
agent to sell up to $50 million of shares of the Company&#8217;s common stock through an &#8220;at the market offering,&#8221;
of which 1,500,000 shares have been sold for net proceeds of $11.3 million to date. (See Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 26, 2018, the Company
entered into the Cystic Fibrosis Program Related Investment Agreement (&#8220;Investment Agreement&#8221;) with the Cystic Fibrosis
Foundation (&#8220;CFF&#8221;), a non-profit drug discovery and development corporation, pursuant to which the Company received
a development award for up to $25 million in funding (the &#8220;2018 CFF Award&#8221;) to support a Phase 2b Clinical Trial (the
&#8220;Phase 2b Clinical Trial&#8221;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25 million
to date. The Company expects the remainder of the 2018 CFF Award will be paid to the Company incrementally upon the achievement
of the remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement. (See
Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company expects the cash on
hand of $62,537,495 at December 31, 2017 together with the $11.3 million of net proceeds received from the January 2018 Sales Agreement
and the $6.25 million that the Company has received to date under the 2018 CFF Award, to be sufficient to meet its operating and
capital requirements at least 12 months from the filing of this 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Should the Company be unable to
raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing
certain clinical activities. The Company will need to raise significant additional capital to continue to fund the clinical trials
for lenabasum. The Company may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility
or another form of third-party funding, or seek other debt financing. The sale of equity and convertible debt securities may result
in dilution to the Company&#8217;s stockholders and certain of those securities may have rights senior to those of the Company&#8217;s
common shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other
debt financing, these securities or other debt could contain covenants that would restrict the Company&#8217;s operations. Any
other third-party funding arrangement could require the Company to relinquish valuable rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The source, timing and availability
of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company&#8217;s
clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of
necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company&#8217;s
planned clinical trials.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LiquidityDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LiquidityDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748529296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>3.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of the significant accounting
policies followed by the Company in the preparation of the financial statements is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The process of preparing financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based
compensation expense, the accrual of research, product development and clinical obligations, and the expected performance period
under the 2015 CFFT Award (See Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Prior to the registration of its
common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not
less than the fair value of its common stock as determined by the board of directors, with input from management. The Company&#8217;s
board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors,
including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold
shares of preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Cash, Cash Equivalents, and
Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company considers only those
investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to
be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2017
and 2016, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2017
and 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Restricted cash as of December 31,
2017 and 2016 included a collateral account for the Company&#8217;s corporate credit cards and is classified in current assets
in the amount of $108,991 and $150,000, respectively. Additionally, as of December 31, 2017 and 2016 restricted cash included a
stand-by letter of credit issued in favor of a landlord for $50,000 which was classified in current assets as of December 31, 2017
and in noncurrent assets as of December 31, 2016 (See Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and restricted
cash consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">206,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,127,530</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Money market fund</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,330,985</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,864,727</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,537,495</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">14,992,257</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Restricted cash, current</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash, noncurrent</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">50,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">62,696,486</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,192,257</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Financial Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The carrying amounts reported in
the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their
fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair
value due to the fact that they are at market terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Property and Equipment </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The estimated life for the Company&#8217;s
property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture
and equipment. The Company&#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their
useful lives or the respective leases. See Note 4 for details of property and equipment and Note 5 for operating and capital lease
commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Research and Development Expenses
and Development Award Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Costs incurred for research and
development are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Nonrefundable advance payments for
goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant
to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the
related goods are delivered or the related services are performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For amounts received under the development
award received from the CFFT (See Note 8), the Company recognized those amounts when the triggering event to receive those payments
occurred, with those amounts being amortized on a straight-line basis over the expected duration of the remaining performance period
of the development program under the award, which concluded in the third quarter of 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Accruals for Research and
Development Expenses and Clinical Trials</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As part of the process of preparing
its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with
vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical
trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company determines accrual estimates by taking into account discussion with
applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the
course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The
Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it
at that time. The Company&#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research
organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from
amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For
the years ended December 31, 2017, 2016 and 2015, there were no material adjustments to the Company&#8217;s prior period estimates
of accrued expenses for clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Leases and Deferred Rent</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company leases its office space.
Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&#8217;s office
space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records
the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between
the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the lessor
are recorded as a reduction to rent expense over the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has no significant off-balance-sheet
concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may
from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company
believes the risk of loss is minimal as these banks are large financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date,
the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing
therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2017 and 2016, all of the Company&#8217;s
assets were located in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For federal and state income taxes,
deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax
basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in
which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax asset when it is not
more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses
since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate
the deferred tax assets amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Tax positions taken or expected
to be taken in the course of preparing the Company&#8217;s tax returns are required to be evaluated to determine whether the tax
positions are &#8220;more-likely-than-not&#8221; of being sustained by the applicable tax authority. Tax positions not deemed to
meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in
the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December
31, 2017 or 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company continually monitors
events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment
loss is recognized when expected undiscounted cash flows of an asset are less than an asset&#8217;s carrying value. Accordingly,
when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating
performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess of the fair value
of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset may not be recoverable.
No impairment charges were recorded for the years ended December 31, 2017, 2016 and 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Share-based Payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company recognizes compensation
costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement
of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option
grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized
as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.
Stock options granted to non-employee consultants are revalued at the end of each reporting period until vested using the Black-Scholes
option-pricing model and the changes in their fair value are recorded as adjustments to expense over the related vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On March 30, 2016, the FASB issued
ASU No. 2016-09, <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
</i>(&#8220;ASU 2016-09&#8221;)<i>. </i>ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment
transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification
in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures
as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have
an impact on the Company&#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the excess
tax benefits in respect of share based payments only when realized (See Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Basic and diluted net loss per share
of the Company&#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding
during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted
loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years
ended December 31, 2017, 2016 and 2015:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Years Ended December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2015</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Basic and diluted net loss per share of common stock:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">&#160;</td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(32,421,612</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">&#160;</td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,998,675</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(8,850,739</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average shares of common stock outstanding</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,176,953</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,137,518</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">31,350,145</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share of common stock-basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.65</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.49</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.28</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following potentially
dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of dilutive weighted
average shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2015</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,969,250</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,610,179</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,982,065</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,133,466</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,898,679</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,951,315</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>Revenue Recognition</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In May 2014, the FASB issued guidance
codified in <i>Accounting Standards Codification (ASC) 606, Revenue Recognition &#8212; Revenue from Contracts with Customers</i>
(&#8220;ASC 606&#8221;) which amends the guidance in former <i>ASC 605, Revenue Recognition</i>, and is effective for public companies
for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from the current accounting
standard in many respects, such as in the accounting for variable consideration received, including milestone payments or contingent
payments. Under the Company&#8217;s accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone
payments were initially recognized only in the period that the payment-triggering event occurred or was achieved (See Note 8).
ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely achieved based
on the Company&#8217;s estimate of the amount of consideration to which it will be entitled in exchange for transferring the services,
subject to management&#8217;s assessment of whether it is probable that a significant reversal in the amount of cumulative revenue
recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company
adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of
initially applying ASC 606 is recognized at the date of initial application. Since the Company has concluded its performance obligations
and has completed recognizing revenue under the agreement with CFFT in the third quarter of 2017 (See Note 8), there was no cumulative
effect to record at the date of the Company&#8217;s adoption of ASC 606. The Company will assess any new agreements it enters into,
including the 2018 CFF Award, (See Note 15) under ASC 606, including if such agreements fall under the scope of such standard.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Accounting for Leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In February 2016, the FASB issued
ASU No<b>. </b>2016-02, <i>Leases (Topic 842) </i>(&#8220;ASU 2016-02&#8221;)<i>. </i>Under ASU 2016-02, a lessee will be required
to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current GAAP, the
recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on
its classification as a finance or operating lease. However, unlike current GAAP, which requires only capital leases to be recognized
on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU 2016-02 will take
effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early application
permitted. The adoption of ASU 2016-02 will have an impact on the Company&#8217;s financial position as the Company has operating
lease commitments for office space as of December 31, 2017 with future non-cancelable lease payments amounting to $5,474,623 (see
Note 5) for which ASU 2016-02 would apply.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915525920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>4.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>PROPERTY AND EQUIPMENT</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Property and Equipment consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Computer hardware and software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">136,522</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">96,131</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Office furniture and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">287,048</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">259,138</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">191,244</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">188,219</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Construction in progress</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,181,730</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Property and equipment, gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,796,544</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">543,488</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(363,889</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(108,237</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Property and equipment, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,432,655</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">435,251</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Depreciation expense was approximately
$256,000, $88,000 and $44,000 for the years ended December 31, 2017, 2016 and 2015, respectively. At December 31, 2017, construction
in progress consisted of purchased property and equipment not placed in service until the Company&#8217;s relocation into 32,733
square feet of office space in February 2018 (See Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 30, 2015, the Company
entered into a lease agreement for a copier machine. The cost of the machine was approximately $12,000 and is included in office
furniture and equipment category in the table above. The lease payments commenced when the machine was placed in service in January
2016. The machine is being amortized over the life of the lease, which is for a three-year term and includes a bargain purchase
option at the end of the term. See Note 5 for details of this capital lease commitment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748517456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>5.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>COMMITMENTS AND CONTINGENCIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Operating Lease Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In September 2016, the Company amended
its commercial lease for office space to expand into an additional 4,088 square feet of office space within the same building for
an aggregate total of 10,414 square feet of leased office space (&#8220;September 2016 Amendment&#8221;). The Company began occupying
this space in early November 2016 and the final lease payment was to be due in January 2021. The September 2016 Amendment required
an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was terminated upon the commencement
date of the August 2017 Lease Agreement discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On August 21, 2017, the Company
entered into a lease agreement (&#8220;August 2017 Lease Agreement&#8221;) with the same landlord, pursuant to which the Company
agreed to lease 32,733 square feet of office space (&#8220;Leased Premises&#8221;). The initial term of the August 2017 Lease Agreement
is for a period of seven years which began with the Company&#8217;s occupancy of the Leased Premises in February 2018. The base
rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately $908,000 for the seventh year.
Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company for $1,080,189 of leasehold improvements.
The reimbursements have been deferred and will be recognized as a reduction of rent expense over the term of the lease. Additionally,
the August 2017 Lease Agreement required a standby irrevocable letter of credit of $400,000, which may be reduced, if the Company
is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement
date, respectively, The Company entered into an unsecured letter of credit for $400,000 in connection with the August 2017 Lease
Agreement for which it incurred interest expense of $9,743 in year ended December 31, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company records the total rent
payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents
paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and deferred rent, noncurrent in
the Company&#8217;s balance sheet as of December 31, 2017 and 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Company&#8217;s
non-cancelable lease agreements in effect at December 31, 2017, the future minimum rent commitments are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">445,333</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">623,958</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">784,243</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">830,600</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">855,150</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,935,339</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,474,623</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Total rent expense for the years
ended December 31, 2017, 2016 and 2015 was $356,547, $229,705 and $55,496, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b>Capital Lease Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The lease payments commenced when
the machine was placed in service in January 2016. The lease is for a three-year term and includes a bargain purchase option at
the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current portion of this capital lease
obligation is classified in accrued expenses and the long-term portion of the capital lease obligation is classified in other long-term
liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital lease commitments are as follows
as of December 31, 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4,543</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">379</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Total future minimum lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,922</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: interest</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(291</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Future capital lease obligations</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,631</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current portion</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(4,256</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long-term portion</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">375</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Interest expense for this capital
lease obligation for the years ended December 31, 2017, 2016 and 2015 was $712, $1,286 and $0, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For commitments under the Company&#8217;s
development award agreements- see Note 8.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6892472128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>6.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>NOTES PAYABLE</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In November 2015, the Company entered
into a loan agreement with a financing company for $207,750 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulated equal monthly payments of principal and interest payments of $23,397 over a nine month period. Interest
on this loan was accrued at an annual rate of 3.25%. This loan was fully repaid in July 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In October 2016, the Company entered
into a loan agreement with a financing company for $348,750 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over a nine-month period. Interest on
this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In November 2017, the Company entered
into a loan agreement with a financing company for $415,265 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest accrues
on this loan at an annual rate of 2.35%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Prepaid expenses and other current
assets as of December 31, 2017 and 2016 included $368,976 and $378,750, respectively, related to these insurance policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Interest expense for notes payable
for the years ended December 31, 2017, 2016 and 2015 totaled $3,632, $3,115 and $2,440, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748410688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>7.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>ACCRUED EXPENSES </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Accrued expenses consisted of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Accrued clinical operations and trials costs</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,003,799</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,647,490</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued product development costs</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,255,439</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">713,426</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,335,672</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">778,250</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Accrued other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">146,609</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">117,289</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,741,519</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,256,455</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901642240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Award and Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardsAbstract', window );"><strong>Development Award And Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardAndDeferredRevenueTextBlock', window );">Development Award and Deferred Revenue</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>8.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>DEVELOPMENT AWARD AND DEFERRED REVENUE </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On April 20, 2015, the Company entered
into an award agreement (the &#8220;2015 CFFT Award Agreement &#8220;) with the CFFT pursuant to which it received a development
award (the &#8220;2015 CFFT Award&#8221;) for up to $5 million in funding. The funding from the 2015 CFFT Award supported a first-in-patient
Phase 2 clinical trial of the Company&#8217;s oral anti-inflammatory drug lenabasum in adults with cystic fibrosis (&#8220;CF&#8221;).
The Company has received $5.0 million in payments since the inception of the 2015 CFFT Award as outlined below. The payments received
under the 2015 CFFT Award were recorded as deferred revenue when the triggering event to receive those amounts had occurred and
were amortized on a straight-line basis over the expected duration of the remaining performance period under the 2015 CFFT Award
which concluded in the third quarter of 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Upon the execution of the 2015 CFFT
Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the Company received a second payment
of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, the Company received a third payment
from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical trial patient.
In January 2017, the Company received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone in December
2016 related to completing the final visit for the final patient, which was billed by the Company to CFFT in December 2016 and
was classified in grants receivable as of December 31, 2016. The Company received the final payment from CFFT in the amount of
$500,000 in November 2017 for achieving the final milestone in September 2017 related to the issuance to CFFT of the final integrated
statistical report for to the Phase 2 CF clinical trial. At that time the Company had completed all its performance obligations
under the contract and therefore the performance period had concluded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the 2015
CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization of lenabasum
in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five times the amount
the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments following
the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum,
(ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up to $5 million,
due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million,
and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses lenabasum in
the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change of control transaction,
with such payment(s) to be credited against the royalty payments due upon commercialization. The Field of Use is defined in the
2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity
pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company may terminate the
agreement for cause, which includes the Company&#8217;s material failure to achieve certain commercialization and development milestones.
The Company&#8217;s payment obligations, if any, would survive the termination of the 2015 CFFT Award Agreement. For the years
ended December 31, 2017, 2016 and 2015, in respect of the 2015 CFFT Award Agreement, the Company recognized revenue of $2,440,195,
$1,911,424 and $648,382, respectively. Deferred revenue consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Deferred revenue</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,940,195</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current portion</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,940,195</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long term portion</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">See Note 15 for the Investment
Agreement entered into by the Company after the balance sheet date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardAndDeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Award and Deferred Revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardAndDeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748510000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>9.</b></font></td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>INCOME TAXES </b></font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 6pt 0 0 24.5pt; text-align: justify">No provision or benefit
for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and
the Company has provided a full valuation allowance against its deferred tax assets.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">At December&#160;31, 2017
and 2016, the Company had federal net operating loss carryforwards of approximately $56,536,000 and $28,644,000, respectively,
of which federal carryforwards will expire in varying amounts beginning in 2029. At December&#160;31, 2017 and 2016, the Company
had Massachusetts net operating loss carryforwards of approximately $53,110,000 and $26,573,000, respectively. In the first quarter
of 2017, the Company adopted ASU 2016-09, which removed the requirement to recognize the deferred tax assets on excess tax benefits
in respect of share based payments only when realized. As such, during the year ended December 31, 2017, the Company&#8217;s gross
deferred tax assets and corresponding valuation allowance each included a one-time increase in respect of an additional federal
and state net operating losses of $1,432,000. The adoption of ASU 2016-09 did not have an impact on the Company&#8217;s balance
sheet, results of operations, cash flows or statement of stockholders&#8217; equity because the Company has a full valuation allowance
on its deferred tax assets. Utilization of net operating losses may be subject to substantial annual limitations due to the &#8220;change
in ownership&#8221; provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in
the expiration of net operating losses before utilization. The Company has not yet conducted a study to determine if any such changes
have occurred that could limit the Company&#8217;s ability to use the net operating losses and tax credit carryforwards. The Company
also had research and development tax credit carryforwards at December&#160;31, 2017 and 2016 of approximately $1,283,000 and $736,000,
respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Significant components of
the Company&#8217;s net deferred tax asset are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">NOL carryforward</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,229,127</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,860,828</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax credits</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,213,347</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">673,690</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock based compensation</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,724,248</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,177,650</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,654</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">302,943</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other temporary differences</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">116,292</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">225,214</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Subtotal</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">18,328,668</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,240,325</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(18,328,668</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(13,240,325</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax asset</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has maintained
a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded
when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company
cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax
assets, a full valuation allowance has been provided. The valuation allowance increased by $5,088,343 and $7,860,985 in 2017 and
2016, respectively, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards. The Company
has no uncertain tax positions at December 31, 2017 and 2016 that would affect its effective tax rate. Since the Company is in
a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities
for all years for which a loss carryforward is available.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Income tax benefits computed
using the federal statutory income tax rate differs from the Company&#8217;s effective tax rate primarily due to the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax provision at statutory rate</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">State taxes, net of federal benefit</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.66</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Permanent differences</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-2.05</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.65</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.62</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax credits</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.59</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.67</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Income tax rate change</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-24.11</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.60</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.13</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Increase in valuation reserve</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-15.69</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-39.31</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-40.85</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>The Tax Cut and Jobs Act
of 2017</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 22, 2017, the
Tax Cut and Jobs Act (the &#8220;Tax Act&#8221;) was enacted into law. The Tax Act, among other things, contains significant changes
to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation
of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses); limitation of the
deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80% of taxable income, indefinite
carryforward of net operating losses generated in tax years after 2018 and elimination of net operating loss carrybacks; changes
in the treatment of offshore earnings regardless of whether they are repatriated; current inclusion in U.S. federal taxable income
of certain earnings of controlled foreign corporations, mandatory capitalization of research and development expenses beginning
in 2022; immediate deductions for certain new investments instead of deductions for depreciation expense over time; further deduction
limits on executive compensation; and modifying, repealing and creating many other business deductions and credits, including the
reduction in the orphan drug credit from 50% to 25% of qualifying expenditures. As of December 31, 2017, we have made a reasonable
estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures by reducing our net federal and state
deferred tax assets by $7,815,832 for the reduction in corporate tax rate. This adjustment to our deferred tax assets is offset
against the valuation allowance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Additionally, the SEC staff
has issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond one year of the
enactment date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application
of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including
computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. Because the Company is
still in the process of analyzing certain provisions of the Tax Act, the Company has determined that the adjustment to its deferred
taxes was a provisional amount as permitted under SAB 118.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748502640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>10.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>COMMON STOCK </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has authorized 150,000,000
shares of common stock, $0.0001 par value per share, of which 55,603,427 shares, 44,681,745 shares, and 37,605,134 shares were
issued and outstanding as of December 31, 2017, 2016, and 2015, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">During the year ended December 31,
2015, the Company issued 11,666,802 shares of common stock upon the exercise of warrants and stock options to purchase common stock
and the Company received net proceeds of $10,819,714 from these exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In June 2016, the Company completed
a sale of shares of its common stock pursuant to the terms of a securities purchase agreement under which the Company sold an aggregate
of 5,960,000 shares of its common stock in a registered direct offering to investors at a purchase price of $2.50 per share with
gross proceeds to the Company totaling approximately $14,900,000 less issuance costs of $25,222. On February 28, 2017, the Company
entered in a securities purchase agreement providing for the issuance and sale by the Company of 3,887,815 shares of its common
stock in a registered direct offering to institutional and accredited investors at a purchase price of $7.00 per share with gross
proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In November 2016, the Company entered
into a sales agreement with Cantor Fitzgerald under which the Company could direct Cantor Fitzgerald as its sales agent to sell
common stock under an &#8220;At the Market Offering&#8221; (&#8220;Sales Agreement&#8221;). Sales of common stock under the Sales
Agreement were made pursuant to an effective registration statement for an aggregate offering of up to $35 million. Under the Sales
Agreement, the Company was obligated to pay Cantor a 3% commission on gross proceeds. In 2016, the Company sold 188,695 shares
of our common stock under the Sales Agreement at an average selling price of approximately $8.54 per share (net of 3% commission
paid to Cantor Fitzgerald) which resulted in proceeds of approximately $1,621,182 and net proceeds of approximately $1,426,145
net of incurred issuance costs. Approximately $330,413 of these proceeds were classified in stock subscriptions receivable as of
December 31, 2016 because the Company did not receive these proceeds until January 2017. During the year ended December 31, 2017,
in the first quarter, the Company sold 1,413,633 shares of its common stock under the Sales Agreement at an average selling price
of approximately $9.71 per share for gross proceeds of $13,724,591 and net proceeds of $13,268,208. The Company did not sell any
shares of its common stock under the Sales Agreement in the second or third quarter of 2017 and terminated the Sales Agreement
in connection with the October 2017 Offering discussed below. The aggregate amount sold under the Sales Agreement as described
above was approximately $15.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">See Note 15 for the January 2018
Sales Agreement entered into by the Company and Cantor Fitzgerald after the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On October 26, 2017, the Company
consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 4,650,000
shares of its common stock to institutional investors at a purchase price of $7.00 per share with gross proceeds to the Company
totaling $32,550,000, less estimated issuance costs incurred of approximately $2,184,000. The Company also granted the underwriters
a 30-day option to purchase up to an additional 697,500 shares of common stock on the same terms as the underwriters were purchasing
the base number of shares, which they exercised in November 2017 with net proceeds to us totaling $4,589,550.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">During the year ended December
31, 2017, the Company issued 272,734 shares of common stock upon the exercise of stock options and warrants to purchase common
stock and the Company received net proceeds of $189,490 from these exercises. During the year ended December 31, 2016, the Company
issued 927,916 shares of common stock upon the exercise of stock options and warrants to purchase common stock and the Company
received net proceeds of $468,442 from these exercises.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748510000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>11.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>STOCK OPTIONS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In April 2014, the Company adopted
the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;). Pursuant to the 2014 Plan,
the Company&#8217;s Board of Directors may grant incentive and nonqualified stock options and restricted stock to employees, officers,
directors, consultants and advisors. On January 1, 2017, pursuant to an annual evergreen provision contained in the 2014 Plan,
the number of shares reserved for future grants was increased by 3,127,722 shares. As of December 31, 2017, there was a total of
13,043,739 shares reserved for issuance under the 2014 Plan and there were 4,460,334 shares available for future grants. Options
issued under the 2014 Plan generally vest over 4 years from the date of grant in multiple tranches and are exercisable for up to
10 years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of an annual
evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically
increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on
December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may
determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective
as of January 1, 2018, the number of shares of common stock available for issuance under the 2014 Plan increased by 2,500,000 shares,
which was less than seven percent (7%) of the outstanding shares of common stock on December 31, 2017. As of January 1, 2018, the
2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares available for future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Share-based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For stock options issued and outstanding
for the years ended December 31, 2017, 2016 and 2015, the Company recorded non-cash, stock-based compensation expense of $5,694,489
($4,640,646 for employees and $1,053,843 for non-employees), $3,163,534 ($2,104,939 for employees and $1,058,595 for non-employees)
and $1,153,302 ($672,071 for employees and $481,231 for non-employees), respectively, net of estimated forfeitures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The fair value of each option award
for employees is estimated on the date of grant and for non-employees is estimated at the end of each reporting period using the
Black-Scholes option pricing model that uses the assumptions noted in the following table. Due to its limited operating history,
the Company estimated its volatility in consideration of a number of factors, including the volatility of comparable public companies
and, commencing in 2015, the Company also included the volatility of its own common stock, taking into account the expected life
of the option. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial
statements, to estimate option exercises and employee terminations in order to estimate its forfeiture rate. The expected term
of options granted under the 2014 Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107,
is based on the average between the vesting period and the contractual life of the options which is 6.25 years. For non-employee
options, the expected term is the contractual term. The risk-free rate is based on the yield of a U.S. Treasury security with a
term consistent with the option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average assumptions
used principally in determining the fair value of options granted to employees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2015</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2.12</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.70</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.85</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected term in years</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.73</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">86.01</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">90.39</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">90.68</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Estimated forfeiture rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.83</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For the year ended December 31,
2017, the assumptions used in determining the fair value of options granted to nonemployees included risk free interest rate ranging
from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years, expected volatility ranging
from 85.58% to 89.58%, and estimated forfeiture rate of 5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of option activity for
years ended December 31, 2017 and 2016 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Exercise </font><br />
<font style="font-size: 10pt">Price</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Remaining </font><br />
<font style="font-size: 10pt">Contractual </font><br />
<font style="font-size: 10pt">Term in </font><br />
<font style="font-size: 10pt">Years</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Intrinsic </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 48%"><font style="font-size: 10pt">Outstanding at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">3,982,065</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.03</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,020,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.42</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(326,886</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.43</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(65,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2.44</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2016</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6,610,179</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.54</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">8.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(272,734</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.67</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.53</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at December 31, 2017</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3.75</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.72</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">29,433,877</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Vested at December 31, 2017</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,514,977</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.98</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.02</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">23,444,225</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average grant-date
fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was $6.22, $3.81 and $1.41 per share, respectively.
The aggregate intrinsic value of options exercised during the years ended December 31, 2017, 2016 and 2015 was approximately $2,092,964.
$1,004,321 and $152,531, respectively. As of December 31, 2017 there was approximately $12,542,918 of total unrecognized compensation
expense, related to non-vested share-based compensation arrangements. The unrecognized compensation expense is estimated to be
recognized over a period of 2.87 years at December 31, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As summary of non-vested stock options
for the years ended December 31, 2017 and 2016 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Fair </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Non-vested at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,035,254</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.85</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,020,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.69</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,194,600</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.57</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(34,380</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.77</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Nonvested at December 31, 2016</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,826,274</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.86</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6.22</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(2,003,806</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.60</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5.03</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Non-vested at December 31, 2017</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,329,989</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.61</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748430288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>12.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>WARRANTS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">At December 31, 2017, there were
warrants outstanding to purchase 1,288,500 shares of common stock with a weighted average exercise price of $1.00 and a weighted
average remaining life of 1.41 years. No warrants were exercised during the year ended December 31, 2017. During the year ended
December 31, 2016, warrants to purchase 679,500 shares of common stock were exercised on a cashless basis resulting in the issuance
of 599,780 shares and 1,250 shares of common stock were exercised on a for cash basis. There were no warrants issued or cancelled
during the year ended December 31, 2017 or 2016</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For warrant issued to CFF after
the balance sheet date &#8211; see Note 15.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904339568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>13.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>RELATED PARTY TRANSACTIONS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On September 20, 2016, the Company
entered into a consulting agreement (the &#8220;2016 Consulting Agreement&#8221;) with Orchestra Medical Ventures, LLC (&#8220;Orchestra&#8221;),
of which a member of the Company&#8217;s Board of Directors, David Hochman, is Managing Partner. Under this agreement, Orchestra
rendered a variety of consulting and advisory services relating principally to identifying and evaluating strategic relationships,
licensing opportunities, and business strategies. The term of the 2016 Consulting Agreement commenced on September 20, 2016 and
expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting Agreement, the Company paid to Orchestra cash compensation
in an aggregate amount of $100,000. In connection with this agreement, the Company granted an equity incentive award to Mr. Hochman
consisting of options to purchase 50,000 shares (&#8220;Option Shares&#8221;) of common stock (the &#8220;Option Award&#8221;)
pursuant to the Company&#8217;s 2014 Equity Compensation Plan, of which fifty percent (50%) vested on the three (3) month anniversary
of the date of grant of the Option Award and the remainder of the Option Shares vested on the six (6) month anniversary of the
date of grant of the Option Award. The Option Shares were granted with an exercise price of $7.14 per share. The Company recorded
stock-based compensation expense of approximately $222,000 during the year ended December 31, 2016 and $171,000 during the first
quarter of 2017 in respect of the Option Award. No stock-based compensation expense was recorded after the first quarter of 2017
related to the Option Shares as they were fully vested in March 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647652592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>14.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Quarters Ended</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 26%"><font style="font-size: 10pt">Revenue from awards</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">1,293,697</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,186</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">796,312</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Operating expenses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Research and development</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6,366,112</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,763,660</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,622,511</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8,286,682</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">General and administrative</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,380,125</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,878,090</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,130,587</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,575,244</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total operating expenses</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,746,237</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,641,750</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,753,098</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,861,926</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Operating loss</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(7,452,540</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(7,291,564</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(6,956,786</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(10,861,926</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Other income (expense):</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Interest income (expense), net</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,366</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,271</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">43,402</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">133,073</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Foreign currency exchange gain (loss)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,265</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(10,594</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(52,212</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">35,163</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Other income (expense), net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12,899</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(5,323</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(8,810</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">168,236</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(7,465,439</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(7,296,887</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(6,965,596</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(10,693,690</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share, basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.16</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.15</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.14</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.20</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average number of common shares outstanding, basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">46,381,482</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,193,726</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,221,597</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">53,828,680</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Quarters Ended</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 26%"><font style="font-size: 10pt">Revenue from awards</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">396,598</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">396,598</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">742,558</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">375,670</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Operating expenses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Research and development</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,173,933</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,567,003</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,315,632</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,380,167</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">General and administrative</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,109,889</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,021,225</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,760,696</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,567,937</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total operating expenses</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,283,822</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,588,228</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,076,328</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,948,104</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Operating loss</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,887,224</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(4,191,630</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(5,333,770</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(7,572,434</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Other income (expense):</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Interest income (expense), net</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(5,360</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,049</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,731</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">57</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Foreign currency exchange gain (loss)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">343</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,810</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,729</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,102</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Other income (expense), net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(5,017</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,239</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12,998</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,159</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(2,892,241</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(4,189,391</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,346,768</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(7,570,275</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share, basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.08</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.11</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.12</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.17</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average number of common shares outstanding, basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">37,605,210</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">38,748,452</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">43,783,504</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">44,348,543</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904339568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>15.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>SUBSEQUENT EVENTS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Evergreen Provision</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of an annual
evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically
increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on
December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may
determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective
as of January 1, 2018, the number of shares of common stock available for issuance under the 2014 Plan increased by 2,500,000 shares,
such amount being less than seven percent (7%) of the outstanding shares of common stock on December 31, 2017. As of January 1,
2018, the 2014 Plan had a total reserve of 15,543,739 shares and there were 6,960,334 shares available for future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>At the Market Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 5, 2018, the Company
entered into a sales agreement with Cantor Fitzgerald under which the Company may direct Cantor Fitzgerald as its sales agent to
sell common stock up to an aggregate offering of up to $50 million under an &#8220;At the Market Offering&#8221; (&#8220;January
2018 Sales Agreement&#8221;). Sales of common stock under the January 2018 Sales Agreement were made pursuant to an effective registration
statement for an aggregate offering of up to $50 million. In February 2018, the Company sold 1,500,000 shares of its common stock
to an institutional investor under the January 2018 Sales Agreement for which it received net proceeds of $11,349,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Cystic Fibrosis Program Related
Investment Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 26, 2018, the Company
entered into the Cystic Fibrosis Program Related Investment Agreement with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;) (&#8220;Investment
Agreement&#8221;), a non-profit drug discovery and development corporation, pursuant to which the Company received an award for
up to $25 million in funding (the &#8220;2018 CFF Award&#8221;) to support a Phase 2b Clinical Trial (the &#8220;Phase 2b Clinical
Trial&#8221;) of lenabasum in patients with cystic fibrosis, of which the Company has received $6.25 million to date. The Company
expects that the remainder of the 2018 CFF Award will be paid incrementally upon the Company&#8217;s achievement of the remaining
milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Investment
Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty payment of one and one-half times
the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval of lenabasum in the United
States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon approval in another major market,
as set forth in the Investment Agreement (the &#8220;Approval Royalty&#8221;). At the Company&#8217;s election, the Company may
satisfy the first of the two Approval Royalties in registered shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Additionally, the Company is obligated
to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty days after any quarter
in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments to CFF of one percent
of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any quarter in which such
net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and its stockholders receive in connection
with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment or prevention of CF, or
a change of control transaction, except that such payment shall not exceed five times the amount of the 2018 CFF Award, with such
payments to be credited against any other net sales royalty payments due. Either CFF or the Company may terminate the Investment
Agreement for cause, which includes the Company&#8217;s material failure to achieve certain commercialization and development milestones.
The Company&#8217;s payment obligations survive the termination of the Investment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Investment
Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&#8217;s common stock
(the &#8220;CFF Warrant&#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable
for 500,000 shares of the Company&#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement
and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable
for the remaining 500,000 shares of the Company&#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares
of the Company&#8217;s common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745289376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The process of preparing financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based
compensation expense, the accrual of research, product development and clinical obligations, and the expected performance period
under the 2015 CFFT Award (See Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Prior to the registration of its
common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not
less than the fair value of its common stock as determined by the board of directors, with input from management. The Company&#8217;s
board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors,
including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company
sold shares of preferred stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Cash, Cash Equivalents, and
Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company considers only those
investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to
be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2017
and 2016, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2017
and 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Restricted cash as of December 31,
2017 and 2016 included a collateral account for the Company&#8217;s corporate credit cards and is classified in current assets
in the amount of $108,991 and $150,000, respectively. Additionally, as of December 31, 2017 and 2016 restricted cash included a
stand-by letter of credit issued in favor of a landlord for $50,000 which was classified in current assets as of December 31, 2017
and in noncurrent assets as of December 31, 2016 (See Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and restricted
cash consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">206,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,127,530</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Money market fund</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,330,985</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13,864,727</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,537,495</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">14,992,257</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Restricted cash, current</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash, noncurrent</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">50,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">62,696,486</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,192,257</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i></i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Financial Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The carrying amounts reported in
the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their
fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair
value due to the fact that they are at market terms.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Property and Equipment </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The estimated life for the Company&#8217;s
property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture
and equipment. The Company&#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their
useful lives or the respective leases. See Note 4 for details of property and equipment and Note 5 for operating and capital lease
commitments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Development Award Agreements</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Research and Development Expenses
and Development Award Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Costs incurred for research and
development are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Nonrefundable advance payments for
goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant
to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the
related goods are delivered or the related services are performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For amounts received under the
development award received from the CFFT (See Note 8), the Company recognized those amounts when the triggering event to receive
those payments occurred, with those amounts being amortized on a straight-line basis over the expected duration of the remaining
performance period of the development program under the award, which concluded in the third quarter of 2017.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock', window );">Accruals for Research and Development Expenses and Clinical Trials</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Accruals for Research and
Development Expenses and Clinical Trials</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As part of the process of preparing
its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with
vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical
trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company determines accrual estimates by taking into account discussion with
applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the
course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates.
The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to
it at that time. The Company&#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract
research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different
from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status
and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular
period. For the years ended December 31, 2017, 2016 and 2015, there were no material adjustments to the Company&#8217;s prior
period estimates of accrued expenses for clinical trials.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeasesAndDeferredRentPolicyTextBlock', window );">Leases and Deferred Rent</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Leases and Deferred Rent</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company leases its office space.
Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&#8217;s office
space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records
the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between
the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the
lessor are recorded as a reduction to rent expense over the term of the lease.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has no significant
off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.
The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However,
the Company believes the risk of loss is minimal as these banks are large financial institutions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date,
the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing
therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2017 and 2016, all of the Company&#8217;s
assets were located in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For federal and state income taxes,
deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax
basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in
which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax asset when it is not
more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses
since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate
the deferred tax assets amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Tax positions taken or expected
to be taken in the course of preparing the Company&#8217;s tax returns are required to be evaluated to determine whether the tax
positions are &#8220;more-likely-than-not&#8221; of being sustained by the applicable tax authority. Tax positions not deemed
to meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense
in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of
December 31, 2017 or 2016.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company continually monitors
events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An
impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&#8217;s carrying value.
Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to
the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess
of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset
may not be recoverable. No impairment charges were recorded for the years ended December 31, 2017, 2016 and 2015.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Share-based Payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company recognizes compensation
costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement
of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option
grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized
as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.
Stock options granted to non-employee consultants are revalued at the end of each reporting period until vested using the Black-Scholes
option-pricing model and the changes in their fair value are recorded as adjustments to expense over the related vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On March 30, 2016, the FASB issued
ASU No. 2016-09, <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
</i>(&#8220;ASU 2016-09&#8221;)<i>. </i>ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment
transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification
in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures
as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have
an impact on the Company&#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the
excess tax benefits in respect of share based payments only when realized (See Note 9).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Basic and diluted net loss per share
of the Company&#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding
during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted
loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years
ended December 31, 2017, 2016 and 2015:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Years Ended December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2015</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Basic and diluted net loss per share of common stock:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">&#160;</td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(32,421,612</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">&#160;</td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,998,675</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(8,850,739</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average shares of common stock outstanding</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,176,953</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,137,518</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">31,350,145</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share of common stock-basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.65</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.49</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.28</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following potentially
dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of dilutive weighted
average shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2016</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2015</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,969,250</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,610,179</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,982,065</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,133,466</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,898,679</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,951,315</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>Revenue Recognition</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In May 2014, the FASB issued guidance
codified in <i>Accounting Standards Codification (ASC) 606, Revenue Recognition &#8212; Revenue from Contracts with Customers</i>
(&#8220;ASC 606&#8221;) which amends the guidance in former <i>ASC 605, Revenue Recognition</i>, and is effective for public companies
for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from the current accounting
standard in many respects, such as in the accounting for variable consideration received, including milestone payments or contingent
payments. Under the Company&#8217;s accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone
payments were initially recognized only in the period that the payment-triggering event occurred or was achieved (See Note 8).
ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely achieved based
on the Company&#8217;s estimate of the amount of consideration to which it will be entitled in exchange for transferring the services,
subject to management&#8217;s assessment of whether it is probable that a significant reversal in the amount of cumulative revenue
recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company
adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of
initially applying ASC 606 is recognized at the date of initial application. Since the Company has concluded its performance obligations
and has completed recognizing revenue under the agreement with CFFT in the third quarter of 2017 (See Note 8), there was no cumulative
effect to record at the date of the Company&#8217;s adoption of ASC 606. The Company will assess any new agreements it enters into,
including the 2018 CFF Award, (See Note 15) under ASC 606, including if such agreements fall under the scope of such standard.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Accounting for Leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In February 2016, the FASB issued
ASU No<b>. </b>2016-02, <i>Leases (Topic 842) </i>(&#8220;ASU 2016-02&#8221;)<i>. </i>Under ASU 2016-02, a lessee will be required
to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current GAAP, the
recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on
its classification as a finance or operating lease. However, unlike current GAAP, which requires only capital leases to be recognized
on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU 2016-02 will take
effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early application
permitted. The adoption of ASU 2016-02 will have an impact on the Company&#8217;s financial position as the Company has operating
lease commitments for office space as of December 31, 2017 with future non-cancelable lease payments amounting to $5,474,623 (see
Note 5) for which ASU 2016-02 would apply.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accruals for research and development expenses and clinical trials [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LeasesAndDeferredRentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases and Deferred Rent [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LeasesAndDeferredRentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748462704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and
restricted cash consists of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 69%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">206,510</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,127,530</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Money market fund</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">62,330,985</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,864,727</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">62,537,495</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">14,992,257</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Restricted cash, current</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">158,991</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Restricted cash, noncurrent</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Restricted cash</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">158,991</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">62,696,486</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,192,257</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The following table sets
forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Years Ended December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Basic and diluted net loss per share of common stock:</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(32,421,612</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="width: 10%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(19,998,675</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(8,850,739</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average shares of common stock outstanding</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,176,953</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">41,137,518</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">31,350,145</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss per share of common stock-basic and diluted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.65</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.49</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.28</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following
potentially dilutive securities for the years ended December 31, 2017, 2016 and 2015 have been excluded from the computation of
dilutive weighted average shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,288,500</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,288,500</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,969,250</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,844,966</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,610,179</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,982,065</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,133,466</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,898,679</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,951,315</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748558496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Property and Equipment consisted
of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 69%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer hardware and software</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">136,522</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">96,131</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Office furniture and equipment</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">287,048</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">259,138</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">191,244</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">188,219</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Construction in progress</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,181,730</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, gross</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,796,544</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">543,488</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: accumulated depreciation</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(363,889</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(108,237</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,432,655</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">435,251</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748555056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rent Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of
the Company&#8217;s non-cancelable lease agreements in effect at December 31, 2017, the future minimum rent commitments are as
follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">445,333</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">623,958</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">784,243</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">830,600</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855,150</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,935,339</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,474,623</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Future Minimum Capital Lease Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Pursuant to the terms of
this capital lease agreement, the future minimum capital lease commitments are as follows as of December 31, 2017:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,543</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">379</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total future minimum lease payments</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,922</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: interest</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(291</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Future capital lease obligations</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,631</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(4,256</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long-term portion</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">375</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6892316672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Accrued expenses consisted
of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 69%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued clinical operations and trials costs</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,003,799</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,647,490</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued product development costs</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,255,439</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">713,426</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued compensation</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,335,672</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">778,250</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued other</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">146,609</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">117,289</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,741,519</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,256,455</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755615424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Award and Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Deferred Revenue</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Deferred revenue consisted
of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred revenue</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,940,195</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,940,195</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Long term portion</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643311520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Asset</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Significant components of
the Company&#8217;s net deferred tax asset are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">NOL carryforward</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,229,127</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,860,828</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax credits</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,213,347</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">673,690</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock based compensation</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,724,248</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,177,650</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,654</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">302,943</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other temporary differences</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">116,292</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">225,214</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Subtotal</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">18,328,668</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,240,325</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(18,328,668</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(13,240,325</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax asset</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Income tax benefits computed
using the federal statutory income tax rate differs from the Company&#8217;s effective tax rate primarily due to the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax provision at statutory rate</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34.00</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">State taxes, net of federal benefit</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.66</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Permanent differences</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-2.05</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.65</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.62</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Tax credits</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.59</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.67</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Income tax rate change</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-24.11</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.60</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-0.13</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Increase in valuation reserve</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-15.69</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-39.31</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-40.85</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748509712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used Principally in Determining Fair Value of Options Granted</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average assumptions
used principally in determining the fair value of options granted to employees were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.12</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.70</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.85</font></td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term in years</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.25</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.66</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.73</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">86.01</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">90.39</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">90.68</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Estimated forfeiture rate</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.00</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.83</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of option activity
for years ended December 31, 2017 and 2016 is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Average&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Exercise&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Average&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Remaining&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Contractual&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Term in&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Years</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Value</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2015</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,982,065</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.03</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,020,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.42</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(326,886</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.43</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(65,000</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.44</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2016</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,610,179</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.54</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,681,500</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8.28</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(272,734</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.67</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(173,979</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.53</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2017</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,844,966</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.75</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,433,877</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Vested at December 31, 2017</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,514,977</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7.02</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">23,444,225</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SummaryOfNonvestedStockOptionsTableTextBlock', window );">Summary of Non-Vested Stock Options</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As summary of non-vested
stock options for the years ended December 31, 2017 and 2016 is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Average&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Fair&#160;</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Value</font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 69%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested at December 31, 2015</font></td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,035,254</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 2%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,020,000</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.69</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,194,600</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.57</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(34,380</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.77</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nonvested at December 31, 2016</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,826,274</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.86</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,681,500</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.22</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,003,806</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.60</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(173,979</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5.03</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested at December 31, 2017</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,329,989</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.61</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_SummaryOfNonvestedStockOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Non-Vested Stock Options [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_SummaryOfNonvestedStockOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608366512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Quarters Ended</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2017</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2017</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2017</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 29%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from awards</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,293,697</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">350,186</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">796,312</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,366,112</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,763,660</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,622,511</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,286,682</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,380,125</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,878,090</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,130,587</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,575,244</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,746,237</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,641,750</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,753,098</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,861,926</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,452,540</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,291,564</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(6,956,786</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(10,861,926</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense):</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,366</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,271</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,402</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">133,073</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Foreign currency exchange gain (loss)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(14,265</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(10,594</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(52,212</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">35,163</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense), net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(12,899</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(5,323</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(8,810</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">168,236</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,465,439</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,296,887</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(6,965,596</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(10,693,690</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss per share, basic and diluted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.16</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.15</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.14</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.20</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average number of common shares outstanding, basic and diluted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">46,381,482</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,193,726</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,221,597</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">53,828,680</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Quarters Ended</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2016</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2016</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2016</b></font></td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 30%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from awards</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">396,598</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">396,598</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">742,558</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">375,670</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,173,933</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,567,003</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,315,632</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,380,167</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,109,889</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,021,225</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,760,696</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,567,937</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,283,822</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,588,228</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,076,328</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,948,104</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,887,224</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(4,191,630</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(5,333,770</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,572,434</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense):</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(5,360</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,049</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,731</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">57</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Foreign currency exchange gain (loss)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">343</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,810</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(14,729</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,102</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense), net</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(5,017</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,239</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(12,998</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,159</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,892,241</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(4,189,391</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(5,346,768</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,570,275</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss per share, basic and diluted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.11</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.12</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(0.17</font></td>
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average number of common shares outstanding, basic and diluted</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">37,605,210</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,748,452</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,783,504</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">44,348,543</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757929760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 65,698,101<span></span>
</td>
<td class="nump">$ 33,276,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">78,891,699<span></span>
</td>
<td class="nump">16,699,133<span></span>
</td>
<td class="nump">$ 11,328,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash on hand</a></td>
<td class="nump">62,537,495<span></span>
</td>
<td class="nump">$ 14,992,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember', window );">2018 CFF Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AmountReceivedForDevelopmentAward', window );">Amount received for development award</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">13,724,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member] | January 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | January 26, 2018 [Member] | Phase 2b Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AmountReceivedForDevelopmentAward', window );">Amount received for development award</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CantorFitzgeraldAndCoMember', window );">Cantor Fitzgerald &amp; Co. [Member] | Sales Agreement [Member] | January 5, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Number of common stock value sold</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock share sold</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AmountReceivedForDevelopmentAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for development award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AmountReceivedForDevelopmentAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_JanuaryTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_JanuaryTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_JanuaryTwentySixTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_JanuaryTwentySixTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_PhaseTwoBClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_PhaseTwoBClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_JanuaryFiveTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_JanuaryFiveTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758475392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 158,991<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredTaxAssetsValuationAllowancePercentage', window );">Valuation allowance</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating lease future non-cancelable lease payments amount</a></td>
<td class="nump">$ 5,474,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember', window );">Corporate Credit Cards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 108,991<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember', window );">Stand-by Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod', window );">Cash equivalents and restricted cash maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_MarketableSecuritiesMaturityPeriod', window );">Marketable investments maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and restricted cash maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DeferredTaxAssetsValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DeferredTaxAssetsValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755359024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 206,510<span></span>
</td>
<td class="nump">$ 1,127,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">62,330,985<span></span>
</td>
<td class="nump">13,864,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">62,537,495<span></span>
</td>
<td class="nump">14,992,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current</a></td>
<td class="nump">158,991<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">158,991<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 62,696,486<span></span>
</td>
<td class="nump">$ 15,192,257<span></span>
</td>
<td class="nump">$ 12,374,650<span></span>
</td>
<td class="nump">$ 6,276,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746215136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,693,690)<span></span>
</td>
<td class="num">$ (6,965,596)<span></span>
</td>
<td class="num">$ (7,296,887)<span></span>
</td>
<td class="num">$ (7,465,439)<span></span>
</td>
<td class="num">$ (7,570,275)<span></span>
</td>
<td class="num">$ (5,346,768)<span></span>
</td>
<td class="num">$ (4,189,391)<span></span>
</td>
<td class="num">$ (2,892,241)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
<td class="num">$ (19,998,675)<span></span>
</td>
<td class="num">$ (8,850,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding</a></td>
<td class="nump">53,828,680<span></span>
</td>
<td class="nump">50,221,597<span></span>
</td>
<td class="nump">50,193,726<span></span>
</td>
<td class="nump">46,381,482<span></span>
</td>
<td class="nump">44,348,543<span></span>
</td>
<td class="nump">43,783,504<span></span>
</td>
<td class="nump">38,748,452<span></span>
</td>
<td class="nump">37,605,210<span></span>
</td>
<td class="nump">50,176,953<span></span>
</td>
<td class="nump">41,137,518<span></span>
</td>
<td class="nump">31,350,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757930144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">9,133,466<span></span>
</td>
<td class="nump">7,898,679<span></span>
</td>
<td class="nump">5,951,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">1,288,500<span></span>
</td>
<td class="nump">1,288,500<span></span>
</td>
<td class="nump">1,969,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">7,844,966<span></span>
</td>
<td class="nump">6,610,179<span></span>
</td>
<td class="nump">3,982,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746245888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 255,652<span></span>
</td>
<td class="nump">$ 87,664<span></span>
</td>
<td class="nump">$ 43,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost of machine</a></td>
<td class="nump">$ 1,796,544<span></span>
</td>
<td class="nump">$ 543,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember', window );">Copier Machine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost of machine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CRBP_FebruaryTwoThousandAndEighteenMember', window );">February 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">32,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_FebruaryTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_FebruaryTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755581040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,796,544<span></span>
</td>
<td class="nump">$ 543,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(363,889)<span></span>
</td>
<td class="num">(108,237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,432,655<span></span>
</td>
<td class="nump">435,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">136,522<span></span>
</td>
<td class="nump">96,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">287,048<span></span>
</td>
<td class="nump">259,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">191,244<span></span>
</td>
<td class="nump">188,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,181,730<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 21, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,547<span></span>
</td>
<td class="nump">$ 229,705<span></span>
</td>
<td class="nump">$ 55,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_OperatingLeaseTerms', window );">Terms of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">32,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">$ 1,080,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Incurred interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Fourth Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | First Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Seventh Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember', window );">September 2016 Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_OperatingLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_OperatingLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount, during the lease term, of each minimum [capital] lease payment allocated to interest expense so as to produce a constant periodic rate of interest on the remaining balance of the capital lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77915053&amp;loc=d3e43161-112731<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLesseeAssetsUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_FourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_FourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=CRBP_FirstYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=CRBP_FirstYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=CRBP_SeventhYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=CRBP_SeventhYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6744351200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 445,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">623,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">784,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">830,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">855,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,935,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 5,474,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900178864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details) - Copier Machine [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">$ 4,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">4,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: interest</a></td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Future capital lease obligations</a></td>
<td class="nump">4,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">(4,256)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758798944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,265<span></span>
</td>
<td class="nump">$ 348,750<span></span>
</td>
<td class="nump">$ 207,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,808,244<span></span>
</td>
<td class="nump">930,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense for notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=CRBP_InsurancePoliciesMember', window );">Insurance Policies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,976<span></span>
</td>
<td class="nump">$ 378,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable Other Payables [Member] | Three Point Two Five Percent Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Monthly loan payments term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable Other Payables [Member] | Two Point Two Five Percent Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Monthly loan payments term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable Other Payables [Member] | Two Point Three Five Percent Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="nump">$ 415,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and interest payable</a></td>
<td class="nump">$ 41,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Monthly loan payments term</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=CRBP_InsurancePoliciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=CRBP_InsurancePoliciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_ThreePointTwoFivePercentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_ThreePointTwoFivePercentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_TwoPointTwoFivePercentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_TwoPointTwoFivePercentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_TwoPointThreeFivePercentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_TwoPointThreeFivePercentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6664842160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccruedClinicalOperationsAndTrialsCosts', window );">Accrued clinical operations and trials costs</a></td>
<td class="nump">$ 2,003,799<span></span>
</td>
<td class="nump">$ 1,647,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccruedProductDevelopmentCosts', window );">Accrued product development costs</a></td>
<td class="nump">1,255,439<span></span>
</td>
<td class="nump">713,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,335,672<span></span>
</td>
<td class="nump">778,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">146,609<span></span>
</td>
<td class="nump">117,289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,741,519<span></span>
</td>
<td class="nump">$ 3,256,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccruedClinicalOperationsAndTrialsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical operations and trials costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccruedClinicalOperationsAndTrialsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccruedProductDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued product development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccruedProductDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760013744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Award and Deferred Revenue (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 20, 2015 </div>
<div>USD ($) </div>
<div>Installments</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 796,312<span></span>
</td>
<td class="nump">$ 350,186<span></span>
</td>
<td class="nump">$ 1,293,697<span></span>
</td>
<td class="nump">$ 375,670<span></span>
</td>
<td class="nump">$ 742,558<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 2,440,195<span></span>
</td>
<td class="nump">$ 1,911,424<span></span>
</td>
<td class="nump">$ 648,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Amount received upon execution of award agreement</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Amount received upon execution of award agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Lenabasum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_NumberOfInstallments', window );">Number of installments | Installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_PaymentDuePeriodAfterTheFirstCommercialSale', window );">Payment due period after the first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_RoyaltyPaymentSalesTarget', window );">Royalty payment, sales target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Development award received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of The Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching The Sales Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Award [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_NumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_NumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_PaymentDuePeriodAfterTheFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment due period after the first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_PaymentDuePeriodAfterTheFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_RoyaltyPaymentSalesTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment sales target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_RoyaltyPaymentSalesTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_LenabasumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_LenabasumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponTransferSaleOrLicensingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponTransferSaleOrLicensingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponCommercializationOfTheProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponCommercializationOfTheProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponReachingTheSalesTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponReachingTheSalesTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748448384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,940,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Less: current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,940,195)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758909872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,536,000<span></span>
</td>
<td class="nump">$ 28,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards excess stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets valuation allowance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,088,343<span></span>
</td>
<td class="nump">7,860,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Taxable income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=CRBP_MassachusettsMember', window );">Massachusett [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,110,000<span></span>
</td>
<td class="nump">$ 26,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,283,000<span></span>
</td>
<td class="nump">$ 736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State And Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Taxable income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,815,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Reduction of corporate tax rate percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Reduction of corporate tax rate percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Reduction of corporate tax rate percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Orphan Drug Credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Reduction of corporate tax rate percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Orphan Drug Credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Reduction of corporate tax rate percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=CRBP_MassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=CRBP_MassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=CRBP_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=CRBP_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745695248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">$ 15,229,127<span></span>
</td>
<td class="nump">$ 10,860,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,213,347<span></span>
</td>
<td class="nump">673,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,724,248<span></span>
</td>
<td class="nump">1,177,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">45,654<span></span>
</td>
<td class="nump">302,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">116,292<span></span>
</td>
<td class="nump">225,214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">18,328,668<span></span>
</td>
<td class="nump">13,240,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(18,328,668)<span></span>
</td>
<td class="num">(13,240,325)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746263056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax provision at statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.66%<span></span>
</td>
<td class="nump">4.76%<span></span>
</td>
<td class="nump">4.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(2.05%)<span></span>
</td>
<td class="num">(0.65%)<span></span>
</td>
<td class="num">(0.62%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">1.59%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Income tax rate change</a></td>
<td class="num">(24.11%)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(0.13%)<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation reserve</a></td>
<td class="num">(15.69%)<span></span>
</td>
<td class="num">(39.31%)<span></span>
</td>
<td class="num">(40.85%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759263248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 26, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
<td class="nump">44,681,745<span></span>
</td>
<td class="nump">37,605,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
<td class="nump">44,681,745<span></span>
</td>
<td class="nump">37,605,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
<td class="nump">326,886<span></span>
</td>
<td class="nump">11,666,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,490<span></span>
</td>
<td class="nump">$ 468,442<span></span>
</td>
<td class="nump">$ 10,819,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,891,699<span></span>
</td>
<td class="nump">16,699,133<span></span>
</td>
<td class="nump">11,328,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,969,837<span></span>
</td>
<td class="nump">260,179<span></span>
</td>
<td class="nump">$ 509,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Stock subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">330,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate common stock sold, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,401,959<span></span>
</td>
<td class="nump">$ 16,300,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember', window );">Institutional Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="nump">4,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="nump">$ 32,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,589,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 2,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,724,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,268,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member] | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,621,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommissionPaidPercentage', window );">Commission paid percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Stock subscriptions receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate common stock sold, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member] | Cantor Fitzgerald [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CommissionPaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission paid percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CommissionPaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalAndAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalAndAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CRBP_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CRBP_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760162288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,694,489<span></span>
</td>
<td class="nump">$ 3,163,534<span></span>
</td>
<td class="nump">$ 1,153,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Average intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,092,964<span></span>
</td>
<td class="nump">$ 1,004,321<span></span>
</td>
<td class="nump">$ 152,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,542,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation expense, not yet recognized period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,640,646<span></span>
</td>
<td class="nump">$ 2,104,939<span></span>
</td>
<td class="nump">$ 672,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,843<span></span>
</td>
<td class="nump">$ 1,058,595<span></span>
</td>
<td class="nump">$ 481,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ForfeituresEstimatedPercentage', window );">Forfeitures estimated, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Option granted risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Option granted risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate common stock available for stock options granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,043,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,460,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock available for issuance</a></td>
<td class="nump">3,127,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member] | January 1, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate common stock available for stock options granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,543,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ForfeituresEstimatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forfeitures estimated, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ForfeituresEstimatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_EvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreationDateAxis=CRBP_JanuaryOneTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreationDateAxis=CRBP_JanuaryOneTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916885168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - Employee Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.12%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">6 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.01%<span></span>
</td>
<td class="nump">90.39%<span></span>
</td>
<td class="nump">90.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate', window );">Estimated forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.83%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745723264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding, Beginning balance</a></td>
<td class="nump">6,610,179<span></span>
</td>
<td class="nump">3,982,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">1,681,500<span></span>
</td>
<td class="nump">3,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(272,734)<span></span>
</td>
<td class="num">(326,886)<span></span>
</td>
<td class="num">(11,666,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(173,979)<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding, Ending balance</a></td>
<td class="nump">7,844,966<span></span>
</td>
<td class="nump">6,610,179<span></span>
</td>
<td class="nump">3,982,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="nump">4,514,977<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">8.28<span></span>
</td>
<td class="nump">4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">6.53<span></span>
</td>
<td class="nump">2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="nump">2.54<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years, Outstanding</a></td>
<td class="text">7 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Vested</a></td>
<td class="text">7 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Average Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 29,433,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Average Intrinsic Value, Vested</a></td>
<td class="nump">$ 23,444,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649630592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Non Vested Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares Non-vested , Beginning balance</a></td>
<td class="nump">3,826,274<span></span>
</td>
<td class="nump">2,035,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">1,681,500<span></span>
</td>
<td class="nump">3,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares, vested</a></td>
<td class="num">(2,003,806)<span></span>
</td>
<td class="num">(1,194,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Shares, Forfeited</a></td>
<td class="num">(173,979)<span></span>
</td>
<td class="num">(34,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares Outstanding, Ending balance</a></td>
<td class="nump">3,329,989<span></span>
</td>
<td class="nump">3,826,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average fair value non vested, Beginning balance</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average fair value, Forfeited</a></td>
<td class="nump">5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average fair value non vested, Ending balance</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745903024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase of common stock shares</a></td>
<td class="nump">1,288,500<span></span>
</td>
<td class="nump">679,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price of warrants</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WarrantsWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life of warrants</a></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis', window );">Issuance of common stock shares exercised on cashless basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_NumberOfCommonStockWereExercisedOnCashBasis', window );">Number of common stock were exercised on a cash basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ClassOfWarrantOrRightCancelled', window );">Number of warrants cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ClassOfWarrantOrRightCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ClassOfWarrantOrRightCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares exercised on cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IssuanceOfCommonStockSharesExercisedOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_NumberOfCommonStockWereExercisedOnCashBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock were exercised on a cash basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_NumberOfCommonStockWereExercisedOnCashBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WarrantsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WarrantsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747319552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember', window );">2014 Equity Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Option vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember', window );">Orchestra Medical Ventures LLC [Member] | 2016 Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CashCompensationAmount', window );">Cash compensation amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Agreement expiry date</a></td>
<td class="text">Mar. 20,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase, shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CashCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash compensation amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CashCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndSixteenConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndSixteenConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747170576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 796,312<span></span>
</td>
<td class="nump">$ 350,186<span></span>
</td>
<td class="nump">$ 1,293,697<span></span>
</td>
<td class="nump">$ 375,670<span></span>
</td>
<td class="nump">$ 742,558<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 396,598<span></span>
</td>
<td class="nump">$ 2,440,195<span></span>
</td>
<td class="nump">$ 1,911,424<span></span>
</td>
<td class="nump">$ 648,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,286,682<span></span>
</td>
<td class="nump">5,622,511<span></span>
</td>
<td class="nump">5,763,660<span></span>
</td>
<td class="nump">6,366,112<span></span>
</td>
<td class="nump">5,380,167<span></span>
</td>
<td class="nump">4,315,632<span></span>
</td>
<td class="nump">3,567,003<span></span>
</td>
<td class="nump">2,173,933<span></span>
</td>
<td class="nump">26,038,965<span></span>
</td>
<td class="nump">15,436,735<span></span>
</td>
<td class="nump">5,888,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,575,244<span></span>
</td>
<td class="nump">2,130,587<span></span>
</td>
<td class="nump">1,878,090<span></span>
</td>
<td class="nump">2,380,125<span></span>
</td>
<td class="nump">2,567,937<span></span>
</td>
<td class="nump">1,760,696<span></span>
</td>
<td class="nump">1,021,225<span></span>
</td>
<td class="nump">1,109,889<span></span>
</td>
<td class="nump">8,964,046<span></span>
</td>
<td class="nump">6,459,747<span></span>
</td>
<td class="nump">3,613,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,861,926<span></span>
</td>
<td class="nump">7,753,098<span></span>
</td>
<td class="nump">7,641,750<span></span>
</td>
<td class="nump">8,746,237<span></span>
</td>
<td class="nump">7,948,104<span></span>
</td>
<td class="nump">6,076,328<span></span>
</td>
<td class="nump">4,588,228<span></span>
</td>
<td class="nump">3,283,822<span></span>
</td>
<td class="nump">35,003,011<span></span>
</td>
<td class="nump">21,896,482<span></span>
</td>
<td class="nump">9,502,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(10,861,926)<span></span>
</td>
<td class="num">(6,956,786)<span></span>
</td>
<td class="num">(7,291,564)<span></span>
</td>
<td class="num">(7,452,540)<span></span>
</td>
<td class="num">(7,572,434)<span></span>
</td>
<td class="num">(5,333,770)<span></span>
</td>
<td class="num">(4,191,630)<span></span>
</td>
<td class="num">(2,887,224)<span></span>
</td>
<td class="num">(32,562,816)<span></span>
</td>
<td class="num">(19,985,058)<span></span>
</td>
<td class="num">(8,853,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">133,073<span></span>
</td>
<td class="nump">43,402<span></span>
</td>
<td class="nump">5,271<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
<td class="num">(5,360)<span></span>
</td>
<td class="nump">183,112<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange gain (loss)</a></td>
<td class="nump">35,163<span></span>
</td>
<td class="num">(52,212)<span></span>
</td>
<td class="num">(10,594)<span></span>
</td>
<td class="num">(14,265)<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
<td class="num">(14,729)<span></span>
</td>
<td class="num">(1,810)<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="num">(41,908)<span></span>
</td>
<td class="num">(14,094)<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">168,236<span></span>
</td>
<td class="num">(8,810)<span></span>
</td>
<td class="num">(5,323)<span></span>
</td>
<td class="num">(12,899)<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
<td class="num">(12,998)<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
<td class="num">(5,017)<span></span>
</td>
<td class="nump">141,204<span></span>
</td>
<td class="num">(13,617)<span></span>
</td>
<td class="nump">2,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,693,690)<span></span>
</td>
<td class="num">$ (6,965,596)<span></span>
</td>
<td class="num">$ (7,296,887)<span></span>
</td>
<td class="num">$ (7,465,439)<span></span>
</td>
<td class="num">$ (7,570,275)<span></span>
</td>
<td class="num">$ (5,346,768)<span></span>
</td>
<td class="num">$ (4,189,391)<span></span>
</td>
<td class="num">$ (2,892,241)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
<td class="num">$ (19,998,675)<span></span>
</td>
<td class="num">$ (8,850,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">53,828,680<span></span>
</td>
<td class="nump">50,221,597<span></span>
</td>
<td class="nump">50,193,726<span></span>
</td>
<td class="nump">46,381,482<span></span>
</td>
<td class="nump">44,348,543<span></span>
</td>
<td class="nump">43,783,504<span></span>
</td>
<td class="nump">38,748,452<span></span>
</td>
<td class="nump">37,605,210<span></span>
</td>
<td class="nump">50,176,953<span></span>
</td>
<td class="nump">41,137,518<span></span>
</td>
<td class="nump">31,350,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746621872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 26, 2018</div></th>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 02, 2017</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,891,699<span></span>
</td>
<td class="nump">$ 16,699,133<span></span>
</td>
<td class="nump">$ 11,328,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercisable price per sahre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,500<span></span>
</td>
<td class="nump">679,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increased number of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,127,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Phase 2b Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Amount received upon execution of award agreement</a></td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cystic Fibrosis Foundation warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercisable price per sahre</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">Jan. 26,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cystic Fibrosis Program Related Investment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Development award received</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investment Agreement [Member] | Cystic Fibrosis Foundation warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At the Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Number of common stock value sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At the Market Offering [Member] | 2018 Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear', window );">Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increased number of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserve under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,543,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase minimum percentage in each year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_EvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_PhaseTwoBClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_PhaseTwoBClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CysticFibrosisFoundationwarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CysticFibrosisFoundationwarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndEighteenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndEighteenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #F16Q,(X> $N\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/:L,P#(=?9?B>R$E&*2;-9:6G#08K;.QF;+4UB_]@:R1]^R5>
MFS*V!]C1TL^?/H%:%83R$9^C#QC)8+H;;>^24&'#3D1! "1U0BM3.27<U#SX
M:"5-SWB$(-6'/"+4G*_ (DDM2<(,+,)"9%VKE5 1)?EXP6NUX,-G[#-,*\ >
M+3I*4)45L&Z>&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33M4
M\/;T^)+7+8Q+))W"Z5<R@LX!-^PZ^;5YV.YWK*MYM2YX4U3UGJ_%_4K4]?OL
M^L/O)FR]-@?SCXVO@ET+O^ZB^P)02P,$%     @ YD5L3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M%GUMTG<4[X:Z"XW%W_H?4$L#!!0    ( .9%;$R 9$%N#@0  '<2   8
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M7##?>=M,:S8Y#OOY!;'E&9=_ %!+ P04    " #F16Q,X&N,*+,!  #2 P
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M'HZ[$!\#7EH8W.),0B5G8]Z"\:W,Z"8( @F%#PP"MPO<@Y2!"&7\G#CIG#(
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M\?BRL?^U,1Y02G*%(]3B!YL-";4/QQL\VW',1L.;;OI!;/[&Q3M02P,$%
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MXT<\VVG,)L.;?OY!;/G&Y2]02P,$%     @ YD5L3+FXC'JT 0  T@,  !D
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M?"5GI5Z]\:4N\,XG! (JZQF86R[P $)X(I?&KX43KY(^<+M_9W\,M;M:SLS
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M^U\A.O"I;&[\"#7^@\V&A,J%XYT_FW',1L-A-_T@-G_C_!]02P,$%     @
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MNU4/0FANA,9W9CM.IC,;)A4_:#O,S%AV[4DWT:+M6Z]HZ/]6_P%02P,$%
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MZ940'8EKB!$)XF.Y^X"&H7??*$84)F%, TLL2VLA(!:SN("MXY[0C\N:X,9
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M]W5W<.D&4E3]H<R[G P7?P%02P,$%     @ YD5L3)!2\@$. @  TP4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL=93;CILP$(9?!?$ :S#G")":
MK5:MU$K15MU>.\D0T!K,VD[8OGUM0Q %YP:?_OF_&6,['QA_%S6 =#Y;VHG"
MK:7L=PB)4PTM$4^LATZM5(RW1*HAOR#1<R!G$]12A#TO1BUI.K?,S=R!ESF[
M2MIT<.".N+8MX7_W0-E0N+Y[GWAM+K74$ZC,>W*!7R!_]P>N1FAV.3<M=*)A
MG<.A*MPO_FZ?:;T1O#4PB$7?T94<&7O7@^_GPO5T0D#A)+4#4<T-GH%2;:32
M^)@\W1FI Y?]N_N+J5W5<B0"GAG]TYQE7;BIZYRA(E<J7]GP#:9Z(M>9BO\!
M-Z!*KC-1C!.CPGR=TU5(UDXN*I66?(YMTYEVF/SO8?8 / 7@.0"/M8P@D_E7
M(DF9<S8X?-S[GNA?[.^PVIN3GC1;8=94\D+-WLH@C'-TTT:39C]J\%*#TUF#
ME/\,P58(-@;!PL"//;M!8#4(C$%D##IC@#T_7:4YBN*%* RC( CLH- *"FV@
M; 7:BF(<9-&#+8FLH,@"PMX*M!4E:8C#!Q7%5E!L _DKT%:4!E[L/?A'B164
MV$!X!=J*TBCRHP>@U I*C4?XWY%-5IQTP_&S0!V&S [*K*!L \K69R[;G+DH
M3$)U'%8<M+B/^KG[2?BEZ81S9%)=;7,!*\8D*$_O2:5=JQ=V'E"HI.XFJL_'
M=V8<2-9/3RB:W_'R'U!+ P04    " #F16Q,Y?"T#@ "  # !0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6QUE&UOFS 0Q[\*XOUJ,$\A J2FU;1)
MFQ1UVO;:22X!U<;,=D+W[6<;PBBX;[#ON/O_[@R^HN?B5=8 RGMCM)6E7RO5
M;1&2QQH8D0^\@U:_.7/!B-*FN"#9"2 GF\0HPD&0(D::UJ\*Z]N+JN!719L6
M]L*35\:(^+L#ROO2#_V[XZ6YU,HX4%5TY (_0/WL]D);:%(Y-0Q:V?#6$W N
M_<=PN\M-O WXU4 O9WO/='+@_-487T^E'YB"@,)1&06BEQL\ :5&2)?Q9]3T
M)Z1)G._OZI]M[[J7 Y'PQ.GOYJ3JTM_XW@G.Y$K5"^^_P-A/XGMC\]_@!E2'
MFTHTX\BIM$_O>)6*LU%%E\+(V[ VK5W[4?^>YD[ 8P*>$O#0RP"RE3\31:I"
M\-X3P]EWQ'SB<(OUV1R-TQZ%?:>+E]I[JZ)X4Z";$1IC=D,,GL?@_S%(ZT\0
M[(1@*Q"]$\C= I%3(+("B15HK0 .PF690U Z"XJ3.')C8B<F=F'R!68=%&4?
M-),X*8D5B-\=^1*2K"!QCK&;DCHIZ9J2! M*NJ)\PGGHIF1.2N:@A M*MNXE
MC3Z@;)R4C8."%Y3-NI<8)ZD;DSLQN0,3+3#YZB>+LF0!0;/+9V;;=R(N32N]
M U?Z'MO;=N9<@=8+'G3%M1ZGDT'AK,PVTWLQ#)7!4+P;YR6:AG;U#U!+ P04
M    " #F16Q,[S7RW6(#  #O#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6R55V%SHC 0_2L,/Z"0!!)PU)FJM7<S=S.==N[N,]6H3(%X$+7W[R]
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MO9=M"]9^2+'7[:77];C3_U!+ P04    " #F16Q,^$@<'2,"   7!@  &0
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M'1F35'ET']3&5:B[TCBHZ%'JUT2]\_["T \D:X?+D#/>R-;_ %!+ P04
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MT]QL)\8D41:])]6JE1J.TX:2D]3+1*WY,"*&C63=./W0-(+SOU!+ P04
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MVQG8<PU<9^#.-?"=@3_7('0&X5R#V!G$<PVD^%!._#1QOS;9BRW/;N5#;JG
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MT_=R]VIM]Z,NMMUKP\'^W>7U_U!+ P04    " #F16Q,,.KH!G8#  !R#P
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MOP7V@T8>] TWN%RS9W\ 4$L#!!0    ( .9%;$Q\+PP)!V8  ,Z0 0 4
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M:PI%M*<'83]'+\Q=5 &);UMD%HQF?%T\B(=E=V0+2/A HE[BK;RE09L8C@:
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M&V!#(JE8DE!"38SY[_9%31]<JKC.DUU"I19TE03*M"$(:&&X9$,^FF :"MR
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MAITPE>EB1C5?^XKV6L7<6 :78#1[4J;!,HV*)4=_M%?Z.3&'^J+UAI6?94'
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MWQZ![SYVA:4N]ZPU<ZTFC*8#N":J>*+.2NE>!5(-=<:"/P&%.GRI.KZU#?>
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MP6!-[P%#!'\BL31(S$HHBGKBQ YKK&:UC641?3&Z5,^^5O*&4U@XZCIINA?
M=A([IG<V1.F+=%?>86$TY8"8#+][HYJNUZIT+.K2QZ,WTEW ZMNDK'ZNC5>^
MM)>M34W,_%;FXCK@Z,S<EG\'C2TPKTILV3LOX[X[![$)==S,TZL0#Y\-4BM,
M,M2RB6IP[G<E=)6(C)MS'L:)I%A\.DN[+U%@8-0-:_.KC+GP /EB[YJ_</EF
MJ92L8[^<2$0U8=2I7NK"FJ.!7ACFW,% CK@TU ,H1Y=W_8DG@<<OE(D7+K1)
M^SG^7.5;BNY^\]I7#Q$M>\(ZQH/X3Y^!DYY_>O?7^.+RP^F'L\O3=_'EAXN/
MG]Z?(EN%A7TX_?SV$GCNFTA6(NW8(]ZN%C H$4*ZP\XL6JN_\BMF.4VG<RYT
M@D77L@56^D#]GOJCS]%0@"V&1VEFBF)$ID>H2K?\ 4;LR<B$EZ?3)(4!)LEL
M"L-/A_!I"J@[2=-XCKUD0./(HM]S3("P/33><2PV4,T,-9LDS2:PPOEL#JKS
M$+Y+87\3T QAH-D$^RM+.G?MK0YFF8VGU.QXEDS'*;4"P98LH&HMYES_)$T6
MV=3:&3>GGR5CU,;'J%?!']D"-*,I6F..L:?\%,3/*;=25B/$;R1371*[CF4-
M;WZ(=*>%[D_L/4L13@"9;);&V,QYF,78YGPX(ZL3Y\=2ZNT2 ]HD89ZZ31WC
M6G$58^JPP>N9+&B9L'HX,O@$NF8Z'?4LCE=PG&;)?$&]H2>@G(WPPSR9I[CY
M%*-L1U,JG4*@.2+@3+G]P!O^,UN@N6S&?Z)_=P++4 ":$FH-I?P*C6'99E#\
M7C+N8%OY HO4' \'*2N;^&FB/]'&AH,,Q_I+5X4RGC#%!;V^]J'9 #U&H/:.
MYQDRVW2!<<=3_ @\$C8QB]$QB^5DYL.=MW'JW,:I?QNG/EWNN8TC;.V]F#N?
M9F.,]YQS[Z=D.AN^[B["I4$U?30"[7LRG:%"'X_A<D^P1P?@'EVSZ6S774R3
M=+B@%N+ 1@ V&=W*V10/>(IW$89=C&;]=W%$]9% ]D!S(C9$S^9 (X:S*9;K
M@5NY&,_1M^U=Q8P2?+*,3G^<8$_UZ6@HR H793:32SJ998"4XZ^_B3C@% <;
M)\,Q[G,V2F,VMAQP#;%<S'$JUP;OY"S#"X(.^VSW]9LD2*SQT0SN%-[&Q6+.
MKTX6SLW#>PI/@:Y/=V*,+4F3T4+^A.4#.L^X\!'" [!X-GG=Q1O.]75+]:>,
M+QXN\E>[>)(?F0&X1DBFYTAQD0#. $LFPS'F56+WI@F U0O4--[><_+V[GU@
MEY([&<37GW^^/O_39^PM@GU$;J[Q-0G^NM+!7[_%C/T6,_;?+V:,-B[J[6U!
M=/5_9^Q89#;]OSMV+)QI:,?^3NPSZ;%9?6,6)88[ORZ',J+DI4[DO I*WI6,
M.#%-<KXNZ5+ POTPOSH#T\X<\M*37IF.&;TN'=- @*ZMT[4\F/CF7I908D_$
MRPOG]ARZ:Z?[\X[,#- %Q@LV/IUQPZ0+U3 )V!#@]:-*-HA,Y6IK'@NU)8]J
M%V[3#[NGB8/3F+97G;<O@,JL1+_6#9YTAR?]7:CJMK;08E1;79T 8+ H&16I
MP<0X] Z^>(*M53DHV9/:93K;J+9?&.[@-;>P6FMU+=-S,MJ[W;FH3"P946'=
MTC#E-CY3[0MNJ$Z]/8[W3$3/V&8\I[&#=+L)M]&RK'#V5MWF612\HW:'95MU
M!)K&"@HV:6-=_L.SL;F[UP4BI9/DDBO*D$E:)_ETS8F=5DMF&@QI,<7XN[UL
MGA AI<P)_MT#8XH&Q&*><*B;!R5SA;!WCXTYA)L'=(I1=5=Z.L;889E^_Q&T
M_E:<!8,EH$&:N^,&+N0;,J9I_R2<5BQDY98>*6WY=YB VJ3H$V'K&R'&TT:;
M%9^YTYO73>0S%C);<>5 R;A0&;$'KS_>MWY>G%X'R79<Y.HQ_Z\:_X\,*XD.
M/5SGJIVJ83_Q>@T+.PW7'R[6;.M/NAP\0O-F>_=B@5%)QU_JN#-/2:%D=KD)
MPUU"L]K<)E0%*H1WD<*[8[^7B\(YFN]+[1Z+DO7J.ZN9#-D?# )8K78L-&(K
M+BY$U7_7_6I(Q+1ZTV#HK=.4)HG]9D>AXTOBXT!S&GM#B&>RA\C9 _R!D0?<
M=N6*6V>VA\Y[Z)9C9\M19\OL/POVUW'.Q!*Y:RZ<'>@U1!UK43:TBJ3K(@%.
M6GFDV;'TW$EH453$2@I'2G\>KMNH>M(U['FT.B^56"X!_:D20,@8;DH(-JC!
MH3XM\>?8E@9XZ+YF.[%4<31ZF"(<K+ABPKZT*PKVKNHC?;J'3V1#.=3!Q]3.
M,T<6ZNAC-[#9V[\FW#SDOTDKFWV]:_Y)G),S='0XA%P*V^793;XW;04/IZ*1
MS05P @DI,@R H&1^H,@T*Y>0,_;)CZ=[@AVE(S0]FWQ]NJ&MJ2ZY?K''H*@S
M7[W8SP ^2U,I:H9H#J3;!/ @=AAQYJQF^&:@;HO";G6BKC4F3*TW'3 JN; +
M!T?8^RJH= ^,0PA:V[K%&D\V 1Z*"IZN@K-O<(66)(K8J>E]N\- 1\W;J325
MJ6K-33S(O+9&'^GVR4\SMZKV6KD85]*:.SY6GSS'Y&=>EPJI]\R>W=^YPZTI
M$\CU#2GZ/)#V(EP%_9PF)\*L3^).UH5=SQM^+YZL#"@6&F,1&F'*4R!=L%55
MQAXI7I7?Z[XO*,/HZJ B95IQ_<0QI$(YXY!J8BR%+9%_FHXKZY([2)0RU,K)
MV>][D'LCJD  =478[6M!Q\0?^&N03E:2&Z0\'I:GO9M^-L!0Q2U;O[!K2J2*
M;:%-0^4M8YM@%S92W1>A;7Y QD3R!]^2QQK-N1:.64-035^M7K6FK4,4\N)+
MG@7W6.=MLG\I"?8FIP7JOGUVUS0%.IW4X+?TW-%V^5B7IYEC 0([F\NIW,7&
M&[?XF)K9R@^3Q+>UB;S!!SH):XXRO=*Q'IVR!)M.T >E T;&O$JXY 2^>V5C
MW/J;4DKG5EFTK5H&=!W+ZFDK--O<(T>75Q0N\L=P"WT6=JZ(L\8N.$PRE9UO
M6!/)4\4;A +BGRH1,3(:+]:6I58WK,Y1-QG5IX#-?G)-;DLXYN5#5:_K>PR?
M6FWA="E/BZJCR6&J1$ %=.QET+6!1&3@,QP&2)\4YV6&XM4BI;1>_#^%/#VC
M?V(CJ/O)E)[ !PZ*]-@Q7M09SPD+4CF>TK:*B$!DUZ:6X,4&P7#_ (^L2QA_
MA?'[^0J;"BPQ_AMH#<HQ6(R6%L*@ T#!@6\;K>MP8!8%1XD6J,B@EL<V=802
M-:ZS,!L9B"E93 ]F>7FC&IP3PL(Q<?5XFK=4NK%T\B)D,RO8V^6MNPHIS0:@
M:SBR]PY'*EX4GJ$=SVV;0;>YJN4!?_6[YA_8B$!+\:NV1IU4 M/;:UFOD?"2
M=UU28.]<#<,23E3):=.8:-4J>=.M1*>JLC-S4Q7?G&C&>;)8Z!238:B[FVMS
MZ*E%:W;5=,!@=AF1S^@$R!@(KQ+B)7L0(0NMJ_ESW7 ZYAJ>7M=LBD7K/8F%
MILC!KJWV+9.."VNZU]5!+TPM_C(!_L(7MXMI2:<&3201I13 J478_;TOZ;X?
MP>=I,DF'%'J%U5XFHV'TOHNY\31+L"HA-IY)1\E\BB$%,QZ">&WW-DPQ?VB6
MC!?P_!@./4NRR2SJ(&VBX9A.&#,$*?P'+1"JOASA1_50F119YB"0Y4&@Y ?:
M!TP;5X7W["YQ5@.Y(]SB=#%-QA2@EDZ2E#?I10C8@7LZ5>2@AXA:4$>%TFK6
MJ(4^::^&)P]2^HK8IQN\KS,+0F>46&4B$1),"5IMQ55U9YT&6E;T)X*G;.QL
M.B?3&=L[;$XH4+MB0E^K<I:EV>+ W2.-HW$8"QI8Z^E.3;)"Q%/;[6ORI>H(
MKYI'$+,A9"8K@<=QKQH,$MJPI0MY)$N1-XYD0ODM/702*^N:$0H]0MDZW=*9
MPY@>04ON\], *VA67Y0BW]9W&_T'OZ):J9M7N<@4-GFH*+,V<B8.RF$47E&@
M_0Z[*3;ULZ5-"%UBR5=Z7?#S#,!'5!ET9IP^7^V5@8/8ML7=%E/NL2NY5K05
M;>?!6JO XUBZ6&"I>I&+@C#$OY@D\L9U3!8CM;54DK=+YI^!_!0K(.VMI2N<
M:]SN_-!I8QS(8]DS8K1O1"[39LHBXO[LMB*1H],TA;J'[*V7MS *N@*1$MV=
M=$]6SZS,*&,B^A;O:VSRAG5J5!('W1#=CP $+(Q( OT'G7KRJS8RM)QWI--%
MK "'WBXHN<E_4P:<B'H[8.<1ZJAB)5;;&9PZNT%;AO4<=7.?5V)Y9/E.][D0
MZY)*X,145!,"SH';.KB;@<&O([HVQ<H@+#^BP81/B8J(H,8$*D.(Q:VI]47W
MO.BP]4.F+1>JD[8BV=L?FX57-1VUE6 K>'E_S^$&9 &7AALX3<2OF'ZSTO,R
M44"U!^0('.MJ4UUT.!.,JCM98[@29\#I.V_J"FP;QT1KO*>^.JV>L6'S)*Y]
MHVGG8D<G@0M00\0XU3LH5/36N^*G;!Y@ GG8?7<]M]X5[QTQ.G1$#$)"+#9Q
M9[X)+**Z+ %#C^=TLSLP.E5=-(,VV8J$<%0$QS*U"X&7J\=W+0(D6G&10K7V
MOAN'%+=3R%!&5&^VY<8JI-^Z[B$)'. &KA1[IP(/-@0LJ=*D(6';]-O"6C;>
M2LO2617W]:94)A[&(>QQS3!0KW$_%/F,2S>M:B.*;F S-$]*!'!5<T/+?",:
MO>J623>"YU%N$Y>Z$ME0S<891-R15FTA;"DQEHQ2^NC<K97!D>2?)VJ!98Z[
MY$[#02OA[0NOG"T:9,%3KVDWG5Q1Y4N,PG2/.?(=VOA;PX=T%TM=\5H9=5IM
MJ3,&/VJ:Z-=>DD+3"CDBZ;%#9:&*ID746>LZ:A@A*2M4T&TX+<</T- 8R:B5
M* JO=[A433KL%&,T?C:2Z-09HEOH%+O2<,R<?D[Q&Z'AW+?I+LX=^ZIC6:6[
MJV#D>,S('FW]J$QVODC>ZE#:0.JN(Y/?\>7!6UPVR^TCJL@(BE\JU'@V-1 B
M+EB&_RL?B[ 8Z8)%';5BJ(08V)M$A7K@0.L7I4YLN7J-MD$K/RVL+-I!=737
MP69UPD*!$*U!?+H&Y-[>NV%'NN,2LRP7SN*:53=W;1K_;KB@C>*0?'!4.DGQ
MT5))R2;"^$XKBELQS6.7/"[^K9#-7"7.?WW6ZHH@![\>[7T=:1:1-I> ,2&P
MX*JVP&X+\N;69*:C>P"?02.1.,878E#E<KO.FTCY!.SB1Z\J56BEKFN/LFGA
MU"TC;OS":$N7V5VD]Q">-"?W=GNBP#O2-H3WBXCX">8_]#F'KK'JPKR4U2ZR
ML0XB]3921,YU%EII68OP>FJ5I>XH5[P90[TMW\RV>:K;(LPG9!D1+4.-9!5@
MLYHRBM9UX6A.\H8T0J\X6JP@_PS U+IV].4#61=>6E].;58<%J:BIU&R$VW=
M<CBQ&LDIVWM%3#NS6_1/D>S1[DARI&[^JJK!12R"LO&B-.FY[D1B?S,J0T.*
M<L?@B-UPBHK\\$9'-JWQ6E^@)R<+7J3&M,0F_<-JWD>LO#*-1ONW&^A,1IG;
MTI*20EW8BHD%UU[UL->6#*ZHY9R+ *E.A(.<, =9VL-9!E0J2L;!_*WNG*DS
MD;2,DZBJ7D9PTW% #U(FQ:G=T^%_(K\A R&R@?^2QBJF7L"=ZI>.$?]"FBV^
M+:@%-)K3M@TQQ3,3GXL6*/F6>V)B(OP73)AQ*V#>@GI8/$N\#&T:@Y1JZHL4
M8TK:8[X6Y;(M9#6(!D!([VTYUHK8#I1Z+^X)QZRTW@,>B4UN6LN_\M12@Z'$
M$BTLX]15H=S3%7?+(!=%G-^"2*5"R% 3X2;2+9SQQEV\F=1N7<W%6DW[2'$8
M8L30G:$UH!(O.?<(Y1G*KXGMKW #]TV]?:)L&OE"/:"ZPI;4*[@%T0P;<,%=
M7)K@([1<M:VXLY7J"523@XO=\T2D?RZ++P7'L\DB%;%C-R;3>5UY(F^=*A<8
M[E)W(9^8FI*BY&KSE!4O);TBFOR)2N$S)\2 MK@AG"GOBA.T]L&J*Q:3[]8Y
M]AFIA=M3I#6&7,,A"5GO*\AE_%12HS-DLQ2;'W%K FE/[(2'L=(Y^X:Z+R)G
MV=4Z'?-^0MU(O=B'IK!M'RRWLA!9/.+%;5Z<OM]V)=" ^J.9 $P9"8_IB[L8
M&-YOKYN69*T#/:K<S(;*&$J$A?3,7N=?VMA27C".3)3%LI)BV?;RE1:UE  (
M#-L Q0.K(@8ZLK+N+[R%G@;.@HUM,8;0AR[;BLC316$ CS4AV"\%N7'SBANM
MJ@A[J_6\5:8^<&3*'MA@4^!_%!0Y@FL";$7>>5\^RWF :K$5*9?[2T=M2;NH
M,$3'BVI^H$LFRG(>W+\.?4N'TO"Z9XU.W5MI5UU$?4^+E#R@CJ3$,#C6!T@5
MCJ-/*&*-@;^7.V(T11/+%))LJ5=OL=DVE4)R8\.YM05'S(?0B8)6 VQ"8;,X
M'$/B"?%<3_A<3_!<3^!<52(5K(L-?"V(WKD=TF%C*8*"FY-N7KI00"19H1V'
M0[Q1(,CCT)3DI&C1L> 40E:"NRY<BO<%Y!^.2Z<07X 3$$^*-[KM2D_4CY;E
M)>5+5BY 5$JZ=;*VE0I2W;AGB6@N,#<!1(T=D*4<1\%0JV#_-%U1RZ>-</AE
MHQR&[^KJ_F1-XN(I8=PK'^_&8P#7887TL08*#>IO)"6F.Q%9KGHO<CY"6<54
MRW==WR*)-WH-<DE0$,-3EA/"7&NJ*'Y:1:59OA*++!I.5$@3.4QD:LGHHQRM
M[$F5I&6B6\0(=<R2^MI8'AP_X2!RR _3/-X?AABAO<0LCPUR5$JQTZA2[I\4
M=79F(!V<Q5Q%7%3Y*K26X M&&+ MW\2NV4&R8]OX/MD2UGP(- G"->["59,_
MML*CL*O"2?V *08EJ1ADG7(/.7%XB<4H0KV7?7#H":(^M/A0V\M'Q]*]JE.D
MI_V:1@B^X!QH;G100%2P*Y)]TS0.MVZE+NYBUC&QXS[L4NYV02(II.'V!W*[
M!7!PJ(J+<_U6W1@$KLRNA5;CBU4V43:?6$%R=I/U^LY&%I+>T6CHK7=/KX3H
M7L7+][4\T,CM5K32;0[B4)N#$Z?-@;>&LC6>*J79Z"!1/)<#; O$!<A!T0&8
MPFLZ+4N:-\'%^+-;;WX073L1F&XE;WW KK^$[@!MZ,#.$-1R4XI,]< O"L%/
MB[\64S!!$P)3SV+AFND\8X5RCG8 @:F^4H#&*;QX<7K]L\1:1:?7GX$P4+>O
MZ<EPD3A5W"2BA^'IE'<[O@%=:AG/TOF;'^)+.V@!UG>N0,SW^6?[/EO1[-'
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MQ:%Z%,[U/XJ_WRUI6#407D$!G@\[<JL@3B52"HH^K[]IMA1_.,[W3+\'W56
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MR[.0G?5J[U!!5L F=54-DYI.<@<P ,)!1CU);KCOB&/?M^WFI_\/4$L#!!0
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MQVV.JJOKJW#NF_EJ9?\94"QC^(+IX@=02P,$%     @ YD5L3,VC$6(# @
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M+RYR96QS4$L! A0#%     @ YD5L3&;S"V""    L0   !
M ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #F16Q,(X> $N\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ YD5L3.1;TQM  @
MO <  !@              ( !&A   'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( .9%;$PD*Q14.08  %4=   8              "  9 2
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #F16Q,\_(2
M,=@$  !\%P  &               @ '_&   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ YD5L3"ZLY+[T 0  Y 0  !@
M ( !#1X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .9%
M;$S>27-F3 4  "P9   8              "  3<@  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #F16Q,HO&P_;$!  #2 P  &
M        @ &Y)0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( .9%;$P#??.2LP$  -(#   9              "
M 4PO  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ YD5L
M3(R@BLZU 0  T@,  !D              ( !-C$  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #F16Q,5[;'?;8!  #2 P  &0
M        @ $B,P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( .9%;$P^9BR@LP$  -(#   9              "  0\U  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ YD5L3!VPFAFT 0  T@,
M !D              ( !^38  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #F16Q,1S#36;4!  #2 P  &0              @ 'D.
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .9%;$R3YJL6
MLP$  -(#   9              "  = Z  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ YD5L3#>KV(2T 0  T@,  !D
M ( !NCP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #F
M16Q,N;B,>K0!  #2 P  &0              @ &E/@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .9%;$S-^/R<M0$  -(#   9
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M970R-BYX;6Q02P$"% ,4    " #F16Q,].HDKK8!  #2 P  &0
M    @ $22P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M .9%;$PL59_PN $  -(#   9              "  ?],  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ YD5L3 N7$$#$ 0  -P0  !D
M             ( ![DX  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #F16Q,4XO.QL\!  "<!   &0              @ 'I4   >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .9%;$PO(:!8MP$
M -(#   9              "  >]2  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ YD5L3)P,$+G) @  "PH  !D              ( !
MW50  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #F16Q,
MTO41+"D#   "#@  &0              @ '=5P  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( .9%;$S?(NGT=0(  # (   9
M      "  3U;  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ YD5L3.GJP]=> P  _@P  !D              ( !Z5T  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #F16Q,.X;OMU<"  !B!P
M&0              @ %^80  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( .9%;$RE.H,<<0(   D(   9              "  0QD  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ YD5L3/Y)B/B2
M @  3@D  !D              ( !M&8  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #F16Q,'VE382P#   E#@  &0
M@ %]:0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .9%
M;$R04O(!#@(  -,%   9              "  >!L  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ YD5L3.7PM X  @  P 4  !D
M         ( !)6\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " #F16Q,[S7RW6(#  #O#@  &0              @ %<<0  >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .9%;$SX2!P=(P(  !<&
M   9              "  ?5T  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ YD5L3+21@)RO P  8!(  !D              ( !3W<
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #F16Q,OAHL
MA-L!  #G!   &0              @ $U>P  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( .9%;$STRT9+;0,  ,$0   9
M  "  4=]  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MYD5L3+"7J5=C @  RP<  !D              ( !ZX   'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #F16Q,*EGH"(@"  "="0  &0
M            @ &%@P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( .9%;$P):XYNL@0  ( 6   9              "  42&  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ YD5L3-MI]7[6 P
M41(  !D              ( !+8L  'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #F16Q,V:><4T "  ".!P  &0              @ $Z
MCP  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .9%;$R$
MY]FC50,  !4-   9              "  ;&1  !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ YD5L3(K)]H.7 @  ,P@  !D
M     ( !/94  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .9%;$Q\+PP)!V8  ,Z0 0 4              "
M 6>G  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( .9%;$PWQ_GM
M/0(  ((*   -              "  : - 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ YD5L3)XY&?PV!   ,"4   \              ( !"! ! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( .9%;$S-HQ%B P(  * B   :
M      "  6L4 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( .9%;$S7)IR=W $  $<B   3              "  :86 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !" $(  !(  +,8 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>271</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://corbuspharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Development Award and Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue</Role>
      <ShortName>Development Award and Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/QuarterlyFinancialInformation</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Development Award and Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables</Role>
      <ShortName>Development Award and Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/StockOptions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/QuarterlyFinancialInformationTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/QuarterlyFinancialInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/Liquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-ComputationOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-PotentialDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Significant Accounting Policies - Potential Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://corbuspharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/NotesPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Development Award and Deferred Revenue (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueDetailsNarrative</Role>
      <ShortName>Development Award and Deferred Revenue (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenueTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardAndDeferredRevenue-ScheduleOfDeferredRevenueDetails</Role>
      <ShortName>Development Award and Deferred Revenue - Schedule of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommonStockDetailsNarrative</Role>
      <ShortName>Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommonStock</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Stock Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptionsDetailsNarrative</Role>
      <ShortName>Stock Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/StockOptionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Stock Options - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails</Role>
      <ShortName>Stock Options - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Stock Options - Summary of Non Vested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfNonVestedStockOptionsDetails</Role>
      <ShortName>Stock Options - Summary of Non Vested Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/Warrants</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/QuarterlyFinancialInformation-ScheduleOfQuarterlyFinancialInformationDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/QuarterlyFinancialInformationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="crbp-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SubsequentEvents</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crbp-20171231.xml</File>
    <File>crbp-20171231.xsd</File>
    <File>crbp-20171231_cal.xml</File>
    <File>crbp-20171231_def.xml</File>
    <File>crbp-20171231_lab.xml</File>
    <File>crbp-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001493152-18-003208-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-18-003208-xbrl.zip
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MR3P;&]@U3+;YRJJLI90H*NU&>-,:KK+R;4!;=B7L!K0J:EEI=\)N0*NB6ZP
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M!02.DH@'RP6@E[Y2* \ECV"" LOD7YCSN>]]IV!N%$^V3V!DHKJ3"&X27D\
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M]ZC$;2'IC!3-MH"XF,O1SF4\;6D'*/P9VP1D>AH1)'>YOC!QMQB,7<ML>#[
MCC@B+<R2!--EKI4@>[%WDH2-J1R:'$5L,1XYD13@,O$O9-2'-#M/X'?I#C(?
MH[%T_1A'D2\BY(0Y]8V+33%@^[2^+#RBB*FK\[N/HM0_P7)^][OTU>M)O/'[
M6)8R5Y89OI/6M>'TE?U1^NG>F]L3::B,?OX@76<SO&"O+F.2XX+B8U902.?Y
M9G\I.\XVN$40!7C9%K8)H+U,UF'F62D \>_@!4$ I^N9^]HH(RSA")DN:\2$
M8E"#C$P3D9HB>-2$-4_XT4I["!4,E7/EX3=31EESHHH#!5:1>QL-28P_?.)-
M?F,K4D3G9JS=.#QCD@J"]54?0)'+("/TO#\PDA)CSWC\!H9+<,6'PT1FM#U+
M/&])8Q8,XLP__L" $-UXU\PI!L<G:A.&6I')*EW'3D8?F.%"$+V<YA>D$8T>
MM;3+@FUCH*;% ^<<$82;[=21P6S,ARF!EY(0I(<(KQBXW\.+;1J6BVW.#("\
MC\L&E!1TQ6 *,2LZL%GB]A?[ZV6 C"'$6UP.!=>@)V$<\UC<3"23BEWD%\AO
MH.D$Z+:<><_,2F6'GW3T2S2&C([.B3;U3 HK@@X!*0E/J9<VR62BCC^T.;&+
M,I,],C[MYAO+NN17L$(^HXET"T1VP=N3$:=KE&K9&AT8Q -($JZ-.A&>#'30
MDPTZQ[!VPFS&SBP^6)DF<>@2?\#K#I'Z3)Y*RWZVB=LF@POWY0M#50UU#I07
MCRS36"[NU1:%<9 MOZ%)X\0R$:K"H(PCW$7H*?5<CZ>4T]Y]L-H7BAH1RA@V
MW#ZC]<=][.A]ZK4-!YMG*/$>61Q)J3,D01(( F<2B7@XH;_&G5\DWGZ%W H8
M6O\D?-"(H"0PYF%I)V!)R/.SD^3L9^X?*F5#=[UG."@GW)"D5?#O 3-[ZLKS
M#V),ETNGE$#<LOQ:UZ%GFP/1=>AI%SX/T:'GF/&YDTK[C>MX5!8!911?GI^6
M*K<?2F*L[*Y7I;NNTOQQ0+ZC4_!F;52A(@]&/Z8%C3>KD_I5G(V*+"-ITK1V
M_DVZ6B4J_YL5-3<8O=SPVU3-_$E395U59$-1:T%I"1!^[O9R1WNIC.7Q>"0;
MPZH2]:3WLL2RMNE(5_.>C^31H"\/M7'SMKQ^':M$"=\2*_C[HN\O]OCEE:Z<
M!W [C;7>TLT['7++#@W*T)#' ^T@^#I1K.N*K&A#>:",.JSO#^N:(FM([_JV
MUNP&Y<<;V,_@ZYLV[-G2/4.CF6H-6D+-FD&_9^R0%FM0_KH-?&L#]:I:7;>!
MS=I =8<R>->Z^(Z;5C0Z? -OP>/ '!&]GMR)S[T0\\DQMI)?[,?W[P&;1#Y/
MM=PD7)S7=J 0A/S=?<&=>S)G'(? HXD6[)'4_A 5&G@H&B]E%^<Z80Q!/%PM
M(3O=;7OS+V^4_GYN;[J+Y,/O=7>1W%9\=A?)W45R>2=G>HE6WK,I@@LKXB7Q
M#6_N?M_JFF2+)G"R.AK)@\I-)0^YX@Y7;<#5V!C+ZJ .7.V(@]3<'3R77;8+
M/KL;/T%3>]L.Y9&N ]'L1,3O1IP?-\(-V5#PNFE;CUF'\)((U^3Q2)7[6_N8
MF]N!O;O_JD .8UG1-%G?FN%U2*\F92C>9X?7!!W2WXQJD,<#1=:VMC8/WV>Z
M3-I@'K2'!+*#)C-^8Y-\$KETZWNNAU6ZTC(D#8%UKQC4QRM@$E_:U!7E@W3&
MP4\@%9TZGQEF27]+>\@0H'9S05Z9S'J(+;_&P@NO>/>C+Y5<D!XCV\(2+03.
MQ+-XOP7;3<LN9*CY#J]YJ'3+!3TI:@#_='YW\;-D] U9*MBKI(Z?HOZ2_$X7
M3A=>MBF7= $P>S/F9ZOU(%3YT@L7.%&V[(+(:#7AA(F&!O&:<!G4#,;/K(8&
M&!1"FLXK"A $HD !WH#A5=L<>+0]H4LRT[5%AC]O#>-&HG+J8M6"I#2!5%R6
M8-B3[N9L0MBD;@FX A=V/A#(%D5&@\PEG:@(:.:+520O4!5GJMG#JTO(22%Y
M4:!AH3;$L^G;_%8,;&CL(L6W-6[*(&<J2\QLA\$NN9E&HYXO"AD\QE4IXI]Z
MTN])6\.BO.@,&'-0^R>OHJ=-W/,G5]V ]CU>0%$%AY&<0I<#@Y?8LG&/J5!-
MIC@;E1808XI:,DF9+_'ZV5*WR;B?)*[\A<H^/F'I>BO7TY+7OA%@R])37/>>
M-R(2A1D%);WFRR709B7 /_ TZ[40V6G_+NPE%<-#=10(CC55'Y+"$W$)$BJ(
M)CI/9:@!0!1%?]+VL'@_'3J<7R2]">A.&NN28$'6.!4][L_$J]-E&MCQ:M]4
MT"1'&E12/*XA$M<*Y379YK[WP MZ4L>F7),%7G27RJ8OKB:M7NOSHT^@9"OU
MX:JP; :OU9&4 TF*;&(S[B#P)C95R$BZQZTX/@ IK#. O895$-F!;?N\T"F.
MWZ<G=4;>)O),>:-9S*U]%OI>TEI\!KCRJ)L8+PF8[MQ"$5]1?,6;$A#I^<"2
MJ53?+H$G5]!0'(^X>)5X+RZTBDL'CD9%@1<K 6>ZF89!KDEJIF$CQP@PTB<S
MTY4N 8"7I.&L.],T-6Z]*"0)=IA=US%UN?TL%E7E/3M2#!$H DOBA/I+ZU_)
MW):Y5[[Y!I$;IW/JD(,\/]M",N3= @+J$BB+/<I6^"%R@*7RIN1R9DW*X&>!
MG(0!I:_:<1G'=*XIEJ9/L1E,O'E:[C$6*R=?9V51&T)&QYM7-4#):P".0,^\
M8@]^A/7=WZKOE9@AHE86?>:5A=1,R2_1&TS4\QKIZL^9TEK%);G4-TMR_2Y.
M1O(&:'M4<!6.3UH,G=>P)I!STMDL+GI/6J"3="0C-I3VZ:*DC1F7XZ8K*2K6
ML V?0$.Z0)D1A GKBG6[/Y^?W\I)#\Y,^TPY6[B0ZZFBE&L2M<6R;8TS%59!
M3@5)?493@/?PFJX>U"_8<ML1S(FWJY3BXE[A8LTO7K::5XIBTG)3M$R[G\C%
M$MH+J^-22:!:U'E:Z.S&2XBGTB>KS>3Z>LK9#>7@QVK6@X>"^G7.4V=6#"P5
M#=I;'A2KI&?EPNY*EZVP#T:B;3D\+61SMN+:'*O3AF&L5107!!.@4]Q?J4I@
M:?&ON*1X'-B7%>?Y:K^<FC"2WA9U$1$UV79_"V7%TQ8IM#Y1'1B+0DYP!WB3
M&SYJH@QS=4XH-3\,9'VHRX:J23\!]1(4)/Y ^N'<G+QR:*!@1-)O,M+LU_=1
M</9HFO,/=ZDFF?+Y6S1-X(C? ]O[Z'B3/W[[S_] +]JO\5NW/F(B?+UU\#W7
MN@2RH_[BGY)JZ\F[9"K!']_8]$_OKN <(@+.^@K\?^C19T4]TY1WO^4X=L*'
M,WZ&K6,;=QNQ&'KS$D$BZGC^_1>I?%3E.G'\EC\T$3%Z;\'#5=XWNF=(;[_=
MW%Y^N_^'=/[UDW3Y__Y^??OE\NM]">CK]\F^I0&\X15KGM,V/K7$KY,CRVVX
M((YT7@S*[LJ$G6@PZYZ*875QRX??ZBYNN:WX/$3<\@9'9KLXVZ%:/L[V@I<8
M]4%=]ZT77LD3QO.FX4M<$/8 \94E -^FL,46T92:(0_4C0O.'"[NM+$8'1NR
MHBDU('1'QVYE<&K9!=YP^W8:^2[5[.9=!&-MLN3"R^Y^52K9?-_4T5#NZV63
M1'<-_Q[7.<#XL.W76;\4*+LB\IAB[7YT\R1]#UI+B,I8D55=/WI"5$8C657*
MQLL=CB_N)F@?G=ZA'TU$DWB\T7WT6>7J>2<8W:S(RDB1AUK5A(\NG'Q#A&>"
MEVI&>7-D2,XUEB@S,C:)+WU&&\ABY2&HHX,3$"8#79/U46.TFIJ%R6<0'!\P
MW(7';3 +[RU]AE$Z<4Q?)U+6X.\GS=#DT6B'"4HE)MVVI,\I[(O2!YU0VXF3
M< ?[4K]X*I&0L(7P<EE9<_PP>20EEM:L,E**K&NJ; SJSC?I-F>38IO:0%8'
M53UOK4H%.GS VZ>,GI&T *6(\#E8M-\IK%H4[_I!'1ARO]^7I1_ TH</Q)Y^
MT'7ZO$D9+SD.[[>?89*>=!X6O3+)6-HBA#2QMM.[;@S+F4?^Y(DWWBODH!09
M/0<JY>'><7M8WGIU52"1SQQ/Q(IA%*L$#&.H:3P&'$-RF31EC,*S<X%"=CZ2
M<)0);1V<=K^_&S>SR[R/ZB#7PIW'IN&E%>T3=J<4051IC#3%*L+NSVT898;I
M B[C\6.\2S />A _+!.T](.B)B1LQWU'.5GP;20@5OC$): ']HB=1N, ;8IK
M,!^\9P'$0LP7AI0Q=Q+W95\$;9DDX>-?31>)A^#@K3_O,Z_9F%5A\^;OO&5R
MVKC7L:=)6#<!DNEUS/$6/@$>S_"H4FBGB/<C%& XY /LIXFG3)PG'D?"H_+R
MO8QI\3!"3TJIF^:P6&C:CF@*B[D=V9C(3(A=80Q;E6BTQ4BVBS1Z#]Z\B+-Z
M,/JMBV5K1"S;H#6Q;!<W7[Y<WV/\VAV%LUW<?+V__OKGRZ\7UY=W)191OVYQ
M="%M"50W21PV70=)Z;EN$I2-PMVU"^_-0RY9T^R%I!7TC+0RKD+%0LFG$&G.
ME9>"G7E7>!$,[F'<-;(M% /P#JA]HY&T3@5*(L;A"YA<>HALWH\;)B(H<,!'
M$.F/F(<4>B@?8 RE+^N*OC@R@6CE)\AF3^17+IWC8K,I>9A*D4]>>H!Y74J4
MF[_&$> DJQ(%CL>K?\4;R&1@T3F6XLN=O)PG6<Z#\JTH*\/A357ADZ\",Y^M
M@1'N[L2GP=.&Y*[U\ HSAB()#'Z'S>!1Y'U29E(54_OYC>D(5 R\=\G=&,U%
M*'VLJ23MV;,Y8N?1(Y ;#WCGI_(\4<@L$*Y1@%OT  KSRZEKN#&J$BNFHGZ;
M2PQ:C?9\$GF<S4FG#70GR_$PJ0[4N" R>4?S-(LRE[V)XUGX.X>#VSAK#W<6
MP,_\;-[Z;&9C*MG2D8L3+$G9?)N8.(N*E561U(RY?)@T*2Q,OA!^AI.%%]EO
M=,!-=_(:3[P [9*EQD%^B/5>/S8WBM[U,5U8I+4O&!CZL)\SC'DJ+->YO<6'
MQ_U1[F%:*2P*'^=IV+="N4]2L=[ (:>XF BD=(=]9L\>@"+RN:TX\0\*L/2^
MK(S&"<-=BL+@P"""DG&XB9-6Y+889DUCEJUK99+1TN1;-#'@=W%W#E,1BF/G
M0V+&9(E%Y&*=)^+'>94%PU[/EF*VBCG6@H/: -PSF/0\-V>!F\*G'_1^G_LY
M.(UANCNM ""F2@+3I?-C!^1:L&GQ9N2$F4S4]7L$S%OCTW%OBBK^\+*9O_C+
MU(NPJ;CINC:EA_L)/1>R[+QK1<X)OCSK<0%6*L<.WRRA@\A"X .7!^:2R_B^
M)8=N:8$$Q'G.5$_2[D&L\<(#E%[&@LR^ ^;'\E#7<!XZ)BN<2"<M6K+[R).Y
M>5(;UY[\3/D*HF\K2LH7I)F<2%QX''P3_;%G#OH3L&-,L.;L$0UF)^05/9#N
MX'"$+TRX-7P*U>(@V%:B+>4GXY4_@I13^'08$B=%G*+)?2(+3R650["[3?XG
MUW/C7VTW80]%0B&7(KDRJ4_X*8V3IKC;C/:P)( *<$N0%:9 9BL#N''I!K/0
MYTL"DV=3@HIJSZ(9)YIL;B;%@@<BL2GHTIKJO,\4H(PJ!.ZC*E71O=.&8/+!
M5L'DNCZ0-:UJS[XV19/#MF\? GJHJ"-#U>3QH#%11SN(@U/[:MDXR^9MQW"D
MRZI>]K2TX6RH9:^SF[<9(ZTO&Z4KVK?D;)1-E&K@=@P&LE*Z:/[ASL9N8KKN
ML;H5%1>I*#I/,.A.D<<::AEUEVNO_R#O)IKN'DWC+7'1A68MU&D656MJ1FL!
MB9U2<-9]XM1)O&2Y,"MQD5"J8R)>^/R@#3![ '[[057'\K _X$Y'$"7ZV%B(
MQCIFGT<?#H+MEKC?O1!A*_N]@VXT;MX,;TH<;V5#G*0TO(D/O&F<DI3$*"4P
M+,4I7:?E@\EUA>[1:MY .5? >([A5_P:8SG0B0=.)85!EWV; (:/):QSY>[(
MZ>H!FZ0UYR9@"X%4Z\;VJ-YL,A#!DBGWUY/6>/:6(K;,_+W2@F]N5737HI..
M7S86X[<6!]XV)ZGSZG5>O9)>/1"J;?3I[<8VJ^#Q.V&K3*N]?59S'"M<;UV0
M$7F=H;5^%UT>[\!KU(Z3S=-2XYOZ[HR_F>ZHCK=-5VI/JF-9&*\X&UBEM[:9
M$QBEZT(=!R=8L'DZAO F0]!E=;##/J4-9PF[\==^7C1]:W8RGICO5ANVO[M>
M4_R(;V=D+ 0Y<O=MZEWA3IE%5\XFN;3<P3M45!GC>-41_^6'_@EY==\"X8K:
M?*6^J6A=9R\"RV* -(_G?)K8H283PW8F!4G_G<(LQFJ9B(MYC)_80U=\OQD)
MBT9K$A:_WMQ?WDFWY_\X__CYL@30A^?4K4M0O'9S"6'YS/4XM)[ B3-[/$IS
MRS7WBCO.X.7#))N!H?:'\G#01X]\TI/&7=NCRW:!/]"#<]'D@]^DD#.?WS^(
M,&Z$ ]8Q%Q6FV+^PW2/U\'%>,ZT0I]A"!T";9YM!H@S+/O*#JLG:>,@#QDW)
MQ6L>&DIDZ^ ]B_ :$ @NEWH$ ^\WR.\]L/F=&[>>]$6JF0:JSH^XBNP;TXCW
M/:2P<KP[BIS7+C@;J/%F$GK%"9_;$J.FC_9#C%O2HC:6%47/TN)9,2W&;: J
MT*):A19/.S5E@3,.=TN,.K!:U1@TGAAU11X/!S$QALQ=18N<[()E_KB"#C6@
MPU,FKUMQWG)7Y?R.6_BEQ.TR[VWWQB5^6O'E!\T8P98)>TD;$L];3)_S&1>:
M_*:<LK*7B.N4-Z?0T'7!-@HDD8I&L&QDV%)J&VV4;&AHWFK [D7DDBKK^FH3
M-[7%5EA3BT:7Z)@6W'*8P6P[Y\+A<QHWT1EEC3#*AJTQRLXO+K[]?OE)NOR_
MMY=?[\ ^ZPRS.EC0^6(H5:XT7-R%M&N#5BVRJ/*54GV]G,J/TO:69[L-\EBW
MA5OL5?7=2+MH[:?G6/-74O9J<*?TL+_>73%+GCBVBW#$[7:!,?- 5]\VG8 J
M-E;MF]&&H,+M^DYA?4I-'HZKAHUUO;S6I489^E#6QU5;CS0A6+/JH9O['I;8
MD;)W6%5.VLZYY]8!-XJL8J9*Z<2V7:]@?RL=*IJLJVV0#I5%@3=#];Q*7XOF
M;8\B:]I -H:'RA[>(R$.1W#H3B7+."92\BK6K,@?072;HANRT3],[/\IHEL9
MRNHN>]QT6=U=9& ^H'FH*_)@ZVR>KAM*'6&;&$DLZ[6WJBDX_TWT/#O+_N;T
MMF?#:YS%VZ"[$+[$"JC,#[ %0?B*T7[=_4\C[G^4?FLN@+"-P,U7Z>[^YN)_
MNLN?VLNB/F%,3Q0^>3Z5&U9X<73\+\$3/)D^H^@ C 7V,/(#CK L_=#OP2.*
M-#=]Z=ET(H8A&Q(]+>/3O#KI .R^/AKG0_X3 *SKLH$-;?5!\A4Z-[4A/#F0
M%4T77TLOS.>74'801*(^LA>%5)>86KD4QRS((K1K1=>D@^&\ 6$'G]+RMBLJ
M!A,LRW&:8@<4138,0Q[U5:F8+-+"^.P[]DK@=8I?3-\WJ;J!:XGG>.4)*O^?
M5*/(#L1C4T1QATP!7P:;:&%C/_3731BS>!21TI='RE@>*CJO+<Z#3F(83CW6
M1/IKY+*"@$=T+CDLC)LH2('IT'ZE>QOWO4CV=[ZJ!@:\C46Q25=(MS2-5N/)
M TOE]-',LZ1L8XLXTFP@CPU>1WL-.%@2!,CB$>^ML:ZQ9?M8)-?#6LM$Z1X\
M\LS@83^@0+$4M+F/554H-K<WZ*?,B^+J" CJ?9S2F5AQ##B%V1 ;6FB4I<MC
M40#<P8YK>'0H\(F<R7S"@:RJ:D^ZR5;2'[W=^>!-)&/=>3MN&4(#);/3T</]
M?7C-+0/CA^71: CG9U"(:2X$RF,;""^,1,\3G!3C]K V.JW@K:T8@DQ9V K1
M@AJA>',K?E#!Y(<-P$I-JY"O&;(Z5DZ=(^2:M+P9>8J$$RR&GEX &P JN[+#
M?S\RWX1CO.J,@W7A)-2R_!K(<22W>!+&N4L "CO!D)<O- 7PBVR_#]YB[8OI
M_P%RX4908Z:K1K[Q#4U3V!&D)_$?EX1:DOA$OQ-4:;U^5%-@ RR68XYF7+$;
M!)8X,_PJ%\8$3I$VY<OV]$E.$D 0S7FW@X$TLQT'7NQ)OZ^#([^)&'8M,N1X
M&.;<?(U1;TK:CSRQ*PBH4I(KY5D=57U:)@QBU<IH)!OCF%7$S-J+_+4HRW28
M$.&Z8#K!5M,NXX(3%K# 34>]@9YA"#^YO+5*;@&<-V"L*ZQSB;Q^%@0)T$8.
MYT(YW6&1?<N&JLC*2"7FM:AH+#VLJX:LZ ,"0<"6MFS(,9^>=)Y_6=.P<9,F
MHJV(#8J)B*+RQ:DX5H/H(9CXMM"=N#K$6RDB= 3$HCIL2 ]L8D8+[4LL0!9V
MX! :U2( O,-GIMS8L">]K3MR^27X1J:'"W;% 9921$R( -G UCFK9?Q&I!03
MYF+?F-Y0R9 3'L %*4_:I"8/55T>C)5"(L#?56,DJ_U1OD-6C%6$1(K%]T8K
MBYM8L8F'1H\O&IL(3%* >QR=G>E*53!2O!M%C4@RF3##A&TN-::B%:8LRIRA
MJXAOWYJ=P6852*H/L7*)O3X+^XH.>GK"X4Y9*">]R)1!HKUE3N"((%G$<ZXU
MS8)FA\11(&RQ*# ]EZ_BATUP3AK_-YG4,&.5+HXQLM%L1J>-.@'! 7@!?3QD
M6%41Y.TD)\-+&E(EK"(<0Y>-09%?9FGL)3U\"\5[E?U#,*2*MZ;* ^$XXIHW
MS&=S/"WHX(EX7.;.*LA=ZHZ=9ZNF$W@ #"!+\+@$[4S4= 6-IG]F@88C"EIF
MO0I<C\KW8C3&0WF0LRQS^/,R31BY@6L&2Q-S*2VF2?LA\DYHDAN15$QH0$XW
M^37Q2Y!DS^6 <<3G! X 'P49$P?DTFB,R#[IT[I>&R$XM*)>@K$G2QUBRSZ]
MDALK[[FB;FVQ8VO9C94QFRNXL6!G]7&_V(=54@,SEKF66/,8K.,Q*(2UK5DJ
M7"^!L'K-.FA2NJZ^Y;=+;ZM*7S,ME8A('KF97F3BJK[Q9+4+9$]WB)N/V+3P
M5F0I=K=6A[RU4EIS:\6OJVYN[Z]OOG8Y2[4YKLY!9W&0S^D+W9HM8%+"V.#?
M^P\@-V_A/,_,"8N(X@/I+QZU5 8 KMU)C\:1.!/!+P -: W?@F(L_82C9/Q&
M]"C^DO<8+1:%3AZ3,Z L)UM_]+ Z#EY?D5<,53/LFTE:#JI( A(R/ST7,ZRY
M*V"9'V,:*:AQ8?(C=J&>S1WOE2&>>1-:/^#@6/%L,J5[14Z8W,N8UK,=P"_D
MEHX-CT2$+KBV1+8U U:"MHC+/<_D34(N:=HN5VY68&11.\)%,!_% UH^HA#J
M(Q<S:#/&S9TMM'$T60%!-E3C.ZB>=+[J(A#C$H75F?3+)B# @N_K8.5KXT((
M$I4UM7"35<3B#0?&?W19-_JRENH2YK-I\S9^2XL!W/*=RXKEHCD>F8OF&BC%
MSU2' ;/C=9$&' M**6XU'1.--(/]M.<P<8BIUD\BYQOU>2%1$ZA(*>:8Z*\:
M-D;"2>N9*VN^)X> W]$4'(0E\I<*27]1#<N3SUI*A!'0T12%L$[B;X[0]^)>
MZ%[F).-$S)SP'LEXCL 4Q$IJH6@3#<;?A#II#W_\.6D!0&?F39"SE_)"\\T<
MQB",AYNC%DA/ :R@O0(<" PP*5]>?;.X@$2\A )^SU_$WXI9*6=WC'O'T,$)
MRPTB[)<:(X=:+?,;,R;Z)Z#E"C O+IC\X=@!P;=H+Q(/VBH8$\\_MT[ID3Q+
M'>V>&G),4D7[-G-[RGDOMT&1'Y*-#DAQU^Q^=EM76\K+_88%/RY:<!Q>($!^
M,JV$,PL&C&\J RP0G^7."SS7H+OADCSWE-D73F*3=HIX.GL@\KA8S"FQ#ZK4
M)3 NX.NP4&'QP[RR51R%1!!M4J<CK[[R5M&,M+VSB1D\R7QVL679-*!<!_"!
M;(Q! QF-"8Z??M!E0^_#?PTZ"(D>R*M_*')_H,DC71/E1MRSY(&?>9T00Y,'
M<*I^0E=<7Y?'< )7C#.2!^-!P3A)X X\I<!L6E^%X8RA*O>'2M%@^DB154TI
M!"E?5$;<KZ6>17AERFP\ZZ=]RM%9.C7M. XO%O1Q=Q\LQ)F0:8I].^ND%:Z?
MO$J)^[.T+?GW3'[W+MH&T;0^HSK$>!-'-9RD*!!N*P+B(\9YG]U-GCRZ:N<P
MHB,:'YIY%G.XL(ZP)@6U'H)S-Q-G$$OD)(9%4IM"(K,9'62,?-]@-3CVC$).
M1 8U//-DHP?\=<DLRWJJX<5GSX'G'30(^;59 .J!N+FG,*=49$]-84KQVDBQ
M;RXS A>7<],GT20N"'B9+EM<G@..Y;@A%(Y@NP7<@3S@206FY4D0<._%78C0
M#,T_^(AHL_$0;^'?PT,% X%-F5R4DL G+.>=[[0-''>4D@X48LKH#W^A2\Z
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M!4^IR#CB&YS50&V2[IU8=6OCBW8W8=D9RQ/;-EOQDZ;*NJK(AE*U$%L&@37
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MU"2>-^V:$N:E&4>]Y,<MS.R0CT%7W'$#&XPE"[I(LGUH @*4T9K+Y&UX#1!
M59OO!&ZW];W=;NOZ0-:TJB4F3^]Z&^BTC='I>\JJ4C5Y/&B![^8PEH_:5]MX
M=;"GW(^1+JMZG35N6\UUU#K5\'93SDCKRT;EM/Q3XCI5@Q!/B'8& UFI7$'@
M1+C._1/S&?5];89C[D@]SHH\UE#Y;D&HRV$XV+T7FDXS2+!S%Z[+"-6'N@PV
M0%L=ACMQ_Y7T*=*KF3$OS+D-L[37H=@'DK/=C1V*=B!-. H6W8:%;L'\L\O^
M09%G2EW'O>FRK[%.G^%J''2.Q,Z1>/2.1'E0V8KOW(B=4KUC!&NU%A%IOSJ]
M*%"Y()T+A:3S%ZSD;N-:O2DM9FD\-M'&7&P6-"24YTB9VT_J>$?NX&V@.-+X
M-&ZF+5@8W@, :QZF?F9[>*-1.3_ZI'CC)/(IG&7N^5VX=MTL4I?5P8YJ_G5,
M<IF@/??Q#%TXS2+FSCV[SB(Z@E)]F_I0%[VRG]B4 3.VOK%GYD;LX^LY-BQX
M)(?C)SN8.%X0'5TCK7C1DL]7?< *?:?B(UW'EMM5-ZPKV[>E\#X>4FAF";FN
M;%]7MF_W9?MJ:I"T*(HKXO$$;JSV5ZAO\W(17;&^INZI(H_UOJR,JYH\IW<3
MV;FFCK,\3;=3.W B;LI&.D=B%4>BU#D2V^1(/$+^U6WWH;>[@(GMSG]<T=N[
M.H27^KU\- -F";?S^8OI6]1>\89W5_R;Z41T3WP>!-&,?]?&<-ZW?,GW3TQZ
MH:T%(]8$*6,^8MQMLF8"* )$27/?=B?VW'2<5RP 8#'D]C9VT.'N9M/VI6?
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M!/254%^$)7SFL*G 06UJ##497/0L=$RE7J8RT(:R/NZ82K,W"B,SQZJL#EK
M5#;515H627CP?*[FCG!PU.Q//-9PUK_E/>BR-.%A:2UDT7MBCH,1<$>EA?AI
M#X;K;L;28CMXZ;RZGGNH(WM*.A&'>:0JZB\M//JGM%-MX1[-,8<7>$K'1SKU
MX<1W2>VWA(D<0@6Y]T+3B:V%HM <:3$L)WCR7ES)=BDF)PC-D&%4% ;IT,]3
MQWMIB.NMRRU;Z[\SQH:L[ZH?UN&Y5[?;ZP25K!S""5A')F'IJ,G%P,NW7BP.
M=WT[<EWMYT-7WYIG%W"5R;\#[024D_W"92PF6_ISSP<1,:$HW@O3MU;$*B]
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MCY=W"R(6ZKZHXMF<G>([WR=X(60\1C<YB,(_24:_C+[=@\N<#*>#N<<_LC@
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M*,S2I:]Y!%%3BH,GOG0HC ?\D:P'2 ;C U: J'=W(._ *OR(Q$:L I\GP(&
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MO(]:!JJ[P'Z#N<4OC]7&?EB-6O( +'[)]&P[NOA 6V;9J.__.C^_N+B\;)!
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M3L03W/?V3-,U?L$3--WKWE]OZI^ U#J<EFHGI]I>N;_>(#]!4WW/D*ZQL4]
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MA,<]1_>-'5&FG9$[<?'ZF&GMAC MCYZN91NVI>T"EK:FZL3S0%WYYH[HTNZ
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M GNB3J/!?1#?,>):]<$XF"G) '30J8+\'R=9KF0@&N$(F  DEUZ1(C11@!@
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MR(]'9W<@Q+T/LC&@O'@[+.X/H>BG$CL(D-I1-V6%JX!;NOSFJSZ:?DYB.$V
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MA$^1)#&[2_*P2"1P)?00@+TF6A1?PR?+GQ%\S(MPNHFX:Z%]Q<+D5 P3C+K
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M03$1WEMR3X9,!Y&64I*4>:HS7JUY<))[5KO=(IRQ1;*4"W!7;H6X?$YD-+!
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M;0-:"LJ#!,+,BA8%0Y')Q@84$I %A)B1%C4UY,@.\J(T:FF!DWS/=%E@HL[
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M53==U=:]GNK[H[JIJR;*N[7M:?8I>NW+9^_&3U]]ACU9R#,<M5+=@9>P8\]
M.W4ZE,4=.'\] Y]BH-76J^L9>%P,-#JTP5W[XK]0/K3VIVV2L$==3(=9\**B
M1Q30ESGQ29)C<0L69?+$?I%_S]A@FO)+HIM4K?,&%U2"4,_=+\FYEVL6=0B\
M#&GN/%*=/T2;"E[#QEME%;>TL(:@>-U."BC[;/OQ)V]T;3_9FSZ1?'A>]XGD
MYTK//I'<)Y*;!SFK)%KSR*8H+FQ)ES(VO'GX?:LTR>8NMZX:GJ?:FO:,,.YI
M]1QHY3N^:MB[H%5'&J1U0$]O=;2L74OK0L]V$R>0K$?G+]Q&8%S5LRP0FDY,
M?#?F_&43W%$='=--VT;,>H(W)+BI^IZA:EO'F)\BU?X<K#[_M84X^*INFJJU
MM<+KB=[.RE"]3X=I@I[H3U8UJ+ZMJ^;6I\T-$KW["]E'TK7!^9N!U;71)^Y\
MSE\1!8BJ"^/7:1(GV!%,&B/Z0N^,WK!!_;*\4D=^&9$/!>N<+.X6*LM? 9/X
M8TA#(MXI)QS\$E(Q"/&!X6WPFVJD!@$:'B_(*^_>'H+E5]A@8H:I*FNAM81R
M-PV'V(J&P!DD0VHFC==:2UPD:?Z*62EJ47-.3XJ&S&_/OI[_K#B:HRI+>%4V
M3-2-]^7GE!\[3^091<HYP)R,62IW)4*HZBTFSG$AN;V$N( ;P X;\F19@1.B
M0;,Q4@D;>H&]%-)J7=%H(1.-&&AN>Y(J$S IX8!R>D$<BDX&?%)&/!4M:N>[
M,Y0M&)3E[1?<4^7KA V(FA$V/*/AS\#Y3!!;='/-I)RB:+T8U)MRE%^@EMK4
MFXAWT5#+YO^B$<5<#XR'( UY$@^._#A4A[.U&(RG2ATTQF'$@$NQ/+TN%0T;
M[HKN&\5'I\KW<FK<LFO<$A@3WG.+1GR4(U!J71R([P4"RSI5>&H%70T,WI@L
M1!Y30QZII1VU4!#O%#USRN9HXNLG"\/\BG%]B/DC]=>\QW$#P]K(0-')CH.M
M*O=B5H&8RR(Z8 I)FM7;0A"S2N!O^:WPM1"%U3@C'*U3P$/](@B.-=TMR@8;
M1:L5:B,G!O%(T@ @BN9&U?1-3*?G$=<7Y3P)2J%C_Q7L?%O<G"_&U?!VS=(\
M+]YZG1JWU$2#^KL7O5**IJR\D]TD36YYYU0:8",/QA#=C:F'_3PV59O@E&]]
M D7N;XA887L0WI.D;'M2=C/%Z<A9E@Q"Z@12#M-:L7T 4L S UX#%B1V<!1_
MF!N<Q=/_93^5IX5<:N,T+K1URO(T*6<]CX%6"0U7XDT4*\[-=4L6369$2]5J
M?V!O6NH*6,)3:P,IMD?1I$M\K^AHBZB#1J/NR_,MEZ5AD7E6:ZHHS:_C% %%
M>A](0[I* 'CK':ZZI9F4Q20Z84EP@.>Z@92+TSVQ>RV?LU)1B$ 15!([-%W
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MF@5%I_+@3K31S;#=\G3"'4$-0[^1<'RK6_V-^H?F]RG-"@]B>;23B/( O__
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M,,LJX>0=66B?3.A]P02/ID&TL ?QZ>]Q6)BPKWEY#RS LK,$?FB,A_(4#AS
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MZ\:)J;_YM4:A$F\)AV6]E'=)TD7BA?@#1YK,?8&V<E.TN E7T?G@8,\)[K$
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M'/11\)#0)X$2P=,1&$0BRT\<0+'Q'X/U**\"M91>^$:<Q(V^Y"AOO\+&_)P
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M7Q3)YAV'KHQY,W+:IYJY!V^H-7G/HR #Z?AG@&OG7](;_/[%#Y8.PHQ=I^&
ME1]FXM-,WWH_ZJ=RRF<C&':&"&6]#*=9UNM\EN7AX#*\39,L!#9,XR&Q\E&L
MU,H>FJ?&/JB2<8D @?[G?3BXGW^'6 )+QE8F" V[2A!V3*I?#<VP^7O7TZ(Y
M&AO&X\^?3&BMSQ=8MFFVC\J?+\]BR6FO33((&R<)??FHT0B*!="3\3C,Z5-*
ML,=(!!8/PJ9A38+JJ<!"RU56<'#5*A0R/@^R>PRD/ 216.8&E##L1%"X^-FG
M  @2YK-6T:<5E3B_7IN?1*2ZW;+M!:?(1%[%@V@ZI""0^&0'\F3X*W+.;6&;
MQ_,Z99,@'(IT*A")(EQG6<;R;,U.;I*2]$W-D/W'!DMU!%VC5*ZG>89E'1"\
M0A:NXFP*.GC KI,HQ(W7)+?O>+[K' )XIP/@7<^5:^$V +ZJX#X;#$#G##^&
MP6T8A3E 4"_;;NJ._MJPBGQ%V7E50?]+C/7CT?I"^O=*N0+]U["PF52]@O_?
M0.%P-*/U!9;E#%7$"MP!O/6%H"0C!4BFC)(H2AY!@;_;(;S+BO:7K)1S3XA%
M438)!@ 3LIY^%TTAZ?<Z-/HD5\X!^]LT5)7_RZ('AO?V (0@SDX$'(_A,+]'
MR+6_O%?$I8@!X!U,,O9.*7YZ4[LY\-15P'7W_62.8(:4I0<>UP$H D7CO[YQ
MWJR]&[*R/=D36&QS->0#&]#V5TQ=W>_ED)?)8N/-!C!NPT"CLWZ>KX!2NYS:
MOK\+S4*A.OY?=D*GPG(-X-T(<S$0'(LS\?(R>.3@%P CL[QMYSX!N;$:\!9"
M6-B5W5"A;8^' AK$;5^M)37-5%V_;7O)I^G6G@DOF:/ZWCBJJX[EJI;?]K;Z
MAASM2&,=HL55H:,F:8)72."T\L"B9#+F1Z#VBND8;B7O2\8,VU:M9]D?^KG0
MV-5-U3)>AK.Q2P=#2@D]0VG<UWXU35MUW.?8%..YT-AU/="*N^P1\P),;8(A
MOKT+X6OJ%:];CNIHS]$PORHNZ:YJ>'U/_Q7D^9;D070<:J)O!+EN'*MKZ:JM
MOQAMTS-[36<U\&X<U;([:KA]R/9/3R4/5S62^!;\X.G)JCHER;+S($UGHR3%
MBK.LUJYATR2U;IE&[9K_I@ L)G^3 6/##!.B4AUR4?[#-K@$M 1ZS[?\6I[W
MB44[@;+MS6G+\2S+V#>4;:]1ZYJG^ZYN;0'GQM63%S\F(0_9MRO1*3JD5%T
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M!/"M*^1OV)T![#J/N[I2F&H 3@<]12]15<9DA.*0S-!9RJ7I97I!A;]M,"R
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M"0&;+<')+-K,3*;@!C6P*+Q3SM/ESCFS60,RAF.]J9#Y#=2R"($$&PF=]R
MAGKI4S;C.&:,12G=?)\V+Q^<=XK2PK-D^4P6*'?/4KLV2EZWI#V\&(<H)#K%
M4Z:8UC+87L0FFDNIX-6++'E^+<3TI2I4 OO>Y1GP*X3IFW$T_/;ZUU_PCNV5
M^>SE\ ;2V%A>C-YI@^"X<TI*YZ'_,5"*N(%,OB(P^6EHR89?OLC1;T_>P^J
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MK8_E8N#QYX+Q:U-EM\3[^L.7(HDTS;U5_@/$F(*8,T=!N5WM']22%$).CTM
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M1*%6DSPT53S2_QY@AL@G_P902P,$%     @ YD5L3#CZ;5E[+P  ER4# !4
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M*S%0*-7FFKU-&5B=+@:DF1A PZRI5I(#^_"#L;2\QR_-T=4:PI3YUC/$^K(
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M$EG+0!E A'%[V-BLS'?&K]\$7T*?"-LF(X\B'W.O@@\GK8DT6;"#J8 PY7M
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M+73+U[%F<K=Y_:J-C<VKTSE%(NKY@JVH\A5JN^7 5BF(U0K'H>&3#C$_UZ7
M-[>@<<I5A[5ZO<VL:B "Y;,-?0%8M]YUCY[-:V.+"/=<JK88(1OZ=RB**?:8
MG<E_^\:O]N.7,XIK/B''4JU!)B=]'WGM%NW8A#L(OI;1^^;2WU',E_Y[Y'$B
M&"]:B*D[#@TE78X@9 P')%50+XL%VVX])+R4;( JSK!G(O_:;Z<7R/P4\IX#
M!$^/I8$=:GZ/T#0)KO%4DB"CT7F <&IS9:=;=Y7MF-T_',[N4WM-=L$WU&6
MZ"EX:=LQ!5@CJVN^'MR7TRA"<<2SK-(Z4T% ?O!$1J:)/5&D%TJ?J37&D)!J
MR)R=._5K[#[B@%E6(T*_,ZHIKQ' N+HED1!\=)Y0FMLN;;]]NB,,">)&K$$
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MXVY]%60)F<7F9.3WN TR_/X@-Z#I:1;]HDNN.BBZ+O,7_!R8=K2\C\-6V55
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M#89,1HC"G*=10+7&C+%(D1WR-B)#4S+6/5PV:T?Y$WXMWL?BX4<;!6>Y(:V
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MD">E$K],@SJ]BF>>:8=G.GG(3#.%M99J4);,Z.Y*<3#$JZ&02^K( 7;)TI<
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MR)O=/H@RRO*[[#+*]VD>Q/P=^-OH!:_XVTR6+)MDRBD#CW"VQ\X)=L $Q"/
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ME:94EE))E^S20.VGE!/$P,0M-39=WOJ6.E0?M09FNU:_!)=N#4DGE=+^."5
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M' ]=K-;*!GKW]=L_H4;);XW^TV9P@L4O?R4@34R!)!DF@Q8-?6(D[\C5/7K
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M[#IS F^V[VPUYJ<[O%H]U0!=[08S=5.WQP,P[_1&L3S[P%BV8Y>T185D*O(
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M2R($*N3O=F1V41"5K3S?5O]R]DHEZ.B,,2'4=-BJ'*.0@'D9KAT:P$ KV^(
M1U\E)<"5K.WW/V.>\RZ<@#6=T^3/%8D<W\M"1SZ2]1.).B3/NTA[V#[%B?6G
M>C(#,(W#-_/(/K!85FX.Y69,T!S'I !9+ $'%;6Q^8[=GBQ^:\2.]<[^-]5Y
M+IP_Y09(=R <"$JUL?EPG2Z+9LS;@\,#;E81R;XKM6O=36T;M)XZ5_-#261@
MR'MXG3F\^.<<D.PE[:W761L.@%(:.!:;[":#SW'Y(M-HAL,T@1:7!N45S4%7
M **J=>?;[DNG/3N!QW,[;ITU4>V9S7P-APYTZB^H=,10_LVL7?]P@M2)MG/Z
M0AX_AX_/81H[ =^K7M'5<T)((#6IX-ZV5SB3$Z!JA37%:6AE+*AX_,R8V#[0
MU_[( H>PO7X>&%XMP9K&N#^T(R!JK.CHP1&U!F3WIR^6RXP1*9*PKK8KC!X*
M2AU!CKD9CHG[]2I\>><1RG=D'_@/'.</E8T8^]7O-V3E^%=!0H6.8M:JU0C'
MMD>^]>VBNV(@#B;A_/O"[2EK4F]A6;9=8FL)MDZQF4W@W3.;>6SZG-=*]DI-
MC[R+M?U 2V!M,P%A%L=9^9X;2,6=TK[)% Q%F^K*XF-;TBJ':JT1#FFW-*1+
MT",Y/\>Z>TO8O"1>6:+ES'73=9K=IUR2)76I] %(=5_;CT$);^M;EV]0.>B7
MG?TQ#[$)V-J2%&WM>I^<+ :5QR5>A$%,/5+4M"8NX154%T'%Q2EQ*^D-8SND
M%ZP*O<2#8X6JD'Z;<BM3A!K'UW&<$N]:&UC *-9=23UP!0L'!ZQW4>@2XL6\
ML!8GU@G</&!Y702-B[$$=+7N+((""!:#S<K@HA=0UCSZK30A\S!J9LL+]O6
M?M9=0TK\@(Q@FG+=E3#/D@LGBK9L@Y ]DB6>=L#NUEU!T*FG)8Z1IQ^Z,L"P
M$&G]5S?? J>A 1[*(LVB< ] 1QPG2;WWA"!\#8Z?[@-&RZ[H '*#)FH:*F--
M9&[PQ55/R<75#Q6AS\MV%/2;S^M DO[HO/("=RI9-YK9]E]TZ$=#TIU\X=A.
M%S4%E2*O-[/M6@"(O(LO'"*_)$_)_NE>N4WO:CMEX][%#XYP\CIED.@]<0\<
M]E^L9U)0S(?27831)F0'*>)F[S2RHZHG#M+/,D0D'6R?U%5Z4\MT43)NJGY$
MX@3>T_:&) GWKN;O8\KC[V4];+\0JB-S .LXE@5A8?CSK3H,'-1YR@L'B$$<
M,>3B"O_LRZI%!=09Q_JBH;#@-Q J3)I:>_CS)R3Z=V9[/S,NV=<?PF7"?U0L
M0<I^MM]QU="[^J($E(BAM6FQ9/: S-,HH+S(>95P*2* ?M:?4.T)"5@D.%:N
M+RSG?YAW2[\(P"B1H6]% / 5 1AINU'$>RLVB+564YY!=4YPA$5"$_YPINIU
M:9! Z*@TGYWE\GI@;&+*M;_=<LHSH,U- <?WMEUH2R?UDUV)M5T00\PI5;F8
M8;UQS!B1YK5?'0"P9*J43#TB)/#JK\E^=!+^.N3VCD0T% 4YZ0YB*ZA8YT*W
MXP342U2&CD,?G>@/DO#9OW^_$X05I*.UJ[)A ,%E@N- U$6O[#JSJ[6U*[;^
M4$GYP82/ZEUMV0%'U=-:T.Y@W*!2L1G$:]A#^RDFR]2_H4M)!"FHL[70W\%:
MH"$;').Y3!G8/9[Y0%9K^2R6=+%VG3@8.*4<#&U86D_X[)]<\/WP,\\%8&NT
MRX6X$H5_:HX!!.E[1"#UX!+3)"O?9-K.P^@3HS/B27F,C[LPIID?[2*-N.#$
M<PX^@K7;Y<%34%=*.+#-=/%ZO7%HQ.W%Q;,3K63[55%[(&Y_Q8>;7 (X4&J\
M#5U[$;A\_^)2EOD"'L#:/>9@'#5EU $LNI26D_T;!H)4GZ:WHDA6V3%9RWWY
MH)O[PEH4!,S"Y8R/G[WVFOU0H2+[Y9Z._.]EWHS-;!F!T)09,ZI^EC/@Y(1;
MS^Z'2;TCE0V7S?T8!F2;NS/F:>#!LPR5'6W'K/<"""@.'-BARA,U%@C?>Z*9
MSQE-PL3Q[?MZ5%XML$9H#V0[?;^7;O04U_1]@BK&;\/ 59UQ=<:P71S B':T
MA81C,4#@\#>6@& $R&.Q_IRM!FLMUNN_ &G%P&&M^2^'[AH&BW)4?<)W6,]C
MJ;./+9;G3DQ=)I1+ZJ?)OH#9'8FRZD;2<_IW^N?TRK?Y43W[>G8L+[X_*PF8
M,0IF&0DH3NA-N:C/YN(>-J^A2)(_7'\3QK*KIWHSR^=TE>R;5TQ=/.)8X7\E
M61EC[XQM*)T5J=416Z1)S+/ &*>-.2G&J>]XM@_VFH@.$]OT=_U-<8'U0]G1
MMF= 4Q& @CCV"E(G=R$;,*&.GS%.7RHQ3%>OKI^R;_$J=[6%OFS:F$QY#</*
M+)*N^-_KK_@[6F<E!;,]M;.2W!E7C>;N8->AI'E6$)UO#.)9A>RW78*)Q[W/
M&'(>7,>:W*B>&A[Y.SC"KC5MVMA"0/+0\4!F;M3/(X_W!1QZ8V;6-8,(1A,:
MDI)C QDZWW8/H'C/SN1'W[1Q'#GBJ,O632$D#4_=$X>F'& &@M0&7>;?K]FK
MG^+Z .7IMM[,]MD<JK#-,WH7L\8*!87N'XN-_-WDO*Q.NZ'M(Z^N?$5\8/)K
M#30!>7%O8\MM.3S.F=5_2SSN8EH' 4G489GG44WQ@-7/_J'IJ2B'RFX;=H,A
M*YLMS&M1>Q( 75&X%,359J#. M4(.+9%8"B%_@ 5GTA.^D(R 6=X2%\<<.HJ
M,#1A#>&)>LION@]#J?NU=\LGR+?7WD?;@!W9:^]S\A3U?#4:UM5V^-^AWAK6
M$22.$]?1UV$UO.QV%&2U7-K[K2 KZH*L&TJBCPYC+5"58.UH:3OZMG?152'7
M.*S@)6&2=&DN1V:SUV&4T#\=^?N4TDZ60]W@9ZE6$2^E)*8?!W46$6>QO&&K
ML^184FECV^'7&\TVHSCFFY"AGR-I/*FJGVV??&^@8 (Q= V2Y8\_DF@M6(HJ
M?[>=Y:4OX 8#Z+W2)P_I>LV.$/N-:H?/NMM5_5>@J_ID5GR#Q\8IW-EO3NPW
M)_:;$_O-B?VE.K'?_".C^T<LN\'?_".H_2.V'ZPY_"%.Y3OYTA^L.?QI38[(
MQ-ZKR0X_SZ'O7:\W4?B27W>H8@FEG= > L6X0=C"!-I%F#WXE[W:<ATPAE=,
MQDK4Y+UL7\+UAPTB#1RX679LX?- :CNVINI2=MUTG6:/)E5=Z.QGGW3XTH5B
MD3BD1_L"VG57Z<X>6<CZ:O=CKG8!67$B[*N=D,5;TL<[EO5"N[SWMC4584R^
M) L[#ZQIDFU<>%&;,,N3)@%/DH8%-/_8]!)71LRKG5;'1!;7+.-^QQ.@WJG>
M,".?<(M/-[\L<OD6IT!Y+QP^AU[P-$Z[<CX'NWFU89$Y;N4DXW';@D2K@P8^
M1^WNM;$'EP1.1$.Y:U;0?'HXR?G!X7(M:?H4Q!NV:5M2MG]3A0^+N^ P=5)]
M:]UB"9DQXT9]()LD.QW7 U$?Z"N/0SUC9'M*!Y[F&+8/%4H=J^5!]I$/#@\#
M=Y8LEI709;F=$S2?K)T3\(,C]+8:4,Z8N@T#9_^;ZCO,*D>>]D X;*)4-UNA
M:9HLFK&49^DJC9.*&7@@+XP 9@4R7_'9*B)$:2IU!['MB>VIIU4+VD]N.$SH
M/6=5;C8K329K*BL\5%PVMN6N,GVU1CC,6DM?N@1MUDS-:10GOQ$GDB=C-5O9
MSA?H0+R6+M7-E:EJ'YF%>E9*L:.=[1+6"CD*.<-A;R>9"-S?[G8G_WYX2_Y]
M2_[%F/S[^$S99X. OI H=J*MU#:*&EM[#=&HP-N65BXL0PO7/$RCY!D*D;"U
MM9<.#XR10EPXUL2=^_!G$JXB9_-,7<<'NJS;72:[5DIXJNQ-;>*4/RM=)4^Y
M^(F[X%C!E+K7!$G,D"&G3):VF,=9/FP<5W0KVM'.5MXM^+JLPY4BXA:'I<K\
M.5>O&QKEP39,=T[%RM_=VEKX6D]8I,S@ B=)V"*W6%Y$Q*-)I8Z]JA:BNJ>U
M&YVAH,%$@@5 [BWE;TDQR?I,U]B^2)+W)VAN+61KA/DE8AX1/LV(<44PKZR/
M-=?_"$A)Q8 $+L9'.?,E -5:67.2#H2D@U4<(%P'S "3.%%:LU9#:W[685 (
M&#:5D;4A?#\2K'9E#42A:9TM@3+^ 8N,A8P@5OD;$L>$G+%_)/&G@,GSPME0
M'C_,R0?/!\4HUGQNHTX6D*B0U.N0A+>>[!.HYRE/"_Q( [I.UWQK4^DFJ]_Q
MX1N]R.R36?E-7L<C_^JL^.R,?[?6'T-!CPE%;X_#<-UNQ37-*!R<\65*+E1/
M;>N.8[GZV* P\)XL8UH-@+1?!X^?0WYI*SE+]!C*=J[@ =%O2W!J"L"^2D93
M@<I@ML-Q#ZL$+2E.3 WXE=586E 9RW8FWT&5H"7#J>D ?1G-$E3&LAUK>E@=
M:,IP4CKP^,P.1LXRD85']AC*=A#@ 36@+<%)*<!@V.U'*AX0[ Z(CRZE6^16
MJ#I)H.Z%TQ'="\7W9QD!;WZ&MRSQMRSQMRSQ"62)'WTYS_ZA>&\E/-]*>$[G
MB1-\93J1/W%2W3$.\DAK#S2QD,R^; X\C*"I9 =E'."Y[C'41"-%>POM"]&7
M@3HRV6!4+>&,ZLA J0EE[,=UD#\F?AV4?QFB(+)1)QH9.X8HIU_=LBJ%Q9-/
M5QEL0%VI=9AHV*U" ,=D,"KL*<-A5/TF&M$+$P>^XT2%UMLP<'NB5^TZT3A@
ML% F?V5Q&R8D9@L.]R>!RLY^>-^\?<B&F!5C("LS>TF>$IV; E%[JT^:/K&]
M 2^;GSDOY,^)=3;&X0.30]%ZO;2##R0O@]5I:YD2%2@W:*X)9+(&H'*#[E+@
MX3F,$IY4P E57P,(FD\-%0$;.#S\+>+4%6<$'7# (E4Q%3 C^>O'0::Z\B^2
M9Q(5/RMK6BH[VO;\*W2N@1)0#CAVZW6K(#=O76UQ3**^*PZF$K%URB"UM,0]
M,*(BL6MB1DP5MHH(N0MIP,N4\LC0.Q*Y_,N5F:LH=@4?P+;Q4NE5O8B5KF ,
M9;*RSP_"!]S==B"\%CJ:0C&-#5>60>@ !K =HMP+'[!@<.P![J+02]UD$3V0
MZ(6ZZEBGCM885QQ%3%,'%SBJ(1>T\1#(@KH8$+HDZH(#&9F.=4/3Q8N9[0#3
MF#1R I>M?#[EWERI]1*VME8^02VWMJU2\(S&,+F$>/&<L5HUHM)Y(.B!:QO6
M<O*UYX"4<QSXU'EBJQT-/>H6M\W0<TNKF^T$53VD0#+ "!?W9X#]_EE;7'ME
M/6"JW&)$HPS:N'<2DE7A](K-H[,"W\[(Q["=[CD$/8AT<*!Z%Y&-0[VBA U;
MBC,/8%[$1AF] .J,ZT2D7LC \L !8*,($>=6#%AG8]N)EGH 2?A%4EOIS'6C
ME)0J5$U\;/Q%FN/X;3/*H.@\*WLWTAI;?\:0OEC>)/#GK#E]CA^K0Q"DG48M
MSIR+[(*UY)6@BV3=,.!??HPH^^Y%&'<&=&;%CJ&]+9<P F!0J^&L)Q1#/KN"
MBN*(>$E>B!]FN2L 1(2=;!^I^B&AD &.5>AJO?'#+2'W)'O3_H8Z3]2G"3NG
M*S<1@*ZV3U@:P,&9P@1?OLG)]4T'.U4_VR<P?>!@DL"!6@_ AF-E[+RECY4.
M3-,,3JT8_?SYF,"[+/BXYR^EI<"0U0_-S61EX%DV<E8VHQQ[5@P^6BRK8)5O
MLB?;'/(.DO9C;CZ:GY$5JA"T19 [KQ1N=:\A8,-4]8GFYUJ'/H64;]"$D$J$
MIY;R#;H 4AXL=A1O<H,PD7.!(W[T[27NR;W$77E+>DZ7_"7IB_G\,5_ ]_2H
M0DXTAK!]L!WA%>X^,L.Q"Y_<&]PZIK']\K;EJ-.WE[</)>F/SBO/TE;)NM',
MMBF2O"_=33 F4U)D7=(_^<.B<1(OEI^"[)$BKZCEPXZX5Z]YECR/M#A;A^QW
M?V;"/=^6]7X6$?OIOXBKV+L9^=C$S)L1&: )RN,DJ:9OHQD.8VEP'K3CEJKL
MF]D/+B+'/PL22H.E[ZS7O-_V,DI7TAV@JI-UGWB7?M5>.@)Q;>C^Z(8$SI,3
M2Y8OWJS5RMI#1%"A"OC"L7SM7N-]<!F9$0V!KT#7FT]L"1%P4?&6VT2DH.E3
M$&^(2Y>4>,KT4W$7'(N#5,N:X(B9,6/J/VW"@%?=()%+^0*6R6:Q?'PFQ36N
MU!Z!>]NV4TJ]JMHL39D86A$X%?<DJVJY8I]^<'Q>1#9:$34D\FY +'Y$@P5$
M"@9!R/Q!2Q+Q;R^B&\K(CQDU2A04_< '3S0X@ 2!8V7_F;&QKQ^T_11$Q.4"
M]51O<RL[6JV2J;R&:BPG0#'@P*RXP[UG)*X"RN7YD;+9GH2\JF_R''KU!G_N
M+Z8['&H]QK):YU(7V?["0@)VN'7\9*M\I[C9SFI126V0.IDTM%3=IMP,+Y8\
M,MGQ?5%I3]ZVNZG50HU@T8KI-RK=(M_H,B5Y!M(9?^F(;4CF-(J3_6:1+XT"
MH6N-8+6,HA86/01C"*)BMA4$57:* D D[:T60=02OY)I).8^7XUD5XZ[%M;2
M? >LPZ:*BN.,X:MDB'1']^VD40OJ^ZYG4%\];T08\V>W:F5=#%H%+)5=K291
MUJ@#LV$]BP2,2"LOLI-A'&:T09PR>EK4WO:E]TC@#(Z>QE9UO<$?I*2SI(OM
M&[>14#["&L[7 ?N1/#JONYQ*13S\]\VE,Q]AE@V!K(+SCCF=55#::=Q:-#O1
MR\+DV\UP7"8!A%NO0M-DPU2$?.5+K3VS6+8WJ.+B1;HAD.@-NFCX'7%G:?(<
M1C39RF^T1>TG@(6" QRQ\&WJ5+?9XA[([$^GABG!,7N9/2=L5,>7WLPUVM@N
M]J'2D*KIZ60/Q\$DBW$X"[P;]@G_'VE$8X]F$?2J<#YE1]O%/J  0?DQZ@)E
M9%ZD_.V4?X1/\9F;+):5-(4'OIWFB0KR1 ZM(: '26,G29WYTT<Z.*87IYR=
M<6ARP3;XVV4897XY>::;N,MT5G<)$SBR.SH)A)065W;$L=PK%0\"V(CUQL>Z
MC8@)$\.S,BVGT<YV 5*@MK6N*+JX-;0"+:+-LQ/PL.F<4D7(>'=CZ*IB;%>F
M*6@9+YB6D<EE_@&7B7;2G^5<EK>DOT-)VFS2WUO67Z?,\^=PE3*O-X/*W-AU
M!$#F78SAD'EN"7>I!/QXF0D.X-X3=)J.>9>R@2-O14 BS-LG[(9C40"H'@PP
ML\Z_CTX<.^YS&I,DD3\PT-G2=N4WD 95-YP2?K&8K%KA6]5R(6@.739P "/G
M!1,Z19W48'43QG'UF"-93V1];(7[B._D.I%1LVWH8%P&-7!795:<6TP)TQJ:
MU[#]C1W<!49LP'A64U@@6 WD#],TTV"C=G6@#OC1']%J@HO&'!TJ,QS(=[M.
M%>EGTDY6<U\T\ -PC@.B7QP_S:7G^^%G_EA34_4NGOFA\3I0X:8_DM5L&PTP
M^\H(!\)EJ=WM/(P^,=JCA&W:&.%W89PES:D+$,-'L)JSHX&HKDQP('FU7!*7
MAS;N..5OU?#TQL!EW.1[<L*S\SD+8CQUQ[&:"J2!:C_Y8,8V3UQ.V;*_?]-!
M%]?N,:QF& W&5"87''B6*T01L%3;I#$FBE/Q.0G(D@)"VX'#6*LQTG-[JR6=
M#F M!ZZ?7(3K31CPW-O%\I8DS6V!-!7L!VD\^\EL/S9/^6*C[].^6)-9]@%4
MB5^[LPJC%9[SU=T+P<P%'+U&.:&B21.3X=?_>(K3+.\([SRHZ0 K&@!+?MD0
M5.7"P8MH^;MB'>&6E/T[%WW@%<M*_, ,.SEW8EZP<M^ %Z_4@W_XU[!DJ0W4
ME;'$/AG%XF%ET4O]^9O6^S:#E GX!=LW=V842$N\(U<=P*!PV;M6.GN,O+WM
M1Z%&V4]464=J#WZ.V%Y' YZBO>UTFS'@J;$^:BHR!F#;_EX-E+LZVT[@&0-R
ML5".I^9 53YZ)U?[@?%C8'S;63-I\O4%*K5Z8"YBB=?FKPJO3;5,S^YCE48S
M_KU9_8,HO#A(2A8<[J;D+*EX'U->Z;[6>-CUB7)PRSX?C1H*8W*-:3\'8:CF
MF*Y8E&'*(1[5MM/(C%JHI#@=?9B'$:&KH-;BDK*.7+94%K(TSNBV'45F] ,J
MU>GHR<YQ.M!25,>Q[>,Q@WU;4M-WY$#X+B.&K@(FOVP+/GS3(1K3MD/(C.;(
M)3@=6Y&_7N_]5QHGHH+5&E)ICV;;WV0&?9'4IH-[J;^#W$^C?\BVJ\JLK>CG
MU4*G2$<8%C8R_,  L:G6I^9%Y?FY*G3_@!7/_+'IMLI'F&5#("N>>?7/E-=4
M4SJ?FNULU_[*'LX6U-,L&C;;X<AN[1:XZ,V\L8IHCBSY&TG%S28+-VA*;@J$
M*T?@!EW1S4?V@<6R\NB[HC!7=_,)82'@ $?)S0I9/';B-@R<_6^R%\R</ 1>
ME8^L/1 .!*7:V !2FT4SF?L/Q$VC+)[E+HW<9R<F9ZN(9$1(\_@!_6R?_WIJ
M8S41%BP=0XG+V9LR0$ ZF]I^;W(,#"0RP'%6NB<^#R>X<Z)D6^%)4>Q+U@F'
M.0,M2%(^<!2*%)"H*A"CZ(8#(X#NP0 S6R"&OQ9'DY1_B#_TGH55<N<[\:Z#
M%_YT8B0O&Z/1W_:R ]*V>E5[3=D86FPNG( UG=/DSQ6_2O>D@(@:VUYPM*4O
MYQK) C.EVI%:B\=;\<BWXI$&BD>:,R]3KATIL(WQ^;;ZEU[;ULXQ<$R-(;O8
M3K9P5#VLTJ6SDYW$]E6BDA+@#KB%[;%K[;M1/35VY2E6(>'VU-".=)PI<1&1
M/(Z:1_U)K5B[)8[I +)5;>(K1QJ[R0Q.ZB=S&CA!]NQTR4S,*54M]+#>.& 2
M*5H[S0' $HK=6.5>-TN3C8LG7?[<WPYWS")9)\MQYN+KN>9L4G..Q+KM"646
M>Q%E''H\CH2__I[1#H)*W-EV$'@?S%2B0(==KF37<9QJ3:VR@^U [/[SJLXR
M4EP6:1(G3N#18*4!3JV7[7#I_@AU,(\#IHS&7'\NTXB1QV8Y#;V<ZNR/BTUV
M;+AZ)9%+8]G,ZC.6[3AF,*3]!84#Z+LH= GQXCF3@":N@*ZV;P; ,(+%@ ,U
MJ=;=DL_9GZ3A4;#^MD.$QYF&+8%,/^^$7]$OEOE^+*(N8#\J[F$[$!@.LH)I
M''.S:DJXVO%(\\6RLO3#+*J@J[6RCT,LJE0,_<L/D C#5*QDICR&9YY'<[_=
MG4.]Z^#"V="$^R%VYJF4!:^");'0PT:U?6D#UI(QA(=CVI^].-3G/L1Y&'%#
MM0]DDX LZ0-V#=C'4,FYJ? )9DQH'#.!<'UAJX'+!;3J6@2SN -A<^L/Y*EE
M+6< TT1H'G(?TJ?8C>@3\<[3Y%- LXE<_#+?9-\3E] 7>3K%L%&MO\;7VT70
M1WHX]$"P)<]\AOV/*,WNUA_,&GI$Z9;'$9Q0.FM_5J*3S[?[)G?.-@O>YT5G
M\S-;&?WML44E^[5$4T;_$E2I$+B?#$D920'VJBL&E/WXW3?-[,<\[;$8 UGZ
MXY[0[&2TPZ\($\AVN1E03Q7X8D#!]8'CVC0;N_IM2M6.1;JMRLP<[Q,X+L?'
M4:.F91E/2ECR1_O:RI81'G$-ND&7GSKV!!QKQ;HQE H;$_?K5?CRSB.4Z]('
M_@-7H0\5%6*_^OV&K!S_*DBH,&"3M6HU.G)0NU@>,S,6"D[^?6%4)FM2;V$9
MEBZQM01;I]A,B.45.R_P1+_@+@I?*'<M2,,KQ<VM1;*T!-7VFZB8Q'%>OO.=
MX-99*^(HZZV.W+IT\HPCP[&D214(WFR' [$N71,(W:S]>?P</CZ':>P$[ B:
M1@F;I'F)DNN .S?9^8S3(;5)>D/8CKCKUINJM>HC$AP6+)_(["MR$]9HAF-&
MF+9A#:9QY-[U9W7/3N!!3:&9K^%0GT[5USWY].(?13#[U7KCAUM"*OXZ5?:!
MI(OUB%N#TZ)9TDXE.!R6_0CR? S;=V&*D.6DQ;<4(1LI0H+=[C^<('6B[2(@
ME4W>%5T]\TV>=),+ZFD[:%I'UZH[7@VQX#"'7VA:MV$3VB,CW'+^Y5M&N) U
M0^[*8KLD3P)OM;(=X0Q+^Q8P9RAX[C8,8-+L:F@["ADF4#&+2):1*189,KT(
MM.H3??]6G^@+J4]$ U!]HGHSJ$/77/4Y=8&B+L9PF""C-:$,UE&9<E&HW;$H
M=^MSZQD&642.="E0=,-A=8Q'C\B%4-G(V?2&UFE3G0P$S9$ "E'6IE.SFR$4
MBXR&A[J_9_K4V$E"JEI= >=X?<J] \&*6-Y*[80\DOXZ<"/"&E^2_-\#;J*&
M?]KV/?-XP8YCQ>_IPH9#2ROY.&4Z8A8Y?\_@C%ZRP/EYFJ01*5,3)5<C^D.A
MOPGKJT6]Q8I#*WK+Y3;EAKC8'<75S,F?65])2+^Y+UJOGH/.4@%!FK@J9O_X
MA<3)SA*?&E"_SJ_8OJC"IW(2,!"IV9.:LZ<F9U>O&YJ_RI?SI="Q<3YAO>Z0
M404;$P9$VM5'7OLD^,6RLK/,-A:%"\B 40-]U7KM)'1&3@,LS&JIJU#V[Q\/
MK H=($XYB;V/N9T[-,HR^\_8^65=UI+;D.SY<A*M55LM0]^T?6^+;UT$ X79
M(@$$V,7G/8W_F$>$7 <)88J0\->4#:R6\$];+UN%;LG4A>T(M?17DD4">F=L
M56!;AW)R7M(7ZI' 1%V07E38K]<U">4%HGF$>ERR^DOHLV%\FFP/:&]%'[=?
M^6P26BO'SE"$WCR,EH1R)WA\%2=TG46\J8K<J3K9KX0V.N 0MH_"JA0W:)D3
M.KXN'#D-@YK]D8?;[]38W#6H-B'VB[6ALS;#,#T.A2Z+K._X?PP3_O!5$M$@
MIJYA+89]W7Y).*RJJX,>#GW=)5V2Z(6ZI%L MV'V\!K)KV;BC*GJWWE5K=LP
M^8TD]\0-5X'\X2:#G[0> &M,,XWC=.3JF$]'MC4J?L7;21R/AZ;#>A3Q]!17
MBBC"FITG#^EZS5,[EY7#U"<N3;8XN'3C^/[V.K@D"8G6-*#!:K?#62RK.R/B
M%74[=[S6BGZ>RHM^LO_.R9B%RUF%D!FG9%8A94:#6868&:=FEI'#>Y;#%13M
M:HF^51!]JR#Z5D&T8V/Y5D%4N&"\51 ]H@JB_14J7U*NV0K[2MBY*:L!'\5Y
MD+^ZD!:L]Y>A%#!9C%F:U!SJJH0A:'\<R.OHN":HJ#*+K-3 ,G8OHZ>CTZQJ
M]19,8?(Y<'3^R@&Q%%,.7QO[#K2\JK=P>UW_M&T3.0T-E\&&R Q_>4&6$[IA
MMQ%D^69RIQTR] 7=X0^*&#JXG@NBC?ISOPN]$2@G'WZTT8\O=7!4\4S@)BC_
MQ9F;L U)LI7>Z[S7N-?)?SDKQWV[G4%Z.S,PVJ22-Y:G:9L+#.KXE.4SM9EK
M&E.(]%[D-MDM]T/B1,F$-W2=D7T_1V%LXA)(]C';YV246BN!!<FIN/NYX(RI
MN+JREO%WLDR8'F/9/L6:T9K>0M4W9C_FQBP@*T[O] U9)<3^&E;+8>R/V3YY
MHC1D$EC>=-;F;O'W]_9/JR@UME-2HVP9KX(IZVSYRAL3?IKAL$B>2?3X[ 2%
MX'[)PD4-&E]M"FS7V<&EWST!1++?'&]6MW)\\[W4741EY1$/1H#M:BRXE+8?
M?%_(V5X8B@9)VQM+[\<DPG8!&#NZ/SZ,$['9*L9;N7N65%B3#MMU8G!J<2\P
MCT21.T[!EE19FQ+KA6-P:G-/1">BST>RF=;P<9@K(3/E_?2;ZZ,JM/Q\?!9X
MN^"PD/_*^FP82I?UHCLHI\@X:!_-O.D36*DT-O>$IVFPWU^$089EZO@\XO*]
M8K(<FACKY57,S1 [N"+:!PT0@+:)$,G%1"BX 1JMUW)!.0W&UP)$LV.</>:A
MBF5)/FG];324FQPE1D>S?S&Z$SQ;K:(L*.%0BCZ ).A$.#(GNVF,1Y\H>$+B
M;\,@%T_US]+(^&\U(N/9Z+-\^$:KMQ!YO"'R [9+N\)B]7?,S.V A1\\VG!Y
M<^A\(1?K;T'S4US#\0?-CW+2/)3=[/[:<0;>&P3F.%1OMR[4[S\MK.(J HXW
M#/]P\!V9SEK>:1YWJ+T9>1V9]VD,(0U]2N- --A^6!2WIO=Y.^/MI'6\C\E\
M6=<-P]^1F7+=I<$'#(LK )B XPWA/QQ\1[;];IXY,&QD>M!TO&']5D$^,F7'
MH-Q*&G0"HR<8V'\P&1[1U>^O3I1MSHI+UUO^GPE]V4_3V@7OA^8%;]E]=VL[
MVXU@\_XVSWE6W\<VVUFT1!>^$\>+92'0173/]7#G("%N&M&$DOC"\7WBG6]+
MP1<-)=ZMP0-;OB_MQK(Q_T>2'HY%J9.96ICY[H\[#B2AI#V'LWW7V!]WJ*@,
MO9!<?@\8_MD!'!]&>Q3;-W1RO'JQ9!0F7G#+"=Q\%[(.@RP**?=$[^IL+8(+
M)W[V21R?.W'GHS=\J%XCV;ZO4L,U0$"&("L->H6>7TE$&M3(H-(:P?;EC1JB
M'@(Q!$VG(<YKV@F@D/:P7<)'+7H PX<4]06?J7QSHR/M2B?;US<]!=YB&TF1
MZ>(P>^=$R?:1T1LSIBKALXICUG?-8U8QW"P;;U8=$-G!2\2W^BBF[HGB]4X1
MF>?;VE^@+W5J#8?CY30HQ,)W-[5X1O+&IH#F&_4+FNJ>.& =I.(-K-4\(WGI
M$L:J_+U+G3&^&*@[N<?QSF65+M6;EEUM<6"HK[D2X$9ZL5*P7UU$3-_XVO"1
M>-1U_%\8=[R SLW-A? I2MX1T,^VCTJL2]6=*U@ .-R/_"'-Q;)R=R*W?X+F
M.*;)F*9.P&C%KV81M&H-J[/ NPT#9_^;*K^JUU^U!\(!M%1I&T!JLVC&+CY^
M#A^?PS1V IZ ^D#9*9,$%^RSJ9]DB:<1R2B2&DG=06Q;S)YZ6C6G_>2&P[;>
M^4YPZZP53ZC76^&88&-:TCI_%4\W F146\)F.QSH=.F50.AF-WN5R3D/TXA/
MS=RU5XW+X*1 K1IL%-N77]W:([!:.H+!8;;NN856'(/W37!,B5%/N7OF*I<^
MM@%1;>5JC7" TE*D+D&;W7;Q&[%:D-@Z3(,NQW1VZ2!H;'L;!?5'UBY0I(PC
M,33=?%U*'QB6=K*],N@B!>$)$V*]<T/R2(*[-'*?^9_F893]6G)K,OJ7;,=@
M]-0-4R+_@O-MLG_P= UV@,RCQ.Y(Y')=6)F(W)9_SG;<R1"U-"7\B1B[+_5I
M%F.!.*9,I-''5R9J/<_\;'#B=4N/E\@+8HEB0OO;CC7JJ5-ZXAE9'6P$,?UG
MRB1$(G\[IX$3N-3QKX-ER)KP#YSLS]?2=M*"@=\W YUV0\UV8\TJ@\W^\BEP
M4H\GFOTK+R=8D,#K"2I[(B@K*!?43@[J8"GM@:P>Z5Y(D,KJK^Q;6$XUZ8E/
MZ^A69QC'UN6>29+1\'P6>)>,0#_<\"5/:=,5W6S[0<9"#" ;'##^3 *V!?$9
MI6?>F@:4\\6#/I5 *CO:=I2, R50/CC 7&P(IRY8%=1);&1'4]O>BW$ $\H
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M2P$"% ,4    " #F16Q,BA.<Y,(2  ")Q0  $0              @ %:X@
M8W)B<"TR,#$W,3(S,2YX<V102P$"% ,4    " #F16Q,M,BL\M03  "2!P$
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E,#$W,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  ([D 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
